AU2003272200A1 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Description

WO 2004/000997 PCT/US2003/017512 THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF USE FIELD OF THE INVENTION The present invention relates to novel polypeptides, and the nucleic acids encoding 5 them, having properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions. 10 WO 2004/000997 PCT/US2003/017512 BACKGROUND OF THE INVENTION Eukaryotic cells are characterized by biochemical and physiological processes, which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such 5 as vertebrates or, more particularly, organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways involve extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells. 10 Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells 15 and receptor cells in close proximity to each other, for example, two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding 20 biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect. 25 Signaling processes may elicit a variety of effects on cells and tissues including, by way of nonlimiting example, induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue. Many pathological conditions involve dysregulation of expression of important 30 effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion of protein effectors. In other classes of pathologies the dysregulation is manifested as increased or up-regulated level of 2 WO 2004/000997 PCT/US2003/017512 synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by altered or mis-regulated levels of a protein effector of interest. Therefore there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level 5 with that characteristic of a nonpathological condition. There also is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed levels of the protein effector of interest. In addition, there is a need for a 10 method of treatment of a pathological condition brought on by a increased or up-regulated levels of the protein effector of interest. Antibodies are multichain proteins that bind specifically to a given antigen, and bind poorly, or not at all, to substances deemed not to be cognate antigens. Antibodies are comprised of two short chains termed light chains and two long chains termed heavy 15. chains. These chains are constituted of immunoglobulin domains, of which generally there are two classes: one variable domain per chain, one constant domain in light chains, and three or more constant domains in heavy chains. The antigen-specific portion of the immunoglobulin molecules resides in the variable domains; the variable domains of one light chain and one heavy chain associate with each other to generate the antigen-binding 20 moiety. Antibodies that bind immunospecifically to a cognate or target antigen bind with high affinities. Accordingly, they are useful in assaying specifically for the presence of the antigen in a sample. In addition, they have the potential of inactivating the activity of the antigen. Therefore there is a need to assay for the level of a protein effector of interest in a 25 biological sample from such a subject, and to compare this level with that characteristic of a nonpathological condition. In particular, there is a need for such an assay based on the use of an antibody that binds immunospecifically to the antigen. There further is a need to inhibit the activity of the protein effector in cases where a pathological condition arises from elevated or excessive levels of the effector based on the use of an antibody that binds 30 immunospecifically to the effector. Thus, there is a need for the antibody as a product of manufacture. There further is a need for a method of treatment of a pathological condition brought on by an elevated or excessive level of the protein effector of interest based on administering the antibody to the subject. 3 WO 2004/000997 PCT/US2003/017512 SUMMARY OF THE INVENTION The invention is based in part upon the discovery of isolated polypeptides including amino acid sequences selected from mature forms of the amino acid sequences selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 5 and 141. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, etc., nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide sequences. The invention also is based in part upon variants of a mature form of the amino 10 acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes the amino acid sequences selected from the group consisting of SEQ ID NO:2n, 15 wherein n is an integer between 1 and 141. In another embodiment, the invention also comprises variants of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between I and 141, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also involves 20 fragments of any of the mature forms of the amino acid sequences selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, or any other amino acid sequence selected from this group. The invention also comprises fragments from these groups in which up to 15% of the residues are changed. In another embodiment, the invention encompasses polypeptides that are naturally 25 occurring allelic variants of the sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141. These allelic variants include amino acid sequences that are the translations of nucleic acid sequences differing by a single nucleotide from nucleic acid sequences selected from the group consisting of SEQ ID NOS: 2n-1, wherein n is an integer between 1 and 141. The variant polypeptide where 30 any amino acid changed in the chosen sequence is changed to provide a conservative substitution. 4 WO 2004/000997 PCT/US2003/017512 In another embodiment, the invention comprises a pharmaceutical composition involving a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, and a pharmaceutically acceptable carrier. In another embodiment, the invention involves a kit, including, in one 5 or more containers, this pharmaceutical composition. In another embodiment, the invention includes the use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease being selected from a pathology associated with a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an 10 integer between 1 and 141, wherein said therapeutic is the polypeptide selected from this group. In another embodiment, the invention comprises a method for determining the presence or amount of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, in a sample, the 15 method involving providing the sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the polypeptide, thereby determining the presence or amount of polypeptide in the sample. In another embodiment, the invention includes a method for determining the 20 presence of or predisposition to a disease associated with altered levels of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, in a first mammalian subject, the method involving measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in this sample to the 25 amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease. In another embodiment, the invention involves a method of identifying an agent 30 that binds to a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, the method including introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. The agent could be a cellular receptor or a downstream effector. 5 WO 2004/000997 PCT/US2003/017512 In another embodiment, the invention involves a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an 5 integer between 1 and 141, the method including providing a cell expressing the polypeptide of the invention and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not 10 observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent. In another embodiment, the invention involves a method for screening for a modulator of activity or of latency or predisposition to a pathology associated with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID 15 NO:2n, wherein n is an integer between 1 and 141, the method including administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of the invention, wherein the test animal recombinantly expresses the polypeptide of the invention; measuring the activity of the polypeptide in the test animal after administering the test compound; and comparing the activity of the protein in the test 20 animal with the activity of the polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the polypeptide of the invention. The recombinant test animal could express a test protein transgene or express the transgene 25 under the control of a promoter at an increased level relative to a wild-type test animal The promoter may or may not b the native gene promoter of the transgene. In another embodiment, the invention involves a method for modulating the activity of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between I and 141, the method including 30 introducing a cell sample expressing the polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In another embodiment, the invention involves a method of treating or preventing a pathology associated with a polypeptide with an amino acid sequence selected from the 6 WO 2004/000997 PCT/US2003/017512 group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, the method including administering the polypeptide to a subject in which such treatment or prevention is desired in an amount sufficient to treat or prevent the pathology in the subject. The subject could be human. 5 In another embodiment, the invention involves a method of treating a pathological state in a mammal, the method including administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n 10 is an integer between 1 and 141, or a biologically active fragment thereof. In another embodiment, the invention involves an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141, a variant of a mature 15 form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an 20 integer between 1 and 141, a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino 25 acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, or any variant of the polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and the complement of any of the nucleic acid molecules. 30 In another embodiment, the invention comprises an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein the nucleic acid 7 WO 2004/000997 PCT/US2003/017512 molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the invention involves an isolated nucleic acid molecule including a nucleic acid sequence encoding a polypeptide having an amino acid sequence 5 selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141, that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the invention comprises an isolated nucleic acid molecule 10 having a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 2n-l, wherein n is an integer between 1 and 141. 15 In another embodiment, the invention includes an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of the 20 nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the 25 nucleotides are so changed; a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, and a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, is changed from that selected from the group consisting of the chosen sequence to a 30 different nucleotide provided that no more than 15% of the nucleotides are so changed. In another embodiment, the invention includes an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given 8 WO 2004/000997 PCT/US2003/017512 SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein the nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between I and 141, or a complement of the nucleotide sequence. 5 In another embodiment, the invention includes an isolated nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein the nucleic acid molecule has a nucleotide sequence in which any nucleotide specified in the coding 10 sequence of the chosen nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides in the chosen coding sequence are so changed, an isolated second polynucleotide that is a complement of the first polynucleotide, or a fragment of any of them. 15 In another embodiment, the invention includes a vector involving the nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141. This vector can have a promoter operably linked to the nucleic acid molecule. This vector can be located within a 20 cell. In another embodiment, the invention involves a method for determining the presence or amount of a nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer 25 between 1 and 141, in a sample, the method including providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in the sample. The presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type. The cell 30 type can be cancerous. In another embodiment, the invention involves a method for determining the presence of or predisposition for a disease associated with altered levels of a nucleic acid molecule having a nucleic acid sequence encoding a polypeptide including an amino acid 9 WO 2004/000997 PCT/US2003/017512 sequence selected from the group consisting of a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141, in a first mammalian subject, the method including measuring the amount of the nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample 5 of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease. Unless otherwise defined, all technical and scientific terms used herein have the 10 same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In 15 the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description and claims. 20 DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the 25 corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides. 10 WO 2004/000997 PCT/US2003/017512 TABLE A. Sequences and Corresponding SEQ ID Numbers SEQ ID SEQ ID NOVX Internal NO NO Assignment Identification (nucleic (amino Homology acid) acid) NOVla CG103945-02 1 2 Semaphorin sem2 (FLJ00014 protein) .__ _ _ _ _ IHomo sapiens . NOVlb CG103945-01 3 4 Semaphorin sem2 (FLJ00014 protein) .I Homo sapiens NOV2a CG106951-01 5 6 Human semaphorin G-like NHP protein NOV2b CG106951-04 7 8 Human semaphorin G-like NHP protein NOV2c 209829549 9 10 Human semaphorin G-like NHP protein NOV2d 209829553 11 12 Human semaphorin G-like NHP protein NOV2e 209829642 113 14 Human semaphorin G-like NHP protein NOV2f 209829670 115 16 Human semaphorin G-like NHP protein NOV2g C...... G106951-02 17 1 8 Human semaphorin G-like NHP protein NOV2h CG106951-03 19 20 Human semaphorin G-like NHP protein NOV2i SNP13382456 21 22 Human semaphorin G-like NHP protein NOV3a CG121295-01 23 24 Endothelin-1 precursor (ET-1) - Homo sapiens NOV4a CG124756-01 25 26 - complement subcomponent C lq chain .... 1..... IB precursor [validated] NOV4b CG124756-02 27 28 complement subcomponent Clq chain I B precursor [validated] NOV4c SNP13382475 29 30 complement subcomponent Clq chain B precursor [validated] NOV4d SNP13382476 31 32 complement subcomponent C1q chain _1 ~B precursor [validated] NOV5a CG50353-01 33 34 Wnt-7a protein precursor - Homo 33 sapiens NOV5b 228753443 35 36 Wnt-7a protein precursor - Homo sapiens NOV5c 169475673 37 38 Wnt-7a protein precursor - Homo .F7 sapiens NOV5d 228753459 39 40 Wnt-7a protein precursor - Homo sapiens NOV5e 228753462 41 42 Wnt-7a protein precursor - Homo .... .. sapiens NOV5f 228753446 43 44 Wnt-7a protein precursor - Homo 2 -sapiens NOV5g 228753465 45 46 Wnt-7a protein precursor -Homo sapiens NOV5h 228753438 47 148 Wnt-7a protein precursor - Homo 3sap i ens 11 WO 2004/000997 PCT/US2003/017512 NOV5i 228753449 49 50 Wnt-7a protein precursor - Homo 45 sapiens NOV5j CG50353-02 51 52 Wnt-7a protein precursor - Homo sapiens NOV5k CG50353-03 53 54 Wnt-7a protein precursor - Homo sapiens NOV51 SNP13382474 55 56 Wnt-7a protein precursor - Homo sapiens NOV6a CG50709-03 57 58 Wnt-9b protein precursor (Wnt-15) 17(Wnt-14b) - Homo sapiens NOV6b 282997951 59 60 Wnt-9b protein precursor (Wnt-15) 9 (Wnt-14b) - Homo sapiens NOV6c CG50709-05 61 62 Wnt-9b protein precursor (Wnt-15) (Wnt-14b) - Homo sapiens NOV6d 277582109 63 64 Wnt-9b protein precursor (Wnt-15) (Wnt-14b) - Homo sapiens NOV6e 277582117 65 66 Wnt-9b protein precursor (Wnt-15) (Wnt-14b) - Homo sapiens NOV6f CG50709-01 67 68 Wnt-9b protein precursor (Wnt-15) (Wnt-14b) - Homo sapiens NOV6g CG50709-02 69 70 Wnt-9b protein precursor (Wnt-15) , (Wnt-14b) - Homo sapiens NOV6h CG50709-04 71 72 Wnt-9b protein precursor (Wnt-15) 71 (Wnt-14b) - Homo sapiens NOV6i CG50709-06 73 74 Wnt-9b protein precursor (Wnt-15) 73 (Wnt-14b) - Homo sapiens NOV6j CG50709-07 75 76 Wnt-9b protein precursor (Wnt- 15) _ (Wnt-14b) - Homo sapiens NOV6k SNP13381605 77 78 Wnt-9b protein precursor (Wnt-15) 77(Wnt-14b) - Homo sapiens NOV61 SNP13381606 79 80 Wnt-9b protein precursor (Wnt-15) (Wnt-14b) - Homo sapiens NOV6m SNP13378337 81 82 Wnt-9b protein precursor (Wnt-15) 1 (Wnt-14b) - Homo sapiens NOV6n SNP13381607 83 84 Wnt-9b protein precursor (Wnt-15) (Wnt-14b) - Homo sapiens NOV6o SNP13378336 85 86 Wnt-9b protein precursor (Wnt-15) _5 _(Wnt-14b) - Homo sapiens NOV6p SNP13378335 87 88 Wnt-9b protein precursor (Wnt-15) (Wnt-14b) - Homo sapiens NOV7a CG53054-02 89 90 Wnt-9a protein precursor (Wnt-14) Homo sapiens NOV7b 170251039 91 92 Wnt-9a protein precursor (Wnt-14) Homo sapiens NOV7c 170251076 93 94 Wnt-9a protein precursor (Wnt-14) Homo sapiens NOV7d CG53054-01 95 96 Wnt-9a protein precursor (Wnt-14) Homo sapiens 12 WO 2004/000997 PCT/US2003/017512 NOV7e CG53054-03 97 98 Wnt-9a protein precursor (Wnt-14) Homo sapiens NOV7f CG53054-04 99 100 Wnt-9a protein precursor (Wnt-14) Homo sapiens OV8a CG53473-02 101 102 Neuromedin B-32 precursor [Contains: Neuromedin B] - Homo sapiens NOV8b CG53473-01 10 3 104 Neuromedin B-32 precursor [Contains: Neuromedin B] - Homo sapiens NOV8c CG53473-03 105 106 Neuromedin B-32 precursor [Contains: Neuromedin B] - Homo sapiens NOV8d SNP13376396 107 108 Neuromedin B-32 precursor [Contains: Neuromedin B] - Homo sapiens NOV8e SNP13376395 109 110 Neuromedin B-32 precursor [Contains: Neuromedin B] -Homo sapiens NOV8f SNP13376394 111 112 Neuromedin B-32 precursor [Contains: Neuromedin B] - Homo sapiens NOV9a CG55184-03 113 114 Cerebellin-like glycoprotein 1 precursor -Homo sapiens NOV9b CG55184-01 115 116 Cerebellin-like glycoprotein 1 precursor - Homo sapiens NOV9c CG55184-02 117 118 Cerebellin-like glycoprotein 1 precursor 1-17 Homo sapiens NOV9d CG55184-04 119 120 Cerebellin-like glycoprotein 1 precursor . - Homo sapiens NOV9e CG55184-05 121 122 Cerebellin-like glycoprotein 1 precursor -Homo sapiens NOV10a CG55274-05 123 124 Human endozepine-like ENDO5 NOVO10b CG55274-01 125 126 Human endozepine-like ENDO5 NOVO10c CG55274-02 127 128 Human endozepine-like ENDO5 NOVIO0d CG55274-03 129 130 Human endozepine-like ENDO5 NOV10e CG55274-04 131 132 Human endozepine-like ENDO5 NOVIla CG55379-04 133 134 HDDM36 - Homo sapiens NOV11b CG55379-01 135 136 HDDM36 - Homo sapiens NOV11c 258065951 137 138 HDDM36 - Homo sapiens NOV11d 209886264 139 140 HDDM36 - Homo sapiens NOV11e 209886345 141 142 HDDM36 - Homo sapiens NOVllf 209886357 143 144 HDDM36 - Homo sapiens NOVllg CG55379-02 145 146 HDDM36 - Homo sapiens NOV11h CG55379-03 147 148 HDDM36 - Homo sapiens NOV12a CG55688-01 150 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 149 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo _sapiens 13 WO 2004/000997 PCT/US2003/017512 NOV12b 254087906 152 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 151 (Insulin-like growth factor-binding Protein 10) (GIG1 protein) - Homo ............. ... sa p ie n s NOV12c 259278648 154 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 153 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV12d 259280032 156 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 155 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV2e 254756530 158 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 157 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV12f 229509618 160 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 159 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV12g 229509658 162 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 161 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV12h CG55688-02 164 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 163 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV12i CG55688-03 166 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 165 (Insulin-like growth factor-binding protein 10) (GIG1 protein)- Homo sapiens NOV12j CG55688-04 168 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 167 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV12k CG55688-05 170 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 169 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens 14 WO 2004/000997 PCT/US2003/017512 NOV121 CG55688-06 172 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 171 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo I_ _sapiens NOV12m SNP13376428 174 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) 173 (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens NOV13a CG56768-01 175 176 Wnt-5a protein precursor - Homo 15 sapiens NOV13b CG56768-02 177 178 Wnt-5a protein precursor - Homo sapiens NOV13c CG56768-03 179 180 Wnt-5a protein precursor - Homo 17 sapiens NOV14a CG57054-03 181 182 Wnt-10b protein precursor (Wnt-12) Homo sapiens NOV14b

C

G57054-01 183 184 Wnt-10b protein precursor (Wnt-12) _ Homo sapiens NOV14c CG57054-02 185 186 Wnt-10b protein precursor (Wnt-12) Homo sapiens NOV15a CG57431-03 187 188 Endothelin-2 precursor (ET-2) - Homo 18 sapiens NOV15b CG57431-02 189 190 Endothelin-2 precursor (ET-2) - Homo sapiens NOV15c CG57431-01 191 192 Endothelin-2 precursor (ET-2) - Homo sapiens NOV15d CG57431-04 193 194 Endothelin-2 precursor (ET-2) - Homo sapiens NOV16a CG59253-01 195 196 Semaphorin 6D isoform 2 - Homo sapiens NOV16b 194877881 198 Semaphorin 6D isoform 2 - Homo 197 sapiens NOV16c CG59253-02 199 200 Semaphorin 6D isoform 2 - Homo sapiens NOV16d 191815765 201 202 Semaphorin 6D isoform 2 - Homo 203 sapiens NOV16e CG59253-03 203 204 Semaphorin 6D isoform 2 - Homo sapiens NOV16f CG59253-04 205 206 Semaphorin 6D isoform 2 - Homo sapiens NOV16g CG59253-05 207 208 Semaphorin 6D isoform 2 - Homo sapiens NOV16h CG59253-06 209 210 Semaphorin 6D isoform 2 - Homo sapiens NOV16i CG59253-07 1 212 Semaphorin 6D isoform 2 - Homo 1 .. sapiens 15 WO 2004/000997 PCT/US2003/017512 NOV16j CG59253-08 213 214 Semaphorin 6D isoform 2 - Homo sapiens NOV16k CG59253-09 215 216 Semaphorin 6D isoform 2 - Homo sapiens NOV161 CG59253-10 217 218 Semaphorin 6D isoform 2 - Homo sapiens NOV16m . SNP13381547 219 220 Semaphorin 6D isoform 2 - Homo sapiens NOV16n SNP13378936 221 222 Semaphorin 6D isoform 2 - Homo sapiens NOV16o SNP13378935 223 224 Semaphorin 6D isoform 2 - Homo sapiens NOV16p SNP13381569 225 226 Semaphorin 6D isoform 2 -Homo sapiens NOV16q SNP13382528 227 228 Semaphorin 6D isoform 2 - Homo sapiens NOV17a CG95430-02 229 230 Energen-related secreted protein - C2P NOV17b CG95430-04 231 232 Energen-related secreted protein - C2P NOVI7c CG95430-01 233 234 Energen-related secreted protein - C2P NOV17d 319194717 235 236 Energen-related secreted protein -C2P NOV17e CG95430-03 237 238 Energen-related secreted protein -C2P NOV17f CG95430-05 239 240 Energen-related secreted protein - C2P NOV17g CG95430-06 241 242 Energen-related secreted protein - C2P NOV17h CG95430-07 243 244 Energen-related secreted protein -C2P NOV17i CG95430-08 245 246 Energen-related secreted protein - C2P NOV17j CG95430-09 247 248 Energen-related secreted protein - C2P NOV17k CG95430-10 249 250 Energen-related secreted protein - C2P NOV171 CG95430-11 251 252 Energen-related secreted protein - C2P NOV17m CG95430-12 253 254 Energen-related secreted protein - C2P NOV17n CG95430-13 255 256 Energen-related secreted protein - C2P NOV17o SNP13379412 257 258 Energen-related secreted protein - C2P NOV17p SNP13381828 259 260 Energen-related secreted protein - C2P NOV17q SNP13379125 261 262 Energen-related secreted protein - C2P NOV17r SNP13381827 263 264 Energen-related secreted protein - C2P NOV17s SNP13381822 265 266 Energen-related secreted protein - C2P NOV17t SNP13381826 267 268 Energen-related secreted protein - C2P NOV18a CG97111-01 269 270 Human IL-1 receptor antagonist protein NOV18b CG97111-02 271 272 Human IL- I receptor antagonist protein NOV18c CG97111-03 273 274 Human IL-1 receptor antagonist protein NOV18d SNP13382516 275 276 Human IL-1 receptor antagonist protein NOV18e SNP13382517 277 278 Human IL-1 receptor antagonist protein NOV18f SNP13382518 279 280 Human IL-1 receptor antagonist protein NOV19a 10132038.0.67 281 282 Domain of CG50513-05 16 WO 2004/000997 PCT/US2003/017512 Table A indicates the homology of NOVX polypeptides to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table A will be 5 useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table A. Pathologies, diseases, disorders, conditions and the like that are associated with NOVX sequences include, but are not limited to, e.g., cardiomyopathy, atherosclerosis, 10 hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, sclerodermnna, obesity, metabolic disturbances associated with obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, diabetes, metabolic 15 disorders, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's 20 Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers, as well as conditions such as transplantation and fertility. NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according 25 to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong. Consistent with other known members of the family of proteins, identified in 30 column 5 of Table A, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A. 17 WO 2004/000997 PCT/US2003/017512 The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the 5 protein families listed in Table A. The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the 10 detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g., detection of a variety of cancers. Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein. NOVX clones 15 NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins 20 that are members of the family to which the NOVX polypeptides belong. The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are 25 described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders. The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a 30 specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a 18 WO 2004/000997 PCT/US2003/017512 small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) a biological defense weapon. 5 In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an 10 integer between 1 and 141, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, 15 wherein n is an integer between 1 and 141, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d). In another specific embodiment, the invention includes an isolated nucleic acid 20 molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO:2n, wherein n is an integer between 1 and 141; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, wherein any amino acid in the 25 mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer 30 between 1 and 141, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of 19 WO 2004/000997 PCT/US2003/017512 SEQ ID NO:2n, wherein n is an integer between 1 and 141, or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules. 5 In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected 10 from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141; and (d) a nucleic acid fragment 15 wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. NOVX Nucleic Acids and Polypeptides 20 One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used 25 herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA. 30 A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a "mature" form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide, precursor form, or proprotein. The naturally 20 WO 2004/000997 PCT/US2003/017512 occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product "mature" form arises, by way of nonlimiting example, as a result of one or 5 more naturally occurring processing steps that may take place within the cell (e.g., host cell) in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor 10 polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further 15 as used herein, a "mature" form of a polypeptide or protein may arise from a post-translational modification step other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them. 20 The term "probe", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), about 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, 25 and much slower to hybridize than shorter-length oligomer probes. Probes may be single or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies. The termn "isolated" nucleic acid molecule, as used herein, is a nucleic acid that is separated from other nucleic acid molecules which are present in the natural source of the 30 nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain 21 WO 2004/000997 PCT/US2003/017512 less than about 5 kb, about 4 kb, about 3 kb, about 2 kb, about 1 kb, about 0.5 kb, or about 0.1 kb, of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA 5 molecule, can be substantially free of other cellular material, or culture medium, or of chemical precursors or other chemicals. A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS: 2n-l, wherein n is an integer between 1 and 141, or a complement of this nucleotide sequence, can be isolated using standard molecular 10 biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2 nd Ed., Cold Spring Harbor Laboratory 15 Press, Cold Spring Harbor, NY, 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993). A nucleic acid of the invention can be amplified using cDNA, mRNA or, alternatively, genomic DNA as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be 20 cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer. As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues. A short oligonucleotide sequence may be based on, or designed from, a genomic 25 or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at 30 least 6 contiguous nucleotides of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, or a complement thereof Oligonucleotides may be chemically synthesized and may also be used as probes. 22 WO 2004/000997 PCT/US2003/017512 In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment 5 encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, that it can hydrogen bond with few or no mismatches to a nucleotide sequence of SEQ ID NOS:2n-1, 10 wherein n is an integer between 1 and 141, thereby forming a stable duplex. As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, 15 non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates. 20 A "fragment" provided herein is defined as a sequence of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, and is at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid 25 sequence of choice. A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 30 5' direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3' direction of the disclosed sequence. 23 WO 2004/000997 PCT/US2003/017512 A "derivative" is a nucleic acid sequence or amino acid sequence formed from the native compounds either directly, by modification or partial substitution. An "analog" is a nucleic acid sequence or amino acid sequence that has a structure similar to, but not identical to, the native compound, e.g. they differs from it in respect to certain 5 components or side chains. Analogs may be synthetic or derived from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. A "homolog" is a nucleic acid sequence or amino acid sequence of a particular gene that is derived from different species. Derivatives and analogs may be full length or other than full length. Derivatives or 10 analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done 15 by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below. 20 A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of 25 RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring 30 allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see 24 WO 2004/000997 PCT/US2003/017512 below) in SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below. A NOVX polypeptide is encoded by the open reading frame ("ORF") of a NOVX 5 nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may 10 be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bonafide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more. The nucleotide sequences determined from the cloning of the human NOVX genes 15 allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region ofnucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 20 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141; or an anti-sense strand nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141; or of a naturally occurring mutant of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141. 25 Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e.g. the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which 30 mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted. 25 WO 2004/000997 PCT/US2003/017512 "A polypeptide having a biologically-active portion of a NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment 5 encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of 10 NOVX. NOVX Nucleic Acid and Polypeptide Variants The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that 15 encoded by the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141. In another embodiment, an isolated nucleic acid molecule of the. invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 141. In addition to the human NOVX nucleotide sequences of SEQ ID NO:2n-1, 20 wherein n is an integer between 1 and 141, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and 25 "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic 30 variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention. 26 WO 2004/000997 PCT/US2003/017512 Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from a human SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and 5 homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the 10 invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes 15 to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other. Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other 20 than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning. As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but 25 to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 oC lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, 30 pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration 27 WO 2004/000997 PCT/US2003/017512 is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 oC for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60 oC for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the 5 addition of destabilizing agents, such as formamide. Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other 10 typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65'C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50 0 C. An isolated nucleic acid molecule of the invention that 15 hybridizes under stringent conditions to a sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). 20 In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Reinhardt's solution, 0.5% 25 SDS and 100 mg/ml denatured salmon sperm DNA at 55 oC, followed by one or more washes in 1X SSC, 0.1% SDS at 37 oC. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY. 30 In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization 28 WO 2004/000997 PCT/US2003/017512 conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCI (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40 0 C, followed by one or more washes in 2X SSC, 25 mM Tris-HCI (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50 oC. Other conditions of 5 low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792. 10 Conservative Mutations In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, thereby leading to changes in the amino acid sequences of 15 the encoded NOVX protein, without altering the functional ability of that NOVX protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 141. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without 20 altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art. 25 Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence 30 encoding a protein, wherein the protein comprises an amino acid sequence at least about 40% homologous to the amino acid sequences of SEQ ID NO:2n, wherein n is an integer between 1 and 141. Preferably, the protein encoded by the nucleic acid molecule is at 29 WO 2004/000997 PCT/US2003/017512 least about 60% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 141; more preferably at least about 70% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 141; still more preferably at least about 80% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 141; even more preferably at least 5 about 90% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 141; and most preferably at least about 95% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 141. An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO:2n, wherein n is an integer between 1 and 141, can be created by 10 introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced any one of SEQ ID NO:2n-1, wherein n is an integer 15 between 1 and 141, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side 20 chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains 25 (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation 30 mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of a nucleic acid of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, the encoded protein can be 30 WO 2004/000997 PCT/US2003/017512 expressed by any recombinant technology known in the art and the activity of the protein can be determined. The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully 5 conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, 10 NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code. In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX 15 protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins). In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release). Interfering RNA 20 In one aspect of the invention, NOVX gene expression can be attenuated by RNA interference. One approach well-known in the art is short interfering RNA (siRNA) mediated gene silencing where expression products of a NOVX gene are targeted by specific double stranded NOVX derived siRNA nucleotide sequences that are complementary to at least a 19-25 nt long segment of the NOVX gene transcript, including 25 the 5' untranslated (UT) region, the ORF, or the 3' UT region. See, e.g., PCT applications WO00/44895, WO99/32619, WO01/75164, WO01/92513, WO01/29058, WO01/89304, W002/16620, and W002/29858, each incorporated by reference herein in their entirety. Targeted genes can be a NOVX gene, or an upstream or downstream modulator of the NOVX gene. Nonlimiting examples of upstream or downstream modulators of a NOVX 30 gene include, e.g., a transcription factor that binds the NOVX gene promoter, a kinase or phosphatase that interacts with a NOVX polypeptide, and polypeptides involved in a NOVX regulatory pathway. 31 WO 2004/000997 PCT/US2003/017512 According to the methods of the present invention, NOVX gene expression is silenced using short interfering RNA. A NOVX polynucleotide according to the invention includes a siRNA polynucleotide. Such a NOVX siRNA can be obtained using a NOVX polynucleotide sequence, for example, by processing the NOVX ribopolynucleotide 5 sequence in a cell-free system, such as but not limited to a Drosophila extract, or by transcription of recombinant double stranded NOVX RNA or by chemical synthesis of nucleotide sequences homologous to a NOVX sequence. See, e.g., Tusehl, Zamore, Lehmann, Bartel and Sharp (1999), Genes & Dev. 13: 3191-3197, incorporated herein by reference in its entirety. When synthesized, a typical 0.2 micromolar-scale RNA synthesis 10 provides about 1 milligram of siRNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format. The most efficient silencing is generally observed with siRNA duplexes composed of a 21-nt sense strand and a 21-nt antisense strand, paired in a manner to have a 2-nt 3' overhang. The sequence of the 2-nt 3' overhang makes an additional small contribution 15 to the specificity of siRNA target recognition. The contribution to specificity is localized to the unpaired nucleotide adjacent to the first paired bases. In one embodiment, the nucleotides in the 3' overhang are ribonucleotides. In an alternative embodiment, the nucleotides in the 3' overhang are deoxyribonucleotides. Using 2'-deoxyribonucleotides in the 3' overhangs is as efficient as using ribonucleotides, but deoxyribonucleotides are 20 often cheaper to synthesize and are most likely more nuclease resistant. A contemplated recombinant expression vector of the invention comprises a NOVX DNA molecule cloned into an expression vector comprising operatively-linked regulatory sequences flanking the NOVX sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands. An RNA molecule that is 25 antisense to NOVX mRNA is transcribed by a first promoter (e.g., a promoter sequence 3' of the cloned DNA) and an RNA molecule that is the sense strand for the NOVX mRNA is transcribed by a second promoter (e.g., a promoter sequence 5' of the cloned DNA). The sense and antisense strands may hybridize in vivo to generate siRNA constructs for silencing of the NOVX gene. Alternatively, two constructs can be utilized to create the 30 sense and anti-sense strands of a siRNA construct. Finally, cloned DNA can encode a construct having secondary structure, wherein a single transcript has both the sense and complementary antisense sequences from the target gene or genes. In an example of this embodiment, a hairpin RNAi product is homologous to all or a portion of the target gene. 32 WO 2004/000997 PCT/US2003/017512 In another example, a hairpin RNAi product is a siRNA. The regulatory sequences flanking the NOVX sequence may be identical or may be different, such that their expression may be modulated independently, or in a temporal or spatial manner. In a specific embodiment, siRNAs are transcribed intracellularly by cloning the 5 NOVX gene templates into a vector containing, e.g., a RNA pol III transcription unit from the smaller nuclear RNA (snRNA) U6 or the human RNase P RNA H 1. One example of a vector system is the GeneSuppressor m RNA Interference kit (commercially available from Imgenex). The U6 and H1 promoters are members of the type III class of Pol III promoters. The +1 nucleotide of the U6-like promoters is always guanosine, whereas the 10 +1 for H1 promoters is adenosine. The termination signal for these promoters is defined by five consecutive thymidines. The transcript is typically cleaved after the second uridine. Cleavage at this position generates a 3' UU overhang in the expressed siRNA, which is similar to the 3' overhangs of synthetic siRNAs. Any sequence less than 400 nucleotides in length can be transcribed by these promoter, therefore they are ideally suited for the 15 expression of around 21-nucleotide siRNAs in, e.g., an approximately 50-nucleotide RNA stem-loop transcript. A siRNA vector appears to have an advantage over synthetic siRNAs where long term knock-down of expression is desired. Cells transfected with a siRNA expression vector would experience steady, long-term mRNA inhibition. In contrast, cells transfected 20 with exogenous synthetic siRNAs typically recover from mRNA suppression within seven days or ten rounds of cell division. The long-term gene silencing ability of siRNA expression vectors may provide for applications in gene therapy. In general, siRNAs are chopped from longer dsRNA by an ATP-dependent ribonuclease called DICER. DICER is a member of the RNase III family of 25 double-stranded RNA-specific endonucleases. The siRNAs assemble with cellular proteins into an endonuclease complex. In vitro studies in Drosophila suggest that the siRNAs/protein complex (siRNP) is then transferred to a second enzyme complex, called an RNA-induced silencing complex (RISC), which contains an endoribonuclease that is distinct from DICER. RISC uses the sequence encoded by the antisense siRNA strand to 30 find and destroy mRNAs of complementary sequence. The siRNA thus acts as a guide, restricting the ribonuclease to cleave only mRNAs complementary to one of the two siRNA strands. 33 WO 2004/000997 PCT/US2003/017512 A NOVX mRNA region to be targeted by siRNA is generally selected from a desired NOVX sequence beginning 50 tol 00 nt downstream of the start codon. Alternatively, 5' or 3' UTRs and regions nearby the start codon can be used but are generally avoided, as these may be richer in regulatory protein binding sites. UTR-binding 5 proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. An initial BLAST homology search for the selected siRNA sequence is done against an available nucleotide sequence library to ensure that only one gene is targeted. Specificity of target recognition by siRNA duplexes indicate that a single point mutation located in the paired region of an siRNA duplex is sufficient to abolish 10 target mRNA degradation. See, Elbashir et al. 2001 EMBO J. 20(23):6877-88. Hence, consideration should be taken to accommodate SNPs, polymorphisms, allelic variants or species-specific variations when targeting a desired gene. In one embodiment, a complete NOVX siRNA experiment includes the proper negative control. A negative control siRNA generally has the same nucleotide 15 composition as the NOVX siRNA but lack significant sequence homology to the genome. Typically, one would scramble the nucleotide sequence of the NOVX siRNA and do a homology search to make sure it lacks homology to any other gene. Two independent NOVX siRNA duplexes can be used to knock-down a target NOVX gene. This helps to control for specificity of the silencing effect. In addition, 20 expression of two independent genes can be simultaneously knocked down by using equal concentrations of different NOVX siRNA duplexes, e.g., a NOVX siRNA and an siRNA for a regulator of a NOVX gene or polypeptide. Availability of siRNA-associating proteins is believed to be more limiting than target mRNA accessibility. A targeted NOVX region is typically a sequence of two adenines (AA) and two 25 thymidines (TT) divided by a spacer region of nineteen (N19) residues (e.g., AA(N19)TT). A desirable spacer region has a G/C-content of approximately 30% to 70%, and more preferably of about 50%. If the sequence AA(NI 9)TT is not present in the target sequence, an alternative target region would be AA(N21). The sequence of the NOVX sense siRNA corresponds to (N19)TT or N21, respectively. In the latter case, 30 conversion of the 3' end of the sense siRNA to TT can be performed if such a sequence does not naturally occur in the NOVX polynucleotide. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3' overhangs. Symmetric 3' overhangs may help to ensure that the 34 WO 2004/000997 PCT/US2003/017512 siRNPs are formed with approximately equal ratios of sense and antisense target RNA-cleaving siRNPs. See, e.g., Elbashir, Lendeckel and Tuschl (2001). Genes & Dev. 15: 188-200, incorporated by reference herein in its entirely. The modification of the overhang of the sense sequence of the siRNA duplex is not expected to affect targeted 5 mRNA recognition, as the antisense siRNA strand guides target recognition. Alternatively, if the NOVX target mRNA does not contain a suitable AA(N21) sequence, one may search for the sequence NA(N21). Further, the sequence of the sense strand and antisense strand may still be synthesized as 5' (N1 9)TT, as it is believed that the sequence of the 3'-most nucleotide of the antisense siRNA does not contribute to 10 specificity. Unlike antisense or ribozyme technology, the secondary structure of the target mRNA does not appear to have a strong effect on silencing. See, Harborth, et al. (2001) J. Cell Science 114: 4557-4565, incorporated by reference in its entirety. Transfection of NOVX siRNA duplexes can be achieved using standard nucleic acid transfection methods, for example, OLIGOFECTAMINE Reagent (commercially 15 available from Invitrogen). An assay for NOVX gene silencing is generally performed approximately 2 days after transfection. No NOVX gene silencing has been observed in the absence of transfection reagent, allowing for a comparative analysis of the wild-type and silenced NOVX phenotypes. In a specific embodiment, for one well of a 24-well plate, approximately 0.84 ptg of the siRNA duplex is generally sufficient. Cells are 20 typically seeded the previous day, and are transfected at about 50% confluence. The choice of cell culture media and conditions are routine to those of skill in the art, and will vary with the choice of cell type. The efficiency of transfection may depend on the cell type, but also on the passage number and the confluency of the cells. The time and the manner of formation of siRNA-liposome complexes (e.g. inversion versus vortexing) are 25 also critical. Low transfection efficiencies are the most frequent cause of unsuccessful NOVX silencing. The efficiency of transfection needs to be carefully examined for each new cell line to be used. Preferred cell are derived from a manmmal, more preferably from a rodent such as a rat or mouse, and most preferably from a human. Where used for therapeutic treatment, the cells are preferentially autologous, although non-autologous cell 30 sources are also contemplated as within the scope of the present invention. For a control experiment, transfection of 0.84 pg single-stranded sense NOVX siRNA will have no effect on NOVX silencing, and 0.84 Pg antisense siRNA has a weak silencing effect when compared to 0.84 pg of duplex siRNAs. Control experiments again 35 WO 2004/000997 PCT/US2003/017512 allow for a comparative analysis of the wild-type and silenced NOVX phenotypes. To control for transfection efficiency, targeting of common proteins is typically performed, for example targeting of lamin A/C or transfection of a CMV-driven EGFP-expression plasmid (e.g. commercially available from Clontech). In the above example, a 5 determination of the fraction of lamin A/C knockdown in cells is determined the next day by such techniques as immunofluorescence, Western blot, Northern blot or other similar assays for protein expression or gene expression. Lamin A/C monoclonal antibodies may be obtained from Santa Cruz Biotechnology. Depending on the abundance and the half life (or turnover) of the targeted NOVX 10 polynucleotide in a cell, a knock-down phenotype may become apparent after 1 to 3 days, or even later. In cases where no NOVX knock-down phenotype is observed, depletion of the NOVX polynucleotide may be observed by immunofluorescence or Western blotting. If the NOVX polynucleotide is still abundant after 3 days, cells need to be split and transferred to a fresh 24-well plate for re-transfection. If no knock-down of the targeted 15 protein is observed, it may be desirable to analyze whether the target mRNA (NOVX or a NOVX upstream or downstream gene) was effectively destroyed by the transfected siRNA duplex. Two days after transfection, total RNA is prepared, reverse transcribed using a target-specific primer, and PCR-amplified with a primer pair covering at least one exon-exon junction in order to control for amplification of pre-mRNAs. RT/PCR of a 20 non-targeted mRNA is also needed as control. Effective depletion of the mRNA yet undetectable reduction of target protein may indicate that a large reservoir of stable NOVX protein may exist in the cell. Multiple transfection in sufficiently long intervals may be necessary until the target protein is finally depleted to a point where a phenotype may become apparent. If multiple transfection steps are required, cells are split 2 to 3 25 days after transfection. The cells may be transfected immediately after splitting. An inventive therapeutic method of the invention contemplates administering a NOVX siRNA construct as therapy to compensate for increased or aberrant NOVX expression oractivity. The NOVX ribopolynucleotide is obtained and processed into siRNA fragments, or a NOVX siRNA is synthesized, as described above. The NOVX 30 siRNA is administered to cells or tissues using known nucleic acid transfection techniques, as described above. A NOVX siRNA specific for a NOVX gene will decrease or knockdown NOVX transcription products, which will lead to reduced NOVX polypeptide production, resulting in reduced NOVX polypeptide activity in the cells or tissues. 36 WO 2004/000997 PCT/US2003/017512 The present invention also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual comprising administering to the individual an RNAi construct that targets the mRNA of the protein (the mRNA that encodes the protein) for degradation. A specific RNAi construct includes a siRNA or a 5 double stranded gene transcript that is processed into siRNAs. Upon treatment, the target protein is not produced or is not produced to the extent it would be in the absence of the treatment. Where the NOVX gene function is not correlated with a known phenotype, a control sample of cells or tissues from healthy individuals provides a reference standard 10 for determining NOVX expression levels. Expression levels are detected using the assays described, e.g., RT-PCR, Northern blotting, Western blotting, ELISA, and the like. A subject sample of cells or tissues is taken from a mammal, preferably a human subject, suffering from a disease state. The NOVX ribopolynucleotide is used to produce siRNA constructs, that are specific for the NOVX gene product. These cells or tissues are treated 15 by administering NOVX siRNA's to the cells or tissues by methods described for the transfection of nucleic acids into a cell or tissue, and a change in NOVX polypeptide or polynucleotide expression is observed in the subject sample relative to the control sample, using the assays described. This NOVX gene knockdown approach provides a rapid method for determination of a NOVX minus (NOVX) phenotype in the treated subject 20 sample. The NOVX- phenotype observed in the treated subject sample thus serves as a marker for monitoring the course of a disease state during treatment. In specific embodiments, a NOVX siRNA is used in therapy. Methods for the generation and use of a NOVX siRNA are known to those skilled in the art. Example techniques are provided below. 25 Production of RNAs Sense RNA (ssRNA) and antisense RNA (asRNA) of NOVX are produced using known methods such as transcription in RNA expression vectors. In the initial experiments, the sense and antisense RNA are about 500 bases in length each. The produced ssRNA and asRNA (0.5 piM) in 10 mM Tris-HC1 (pH 7.5) with 20 mM NaCl 30 were heated to 950 C for 1 min then cooled and annealed at room temperature for 12 to 16 h. The RNAs are precipitated and resuspended in lysis buffer (below). To monitor annealing, RNAs are electrophoresed in a 2% agarose gel in TBE buffer and stained with 37 WO 2004/000997 PCT/US2003/017512 ethidium bromide. See, e.g., Sambrook et al., Molecular Cloning. Cold Spring Harbor Laboratory Press, Plainview, N.Y. (1989). Lysate Preparation Untreated rabbit reticulocyte lysate (Ambion) are assembled according to the 5 manufacturer's directions. dsRNA is incubated in the lysate at 300 C for 10 min prior to the addition of mRNAs. Then NOVX mRNAs are added and the incubation continued for an additional 60 min. The molar ratio of double stranded RNA and mRNA is about 200:1. The NOVX mRNA is radiolabeled (using known techniques) and its stability is monitored by gel electrophoresis. 10 In a parallel experiment made with the same conditions, the double stranded RNA is internally radiolabeled with a 32 P-ATP. Reactions are stopped by the addition of 2 X proteinase K buffer and deproteinized as described previously (Tuschl et al., Genes Dev., 13:3191-3197 (1999)). Products are analyzed by electrophoresis in 15% or 18% polyacrylamide sequencing gels using appropriate RNA standards. By monitoring the gels 15 for radioactivity, the natural production of 10 to 25 ut RNAs from the double stranded RNA can be determined. The band of double stranded RNA, about 21-23 bps, is eluded. The efficacy of these 21-23 mers for suppressing NOVX transcription is assayed in vitro using the same rabbit reticulocyte assay described above using 50 nanomolar of double stranded 21-23 20 mer for each assay. The sequence of these 21-23 mers is then determined using standard nucleic acid sequencing techniques. RNA Preparation 21 nt RNAs, based on the sequence determined above, are chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, 25 Germany). Synthetic oligonucleotides are deprotected and gel-purified (Elbashir, Lendeckel, & Tuschl, Genes & Dev. 15, 188-200 (2001)), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, et al., Biochemistry, 32:11658-11668 (1993)). These RNAs (20 pM) single strands are incubated in annealing buffer (100 mM 30 potassium acetate, 30 mM HEPES-KOH at pH 7.4,2 mM magnesium acetate) for 1 min at 900 C followed by I h at 370 C. 38 WO 2004/000997 PCT/US2003/017512 Cell Culture A cell culture known in the art to regularly express NOVX is propagated using standard conditions. 24 hours before transfection, at approx. 80% confluency, the cells are trypsinized and diluted 1:5 with fresh medium without antibiotics (1-3 X 105 cells/ml) and 5 transferred to 24-well plates (500 ml/well). Transfection is performed using a commercially available lipofection kit and NOVX expression is monitored using standard techniques with positive and negative control. A positive control is cells that naturally express NOVX while a negative control is cells that do not express NOVX. Base-paired 21 and 22 nt siRNAs with overhanging 3' ends mediate efficient sequence-specific mRNA 10 degradation in lysates and in cell culture. Different concentrations of siRNAs are used. An efficient concentration for suppression in vitro in mammalian culture is between 25 nM to 100 nM final concentration. This indicates that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments. 15 The above method providesa way both for the deduction of NOVX siRNA sequence and the use of such siRNA for in vitro suppression. In vivo suppression may be performed using the same siRNA using well known in vivo transfection or gene therapy transfection techniques. Antisense Nucleic Acids 20 Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid 25 encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, 30 derivatives and analogs of a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1 and 141, or antisense nucleic acids complementary to a NOVX nucleic acid 39 WO 2004/000997 PCT/US2003/017512 sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141, are additionally provided. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding a NOVX protein. The 5 term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids 10 (i.e., also referred to as 5' and 3' untranslated regions). Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an 15 oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed 20 using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids 25 (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used). Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetyleytosine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyluracil, dihydrouracil, 30 beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 5-methoxyuracil, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 2-thiouracil, 40 WO 2004/000997 PCT/US2003/017512 4-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 5 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection). 10 The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the 15 case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic 20 administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs 25 in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred. In yet another embodiment, the antisense nucleic acid molecule of the invention is an ac-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the 30 usual f3-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) 41 WO 2004/000997 PCT/US2003/017512 or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987. FEBSLett. 215: 327-330. Ribozymes and PNA Moieties Nucleic acid modifications include, by way of non-limiting example, modified 5 bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In one embodiment, an antisense nucleic acid of the invention is a ribozyme. 10 Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme 15 having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i.e., SEQ ID NO:2n-1, wherein n is an integer between 1 and 141). For example, a derivative of a Tetrahymnena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. 20 See, e.g., U.S. Patent 4,987,071 to Cech, et al. and U.S. Patent 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a poolof RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418. Alternatively, NOVX gene expression can be inhibited by targeting nucleotide 25 sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15. 30 In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the 42 WO 2004/000997 PCT/US2003/017512 nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bioorg Med Chemin 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural 5 nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O'Keefe, et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675. 10 PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial 15 restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra). In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the 20 formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. 25 PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using 30 standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, et al., 1989. NuclAcidRes 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule 43 WO 2004/000997 PCT/US2003/017512 with a 5' PNA segment and a 3' DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124. In other embodiments, the oligonucleotide may include other appended groups 5 such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization 10 triggered cleavage agents (see, e.g., Krol, et al., 1988. BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like. 15 NOVX Polypeptides A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 141. The invention also includes a mutant or variant protein any of whose residues may be changed from the 20 corresponding residues shown in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 141, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof. In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by 25 other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above. 30 One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to 44 WO 2004/000997 PCT/US2003/017512 raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein 5 or polypeptide can be synthesized chemically using standard peptide synthesis techniques. An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from 10 chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry 15 weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., 20 culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one 25 embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% 30 chemical precursors or non-NOVX chemicals. Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence of SEQ ID NO:2n, wherein n is an 45 WO 2004/000997 PCT/US2003/017512 integer between 1 and 141) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide 5 which is, for example, 10, 25, 50, 100 or more amino acid residues in length. Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein. In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID 10 NO:2n, wherein n is an integer between 1 and 141. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 141, and retains the functional activity of the protein of SEQ ID NO:2n, wherein n is an integer between 1 and 141, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another 15 embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 141, and retains the functional activity of the NOVX proteins of SEQ ID NO:2n, wherein n is an integer between 1 and 141. Determining Homology Between Two or More Sequences 20 To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then 25 compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The nucleic acid sequence homology may be determined as the degree of identity 30 between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. JMolBiol 48: 443-453. Using GCG GAP software with 46 WO 2004/000997 PCT/US2003/017512 the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence 5 of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141. The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number 10 of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a 15 characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region. Chimeric and Fusion Proteins 20 The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX "chimeric protein" or "fusion protein" comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1 and 141, whereas a "non-NOVX polypeptide" 25 refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one 30 biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active 47 WO 2004/000997 PCT/US2003/017512 portions of a NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide. 5 In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides. In another embodiment, the fusion protein is a NOVX protein containing a 10 heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence. In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of 15 the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a 20 NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening 25 assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand. A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, 30 restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR 48 WO 2004/000997 PCT/US2003/017512 amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & 5 Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein. NOVX Agonists and Antagonists 10 The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. 15 An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant 20 having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins. Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries 25 of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene 30 sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods 49 WO 2004/000997 PCT/US2003/017512 which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, 5 in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochenm. 53: 323; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11: 477. 10 Polypeptide Libraries In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment 15 of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different - nicked products, removing single stranded portions from reformed duplexes by treatment with S, nuclease, and ligating the resulting fragment library into an expression vector. 20 By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins. Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for 25 rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in 30 which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in 50 WO 2004/000997 PCT/US2003/017512 combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al., 1993. Protein Engineering 6:327-331. NOVX Antibodies 5 The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab, Fab' and F(ab)2 fragments, and an Fab expression library. In general, antibody 10 molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgGI, IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and 15 types of human antibody species. An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, 20 the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 141, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full 25 length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions. 30 In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will 51 WO 2004/000997 PCT/US2003/017512 indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the 5 art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or 10 homologs thereof, are also provided herein. The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as 15 specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (KD) is 1 pM, preferably _ 100 nM, more preferably _ 10 nM, and most preferably < 100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays 20 known to those skilled in the art. A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components. Various procedures known within the art may be used for the production of 25 polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below. 30 Polyclonal Antibodies For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with 52 WO 2004/000997 PCT/US2003/017512 the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, 5 the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete 10 and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic 15 trehalose dicorynomycolate). The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific 20 antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28). 25 Monoclonal Antibodies The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining 30 regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it. 53 WO 2004/000997 PCT/US2003/017512 Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing 5 antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro. The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if 10 non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or 15 mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and 20 thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine 25 myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques 30 and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63). The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is 54 WO 2004/000997 PCT/US2003/017512 determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and 5 Pollard, Anal. Biochem. 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen. After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding,1986). Suitable 10 culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1 640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal. The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification 15 procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional 20 procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise 25 produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the 30 coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody. 55 WO 2004/000997 PCT/US2003/017512 Humanized Antibodies The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against 5 the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of 10 Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human 15 residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are 20 those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fe), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)). Human Antibodies 25 Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol 30 Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the 56 WO 2004/000997 PCT/US2003/017512 present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). 5 In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies canbe made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon 10 challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368 15 812-13 (1994)); Fishwild et al,( Nature Biotechnology 1, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)). Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the 20 animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial 25 chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse T M as disclosed in PCT publications WO 96/33735 and WO 96/34096. This 30 animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. 57 WO 2004/000997 PCT/US2003/017512 Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules. An example of a method of producing a nonhuman host, exemplified as a mouse, 5 lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector 10 containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker. A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that 15 contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain. In a further improvement on this procedure, a method for identifying a clinically 20 relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049. Fab Fragments and Single Chain Antibodies According to the invention, techniques can be adapted for the production of 25 single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that 30 contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an 58 WO 2004/000997 PCT/US2003/017512 F(ab)2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments. Bispecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies 5 that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit. Methods for making bispecific antibodies are known in the art. Traditionally, the 10 recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture often different antibody molecules, of which only one has the 15 correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991). Antibody variable domains with the desired binding specificities (antibody-antigen 20 combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred, to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if 25 desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986). According to another approach described in WO 96/27011, the interface between a 30 pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or 59 WO 2004/000997 PCT/US2003/017512 more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. 5 alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, 10 bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate 15 (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes. Additionally, Fab' fragments can be directly recovered from E. coli and chemically 20 coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab') 2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well 25 as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets. Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 30 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of 60 WO 2004/000997 PCT/US2003/017512 antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short 5 to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994). 10 Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991). Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a 15 triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcyR), such as FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD 16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and 20 an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF). Heteroconjugate Antibodies Heteroconjugate antibodies are also within the scope of the present invention. 25 Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving 30 crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this 61 WO 2004/000997 PCT/US2003/017512 purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. Effector Function Engineering It can be desirable to modify the antibody of the invention with respect to effector 5 function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). 10 See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. 15 See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989). Immunoconjugates The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments 20 thereof), or a radioactive isotope (i.e., a radioconjugate). Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, 25 alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212Bi, 131, 131n, 90Y, and "6Re. 30 Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as 62 WO 2004/000997 PCT/US2003/017512 dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 5 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See 10 WO94/11026. In another embodiment, the antibody can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is 15 in turn conjugated to a cytotoxic agent. Immunoliposomes The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., 20 Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through 25 filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martinet al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989). 30 Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for 63 WO 2004/000997 PCT/US2003/017512 use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active 5 compounds (see below). An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. 10 Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by 15 coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, 13-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include 20 streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 1251, 1 3 1 35S or 3 H. 25 Antibody Therapeutics Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is 30 administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the 64 WO 2004/000997 PCT/US2003/017512 first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction 5 pathway for which ligand is responsible. Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a 10 receptor-based signal transduction event by the receptor. A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological 15 response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 20 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week. Pharmaceutical Compositions of Antibodies Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the 25 treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement : Concepts, Possibilities, Limitations, And Trends, 30 Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York. 65 WO 2004/000997 PCT/US2003/017512 If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target 5 protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active 10 compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the 15 purpose intended. The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, 20 albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Sustained-release preparations can be prepared. Suitable examples of 25 sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and y 30 ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT m (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and 66 WO 2004/000997 PCT/US2003/017512 lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. ELISA Assay An agent for detecting an analyte protein is an antibody capable of binding to an 5 analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab)2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect 10 labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, 15 as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection 20 of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in '"ELISA: Theory 25 and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an 30 analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. 67 WO 2004/000997 PCT/US2003/017512 NOVX Recombinant Expression Vectors and Host Cells Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule 5 capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., 10 bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as 15 "expression vectors". In general, useful expression vectors in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and 20 adeno-associated viruses), which serve equivalent functions. The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked 25 to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). 30 The term "regulatory sequence" is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: 68 WO 2004/000997 PCT/US2003/017512 METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by 5 those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion 10 proteins, etc.). The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are 15 discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase. Expression of proteins in prokaryotes is most often carried out in Escherichia coli 20 with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the 25 purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and 30 enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase 69 WO 2004/000997 PCT/US2003/017512 (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11 d (Studier et al., GENE EXPRESSION 5 TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89). One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN 10 ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis 15 techniques. In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec 1 (Baldari, et al., 1987. EMBOJ. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54:113-123), pYES2 (Invitrogen 20 Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.). Alternatively, NOYX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39). 25 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987.EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For 30 example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., 70 WO 2004/000997 PCT/US2003/017512 MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., 5 tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and 10 Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Banerji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 15 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the oc-fetoprotein promoter (Campes and Tilghman, 1989. Genes Devi. 3: 537-546). The invention further provides a recombinant expression vector comprising a DNA 20 molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of 25 the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression ofantisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the 30 activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., "Antisense RNA as a molecular tool for genetic analysis," Reviews-Trends in Genetics, Vol. 1(1) 1986. 71 WO 2004/000997 PCT/US2003/017512 Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of 5 such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells 10 (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized 15 techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor 20 Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals. For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is 25 generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug 30 selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die). A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further 72 WO 2004/000997 PCT/US2003/017512 provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further 5 comprises isolating NOVX protein from the medium or the host cell. Transgenic NOVX Animals The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been 10 introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As 15 used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that 20 remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA 25 molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal. A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a 30 pseudopregnant female foster animal. The human NOVX cDNA sequences, i.e., any one of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human 73 WO 2004/000997 PCT/US2003/017512 homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX eDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific 5 regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, 10 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, 15 transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes. To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene 20 can be a human gene (e.g., the cDNA of any one of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the 25 mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still 30 encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to 74 WO 2004/000997 PCT/US2003/017512 occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included 5 in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992. Cell 69: 915. 10 The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the 15 homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; 20 WO 91/01140; WO 92/0968; and WO 93/04169. In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. Proc. Natl. 25 Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gormnan, et al., 1991. Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of 30 "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. 75 WO 2004/000997 PCT/US2003/017512 Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. Nature 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through 5 the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated. 10 Pharmaceutical Compositions The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the 15 nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical 20 Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as 25 any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include 30 parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following 76 WO 2004/000997 PCT/US2003/017512 components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); 5 buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Pharmaceutical compositions suitable for injectable use include sterile aqueous 10 solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL M (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability 15 exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, 20 by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols 25 such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate 30 solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those-enumerated above. In the case of sterile powders for the 77 WO 2004/000997 PCT/US2003/017512 preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Oral compositions generally include an inert diluent or an edible carrier. They can 5 be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible 10 binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a 15 glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. 20 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the 25 use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention 30 enemas for rectal delivery. In one embodiment, the active compounds-are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, 78 WO 2004/000997 PCT/US2003/017512 biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal 5 suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811. It is especially advantageous to formulate oral or parenteral compositions in dosage 10 unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and 15 directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals. The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for 20 example, intravenous.injection, local administration (see, e.g., U.S. Patent No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene 25 delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system. The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. 30 Screening and Detection Methods The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy 79 WO 2004/000997 PCT/US2003/017512 applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or 5 excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious 10 disease(possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion. 15 The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra. Screening Assays The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, 20 peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein. In one embodiment, the invention provides assays for screening candidate or test 25 compounds which bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring 30 deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, 80 WO 2004/000997 PCT/US2003/017512 non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12:145. A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small 5 molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention. Examples of methods for the synthesis of molecular libraries can be found in the 10 art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. US.A. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261: 1303; Carrell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J. Med. Chem. 37: 1233. 15 Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. 20 Science 249: 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J Mol. BioL 222: 301-310; Ladner, U.S. Patent No. 5,233,409.). In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind 25 to a NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound 30 in a complex. For example, test compounds can be labeled with 125j, 35 S, 14C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the 81 WO 2004/000997 PCT/US2003/017512 enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, 5 contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound. 10 In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to 15 modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a "target molecule" is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of 20 a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. a NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of 25 a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX. Determining the ability of the NOVX protein to bind to or interact with a NOVX 30 target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determiningthe activity of the target molecule. For example, the activity of the target 82 WO 2004/000997 PCT/US2003/017512 molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca 2 + , diacylglycerol, IP 3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid 5 encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation. In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein 10 or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test 15 compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound. In still another embodiment, an assay is a cell-free assay comprising contacting 20 NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target 25 molecule by one of the methods described above for determining direct binding. In an S alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, 30 supra. In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and 83 WO 2004/000997 PCT/US2003/017512 determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule. 5 The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as 10 n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton" X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)n, N-dodecyl--N,N-dimethyl-3-ammonio-l-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1 -propane sulfonate (CHAPS), or 3

-(

3 -cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO). 15 In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and 20 absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto 25 glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove 30 any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques. 84 WO 2004/000997 PCT/US2003/017512 Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS 5 (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX 10 protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule. 15 In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The 20 candidate compound can then be identified as a modulator ofNOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or 25 protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor ofNOVX mRNA or protein expression. The level ofNOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein. In yet another aspect of the invention, the NOVX proteins can be used as "bait 30 proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993. Oncogene 8:1693-1696; and Brent WO 94/10300), to identify other proteins that bind to 85 WO 2004/000997 PCT/US2003/017512 or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway. 5 The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA 10 sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is 15 operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX. The invention further pertains to novel agents identified by the aforementioned 20 screening assays and uses thereof for treatments as described herein. Detection Assays Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) 25 map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below. Chromosome Mapping 30 Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of a NOVX sequence, 86 WO 2004/000997 PCT/US2003/017512 i.e., of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease. 5 Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human 10 chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment. Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse 15 chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of 20 mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions. PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular 25 sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes. Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase 30 chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern 87 WO 2004/000997 PCT/US2003/017512 of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple 5 detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988). Reagents for chromosome mapping can be used individually to mark a single 10 chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping. 15 Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be 20 identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987. Nature, 325: 783-787. Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected 25 individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to 30 confirm the presence of a mutation and to distinguish mutations from polymorphisms. 88 WO 2004/000997 PCT/US2003/017512 Tissue Typing The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield 5 unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057). Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of 10 an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it. Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a 15 unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation 20 between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs). Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. 25 Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NOS:2n-1, wherein n is an integer between 1 and 141, 30 are used, a more appropriate number of primers for positive individual identification would be 500-2,000. 89 WO 2004/000997 PCT/US2003/017512 Predictive Medicine The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. 5 Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic 10 disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for 15 prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX 20 protein, nucleic acid expression, or biological activity. Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) 25 for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.) Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials. 30 These and other agents are described in further detail in the following sections. 90 WO 2004/000997 PCT/US2003/017512 Diagnostic Assays An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX 5 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS:2n-1, wherein n is an integer 10 between 1 and 141, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein. An agent for detecting NOVX protein is an antibody capable of binding to NOVX 15 protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab') 2 ) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or 20 antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and 25 fluids present within a subject.. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection ofNOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, 30 immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection ofNOVX protein include introducing into a subject a labeled anti-NOVX 91 WO 2004/000997 PCT/US2003/017512 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test 5 subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of 10 NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample. The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent 15 capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid. 20 Prognostic Assays The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject 25 having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic 30 acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" 92 WO 2004/000997 PCT/US2003/017512 refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue. Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, 5 peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with 10 aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity). The methods of the invention can also be used to detect genetic lesions in a NOVX 15 gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the 20 NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant 25 modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification ofa NOVX protein. As described herein, there are a large number of assay techniques known in the art which can 30 be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells. 93 WO 2004/000997 PCT/US2003/017512 In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988. Science 241: 1077-1080; and 5 Nakazawa, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that 10 specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the 15 techniques used for detecting mutations described herein. Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); QP3 Replicase (see, Lizardi, et al, 1988. BioTechnology 6:1197), or any other nucleic acid 20 amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In an alternative embodiment, mutations in a NOVX gene from a sample cell can 25 be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific 30 ribozymes (see, e.g., U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. In other embodiments, genetic mutations in NOVX can be identified by hybridizing sample and control nucleic acids, e.g., DNA or RNA to high-density arrays 94 WO 2004/000997 PCT/US2003/017512 containing hundreds or thousands of oligonucleotide probes. See, e.g., Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a 5 first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays 10 complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene. In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing 15 the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 20 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Apple. Biochem. Biotechnol. 38: 147-159). Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA 25 or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such 30 as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S 1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with 95 WO 2004/000997 PCT/US2003/017512 hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. NatL. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. 5 Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection. In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations 10 in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test 15 cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039. In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation 20 polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Apple. 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of 25 single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes 30 heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7: 5. In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing 96 WO 2004/000997 PCT/US2003/017512 gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient 5 is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753. Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the 10 known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane 15 and hybridized with labeled target DNA. Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential 20 hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell 25 Probes 6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification. 30 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to 97 WO 2004/000997 PCT/US2003/017512 diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene. Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. 5 However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells. Pharmacogenomics Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein 10 can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X 15 and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and 20 blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, 25 or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. 30 Clin. 'Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors 98 WO 2004/000997 PCT/US2003/017512 altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of 5 oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans. As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 10 2) and cytochrome Pregnancy Zone Protein Precursor enzymes CYP2D6 and CYP2C 19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence 15 of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no 20 therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification. Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or 25 mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can 30 avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein. 99 WO 2004/000997 PCT/US2003/017512 Monitoring of Effects During Clinical Trials Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. 5 For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent detennrmined by a screening assay to decrease NOVX gene 10 expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune 15 responsiveness of a particular cell. By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for 20 example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of 25 activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent. In one embodiment, the invention provides a method for monitoring the 30 effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a 100 WO 2004/000997 PCT/US2003/017512 pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, 5 or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to 10 increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent. Methods of Treatment 15 The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, 20 subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; 25 multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, and other diseases, disorders and conditions of the like. These methods of treatment will be discussed more fully, below. Diseases and Disorders Diseases and disorders that are characterized by increased (relative to a subject not 30 suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that 101 WO 2004/000997 PCT/US2003/017512 may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (i.e., due to a heterologous insertion 5 within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators ( i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction 10 between an aforementioned peptide and its binding partner. Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that 15 may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability. Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or 20 mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like). 25 Prophylactic Methods In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant 30 NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX 102 WO 2004/000997 PCT/US2003/017512 aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic 5 methods of the invention are further discussed in the following subsections. Therapeutic Methods Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of 10 NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX 15 protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent 20 to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or 25 activity. In another embodiment, the method involves administering a NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity. Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a 30 beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia). 103 WO 2004/000997 PCT/US2003/017512 Determination of the Biological Effect of the Therapeutic In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue. 5 In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. 10 Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects. Prophylactic and Therapeutic Uses of the Compositions of the Invention The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, 15 but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. 20 As an example, a eDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, 25 neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias. Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use 30 could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of 104 WO 2004/000997 PCT/US2003/017512 antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods. The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. 5 EXAMPLES Example A: Polynucleotide And Polypeptide Sequences, And Homology Data Example 1. The NOVI1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table lA. 10 Table 1A. NOVI Sequence Analysis NOVla, CG103945-02 SEQ ID NO: 1 12414 bp DNA Sequence ORF Start: ATG at 1 JORF Stop: TAG at 2401 ATGGCCCCCTCGGCCTGGGCCATTTGCTGGCTGCTAGGGGGCCTCCTGCTCCATGGGGGTAGCTCTGGCCCCA CCCCCGGCCCCAGTGTGCCCCGCCTGCGGCTCTCCTACCGAGGAGCCGTGGTCCGAAAGCCTTCCAGCACCAT GTGGATGGAAACATTTTCCAGATACCTCCTGTCTGCCAACCGCTCTGCCATCTTTCTGGGCCCCCAGGGCTCC CTGAACCTCCAGGCCATGTACCTAGATGAGTACCGAGACCGCCTCTTTCTGGGTGGCCTGGACGCCCTCTACT CTCTGCGGCTGGACCAGGCATGGCCAGATCCCCGGGAGGTCCTGTGGCCACCGCAGCCAGGACAGAGGGAGGA GTGTGTTCGAAAGGGAAGAGATCCTTTGACAGAGTGCGCCAACTTCGTGCGGGTGCTACAGCCTCACAACCGG ACCCACCTGCTAGCCTGTGGCACTGGGGCCTTCCAGCCCACCTGTGCCCTCATCACAGTTGGCCACCGTGGGG AGCATGTGCTCCACCTGGAGCCTGGCAGTGTGGAAAGTGGCCGGGGGCGGTGCCCTCACGAGCCCAGCCGTCC CTTTGCCAGCACCTTCATAGACGGGGAGCTGTACACGGGTCTCACTGCTGACTTCCTGGGGCGAGAGGCCATG ATCTTCCGAAGTGGAGGTCCTCGGCCAGCTCTGCGTTCCGACTCTGACCAGAGTCTCTTGCACGACCCCCGGT TTGTGATGGCCGCCCGGATCCCTGAGAACTCTGACCAGGACAATGACAAGGTGTACTTCTTCTTCTCGGAGAC GGTCCCCTCGCCCGATGGTGGCTCGAACCATGTCACTGTCAGCCGCGTGGGCCGCGTCTGCGTGAATGATGCT GGGGGCCAGCGGGTGCTGGTGAACAAATGGAGCACTTTCCTCAAGGCCAGGCTGGTCTGCTCGGTGCCCGGCC CTGGTGGTGCCGAGACCCACTTTGACCAGCTAGAGGATGTGTTCCTGCTGTGGCCCAAGGCCGGGAAGAGCCT CGAGGTGTACGCGCTGTTCAGCACCGTCAGTGCCGTGTTCCAGGGCTTCGCCGTCTGTGTGTACCACATGGCA GACATCTGGGAGGTTTTCAACGGGCCCTTTGCCCACCGAGATGGGCCTCAGCACCAGTGGGGGCCCTATGGGG GCAAGGTGCCCTTCCCTCGCCCTGGCGTGTGCCCCAGCAAGATGACCGCACAGCCAGGACGGCCTTTTGGCAG CACCAAGGACTACCCAGATGAGGTGCTGCAGTTTGCCCGAGCCCACCCCCTCATGTTCTGGCCTGTGCGGCCT CGACATGGCCGCCCTGTCCTTGTCAAGACCCACCTGGCCCAGCAGCTACACCAGATCGTGGTGGACCGCGTGG AGGCAGAGGATGGGACCTACGATGTCATTTTCCTGGGGACTGACTCAGGGTCTGTGCTCAAAGTCATCGCTCT CCAGGCAGGGGGCTCAGCTGAACCTGAGGAAGTGGTTCTGGAGGAGCTCCAGGTGTTTAAGGTGCCAACACCT ATCACCGAAATGGAGATCTCTGTCAAAAGGCAAATGCTATACGTGGGCTCTCGGCTGGGTGTGGCCCAGCTGC GGCTGCACCAATGTGAGACTTACGGCACTGCCTGTGCAGAGTGCTGCCTGGCCCGGGACCCATACTGTGCCTG GGATGGTGCCTCCTGTACCCACTACCGCCCCAGCCTTGGCAAGCGCCGGTTCCGCCGGCAGGACATCCGGCAC GGCAACCCTGCCCTGCAGTGCCTGGGCCAGAGCCAGGAAGAAGAGGCAGTGGGACTTGTGGCAGCCACCATGG TCTACGGCACGGAGCACAATAGCACCTTCCTGGAGTGCCTGCCCAAGTCTCCCCAGGCTGCTGTGCGCTGGCT CTTGCAGAGGCCAGGGGATGAGGGGCCTGACCAGGTGAAGACGGACGAGCGAGTCTTGCACACGGAGCGGGGG CTGCTGTTCCGCAGGCTTAGCCGTTTCGATGCGGGCACCTACACCTGCACCACTCTGGAGCATGGCTTCTCCC AGACTGTGGTCCGCCTGGCTCTGGTGGTGATTGTGGCCTCACAGCTGGACAACCTGTTCCCTCCGGAGCCAAA GCCAGAGGAGCCCCCAGCCCGGGGAGGCCTGGCTTCCACCCCACCCAAGGCCTGGTACAAGGACATCCTGCAG CTCATTGGCTTCGCCAACCTGCCCCGGGTGGATGAGTACTGTGAGCGCGTGTGGTGCAGGGGCACCACGGAAT GCTCAGGCTGCTTCCGGAGCCGGAGCCGGGGCAAGCAGGCCAGGGGCAAGAGCTGGGCAGGGCTGGAGCTAGG CAAGAAGATGAAGAGCCGGGTGCATGCCGAGCACAATCGGACGCCCCGGGAGGTGGAGGCCACGTAGAAGGGG GCAGA 105 WO 2004/000997 PCT/US2003/017512 NOVla, CG103945-02 SEQ ID NO: 2 800 aa MW at 88800.3kD Protein Sequence

I

MAPSAWAICWLLGGLLLHGGSSGPSPGPSVPRLRLSYRGAVVRKPSSTMWMETFSRYLLSANRSAIFLGPQGS LNLQAMYLDEYRDRLFLGGLDALYSLRLDQAWPDPREVLWPPQPGQREECVRKGRDPLTECANFVRVLQPHNR THLLACGTGAFQPTCALITVGHRGEHVLHLEPGSVESGRGRCPHEPSRPFASTFIDGELYTGLTADFLGREAM IFRSGGPRPALRSDSDQSLLHDPRFVMAARIPENSDQDNDKVYFFFSETVPSPDGGSNVTVSRVGRVCVNDA GGQRVLVNKWSTFLKARLVCSVPGPGGAETHFDLEDVFLLWPKAGKSLEVYALFSTVSAVFQGFAVCVYHMA DIWEVFNGPFAHRDGPQHQWGPYGGKVPFPRPGVCPSKMTAQPGRPFGSTKDYPDEVLQFARAHPLMFWPVRP RHGRPVLVKTHLAQQLHQIVVDRVEAEDGTYDVIFLGTDSGSVLKVIALQAGGSAEPEEVVLEELQVFKVPTP ITEMEISVKRQMLYVGSRLGVAQLRLHQCETYGTACAECCLARDPYCAWDGASCTHYRPSLGKRRFRRQDIRH GNPALQCLGQSQEEEAVGLVAATMVYGTEHNSTFLECLPKSPQAAVRWLLQRPGDEGPDQVKTDERVLHTERG LLFRRLSRFDAGTYTCTTLEHGFSQTVVRLALVVIVASQLDNLFPPEPKPEEPPARGGLASTPPKAWYKDILQ LIGFANLPRVDEYCERVWCRGTTECSGCFRSRSRGQARGKSWAGLELGKKMKSRVHAEHNRTPREVEAT NOVIb, CG103945-01 SEQ ID NO: 3 14700 bp DNA Sequence _ ORF Start: ATG at 1 IORF Stop: TAG at 2347 ATGGCCCCCTCGGCCTGGGCCATTTGCTGGCTGCTAGGGGGCCTCCTGCTCCATGGGGGTAGCTCTGGCCCCA GCCCCGGCCCCAGTGTGCCCCGCCTGCGGCTCTCCTACCGAGACCTCCTGTCTGCCAACCGCTCTGCCATCTT TCTGGGCCCCCAGGGCTCCCTGAACCTCCAGGCCATGTACCTAGATGAGTACCGAGACCGCCTCTTTCTGGGT GGCCTGGACGCCCTCTACTCTCTGCGGCTGGACCAGGCATGGCCAGATCCCCGGGAGGTCCTGTGGCCACCGC AGCCAGGACAGAGGGAGGAGTGTGTTCGAAAGGGAAGAGATCCTTTGACAGAGTGCGCCAACTTCGTGCGGGT GCTACAGCCTCACAACCGGACCCACCTGCTAGCCTGTGGCACTGGGGCCTTCCAGCCCACCTGTGCCCTCATC ACAGTTGGCCACCGTGGGGAGCATGTGCTCCACCTGGAGCCTGGCAGTGTGGAAAGTGGCCGGGGGCGGTGCC CTCACGAGCCCAGCCGTCCCTTTGCCAGCACCTTCATAGACGGGGAGCTGTACACGGGTCTCACTGCTGACTT CCTGGGGCGAGAGGCCATGATCTTCCGAAGTGGAGGTCCTCGGCCAGCTCTGCGTTCCGACTCTGACCAGAGT CTCTTGCACGACCCCCGGTTTGTGATGGCCGCCCGGATCCCTGAGAACTCTGACCAGGACAATGACAAGGTGT ACTTCTTCTTCTCGGAGACGGTCCCCTCGCCCGATGGTGGCTCGAACCATGTCACTGTCAGCCGCGTGGGCCG CGTCTGCGTGAATGATGCTGGGGGCCAGCGGGTGCTGGTGAACAAATGGAGCACTTTCCTCAAGGCCAGGCTG GTCTGCTCGGTGCCCGGCCCTGGTGGTGCCGAGACCCACTTTGACCAGCTAGAGGATGTGTTCCTGCTGTGGC CCAAGGCCGGGAAGAGCCTCGAGGTGTACGCGCTGTTCAGCACCGTCAGTGCCGTGTTCCAGGGCTTCGCCGT CTGTGTGTACCACATGGCAGACATCTGGGAGGTTTTCAACGGGCCCTTTGCCCACCGAGATGGGCCTCAGCAC CAGTGGGGGCCCTATGGGGGCAAGGTGCCCTTCCCTCGCCCTGGCGTGTGCCCCAGCAAGATGACCGCACAGC CAGGACGGCCTTTTGGCAGCACCAAGGACTACCCAGATGAGGTGCTGCAGTTTGCCCGAGCCCACCCCCTCAT GTTCTGGCCTGTGCGGCCTCGACATGGCCGCCCTGTCCTTGTCAAGACCCACCTGGCCCAGCAGCTACACCAG ATCGTGGTGGACCGCGTGGAGGCAGAGGATGGGACCTACGATGTCATTTTCCTGGGGACTGACTCAGGGTCTG TGCTCAAAGTCATCGCTCTCCAGGCAGGGGGCTCAGCTGAACCTGAGGAAGTGGTTCTGGAGGAGCTCCAGGT GTTTAAGGTGCCAACACCTATCACCGAAATGGAGATCTCTGTCAAAAGGCAAATGCTATACGTGGGCTCTCGG CTGGGTGTGGCCCAGCTGCGGCTGCACCAATGTGAGACTTACGGCACTGCCTGTGCAGAGTGCTGCCTGGCCC GGGACCCATACTGTGCCTGGGATGGTGCCTCCTGTACCCACTACCGCCCCAGCCTTGGCAAGCGCCGGTTCCG CCGGCAGGACATCCCGCACGGCAACCCTGCCCTGCAGTGCCTGGGCCAGAGCCAGGAAGAAGAGGCAGTGGGA CTTGTGGCAGCCACCATGGTCTACGGCACGGAGCACAATAGCACCTTCCTGGAGTGCCTGCCCAAGTCTCCCC AGGCTGCTGTGCGCTGGCTCTTGCAGAGGCCAGGGGATGAGGGGCCTGACCAGCTGAAGACGGACGAGCGAGT CTTGCACACGGAGCGGGGGCTGCTGTTCCGCAGGCTTACCGTTTCGATGCGGGCACCTACACCTGCACCACT CTGGAGCATGGCTTCTCCCAGACTGTGGTCCGCCTGGCTCTGGTGGTGATTGTGGCCTCACAGCTGGACAACC TGTTCCCTCCGGAGCCAAAGCCAGAGGAGCCCCCAGCCCGGGGAGGCCTGGCTTCCACCCCACCCAAGGCCTG GTACAAGGACATCCTGCAGCTCATTGGCTTCGCCAACCTGCCCCGGGTGGATGAGTACTGTGAGCGCGTGTGG TGCAGGGGCACCACGGAATGCTCAGCCTGCTTCCGGAGCCGGAGCCGGCGCAAGCAGGCCAGGGGCAAGAGCT GGGCAGGGCTGGAGCTAGGCAAGAAGATGAAGAGCCGGGTGCATGCCGAGCACAATCGGACGCCCCGGGAGGT GGAGGCCACGTAGAAGGGGGCAGAGGAGGGGTGGTCAGGATGGGCTGGGGGGCCCACTAGCAGCCCCCAGCAT CTCCCACCCACCCAGCTAGGGCAGAGGGGTCAGGATGTCTGTTTGCCTCTTAGAGACAGGTGTCTCTGCCCCC ACACCGCTACTGGGGTCTAATGGAGGGGCTGGGTTCTTGAAGCCTGTTCCCTGCCCTTCTCTGTGCTCTTAGA CCCAGCTGGAGCCAGCACCCTCTGGCTGCTGGCAGCCCCAAGGGATCTGCCATTTGTTCTCAGAGATGGCCTG GCTTCCGCAACACATTTCCGGGTGTGCCCAGAGGCAAGAGGGTTGGGTGGTTCTTTCCCAGCCTACAGAACAA TGGCCATTCTGAGTGACCCTCAGAGTGGGTGTGTGGGTGCGTCTAGGGGGTATCCCGGTAGGGGGCCTGCAGG GAGCCAGAGGGTGGAAATGGCCTCTAAGCTAGCACCCCGTAAGAAGAGCCTACCTGACCGACTTGGGGAGGGA 106 WO 2004/000997 PCT/US2003/017512 ACACAGAGGTGTTGGGAAGGTGGAGCAACAATGCACCTCCCCTCCTGTCGCGCCGTGATATCTTGGTGGCTCC CTGCCACTGCCCACCGCCTCTTCTCCATCTGAGAATCACGGAGAGGTGTAGATAATCTAGAGGCATAGACTGC TAGAGCCCCCAGGGATCTGGGGTGGTCAGGGCTCAGGCTTCACTTTGTAAACCAGGTGGGGGCATCTCACAGC CTGACTTCCCTTCCCCAGGCCAGGGTTGCTGGGATGCCTGCCCCTCCTGAGAGGACCCCCTCCCCATTGTCAG GCTCTCCATGTCCACGAGCGGGGAGGGGTGGGTTCTGGGGCATTGTTGTCCCTTGTGTCTGTGGACTAGAGAT AGGGTGGGGGAGCTGGGGAAGGGTGCAGGCGGGAAGAGTGGGCTGTCTTTCCCAGGGTGATGCAAGCATGCCG CAGCCCTGGAGGCTGGGAATGTGGAGGCTCTGTGAGCCCTGCAGCCC TCAGAATCAGGGCCAGGGATGCAGAAGATTGAGAGGATATGGAGATGGATAGAGGGCAGGAGACCCTTAGGAT AGATTGTGGGACCCAGGCAGGAACAGGTGTCCACAAGAACTCAGGATGGCATCAGTTAGCTCAGAAGCCACCT GGAAGACCCAGTGTTTCCATCTCTGGAATCTCTGTTTTATGCTAAATCGATTTAGGAAGACTGTTTTTCTTTT AAGGGGGAAACAAGGTAGAGAAAAGGACGAAGAAGTGTAAGTCCCGCTGATTCTCGGGGGTAAGGCTCGGATG GCAAGGACGCGTTCTGCCTGGGCATGTAGGGGAGGTGTTTTTGCCATCACCAGTTTCTCAGGCTGGGGAGCAC AGAGGGGAGGAGGAGGACTAAATGAAAAGTTGTTCCCAGCCTGCACATGAACACATTCATGACACACAAAACT GGCTGGAAGGAGATAAGAGCACTGGGTTTGAGATTCCCTCCATTAAAACAACCAAGACAAAGAAAGGAGGGGA AAAAAAGATAAAAAGCAAGCCAGGGTTCCCTGCCCTATTGAAACTCAAACCCAGACTGCCTTGGGTTTTATCT TTCCCTTACCCCTGGCACCTCCAGAGAACTGGGACCTGAAATAGTCCCTCCGTTCTCCCCTTTGACCATGTAA TAAATGAACCAGAAGCACTGAGATTAACCTATCAACGCCCTGAGAAGCCTTCCAGCCTGCGGTGCTGTCTGCT GGGAGGTCAGCTGGTCAAGGCAGAGGAGGAGAGGAGGAAAGGATGGGGGCTGAAGAGCAGAAGGGAGGGGAGA CAGAGGGGATTAAAGAGGGGAGGAGAGAGTGCAGAGCTCCAGGAAAGGGTATCAGAGCTGCAGCCAGCTCTGC CCTCTACCCTAGGGAGGCCAGAAAGACACAAACAGCCCTCCGGGCCTTTACGCTGGACTCTGGCTTGGCAGGC TCCAGGCAGGGTCCTCTGGGAAGTTACTCTAGAAAACGAAGGGAGGAGGAGCACAAGATCCTCAGCAACGAAC ACCTGCACTTAGAAAAAGTGGACAGCTTCTGCCAACCACACCCTACCCATGGTACTGTATGCTATTAACTCCT GGAAACGCCCCGTAAATGCGAGTTGTTTTTGTATTTGTGTGTTGAGATGGGCCTTGTGGTTTCTCTGTACTCA GAGCACATTTCTTGTAATTACTATTGTTATTTTTATTGTCATGACTGCCCCTGAGCTCTGGTGAGAAAAGCTG AATTTACAAGGAAAGGGATGAAGTTAATATTTGCATCACATAATTATATCATTACTGTGTATCTGTGTATTGT ACTAAATGGACTGATGCTGCGCACATGAGCTGAAAATGAAGAGCCCTCCCATCC NOV1b, CG103945-01 1SEQ IDNO: 4 782 aa MW at86699.9kD Protein Sequence MAPSAWAICWLLGGLLLEGGSSGPSPGPSVPRLRLSYRDLLSANRSAIFLGPQGSLNLQAMYLDEYRDRLFLG GLDALYSLRLDQAWPDPREVLWPPQPGQREECVRKGRDPLTECANFVRVLQPHNRTHLLACGTGAFQPTCALI TVGHRGEHVLHLEPGSVESGRCRCPHEPSRPFASTFIDGELYTGLTADFLGREAMIFRSGGPRPALRSDSDQS LLHDPRFVMAARIPENSDQDNDKVYFFFSETVPSPDGGSNHVTVSRVGRVCVNDAGGQRVLVNKWSTFLKARL VCSVPGPGGAETHFDQLEDVFLLWPKAGKSLEVYALFSTVSAVFQGFAVCVYHMADIWEVFNGPFAHRDGPQH QWGPYGGKVPFPRPGVCPSKMTAQPGRPFGSTKDYPDEVLQFARAHPLMFWPVRPRHGRPVLVKTHLAQQLHQ IVVDRVEAEDGTYDVIFLGTDSGSVLKVIALQAGGSAEPEEVVLEELQVFKVPTPITEMEISVKRQMLYVGSR LGVAQLRLHQCETYGTACAECCLARDPYCAWDGASCTHYRPSLGKRRFRRQDIRHGNPALQCLGQSQEEEAVG LVAATMVYGTEHNSTFLECLPKSPQAAVRWLLQRPGDEGPDQVKTDERVLHTERGLLFRRLSRFDAGTYTCTT LEHGFSQTVVRLALVVIVASQLDNLFPPEPKPEEPPARGGLASTPPKAWYKDILQLIGFANLPRVDEYCERVW CRGTTECSGCFRSRSRGKQARGKSWAGLELGKKMKSRVHAEHNRTPREVEAT A ClustalW comparison of the above protein sequences yields the following sequence 5 alignment shown in Table lB. 107 WO 2004/000997 PCT/US2003/017512 Table 1B. Comparison of the NOVI protein sequences. NOVIa MAPSAWAICWLLGGLLLGGSSGPSPGPSVPRLRLSYRGAVVRKPSSTMWMETFSRYLLS NOVib MAPSAWAICWLLGGLLLHGGSSGPSPGPSVPRLRLSYR------------D-----LLS NOVIa ANRSAIFLGPQGSLNLQAMYLDEYRDRLFLGGLDALYSLRLDQAWPDPREVLWPPQPGQR NOVIb ANRSAIFLGPQGSLNLQAMYLDEYRDRLFLGGLDALYSLRLDQAWPDPREVLWPPQPGQR NOVia EECVRKGRDPLTECANFVRVLQPHNRTHLLACGTGAFQPTCALITVGHRGEHVLHLEPGS NOVIb EECVRKGRDPLTECANFVRVLQPHNRTHLLACGTGAFQPTCALITVGHRGEHVLHLEPGS NOVIa VESGRGRCPHEPSRPFASTFIDGELYTGLTADFLGREAMIFRSGGPRPALRSDSDQSLLH NOVIb VESGRGRCPHEPSRPFASTFIDGELYTGLTADFLGREAMIFRSGGPRPALRSDSDQSLLH NOVia DPRFVMAARIPENSDQDNDKVYFFFSETVPSPDGGSNHVTVSRVGRVCVNDAGGQRVLVN NOVIb DPRFVMAARIPENSDQDNDKVYFFFSETVPSPDCGSNHVTVSRVGRVCVNDAGGQRVLVN NOVia KWSTFLKARLVCSVPGPGGAETHFDQLEDVFLLWPKAGKSLEVYALFSTVSAVFQGFAVC NOVIb KWSTFLKARLVCSVPGPGGAETHFDQLEDVFLLWPKAGKSLEVYALFSTVSAVFQGFAVC NOVIa VYHMADIWEVFNGPFAHRDGPQHQWGPYGGKVPFPRPGVCPSKMTAQPGRPFGSTKDYPD NOVIb VYHMADIWEVFNGPFAHRDGPQHQWGPYGGKVPFPRPGVCPSKMTAQPGRPFGSTKDYPD NOVia EVLQFARAHPLMFWPVRPRHGRPVLVKTHLAQQLHQIVVDRVEAEDGTYDVIFLGTDSGS NOVib EVLQFARAHPLMFWPVRPRHGRPVLVKTHLAQQLHQIVVDRVEAEDGTYDVIFLGTDSGS NOVIa VLKVIALQAGGSAEPEEVVLEELQVFKVPTPITEMEISVKRMLYVGSRLGVAQLRLHQC NOVib VLKVIALQAGGSAEPEEVVLEELQVFKVPTPITEMEISVKRQMLYVGSRLGVAQLRLHQC NOVia ETYGTACAECCLARDPYCAWDGASCTHYRPSLGKRRFRRQDIRHGNPALQCLGQSQEEEA NOV1b ETYGTACAECCLARDPYCAWDGASCTHYRPSLGKRRFRRQDIRHGNPALQCLGQSQEEEA NOVIa VGLVAATMVYGTEHNSTFLECLPKSPQAAVRWLLQRPGDEGPDQVTDERVLHTERGLLF NOV1b VGLVAATMVYGTEHNSTFLECLPKSPQAAVRWLLQRPGDEGPDQVKTDERVLHTERGLLF NOVla RRLSRFDAGTYTCTTLEHGFSQTVVRLALVVIVASQLDNLFPPEPKPEEPPARGGLASTP NOVib RRLSRFDAGTYTCTTLEHGFSQTVVRLALVVIVASQLDNLFPPEPKPEEPPARGGLASTP NOVla PKAWYKDILQLIGFANLPRVDEYCERVWCRGTTECSGCFRSRSRGKQARGKSWAGLELGK NOVib PKAWYKDILQLIGFANLPRVDEYCERVWCRGTTECSGCFRSRSRGKQARGKSWAGLELGK NOVIa KMKSRVHAEHNRTPREVEAT NOV1b KMKSRVHAEHNRTPREVEAT NOVia (SEQ ID NO: 2) NOVIb (SEQ ID NO: 4) Further analysis of the NOVI a protein yielded the following properties shown in Table ic. 5 108 WO 2004/000997 PCT/US2003/017512 Table 1C. Protein Sequence Properties NOVla SignalP analysis: Cleavage site between residues 23 and 24 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 0; pos.chg 0; neg.chg 0 H-region: length 31; peak value 9.35 PSG score: 4.95 GvH: von Heijne's method for signal seq- recognition GvH score (threshold: -2.1): 1.50 possible cleavage site: between 22 and 23 >>> Seems to have a cleavable signal peptide (1 to 22) ALOM: Klein et al's method for TM region allocation Init position for calculation: 23 Tentative number of TMS(s) for the threshold 0.5: 3 Number of TMS(s) for threshold 0.5: 1 INTEGRAL Likelihood = -2.02 Transmembrane 345 - 361 PERIPHERAL Likelihood = 2.86 (at 150) ALOM score: -2.02 (number of TMSs: 1) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 11 Charge difference: 0.5 C( 1.5) - N( 1.0) C > N: C-terminal side will be inside >>>Caution: Inconsistent mtop result with signal peptide >>> membrane topology: type la (cytoplasmic tail 362 to 800) MITDISC: discrimination of mitochondrial targeting seq R content: 4 Hyd Moment(75): 2.13 Hyd Moment(95): 2.46 G content: 7 D/E content: 1 S/T content: 9 Score: -2.94 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 73 NRSIAI NUCDISC: discrimination of nuclear localization signals pat4: none pat7: PSLGKRR (3) at 570 bipartite: none content of basic residues: 11.4% NLS Score: -0.22 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none 109 WO 2004/000997 PCT/US2003/017512 NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: too long tail Dileucine motif in the tail: found LL at 633 LL at 658 checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 89 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 44.4 %: endoplasmic reticulum 22.2 %: Golgi 22.2 %: extracellular, including cell wall 11.1 %: plasma membrane >> prediction for CG103945-02 is end (k=9) A search of the NOVI a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D. 5 110 WO 2004/000997 PCT/US2003/017512 Table 1D. Geneseq Results for NOVla NOVia Identities/ Geneseq Protein/Organism/Length [Patent #, Residues! Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAG65620 Novel human protein (NHP) sequence 1..800 781/800 (97%) 0.0 - Homo sapiens, 782 aa. 1..782 781/800 (97%) [WO200170806-A2, 27-SEP-2001] AAG65619 Novel human protein (NHP) sequence 1..800 781/800 (97%) 0.0 - Homo sapiens, 875 aa. 94..875 781/800 (97%) [WO200170806-A2, 27-SEP-2001] AAB23609 Human secreted protein SEQ ID NO: 1..800 781/800 (97%) 0.0 18 - Homo sapiens, 782 aa. 1..782 781/800 (97%) [WO200049134-A1, 24-AUG-2000] AAB23636 Human secreted protein SEQ ID NO: 1..800 781/803 (97%) 0.0 92 - Homo sapiens, 785 aa. 1..785 781/803 (97%) [WO200049134-A1, 24-AUG-2000] AAG78481 Human ZSMF-16 - Homo sapiens, 1..800 778/800 (97%) 0.0 779 aa. [US2001049432-A1, 1..779 779/800 (97%) 06-DEC-2001] In a BLAST search of public sequence databases, the NOV1 a protein was found to have homology to the proteins shown in the BLASTP data in Table 1E. 5 111 WO 2004/000997 PCT/US2003/017512 Table 1E. Public BLASTP Results for NOVIa Protein NOVla Identities/ Accession Protein/Organisni/Length Residues/ Similarities for Expect Accession Match the Matched Value Number Residues Portion Q9NS98 Semaphorin sem2 (FLJ00014 1..800 781/800 (97%) 0.0 protein) - Homo sapiens (Human), 1..782 781/800 (97%) 782 aa. CAC42673 Sequence 1 from Patent WO0140278 1..800 778/800 (97%) 0.0 - Homo sapiens (Human), 779 aa. 1..779 779/800 (97%) Q9QX23 Semaphorin M-SemaK - Mus 1..795 399/805 (49%) 0.0 musculus (Mouse), 775 aa. 1..770 525/805 (64%) P70275 Semaphorin 3E precursor 1..795 398/805 (49%) 0.0 (Semaphorin H) (Sema H) - Mus 1..770 524/805 (64%) musculus (Mouse), 775 aa. 042237 Semaphorin 3E precursor 1..797 398/806 (49%) 0.0 (Collapsin-5) (COLL-5) - Gallus 5..782 519/806 (64%) gallus (Chicken), 785 aa. I PFam analysis predicts that the NOVIa protein contains the domains shown in the Table 1F. 5 Table IF. Domain Analysis of NOVIa Identities/ PfamDomain NOVIa Match Region Similarities Expect Value for the Matched Region Sema 76..521 217/497 (44%) 1.3e-176 360/497 (72%) PSI 539..622 14/101 (14%) 0.76 56/101 (55%) ig 614..675 15/66 (23%) 0.0061 45/66 (68%) Example 2. The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A. 10 112 WO 2004/000997 PCT/US2003/017512 Table 2A. NOV2 Sequence Analysis NOV2a, CG106951-01 SEQ ID NO: 5 16408 bp DNA Sequence ORF Start: ATG at 1400 ORF Stop: TGA at 5456 CCTGGGACTCTGGGAGAATGGTCCAGAGCTCATTGTCCTTGTTGATAAAATGATAGATTTGGACTCAATATCC CATGCTGCCTCTTCCAACTTGATTTTTACCCCAGACTGGGCTACCAGACTGGTATGCCCACACATGCCCGTTT CCTTTCTTTTCTTCTCTGCATCTCTGCCTTTGTGTCCAGAGCGTGTTTTCCCTTTGCAAGTTTCTCTCCATTC TGCACATTATGAGTTTCAGCATTTCTGTTGCCCTAGAAAGTCTATCTTTGAGATCTTGCACTGTTTCTCTTTT TACAGTGTCTCATAAACTCCCTTCTTGGATTCAGAACCACCCTTTCTTTCCCATTATCCTGTCAAACTGCTTC TTGCCATGGTCCAGGGGTAGGAGGATGGCAGGCAGGAGGTGCTTCTCTGGGGCTCTTAGTGTCTCAATTCTTC TGCTTTATCTGGGTTTTCCTTTACCCAGAATTTTATTATGTAAAATGCTTCACTCAGACTTTGTTCTAATTAT CCAATTTTTGGCATACTCTAGAAAGTCTTTTGATATTTTCCTTCCTCCAACTTATCTATTTTTATTTCATAGT TCTCTTTGGTTATCTCTTAGAATCACACTTTCCTGGTTTTAATTTTTCAAATCCTTTGTCTTTCTCACTCGTT CTTAGGTCACCTTTTTTTACATTTTCAAATATATTTTTTGTTCAGCAGAGGGCTCCCTTCCCATCCCTCTTGC AGCCCGGGCAGCTAGGATTTGAAGCTTGCCCCTTGAATCTTTCTCTCCCGCCTTCTAGCCATCAGAAACACTA GATCACTTAAACTTGTAAACAATTCGGCCTCGCTCCTTGTGATTGCGCTAAACCTTCCGTCCTCAGCTGAGAA CGCTCCACCACCTCCCCGGATCGCTCATCTCTTGGCTGCCCTCCCACTGTTCCTGATGTTATTTTACTCCCCG TATCCCCTACTCGTTCTTCACAATTCTGTAGGGTGCGTATTACTAACCCCAGTTTACAGCTGAGGAAACTGAG GCTTGGAGAGGTTCGCTCGGTATCGTACAGTTTGCAAGGTTAACCCTAATCCGGCCAGTTCTGGCTTTCCAGC CCAGCCCAGCAGCCTAGCCTCCCTCTCTGCCGCTGCAGGTTATAACGGCTCTCCCCCGTTTTACACGAGGTCC CTTCCCCTTCAAATCCACAGGCAGGAAGATCGTTCCGAACTGACGGGGCTGGGGAATGTGGGAGTCCGGAGTG GGGTTTGGGGGAGCTTCCTCAGGCCCTGAGTGTTGGGGTGGGCAGGCCGCGCCGATGGCCCTCGGGGATGTCA CATTCGAGATGGGGTGACCGAGAACGGCAAGGCGGGATGTGGCAAACGGCGGCAAGTGCTCGGAGTCCTAGGT CTTGCCGCCGGAATGCCGGCCGGGGAAGGGGCTTCGGCCCACCGGGCTGGTCACCACACTCGGCAGGCCCGGG GCGGGAGTCGGCCGAGCAGCCGCCGGGATCCAGGCCGCCCCCTCGCGCTCCTCCGCGCGCCTCGAGGCTGGCGG GTGCAGCGCCCGCCGCGGCAGGTCTGCTCCAGCCCCCTCCTCTTTTTCGCTCCCGCTCCCCTCCTTCTCTCCC TTTGCTTGCAACTCCTCCCCCACCGCCCCCTCCCTCCTTCTGCTCCCGCGGTCTCCTCCTCCCTGCTCTCTCC GAGCGCCGGGTCGGGAGCTAGTTGGAGCGCGGGGGTTGGTGCCAGAGCCCAGCTCCGCCGAGCCGGGCGGGTC GGCAGCGCATCCAGCGGCTGCTGGGAGCCCGAGCGCAGCGGGCGCGGGCCCGGGTGGGGACTGCACCGGAGCG CTGAGAGCTGGAGGCCGTTCCTGCGCGGCCGCCCCATTCCCAGACCGGCCGCCAGCCCATCTGGTTAGCTCCC GCCGCTCCGCGCCGCCCGGGAGTCGGGAGCCGCGGGGAACCGGGCACCTGCACCCGCCTCTGGGAGTGAGTGG TTCCAGCTGGTGCCTGGCCTGTGTCTCTTGGATGCCCTGTGGCTTCAGTCCGTCTCCTGTTGCCCACCACCTC GTCCCTGGGCCGCCTGATACCCCAGCCCAACAGCTAAGGTGTGGATGGACAGTAGGGGGCTGGCTTCTCTCAC TGGTCAGGGGTCTTCTCCCCTGTCTGCCTCCCGGAGCTAGGACTGCAGAGGGGCCTATCATGGTGCTTGCAGG CCCCCTGGCTGTCTCGCTGTTGCTGCCCAGCCTCACACTGCTGGTGTCCCACCTCTCCAGCTCCCAGGATGTC TCCAGTGAGCCCAGCAGTGAGCAGCAGCTGTGCGCCCTTAGCAAGCACCCCACCGTGGCCTTTGAAGACCTGC AGCCGTGGGTCTCTAACTTCACCTACCCTGGAGCCCGGGATTTCTCCCAGCTGGCTTTGGACCCCTCCGGGAA CCAGCTCATCGTGGGAGCCAGGAACTACCTCTTCAGACTCAGCCTTGCCAATGTCTCTCTTCTTCAGGCCACA GAGTGGGCCTCCAGTGAGGACACGCGCCGCTCCTGCCAAAGCAAAGGGAAGACTGAGGAGGAGTGTCAGAACT ACGTGCGAGTCCTGATCGTCGCCGGCCGGAAGGTGTTCATGTGTGGAACCAATGCCTTTTCCCCCATGTGCAC CAGCAGACAGGTGGGGAACCTCAGCCGGACTACTGAGAAGATCAATGGTGTGGCCCGCTGCCCCTATGACCCA CGCCACAACTCCACAGCTGTCATCTCCTCCCAGGGGGAGCTCTATGCAGCCACGGTCATCGACTTCTCAGGTC GGGACCCTGCCATCTACCGCAGCCTGGGCAGTGGGCCACCGCTTCGCACTGCCCAATATAACTCCAAGTGGCT TAATGAGCCAAACTTCGTGGCAGCCTATCATATTCGGCTGTTTGCATACTTCTTCCTGCGGGAGAACGCAGTG GAGCACGACTGTGGACGCACCGTGTACTCTCGCGTGGCCCGCGTGTGCAAGAATGACGTGGGGGGCCGATTCC TGCTGGAGGACACATGGACCACATTCATGAAGGCCCGGCTCAACTGCTCCCGCCCGGGCGAGGTCCCCTTCTA CTATAACGAGCTGCAGAGTGCCTTCCACTTGCCAGAGCAGGACCTCATCTATGGAGTTTTCACAACCAACGTA AACAGCATCGCGGCTTCTGCTGTCTGCGCCTTCAACCTCAGTGCTATCTCCCAGGCTTTCAATGGCCCATTTC GCTACCAGGAGAACCCCAGGGCTGCCTGGCTCCCCATAGCCAACCCCATCCCCAATTTCCAGTGTOGCACCCT GCCTGAGACCGGTCCCAACGAGAACCTGACGGAGCGCAGCCTGCAGGACGCGCAGCGCCTCTTCCTGATGAGC GAGGCCGTGCAGCCGGTGACACCCGAGCCCTGTGTCACCCAGGACAGCGTGCGCTTCTCACACCTCGTGGTGG ACCTGGTGCAGGCTAAAGACACGCTCTACCATGTACTCTACATTGGCACCGAGTCGGGCACCATCCTGAAGGC GCTGTCCACGGCGAGCCGCAGCCTCCACGGCTGCTACCTGGAGGAGCTGCACGTGCTGCCCCCCGGGCGCCGC GAGCCCCTGCGCAGCCTGCGCATCCTGCACAGCGCCCGCGCGCTCTTCGTGGGGCTGAGAGACGGCGTCCTGC GGGTCCCACTGGAGAGGTGCGCCGCCTACCGCAGCCAGGGGGCATGCCTGGGGGCCCGGGACCCGTACTGTGG CTGGGACGGGAAGCAGCAACGTTGCAGCACACTCGAGGACAGCTCCAACATGAGCCTCTGGACCCAGAACATC ACCGCCTGTCCTGTGCGGAATGTGACACGGGATGGGGGCTTCGGCCCATGGTCACCATGGCAACCATGTGAGC ACTTGGATGGGGACAACTCAGGCTCTTGCCTGTGTCGAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGG 113 WO 2004/000997 PCT/US2003/017512 GGGCCTTGACTGCCTGGGGCCAGCCATCCACATCGCCAACTGCTCCAGGAATGGGGCGTGGACCCCGTGGTCA TCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGCTTCCAGGTCCGCCAGCGAAGTTGCAGCAACCCTGCTC CCCGCCACGGGGGCCGCATCTGCGTGGGCAAGAGCCGGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCC GGTGCCCATCTTCTGGGCTTCCTGGGGCTCCTGGAGCAAGTGCAGCAGCAACTGTGGAGGGGGCATGCAGTCG CGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTGGGCTGCGGCGTGGAGTTCAAGACGTGCAACCCCGAGG GCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGCCGTCGCTGCCCGTCAACGTGACGCAGGGCGGGGCACG GCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCCCCTTGCAGACCCGCACGGCCTGCAGTTCGGCAGGAGA AGGACCGAGACGAGGACCTGTCCCGCGGACGGCTCCGGCTCCTGCGACACCGACGCCCTGGTGGAGGACCTCC TGCGC-AGCGGGAGCACCTCCCCGCACACGGTGAGCGGGGGCTGGGCCGCCTGGGGCCCGTGGTCGTCCTGCTC CCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAGAACGTGCACTAACCCGGAGCCCCGCAACGGsGGGCCTG CCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGCAACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCT GCTGGACCTCATGGTCTCCATGCTCAGCTTCCTGTGGTGGGGGTCACTATCAACGCACCCGTTCCTGCACCAG CCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCGGGCTGCACACGGAGGAGGCACTATGTGCCACACAGGCC TGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGTAAGTGCACTGACGAcGGAGCCAGAccG~CCCCGGC ACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTGCTGGAAACAGCAGCCAGAGCCGCCCCTGCCCCTACAG CGAGATTCCCGTCATCCTGCCAGCCTCCAGCATGGAGGAGQCCACCGGCTGTGCAGGGTTCAATCTCATcCA TTGGTGGCCACGGGCATCTCCTGCTTCTTGGGCTCTGGGCTCCTGACCCTA4CAGTrGTACCTGTCTTGCCAGC ACTCCCAGCGTCAGTCCCAGGAGTCCACACTGGTCCATCCTGCCACCCCCAACCATTTGCACTACAAGGGCGG AGGCACCCCGAAGAATGAAAAGTACACACCCATGGAATTCAAGACCCTGAACAAGAATAACTTGATCCCTGAT GACGAGCCACTTCTACCCATTGCAGCAGACCAAGTGTACACGACTACTTACTACCCAAGCCCCCTGAC AACACAGCTTCCGGCCCGAGGCCTCACCTGGACAACGGTGCTTCCCCAACAGCTGATACCGCCGTCCTGGGGA CTTGGGCTTCTTGCCTTCATAAGGCACAGAGCAGATGGAGATGGGACAGTGGAGCCAGTTTGGTTTTCTCCCT CTGCACTAGGCCAAGAACTTGCTGCCTTGCCTGTGGGGGGTCCCATCCGGCTTCAGAGAGCTCTGGCTGGCAT TGACCATGGGGGAAAGGGCTGGTTTCAGGCTGACATATGGCCGCAGGTCCAGTTCAGCCCAGGTCTCTCATGG TTATCTTCCAACCCACTGTCACGCTGACACTATGCTGCCATGCCTGGGCTGTGGACCTACTGGGCATTTGAGG AACTGGAGAAZTGGAGATGGCAAGAGGGCAGGCTTTTAAGTTTGGGTTGGAGACAACTTCCTGTGGCCCCACA AGCTGAGTCTGGCCTTCTCCAGCTGGCCCCAAAAAAGGCCTTTGCTACATCCTGATTATCTCTGAAGTATC ATCAAGTGGCTCCAGTAGCTCTGGATTTTCTGCCAGGGCTGGGCC-ATTGTGGTGCTGCCCCAGTATGACATG GGACCAAGGCCAGCGCAGGTTATCCACCTCTGCCTGGAAGTCTATACTCTACCCAGGGCATCCCTCTGGTCAG AGGCAGTGAGTACTGGGAACTGGAGGCTGACCTTCTTAGAAGTCCTTTAATCTGGGCTGGTACAGGCCTCA GCCTTGCCCTCAATGCACG-AZAGGTGGCCCAGGAGAGAGGATCAATGCCACAGGAG~CAGAAGTCTGGCCTCT GTCCCTCTATGGAGACTATCTTCCAGTTGCTGCTCAACAGAGTTGTTGGCTGAGACCTGCTTGGGAGTCTCTG CTGGCCCTTCATCTGTTCAGGAACACACACACACACACACTCACAr-ACGCACACACATCACAATTTGCTACA IGCAACAAAAAAGACATTGGGCTGTGGCATTATTAATTAAAGATGATATCCAGTCTCC fNOV2a, CG106951-O1 SEQ ID NOI 15a W t157.k Protein Sequence MPAGEGASARAGHHTRQARGGSRSSRGMQGAPSRSSARLEAGGCSARGRSAPAPSSFSLPL'SFSPFACN SSTPLLPSPCLAGEVAGVESAPOAHAASSAAPGCGLA GRSCAAPFPDRPPHLVSSRRSAPPGSREPRGTGHLHPPLGVSGSSWCLACVSWMPCGFSPSPVAHjHLVPGP PDTPAQQLRCGWTVGGWLLSLVRGLLPCLPPGARTAEGPIMVLAGPLAVSLLLPSLTLLVSHLSSSQDVSEP SSEQQLCALSKPTVAFDLQPVSNF'TYPGRDSQLALDPSGNQLIVGARN'YLFRLSLANVSLLQATEWAS SEDTRRSCQSKGKTEBECQNYVRVLIVAGRKVFMCGTNAFSPMCTSRQVGNLSRTTEKINGVARCPYnPRHNS TAVISSQGELYAATVIDFSGRDPAIYRSLGSGPPLRTAQYNSKWLNEPNFVAAYDIGLFAYFFLRENAVEHDC GRTYSRVARVCKNDVGGRFLLEDTWTTFMKARLNCSRPGEVPFYYNELQSAFHLPEQDLIYGVFTTNVNSIA ASAVCAFNLSAISQAFNGPFRYQENPRAAWLPIANPIPNFQCGTLPETGPNENLTERSLQDAQRLFLMSEAVQ PVTPEPCVTQDSVRFSHLVVDLVQADTLYHVLYIGTESGTILKSTASRSLGCYLEELHVL~PGRRPpLR SLRILHSARALFVGLRDGVLRVPLERCAAYRSQGACLGARDPYCGWDGKQQRCSTLEDSSNMSLWTQNITACP VR2NVTRfGGFGPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWAL CSTSCGIGFQVRQRSCSNPAPRGGRICVKSREERFCNENTPCPVPI FWASWGSWSKCSSNCGGGMQSRRRA CENGNSCLGCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLAPHGLQFGJRRTET RTCPAGSGSCDTDAIAEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKITCTNPEPNGLPCVG DAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCATQACPEG WSPWSEWSECTDDGAQSRSRHCEELLPCSACAGNSSQSRPCPYSEIPVILPASMEEATGCAGFNLIILVAT GISCFLGSGLTLAVYLSCQ1CQRQSQESTLVHPATPNHL1YKGGGTPKNEKYTPMEFKTLNtNLIPDDRA FYPIQQTNVYTTTYYPSPLNKHSFRPEASPGQRCFPNS 114 WO 2004/000997 PCT/US2003/017512 NOV2b, CGI06951-04 SEQ ID NO: 7 ~ 3631 bp DNA Sequence lORE Start: ATG at 154_, JORE Stop: TGA at 3544 GCGGCCGCCCCATT CCAAC'CGGCCGCCAGCCCCATCTGGTTAGCTCCCGCCGCTCCGCGCCGCCCGGGAGTC GGGAGCCGCGGGGAACCGGGCACCTGCACCCGCCTCTGGGAGTGAGTGGTTCCAGCTGTGCCTGGCCTGTGT CTCTTGGATGCCCTGTGGCTTCAGTCCGTCTCCTGTTGCCCACCACCTCGTCCCTGGGCCGCCTGATACCCCA GCCCAACAGCTAAGGTGTGGATGGACAGTAGGGGGCTGGCTTCTCTACTGGTCAGGGGTCTTCTCCCCTGTC TGCCTCCCGGAGCTAGGACTGCAGAGGGGCCTATCATGGTGCTTGCAGG3CCCCCTGGCTGTCTCGCTGTTCCT GCCCAGCCTACACTCTGGTGTCCCACCTCTCCAGCTCCCAGGATGTCTCCAGTGAGCCCAGCAGTGAGCAG CAGCTGTGCGCCCTTAGCAAGCACCCCACCGTGGCCTTTGAAGACCTGCAGCCGTGGGTCTCTAACTTCACCT ACCCTGGAGCCCGGGATTTCTCCCACTGGCTTTGGACCCCTCCGGGACCGCTCTCGTGGGAGCCAGGAA CTACCTCTTCAGACTCAGCCTTGCCAATGTCTCTCTTCTTCAGGCCACAGAGTGCGCCTCCAGTGAGGACACG CGCCGCTCCTGCCAAAGCAAAGGGAAIACTGAGGAGGAGTGTCAGACTACGTGCGAGTCCTGATCGTCGCCG GCCGGAAGGTGTTCATGTGTGGAACCAATGCCTTTTCCCCCATGTGCACCAGCAGACAGGTGGGGACCTCAG CCGGACTACTGAGAAGATCATGGTGTGGCCCGCTGCCCCTATGACCCACGCCACACTCCACAGCTGTCATC TCCTCCCAGGGGGAGCTCTATGCAGCCACGGTCATCGACTTCTCAGGTCGGGACCCTGCCATCTACCGCAGCC TGGGCAGTGGGCCACCGCTTCGCACTGCCCTATACTCCAAGTGGCTTATGAGCCAAACTTCGTGGCAGC CTATGATATTGGGCTGTTTGCATACTTCTTCCTGCGGGAGAACGCGTGGAGCACGACTGTGGACGCACCGTG TACTCTCGCGTGGCCCGCGTGTGCAAGAATGACGTGGGGGGCCGATTCCTGCTGGAGGACACATGACCAcAT, TCATGAGGCCCGGCTCAACTGCTCCCGCCCGGGCGAGGTCCCCTTCTACTATJACGAGCTGCAGAGTGCCTT CCACTTCCCAGAGCAGGACCTCATCTATGGAGTTTTCACAACCAJACGTACAGCATCGCGGCTTCTGCTGTC TGGCTACTATCACCCGCTCAGCCTTGTCAGGACC!GGT CCTGGCTCCCCATAGCCAACCCCATCCCCAATTTCCAGTGTGGCACCCTGCCTGAGACCGGTCCCLCGAGA CCTGACGGAGCGCAGCCTGCAGGACGCGCAGCGCCTCTTCCTGATGAGCGAGGCCGTGCAGCCGGTGACACCC GAGCCCTGTGTCACCCAGGACAGCGTGCGCTTCTCACACCTCGTGGTGGACCTGGTGCAGGCTAAAGACACGC * TCAGATTCATGACATGGACACTAGCCGCCCGGGCCGC CCACGGCTGCTACCTGCAGGACCTGCACGTGCTGCCCCCCGGGCGCCGCGAGCCCCTGCGCAGCCTGCGCATC CTGCACAGCGCCCGCGCGCTCTTCGTGGGGCTGAGAGACGGCGTCCTGCGGGTCCCACTGGAGAGGTGCGCCG CCTACCGCAGCCAGGGGCATGCCTGGGGGCCCGGGACCCGTACTGTGGCTGGGACGGGAJAGCAGCACGTTG CAGCACACTCGAGGACAGCTCCACATGAGCCTCTGACCCAGACATCACCGCCTGTCCTGTGCGATGTG ACACGGGATGGGGGCTTCGGCCCATGGTCACCATGGCAACCATGTGAGCACTTGGATGGGGACAACTCAGGCT CTTGCCTGTGTCGAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGGGGGCCTTGACTGCCTGGGCCAGC CATCCACATCGCCA-ACTGCTCCAGcAATGGGGCGTGGACCCCGTGGTCATCGTGGGCGCTGTGCAGCACGTCC TGTGGCATCGGCTTCCAGGTCCGCCACGAGTTGCAGCACCCTGCT CCCCCACGGGCCGCATCTGCG TGGGCAAG.AGCCGGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCCGGTGCCCATCTTCTGGGCTTCCTG GGGCTCCTGGAGCAAGTGCAGCAGCAACTGTGGAGGtGGGCATGCAGTCGCGGCGTCGGGCCTGCGAGAACGGC AACTCCTGCCTGGGCTGCGGCGTGGAGTTAGACGTGCACCCCGAGGGCTGCCCCAGTGCGGCGCACA CCCCCTGGACGCCGTGGCTGCCCGTGAACGTGACGCAGGGCGGGGCACGGAGGAGCAGCGTTCCGCTTC CTGCCGCGCGCCCCTTGCAGACCCCCACGOCCTGC-GTTCGGCAG3GAGAGGACCGAGACGAGGACCTGTCCC GCGGACGGCTCCGGCTCCTGCGACACCGACGCCCTGGTGGAGGACCTCCTGCGCAGCCGGAGCACCTCCCCGC ACACGGTGAGCGGGGGCTGGGCCGCCTCGGGCCCGTGGTCGTCCTGCTCCCGGGACTGCGAGCTGGGCTTCCG CGTCCGCAAGAGAACGTGCACTAACCCGGAGCCCCGCAACGGGGGCCTGCCCTGCGTGGGCGATGCTGCCGAG TACCAGGACTGCAACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCTGCTGGACCTQATGGTCTCCATGCT CAGCTTCCTGTGGTGGGGGTCACTATCAACGCACCCGTTCCTGCACCAGCCCCGCACCCTCCCCAGAAGGCTG GTCGCCCTGGTCTGAGTGGAGTAAGTGCACTGACGACGGAGCCCAGAGCCGAAGCCGGCACTGTGAGGAGCTC CTCCCAkGGGTCCAGCGCCTGTGCTGGAAACAGCAGCCAGAGCCGCCCCTGCCCCTACAGCGAGATTCCCGTCA TCCTGCCAGCCTCCAGCATGGAGGAGGCCACCGGCTGTGCAGGGTTCAATCTCATCCACTTGGTGGCCACGGG CATCTCCTGCTTCTTCGGCTCTGGGCTCCTGACCCTAGCAGTGTACCTGTCTTGCCAGCCTGCCAGCGTCAG TCCCAGGAGTCCACACTGGTCCATCCTGCCACCCCACCATTTGCACTACAGGGCGGAGGCACCCCGAAGA ATGAAAAGTACACACCCATGGAATTCAAGACCCTGACAAGATAACTTGATCCCTGATGACAGAGCCAACTT CTACCCATTGCAGCAGACCAATGTGTACACGACTACTTACTACCAGCCCCCTGACAACACAGCTTCCGG CCCGAGGCCTCACCTGGACAACGGTGCTTCCCCAACAGCTGATACCGCCGTCCTGGGGACTTGGGCTTCTTGC CTTCATAAGGCACAGAGCAGATGGAGATGGGACAGTGGAGCCAGTTTGGTTTCT 115 WO 2004/000997 PCT/US2003/017512 NOV2b, CG106951-04 SEQ ID NO: 8 1130 aa :MW at 123700.9kD Protein Sequence MPCGFSPSPVAHHLVPGPPDTPAQQLRCGWTVGGWLLSLVRGLLPCLPPGARTAEGPIMVLAGPLAVSLLLPS LTLLVSHLSSSQDVSSEPSSEQQLCALSKHPTVAFEDLQPWVSNFTYPGARDFSQLALDPSGNLIVGARNYL FRLSLANVSLLQATEWASSEDTRRSCQSKGKTEEECQNYVRVLIVAGRKVFMCGTNAFSPMCTSRQVGNLSRT TEKINGVARCPYDPRHNSTAVISSQGELYAATVIDFSGRDPAIYRSLGSGPPLRTAQYNSKWLNEPNFVAAYD IGLFAYFFLRENAVEHDCGRTVYSRVARVCKNDVGGRFLLEDTWTTFMKARLNCSRPGEVPFYYNELQSAFHL PEQDLIYGVFTTNVNSIAASAVCAFNLSAISQAFNGPFRYQENPRAAWLPIANPIPNFQCGTLPETGPNENLT ERSLQDAQRLFLMSEAVQPVTPEPCVTQDSVRFSHLVVDLVQAKDTLYHVLYIGTESGTILKALSTASRSLHG CYLEELHVLPPGRREPLRSLRILHSARALFVGLRDGVLRVPLERCAAYRSQGACLGARDPYCGWDGKQQRCST LEDSSNMSLWTQNITACPVRNVTRDGGFGPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPAIH IANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHGGRICVGKSREERFCNENTPCPVPIWASWGS WSKCSSNCGGGMQSRRRACENGNSCLGCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCR APLADPHGLQFGRRRTETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVR KRTCTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTSPAPSPEGWSP WSEWSKCTDDGAQSRSRHCEELLPGSSACAGNSSQSRPCPYSEIPVILPASSMEEATGCAGFNLIHLVATGIS CFLGSGLLTLAVYLSCQHCQRQSQESTLVHPATPNHLHYKGGGTPKNEKYTPMEFKTLNKNLIPDDRANFYP LQQTNVYTTTYYPSPLNKHSFRPEASPGQRCFPNS NOV2c, 209829549 ISEQDNO:9 .12031bp DNA Sequence RORF Start: at 1 OF Stop: end of sequence GATCCGGCCCATGGTCACCATGGCAACCATGTGAGCACTTGGATGGGGACAACTCAGGCTCTTGCCTGTGTC GAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGGGGGCCTTGACTGCCTGGGGCCAGCCATCCACATCGC CAACTGCTCCAGGAATGGGGCGTGGACCCCGTGGTCATCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGC TTCCAGGTCCGCCAGCGAAGTTGCAGCAACCCTGCTCCCCGCCACGGGGGCCGCATCTGCGTGGGCAAGAGCC GGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCCGGTGCCCATCTTCTGGGCTTCCTGCGGCTCCTGGAG CAAGTGCAGCAGCAACTGTGGAGGGGGCATGCGGTCGCGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTG GGCTGCGGCGTGGAGTTCAAGACGTGCAACCCCGAGGGCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGC CGTGGCTGCCCGTGAACGTGACGCAGGGCGGGGCACGGCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCC CCTTGCAGACCCGCACGGCCTGCAGTTCGGCAGGAGAAGGACCGAGACGAGGACCTGTCCCGCGGACGGCTCC GGCTCCTGCGACACCGACGCCCTGGTGGAGGACCTCCTGCGCAGCGGGAGCACCTCCCCGCACACGGTGAGCG GGGGCTGGGCCGCCTGGGGCCCGTGGTCGTCCTGCTCCCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAG AACGTGCACTAACCCGGAGCCCCGCAACGGGGGCCTGCCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGC AACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCTGCTGGACCTCATGGTCTCCATGCTCAGCTTCCTGTG GTGGGGGTCACTATCAACGCACCCGTTCCTGCACCAGCCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCGG GCTGCACACGGAGGAGGCACTATGTGCCACACAGGCCTGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGT AAGTGCACTGACGACGGAGCCCAGAGCCGAAGCCGGCACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTG CTGGAAACAGCAGCCAGAGCCGCCCCTGCGTCGAC 5 116 WO 2004/000997 PCT/US2003/017512 NOV2c, 209829549 SEQ ID NO: 10 1401 aa 1MW at 43284.5kD Protein Sequence I GSGPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIG FQVRQRSCSNPAPRHGGRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMRSRRRACENGNSCL GCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRTETRTCPADGS GSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRTCTNPEPRNdGLPCVGDAAEYQDC NPQACPVRGAWSCWTSWSPCSASCGGGHYRTRSCTSPAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWS KCTDDGAQSRSRHCEELLPGSSACAGNSSQSRPCVD NOV2d, 209829553 ISEQIDNO:11 1203bp DNA Sequence jORF Start- at 1 ORF Stop: end of sequence GGATCCGGCCCATGGTCACCATGGCAACCATGTGAGCACTTGGATGGGGACAACTCAGGCTCTTGCCTGTGTC GAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGGGGGCCTTGACTGCCTGGGGCCAGCCATCCACATCGC CAACTGCTCCAGGAATGGGGCGTGGACCCCGTGGTCATCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGC TTCCAGGTCCGCCAGCGAAGTTGCACCAACCCTGCTCCCCGCCACGGGGGCCGCATCTGCGTGGGCAAGAGCC GGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCCGGTGCCCATCTTCTGGGCTTCCTGGGGCTCCTGGAG CAAGTGCAGCAGCAACTGTGGAGGGGGCATGCAGTCGCGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTG GGCTGCGGCGTGGAGTTCAAGACGTGCAACCCCGAGGGCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGC CGTGGCTGCCCGTGAACGTGACGCAGGGCGGGGCACGGCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCC CCTTGCAGACCCGCACGGCCTGCAGTTCGGCAGGAGAAGGACCGAGACGAGGACCTGTCCCGCGGACGGCTCC GGCTCCTGCGACACCGACGCCCTGGTGGAGGACCTCCTGCGCAGCGGGAGCACCTCCCCGCACACGGTGAGCG GGGGCTGGGCCGCCTGGGGCCCGTGGTCGTCCTGCTCCCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAG AACGTGCACTAACCCGGAGTCCCGCAACGGGGGCCTGCCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGC AACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCTGCTGGACCTCATGGTCTCCATGCTCAGCTTCCTGTG GTGGGGGTCACTATCAACGCACCCGTTCCTGCACCAGCCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCGG GCTGCACACGGAGGAGGCACTATGTGCCACACAGGCCTGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGT AAGTGCACTGACGACGGAGCCCAGAGCCGAAGCCGGCACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTG CTGGAAACAGCAGCCAGAGCCGCCCCTGCGTCGAC 5 NOV2d, 209829553 SIEQ IDNO: 12 .401.aa .MW at 43246.41D Protein Sequence GSGPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIG FQVRQRSCSNPAPRHGGRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRACENGNSCL GCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRTETRTCPADGS GSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRTCTNPESRNGGLPCVGDAAEYQDC NPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWS KCTDDGAQSRSRHCEELLPGSSACAGNSSQSRPCVD 117 WO 2004/000997 PCT/US2003/017512 OV2e, 209829642 SEQ IDNO: 13 1203 bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence GGATCCGGCCCATGGTCACCATGGCAACCATGTGAGCACTTGGATGGGGACAACTCAGGCTCTTGCCTOTGTC GAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGGGGGCCTTGACTGCCTGGGGCCAGCCATCCACATCGC CAACTGCTCCAGGAATGGCGCGTGGACCCCGTGGTCATCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGC TTCCAGGTCCGCCAGCGAAGTTGCAGCAACCCTGCTCCCCGCCACGGGGGCCGCATCTGCGTGGGCAAGAGCC GGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCCGGTGCCCATCTTCTGGGCTTCCTGGGGCTCCTGGAG CAAGTGCAGCAGCAACTGTGGAGGGGGCATGCAGTCGCGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTG GGCTGCGGCGTGGAGTTCAAGACGTGCAACCCCGAGGGCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGC CGTGGCTGCCCGTGAACGTGACGCAGGGCGGGGCACGGCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCC CCTTGCAGACCCGCACGGCCTGCAGTTCGGCAGGAGAAGGACCGAGACGAGGACCTGTCCCGCGGACGGCTCC GGCTCCTGCGACACCGACGCCCTGGTGGAGGACCTCCTGCGCAGCGGGAGCACCTCCCCGCACACGGTGAGCG GGGGCTGGGCCGCCTGGGGCCCGTGGTCGTCCTGCTCCCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAG AACGTGCACTAACCCGGAGCCCCGCAACGGGGGCCTGCCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGC AACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCTGCTGGACCTCATGGTCTCCATGCTCAGCTTCCTGTG GTGGGGGTCACTATCAACGCACCCGTTCCTGCACCAGCCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCGG GCTGCACACGGAGGAGGCACTATGTGCCACACAGGCCTGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGT AAGTGCACTGACGACGGAGCCCAGAGCCGAAGCCGGCACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTG CTGGAAACAGCAGCCAGAGCCGCCCCTGCGTCGAC INOV2e, 209829642 SEQ0DNO:14 401aa MWat43256.4kD Protein Sequence GSGPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIG FQVRQRSCSNPAPRHGGRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMSRRRACENGNSCL GCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRTETRTCPADGS GSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRTCTNPEPRNGGLPCVGDAAEYQDC NPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWS KCTDDGAQSRSRHCEELLPGSSACAGNSSQSRPCVD 5 NOV2f, 209829670 ISEQ D NO: 15 1203bp DNA Sequence bORF Start: at 1 JORF Stop: end of sequence GGATCCGGCCCATGGTCACCATGGCAACCATGTGAGCACTTGGATGGGGACAACTCAGGCTCTTGCCTGTGTC GAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGGGGGCCTTGACTGCCTGGGGCCAACCATCCACATCGC CAACTGCTCCAGGAATGGGGCGTGGACCCCGTGGTCATCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGC TTCCAGGTCCGCCAGCGAAGTTGCAGCAACCCTGCTCCCCGCCACGGGGGCCGCATCTGCGTGGGCAAGAGCC GGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCCGGTGCCCATCTTCTGGGCTTCCTGGGGCTCCTGGAG CAAGTGCGGCAGCAACTGTGGAGGGGGCATGCAGTCGCGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTG GGCTCCGGCGTCGAGTTCAAGACGTGCAACCCCCAGGGCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGC CGTGGCTGCCCGTGAACGTGACGCAGGGCGGGGCACGGCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCC CCTTGCAGACCCGCACGGCCTGCAGTTCGGCAGGAGAAGGACCGAGACGAGGACCTGTCCCGCGGACGGCTCC GGCTCCTGCGACACCGACGCCCTGGTGGAGGTCCTCCTGCGCAGCGGGAGCACCTCCCCGCACACGGTGAGCG GGGGCTGGGCCGCCTGGGGCCCGTGGTCGTCCTGCTCCCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAG AACGTGCACTAACCCGGACCCCCGCAACGGGGGCCTGCCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGC AACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCTGCTGGACCTCATGGTCTCCATGCTCAGCTTCCTGTG GTGGGGGTCACTATCAACGCACCCGTTCCTGCACCAGCCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCGG GCTGCACACGGAGGAGGCACTATGCGCCACACAGGCCTGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGT AAGTGCACTGACGACGGAGCCCAGAGCCGAAGCCGGCACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTG CTGGAAACAGCAGCCAGAGCCGCCCCTGCGTCGAC 118 WO 2004/000997 PCT/US2003/017512 NOV2f, 209829670 SEQ ID NO: 16 401 aa MW at 43240.5kD Protein Sequence GSGPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPTIHIANCSRNGAWTPWSSWALCSTSCGIG FQVRQRSCSNPAPRHGGRICVGKSREERFCNENTPCPVPIFWASWGSWSKCGSNCGGGMQSRRRACENGNSCL GCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRTETRTCPADGS GSCDTDALVEVLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRTCTNPEPRNGGLPCVGDAAEYQDC NPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWS KCTDDGAQSRSRHCEELLPGSSACAGNSSQSRPCVD NOV2g,CG106951-02 ISEQ ID NO: 17 4233bp DNA Sequence ORF Start: ATG at 2 ORF Stop: TGA at 3281 CATGGTGCTTGCAGGCCCCCTGCCTGTCTCGCTGTTGCTGCCCAGCCTCACACTGCTGGTGTCCCACCTCTCC AGCTCCCAGGATGTCTCCAGTGAGCCCAGCAGTGAGCAGCAGCTGTGCGCCCTTAGCAAGCACCCCACCGTGG CCTTTGAAGACCTGCAGCCGTGGGTCTCTAACTTCACCTACCCTGGAGCCCGGGATTTCTCCCAGCTGGCTTT GGACCCCTCCGGGAACCAGCTCATCGTGGGAGCCAGGAACTACCTCTTCAGACTCAGCCTTGCCAATGTCTCT CTTCTTCAGGCCACAGAGTGGGCCTCCAGTGAGGACACGCGCCGCTCCTGCCAAAGCAAAGGGAAGACTGAGG AGGAGTGTCAGAACTACGTGCGAGTCCTGATCGTCGCCGGCCGGAAGGTGTTCATGTGTGGAACCAATGCCTT TTCCCCCATGTGCACCAGCAGACAGGTGGGGAACCTCAGCCGGACTACTGAGAAGATCAATGGTGTGGCCCGC TGCCCCTATGACCCACGCCACAACTCCACAGCTGTCATCTCCTCCCAGGGGGAGCTCTATGCAGCCACGGTCA TCGACTTCTCAGGTCGGGACCCTGCCATCTACCGCAGCCTGGGCAGTGGGCCACCGCTTCGCACTGCCCAATA TAACTCCAAGTGGCTTAATGAGCCAAACTTCGTGGCAGCCTATGATATTGGGCTGTTTGCATACTTCTTCCTG CGGGAGAACGCAGTGGAGCACGACTGTGGACGCACCGTGTACTCTCGCGTGGCCCGCGTGTGCAAGAATGACG TGGGGGGCCGATTCCTGCTGGAGGACACATGGACCACATTCATGAAGGCCCGGCTCAACTGCTCCCGCCCGGG CGAGGTCCCCTTCTACTATAACGAGCTGCAGAGTGCCTTCCACTTGCCAGAGCAGGACCTCATCTATGGAGTT TTCACAACCAACGTAAACAGCATCGCGGCTTCTGCTGTCTGCGCCTTCAACCTCAGTGCTATCTCCCAGGCTT TCAATGCCCCATTTCGCTACCAGGAGAACCCCAGGGCTGCCTGGCTCCCCATAGCCAACCCCATCCCCAATTT CCAGTGTGGCACCCTGCCTGAGACCGGTCCCAACGAGAACCTGACGGAGCGCAGCCTGCAGGACGCGCAGCGC CTCTTCCTGATGAGCGAGGCCGTGCAGCCGGTGACACCCGAGCCCTGTGTCACCCAGGACAGCGTGCGCTTCT CACACCTCGTGGTGGACCTGGTGCAGGCTAAAGACACGCTCTACCATGTACTCTACATTGGCACCGAGTCGGG CACCATCCTGAAGGCGCTGTCCACGGCGAGCCGCAGCCTCCACGGCTGCTACCTGGAGGAGCTGCACGTGCTG CCCCCCGGGCGCCGCGAGCCCCTGCGCAGCCTGCGCATCCTGCACAGCGCCCGCGCGCTCTTCGTGGGGCTGA GAGACGGCGTCCTGCGGGTCCCACTGGAGAGGTGCGCCGCCTACCGCAGCCAGGGGGCATGCCTGGGGGCCCG GGACCCGTACTGTGGCTGGGACGGGAAGCAGCAACGTTGCAGCACACTCGAGGACAGCTCCAACATGAGCCTC TGGACCCAGAACATCACCGCCTGTCCTGTGCGGAATGTGACACGGGATGGGGGCTTCGGCCCATGGTCACCAT GGCAACCATGTGAGCACTTGGATGGOGACAACTCAGGCTCTTGCCTGTGTCGAGCTCGATCCTGTGATTCCCC TCGACCCCGCTGTGGGGGCCTTGACTGCCTGGGGCCAGCCATCCACATCGCCAACTGCTCCAGGAATGGGGCG TGGACCCCGTGGTCATCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGCTTCCAGGTCCGCCAGCGAAGTT GCAGCAACCCTGCTCCCCGCCACGGGGGCCGCATCTGCGTGGGCAAGAGCCGGGAGGAACGGTTCTGTAATGA GAACACGCCTTGCCCGGTGCCCATCTTCTGGGCTTCCTGGGGCTCCTGGAGCAAGTGCAGCAGCAACTGTGGA GGGGGCATGCAGTCGCGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTGGGCTGCGGCGTGGAGTTCAAGA CGTGCAACCCCGAGGGCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGCCGTGGCTGCCCGTGAACGTGAC GCAGGGCGGGGCACGGCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCCCCTTGCAGACCCGCACGGCCTG CAGTTCGGCAGGAGAAGGACCGAGACGAGGACCTGTCCCGCGGACGGCTCCGGCTCCTGCGACACCGACGCCC TGGTGGAGGACCTCCTGCGCAGCGGGAGCACCTCCCCGCACACGGTGAGCGGGGGCTGGGCCGCCTGGGGCCC GTGGTCGTCCTGCTCCCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAGAACGTGCACTAACCCGGAGCCC CGCAACGGGGGCCTGCCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGCAACCCCCAGGCTTGCCCAGTTC GGGGTGCTTGGTCCTGCTOGACCTCATGGTCTCCATGCTCAGCTTCCTGTGGTGGGGGTCACTATCAACGCAC CCGTTCCTGCACCAGCCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCGGGCTGCACACGGAGGAGGCACTA TGTGCCACACAGGCCTGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGTAAGTGCACTGACGACGGAGCCC AGAGCCGAAGCCGGCACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTGCTGGAAACAGCAGCCAGAGCCG CCCCTGCCCCTACAGCGAGATTCCCGTCATCCTGCCAGCCTCCAGCATGGAGGAGGCCACCGGCTGTGCAGGG TTCAATCTCATCCACTTGGTGGCCACGGGCATCTCCTGCTTCTTGGGCTCTGGGCTCCTGACCCTAGCAGTGT ACCTGTCTTGCCAGCACTGCCAGCGTCAGTCCCAGGAGTCCACACTGGTCCATCCTGCCACCCCCAACCATTT GCACTACAAGGGCGGAGGCACCCCGAAGAATGAAAAGTACACACCCATGGAATTCAAGACCCTGAACAAGAAT AACTTGATCCCTGATGACAGAGCCAACTTCTACCCATTGCAGCAGACCAATGTGTACACGACTACTTACTACC 119 WO 2004/000997 PCT/US2003/017512 CAAGCCCCCTGAACAAACACAGCTTCCGGCCCGAGGCCTCACCTCGACAACGGTGCTTCCCCAACAGCTGATA CCGCCGTCCTGGGGACTTGGGCTTCTTGCCTTCATAAGGCACAGAGCAGATGGAGATGGGACAGTGGAGCCAG TTTGGTTTTCTCCCTCTGCACTAGGCCAAGAACTTGCTGCCTTGCCTGTGGGGGGTCCCATCCGGCTTCAGAG AGCTCTGGCTGGCATTGACCATGGGGGAAAGGGCTGGTTTCAGGCTGACATATGGCCGCAGGTCCAGTTCAGC CCAGGTCTCTCATGGTTATCTTCCAACCCACTGTCACGCTGACACTATGCTGCCATGCCTGGGCTGTGGACCT ACTGGGCATTTGAGGAACTGGAGAATGGAGATGGCAAGAGGGCAGGCTTTTAAGTTTGGGTTGGAGACAACTT CCTGTGGCCCCCACAAGCTGAGTCTGGCCTTCTCCAGCTGGCCCCAAAAAAGGCCTTTGCTACATCCTGATTA TCTCTGAAAGTAATCAATCAAGTGGCTCCAGTAGCTCTGGATTTTCTGCCAGGGCTGGGCCATTGTGGTGCTG CCCCAGTATGACATGGGACCAAGGCCAGCGCAGGTTATCCACCTCTGCCTGGAAGTCTATACTCTACCCAGGG CATCCCTCTGGTCAGAGGCAGTGAGTACTGGGAACTGGAGGCTGACCTGTGCTTAGAAGTCCTTTAATCTGGG CTGGTACAGGCCTCAGCCTTGCCCTCAATGCACGAAAGGTGGCCCAGGAGAGAGGATCAATGCCACAGGAGGC AGAAGTCTGGCCTCTGTGCCTCTATGGAGACTATCTTCCAGTTGCTGCTCAACAGAGTTGTTGGCTGAGACCT GCTTGGGAGTCTCTGCTGGCCCTTCATCTGTTCAGGAACACACACACACACACACTCACACACGCACACACAA TCACAATTTGCTACAGCAACAAAAAAGACATTGGGCTGTGGCATTATTAATTAAAGATGATATCCAGTCTCC NOV2g, CG106951-02 SEQ ID NO: 18 1093 aa MWat 119865.3kD Protein Sequence MVLAGPLAVSLLLPSLTLLVSHLSSSQDVSSEPSSEQQLCALSKHPTVAFEDLQPWVSNFTYPGARDFSQLAL DPSGNQLIVGARNYLFRLSLANVSLLQATEWASSEDTRRSCQSKGKTEEECQNYVRVLIVAGRKVFMCGTNAF SPMCTSRQVGNLSRTTEKINGVARCPYDPRHNSTAVISSQGELYAATVIDFSGRDPAIYRSLGSGPPLRTAQY NSKWLNEPNFVAAYDIGLFAYFFLRENAVEHDCGRTVYSRVARVCKNDVGGRFLLEDTWTTFMKARLNCSRPG EVPFYYNELQSAFHLPEQDLIYGVFTTNVNSIAASAVCAFNLSAISQAFNGPFRYQENPRAAWLPIANPIPNF QCGTLPETGPNENLTERSLQDAQRLFLMSEAVQPVTPEPCVTQDSVRFSHLVVDLVQAKDTLYHVLYIGTESG TILKALSTASRSLHGCYLEELHVLPPGRREPLRSLRILHSARALFVGLRDGVLRVPLERCAAYRSQGACLGAR DPYCGWDGKQQRCSTLEDSSNMSLWTQNITACPVRNVTRDGGFGPWSPWQPCEHLDGDNSGSCLCRARSCDSP RPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHGGRICVGKSREERFCNE NTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRACENGNSCLGCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVT QGGARQEQRFRFTCRAPLADPHGLQFGRRRTETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGP WSSCSRDCELGFRVRKRTCTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRT RSCTSPAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSACAGNSSQSR PCPYSEIPVILPASSMEEATGCAGFNLIHLVATGISCFLGSGLLTLAVYLSCQHCQRQSQESTLVHPATPNHL HYKGGGTPKNEKYTPMEFKTLNKNNLIPDDRANFYPLQQTNVYTTTYYPSPLNKHSFRPEASPGQRCFPNS NOV2h, CG106951-03 SEQ ID NO: 19 1203bp DNA Sequence ORF Start: at 7 ORE Stop: at 1198 GGATCCGGCCCATGGTCACCATGGCAACCATGTGAGCACTTGGATGGGGACAACTCAGGCTCTTGCCTGTGTC GAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGGGGGCCTTGACTGCCTGGGGCCAACCATCCACATCGC CAACTGCTCCAGGAATGGGGCGTGGACCCCGTGGTCATCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGC TTCCAGGTCCGCCACCGAAGTTGCACCAACCCTGCTCCCCGCCACCGGGCCGCATCTGCGTGGGCAAGAGCC GGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCCGGTGCCCATCTTCTGGGCTTCCTGGGGCTCCTGGAG CAAGTGCGGCAGCAACTGTGGAGGGGGCATGCAGTCGCGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTG GGCTGCGGCGTGGAGTTCAAGACGTGCAACCCCGAGGGCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGC CGTGGCTGCCCGTGAACGTGACGCAGGGCGGGGCACGGCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCC CCTTGCAGACCCCCACGGCCTGCAGTTCGCCAGGAGAAGGACCCAGACGAGCACCTGTCCCGCGGACGGCTCC GGCTCCTGCGACACCGACGCCCTGGTGGAGGTCCTCCTGCGCAGCGGGAGCACCTCCCCGCACACGGTGAGCG GGGGCTGGGCCGCCTGGGGCCCGTGGTCGTCCTGCTCCCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAG AACGTGCACTAACCCGGAGCCCCGCAACGGGGGCCTGCCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGC AACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCTGCTGGACCTCATGGTCTCCATGCTCAGCTTCCTGTG GTGGGGGTCACTATCAACGCACCCGTTCCTGCACCAGCCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCCG GCTGCACACGGAGGAGGCACTATGTGCCACACAGGCCTGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGT AAGTGCACTGACGACGGAGCCCAGAGCCGAAGCCGGCACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTG CTGGAAACAGCAGCCAGAGCCGCCCCTGCGTCGAC 5 120 WO 2004/000997 PCT/US2003/017512 NOV2h, CG106951-03 SEQ tI NO: 20 397 aa MW at42882.1kD Protein Sequence GPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPTIHIANCSRNGAWTPWSSWALCSTSCGIGFQ VRQRSCSNPAPRHGGRICVGKSREERFCNENTPCPVPIFWASWGSWSKCGSNCGGGMQSRRRACENGNSCLGC GVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFRRRTETRTCPADGSGS CDTDALVEVLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRTCTNPEPRNGGLPCVGDAAEYQDCNP QACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKC TDDGAQSRSRHCEELLPGSSACAGNSSQSRPC NOV2i, SNP13382456 of SEQ ID NO: 21 6408 bp CG106951-01, DNA Sequence ORF Start: ATG at 1400 ORF Stop: TGA at 5456 SNP Pos: 5770 SNP Change: C to T CCTGGGACTCTGGGAGAATGGTCCAGAGCTCATTGTCCTTGTTGATAAAATGATAGATTTGGACTCAATATCC CATGCTGCCTCTTCCAACTTGATTTTTACCCCAGACTGGGCTACCAGACTGGTATGCCCACACATGCCCGTTT CCTTTCTTTTCTTCTCTGCATCTCTGCCTTTGTGTCCAGAGCGTGTTTTCCCTTTGCAAGTTTCTCTCCATTC TGCACATTATGAGTTTCAGCATTTCTGTTGCCCTAGAAAGTCTATCTTTGAGATCTTGCACTGTTTCTCTTTT TACAGTGTCTCATAAACTCCCTTCTTGGATTCAGAACCACCCTTTCTTTCCCATTATCCTGTCAAACTGCTTC TTGCCATGGTCCAGGGGTAGGAGGATGGCAGGCAGGAGGTGCTTCTCTGGGGCTCTTAGTGTCTCAATTCTTC TGCTTTATCTGGGTTTTCCTTTACCCAGAATTTTATTATGTAAAATGCTTCACTCAGACTTTGTTCTAATTAT CCAATTTTTGGCATACTCTAGAAAGTCTTTTGATATTTTCCTTCCTCCAACTTATCTATTTTTATTTCATAGT TCTCTTTGGTTATCTCTTAGAATCACACTTTCCTGGTTTTAATTTTTCAAATCCTTTGTCTTTCTCACTCGTT CTTAGGTCACCTTTTTTTACATTTTCAAATATATTTTTTGTTCAGCAGAGGGCTCCCTTCCCATCCCTCTTGC AGCCCGGGCAGCTAGGATTTGAAGCTTGCCCCTTGAATCTTTCTCTCCCGCCTTCTAGCCATCAGAAACACTA GATCACTTAAACTTGTAAACAATTCGGCCTCGCTCCTTGTGATTGCGCTAAACCTTCCGTCCTCAGCTGAGAA CGCTCCACCACCTCCCCGGATCGCTCATCTCTTGGCTGCCCTCCCACTGTTCCTGATGTTATTTTACTCCCCG TATCCCCTACTCGTTCTTCACAATTCTGTAGGGTGCGTATTACTAACCCCAGTTTACAGCTGAGGAAACTGAG GCTTGGAGAGGTTCGCTCGGTATCGTACAGTTTGCAAGGTTAACCCTAATCCGGCCAGTTCTGGCTTTCCAGC CCAGCCCAGCAGCCTAGCCTCCCTCTCTGCCGCTGCAGGTTATAACGGCTCTCCCCCGTTTTACACGAGGTCC CTTCCCCTTCAAATCCACAGGCAGGAAGATCGTTCCGAACTGACGGGGCTGGGGAATGTGGGAGTCCGGAGTG GGGTTTGGGGGAGCTTCCTCAGGCCCTGAGTGTTGGGGTGGGCAGGCCGCGCCGATGGCCCTCGGGGATGTCA CATTCGAGATGGGGTGACCGAGAACGGCAAGGCGGGATGTGGCAAACGGCGGCAAGTGCTCGGAGTCCTAGGT CTTGCCGCCGGAATGCCGGCCGGGGAAGGGGCTTCGGCCCACCGGGCTGGTCACCACACTCGGCAGGCCCGG GCGGGAGTCGGCCGAGCAGCCGCGGGATGCAGGGCGCCCCCTCGCGCTCCTCCGCGCGCCTCGAGGCTGGCGG GTGCAGCGCCCGCCGCGGCAGGTCTGCTCCAGCCCCCTCCTCTTTTTCGCTCCCGCTCCCCTCCTTCTCTCCC TTTGCTTGCAACTCCTCCCCCACCGCCCCCTCCCTCCTTCTGCTCCCGCGGTCTCCTCCTCCCTGCTCTCTCC GAGCGCCGGGTCGGGAGCTAGTTGGAGCGCGGGGGTTGGTGCCAGAGCCCAGCTCCGCCGAGCCGGGCGGGTC GGCAGCGCATCCAGCGGCTGCTGGGAGCCCGAGCGCAGCGGGCGCGGGCCCGGGTGGGGACTGCACCGGAGCG CTGAGAGCTGGAGGCCGTTCCTGCGCGGCCGCCCCATTCCCAGACCGGCCGCCAGCCCATCTGGTTAGCTCCC GCCGCTCCGCGCCGCCCGGGAGTCGGGAGCCGCGGGGAACCGGGCACCTGCACCCGCCTCTGGGAGTGAGTGG TTCCAGCTGGTGCCTGGCCTGTGTCTCTTGGATGCCCTGTGGCTTCAGTCCGTCTCCTGTTGCCCACCACCTC GTCCCTGGGCCGCCTGATACCCCAGCCCAACAGCTAAGGTGTGGATGGACAGTAGGGGGCTGGCTTCTCTCAC TGGTCAGGGGTCTTCTCCCCTGTCTGCCTCCCGGAGCTAGGACTGCAGAGGGGCCTATCATGGTGCTTGCAGG CCCCCTGGCTGTCTCGCTGTTGCTGCCCAGCCTCACACTGCTGGTGTCCCACCTCTCCAGCTCCCAGGATGTC TCCAGTGAGCCCAGCAGTGAGCAGCAGCTGTGCGCCCTTAGCAAGCACCCCACCGTGGCCTTTGAAGACCTGC AGCCGTGGGTCTCTAACTTCACCTACCCTGGAGCCCGGGATTTCTCCCAGCTGGCTTTGGACCCCTCCGGGAA CCAGCTCATCGTGGGAGCCAGGAACTACCTCTTCAGACTCAGCCTTGCCAATGTCTCTCTTCTTCAGGCCACA GAGTGGGCCTCCAGTGAGGACACGCGCCGCTCCTGCCAAAGCAAAGGGAAGACTGACGAGGAGTGTCAGAACT ACGTGCGAGTCCTGATCGTCGCCGGCCGGAAGGTGTTCATGTGTGGAACCAATGCCTTTTCCCCCATGTGCAC CAGCAGACAGGTGGGGAACCTCAGCCGGACTACTGAGAAGATCAATGGTGTGGCCCGCTGCCCCTATGACCCA CGCCACAACTCCACAGCTGTCATCTCCTCCCAGGGGGAGCTCTATGCAGCCACGGTCATCGACTTCTCAGGTC GGGACCCTGCCATCTACCGCAGCCTGGGCAGTGGGCCACCGCTTCGCACTGCCCAATATAACTCCAAGTGGCT TAATGAGCCAAACTTCGTGGCAGCCTATGATATTGGGCTGTTTGCATACTTCTTCCTGCGGGAGAACGCAGTG GAGCACGACTGTGGACGCACCGTGTACTCTCGCGTGGCCCGCGTGTGCAAGAATGACGTGGGGGGCCGATTCC TGCTGGAGGACACATGGACCACATTCATGAAGGCCCGGCTCAACTGCTCCCGCCCGGGCGAGGTCCCCTTCTA CTATAACGAGCTGCAGAGTGCCTTCCACTTGCCAGAGCAGGACCTCATCTATGGAGTTTTCACAACCAACGTA 121 WO 2004/000997 PCT/US2003/017512 AAACTGGCTTCGCGGCTACTATCACCCGCTCAGCCTT GCTACCAGGAGAACCCCAGGGCTGCCTGGCTCCCCATAGCACCCCATCCCCATTTCCGTGTGGCACCCT GCCTGAGACCGGTCCCAACGAGAACCTGACGGAGCGCAGCCTGCAGGACGCGCAGCGCCTCTTCCTGATGAGC GAGLGCCGTGCAGCCGGTGACACCCGAGCCCTGTGTCACCCAGGACAGCGTGCGCTTCTCACACCTCGTGGTGG ACCTGGTGCAGGCTAAAGACACGCTCTACCATGTACTCTACATTGGCACCGAGTCGGGCACATCCTGAGC GCTGTCCACGGCGAGCCGCAGCCTCCACGGCTGCTACCTGGAGGAGCTGCACGTGCTGCCCCCCGGGCGCCGC GAGCCCCTGCGCAGCCTGCGCATCCTGCACAGCGCCCGCGCGCTCTTCGTGGGGCTGAGAGACGGCGTCCTGC GGGTCCCACTGGAGAGGTGCGCCGCCTACCGCAGCCAGGGGGCATGCCTGGGGGCCCGGGACCCGTACTGTGG CTGGGACGGGAAGCAGCAACGTTGCAGACACTCGAGGACAGCTCCAACATGAGCCTCTGGACCAGACATC ACGCGCTTCGAGGCCGAGGGTCGCAGTACTGACAGGG ACTTGGATGGGGACAACTCAGGCTCTTGCCTGTGTCGAGCTCGATCCTGTGATTCCCCTCGACCCCGCTGTGG GGGCCTTGACTGCCTGGGGCCAGCCATCCACATCGCCAACTGCTCCAGGAATGGGGCGTGGACCCCGTGGTCA TCGTGGGCGCTGTGCAGCACGTCCTGTGGCATCGGCTTCCAGGTCCGCCAGCGAGTTGAGCAACCCTGCTC CCCCCACGGGGGCCGCATCTGCGTGGGCAAGAGCCGGGAGGAACGGTTCTGTAATGAGAACACGCCTTGCCC GGTGCCCATCTTCTGGGCTTCCTGGCTCCTGGCAGGAGTGCAGCAGCAACTGTGGAGGGGCATGCAGTCG CGGCGTCGGGCCTGCGAGAACGGCAACTCCTGCCTGGGCTGCGGCGTGGAGTTCAAGACGTGCAACCCCGAGG GCTGCCCCGAAGTGCGGCGCAACACCCCCTGGACGCCGTGGCTGCCCGTGAACGTGACGCAGGGCGGGGCACG GCAGGAGCAGCGGTTCCGCTTCACCTGCCGCGCGCCCCTTGCAGACCCGACGGCCTGCAGTTCGGCAGGAGA AGGACCGAGACGAGGACCTGTCCCGCGGACGGCTCCGGCTCCTGCGACACCGACGCCCTGGTGGAGIIACCTCC TGCGCAGCGGGAGCACCTCCCCGCACACGGTGAGCGGGGGCTC.GGCCGCCTGGGGCCCGTGGTCGTCCTGCTC CCGGGACTGCGAGCTGGGCTTCCGCGTCCGCAAGAGAACGTGCACTAACCCGGAGCCCCGCAACGGGGGCCTG CCCTGCGTGGGCGATGCTGCCGAGTACCAGGACTGCAACCCCCAGGCTTGCCCAGTTCGGGGTGCTTGGTCCT GCTGGACCTCATGGTCTCCATGCTCAGCTTCCTGTGGTGGGGGTCACTATCACGCACCCGTTCCTGCACCAG CCCCGCACCCTCCCCAGGTGAGGACATCTGTCTCGGGCTGCACACGGAGCAGGCACTATGTGCCACACAGGCC TGCCCAGAAGGCTGGTCGCCCTGGTCTGAGTGGAGTAAGTGCACTGACGACGGAGCCCAGAGCCGAAGCCGGC ACTGTGAGGAGCTCCTCCCAGGGTCCAGCGCCTGTGCTGGAAACAGCAGCCAGAGCCGCCCCTGCCCCTACAG CGAGATTCCCGTCATCCTGCCAGCCTCCAGCATGAGGAGGCCACCGGCTGTGAGGGTTCATCTCATCC TTGGTGGCCACGGGCATCTCCTGCTTCTTGGGCTCTGGGCTCCTGACCCTAGCAGTGTACCTGTCTTGCCAGC ACTGCCAGCGTCAGTCCCAGGAGTCCACACTGGTCCATCCTGCCACCCCCAACCATTTGCACTACAGCGCGG ACCCCCAATAAATCCCCTGATCAACTACAATATGTCTA GACAGAGCCAACTTCTACCCATTGCAGCAGACCAATGTGTACACGACTACTTACTACCACCCCCTGAACA AACACAGCTTCCGGCCCGAOGCCTCACCTGGACAACGGTGCTTCCCCACAGCTGATACCGCCGTCCTGGGGA CTTGGGCTTCTTGCCTTCATAAGGCACAGAGCAGATGGAGATGGGACAGTGGAGCCAGTTTGGTTTTCTCCCT CTGCACTAGGCCAAGAACTTGCTGCCTTGCCTGTGGGGGGTCCCATCCGGCTTCAGAGAGCTCTGGCTGGr-T TCACCATGGGGGAAAlGGGCTGGTTTCAGGCTGACATATGGCCGCAGGTCCAGTTCAGCCCAGGTCTCTCATGG TTATCTTCCAACCCACTGTCACGCTGACACTATGCTGCCATGCCTGGGCTGTGGACCTACTGGGCATTTGAGG AATTGGAGAATGGAGATGGCAAGAGGGCAGGCTTTTAAGTTTGGTTGGAGACAACTTCCTGTGGCCCCCACA AGCTGAGTCTGGCCTTCTCCAGCTGGCCCCAAAAAGGCCTTTGCTACATCCTGATTATCTCTGAAGTAATC AATCAAGTGGCTCCAGTAGCTCTGGATTTTCTGCCAGGGCTGGGCCATTGTGGTGCTGCCCCAGTATGACATG GG.ACCAAGGCCAGCGCAGGTTATCC-ACCTCTGCCTGGAAGTCTATACTCTACCCAGGGCATCCCTCTGGTCAG AGGCAGTGAGTACTGGGAACTGGAGGCTGACCTGTGCTTAGAAGTCCTTTAATCTGG3GCTGGTACAGGCCTCA GCCTTGCCCTCAATGCACGAGGTGGCCCAGGAGAGAGGATCTGCCACGAGGCAGAATCTGGCCTCT GTGCCTCTATGGAGACTATCTTCCAGTTGCTGCTCAACAGAGTTGTTGGCTGAGACCTGCTTGGGAGTCTCTG CTGGCCCTTCATCTGTTCAGGAACACACACACACACACACTCAACACGCACACACATCACAATTTGCTACA GCAPACAAAAAAGACATTGGGCTGTGGCATTATTAATTAAAGATGATATCCAGTCTCC 122 WO 2004/000997 PCT/US2003/017512 NOV21, SNP13382456 of SEQ ID NO: 22 .1352aa MW at 145674.1kD CG106951-01, Protein Sequence I SNP Change: no change MPAGEGASAHRAGHHTRQARGGSRPSSRGMQGAPSRSSARLEAGGCSARRGRSAPAPSSFSLPLPSFSPFACN SSPTAPSLLLLPRSPPPCSLRAPGRELVGARGLVPEPSSAEPGGSAAHPAAAGSPSAAGAGPGGDCTGALRAG GRSCAAAPFPDRPPAHLVSSRRSAPPGSREPRGTGHLHPPLGVSGSSWCLACVSWMPCGFSPSPVAHHLVPGP PDTPAQQLRCGWTVGGWLLSLVRGLLPCLPPGARTAEGPIMVLAGPLAVSLLLPSLTLLVSHLSSSQDVSSEP SSEQQLCALSKHPTVAFEDLQPWVSNFTYPGARDFSQLALDPSGNQLIVGARNYLFRLSLANVSLLQATEWAS SEDTRRSCQSKGKTEEECQNYVRVLIVAGRKVFMCGTNAFSPMCTSRQVGNLSRTTEKINGVARCPYDPRHNS TAVISSQGELYAATVIDFSGRDPAIYRSLGSGPPLRTAQYNSKWLNEPNFVAAYDIGLFAYFFLRENAVEHDC GRTVYSRVARVCKNDVGGRFLLEDTWTTFMKARLNCSRPGEVPFYYNELQSAFHLPEQDLIYGVFTTNVNSIA ASAVCAFNLSAISQAFNGPFRYQENPRAAWLPIANPIPNFQCGTLPETGPNENLTERSLQDAQRLFLMSEAVQ PVTPEPCVTQDSVRFSHLVVDLVQAKDTLYHVLYIGTESGTILKALSTASRSLHGCYLEELHVLPPGRREPLR SLRILHSARALFVGLRDGVLRVPLERCAAYRSQGACLGARDPYCGWDGKQQRCSTLEDSSNMSLWTQNITACP VRNVTRDGGFGPWSPWQPCEHLDGDNSGSCLCRARSCDSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWAL CSTSCGIGFQVRQRSCSNPAPRHGGRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRA CENGNSCLGCGVEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRTET RTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRTCTNPEPRNGGLPCVG DAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTSPAPSPGEDICLGLHTEEALCATQACPEG WSPWSEWSKCTDDGAQSRSRHCEELLPGSSACAGNSSQSRPCPYSEIPVILPASSMEEATGCAGFNLIHLVAT GISCFLGSGLLTLAVYLSCQHCQRQSQESTLVHPATPNHLHYKGGGTPKNEKYTPMEFKTLNKNNLIPDDRAN FYPLQQTNVYTTTYYPSPLNKHSFRPEASPGQRCFPNS A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 2B. 5 Table 2B. Comparison of the NOV2 protein sequences. NOV2a MPAGEGASAHRAGHHTRQARGGSRPSSRGMQGAPSRSSARLEAGGCSARRGRSAPAPSSF NOV2b ------------------ --- - - - - - - - - - - - NOV2c

--------------------

NOV2d -----------------------.. . NOV2e ---------------------- - - - - - - - - - - - - - - - - - NOV2f ---------------------- N OV 2g - - - - - - - -- - - - - -- - - ---.. . . . . . . NOV2h ------------------------- - - - - - - - - - - - - - - - - NOV2a SLPLPSFSPFACNSSPTAPSLLLLPRSPPPCSLRAPGRELVGARGLVPEPSSAEPGGSAA NOV2b ---------------------.. . . . . NOV2c ----------- ---- -- - - - - - - - - - NOV 2d ---------------- ----.. . . . . . NOV2e ------------------------... NOV2f --------------------- NOV2g ----------------------- NOV2h ------------------------------- NOV2a HPAAAGSPSAAGAGPGGDCTGALRAGGRSCAAAPFPDRPPAHLVSSRRSAPPGSREPRGT NOV2b -------------------------- NOV2c -------------------------- - - - - - - - - - - NOV2d -------------------------.... NOV2e -------------------------- - - - - - - - - - - - - - - - NOV2f -------------------------.. . . NOV2g

-----------------------

NOV2h

------------------------

123 WO 2004/000997 PCT/US2003/017512 NOV2a GHLHPPLGVSGSSWCLACVSWMPCGFSPSPVAHHLVPGPPDTPAQQLRCGWTVGGWLLSL NOV2b ---------------------- MPCGFSPSPVAHHLVPGPPDTPAQQLRCGWTVGGWLLSL NOV2c . . . . . . - ---------------------- NOV2d ----------------------------- NOV2e -------------- -- ---.. . . . . . NOV2f ---------------------- --- - - - - - - - - - - - - - - - NOV2g ---------------------.. . . . . . NOV2h --------------------------------- NOV2a VRGLLPCLPPGARTAEGPIMVLAGPLAVSLLLPSLTLLVSHLSSSQDVSSEPSSEQQLCA NOV2b VRGLLPCLPPGARTAEGPIMVLAGPLAVSLLLPSLTLLVSHLSSSQDVSSEPSSEQQLCA NOV2c ----------------------------- NOV2d

--------------------------

NOV2e

-----------------------

NOV2f ---------------------- - --- - - - - - - NOV2g -------------------MVLAGPLAVSLLLPSLTLLVSHLSSSQDVSSEPSSEQQLCA NOV2h ------------------------------- NOV2a LSKHPTVAFEDLQPWVSNFTYPGARDFSQLALDPSGNQLIVGARNYLFRLSLANVSLLQA NOV2b LSKHPTVAFEDLQPWVSNFTYPGARDFSQLALDPSGNQLIVGARNYLFRLSLANVSLLQA NOV2c ------------------------------------------------- NOV2d

------------------

NOV2e ------------------------------------------------------------------ N O V 2 f - - - - - - - - - - - - - - - - - --.- -.. . . . . . . NOV2g LSKHPTVAFEDLQPWVSNFTYPGARDFSQLALDPSGNQLIVGARNYLFRLSLANVSLLQA NOV2h ----------------- -- - ------ - - - - - - - - NOV2a TEWASSEDTRRSCQSKGKTEEECQNYVRVLIVAGRKVFMCGTNAFSPMCTSRQVGNLSRT NOV2b TEWASSEDTRRSCQSKGKTEEECQNYVRVLIVAGRKVFMCGTNAFSPMCTSRQVGNLSRT NOV2c -----------

----

NOV2d ------------------------ - - - - - - - NOV2e --------------------.. . NOV2f ----------------------------- NOV2g TEWASSEDTRRSCQSKGKTEEECQNYVRVLIVAGRKVFMCGTNAFSPMCTSRQVGNLSRT NOV2h --------------------- - ------------- NOV2a TEKINGVARCPYDPRHNSTAVISSQGELYAATVIDFSGRDPAIYRSLGSGPPLRTAQYNS NOV2b TEKINGVARCPYDPRHNSTAVISSQGELYAATVIDFSGRDPAIYRSLGSGPPLRTAQYNS NOV2c ------------------------------ NOV2d ---------------

-----------

NOV2e ---------------------

----

NOV2f ---------- - ---- -- ----- ---- - - - - - - - NOV2g TEKINGVARCPYDPRHNSTAVISSQGELYAATVIDFSGRDPAIYRSLGSGPPLRTAQYNS NOV2h ----------

-------------------

NOV2a KWLNEPNFVAAYDIGLFAYFFLRENAVEHDCGRTVYSRVARVCKNDVGGRFLLEDTWTTF NOV2b KWLNEPNFVAAYDIGLFAYFFLRENAVEHDCGRTVYSRVARVCKNDVGGRFLLEDTWTTF NOV2c --------------------------- NOV2d ------------------------------

------

NOV2e -------------- ---------- - - -- - - - - - - - - - - - NOV2f ---------------------------- - - - - - - NOV2g KWLNEPNFVAAYDIGLFAYFFLRENAVEHDCGRTVYSRVARVCKNDVGGRFLLEDTWTTF NOV2h ----------------------------- ---- ---------- NOV2a MKARLNCSRPGEVPFYYNELQSAFHLPEQDLIYGVFTTNVNSIAASAVCAFNLSAISQAF NOV2b MKARLNCSRPGEVPFYYNELQSAFHLPEQDLIYGVFTTNVNSIAASAVCAFNLSAISQAF NOV2c ------------------------- --- - - - - - - - - - - - - - NOV2d -. ------------------------ ---- - - - - - - - - - - - - - NOV2e ---------------------------------- -- - - - - - - - - - 124 WO 2004/000997 PCT/US2003/017512 NOV2f ------------------ NOV2g MKARLNCSRPGEVPFYYINELQSAFHLPEQDLIYGVFTTNVNSIAASAVCAFNLSAISQAF NOV2h -------------------- NOV2a NGPFRYQENPRAAWLPIANPIPNFQCGTLPETGPNENLTERSLQDAQRLFLMSEAVQPVT NOV2b NGPFRYQENPRAAWLPIANPIPNFQCGTLPETGPNENLTERSLQDAQRLFLMSEAVQPV T NOV2c ---------------- NOV2d ------------------ - - - - - - - - - - - - - - - - - - - NOV2e ------------------ - - - - - - - - - - - - - - - - - - - NOV2f ---------------- NOV2g NGPFRYQENPRAAWLPIANPIPNFQCGTLPETGPNENLTERSLQDAQRLFLMSEAVQPVT NOV2h ---------------- NOV2a PEPCVTQDSVRFSHLVVDLVQAKDTLYHVLYIGTESGTILKALSTASRSLHGCYLEELHV NOV2b PEPCVTQDSVRFSHLVVDLVQAKDTLYHVLYIGTESGTILKALSTASRSLHGCYLEELHV NOV2c ------------------ - - - - - - - - - - - - - - - - - - - NOV2d ------------------- - - - - - - - - - - - - - - - - - - - NOV2e ---------------- NOV2f --.-.---- ------- - - - - - - - - - - - - - - - - NOV2g PEPCVTQDSVRFSHLVVDLVQAKDTLYHVLYIGTESGTILKALSTASRSLHGCYLEELHV NOV2h ------------------ NOV2a LPPGRREPLRSLRILHSARALFVGLRDGVLRVPLERCAAYRSQGACLGARDPYCGWDGKQ NOV2b LPPGRREPLRSLRILHSARALFVGLRDGVLRVPLERCAAYRSQGACLGARDPYCGWDGKQ NOV2c ----------------- - - - - - - - - - - - - - - - - - - - - NOV2d ---- ----------.. . . . . . . . . . . NOV2e ----------------- - - - - - - - - - - - - - - - - - - - - NOV2f ----------------- - - - - - - - - - - - - - - - - - - - - NOV2g LPPGRREPLRSLRILHSARALFVGLRDGVLRVPLERCAAYRSQGACLGARDPYCGWDGKQ NOV2h ---------------- NOV2a QRCSTLEDSSNMSLWTQNITACPVRNVTRDGGFGPWSPWQPCEHLDGDNSGSCLCRARSC NOV2b QRCSTLEDSSNMSLWTQNITACPVRNVTRDGGFGPWSPWQPCEHLDGDNSGSCLCRARSC NOV2c --------------------------------- GSGPWSPWQPCEHLDGDNSGSCLCRARSC NOV2d ---------------- -----------------GSGPWSPWQPCEHLDGDNSGSCLCRARSC NOV2e -- ------------------------------- GSGPWSPWQPCEHLDGDNSGSCLCRARSC NOV2f --------------------------------- GSGPWSPWQPCEHLDGDNSGSCLCRARSC NOV2g QRCSTLEDSSNMSLWTQNITACPVRNVTRDGGFGPWSPWQPCEHLDGDNSGSCLCRARSC NOV2h ----------------------------------- GPWSPWQPCEHLDGDNSGSCLCRARSC NOV2a DSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2b DSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2c DSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2d DSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2e DSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2f DSPRPRCGGLDCLGPTIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2g DSPRPRCGGLDCLGPAIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2h DSPRPRCGGLDCLGPTIHIANCSRNGAWTPWSSWALCSTSCGIGFQVRQRSCSNPAPRHG NOV2a GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRACENGNSCLGCG NOV2b GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRACENGNSCLGCG NOV2c GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMRSRRRACENGNSCLGCG NOV2d GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRACENGNSCLGCG NOV2e GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRACENGNSCLGCG NOV2f GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCGSNCGGGMQSRRRACENGNSCLGCG NOV2g GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCSSNCGGGMQSRRRACENGNSCLGCG NOV2h GRICVGKSREERFCNENTPCPVPIFWASWGSWSKCGSNCGGGMQSRRRACENGNSCLGCG NOV2a VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT 125 WO 2004/000997 PCT/US2003/017512 NOV2b VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT NOV2c VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT NOV2d VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT NOV2e VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT NOV2f VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT NOV2g VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT NOV2h VEFKTCNPEGCPEVRRNTPWTPWLPVNVTQGGARQEQRFRFTCRAPLADPHGLQFGRRRT NOV2a ETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2b ETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2c ETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2d ETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2e ETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2f ETRTCPADGSGSCDTDALVEVLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2g ETRTCPADGSGSCDTDALVEDLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2h ETRTCPADGSGSCDTDALVEVLLRSGSTSPHTVSGGWAAWGPWSSCSRDCELGFRVRKRT NOV2a CTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2b CTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2c CTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2d CTNPESRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2e CTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2f CTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2g CTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2h CTNPEPRNGGLPCVGDAAEYQDCNPQACPVRGAWSCWTSWSPCSASCGGGHYQRTRSCTS NOV2a PAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2b PAPSP- -------------------- EGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2c PAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2d PAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2e PAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2f PAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2g PAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2h PAPSPGEDICLGLHTEEALCATQACPEGWSPWSEWSKCTDDGAQSRSRHCEELLPGSSAC NOV2a AGNSSQSRPCPYSEIPVILPASSMEEATGCAGFNLIHLVATGISCFLGSGLLTLAVYLSC NOV2b AGNSSQSRPCPYSEIPVILPASSMEEATGCAGFNLIHLVATGISCFLGSGLLTLAVYLSC NOV2c AGNSSQSRPCVD----------------------------------------------- NOV2d AGNSSQSRPCVD------------------------------------------------- NOV2e AGNSSQSRPCVD----------------------------------------

--

NOV2f AGNSSQSRPCVD---------------------------------------------- NOV2g AGNSSQSRPCPYSEIPVILPASSMEEATGCAGFNLIHLVATGISCFLGSGLLTLAVYLSC NOV2h AGNSSQSRPC ------------------------------------------------- NOV2a QHCQRQSQESTLVHPATPNHLHYKGGGTPKNEKYTPMEFKTLNKNNLIPDDRANFYPLQQ NOV2b QHCQRQSQESTLVHPATPNHLHYKGGGTPKNEKYTPMEFKTLNKNNLIPDDRANFYPLQQ NOV2c ---------------------------------------------------------- NOV2d -------------------------------------------------- NOV2e --------------------------------------------------- NOV2f -----------------------------

------------

NOV2g QHCQRQSQESTLVHPATPNHLHYKGGGTPKNEKYTPMEFKTLNKNNLIPDDRANFYPLQQ NOV2h -------------------------------------------------- NOV2a TNVYTTTYYPSPLNKHSFRPEASPGQRCFPNS NOV2b TNVYTTTYYPSPLNKHSFRPEASPGQRCFPNS NOV2c ------------------------------- NOV2d ------------------------------- NOV2e ------------------------------- NOV2f ----------------------------- 126 WO 2004/000997 PCT/US2003/017512 NOV2g TNVYTTTYYPSPLNKHSFRPEASPGQRCFPNS NOV2h ------------------------------- NOV2a (SEQ ID NO: 6) NOV2b (SEQ ID NO: 8) NOV2c (SEQ ID NO: 10) NOV2d (SEQ ID NO: 12) NOV2e (SEQ ID NO: 14) NOV2f (SEQ ID NO: 16) NOV2g (SEQ ID NO: 18) NOV2h (SEQ ID NO: 20) Further analysis of the NOV2a protein yielded the following properties shown in Table 2C. Table 2C. Protein Sequence Properties NOV2a SignalP analysis: No Known Signal Sequence Predicted PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 11; pos.chg 1; neg.chg 1 H-region: length 5; peak value -8.91 PSG score: -13.31 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -7.65 possible cleavage site: between 53 and 54 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 3 Number of TMS(s) for threshold 0.5: 1 INTEGRAL Likelihood = -4.83 Transmembrane 259 - 275 PERIPHERAL Likelihood = 1.54 (at 232) ALOM score: -4.83 (number of TMSs: 1) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 266 Charge difference: -3.5 C(-2.5) - N( 1.0) N >= C: N-terminal side will be inside >>> membrane topology: type 2 (cytoplasmic tail 1 to 259) MITDISC: discrimination of mitochondrial targeting seq R content: 7 Hyd Moment(75): 4.89 Hyd Moment(95): 4.42 G content: 7 D/E content: 2 S/T content: 8 Score: -1.94 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 104 LRAIPG NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none 127 WO 2004/000997 PCT/US2003/017512 content of basic residues: 9.3% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2; 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: too long tail Dileucine motif in the tail: found LL at 81 LL at 82 LL at 83 LL at 237 checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 47.8 %: nuclear 26.1 %: mitochondrial 8.7 %: cytoplasmic 4.3 %: Golgi 4.3 %: plasma membrane 4.3 %: extracellular, including cell wall 4.3 %; peroxisomal >> prediction for CG106951-01 is nuc (k=23) A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D. 128 WO 2004/000997 PCT/US2003/017512 Table 2D. Geneseq Results for NOV2a NOV2a Identities/ Geneseq Protein/Organism/Length [Patent Residues/ Similarities for the Expect Identifier #, Date] Match Matched Region Value .eide Matched Region Residues AAE18212 Human MOL4 protein - Homo 1.1352 1352/1352 (100%) 0.0 sapiens, 1352 aa. 1..1352 1352/1352 (100%) [WO200206339-A2, 24-JAN-2002] AAG68293 Human semaphorin G-like NHP 202..1352 1150/1151 (99%) 0.0 protein SEQ ID NO:10 - Homo 1..1151 1150/1151 (99%) sapiens, 1151 aa. [WO200188133-A2, 22-NOV-2001] AAG68294 Human semaphorin G-like NHP 202..1352 1135/1151 (98%) 0.0 protein SEQ ID NO:12 -Homo 1..1136 1135/1151 (98%) sapiens, 1136 aa. [WO200188133-A2, 22-NOV-2001] AAG68290 Human semaphorin G-like NHP 260..1352 1092/1093 (99%) 0.0 protein SEQ ID NO:4 - Homo 1..1093 1092/1093 (99%) sapiens, 1093 aa. [WO200188133-A2, 22-NOV-2001] AAG68292 Human semaphorin G-like NHP 260..1352 1077/1093 (98%) 0.0 protein SEQ ID NO:8 - Homo 1..1078 1077/1093 (98%) sapiens, 1078 aa. [WO200188133-A2, 22-NOV-2001] In a BLAST search of public sequence databases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E. 5 129 WO 2004/000997 PCT/US2003/017512 Table 2E. Public BLASTP Results for NOV2a . NOV2a Protein NOV2a Identities/ Accession Protein/Organism/Length Residues/ Similarities for the Expect Number Match Matched Portion Value Residues Q9P283 Hypothetical protein KIAA1445 - 151..1352 1202/1202 (100%) 0.0 Homo sapiens (Human), 1202 aa 1..1202 1202/1202 (100%) (fragment). Q60519 Semaphorin 5B precursor 260..1352 1021/1093 (93%) 0.0 (Semaphorin G) (Sema G) - Mus 1..1093 1053/1093 (95%) musculus (Mouse), 1093 aa. Q13591 Semaphorin 5A precursor 299..1336 616/1043 (59%) 0.0 (Semaphorin F) (Sema F) - Homo 30..1071 781/1043 (74%) sapiens (Human), 1074 aa. Q62217 Semaphorin SA precursor 299..1336 617/1046 (58%) 0.0 (Semaphorin F) (Sema F) - Mus 30..1074 776/1046 (73%) musculus (Mouse), 1077 aa. Q8BXU8 Sema domain - Mus musculus 299..1109 507/811 (62%) 0.0 L ___(Mouse), 844 aa. 30..839 632/811 (77%) PFam analysis predicts that the NOV2a protein contains the domains shown in the Table 2F. 5 130 WO 2004/000997 PCT/US2003/017512 Table 2F. Domain Analysis of NOV2a Identities/ Pfam Domain NOV2a Match Region Similarities Expect Value for the Matched Region Sema 327..738 217/491 (44%) 7e-202 372/491 (76%) PSI 756..803 18/67 (27%) 2.5e-14 40/67(60%) tspl 869..920 23/54 (43%) 3.5e-12 38/54 (70%) tspl 927..971 17/53 (32%) 4.3e-06 31/53 (58%) tspl 1058..1108 24/53 (45%) 9.1e-11 34/53 (64%) tsp_l 1115..1165 23/53 (43%) 5.9e-08 35/53 (66%) tspl 1170..1210 17/53 (32%) 0.0034 27/53 (51%) _003 Example 3. The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are 5 shown in Table 3A. Table 3A. NOV3 Sequence Analysis NOV3a, CG121295-01 SEQ ID NO: 23 750 bp DNA Sequence ORF Start: ATG at 41 ORF Stop: TGA at 701 TTCAGTTTGAACGGGAGGTTTTTGATCCCTTTTTTTCAGAATGGATTATTTGCTCATGATTTTCTCTCTGCTG TTTGTGGCTTGCCAAGGAGCTCCAGAAACAGCAGTCTTAGGCGCTGAGCTCAGCGCGGTGGGTGAGAACGGCG GGGAGAAACCCACTCCCAGTCCACCCTGGCGGCTCCGCCGGTCCAAGCGCTGCTCCTGCTCGTCCCTGATGGA TAAAGAGTGTGTCTACTTCTGCCACCTGGACATCATTTGGGTCAACACTCCCGATTTCTTTCTCTCTTTGGAT AATAGGCACGTTGTTCCGTATGGACTTGGAAGCCCTAGGTCCAAGAGAGCCTTGGAGAATTTACTTCCCACAA AGGCAACAGACCGTGAGAATAGATGCCAATGTGCTAGCCAAAAAGACAAGAAGTGCTGGAATTTTTGCCAAGC AGGAAAAGAACTCAGGGCTGAAGACATTATGGAGAAAGACTGGAATAATCATAAGAAAGGAAAAGACTGTTCC AAGCTTGGGAAAAAGTGTATTTATCAGCAGTTAGTGAGAGGAAGAAAAATCAGAAGAAGTTCAGAGGAACACC TAAGACAAACCAGGTCGGAGACCATGAGAAACAGCGTCAAATCATCTTTTCATGATCCCAAGCTGAAAGGCAA GCCCTCCAGAGAGCGTTATGTGACCCACAACCGAGCACATTGGTGACAGACCTTCGGGGCCTGTCTGAAGCCA TAGCCTCCACGGAGAGCCCT 131 WO 2004/000997 PCT/US2003/017512 NOV3a, CG121295-01 SEQ IDNO: 24 220 aa MW at 25403.9kD Protein Sequence MDYLLMIFSLLFVACQGAPETAVLGAELSAVGENGGEKPTPSPPWRLRRSKRCSCSSLMDKECVYFCHLDIIW VNTPDFFLSLDNRHVVPYGLGSPRSKRALENLLPTKATDRENRCQCASQKDKKCWNFCQAGKELRAEDIMEKD WNNHKKGKDCSKLGKKCIYQQLVRGRKIRRSSEEHLRQTRSETMRNSVKSSFHDPKLKGKPSRERYVTHNRAH Further analysis of the NOV3a protein yielded the following properties shown in Table 3B. 5 Table 3B. Protein Sequence Properties NOV3a SignalP analysis: Cleavage site between residues 18 and 19 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 2; pos.chg 0; neg.chg 1 H-region: length 17; peak value 0.00 PSG score: -4.40 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): 1.68 possible cleavage site: between 17 and 18 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 0 PERIPHERAL Likelihood = 6.31 (at 67) ALOM score: -1.59 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 4.56 Hyd Moment(95): 7.21 G content: 1 D/E content: 2 S/T content: 1 Score: -7.31 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: none pat7: PPWRLRR (3) at 43 pat7: PWRLRRS (4) at 44 pat7: PRSKRAL (5) at 96 bipartite: KKCIYQQLVRGRKIRRS at 161 content of basic residues: 18.6% NLS Score: 1.05 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none 132 WO 2004/000997 PCT/US2003/017512 VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 69.6 %: nuclear 13.0 %: mitochondrial 8.7 %: extracellular, including cell wall 8.7 %: cytoplasmic >> prediction for CG121295-01 is nuc (k=23) A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3C. 133 133 WO 2004/000997 PCT/US2003/017512 Table 3C. Geneseq Results for NOV3a NOV3a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region ABU03518 Angiogenesis-associated human protein 1..220 211/220 (95%) e-125 sequence #63 - Homo sapiens, 212 aa. 1..212 212/220 (95%) [WO200279492-A2, 10-OCT-2002] , ABP65215 Hypoxia-regulated protein #89 - Homo 1..220 211/220 (95%) e-125 sapiens, 212 aa. [WO200246465-A2, 1..212 212/220 (95%) 13-JUN-2002] AAG64862 Heart muscle cell differentiation related 1..220 211/220 (95%) e-125 protein SEQ ID NO: 65 - Homo 1..212 212/220 (95%) sapiens, 212 aa. [WO200148151-A1, 05-JUL-2001] AAB99933 Human ET1 protein sequence SEQ ID 1..220 211/220(95%) e-125 NO:65 - Homo sapiens, 212 aa. 1..212 212/220 (95%) [WO200148150-A1, 05-JUL-2001] AAB00197 Preproendothelin-1 -Homo sapiens, 1..220 211/220 (95%) e-125 212 aa. [WO200055314-A2, 1..212 212/220 (95%) 21-SEP-2000] In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3D. 5 Table 3D. Public BLASTP Results for NOV3a NOV3a Protein NOV3a Identities/ Resiues/Expect Accession Protein/Organism/LengthMatch Residues/ Similarities for the Valuexpect Number Residues Matched Portion Residues P05305 Endothelin-1 precursor (ET-1) - 1..220 211/220 (95%) e-124 Homo sapiens (Human), 212 aa. 1..212 212/220 (95%) P17322 Endothelin-1 precursor (ET-1) - 1..219 148/220 (67%) 3e-80 Bos taurus (Bovine), 202 aa. 1..202 167/220 (75%) P09558 Endothelin-1 precursor (ET-1) - Sus 1L.219 145/221 (65%) 7e-78 scrofa (Pig), 203 aa. 1..203 168/221 (75%) P22387 Endothelin-1 precursor (ET-1) - 1..219 147/220 (66%) le-77 Mus musculus (Mouse), 202 aa. 1..202 165/220 (74%) Q9BG76 Preproendothelin-1 - Ovis aries 1..219 142/220 (64%) 9e-76 (Sheep), 202 aa. 1..202 164/220 (74%) 134 WO 2004/000997 PCT/US2003/017512 PFam analysis predicts that the NOV3a protein contains the domains shown in the Table 3E. Table 3E. Domain Analysis of NOV3a Identities/ PfamDomain NOV3a Match Region Similarities Expect Value for the Matched Region endothelin 48..78 26/31 (84%) 8.6e-20 31/31 (100%) 5 Example 4. The NOV4 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 4A. Table 4A. NOV4 Sequence Analysis NOV4a, CG124756-01 SEQ ID NO: 25 1076 bp DNA Sequence ORF Start: ATG at 75 ORF Stop: TGA at 834 GGCTCCTGGTCCCACTGCTGCTCAGCCCAGTGGCCTCACAGGACACCAGCTTCCCAGGAGGCGTCTGACACAG TATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATC TCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCC CCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGA GTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCT AAAGGTGGCCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAA TCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGTGAT CACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCCCGGTCTCTACTACTTC ACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGG TCACCTTCTGTGACTATGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGG GGAGAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCC GGGTTCCTGCTCTTTCCAGATATGGAGGCCTGACCTGTGGGCTGCTTCACATCCACCCCGGCTCCCCCTGCCA GCAACGCTCACTCTACCCCCAACACCACCCCTTGCCCAGCCAATGCACACAGTAGGGCTTGGTGAATGCTGCT GAGTGAATGAGTAAATAAACTCTTCAAGGCCAAGGOGAAAAAAAAA 10 NOV4a, CG124756-01 SEQ ID NO: 26 253 aa MW 26721.5kD P rotein S equ ence .... MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEKGLPGLAGDHGE FGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKIAFSATRTINVPLRRDQTIRFDHVI TNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQG ENVFLQATDKNSLLGMEGANSIFSGFLLFPDMEA 135 WO 2004/000997 PCT/US2003/017512 NOV4b, CG124756-02 SEQ IDNO: 27 816 bp DNA Sequence IORF Start: ATG at 48 IORF Stop: TGA at 807 GTGGTAACCTTCACATTGTCTTCTCCACAGGAGGCGTCTGACACAGTATGATGATGAAGATCCCATCGGGCAG CATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGG CCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGA TAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGAT TCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGGAGCC CCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTCTGCCACAAGAACCATCA ACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCC CCGCAGTGGCAAGTTCACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAAC CTGTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACA CCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCAGGCCACCGA CAAGAACTCACTACTGGGCATGGAGGGTGCCAACACCATCTTTTCCGGGTTCCTCCTCTTTCCAGATATGGAG GCCTGACCTGTGG NOV4b, CG124756-02 SEQ ID NO: 28 2aa 1W at 26721.5kD Protein Sequence MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEKGLPGLAGDHGE FGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKIAFSATRTINVPLRRDQTIRFDHVI TNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQG ENVFLQATDKNSLLGMEGANSIFSGFLLFPDMEA 5 NOV4c, SNP13382475 of SEQ IDNO: 29 1076 bp CG124756-01, DNA Sequence ORF Start: ATG at 75 ORF Stop: TGA at 834 SNP Pos: 302 SNP Change: G to T GGCTCCTGGTCCCACTGCTGCTCAGCCCAGTGGCCTCACAGGACACCAGCTTCCCAGGAGGCGTCTGACACAG TATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATC TCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCC CCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGA GTTCGGAGATAAGGGAGACCCAGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCT AAAGGTGGCCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAA TCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGTGAT CACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCCCGGTCTCTACTACTTC ACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGG TCACCTTCTGTGACTATGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGG GGAGAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCC GGGTTCCTGCTCTTTCCAGATATGGAGGCCTGACCTGTGGGCTGCTTCACATCCACCCCGGCTCCCCCTCCCA GCAACGCTCACTCTACCCCCAACACCACCCCTTGCCCAGCCAATGCACACAGTAGGGCTTGGTGAATGCTGCT GAGTGAATGAGTAAATAAACTCTTCAAGGCCAAGGG 136 WO 2004/000997 PCT/US2003/017512 NOV4c, SNP13382475 of kSEQ ID NO: 30 253 aa MW at 26707.5kD CG124756-01, Protein Sequence SNP Pos: 76 SNP Change: Glu to MMMKIPWGSPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEKGLPGLAGDHGE FGDKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKIAFSATRTINVPLRRDQTIRFDHVI TNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQG ENVFLQATDKNSLLGMEGANSIFSGFLLFPDMEA NOV4d, SNP13382476 of SEQ ID NO: 31 1076 bp CG124756-01, DNA Sequence ORF Start: ATG at 75 ORF Stop: TGA at 834 SNP Pos: 433 SNP Change: A to G GGCTCCTGGTCCCACTGCTGCTCAGCCCAGTGGCCTCACAGGACACCAGCTTCCCAGGAGGCGTCTGACACAG TATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGCCTAATCGATATC TCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCC CCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGA GTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCT AAAGGTGGCCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCGGAAAA TCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGTGAT CACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCCCGGTCTCTACTACTTC ACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGG TCACCTTCTGTGACTATGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGG GGAGAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCC GGGTTCCTGCTCTTTCCAGATATGGAGGCCTGACCTGTGGGCTGCTTCACATCCACCCCGGCTCCCCCTGCCA GCAACGCTCACTCTACCCCCAACACCACCCCTTGCCCAGCCAATGCACACAGTAGGGCTTGGTGAATGCTGCT GAGTGAATGAGTAAATAAACTCTTCAAGGCCAAGGGAAAAA 5 NOV4d, SNP13382476 of SEQ ID NO: 32 253 aa MW at 26749.6kD CG124756-01, Protein Sequence SNP Pos: 120 ISNP Change: Gln to Arg MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEKGLPGLAGDHGE FGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATRKIAFSATRTINVPLRRDQTIRFDHVI TNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQG ENVFLQATDKNSLLGMEGANSIFSGFLLFPDMEA A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 4B. 137 WO 2004/000997 PCT/US2003/017512 Table 4B. Comparison of the NOV4 protein sequences. NOV4a MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG NOV4b MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG NOV4a EKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ NOV4b EKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ NOV4a KIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL NOV4b KIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL NOV4a CVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS NOV4b CVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS NOV4a IFSGFLLFPDMEA NOV4b IFSGFLLFPDMEA NOV4a (SEQ ID NO: 26) NOV4b (SEQ ID NO: 28) Further analysis of the NOV4a protein yielded the following properties shown in Table 4C. 5 Table 4C. Protein Sequence Properties NOV4a SignalP analysis: Cleavage site between residues 28 and 29 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 4; pos.chg 1; neg.chg 0 H-region: length 18; peak value 11.91 PSG score: 7.51 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): 4.21 possible cleavage site: between 27 and 28 >>> Seems to have a cleavable signal peptide (1 to 27) ALOM: Klein et al's method for TM region allocation Init position for calculation: 28 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 2.60 (at 232) ALOM score: 2.60 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al-) Center position for calculation: 13 Charge difference: -3.0 C(-1.0) - N( 2.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 6.93 Hyd Moment(95): 5.45 G content: 2 D/E content: 1 S/T content: 1 Score: -5.61 138 WO 2004/000997 PCT/US2003/017512 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 9.5% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 76.7 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 22.2 %: extracellular, including cell wall 22.2 %: vacuolar 22.2 %: mitochondrial 22.2 %: endoplasmic reticulum 11.1 %: Golgi >> prediction for CG124756-01 is exc (k=9) 139 WO 2004/000997 PCT/US2003/017512 A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4D. Table 4D. Geneseq Results for NOV4a NOV4a Identities/ Geneseq Protein/Organism/Length IPatent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAM40607 Human polypeptide SEQ ID NO 5538 1..253 253/253 (100%) e-151 - Homo sapiens, 255 aa. 3..255 253/253 (100%) [WO200153312-A1, 26-JUL-2001] AAM38821 Human polypeptide SEQ IDNO 1966 l..253 253/253 (100%) e-151 - Homo sapiens, 253 aa. 1..253 253/253 (100%) [WO200153312-A1, 26-JUL-2001] ABB57231 Mouse ischaemic condition related 3..253 201/253 (79%) e-117 protein sequence SEQ ID NO:599 - 1..253 218/253 (85%) Mus musculus, 253 aa. [WO200188188-A2, 22-NOV-2001] AAU32411 Novel human secreted protein #2902 - 1..248 203/267 (76%) e-103 Homo sapiens, 309 aa. 3..269 212/267 (79%) [WO200179449-A2, 25-OCT-2001] AAU30709 Novel human secreted protein #1200 - 23..248 195/243 (80%) e-102 Homo sapiens, 287 aa. 2..244 199/243 (81%) [WO200179449-A2, 25-OCT-2001] 5 In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4E. 140 WO 2004/000997 PCT/US2003/017512 Table 4E. Public BLASTP Results for NOV4a NOV4a Protein Residues Identities/ Accession Protein/Organism/Length MatchResidue Similarities for the Expect Number Match Valurte frth xet NumberResidues Matched Portion Value C1HUQB complement subcomponent Clq 1..253 253/253 (100%) e-151 chain B precursor [validated] - 1..253 253/253 (100%) human, 253 aa. P02746 Complement Clq subcomponent, B 3..253 251/251 (100%) e-150 chain precursor - Homo sapiens 1..251 251/251 (100%) (Human), 251 aa. P14106 Complement Clq subcomponent, B 3..253 201/253 (79%) e-117 chain precursor - Mus musculus 1..253 219/253 (86%) (Mouse), 253 aa. 149560 complement Clq B chain precursor - 3..253 201/253 (79%) e-117 mouse, 253 aa. 1..253 218/253 (85%) P31721 Complement Clq subcomponent, B 3..252 197/252 (78%) e-115 chain precursor - Rattus norvegicus 1..252 217/252 (85%) (Rat), 253 aa. PFam analysis predicts that the NOV4a protein contains the domains shown in the Table 4F. 5 Table 4F. Domain Analysis of NOV4a Identities/ Pfam Domain NOV4a Match Region Similarities Expect Value for the Matched Region Collagen 51..110 35/60 (58%) 8.7e-09 45/60 (75%) Clq 123..247 69/138 (50%) 2.4e-72 124/138 (90%) Example 5. The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A. 10 141 WO 2004/000997 PCT/US2003/017512 Table 5A. NOV5 Sequence Analysis NOV5a, CG50353-01 ISEQ ID NO: 33 1628 bp DNA Sequence IORF Start: ATG at 1 ORF Stop: TGA at 1048 ATGAACCGGAAAGCGCGGCGCTCCCTGGGCCACCTCTTTCTCAGCCTGGGCATGGTCTGTCTCCTAGCATGTG GCTTCTCCTCAGTGGTAGCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCG GGCGATCTGCCAGAGCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGT CAGTTTCAGTTCCGCAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCA AAGTGGGGAGCCGGGACGGTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGC CTGTACCCATCGCAACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGC TGGAAGTGGGGTGGCTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTCGTGGACGCTCGGG AGATCATGAAGAACGCGCGGCGCCTCATGAACCTGCATAACAATGAGGCCGGCAGGAAGGTTCTAGAGGACCG GATGCAGCTGGAGTGCAAGTGCCACGGCGTGTCTGGCTCCTGCACCACCAAAACCTGCTGGACCACGCTGCCC AAGTTCCGAGAGGTGGGCCACCTGCTGAAGGAGAAGTACAACGCGGCCGTGCAGGTGGAGGTGGTGCGGGCCA GCCGTCTGCGGCAGCCCACCTTCCTGCGCATCAAACAGCTGCGCAGCTATCGCAAGCCCATGAAGACGGACCT GGTGTACATCGAGAAGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACGCAGGGCCGC GCCTGCAACAAGACGGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACC AGTACGCCCGCGTGTGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACCTGCAGCGA GCGCACGGAGATGTACACGTGCAAGTGAGCCCCGTGTGCACACCACCCTCCCGCTGCAAGTCAGATTGCTGGG AGGACTGGACCGTTTCCAAGCTGCGGGCTCCCTGGCAGGATGCTGAGCTTGTCTTTTCTGCTGAGGAGGGTAC TTTTCCTGGGTTTCCTGCAGGCATCCGTGGGGGAAAAAAAATCTCTCAGAGCCCTCAACTATTCTGTTCCACA CCCAATGCTGCTCCACCCTCCCCCAGACACAGCCCAGGTCCCTCCGCGGCTGGAGCGAAGCCTTCTGCAGCAG GAACTCTGGACCCCTGGGCCTCATCACAGCAATATTTAACAATTTATTCTGATAAAAATAATATTAATTTATT TAATTAAAAAGAATTCTTCCACCTCGTCGGGATCCGTTTTCTGCAATCAAAGTGGACTGCTTGCTTTCCTAGC AGGATGATTTTGTTGCTAGGACAAGGAGCCGTGTAGAAGTGTACATAACTATTCTTTATGCAGATATTTCTAC TAGCTGATTTTGCAGGTACCCACCTTGCAGCACTAGATGTTTAAGTACAAGAGGAGACATCTTTTATGCATAT ATAGATATACACACACGAAAAA NOV5a, CG50353-01 SEQ ID NO: 34 349 aa MW at 38980.7kD Protein Sequence MNRKARRCLGHLFLSLGMVCLLACGFSSVVALGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDEC QFQFRNGRWNCSALGERTVFGKELKVGSRDGAFTYAIIAAGVAHAITAACTHGNLSDCGCDKEKQGQYHRDEG WKWGGCSADIRYGIGFAXVFVDAREIMKNARRLMNLHNNEAGRKVLEDRMQLECKCHGVSGSCTTKTCWTTLP KFREVCHLLKEKYNAAVQVEVVRASRLRQPTFLRIKQLRSYRKPMKTDLVYIEKSPNYCEEDPVTGSVGTQGR ACNKTAPQASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK 5 NOV5b, 228753443 SEQ ID NO: 35 1966 bp DNA Sequence JORF Start: at JORF Stop: end of sequence AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGACCCGG GAGGCTGCATTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTGTACCCAGGGCA ACCTGAGCGACTGTGCCTGCGACAAAGAGAAGCAAGGCCACTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCCGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCGTGCCAGCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC GGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG 142 WO 2004/000997 PCT/US2003/017512 NOV5b, 228753443 SIllO:36 322aa JMH at 36054.9l1D Protein Sequence RSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSR EAAFTYAIIAAGVAHAITAACTQGNLSDCGCDEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQN ARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKR PTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARV WQCNCKFHIWCCYVKCNTCSERTEMYTCKLE NOV5c, 169475673 0SEQ:IDNO:37 1966bp DNA Sequence ORF Start: at 1 JORF Stop: end of sequence AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGG GAGGCTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTGTACCCAGGGCA ACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCGTGCCAGCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC GGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG 5 NOV5c, 169475673 SEQ ID NO: 38 322 aa MW at 36054.9kD Protein Sequence RSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSR EAAFTYAIIAAGVAHAITAACTGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQN ARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKR PTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARV WQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5d, 228753459 0SEQLDNO:39 966bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGG GAGGCTGCATTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTOTACCCAGGGCA ACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCCGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTACTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCGTGCCAGCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC GGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG 143 WO 2004/000997 PCT/US2003/017512 NOV5d,228753459 ]SEQ IDNO: 40 -322 aa tat 36054.9k]) Protein Sequence RSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSR EAAFTYAIIAAGVAHAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQN ARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKR PTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARV WQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5e, 228753462 JSEQ ID NO: 41 _ 966 bp DNA Sequence JORF Start: at 1 1ORF Stop: end of sequence AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGG GAGGCTGCATTCACCTACGCCATCATTGCCGCCGGCGTGGTCCACGCCATCACAGCTGCCTGTACCCAGGGCA ACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCCGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCGTGCCAGCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC GGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG 5 NOV5e, 228753462 SEQ ID NO: 42 (322 aa MW at 36083.0kD Protein Sequence RSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDCQFQFRNGRWNCSALGERTVFGKELKVGSR EAAFTYAIIAAGVVRAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQN ARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKR PTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNTAPQASGCDLMCCGRGYNTHQYARV WQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5f, 228753446 SEQ ID NO: 43 985 bp DNA Sequence ORF Start: at 2 lORF Stop: end of sequence ATCTGCAGAATTCGCCCTTAGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGA CAGCGGGCGATCTGCCAGAGCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACG AGTGTCAGTTTCAGTTCCGCAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGA GCTCAAAGTGGGGAGCCGGGAGGCTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACA GCTGCCTGTACCCAGGGCAACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACG AGGGCTGGAAGTGGGGTGGCTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGC CCGGGAGATCAAGCAGAATGCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAG GAGAACNIGAAGCTGGAATGTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACAC TGCCACAGTTTCGGGAGCTGGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCG TGCCAGCCGCAACAAGCGGCCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAACCCCATGGACACG GACCTGGTGTACATCGAGAAGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGG GCCGCGCCTGCAACAAGACGGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACAC CCACCAGTACGCCCGCGTGTGGCAGTGCAACTGTAAGTTCCACTGGTGCTACTATGTCAAGTGCAACACGTGC AGCGAGCGCACGGAGATGTACACGTGCAAGCTCGAG 144 WO 2004/000997 PCT/US2003/017512 NOV5f, 228753446 SEQ ID NO: 44 328 aa MW at 36733.6kD Protein Sequence SAEFALRSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKE LKVGSREAAFTYAIIAAGVAAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDA REIKQNARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVR ASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTGRACNKTAPQASGCDLMCCGRGYNT HQYARVWQCNCKFHWCYYVKCNTCSERTEMYTCKLE NOV5g, 228753465 SEQ ID NO: 45 966 bp DNA Sequence _ OR Start: at 1 ORE Stop: end of sequence AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGG GAGGCTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTGTACCCAGGGCA ACCTGAGCGACTGTGACTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCGTGCCAGCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC GGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGCCAGTACAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG NOV5g, 228753465 ISEQ ID NO: 46 322 aa MW at 36173.OkD Protein Sequence RSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSR EAAFTYAIIAAGVAHAITAACTQGNLSDCDCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQN ARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKR PTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARV WQYNCKFHWCCYVKCNTCSERTEMYTCKLE 5 NOV5h, 228753438 SEQ ID NO: 47 966 bp DNA Sequence ORF Start: at 1 OR Stop: end of sequence AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGG GAGGCTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTGTACCCAGGGCA ACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTCTGCGTGCCAGCCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGACCAACTGCTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC GGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG 145 WO 2004/000997 PCT/US2003/017512 NOV5h, 228753438 SEQ IDNO: 48 322 aa MW at 35998.9kD Protein Sequence RSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDCQFQFRNGRWNCSALGERTVFGKELKVGSR EAAFTYAIIAAGVAHAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQN ARTLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKR PTFLKIKKPLSYRKPMDTDLVYIEKSTNCCEEDPVTSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARV WQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5i, 228753449 SEQ ID NO: 49 966 bp DNA Sequence ORFStart: atI ORF Stop: end of sequence AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGG GAGGCTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTGTACCCAGGGCA ACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGGAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCGTGCCAGCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGACCAACTGCTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC CGCTCCCCAGGCCACCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG 5 NOV5i, 228753449 SEQ1)D NO: 50 322 aa 1MW at 35926.8kD Protein Sequence RSLGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSR EAAFTYAIIAAGVAHAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQN ARTLMNLHNNEAGRKILEENMKLGCKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKR PTFLKIKKPLSYRKPMDTDLVYIEKSTNCCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARV WQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5j, CG50353-02 SEQ ID NO: 51 966 bp DNA Sequence .ORF Start: at 7 ORF Stop: at 961 AGATCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGA GCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTCCG CAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAAGTGGGGAGCCGG GAGGCTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGCCTGTACCCAGGGCA ACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGCTGGAAGTGGGGTGG CTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTTGTGGATGCCCGGGAGATCAAGCAGAAT GCCCGGACTCTCATGAACTTGCACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAAT GTAAGTGCCACGGCGTGTCAGGCTCGTGCACCACCAAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCT GGGCTACGTGCTCAAGGACAAGTACAACGAGGCCGTTCACGTGGAGCCTGTGCGTGCCAGCCGCAACAAGCGG CCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACGGACCTGGTGTACATCGAGA AGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACCCAGGGCCGCGCCTGCAACAAGAC GGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACCAGTACGCCCGCGTG TGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGT ACACGTGCAAGCTCGAG 146 WO 2004/000997 PCT/US2003/017512 NOV5j, CG50353-02 SEQ ID NO: 52 318 aa MW at 35569.4kD Protein Sequence LGATVICNKIPGLAPRQRAICQSRPDATIVIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREA AFTYAIIAAGVAHAITAACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNAR TLMNLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEPVRASRNKRPT FLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQASGCDLMCCGRGYNTHQYARVWQ CNCKFHWCCYVKCNTCSERTEMYTCK NOV5k, CG50353-03 ISEQ ID NO: 53 1057 bp DNA Sequence _ ORF Start: ATG at 1 IORF Stop: TGA at 1048 ATGAACCGGAAAGCGCGGCGCTGCCTGGGCCACCTCTTTCTCAGCCTGGGCATGGTCTGTCTCCTAGCATGTG GCTTCTCCTCAGTGGTAGCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCG GGCGATCTGCCAGAGCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGT CAGTTTCAGTTCCGCAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCA AAGTGGGGAGCCGGGACGGTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGC CTGTACCCATGGCAACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGC TGGAAGTGGGGTGGCTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTCGTGGACGCTCGGG AGATCATGAAGAACGCGCGGCGCCTCATGAACCTGCATAACAATGAGGCCGGCAGGAAGGTTCTAGAGGACCG GATGCAGCTGGAGTGCAAGTGCCACGGCGTGTCTGGCTCCTGCACCACCAAAACCTGCTGGACCACGCTGCCC AAGTTCCGAGAGGTGGGCCACCTGCTGAAGGAGAAGTACAACGCGGCCGTGCAGGTGGAGGTGGTGCGGGCCA GCCGTCTGCGGCAGCCCACCTTCCTGCGCATCAAACAGCTGCGCAGCTATCGCAAGCCCATGAAGACGGACCT GGTGTACATCGAGAAGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACGCAGGGCCGC GCCTGCAACAAGACGGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACC AGTACGCCCGCGTGTGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGA GCGCACGGAGATGTACACGTGCAAGTGAGCCCCGT 5 NOV5k, CG50353-03 SEQ IDNO: 54 aa at 38980.7kD Protein Sequence MNRKARRCLGHLFLSLGMVCLLACGFSSVVALGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDEC QFQFRNGRWNCSALGERTVFGKELVGSRDGAFTYAIIAAGVAHAITAACTHGNLSDCGCDKEKQGQYHRDEG WKWGGCSADIRYGIGFAKVFVDAREIMKNARRLMNLHNNEAGRKVLEDRMQLECKCHGVSGSCTTKTCWTTLP KFREVGHLLKEKYNAAVQVEVVRASRLRQPTFLRIKQLRSYRKPMKTDLVYIEKSPNYCEEDPVTGSVGTQGR ACNKTAPQASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK 147 WO 2004/000997 PCT/US2003/017512 NOV51, SNP13382474 of SEQ ID NO: 55 1628bp CG50353-01, DNA Sequence OR Start: ATG at 1 ORF Stop: TGA at 1048 SNP Pos: 951 SNP Change: G to T ATGAACCGGAAAGCGCGGCGCTGCCTGGGCCACCTCTTTCTCAGCCTGGGCATGGTCTGTCTCCTAGCATGTG GCTTCTCCTCAGTGGTAGCTCTGGGCGCAACGGTCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCG GGCGATCTGCCAGAGCCGGCCCGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGT CAGTTTCAGTTCCGCAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCA AAGTGGGGAGCCGGGACGGTGCGTTCACCTACGCCATCATTGCCGCCGGCGTGGCCCACGCCATCACAGCTGC CTGTACCCATGGCAACCTGAGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAGTACCACCGGGACGAGGGC TGGAAGTGGGGTCGCTGCTCTGCCGACATCCGCTACGGCATCGGCTTCGCCAAGGTCTTCGTGGACGCTCGGG AGATCATGAAGAACGCGCGGCGCCTCATGAACCTGCATAACAATGAGGCCGGCAGGAAGGTTCTAGAGGACCG GATGCAGCTGGAGTGCAAGTGCCACGGCGTGTCTGGCTCCTGCACCACCAAAACCTGCTGGACCACGCTGCCC AAGTTCCGAGAGGTGGGCCACCTGCTGAAGGAGAAGTACAACGCGGCCGTGCAGGTGGAGGTGGTGCGGGCCA GCCGTCTGCGGCAGCCCACCTTCCTGCGCATCAAACAGCTGCGCAGCTATCGCAAGCCCATGAAGACGGACCT GGTGTACATCGAGAAGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTGGGCACGCAGGGCCGC GCCTGCAACAAGACGGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGCTGTGGGCGTGGCTACAACACCCACC ATTACGCCCGCGTGTGGCAGTGCAACTGTAAGTTCCACTGGTGCTGCTATGTCAAGTGCAACACGTGCAGCGA GCGCACGGAGATGTACACGTGCAAGTGAGCCCCGTGTGCACACCACCCTCCCGCTGCAAGTCAGATTGCTGGG AGGACTGGACCGTTTCCAAGCTGCGGGCTCCCTGGCAGGATGCTGAGCTTGTCTTTTCTGCTGAGGAGGGTAC TTTTCCTGGGTTTCCTGCAGGCATCCGTGGGGGAAAAAAAATCTCTCAGAGCCCTCAACTATTCTGTTCCACA CCCAATGCTGCTCCACCCTCCCCCAGACACAGCCCAGGTCCCTCCGCGGCTGGAGCGAAGCCTTCTGCAGCAG GAACTCTGGACCCCTGGGCCTCATCACAGCAATATTTAACAATTTATTCTGATAAAAATAATATTAATTTATT TAATTAAAAAGAATTCTTCCACCTCGTCGGGATCCGTTTTCTGCAATCAAAGTGGACTGCTTGCTTTCCTAGC AGGATGATTTTGTTGCTAGGACAAGGAGCCGTGTAGAAGTGTACATAACTATTCTTTATGCAGATATTTCTAC TAGCTGATTTTGCAGGTACCCACCTTGCAGCACTAGATGTTTAAGTACAAGAGGAGACATCTTTTATGCATAT ATAGATATACACACACGAAAAA NOV51, SNP13382474 of SEQ ID NO: 56 1349 aa JMW at 38989.7kD CG50353-01, Protein Sequence SPPos: 317 SNP Change: Gin to His MNRKARRCLGHLFLSLGMVCLLACGFSSVVALGATVICNKIPGLAPRQRAICQSRPDAIIVIGEGSQMGLDEC QFQFRNGRWNCSALGERTVFGKELKVGSRDGAFTYAIIAAGVAHAITAACTHGNLSDCGCDKEKQGQYHRDEG WKWGGCSADIRYGIGFAKVFVDAREIMKNARRLMNLHNNEAGRKVLEDRMQLECKCHGVSGSCTTKTCWTTLP KFREVGHLLKEKYNAAVQVEVVRASRLRQPTFLRIKQLRSYRKPMKTDLVYIEKSPNYCEEDPVTGSVGTQGR ACNKTAPQASGCDLMCCGRGYNTHHYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK 5 A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table SB. 148 WO 2004/000997 PCT/US2003/017512 Table 5B. Comparison of the NOV5 protein sequences. NOV5a MNRKARRCLGHLFLSLGMVCLLACGFSSVVALGATVICNKIPGLAPRQRAICQSRPDAII NOV5b ----------------------------- RSLGATVICNKIPGLAPRQRAICQSRPDAII NOV5c ----------------------------- RSLGATVICNKIPGLAPRQRAICQSRPDAII NOV5d ----------------------------- RSLGATVICNKIPGLAPRQRAICQSRPDAII NOVee ----------------------------- RSLGATVICNKIPGLAPRQRAICQSRPDATI NOV5f ----------------------- SAEFALRSLGATVICNKIPGLAPRQRAICQSRPDAII NOV5g ----------------------------- RSLGATVICNKIPGLAPRQRAICQSRPDAII NOV5h ----------------------------- RSLGATVICNKIPGLAPRQRAICQSRPDAII NOV5i ----7------------------------RSLGATVICNKIPGLAPRQRAICQSRPDAII NOV5j ------------------------------- LGATVICNKIPGLAPRQRAICQSRPDATI NOV5k MNRKARRCLGHLFLSLGMVCLLACGFSSVVALGATVICNKIPGLAPRQRAICQSRPDAII NOV5a VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSRDGATYAIIAAGVAHAIT NOV5b VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVAHAIT NOV5c VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGBREAAPTYAIIAAGVAHAIT NOV5d VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAPTYAIIAAGVAHAIT NOV5e VIGEGSQMGLDECQFQPRNGRWNCSALGERTVFGKELKYGSREAAPTYAIIAAGVVHAIT NOV5f VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVAHAIT NOV5g VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVRAAIT NOV5h VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFKELKVGSREFAATYAIIAAGVAHAIT NOV5i VIGEGSQMGLDECQFQFRNGRWNCSALGERYVFGKELKVGSREAAFTYAIIAAGVARAIT NOV5j VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSREAAFTYAIIAAGVAHAIT NOV5k VIGEGSQMGLDECQFQFRNGRWNCSALGERTVFGKELKVGSRDGAFTYAIIAAGVAHAIT NOV5a AACTHGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIMKNARRLM NOV5b AACTQGNLSDCGCDREKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV5c AACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV5d AACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV5e AACTQGNLSDCGCDREKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV5f AACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV~g AACTQGNLSDCDCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV5h AACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV5i AACTQGNLSDCGCDREKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLM NOV5j AACTQGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIKQNARTLN NOV5k AACTHGNLSDCGCDKEKQGQYHRDEGWKWGGCSADIRYGIGFAKVFVDAREIMKNARRLN NOV5a NLHNNEAGRKVLEDRMQLECKCHGVSGSCTTKTCWTTLPKFREVGHLLKEKYNAAVQVEV NOV5b NLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV c NLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5d NLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5e NLKNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5f NLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5g NLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5h NLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5i NLHNNEAGRKILEENMKLGCKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5j NLHNNEAGRKILEENMKLECKCHGVSGSCTTKTCWTTLPQFRELGYVLKDKYNEAVHVEP NOV5k NLHNNEAGRKVLEDRMQLECKCHGVSGSCTTKTCWTTLPKFREVGHLLKEKYNAAVQVEV NOV5a VRASRLRQPTFLRIKQLRSYRKPMKTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOV5b VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOV5c VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOV5d VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOVSe VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOV5f VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOVSg VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOVSh VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSTNCCEEDPVTGSVGTQGRACNKTAPQ 149 WO 2004/000997 PCT/US2003/017512 NOV5i VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSTNCCEEDPVTGSVGTQGRACNKTAPQ NOV5j VRASRNKRPTFLKIKKPLSYRKPMDTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOV5k VRASRLRQPTFLRIKQLRSYRKPMKTDLVYIEKSPNYCEEDPVTGSVGTQGRACNKTAPQ NOV5a ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK- NOV5b ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5c ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5d ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5e ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5f ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCYYVKCNTCSERTEMYTCKLE NOV5g ASGCDLMCCGRGYNTHQYARVWQYNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5h ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5i ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCKLE NOV5j ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK- NOV5k ASGCDLMCCGRGYNTHQYARVWQCNCKFHWCCYVKCNTCSERTEMYTCK- NOV5a (SEQ ID NO: 34) NOV5b (SEQ ID NO: 36) NOV5c (SEQ ID NO: 38) NOVSd (SEQ ID NO: 40) NOV5e (SEQ ID NO: 42) NOV5f (SEQ ID NO: 44) NOV5g (SEQ ID NO: 46) NOV5h (SEQ ID NO: 48) NOVSi (SEQ ID NO: 50) NOV5j (SEQ ID NO: 52) NOV5k (SEQ ID NO: 54) Further analysis of the NOV5a protein yielded the following properties shown in Table 5C. H-region: length 32; peak value 10.30 PSG score: 5.90 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -0.60 possible cleavage site: between 27 and 28 >>> Seems to have a cleavable signal peptide (1 to 27) ALOM: Klein et al's method for TM region allocation Init position for calculation: 28 Tentative number of TMS(s) for the threshold 0.5: 2 Number of TMS(s) for threshold 0.5: 0 PERIPHERAL Likelihood = 6.89 (at 151) ALOM score: 0.05 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 13 Charge difference: -2.5 C( 3.0) - N( 5.5) 150 WO 2004/000997 PCT/US2003/017512 N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 6 Hyd Moment(75): 11.39 Hyd Moment(95): 16.83 G content: 5 D/E content: 1 S/T content: 5 Score: 1.59 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at q5 SRPIDA NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 14.6% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: NRKA none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: found TLPK at 217 RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 55.5 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 65.2 %: mitochondrial 151 WO 2004/000997 PCT/US2003/017512 13.0 %: Golgi 8.7 %: extracellular, including cell wall 8.7 %: endoplasmic reticulum 4.3 %: cytoplasmic >> prediction for CG50353-01 is mit (k=23) A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5D. 5 Table 5D. Geneseq Results for NOV5a NOV5a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region ABJ10594 Human novel protein NOV5a SEQ ID 1..349 349/349 (100%) 0.0 NO: 16 - Homo sapiens, 349 aa. 1..349 349/349 (100%) [WO200259315-A2, 01-AUG-2002] AAY57598 Human Wnt-7a protein - Homo 1..349 321/349 (91%) 0.0 sapiens, 349 aa. [WO9957248-A1, 1.349 335/349 (95%) 11-NOV-1999] AAY70737 Human Wnt-7a protein - Homo 1.349 321/349 (91%) 0.0 sapiens, 349 aa. [WO200021555-A1, 1..349 335/349 (95%) 20-APR-2000] AAB19789 Human Wnt-7a protein involved in 1..349 321/349 (91%) 0.0 kidney tubulogenesis - Homo sapiens, 1..349 335/349 (95%) 349 aa. [WO200061630-A1, 19-OCT-2000] AAE34043 WNT-7A protein - Unidentified, 349 1..349 317/349 (90%) 0.0 aa. [WO200290992-A2, 1..349 333/349 (94%) 14-NOV-2002] In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5E. 152 WO 2004/000997 PCT/US2003/017512 Table 5E. Public BLASTP Results for NOV5a Protein NOV5a Identities/ Protein Residues/ Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion 000755 Wnt-7a protein precursor - Homo 1..349 321/349 (91%) 0.0 sapiens (Human), 349 aa. 1..349 335/349 (95%) Q96H90 Hypothetical protein - Homo sapiens 1..349 317/349 (90%) 0.0 (Human), 349 aa. 1..349 333/349 (94%) AAH49093 Hypothetical protein - Mus 1..349 315/349 (90%) 0.0 musculus (Mouse), 433 aa 85..433 332/349 (94%) (fragment). Q9DBY3 Wingless-related MMTV integration 1..349 315/349 (90%) 0.0 site 7A - Mus musculus (Mouse), 1..349 332/349 (94%) 349 aa. P24383 Wnt-7a protein precursor - Mus 1..349 313/349 (89%) 0.0 musculus (Mouse), 349 aa. 1..349 330/349 (93%) PFam analysis predicts that the NOV5a protein contains the domains shown in the Table SF. 5 Table 5F. Domain Analysis of NOV5a Identities/ Pfam Domain NOV5a Match Region Similarities Expect Value for the Matched Region wnt 37..349 180/352 (51%) 3.2e-212 298/352 (85%) Example 6. The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A. 10 153 WO 2004/000997 PCT/US2003/017512 Table 6A. NOV6 Sequence Analysis NOV6a, CG50709-03 SEQ ID NO: 57 993 bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence CTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGGCCC ACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGC TGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAAC TGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCT CTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTC TCCGGGGCTGGAGAGCCGACAGGCCTGGCAATGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTT CTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACG TGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGT GCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGGCT GTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCC TCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAG CAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGG GGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGT GCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCAC NOV6a, CG50709-03 SEQ IDNO: 58 331 aa MW at 36432.2kD Protein Sequence LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSA VKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGR GYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH 5 NOV6b, 282997951 SEQ ID NO: 59 928 bp DNA Sequence ORF Start: at 2 OR Stop end of sequence CACCGGATCCCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTG GCTGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGA ACTGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTC CTCTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGAC TCTCCGGGGCTGGAGAGCCGGCAGGCCTGGCAGTGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGT TTCTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCA CGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCC GTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGG CTGTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAG CCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCC AGCAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGC GGCGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGA GTGCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCTCGAGGGC 154 WO 2004/000997 PCT/US2003/017512 NOV6b, 282997951 SEQ ID NO: 60 1309 aa 1MW at 34226.6kD Protein Sequence TGSQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKETAFLYAVS SAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNFLGSKRGNKDLRARADAHNTH VGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSAVKVSSATNEALGRLELWAPARQGS LTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVE CQQCVQEELVYTCKLEG NOV6c, CG50709-05 SEQ ID NO: 61 1464 bp DNA Sequence ORF Start: ATG at 38 ORF Stop: TAG at 1109 GCGAGGAGATGCTAGAGGGCGCAGCGCCGCCAGCACCATGCGCCCCCCGCCCGCGCTGGCCCTGGCCGGGCTC TGCCTGCTGGCGCTGCCCGCCGCCGCCGCCTCCTACTTCGGCCTGACCGGCCGGGAAGTCCTGACGCCCTTCC CAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGGCCCACCTGAAGCAGTGTGACCTGCTGAAGCTGTC CCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGCTGAGACCCTGAGGGATGCTGCGCACCTCGGC CTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAACTGTAGCCTGGAGGGCAGGACGGGCCTGCTCA AGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCTCTGCCGCCCTCACCCACACCCTGGCCCGGGC CTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTCTCCGGGGCTGGAGAGCCGGCAGGCCTGGCAG TGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTTCTGAGCAACTTCCTGGGGTCCAAGAGAGGAA ACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAG GACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTC CGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGGCTGTCAAGGTGTCCAGTGCCACCAATGAGGCCT TGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGA CCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAGCAAGTACTCACCTGGCACAGCAGGTAGGGTG TGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGGGGCTATGACACCCAGAGCCGCCTGGTGGCCT TCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGTGCCAGCAATGTGTGCAGGAGGAGCTTGTGTA CACCTGCAAGCACTAGGCCTACTGCCCAGCAAGCCAGTCTGGCACTGCCAGGACCTCCTGTGGCACCCTTCAA GCTGCCCAGCCGGCCCTCTGGGCAGACTGTCATCACATGCATGCATAAACCGGCATGTGTGCCAATGCACACG AGTGTGCCACTCACCACCATTCCTTGGCCAGCCTTTTGCCTCCCTCGATACTCAACAAAGAGAAGCAAAGCCT CCTCCCTTAACCCAAGCATCCCCAACCTTGTTGAGGACTTGGAGAGGAGGGCAGAGTGAGAAAGACATGGAGG GAAATAAGGGAGACCAAGAGCACAGCAGGACTGAAATTTTGGACGGGAGAGAGGGGCTATTCCATCTTGCTTC CTGG 5 NOV6c, CG50709-05 SEQ ID NO: 62 357 aa MW at 38970.2kD Protein Sequence MRPPPALALAGLCLLALPAAAASYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPG LAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCD DSPGLESRQAWQWGVCGDNLKYSTKFLSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSC AVRTCWKQLSPFRETGQVLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCR PSKYSPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH 155 WO 2004/000997 PCT/US2003/017512 NOV6d, 277582109 ISEQ ID NO: 63 1093 bp DNA Sequence IORF Start: at 2 ORF Stop: end of sequence CACCGGATCCACCATGCGCCCCCCGCCCGCGCTGGCCCTGGCCGGGCTCTGCCTGCTGGCGCTGCCCGCCGCC GCCGCCTCCTACTTCGGCCTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCC CGGCACAGGGCGGGGCCCACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCG GAGGGAGCCCGGCCTGGCTGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTC CGGCATGAGCGCTGGAACTGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTT TCCTGTACGCGGTGTCCTCTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCG CTGCACCTGTGATGACTCTCCGGGGCTGGAGAGCCGGCAGGCCTGGCAGTGGGGCGTGTGCGGTGACAACCTC AAGTACAGCACCAAGTTTCTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAG ACGCCCACAATACCCACGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGT ATCAGGCTCCTGTGCCGTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAA CTGCGCTATGACTCGGCTGTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCC CTGCCAGGCAGGGCAGCCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACC CAGCTTCTGCCGGCCCAGCAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGC AGCCTGTGCTGCGGGCGGGGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGT GGTGCTGCTACGTGGAGTGCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCACCTCGAGGGC NOV6d, 277582109 SEQ ID NO: 64 364 aa MW at 39615.9kD Protein Sequence TGSTMRPPPALALAGLCLLALPAAAASYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCR REPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMER CTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGV SGSCAVRTCWKQLSPFRETGQVLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSP SFCRPSKYSPGTAGRVCSREASCSSLCCGRGYDTQSRVAFSCHCQVQWCCYVECQQCVQEELVYTCKHLEG 5 NOV6e, 277582117 SEQ ID NO: 65 1024 bp DNA Sequence ORF Start: at 2 ORF Stop: end of sequence AACCGGATCCTCCTACTTCGGCCTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCA GCCCCGGCACAGGGCGGGGCCCACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCT GCCGGAGGGAGCCCGGCCTGGCTGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCA GTTCCGGCATGAGCGCTGGAACTGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACA GCTTTCCTGTACGCGGTGTCCTCTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGG AGCGCTGCACCTGTGATGACTCTCCGGGGCTGGAGAGCCGGCAGCCCTGGCAGTGGGGCGTGTGCGGTGACAA CCTCAAGTACAGCACCAAGTTTCTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGG GCAGACGCCCACAATACCCACGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATG GCGTATCAGGCTCCTGTGCCGTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCT GAAACTGCGCTATGACTCGGCTGTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGG GCCCCTGCCAGGCAGGGCAGCCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACT CACCCAGCTTCTGCCGGCCCAGCAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTG CAGCAGCCTGTGCTGCGGGCGGGGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTG CAGTGGTGCTGCTACGTGGAGTGCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCACCTCGAGG GC 156 WO 2004/000997 PCT/US2003/017512 NOV6e, 277582117 SEQ ID NO: 66 341 aa MW at 37431.2kD Protein Sequence TGSSYFGLTGREVLTPFPGLGTAAAPAQGGARLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQ FRHERWNCSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDN LKYSTKFLSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVL KLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASC SSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKHLEG NO16f, C050709-01 SEQID NO: 67 1021 bp DNA Sequence R Start: at 3 ORF Stop: TAG at 996 TCCTGACCGGGCGGGAAGTCCTGACGCCCTTCCAGGATTGGCACTGCGGCAGCCCCGGCACAGGGCGGGGC CCACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTG GCTGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGA ACTGTAGCCTGGAGGGCAGGATGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTC CTCTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGAC TCTCCGGGGCTGGAGAGCCGGCAGGCCTGGCAGTGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGT TTCTGAGCAACTTCCTGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCA CGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCC GTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGG CTGTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAG CCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCC AGCAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGC GGGGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGA GTGCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCACTAGGCCTACTGCCCAGCAAGCCAGTC NOV6f, CG50709-01 ISEQ ID NO: 68 .331 aa MW at 36462.3kD Protein Sequence LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRMGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSA VKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGR GYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH 5 NOV6g, CG50709-02 ISEQ ID NO: 69 933bp DNA Sequence Start: ATG at 274 ORF Stop: TAG at 928 GGGGCCCACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCG GCCTGGCTGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCG CTGGAACTGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCG GTGTCCTCTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTG ATGACTCTCCGGGGCTGGAGAGCCGGCAGGCCTGGCAGTGGGGCGTGTGCGGTGACAACCTCAAGTACAGCAC CAAGTTTCTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAAT ACCCACGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCT GTGCCGTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGA CTCGGCTGTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAG GGCAGCCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCC GGCCCAGCAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTG CGGGCGGGGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTAC GTGGAGTGCCAGCAATGTGTGCAGGAGGAGCTGGTGTACACCTGCAAGCACTAGGCC 157 WO 2004/000997 PCT/US2003/017512 NOV6g, CG50709-02 SEQ ID NO: 70 218 aa MW at 24076.lkD Protein Sequence MERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKC HGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYME DSPSFCRPSKYSPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYCQQCVQEELVYTCKB NOV6h, CG50709-04 SEQ ID NO: 71 __ 849b DNA Sequence ORF Start: at 1 ORF Stop: end of sequence AAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGCTGAGA CCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAACTGTAG CCTGGAGGGCAGGATGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCTCTGCC GCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTCTCCGG GGCTGGAGAGCCGGCAGGCCTGGCAGTGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTTCTGAG CAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACGTGGGC ATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGTGCGCA CCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGCCAGGTGCTGAAACTGCGCTATGACTCGGCTGTCAA GGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCCTCACC AAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAGCAAGT ACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGGGGCTA TGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTG 5 NOV6h, CG50709-04 SEQ ID NO: 72 283 aa MW at 31272.4kD Protein Sequence KQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRMGLLKRGFKETAFLYAVSSA ALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNFLGSKRGNKDLRARADAHNTHVG IKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPPRETGQVLKLRYDSAVKVSSATNEALGRLELWAPARQGSLT KGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQV NOV6i, CG50709-06 SEQ ID NO: 73 1093bp DNA Sequence ORF Start: ATG at 14 ORF Stop: end of sequence CACCCGATCCACCATGCGCCCCCCGCCCGCGCTGGCCCTGGCCGGGCTCTGCCTGCTGGCGCTGCCCGCCGCC GCCGCCTCCTACTTCGGCCTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCC CGGCACAGGGCGGGGCCCACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCG GAGGGAGCCCGGCCTGGCTGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTC CGGCATGAGCGCTGGAACTGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTT TCCTGTACGCGGTGTCCTCTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCG CTGCACCTGTGATGACTCTCCGGGGCTGGAGAGCCGGCAGGCCTGGCAGTGGGGCGTGTGCGGTGACAACCTC AAGTACAGCACCAAGTTTCTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAG ACGCCCACAATACCCACGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGT ATCAGGCTCCTGTGCCGTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAA CTGCGCTATGACTCGGCTGTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCC CTGCCAGGCAGGGCAGCCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACC CAGCTTCTGCCGGCCCAGCAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGC AGCCTGTGCTGCGGGCGGGGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGT GGTGCTGCTACGTGGAGTGCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCACCTCGAGGGC 158 WO 2004/000997 PCT/US2003/017512 NOV6i, CG50709-06 SEQ ID NO: 74 1360 aa MW at 39269.6kD Protein Sequence MRPPPALALAGLCLLALPAAAASYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPG LAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCD DSPGLESRQAWQWGVCGDNLKYSTKFLSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSC AVRTCWKQLSPFRETGQVLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCR PSKYSPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCVQWCCYVECQQCVQEELVYTCKHLEG NOV6j, CG50709-07 ISEQ ID NO: 75 1024 bp DNA Sequence ORF Start: at 2 ORF Stop: end of sequence AACCGGATCCTCCTACTTCGGCCTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCA GCCCCGGCACAGGGCGGGGCCCACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCT GCCGGAGGGACCCCGGCCTGGCTGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCA GTTCCGGCATGAGCGCTGGAACTGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACA GCTTTCCTGTACGCGGTGTCCTCTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGG AGCGCTGCACCTGTGATGACTCTCCGGGGCTGGAGAGCCGGCAGGCCTGGCAGTGGGGCGTGTGCGGTGACAA CCTCAAGTACAGCACCAAGTTTCTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGG GCAGACGCCCACAATACCCACGTGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATG GCGTATCAGGCTCCTGTGCCGTGCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCT GAAACTGCGCTATGACTCGGCTGTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGG GCCCCTGCCAGGCAGGGCAGCCTCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACT CACCCAGCTTCTGCCGGCCCAGCAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTG CAGCAGCCTGTGCTGCGGGCGGGGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTG CAGTGGTGCTGCTACGTGGAGTGCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCACCTCGAGG GC 5 NOV6j, CG50709-07 SEQ ID NO: 76 341 aa MW at 37431.2kD Protein Sequence TGSSYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQ FRHERWNCSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDN LKYSTKFLSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVL KLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASC SSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKHLEG 159 WO 2004/000997 PCT/US2003/017512 NOVTk, SNP13381605 of -SEQID NO: 77 993 bp CG50709-03, DNA Sequence ORF Start: at 1 ORF Stop: end of sequence SNP Pos: 653 SNP Change: C to T CTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGCCC ACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGC TGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAAC TGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCT CTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTC TCCGGGGCTGGAGAGCCGACAGGCCTGGCAATGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTT CTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACG TGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGT GCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTTGGCT GTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCC TCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAG CAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGG GGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGT GCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCAC NOV6k, SNP13381605 of JSEQ ID NO: 78 331 aa .MW at 36458.3kD CG50709-03, Protein Sequence SNP Pos: 218 SNP Change Ser to Leu LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDLA VKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGR GYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH 5 NOV61, SNP13381606 of SEQ ID NO: 79 993 bp CG50709-03, DNA Sequence ORF Start: at 1 ORF Stop: end of sequence SNP Pos: 743 SNP Change: T to C CTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGGCCC ACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGC TGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAAC TGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCT CTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTC TCCGGGGCTGGAGAGCCGACAGGCCTGGCAATGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTT CTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACG TGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGT GCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGGCT GTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCC TCACCAAAGGCCCGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAG CAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGG GGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGT GCCAGCAATGTGTGCACGAGGAGCTTGTGTACACCTGCAAGCAC 160 WO 2004/000997 PCT/US2003/017512 NOV61, SNP13381606 of 1SEQ IDNO: 80 331 aa JMW at 36416.2kD CG50709-03, Protein Sequence SNP Pos: 248 SNP Change: Leu to Pro LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSA VKVSSATNEALGRLELWAPARQGSLTKGPAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGR GYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH NOV6m, SNP13378337 of SEQ ID NO: 81 993 bp CG50709-03, DNA Sequence ORF Start: at 1 ORF Stop: end of sequence SNP Pos: 764 SNP Change: T to C CTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGGCCC ACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGC TGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAAC TGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCT CTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTC TCCGGGGCTGGAGAGCCGACAGGCCTGGCAATGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTT CTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACG TGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGT GCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGGCT GTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCC TCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCCGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAG CAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGG GGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGT GCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCAC 5 NOV6m, SNP13378337 of SEQ ID NO: 82 331 aa MW at 36416.2kD CG50709-03, Protein Sequence SNP Pos: 255 SNP Change: Leu to Pro LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSA VKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDPVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGR GYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH 161 WO 2004/000997 PCT/US2003/017512 NOV6n, SNP13381607 of SEQ ID NO: 83 993bp CG50709-03, DNA Sequence jORF Start: at 1 ORF Stop: end of sequence SNP Pos: 799 SNP Change: C to T CTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGGCCC ACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGC TGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAAC TGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCT CTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTC TCCGGGGCTGGAGAGCCGACAGGCCTGGCAATGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTT CTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGCACGGGCAGACGCCCACAATACCCACG TGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGT GCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGGCT GTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCC TCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGTCCAG CAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGG GGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGT GCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCAC NOV6n, SNP13381607 of SEQ ID NO: 84 331 aa MW at 36422.2kD CG50709-03, Protein Sequence SNP Pos: 267 SNP Change: Pro to Ser LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSA VKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRSSKYSPGTAGRVCSREASCSSLCCGR GYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH 5 DNOV6o, SNP13378336 of SEQ ID NO: 85 993 bp CG50709-03, DNA Sequence ORF Start: at 1 ORF Stop: end of sequence SNP Pos: 881 ISNP Change: A to G CTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGGCCC ACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGC TGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGAAC TGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCT CTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTC TCCGGGGCTGGAGAGCCGACAGGCCTGGCAATGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTT CTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACG TGGGCATCAAGGCTGTGAAGAGTCGCCTCAGGACCACGTGTAACTCCCATGGCGTATCAGGCTCCTGTGCCGT GCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGGCT GTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCC TCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAG CAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGG GGCTGTGACACCCAGAGCCGCCTCGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGT GCCAGCAATGTGTGCAGGAGGAGCTTGTGTACACCTGCAAGCAC 162 WO 2004/000997 PCT/US2003/017512 NOV6o, SNP13378336 of ISEQ ID NO: 86 1331 aa MW at 36372.2kD CG50709-03, Protein Sequence ISNP Pos: 294 SNP Change: Tyr to Cys LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSA VKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGR GCDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCKH NOV6p, SNP13378335 of SEQ ID NO: 87 993 bp CG50709-03, DNA Sequence ORF Start: at 1 ORF Stop: end of sequence SNP Pos: 977 SNP Change: T to C CTGACCGGGCGGGAAGTCCTGACGCCCTTCCCAGGATTGGGCACTGCGGCAGCCCCGGCACAGGGCGGGGCCC ACCTGAAGCAGTGTGACCTGCTGAAGCTGTCCCGGCGGCAGAAGCAGCTCTGCCGGAGGGAGCCCGGCCTGGC TGAGACCCTGAGGGATGCTGCGCACCTCGGCCTGCTTGAGTGCCAGTTTCAGTTCCGGCATGAGCGCTGGAAC TGTAGCCTGGAGGGCAGGACGGGCCTGCTCAAGAGAGGCTTCAAAGAGACAGCTTTCCTGTACGCGGTGTCCT CTGCCGCCCTCACCCACACCCTGGCCCGGGCCTGCAGCGCTGGGCGCATGGAGCGCTGCACCTGTGATGACTC TCCGGGGCTGGAGAGCCGACAGGCCTGGCAATGGGGCGTGTGCGGTGACAACCTCAAGTACAGCACCAAGTTT CTGAGCAACTTCCTGGGGTCCAAGAGAGGAAACAAGGACCTGCGGGCACGGGCAGACGCCCACAATACCCACG TGGGCATCAAGGCTGTGAAGAGTGGCCTCAGGACCACGTGTAAGTGCCATGGCGTATCAGGCTCCTGTGCCGT GCGCACCTGCTGGAAGCAGCTCTCCCCGTTCCGTGAGACGGGCCAGGTGCTGAAACTGCGCTATGACTCGGCT GTCAAGGTGTCCAGTGCCACCAATGAGGCCTTGGGCCGCCTAGAGCTGTGGGCCCCTGCCAGGCAGGGCAGCC TCACCAAAGGCCTGGCCCCAAGGTCTGGGGACCTGGTGTACATGGAGGACTCACCCAGCTTCTGCCGGCCCAG CAAGTACTCACCTGGCACAGCAGGTAGGGTGTGCTCCCGGGAGGCCAGCTGCAGCAGCCTGTGCTGCGGGCGG GGCTATGACACCCAGAGCCGCCTGGTGGCCTTCTCCTGCCACTGCCAGGTGCAGTGGTGCTGCTACGTGGAGT GCCAGCAATGTGTGCAGGAGGAGCTTGCGTACACCTGCAAGCAC 5 NOV6p, SNP13378335 of SEQ ID NO: 88 331 aa MW at 36404.1kD CG50709-03, Protein Sequence SNP Pos: 326 S Val to Ala LTGREVLTPFPGLGTAAAPAQGGAHLKQCDLLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWN CSLEGRTGLLKRGFKETAFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKF LSNFLGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQVLKLRYDSA VKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKYSPGTAGRVCSREASCSSLCCGR GYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELAYTCKH A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 6B. Table 6B. Comparison of the NOV6 protein sequences. NOV6a --------------------------------LTGREVLTPFPGLGTAAAPAQGGAHLKQCD NOV6b ------------------------------------------------------- TGSQCD NOV6c ----MRPPPALALAGLCLLALPAAAASYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCD NOV6d TGSTMRPPPALALAGLCLLALPAAAASYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCD NOV6e ------------------------ TGSSYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCD NOV6f -------------------------------- LTGREVLTPFPGLGTAAAPAQGGAHLKQCD NOV6g ----------------------------------------------------------- NOV6h -------------------------------------------------------- KQCD NOV6i ----MRPPPALALAGLCLLALPAAAASYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCD 163 WO 2004/000997 PCT/US2003/017512 NOV6j -----------------------TGSSYFGLTGREVLTPFPGLGTAAAPAQGGAHLKQCD NOV6a LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKET NOV6b LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKET NOV6c LLKLSRRQKQLCRREPCLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKET NOVGd LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKET NOV6e LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKET NOV6f LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRMGLLKRGFKET NOV6g -------------------------------------------

--------

NOVGh LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRMGLLKRGFKET NOV6i LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGFKET NOV6j LLKLSRRQKQLCRREPGLAETLRDAAHLGLLECQFQFRHERWNCSLEGRTGLLKRGPKET NOV6a AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRAWQWGVCGDNLKYSTKFLSNF NOVGb AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOV6c AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOV6d AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOV6e AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOV~f AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOV6g ----------------------- MERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOVGh AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOVGi AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOVGj AFLYAVSSAALTHTLARACSAGRMERCTCDDSPGLESRQAWQWGVCGDNLKYSTKFLSNF NOV6a LGSKRGNKDLRARADAHNTHVGIKA3VKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6b LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6c LCSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6d LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6e LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6f LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6g LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6h LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6i LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6j LGSKRGNKDLRARADAHNTHVGIKAVKSGLRTTCKCHGVSGSCAVRTCWKQLSPFRETGQ NOV6a VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOV6b VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOV6c VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOV6d VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOV6e VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOV6f VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOV6g VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOVGh VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSPCRPSKY NOV6i VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOV~j VLKLRYDSAVKVSSATNEALGRLELWAPARQGSLTKGLAPRSGDLVYMEDSPSFCRPSKY NOVGa SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV6b SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV6c SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV6d SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV6e SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV~f SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV6g SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV6h SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQV-------------------- NOVGi SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOV6j SPGTAGRVCSREASCSSLCCGRGYDTQSRLVAFSCHCQVQWCCYVECQQCVQEELVYTCK NOVGa H-- NOVGb LEG 164 WO 2004/000997 PCT/US2003/017512 NOV6c H-- NOV6d HLEG NOV6e HLEG NOV6f H-- NOV6g H-- NOV6h

---

NOV6i HLEG NOV6j HLEG NOV6a (SEQ ID NO: 58) NOV6b (SEQ ID NO: 60) NOV6C (SEQ ID NO: 62) NOV6d (SEQ ID NO: 64) NOV6e (SEQ ID NO: 66) NOV6f (SEQ ID NO: 68) NOV6g (SEQ ID NO: 70) NOV6h (SEQ ID NO: 72) NOV6i (SEQ ID NO: 74) NOV6j (SEQ ID NO: 76) Further analysis of the NOV6a protein yielded the following properties shown in Table 6C. Table 6C. Protein Sequence Properties NOV6a SignalP analysis: No Known Signal Sequence Predicted PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 5; pos.chg 1; neg.chg 1 H-region: length 21; peak value 7.18 PSG score: 2.78 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -5.38 possible cleavage site: between 22 and 23 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 4.08 (at 90) ALOM score: 4.08 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 6 Charge difference: 3.5 C( 4.5) - N( 1.0) C > N: C-terminal side will be inside >>>Caution: Inconsistent mtop result with signal peptide MITDISC: discrimination of mitochondrial targeting seq R content: 1 Hyd Moment(75): 11.91 Hyd Moment(95): 8.21 G content: 5 D/E content: 2 S/T content: 3 Score: -6.56 165 WO 2004/000997 PCT/US2003/017512 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 53 CRRIEP NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 14.2% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: TGRE KKXX-like motif in the C-terminus: YTCK SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: found KLSRRQKQL at 33 VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 76.7 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 78.3 %: nuclear 13.0 %: mitochondrial 8.7 %: cytoplasmic >> prediction for CG50709-03 is nuc (k=23) 166 WO 2004/000997 PCT/US2003/017512 A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6D. Table 6D. Geneseq Results for NOV6a NOV6a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE17306 Human WNT15 protein, 1..331 330/331 (99%) 0.0 sbg389686WNT15a #2 -Homo 31..361 330/331 (99%) sapiens, 361 aa. [WO200198342-A1, 27-DEC-2001] AAE17305 Human WNT15 protein, 1..331 330/331 (99%) 0.0 sbg389686WNT15a #1 - Homo 17..347 330/331 (99%) sapiens, 704 aa. [WO200198342-A1, 27-DEC-2001] ABB77769 Amino acid sequence of human Wnt 1..331 330/331 (99%) 0.0 (Zwnt5) polypeptide variant - Homo 4..334 330/331 (99%) sapiens, 334 aa. [WO200231148-A2, 18-APR-2002] ABB77768 Amino acid sequence of human Wnt 1..331 330/331 (99%) 0.0 (Zwnt5) polypeptide - Homo sapiens, 31..361 330/331 (99%) 361 aa. [WO200231148-A2, 18-APR-2002] ABB83080 Wnt family related protein 2 - Homo 1..331 330/331 (99%) 0.0 sapiens, 363 aa. [WO200250278-A2, 33..363 330/331 (99%) 27-JUN-2002] 5 In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6E. 167 WO 2004/000997 PCT/US2003/017512 Table 6E. Public BLASTP Results for NOV6a Protein NOV6a Identities/ Accession Protein/Organism/Length Residues/ Similarities for the Expect Number Match Matched Portion Value Residues 014905 Wnt-9b protein precursor (Wnt-15) 1..331 331/331 (100%) 0.0 (Wnt-14b) - Homo sapiens (Human), 27..357 331/331 (100%) 357 aa. Q8C718 WNT14B - Mus musculus (Mouse), 1..330 310/330 (93%) 0;0 359 aa. 29..358 319/330 (95%) 035468 Wnt-9b protein precursor (Wnt-15) 1..330 310/330 (93%) 0.0 (Wnt-14b) - Mus musculus (Mouse), 29..358 319/330 (95%) 359 aa. 014904 Wnt-9a protein precursor (Wnt-14) - 1..330 209/335 (62%) e-124 Homo sapiens (Human), 365 aa. 33..364 255/335 (75%) QSR5M2 Wnt-9a protein precursor (Wnt-14) - 1..330 208/335 (62%) e-123 Mus musculus (Mouse), 365 aa. 33..364 255/335 (76%) PFam analysis predicts that the NOV6a protein contains the domains shown in the Table 6F. 5 Table 6F. Domain Analysis of NOV6a Identities/ Pfam Domain NOV6a Match Region Similarities Expect Value for the Matched Region wnt 28..330 132/354 (37%) 2.1e-104 234/354 (66%) Example 7. The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A. 10 168 WO 2004/000997 PCT/US2003/017512 Table 7A. NOV7 Sequence Analysis NOV7a, CG53054-02 jSEQ ID NO: 89 11128 bp DNA Sequence IORF Start: ATG at 31 1ORF Stop: TGA at 1102 TCCCGGCCCTCCGCGCCCTCTCGCGCGGCGATGGCCCCACTCGGATACTTCTTACTCCTCTGCAGCCTGAAGC AGGCTCTGGGCAGCTACCCGATCTGGTGGCTGACGGGCAGCGAGCCCCTGACCATCCTCCCGCTGACCCTGGA GCCAGAGGCGGCTGCCCAGGCGCACTACAAGGCCTGCGACCGGCTGAAGCTGGAGCGGAAGCAGCGGCGCATG TGCCGCCGGGACCCGGGCGTGGCAGAGACGCTGGTGGAGGCCGTGAGCATGAGTGCGCTCGAGTGCCAGTTCC AGTTCCGCTTTGAGCGCTGGAACTGCACGCTGGAGGGCCGCTACCGGGCCAGCCTGCTCAAGCGAGGTTTCAA GGAGACTGCCTTCCTCTATGCCATCTCCTCGGCTGGCCTGACGCACGCACTGGCCAAGGCGTGCAGCGCGGGC CGCATGGAGCGCTGTACCTGCGATGAGGCACCCGACCTGGAGAACCGTGAGGCCTGGCAGTGGGGGGCTGCG GAGACAACCTTAAGTACAGCAGCAAGTTCGTCAAGGAATTCCTGGGCAGACGGTCAAGCAAGGATCTGCGAGC CCGTGTGGACTTCCACAACAACCTCGTGGGTGTGAAGGTGATCAAGGCTGGGGTGGAGACCACCTGCAAGTGC CACGGCGTGTCAGGCTCATGCACGGTGCGGACCTGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGGGCAAGC ATCTGAAGCACAAGTATGAGACGGCACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCAGGTGC CATCTCCCCACCACGGGGCCGTGCCTCGGGGGCAGGTGGCAGCGACCCGCTGCCCCGCACTCCAGAGCTGGTG CACCTGGATGACTCGCCTAGCTTCTGCCTGGCTGGCCGCTTCTCCCCGGGCACCGCTGGCCGTAGGTGCCACC GTGAGAAGAACTGCGAGAGCATCTGCTGTGGCCGCGGCCATAACACACAGAGCCGGGTGGTGACAAGGCCCTG CCAGTGCCAGGTGCGTTGOTGCTGCTATGTGGAGTGCAGGCAGTGCACGCAGCGTGAGGAGGTCTACACCTGC AAGGGCTGAGTTCCCAGGCCCTGCCAGCCCTGC NOV7a, CG53054-02 SEQ ID NO: 90 357aa MWat 39756.lkD Protein Sequence MAPLGYFLLLCSLKQALGSYPIWWLTGSEPLTILPLTLEPEAAAQAHYKACDRLKLERKQRRMCRRDPGVAET LVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFKETAFLYAISSAGLTHALAKACSAGRMERCTCDEA PDLENREAWQWGGCGDNLKYSSKFVKEFLGRRSSKDLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVR TCWRQLAPFHEVGKHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFCL AGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREEVYTCKG 5 NOVh 170251039 SEQ IDNO:91 11029 bp DNA Sequence ORF Start: at 1 IORF Stop: end of sequence GGATCCAGCTACCCGATCTGGTGGCTGACGGGCAGCGAGCCCCTGACCATCCTCCCGCTCACCCTGGAGCCAG AGGCGGGCGCCCAGGCGCACTACAAGGCCTGCGACCGGCTGAAGCTGGAGCGGAAGCAGCGGCGCATGTGCCG CCGGGACCCGGGCGTGGTAGAGACGCTGGTGGAGGCCGTGAGCATGAGTGCGCTCGAGTGCCAGTTCCAGTTC CGCTTTGAGCGCTGGAACTGCACGCTGGAGGGCCGCTACCGGGCCAGCCTGCTCAAGCGAGGCTTCAAGGAGA CTGCCTTCCTCTATGCCATCTCCTCGGCTGGCCTGACGCACGCACTGGCCAAGGCGTGCAGCGCGGGCCGCAT GGAGCGCTGTACCTGCGATGAGGCACCCGACCTGGAGAACCGTGAGGCCTGGCAGTGGGGGGGCTGCGGAGAC AACCTTAAGTACAGCAGCAAGTTCGTCAAGGAATTCCTGGGCAGACGGTCAAGCAAGGATCTGCGAGCCCGTG TGGACTTCCACAACAACCTCGTGGGTGTGAAGGTGATCAAGGCTGGGGTGGAGACCACCTGCAAGTGCCACGG CGTGTCAGGCTCATGCACGGTGCGGACCTGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGGGCAAGCATCTG AAGCACAAGTATGAGACGGCACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCAGGTGCCATCT CCCCACCACGGGGCCGTGCCTCGGGGGCAGGTGGCAGCGACCCGCTGCCCCGCACTCCAGAGCTGGTGCACCT GGATCACTCGCCTAGCTTCTGCCTGGCTGGCCGCTTCTCCCCGGGCACCGCTGGCCGTAGGTGCCACCGTGAG AAGAACTGCGAGAGCATCTGCTGTGGCCGCGGCCATAACACACAGAGCCGGGTGGTGACAAGGCCCTGCCAGT GCCAGGTGCGTTGGTGCTGCTATGTGGAGTGCAGGCAGTGCACGCAGCGTGAGGAGGTCTACACCTGCAAGGG CGTCGAC 169 WO 2004/000997 PCT/US2003/017512 NOV7b, 170251039 SEQD NO:92 1343aa MPat382081kD Protein Sequence GSSYPIWLTGSEPLTILPLTLEPEAGAQAHYKACDRLKLERKQRRMCRRDPGVVETLVEAVSMSALECQFQF RFERWNCTLEGRYRASLLKRGFKETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGD NLKYSSKFVKEFLGRRSSKDLRARVDFHNNLVGVKVIKAGVETTCKCGVSGSCTVRTCWRQLAPFHEVGKHL KHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFCLAGRFSPGTAGRRCHRE KNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREEVYTCKGVD NOV7c, 170251076 SEQIDNO:93 1029 bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence GGATCCAGCTACCCGATCTGGTGGCTGACGGGCAGCGAGCCCCTGACCATCCTCCCGCTGACCCTGGAGCCAG AGGCGGCCGCCCAGGCGCACTACAAGGCCTGCGACCGGCTGAAGCTGGAGCGGAAGCAGCGGCGCATGTGCCG CCGGGACCCGGGCGTGGCAGAGACGCTGGTGGAGGCCGTGAGCATGAGTGCGCTCGAGTGCCAGTTCCAGTTC CGCTTTGAGCGCTGGAACTGCACGCTGGAGGGCCGCTACCGGGCCAGCCTGCTCAAGCGAGGCTTCAAGGAGA CTGCCTTCCTCTATGCCATCTCCTCGGCTGGCCTGACGCACGCACTGGCCAAGGCGTGCAGCGCGGGCCGCAT GGAGCGCTGTACCTGCGATGAGGCACCCGACCTGGAGAACCGTGAGGCCTGGCAGTGGGGGGGCTGCGGAGAC AACCTTAAGTACAGCAGCAAGTTCGTCAAGGAATTCCTGGCAGACGGTCAAGCAAGGATCTGCGAGCCCGTG TGGACTTCCACAACAACCTCGTGGGTGTGAAGGTGATCAAGGCTGGGGTGGAGACCACCTGCAAGTGCCACGG CGTGTCAGGCTCATGCACGGTGCGGACCTGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGCGCAAGCATCTG AAGCACAAGTATGAGACGGCACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCAGGTGCCATCT CCCCACCACGGGGCCGTGCCTCGGGGGCAGGTGGCAGCGACCCGCTGCCCCGCACTCCAGAGCTGGTGCACCT GGATGACTCGCCTAGCTTCTGCCTGGCTGGCCGCTTCTCCCCGGGCACCGCTGGCCGTAGGTGCCACCGTGAG AAGAACTGCGAGAGCATCTGCTGTGGCCGCGGCCATAACACACAGAGCCGGGTGGTGACAAGGCCCTGCCAGT GCCAGGTGCGTTGGTGCTGCTATGTGGAGTGCAGGCAGTGCACGCAGCGTGAGGAGGTCTACACCTGCAAGGG CGTCGAC 5 NOV7c, 170251076 Protein Sequence ISQID.NO:94 . IM~at3819 k GSSYPIWWLTGSEPLTILPLTLEPEAAAQAHYKACDRLKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQF RFERWNCTLEGRYRASLLKRGFKETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGD NLKYSSKFVKEFLGRRSSKDLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEVGKHL KHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFCLAGRFSPGTAGRRCHRE KNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRCTQREEVYTCKGVD 170 WO 2004/000997 PCT/US2003/017512 NOV7d, CG53054-01 SEQ ID NO: 95 11085 bp DNA Sequence Start: ATG at 13 :RF StopGA at 1078 TAGTGAGCCGAGATGGCACTACTATATTCCAGCTTGGGTGTGGTTGTGTGCACCTGTAGTCCTAGTTACTTTG GACTGACGGGCAGCGAGCCCCTGACCATCCTCCCGCTGACCCTGGAGCCAGAGGCGGCTGCCCAGGCGCACTA CAAGGCCTGCGACCGGCTGAAGCTGGAGCGGAAGCAGCGGCGCATGTGCCGCCGGGACCCGGGCGTGGCAGAG ACGCTGGTGGAGGCCGTGAGCATGAGTGCGCTCGAGTGCCAGTTCCAGTTCCGCTTTGAGCGCTGGAACTGCA CGCTGGAGGGCCGCTACCGGGCCAGCCTGCTCAAGCGAGGTTTCAAGGAGACTGCCTTCCTCTATGCCATCTC CTCGGCTGGCCTGACGCACGCACTGGCCAAGGCGTGCAGCGCGGGCCGCATGGAGCGCTGTACCTGCGATGAG GCACCCGACCTGGAGAACCGTGAGGGCTGGAAGTGGGGTGGCTGTAGCGAGGACATCGAGTTTGGTGGGATGG TGTCTCGGGAGTTCGCCGACGCCCGGGAGAACCGGCCAGATGCCCGCTCAGCCATGAACCGCCACAACAACGA GGCTGGGCGCCAGGTGATCAAGGCTGGGGTGGAGACCACCTGCAAGTGCCACGGCGTGTCAGGCTCATGCACG GTGCGGACCTGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGGGCAAGCATCTGAAGCACAAGTATGAGTCGG CACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCAGGTGCCATCTCCCCACCACGGGGCCGTGC CTCGGGGGCAGGTGGCAGCGACCCGCTGCCCCGCACTCCAGAGCTGGTGCACCTGGATGACTCGCCTAGCTTC TGCCTGGCTGGCCGCTTCTCCCCGGGCACCGCTGGCCGTAGGTGCCACCGTGAGAAGAACTGCGAGAGCATCT GCTGTGGCCGCGGCCATAACACACAGAGCCGGGTGGTGACAAGGCCCTGCCAGTGCCAGGTGCGTTGGTGCTG CTATGTGGAGTGCAGGCAGTGCACGCAGCGTGAGGAGGTCTACACCTGCAAGGGCTGAGTTCC NOV7d, CG53054-01 SEQ ID NO: 96 355 aa MW at 39194.lkD Protein Sequence a MALLYSSLGVVVCTCSPSYFGLTGSEPLTILPLTLEPEAAAQAYKACDRLKLERKQRRMCRRDPGVABTLVE AVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFKETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDL ENREGWKWGGCSEDIEFGGMVSREFADARENRPDARSAMNRHNNEAGRQVIKAGVETTCKCHGVSGSCTVRTC WRQLAPFHEVGKHLKHKYESALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFCLAG iRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREEVYTCKG 5 NOV7e, CG53054-03 SEQ ID NO: 97 1029 bp DNA Sequence ORF Start: at 7 ORF Stop: at 1024 GGATCCAGCTACCCGATCTGGTGGCTGACGGGCAGCGAGCCCCTGACCATCCTCCCGCTGACCCTGGAGCCAG AGGCGGCCGCCCAGGCGCACTACAAGGCCTGCGACCCGCTGAAGCTGGAGCGGAAGCAGCGGCGCATGTGCCG CCGGGACCCGGGCGTGGCAGAGACGCTGGTGGAGGCCGTGAGCATGAGTGCGCTCGAGTGCCAGTTCCAGTTC CGCTTTGAGCGCTGGAACTGCACGCTGGAGGGCCGCTACCGGGCCAGCCTGCTCAAGCGAGGCTTCAAGGAGA CTGCCTTCCTCTATGCCATCTCCTCGGCTGGCCTGACGCACGCACTGGCCAAGGCGTGCACCGCGGGCCGCAT GGAGCGCTGTACCTGCGATGAGGCACCCGACCTGGAGAACCGTGAGGCCTGGCAGTGGGGGGGCTGCGGAGAC AACCTTAAGTACAGCAGCAAGTTCGTCAAGGAATTCCTGGGCAGACGGTCAAGCAAGGATCTGCGAGCCCGTG TGGACTTCCACAACAACCTCGTGGGTGTGAAGGTGATCAAGGCTGGGGTGGAGACCACCTGCAAGTGCCACGG CGTGTCAGGCTCATGCACGGTGCGGACCTGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGGGCAAGCATCTG AAGCACAAGTATGAGACGGCACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCAGGTGCCATCT CCCCACCACGGGGCCGTGCCTCGGGGGCAGGTGGCAGCGACCCGCTGCCCCGCACTCCAGAGCTGGTGCACCT GGATGACTCGCCTAGCTTCTGCCTCGCTGGCCGCTTCTCCCCGGGCACCGCTGGCCGTAGGTGCCACCGTGAG AAGAACTGCGAGAGCATCTGCTGTGGCCGCGGCCATAACACACAGAGCCGGGTGGTGACAAGGCCCTGCCAGT GCCAGGTGCGTTGGTGCTGCTATGTGGAGTGCAGGCAGTGCACGCAGCGTGAGGAGGTCTACACCTGCAAGGG CGTCGAC 171 WO 2004/000997 PCT/US2003/017512 NOV7e, CG53054-03 SEQ ID NO: 98 339 aa MW at 37835.8kD Protein Sequence SYPIWWLTGSEPLTILPLTLEPEAAAQAHYKACDRLKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQFRF ERWNCTLEGRYRASLLKRGFKETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGDNL KYSSKFVKEFLGRRSSKDLRARVDFHNNEVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEVGKHLKH KYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFCLAGRFSPGTAGRRCHREKN CESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREEVYTCKG NOV7f, CG53054-04 ISEQ ID NO: 99 1631 bp DNA Sequence ORF Start: ATG at 12 ORF Stop: TGA at 1107 GGCGCGGCAAGATGCTGGATGGGTCCCCGCTGGCGCGCTGGCTGGCCGCGGCCTTCGGGCTGACGCTGCTGCT CGCCGCGCTGCGCCCTTCGGCCGCCTACTTCGGGCTGACGGGCAGCGAGCCCCTGACCATCCTCCCGCTGACC CTGGAGCCAGAGGCGGCCGCCCAGGCGCACTACAAGGCCTGCGACCGGCTGAAGCTGGAGCGGAAGCAGCCGC GCATGTGCCGCCGGGACCCGGGCGTGGCAGAGACGCTGGTGGAGGCCGTGAGCATGAGTGCGCTCGAGTGCCA GTTCCAGTTCCGCTTTGAGCGCTGGAACTGCACGCTGGAGGGCCGCTACCGGGCCAGCCTGCTCAAGCGAGGC TTCAAGGAGACTGCCTTCCTCTATGCCATCTCCTCGGCTGGCCTGACGCACGCACTGGCCAAGGCGTGCAGCG CGGGCCGCATGGAGCGCTGTACCTGCGATGAGGCACCCGACCTGGAGAACCGTGAGGCCTGGCAGTGGGGGGG CTGCGGAGACAACCTTAAGTACAGCAGCAAGTTCGTCAAGGAATTCCTGGGCAGACGGTCAAGCAAGGATCTG CGAGCCCGTGTGGACTTCCACAACAACCTCGTGGGTGTGAAGGTGATCAAGGCTGGGGTGGAGACCACCTGCA AGTGCCACGGCGTGTCAGGCTCATGCACGGTGCGGACCTGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGGG CAAGCATCTGAAGCACAAGTATGAGACGGCACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCA GGTGCCATCTCCCCACCACGGGGCCGTGCCTCGGGGGCAGGTGGCAGCGACCCGCTGCCCCGCACTCCAGAGC TGGTGCACCTGGATGACTCGCCTAGCTTCTGCCTGGCTGGCCGCTTCTCCCCGGGCACCGCTGGCCGTAGGTG CCACCGTGAGAAGAACTGCGAGAGCATCTGCTGTGGCCGCGGCCATAACACACAGAGCCGGGTGGTGACAAGG CCCTGCCAGTGCCAGGTGCGTTGGTGCTGCTATGTGGAGTGCAGGCAGTGCACGCAGCGTGAGGAGOTCTACA CCTGCAAGGGCTGAGTTCCCAGGCCCTGCCAGCCCTGCTGCACAGGGTGCAGGCATTGCACACGGTGTGAAGG GTCTACACCTGCACAGGCTGAGTTCCTGGGCTCGACCAGCCCAGCTGCGTGCGGTACAGGCATTGCACACAGT GTGAATGGGTCTACACCTGCATGGGCTGAGTCCCTGGGCTCAGACCTAGCAGCGTGGGGTAGTCCCTGGGCTC AGTCCTAGCTGCATGGGGTGCAGGCATTGCACAGAGCATGAATGGGCCTACACCTGCCAAGGCTGAATCCCTG GGCCCAGCCAGCCCTGCTGCACATGGCACAGGCATTGCACACGGTGTGAGGAGTGTACACCTGCAAGGCTGA GGCCCTGGGCCCAGTCAGCCCTGCTGCTCAGAGTGCAGGCATTGCACATGGTGTGAGAAGGTCTACACCTGCA AGGGACGAGTCCCCGGGCCTGGCCAACCCTGCTGTGCAGGGTGAGGGCCATGCATGCTAGTATGAGGGGTCTA CACCTGCAAGGACTGAGAGGCTTTT 5 NOV7f, CG53054-04 SEQ ID NO: 100 365 aa MWat 40319.7kD Protein Sequence MLDGSPLARWLAAAFGLTLLLAALRPSAAYFGLTGSEPLTILPLTLEPEAAAQARYKACDRLKLERKQRRMCR RDPGVAETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFKETAFLYAISSAGLTHALAKACSAGRM ERCTCDEAPDLENREAWQWGGCGDNLKYSSKFVKEFLGRRSSKDLRARVDFHNNLVGVKVIKAGVETTCKCHG VSGSCTVRTCWRQLAPFHEVGKHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHL DDSPSFCLAGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREEVYTCKG A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 7B. 172 WO 2004/000997 PCT/US2003/017512 Table 7B. Comparison of the NOV7 protein sequences. NOV7a -------- MAPLGYFLLLCSLKQALGSYPIWWLTGSEPLTILPLTLEPEAAAQAHYKACD NOV7b ------------------------ GSSYPIWWLTGSEPLTILPLTLEPEAGAQAHYKACD NOV7c ------------------------ GSSYPIWWLTGSEPLTILPLTLEPEAAAQAHYKACD NOV7d ----------- MALLYSSLGVVVCTCSPSYFGLTGSEPLTILPLTLEPEAAAQAHYKACD NOV7e -------------------------- SYPIWWLTGSEPLTILPLTLEPEAAAQAHYKACD NOV7f MLDGSPLARWLAAAFGLTLLLAALRPSAAYFGLTGSEPLTILPLTLEPEAAAQAHYKACD NOV7a RLKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFK NOV7b RLKLERKQRRMCRRDPGVVETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFK NOV7c RLKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFK NOV7d RLKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFK NOV7e RLKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFK NOV7f RLKLERKQRRMCRRDPGVAETLVEAVSMSALECQFQFRFERWNCTLEGRYRASLLKRGFK NOV7a ETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGDNLKYSSKFVK NOV7b ETAFLYAISSAGLTRALAKACSAGRMERCTCDEAPDLENREAWQWGGCGDNLKYSSKFVK NOV7c ETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGDNLKYSSKFVK NOV7d ETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREGWKWGGCSEDIEFGGMVSR NOV7e ETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGDNLKYSSKFVK NOV7f ETAFLYAISSAGLTHALAKACSAGRMERCTCDEAPDLENREAWQWGGCGDNLKYSSKFVK NOV7a EFLGRRSSK-DLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEV NOV7b EFLGRRSSK-DLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEV NOV7c EFLGRRSSK-DLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEV NOV7d EFADARENRPDARSAMNRHNNEAGRQVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEV NOV7e EFLGRRSSK-DLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEV NOV7f EFLGRRSSK-DLRARVDFHNNLVGVKVIKAGVETTCKCHGVSGSCTVRTCWRQLAPFHEV NOV7a GKHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFC NOV7b GKHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFC NOV7c GKHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFC NOV7d GKHLKHKYESALKVGSTTNEAACEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFC NOV7e GKHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFC NOV7f GKHLKHKYETALKVGSTTNEAAGEAGAISPPRGRASGAGGSDPLPRTPELVHLDDSPSFC NOV7a LAGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREE NOV7b LAGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREE NOV7c LAGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCOCQVRWCCYVECRQCTQREE NOV7d LAGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREE NOV7e LAGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREE NOV7f LAGRFSPGTAGRRCHREKNCESICCGRGHNTQSRVVTRPCQCQVRWCCYVECRQCTQREE NOV7a VYTCKG- NOV7b VYTCKGVD NOV7c VYTCKGVD NOV7d VYTCKG- NOV7e VYTCKG- NOV7f VYTCKG- NOV7a (SEQ ID NO: 90) NOV7b (SEQ ID NO: 92) NOV7c (SEQ ID NO: 94) NOV7d (SEQ ID NO: 96) NOV7e (SEQ ID NO: 98) NOV7f (SEQ ID NO: 100) 173 WO 2004/000997 PCT/US2003/017512 Further analysis of the NOV7a protein yielded the following properties shown in Table 7C. Table 7C. Protein Sequence Properties NOV7a SignaP analysis: Cleavage site between residues 19 and 20 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 0; pos.chg 0; neg.chg 0 H-region: length 13; peak value 9.00 PSG score: 4.60 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): 0.73 possible cleavage site: between 18 and 19 >>> Seems to have a cleavable signal peptide (1 to 18) ALOM: Klein et al's method for TM region allocation Init position for calculation: 19 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 3.76 (at 114) ALOM score: 3.76 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 9 Charge difference: 0.0 C( 1.0) - N( 1.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 1.56 Hyd Moment(95): 3.50 G content: 3 D/E content: 1 S/T content: 4 Score: -6.15 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 14.8% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: KKXX-like motif in the C-terminus: YTCK SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none 174 WO 2004/000997 PCT/US2003/017512 type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 70.6 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 55.6 %: extracellular, including cell wall 22.2 %: mitochondrial 11.1 %: vacuolar 11.1 %: nuclear >> prediction for CG53054-02 is exc (k=9) A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7D. 5 175 WO 2004/000997 PCT/US2003/017512 Table 7D. Geneseq Results for NOV7a NOV7a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE34048 WNT-14 protein - Unidentified, 365 2..357 339/356 (95%) 0.0 aa. [WO200290992-A2, 13..365 343/356 (96%) 14-NOV-2002] ABU55894 Human WNT-14 protein - Homo 2..357 339/356 (95%) 0.0 sapiens, 365 aa. [WO200277204-A2, 13..365 343/356 (96%) 03-OCT-2002] ABG69638 Human secreted protein SCEP-18 - 2..357 311/357 (87%) 0.0 Homo sapiens, 366 aa. 13..366 327/357 (91%) [WO200248337-A2, 20-JUN-2002] AAO18744 HumanNOV8 protein - Homo sapiens, 25..357 302/334 (90%) 0.0 355 aa. [WO200257450-A2, 22..355 316/334 (94%) 25-JUL-2002] AAE17305 Human WNT15 protein, 22..356 210/338 (62%) e-124 sbg389686WNT15a #1 - Homo 14..346 257/338 (75%) sapiens, 704 aa. [WO200198342-A1, 27-DEC-2001] In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7E. 5 Table 7E. Public BLASTP Results for NOV7a Protein NOV7a Identities/ Protein Residues/ Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion 014904 Wnt-9a protein precursor (Wnt-14) - 2..357 339/356 (95%) 0.0 Homo sapiens (Human), 365 aa. 13..365 343/356 (96%) Q8R5M2 Wnt-9a protein precursor (Wnt-14) - 2..357 333/356 (93%) 0.0 Mus musculus (Mouse), 365 aa. 13..365 340/356 (94%) 042280 Wnt-9a protein precursor (Wnt-14) - 25..356 283/333 (84%) e-173 Gallus gallus (Chicken), 354 aa. 24..353 310/333 (92%) Q8C718 WNT14B - Mus musculus (Mouse), 8..356 216/354 (61%) e-125 359 aa. 12..358 264/354 (74%) .. 035468 Wnt-9b protein precursor (Wnt-15) 8..356 216/354 (61%) e-125 (Wnt-14b) - Mus musculus (Mouse), 12..358 264/354 (74%) 359 aa. 176 WO 2004/000997 PCT/US2003/017512 PFam analysis predicts that the NOV7a protein contains the domains shown in the Table 7F. Table 7F. Domain Analysis of NOV7a Identities/ Pfam Domain NOV7a Match Region Similarities Expect Value for the Matched Region wnt 50..356 129/359 (36%) 4.6e-103 234/359 (65%) 5 Example 8. The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A. Table 8A. NOV8 Sequence Analysis NOV8a, CG53473-02 SEQ ID NO: 101 514 bp DNA Sequence .ORF Start: ATG at 37 ORF Stop: TGA at 400 CGCGCGCCCGAACGAAGCCGCGGCCCGGGCACAGCCATGGCCCGGCGGGCGGGGGGCGCTCGGATGTTCGGCA GCCTCCTGCTCTTCGCCCTGCTCGCTGCCGGCGTCGCCCCGCTCAGCTGGGATCTCCCGGAGCCCCGCAGCCG AGCCAGCAAGATCCGAGTGCACTCGCGAGGCAACCTCTGGGCCACCGGTCACTTCATGGGCAAGAAGAGTCTG GAGCCTTCCAGCCCATCCCCATTGGGGACAGCTCCCCACACCTCCCTGAGGGACCAGCGACTGCAGCTGAGTC ATGATCTGCTCGGAATCCTCCTGCTAAAGAAGGCTCTGGGCGTGAGCCTCAGCCGCCCCGCACCCCAAATCCA GTACAGGAGGCTGCTGGTACAAATACTGCAGAAATGACACCAATAATGGGGCAGACACAACAGCGTGGCTTAG ATTGTGCCCACCCAGGGAAGGTGCTGAATGGGACCCTGTTGATGGCCATCAACAGGGTCCCATTCAGCACAGG CTG 10 OV8a, CG53473-02 SEQ ID NO: 102 121 aa MW at 13251.4kD Protein Sequence MARRAGGARMFGSLLLFALLAAGVAPLSWDLPEPRSRASKIRVHSRGNLWATGHFMGKKSLEPSSPSPLGTAP HTSLRDQRLQLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQK NOV8b, CG53473-01 SEQ IDNO- 103 646 bp DNA Sequence ORF Start: ATG at 62 ORF Stop: TGA at 398 AGCGCCCGAACGAAGCCGCGGCCCGGGCACAGCATGGCCCGCGGCGGGAGGGCGCTCGGATGTTCGGCAGC CTCCTGCACTTCGCCCTGCTCGCTGCCGGCGTCGTCCCGCTCAGCTGGGATCTCCCGGAGCCCCGCAGCCGAG CCAGCAAGATCCGAGTGCACTCGCGAGGCAAGCTCTGGGCCATCGGTCACTTCATGGGCAAGAAGAGTCTGGA GCCTTCCAGCCCATCCCCATTGGGGACAGCTCCCCACACCTCCCTGAGGGACCAGCGACTGCAGCTGAGTCAT GATCTGCTCGGAATCCTCCTGCTAAAGAAGGCTCTGGGCGTGAGCCTCAGCCGCCCCGCACCCCAAATCCAGT ACAGGAGGCTGCTGGTACAAATACTGCAGAAATGACACCAATAATGGGGCAGACACAACAGCGTGGCTTAGAT TGTGCCCACCCAGGGAAGGTGCTGAATGGGACCCTGTTGATGGCCCCATCTGGATGTAAATCCTGAGCTCAAA TCTCTGTTACTCCATTACTGTGATTTCTGGCTGGGTCACCAGAAATATCGCTGATGCAGACACAGATTATGTT CCTGCTGTATTTCCTGCTTCCCTGTTGAATTGGTGAATAAAACCTTGCTCTATACATACAAA 177 WO 2004/000997 PCT/US2003/017512 NOV8b, CG53473-01 SEQ IDNO: 104 112 aa MWat 12402.5kD Protein Sequence MFGSLLHFALLAAGVVPLSWDLPEPRSRASKIRVHSRGKLWAIGHFMGKKSLEPSSPSPLGTAPHTSLRDQRL QLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQK NOV8c, CG53473-03 SEQ ID NO: 105 130 bp DNA Sequence ORF Start: at ORF Stop: end of sequence GGCAAGCTCTGGGCCATCGGTCACTTCATG NOV8c, CG53473-03 SEQ ID NO: 106 10 aa MW at 1159.4kD Protein Sequence GKLWAIGHFM NOV8d, SNP13376396 of SEQ ID NO: 107 '514bp CG53473-02, DNA Sequence ORF Start: ATG at 37 ORF Stop: TGA at 400 SNP Pos: 190 _ SNP Change: A to G CGCGCGCCCGAACGAAG 5CCGCGGCCCGGGCACAGCCATGGCCCGGCGGGCGGGGGGCGCTCGGATGTTCGGCA GCCTCCTGCTCTTCGCCCTGCTCGCTGCCGGCGTCGCCCCGCTCAGCTGGGATCTCCCGGAGCCCCGCAGCCG AGCCAGCAAGATCCGAGTGCACTCGCGAGGCAACCTCTGGGCCGCCGGTCACTTCATGGGCAAGAAGAGTCTG CAGCCTTCCAGCCCATCCCCATTGGGGACAGCTCCCCACACCTCCCTGAGGGACCAGCGACTGCAGCTGAGTC ATGATCTGCTCGGAATCCTCCTGCTAAAGAAGGCTCTGGGCGTGAGCCTCAGCCGCCCCGCACCCCAAATCCA GTACAGGAGGCTGCTGGTACAAATACTGCAGAAATGACACCAATAATGGGGCAGACACAACAGCGTGGCTTAG ATTGTGCCCACCCAGGGAAGGTGCTGAATGGGACCCTGTTGATGGCCATCAACAGGGTCCCATTCAGCACAGG CTG NOV8d, SNP13376396 of SEQ ID NO: 108 121 aa MW at 13221.4kD CG53473-02, Protein Sequence SNP Pos: 52 SNP Change: Thr to Ala MARRAGGARMFGSLLLFALLAAGVAPLSWDLPEPRSRASKIRVHSRGNLWAAGHFMGKKSLEPSSPSPLGTAP HTSLRDQRLQLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQK 10 178 WO 2004/000997 PCT/US2003/017512 NOV8e, SNP13376395 of SEQ ID NO: 109 514 bp CG53473-02, DNA Sequence ORF Start: ATG at 37 ORF Stop: TGA at 400 SNP Pos: 253 SNP Change: C to A CGCGCGCCCGAACGAAGCCGCGGCCCGGGCACAGCCATGGCCCGGCGGGCGGGGGGCGCTCGGATGTTCGGCA GCCTCCTGCTCTTCGCCCTGCTCGCTGCCGGCGTCGCCCCGCTCAGCTGGGATCTCCCGGAGCCCCGCAGCCG AGCCAGCAAGATCCGAGTGCACTCGCGAGGCAACCTCTGGGCCACCGGTCACTTCATGGGCAAGAAGAGTCTG GAGCCTTCCAGCCCATCCCCATTGGGGACAGCTACCCACACCTCCCTGAGGGACCAGCGACTGCAGCTGAGTC ATGATCTGCTCGGAATCCTCCTGCTAAAGAAGGCTCTGGGCGTGAGCCTCAGCCGCCCCGCACCCCAAATCCA GTACAGGAGGCTGCTGGTACAAATACTGCAGAAATGACACCAATAATGGGGCAGACACAACAGCGTGGCTTAG ATTGTGCCCACCCAGGGAAGGTGCTGAATGGGACCCTGTTGATGGCCATCAACAGGGTCCCATTCAGCACAGG CTG NOV8e, SNP13376395 of iSEQ ID NO: 110 1121 aa MW at 13255.4kD CG53473-02, Protein Sequence ISNP Pos: 73SNP Change: Pro to Thr MARRAGGARMFGSLLLFALLAAGVAPLSWDLPEPRSRASKIRVHSRGNLWATGHFMGKKSLEPSSPSPLGTAT HTSLRDQRLQLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQK 5 NOV8f, SNP13376394 of SEQ ID NO: 111 1514 bp CG53473-02, DNA Sequence ORF Start: ATG at 37 IORF Stop: TAA at 400 SNP Pos: 401 SNP Change: G to A CGCGCGCCCGAACGAAGCCGCGGCCCGGGCACAGCCATGGCCCGGCGGGCGGGGGGCGCTCGGATGTTCGGCA GCCTCCTGCTCTTCGCCCTGCTCGCTGCCGGCGTCGCCCCGCTCAGCTGGGATCTCCCGGAGCCCCGCAGCCG AGCCAGCAAGATCCGAGTGCACTCGCGAGGCAACCTCTGGGCCACCGGTCACTTCATGGGCAAGAAGAGTCTG GAGCCTTCCAGCCCATCCCCATTGGGGACAGCTCCCCACACCTCCCTGAGGGACCAGCGACTGCAGCTGAGTC ATGATCTGCTCGGAATCCTCCTGCTAAAGAAGGCTCTGGGCGTGAGCCTCAGCCGCCCCGCACCCCAAATCCA GTACAGGAGGCTGCTGGTACAAATACTGCAGAAATAACACCAATAATGGGGCAGACACAACAGCGTGGCTTAG ATTGTGCCCACCCAGGGAAGGTGCTGAATGGGACCCTGTTGATGGCCATCAACAGGGTCCCATTCAGCACAGG CTG NOV8f, SNP13376394 of ISEQ ID NO: 112 121 aa MW at 13251.4kD CG53473-02, Protein Sequence [ SNP Change: no change MARRAGGARMFGSLLLFALLAAGVAPLSWDLPEPRSRASKIRVHSRGNLWATGHFMGKKSLEPSSPSPLGTAP HTSLRDQRLQLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQK A ClustalW comparison of the above protein sequences yields the following sequence 10 alignment shown in Table 8B. 179 WO 2004/000997 PCT/US2003/017512 Table 8B. Comparison of the NOV8 protein sequences. NOV8a MARRAGGARMFGSLLLFALLAAGVAPLSWDLPEPRSRASKIRVHSRGNLWATGHFMGKKS NOV8b --------- MFGSLLHFALLAAGVVPLSWDLPEPRSRASKIRVHSRGKLWAIGHFMGKKS NOV8c ----------------------------------------------- GKLWAIGHFM--- NOV8a LEPSSPSPLGTAPHTSLRDQRLQLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQ NOV8b LEPSSPSPLGTAPHTSLRDQRLQLSHDLLGILLLKKALGVSLSRPAPQIQYRRLLVQILQ NOV8c ------------------------------------------ ---------- NOV8a K NOV8b K NOV8c NOV8a (SEQ ID NO: 102) NOV8b (SEQ ID NO: 104) NOV8c (SEQ ID NO: 106) Further analysis of the NOV8a protein yielded the following properties shown in Table 8C. 5 Table 8C. Protein Sequence Properties NOV8a SignalP analysis: Cleavage site between residues 27 and 28 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 9; pos.chg 3; neg.chg 0 H-region: length 20; peak value 10.93 PSG score: 6.53 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): 2.23 possible cleavage site: between 26 and 27 >>> Seems to have a cleavable signal peptide (1 to 26) ALOM: Klein et al's method for TM region allocation Init position for calculation: 27 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 1.85 (at 87) ALOM score: 1.85 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 13 Charge difference: -1.5 C( 2.5) - N( 4.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 3 Hyd Moment(75): 12.45 Hyd Moment(95): 10.60 G content: 4 D/E content: 1 S/T content: 2 Score: -2.16 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 19 ARM IFG 180 WO 2004/000997 PCT/US2003/017512 NUJCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 14.9% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: ARRA none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 89 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 44.4 %: extracellular, including cell wall 33.3 %: mitochondrial 22.2 %: nuclear >> prediction for CG53473-02 is exc (k=9) A search of the NOVSa protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8D. 181 WO 2004/000997 PCT/US2003/017512 Table 8D. Geneseq Results for NOV8a NOV8a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE17605 Human extracellular messenger 1..121 121/121 (100%) le-63 (XMES)-7 protein - Homo sapiens, 1..121 121/121 (100%) 121 aa. [WO200194587-A2, 13-DEC-2001] ABP51992 NOVNEURhomologous amino acid 1..121 114/121 (94%) 3e-58 sequence SEQ ID NO:29 - Homo 1..121 114/121 (94%) sapiens, 121 aa. [US2002068279-A1, 06-JUN-2002] ABP51987 NOVNEUR homologous amino acid 4..121 112/118 (94%) 7e-58 sequence SEQ ID NO:24 - Homo 1.118 112/118 (94%) sapiens, 118 aa. [US2002068279-A1, 06-JUN-2002] ABP51989 NOVNEUR homologous amino acid 4..121 111/118 (94%) le-56 sequence SEQ ID NO:26 - Homo 1-.118 111/118 (94%) sapiens, 118 aa. [US2002068279-A1, 06-JUN-2002] ABP51990 NOVNEUR homologous amino acid 10..121 108/112 (96%) 7e-56 sequence SEQ ID NO:27 - Homo 1..112 108/112 (96%) sapiens, 112 aa. [US2002068279-A1, 06-JUN-2002] In a BLAST search of public sequence databases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8E. 5 182 WO 2004/000997 PCT/US2003/017512 Table 8E. Public BLASTP Results for NOV8a NOV8a Identities/ Protein Residues/ Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion P08949 Neuromedin B-32 precursor 1..121 120/121 (99%) 2e-62 [Contains: Neuromedin B] - Homo 1..121 120/121 (99%) sapiens (Human), 121 aa. Q9CR53 Neuromedin B-32 precursor 1..121 89/121 (73%) 2e-43 [Contains:Neuromedin B] - Mus 1..121 99/121 (81%) musculus (Mouse), 121 aa. A37178 neuromedin B precursor - rat, 117 aa. 1..115 84/115 (73%) 2e-41 1..115 94/115(81%) A28945 neuromedin B precursor - human, 76 1..73 69/73 (94%) 5e-33 aa. 1..73 69/73 (94%) P01297 Neuromedin B-32 [Contains: 25..56 30/32 (93%) 2e-11 I Neuromedin B] - Sus scrofa (Pig), 32 1..32 30/32 (93%) aa. PFam analysis predicts that the NOV8a protein contains the domains shown in the Table 8F. 5 Table 8F. Domain Analysis of NOV8a Identities/ Pfam Domain NOV8a Match Region Similarities Expect Value for the Matched Region Bombesin 47..56 8/10 (80%) 0.26 10/10 (100%) Example 9. The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A. 10 183 WO 2004/000997 PCT/US2003/017512 Table 9A. NOV9 Sequence Analysis NOV9a, CG55184-03 ISEQ ID NO: 113 614 bp DNA Sequence ORF Start: ATG at 4 ORF Stop: TAG at 607 ACCATGGGCTCCGGGCGCCGGGICGCTGTCCGCGGTGCCGGCCGTGCTGCTGGTCCTCACGCTGCCGGGGCTGC CCGTCTGGGCACAGAACGACACGGAGCCCATCGTGCTGGAGGGCAAGTGTCTGGTGGTGTGCGACTCGAACCC GGCCACGGACTCCAAGGGCTCCTCTTCCTCCCCGCTGGGGATATCGGTCCGGGCGGCCAACTCCAAGGTCGCC TTCTCGGCGGTGCGGAGCACCAACCACGAGCCATCCGAGATGAGCAACAAGACGCGCATCATTTACTTCGATC AGATCCTGGTGAATGTGGGTAATTTTTTCACATTGGAGTCTGTCTTTGTAGCACCAAGAAAAGGAATTTACAG TTTCAGTTTTCACGTGATTAAAGTCTACCAGAGCCAAACTATCCAGGTTAACTTGATGTTAAATGGAAAACCA GTAATATCTGCCTTTGCGGGGGACAAAGATGTTACTCGTGAAGCTGCCACGAATGGTGTCCTGCTCTACCTAG ATAAAGAGGATAAGGTTTACCTAAAACTGGAGAAAGGTAATTTGTTGGAGGCTGGCAGTATTCCACGTTTTC TGGCTTTCTGGTGTTCCCCCTATAGGATTC NOV9a, CG55184-03 SEQ ID NO: 114 201 aa MW at 21807.9kD Protein Sequence MGSGRRALSAVPAVLLVLTLPGLPVWAQNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPLGISVRAANSKVAF SAVRSTNHEPSEMSNKTRIIYFDQILVNVGNFFTLESVFVAPRKGIYSFSFHVIKVYQSQTIQVNLMLNGKPV ISAFAGDKDVTREAATNGVLLYLDKEDKVYLKLEKGNLVGGWQYSTFSGFLVFPL 5 NOV9b, CG55184-01 SEQ IDNO: 115 614 bp DNA Sequence ORF Start ATG at 4 ORF Stop: TAG at 607 ACCATGGOCTCCGGGCGCCGGGCGCTGTCCGCGGTGCCGGCCGTGCTGCTGGTCCTCACGCTGCCGGGGCTGC CCGTCTGGGCACAGAACGACACGGAGCCCATCGTGCTGGAGGGCAAGTGTCTGGTGGTGTGCGACTCGAACCC GGCCACGGACTCCAAGGGCTCCTCTTCCTCCCCGCTGGGGATATCGGTCCGGGCGGCCAACTCCAAGGTCGCC TTCTCGGCGGTGCGGAGCACCAACCACGAGCCATCCGAGATGAGCAACAAGACGCGCATCATTTACTTCGATC AGATCCTGGTGAATGTGGGTAATTTTTTCACATTGGAGTCTGTCTTTGTAGCACCAAGAAAAGGAATTTACAG TTTCAGTTTTCACGTGATTAAAGTCTACCAGAGCCAAACTATCCAGGTTAACTTGATGTTAAATGGAAAACCA GTAATATCTGCCTTTGCGGGGGACAAAGATGTTACTCGTGAAGCTGCCACGAATCGTGTCCTGCTCTACCTAG ATAAAGAGGATAAGGTTTACCTAAAACTGGAGAAAGGTAATTTGGTTGGAGGCTGGCAGTATTCCACGTTTTC TGGCTTTCTGGTGTTCCCCCTATAGGATTC NOV9b, CG55184-01 SEQ ID NO: 116 201 aa at 21807.9kD Protein Sequence I MGSGRRALSAVPAVLLVLTLPGLPVWAQNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPLGISVRAANSKVAF SAVRSTNHEPSEMSNKTRIIYFDILVNVGNFFTLESVFVAPRKGIYSFSFHVIKVYQSQTIQVNLMLNGKPV ISAFAGDKDVTREAATNGVLLYLDKEDKVYLKLEKGNLVGGWQYSTFSGFLVFPL 184 WO 2004/000997 PCT/US2003/017512 NOV9c, CG55184-02 SEQ ID NO: 117 522bp DNA Sequence ORF Start: at 1 JORF Stop: end of sequence CAGAACGACACGGAGCCCATTGTGCTGGAGGGCAAGTGTCTGGTGGTGTGCGACTCGAACCCGGCCACGGACT CCAAGGGCTCCTCTTCCTCCCCGCTGGGGATATCGGTCCGGGCGGCCAACTCCAAGGTCGCCTTCTCGGCGGT GCGGAGCACCAACCACGAGCCATCCGAGATGAGCAACAAGACGCGCATCATTTACTTCGATCAGATCCTGGTG AATGTGGGTAATTTTTTCACATTGGAGTCTGTCTTTGTAGCACCAAGAAAAGGAATTTACAGTTTCAGTTTTC ACGTGATTAAAGTCTACCAGAGCCAAACTATCCAGGTTAACTTGATGTTAAATGGAAAACCAGTAATATCTGC CTTTGCGGGGGACAAAGATGTTACTCGTGAAGCTGCCACGAATGGTGTCCTGCTCTACCTAGATAAAGAGGAT AAGGTTTACCTAAAACTGGAGAAAGGTAATTTGGTTGGAGGCTGGCAGTATTCCACGTTTTCTGGCTTTCTGG TGTTCCCCCTA NOV9c, CG55184-02 SEQ ID NO: 118 174 aa MW at 19080.6kD Protein Sequence QNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPLGISVRAANSKVAFSAVRSTNHEPSEMSNKTRIIYFDQILV NVGNFFTLESVFVAPRKGIYSFSFHVIKVYQSQTIQVNLMLNGKPVISAFAGDKDVTREAATNGVLLYLDKED KVYLKLEKGNLVGGWQYSTFSGFLVFPL 5 NOV9d, CG55184-04 SEQ ID NO: 119 48 bp DNA Sequence JORF Start: at 1 ORF Stop: end of sequence GCGGCCAACTCCAAGGTCGCCTTCTCGGCGGTGCGGAGCACCAACCAC NOV9d, CG55184-04 SEQ ID NO: 120 16 aa W at 1659.8kD Protein Sequence AANSKVAFSAVRSTNH NOV9e, CG55184-05 ISEQ ID NO: 121 45bp DNA Sequence .ORF Start: at 1 ORF Stop: end of sequence GCCAACTCCAAGGTCGCCTTCTCGGCGGTGCGGAGCACCAACCAC 10 NOV9e, CG55184-05 SEQ ID NO: 122 15 aa MW at 1588.7kD Protein _Sequence ANSKVAPgAVRSTNH A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 9B. 15 185 WO 2004/000997 PCT/US2003/017512 Table 9B. Comparison of the NOV9 protein sequences. NOV9a MGSGRRALSAVPAVLLVLTLPGLPVWAQNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPL NOV9b MGSGRRALSAVPAVLLVLTLPGLPVWAQNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPL NOV9c ---------------------------- QNDTEPIVLEGKCLVVCDSNPATDSKGSSSSPL NOV9d ----------------------------------------------------------- NOV9e ----------------------------------------------------------- NOV9a GISVRAANSKVAFSAVRSTNHEPSEMSNKTRIIYFDQILVNVGNFFTLESVFVAPRKGIY NOV9b GISVRAANSKVAFSAVRSTNHEPSEMSNKTRIIYFDQILVNVGNFFTLESVFVAPRKGIY NOV9c GISVRAANSKVAFSAVRSTNHEPSEMSNKTRIIYFDQILVNVGNFFTLESVFVAPRKGIY NOV9d ------ AANSKVAFSAVRSTNH--- -------------------------------------- NOV9e ------ ANSKVAFSAVRSTNH--- -------------------------------------- NOV9a SFSFHVIKVYQSQTIQVNLMLNGKPVISAFAGDKDVTREAATNGVLLYLDKEDKVYLKLE NOV9b SFSFHVIKVYQSQTIQVNLMLNGKPVISAFAGDKDVTREAATNGVLLYLDKEDKVYLKLE NOV9c SFSFHVIKVYQSQTIQVNLMLNGKPVISAFAGDKDVTREAATNGVLLYLDKEDKVYLKLE NOV9d ----------------------------------------------------------- NOV9e --------------------------------------------------------- NOV9a KGNLVGGWQYSTFSGFLVFPL NOV9b KGNLVGGWQYSTFSGFLVFPL NOV9c KGNLVGGWQYSTFSGFLVFPL NOV9d

--------------------

NOV9e -------------------- NOV9a (SEQ ID NO: 114) NOV9b (SEQ ID NO: 116) NOV9c (SEQ ID NO: 118) NOV9d (SEQ ID NO: 120) NOV9e (SEQ ID NO: 122) Further analysis of the NOV9a protein yielded the following properties shown in Table 9C. 5 Table 9C. Protein Sequence Properties NOV9a SignalP analysis: Cleavage site between residues 28 and 29 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 6; pos.chg 2; neg.chg 0 H-region: length 23; peak value 10.04 PSG score: 5.64 GvHR: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): 0.95 possible cleavage site: between 27 and 28 >>> Seems to have a cleavable signal peptide (1 to 27) ALOM: Klein et al's method for TM region allocation Init position for calculation: 28 Tentative number of TMS(s) for the threshold 0.5: 1 186 WO 2004/000997 PCT/US2003/017512 Number of TMS(s) for threshold 0.5: 0 PERIPHERAL Likelihood = 5.67 (at 60) ALOM score: 0.10 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 13 Charge difference: -5.0 C(-2.0) - N( 3.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 2 Hyd Moment(75): 11.01 Hyd Moment(95): 9.83 G content: 3 D/E content: 1 S/T content: 3 Score: -2.58 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 16 RRAILS NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 9.5% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: GSGR none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues 187 WO 2004/000997 PCT/US2003/017512

-------------------------

Final Results (k = 9/23): 33.3 %: extracellular, including cell wall 33.3 %: mitochondrial 22.2 %: endoplasmic reticulum 11.1 %: Golgi >> prediction for CG55184-03 is exc (k=9) A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9D. 5 Table 9D. Geneseq Results for NOV9a NOV9a Identities/ Geneseq Protein/Organism/Length [Patent#, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE16346 Human cerebellin-like protein, 1 .. 201 201/201 (100%) e-111 POLY10 - Homo sapiens, 201 aa. 1..201 201/201 (100%) [WO200185767-A2, 15-NOV-2001] ABB84924 Human PROl382 protein sequence 1..201 201/201 (100%) e-111 SEQ ID NO:216 - Homo sapiens, 201 1..201 201/201 (100%) aa. [WO200200690-A2, 03-JAN-2002] ABB95530 Human angiogenesis related protein 1.201 201/201 (100%) e-111 PRO1382 SEQ ID NO: 216 - Homo 1..201 201/201 (100%) sapiens, 201 aa. [WO200208284-A2, 31-JAN-2002] AAO15422 Human genset metabolic gene 1.201 201/201 (100%) e-111 (GMG-8) protein - Homo sapiens, 201 1..201 201/201 (100%) aa. [WO200255694-A2, 18-JUL-2002] AAB66151 Protein of the invention #63 - 1..201 201/201 (100%) e-111 Unidentified, 201 aa. 1.201 201/201 (100%) [WO200078961-A1, 28-DEC-2000] In a BLAST search of public sequence databases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9E. 188 WO 2004/000997 PCT/US2003/017512 Table 9E. Public BLASTP Results for NOV9a Protein NOV9a Identities/ Accession Protein/Organisnim/Length Residues/ Similarities for the Expect Number Match Matched Portion Value Residues Matched Portion Value Q9NTU7 Cerebellin-like glycoprotein 1 1..201 201/201 (100%) e-111 precursor - Homo sapiens (Human), 1.201 201/201 (100%) 201 aa. Q8BME9 CEREBELLIN-like glycoprotein 1..201 193/201 (96%) e-105 precursor - Mus musculus (Mouse), 1..198 195/201 (96%) 198 aa. Q8BMFO CEREBELLIN-like glycoprotein 1..201 192/201 (95%) e-104 precursor - Mus musculus (Mouse), 1..198 194/201 (95%) 198 aa. QSBGU2 Cerebellin 2 precursor protein - Mus 7..201 145/196 (73%) 2e-76 musculus (Mouse), 224 aa. 31..224 170/196 (85%) P98087 Cerebellin-like glycoprotein 1 - 7..201 144/196 (73%) 6e-76 Rattus norvegicus (Rat), 224 aa. 31..224 169/196 (85%) PFam analysis predicts that the NOV9a protein contains the domains shown in the Table 9F. 5 Table 9F. Domain Analysis of NOV9a Identities/ Pfam Domain NOV9a Match Region Similarities Expect Value for the Matched Region Clq 72..198 48/137 (35%) 1.4e-48 113/137 (82%) Example 10. The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A. 10 Table 10A. NOV10 Sequence Analysis NOV10a, CG55274-05 SEQ ID NO: 123 274bp DNA Sequence JORF Start: ATG at 7 JORF Stop: TAG at 265 ACCACCATGGCACTGCAGGCTGAATTCGACAAGGCTGCAGAAGACGTGAGGAAGCTGCCAACAAGACCAGCAG ATAATAAAGAACTGAAAAAACTCGATGGACTTTACAAACAAGCTATAATTGGAGACATTAATATTGAGTATCT GGGAATGCTGGATTTAAAGGGCAAGGCCAAATGCGCAGCATGGACCCTCCAAAAAAGGTTGTCAAAGGAAGAT GCAACGAGTGTCTCTATTTCTAAGGCAAAAGAGCCGATAGAAAAATAGGACATTT 189 WO 2004/000997 PCT/US2003/017512 NOV10a, CG55274-05 SEQ ID NO: 124 86 aa MW at 9590.OkD Protein Sequence MALQAEFDKAAEDVRKLPTRPADNKELKKLDGLYKQAIIGDINIEYLGMLDLKGKAKCAAWTLQKRLSKEDAT SVSISKAKEPIEK NOV10b, CG55274-01 SEQ ID NO: 125 280 bp DNA Sequence ORF Start: ATG at 7 ORF Stop: TAG at 265 ACCACCATGGCACTGCAGGCTGAATTCGACAAGGCTGCAGAAGACGTGAGGAAGCTGCCAACAAGACCAGCAG ATAATAAAGAACTGAAAAAACTCGATGGACTTTACAAACAAGCTATAATTGGAGACATTAATATTGAGTATCT GGGAATGCTGGACTTTAAGGGCAAGGCCAAATGCGCAGCATGGACCCTCCAAAAAAGGTTGTCAAAGGAAGAT GCAACGAGTGTCTCTATTTCTAAGGCAAAAGAGCCGATAGAAAAATAGGACATTTAGAATA 5 NOVO10b, CG55274-01 SEQ IDNO: 126 86 aa MW at 9624.lkD Protein Sequence MALQAEFDKAAEDVRKLPTRPADNKELKKLDGLYKQAIIGDINIEYLGMLDFKGKAKCAAWTLQKRLSKEDAT ISVSISKAKEPIEK NOV10c, CG55274-02 SEQ ID NO: 127 289bp DNA Sequence ORF Start: ATG at 17 ORF Stop: TAG at 272 TGCGGCCGCCACCACCATGGCACTGCAGGCTGATCGAGACAAGGCTGCAGAAGACGTGAGGAAGCTGCCAACA AGACCAGATGAGAAAGAACTGAAAAAACTCGATGGACTTTACAAACAAGCTATAATTGGAGACATTAATATTG AGTATCTGGGAATGCTGGATTTAAAGGGCAAGGCCAAATGCGCAGCATGGACCCTCCAAAAAAGGTTGTCAAA GGAAGATGCAACGAGTGTCTCTATTTCTAAGGCAAAAGAGCCGATAGAAAAATAGGACATTTAGAATACA NOV10c, CG55274-02 ISEQ ID NO: 128 85aa MW at 9528.9kD Protein Sequence MALQADRDKAAEDVRKLPTRPDEKELKKLDGLYKQAI IGDINIEYLGMLDLKGKAKCAAWTLQKRLSKEDATS VSISKAKEPIEK 10 NOV10d, CG55274-03 SEQ ID NO: 129 60bp DNA Sequence OR Start: at 1 . ORF Stop: end of sequence CAAGCTATAATTGGAGACATTAATATTGAGTATCTGGGAATGCTGGATTTAAAGGGCAAG NOV10d, CG55274-03 iSEQ IDNO: 130 20 aa MW at 2204.6kD Protein Sequence .. QAIIGDINIEYLGMLDLKGK 15 190 WO 2004/000997 PCT/US2003/017512 NOV10e, CG55274-04 SEQ ID NO: 131 54 bp DNA Sequence JORF Start: at 1 ORF Stop: end of sequence CAAGCTATAATTGGAGACATTAATATTGAGTATCTGGGAATGCTGGACTTTAAG NOV10e, CG55274-04 SEQ ID NO: 132 18 aa MW at 2053.4kD Protein Sequence QAIIGDINIEYLGMLDFK 5 A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 10B. Table 10B. Comparison of the NOV10 protein sequences. NOV10a MALQAEFDKAAEDVRKLPTRPADNKELKKLDGLYKQAIIGDINIEYLGMLDLKGKAKCAA NOV10b MALQAEFDKAAEDVRKLPTRPADNKELKKLDGLYKQAIIGDINIEYLGMLDFKGKAKCAA NOV10c MALQADRDKAAEDVRKLPTRPDE-KELKKLDGLYKQAIIGDINIEYLGMLDLKGKAKCAA NOV10d -------------------------------------

QAIIGDINIEYLGMLDLKGK----

NOV10e --------------------------------------

QAIIGDINIEYLGMLDFK------

NOV10a WTLQKRLSKEDATSVSISKAKEPIEK NOV10b WTLQKRLSKEDATSVSISKAKEPIEK NOV10c WTLQKRLSKEDATSVSISKAKEPIEK NOV10d ---------------- NOV10e ------------------------ NOV10a (SEQ ID NO: 124) NOV10b (SEQ ID NO: 126) NOV10c (SEQ ID NO: 128) NOV10d (SEQ ID NO: 130) NOV10e (SEQ ID NO: 132) Further analysis of the NOV 10a protein yielded the following properties shown in Table 10 10C. Table 10C. Protein Sequence Properties NOV10a SignalP analysis: No Known Signal Sequence Predicted PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 9; pos.chg 1; neg.chg 2 H-region: length 2; peak value 0.00 PSG score: -4.40 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -10.68 possible cleavage site: between 58 and 59 191 WO 2004/000997 PCT/US2003/017512 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS{s) .. fixed PERIPHERAL Likelihood = 7.11 (at 36) ALOM score: 7.11 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment{75): 3.71 Hyd Moment(95): 2.95 G content: 0 D/E content: 2 S/T content: 0 Score: -7.75 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 19.8% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 76.7 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues 192 WO 2004/000997 PCT/US2003/017512 Final Results (k = 9/23): 82.6 %: nuclear 4.3 %: cytoskeletal 4.3 %: mitochondrial 4.3 %: cytoplasmic 4.3 %: peroxisomal >> prediction for CG55274-05 is nuc (k=23) A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10 OD. 5 Table 10D. Geneseq Results for NOV10a NOV10a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAB81814 Human endozepine-like ENDO5 SEQ 1..86 85/86 (98%) le-42 ID NO: 10 - Homo sapiens, 86 aa. 1..86 85/86 (98%) [WO200125436-A2, 12-APR-2001] ABU11538 Human MDDT polypeptide SEQ ID 485 1..86 64/86 (74%) le-26 - Homo sapiens, 100 aa. 13..97 70/86 (80%) [WO200279449-A2, 10-OCT-2002] AAB81811 Human endozepine-like ENDO4 SEQ 3..86 61/84 (72%) 5e-25 ID NO: 8 - Homo sapiens, 96 aa. 11..93 68/84 (80%) -_- _[WO200125436-A2, 12-APR-2001] ABJ05397 Frog acyl coenzyme A binding protein 4..86 57/83 (68%) 2e-23 (ACBP) - Rana sp, 86 aa. 2..83 66/83 (78%) [WO200261096-A1, 08-AUG-2002] ABJ05396 Duck acyl coenzyme A binding protein 4..86 55/83 (66%) 3e-23 (ACBP) 2 - Anas sp, 86 aa. 2..83 66/83 (79%) [WO200261096-A1, 08-AUG-2002] _ _ _ In a BLAST search of public sequence databases, the NOV 10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10E. 193 WO 2004/000997 PCT/US2003/017512 Table 10E. Public BLASTP Results for NOV10a NOV10a Identities/ Protein Residues/ Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion Q8N6N7 Similar to RIKEN cDNA 9230116B18 1..86 64/86 (74%) 4e-26 gene - Homo sapiens (Human), 88 aa. 1..85 70/86 (80%) Q9D258 9230116Bl8Rik protein - Mus musculus 1..86 60/86 (69%) 3e-25 (Mouse), 88 aa. 1..85 70/86 (80%) A57711 diazepam-binding inhibitor - laughing 1..86 58/86 (67%) 2e-23 frog, 88 aa. 1..85 68/86 (78%) P45883 Acyl-CoA-binding protein homolog 4..86 57/83 (68%) 4e-23 (ACBP) (Diazepam binding inhibitor 3..84 66/83 (78%) homolog) (DBI) - Rana ridibunda (Laughing frog) (Marsh frog), 87 aa. P45882 Acyl-CoA-binding protein (ACBP) 4..86 55/83 (66%) 7e-23 (Diazepam binding inhibitor) (DBI) 19..100 66/83 (79%) (Endozepine) (EP) - Anas platyrhynchos (Domestic duck), 103 aa. PFam analysis predicts that the NOV10 Oa protein contains the domains shown in the Table 10 OF. 5 Table 10F. Domain Analysis of NOV10a Identities/ PfamDomain NOV10a Match Region Similarities Expect Value for the Matched Region ACBP 3..86 42/90 (47%) 5.1e-18 S66/90 (73%) Example 11. The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A. 10 194 WO 2004/000997 PCT/US2003/017512 Table 11A. NOV11 Sequence Analysis NOV1la, CG55379-04 ISEQ ID NO: 133 J6291 bp DNA Sequence ORF Start: ATG at 1 JORF Stop: TAG at 3763 ATGGCGCGGGGGGACGCCGGCCGCGGCCGCGGGCTCCTCGCGTTGACCTTCTGCCTGTTGGCCGCGCGCGGGG AGCTGCTGTTGCCCCAGGAGACGACTGTGGAGCTGAGCTGTGGAGTGGGGCCACTGCAAGTGATCCTGGGCCC AGAGCAGGCTGCAGTGCTAAACTGTAGCCTGGGGGCTGCTGCCGCTGGACCCCCCACCAGGGTGACCTGGAGC AAGGATGGGGACACCCTGCTGGAGCACGACCACTTACACCTGCTGCCCAATGGTTCCCTGTGGCTGTCCCAGC CACTAGCACCCAATGGCAGTGACGAGTCAGTCCCTGAGGCTGTGGGGGTCATTGAAGGCAACTATTCGTGCCT AGCCCACGGCCCCCTCGGAGTGCTGGCCAGCCAGACTGCTGTCGTCAAGCTTGCCAGTCTCGCAGACTTCTCT CTGCACCCGGAGTCTCAGACGGTGGAGGAGAACGGGACAGCTCGCTTTGAGTGCCACATTGAAGGGCTGCCAG CTCCCATCATTACTTGGGAGAAGGACCAGGTGACATTGCCTGAGGAGCCTCGGCTCATCGTGCTTCCCAACGG CGTCCTTCAGATCCTGGATGTTCAGGAGAGTGATGCAGGCCCCTACCGCTGCGTGGCCACCAACTCAGCTCGC CAGCACTTCAGCCAGGAGGCCCTACTCAGTGTOGCCCACAGAGGTTCCCTGGCGTCCACCAGGGGGCAGGACG TGGTCATTGTGGCAGCCCCAGAGAACACCACAGTGGTGTCTGGCCAGAGTGTGGTGATGGAATGTGTGGCCTC AGCTGACCCCACCCCTTTTGTGTCCTGGGTCCGAGACGGGAAGCCCATCTCCACAGATGTCATCGTCCTGCGC CGCACCAACCTACTAATTGCCAACGCGCAGCCCTGGCACTCCGGCGTCTATGTCTGCCGCGCCAACAAGCCCC GCACGCGCGACTTCGCCACTGCAGCCGCTGAGCTCCGTGTGCTGCTAGCGGCTCCCGCCATCACTCAGGCGCC CGAGGCGCTGTCGCGGACGCGGGCGAGCACAGCGCGCTTCGTGTGCCGCGCGTCGGGGGAGCCGCGGCCAGCG CTGCGCTGGCTGCACAACGGGGCGCCGCTGCGGCCCAACGGGCGCGTCAAGGTCCAGGGCGGCGGTGGCAGCC TGGTCATCACACAGATCGGCCTGCAGGACGCCGGCTACTACCAGTGCGTGGCTCAGAACAGCGCGGGAATGGC GTGCGCTGCCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACG CCACTGAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCACAGCGAGCAGATCATCGGCTTCT CTCTCCACTACCAGAAGGCACGGGGTATGGACAATGTGGAATACCAGTTTGCAGTGAACAACGACACCACAGA ACTACAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTGGTGGCCTACTCCCAGCTGGGAGCC AGCCGCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTGCAGCACCCCAGCTCTCCCTGT CCAGCCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAGCCTGAGCAATGGGCAGGTGGT GAAGTACAAGATAGAATACGGTTTGGGAAAGGAAGGTGAGTGGGGGGATCAGATTTTCTCTACTGAGGTGCGA GGAAATGAGACACAGCTTATGCTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTA CAGCAGCCGGCTTCGGGGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGT CCCTTTTGCCCCTGCAGAGTTGAAGGTGCAGGCAAAGATGGAGTCCCTGGTCGTGTCATGGCAGCCACCCCCT CACCCCACCCAGATCTCTGGCTACAAACTATATTGGCGGGAGGTGGGGGCTGAGGAGGAGGCCAATGGCGATC GCCTGCCAGGGGGCCGTGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGGCTCAAGAAGAAAGTGAAGCAGTA TGAGCTGACCCAGCTAGTCCCTGGCCGGCTGTACGAGGTGAAGCTCGTGGCTTTCAACAAACATGAGGATGGC TATGCAGCAGTGTGGAAGGGCAAGACGGAGAAGGCGCCCCCACCAGACATGCCTATCCAGAGGGGACCACCCC TGCCTCCAGCCCACGTCCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGGAAAAAGCCAGATTT CACCACAGTCAAGATTGTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCAGGAATGCCTCCCTGGTCACC TATTACACCAGTTCTGGAGAAGACATCCTCATTGGCGGCTTGAAGCCATTCACCAAATACGAGTTTGCAGTGC AGTCTCACGGCGTGGACATGGATGGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGGCCCTC CACACCCCCATCCGACCTOCGACTGAGCCCCCTGACACCGTCCACGGTTCGGCTGCACTGGTGCCCCCCCACA GAGCCCAACGGGGAGATCGTGGAGTATCTGATCCTGTACAGCAGCAACCACACGCAGCCTGAGCACCAGTGGA CCTTGCTCACCACGCAGGGAAACATCTTCAGTGCTGAGGTCCATGGCCTGGAGAGCGACACTCGGTACTTCTT CAAGATGGGGGCGCGCACAGAGGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAG AAGCTGTCAGACTCGCTGGACATGCACTCAGTCACGGGCATCATCGTGGGTGTCTGCCTGGGCCTCCTCTGCC TCCTGGCCTGCATGTGTGCTGGCCTGCGCCGCAGCCCCCACAGGGAATCCCTCCCAGGCCTGTCCTCCACCGC CACCCCCGGGAATCCCGCGCTGTACTCCAGAGCTCGGCTTGGCCCCCCCAGCCCCCCAGCTGCCCATGAATTG GAGTCCCTTGTGCACCCCCATCCCCAGGACTGGTCCCCGCCACCCTCAGACGTGGAGGACAGGGCTGAAGTGC ACAGCCTTATGGGTGGCGGTGTTTCTGAAGGCCGGAGTCACTCCAAAAGAAAGATCTCCTGGGCTCAACCAAG CGGGCTGAGCTGGGCTGGTTCCTGGGCAGGCTGTGAGCTGCCCCAGGCAGGCCCCCGGCCGGCTCTGACCCGG GCCCTGCTGCCCCCTGCTGGAACTGGGCAGACGCTGTTGCTGCAGGC TCTGGTGTACGACGCCATAAAGGGCAATGGGAGGAAGAAGTCACCCCCAGCCTGCAGGAACCAGGTGGAGGCT GAAGTCATTGTCCACTCTGACTTTAGTGCATCTAACGGGAACCCTGACCTCCATCTCCAAGACCTGGAGCCTG AGGACCCCCTGCCTCCAGAGGCTCCTGATCTCATCTCGGGTGTTGGGGATCCAGGGCAGGGGGCAGCCTGGCT GGACAGGGAGTTGCGAGGGTGTGAGCTGGCAGCCCCCGGGCCAGACAGACTTACCTGCTTGCCAGAGGCAGCC AGTGCTTCCTGCTCCTACCCGGACCTCCAGCCAGGCGAGGTGCTAGAGGAGACCCCTGGAGATAGCTGCCAGC TCAAATCCCCCTGCCCTCTAGGAGCCAGCCCAGGCCTGCCCAGATCCCCGGTCTCCTCCTCTGCCTAGCTCTT CCCAGAGGATGTGGTTTGGGGCAGGCAGGTATGGATCACATAGGATGCGATACCTGTGGCCGTGTATGTCCAC ATGTGTGCCTGTAGATACATCATCAAGCCCTTTGGAGCTTCCTAAGTTGCTTTGGCTGAGGGGAGAGGAAAAC 195 WO 2004/000997 PCT/US2003/017512 ATGGATTATTCACTCCCCCCATACTCTTTGTGATACACATGTGACATGTGAAAGACATACGAGACATAGCTAC ATGTGATGTGCACATGTGTGAAGTGCATGTATGCGTACTGGTTGTTGAGCTGGGAAACCGTGGCCCAGGCAGT GGTCACTACAGCCTGATTGGTCCTCCAGGTCAGAACGGTGCCCCACAGTGGTCAGTCCCCAGCCCTGTGGGCC CCCACCTCCATCGCCCAGCCTTTTATTACACACTCTGAGAGTGTCTCCAATGCCTGTCTGACAAAGACAGTCC CAGCCCATTCTCCTGTCTGGCTGGTTGGGTGCAAGCAGGCTCTGAATGCCTGGCATTTCAGCTGCATCACCT CCCAGCTCCTTATTGCCCAAATAGAGAGGGTGGCCCTGGCTCCCCTCCGAGCAACTCTGCATTTAATTTTGTA ATCTGGGAAGTGCCTGGTTTTGAAAATCCGCTTTCTCTCACTCTTCCCCTCCTTCCTTGCCCCTGGCTGCTCT AGTGTTCTGTCTCCCAGTCACCTCGCTCTCCCAGCACCAGTGCCCTTCTCCTGCTCCCAGATACTCTTTCCTT TCCTCTCTCCTGTTTTCCTTCCTCTGCTATCTCTCACACCTCTCCCAGACTATGTCATCTTGTTCTCCTGCCT GGGTTCAAACTCTGCATCCTTCTCTAACAACGTGACTACCTCATGTCTGCTTCAAGGCCCCCGTCCCCTTCCT GTATCCGCGGCTGCCGCGCACTCGCCTGCCATCCTCCTGCCTCCTCTTCACTCAGTGCTTCTGCTTGCCCTGC CCCAGGCAGCCCACCCACGCCCAGTGCGGGTGTGGAGAAGATCTTCTGGCTTCCCTGCATCTTGCCTTTGGGA TTGGGATCCAAGGGTTCTCCATGGATGGATCCAAGTCATAGAGGGGAATGTTTGAGACAGGGAAGGGGGCTGT GATCCAGAGGCTCAGAATAAAAAGATGCCCTCCCTTCTATGCAGGGGGGCAAGTTTACTGGATGGAGATGATT TGGGCCTCTCTTCCAGAAGAAGCTAAAGGAAGAGAAGGGGAGTGAGAGTTCAGGGAGGCCCTTCCCACCCTGT GAGGCTTGACTTGATCTGGATTGGGGATGACAGGAATCTCACCCTCTGGGGTGCTGGCAAGGAGGTCTTTGCA CAGGAAAAGGGGTAGCTCATTTCAGTTTGTTTTTTCTTTAAATTGAATCCTCAAGTCATTTTCTGTTCACCTG CCGCACAGGGACAAGCTTGACTTCTATTTTCTGTGTAGTGAAAACAATGTCATTTATTTGGTTTTTCACCTCA GCCCTCTCATAGGAGCATAGAATGTTAGGGTCTTTACTCCCTAATGATGTCTGATTGGCACATCAAGAGTTAA CTCTGCCTTCTGGGCCAAATTCGAAATAACCAGTCCATTTTTCCTTTTTTTTTTTTTTTTTTTTTTTTAAATG GTGGAATGTCTCTCAGCACAGTTGCGGCTTCCTCAAACCCTGAAAGCATCTGTGTTTATTATACTCGGGTGTC ACTCACTGTTGATGTCTGCACCTACGTTTCCACCTCCTCCCCCTCCTTCAGCCAGCCTATGATAACACTAAAG ATTATTAATGTTGGTTTTGTATCTCGTTAAAGACAGAATTGTCACTTGTAGTATTTCTGTAGCATTCAGCGCT GCTGTGGCTAACACCACTGTGTATGTTTCATCATTGCTCTGAAGGTCAAAAGCCTCATTTTATTTTGCTGGTT TGATTTTTTTTTTTTAAAGAAGAAAAAAAAACTCCCCTGAATTAAATGGCTGTTTTAACAGTAGGCTCTTAGC ATTATACCACATAGTCATTTTTCATGTTCTTGTTTAACAGGCACTGAGGTTCTGGTTTAAATTAAATAGCTGC AAATGAGACAATTTATAACCCATTAGGTTGGGTGGAAAATTGTTTCTCAAAAGCAAATAAGTAATAAATCTGG TATCTGCCTATAACTCACAGTTGATAAGAAAGTGGCCATTTCTCACTAGCACTATATATGATTTGGGCTCTGG GTAATTTGGAAGTGTTAGGTTTGTGTCTTTGTAGCAGTATTTTTATTAGAAAAGAATCTATTGGCCTTTTACA GGGTATTAATCCCTTTGTCACCTACCATTGATGCCTTAAGTTTTCTGAGTCTCAATTAAAAATCTTCCTTTTC TTGATGCATGACAAGTGTAATCAGTACTTGCTCATTTATTTGTCTGTATTTAGTTTATGCTGTACTATTTAAT TATCCTTCCAGCGTTTTTTTTTTCTCCTTACAAATATGATACTCTTTAGTGTTAAGCTAAGGCATTGATTCAT GTATCTGTCCTTATAATGAATTAATAAACTATTTTCCAG NOVIla, CG55379-04 ,SEQ ID NO: 134 1254aa M at 134608.7kD Protein Sequence MARGDAGRGRGLLALTFCLLAARGELLLPQETTVELSCGVGPLQVILGPEQAAVLNCSLGAAAAGPPTRVTWS KDGDTLLEHDHLHLLPNGSLWLSQPLAPNGSDESVPEAVGVIEGNYSCLAHGPLGVLASQTAVVKLASLADFS LHPESQTVEENGTARFECHIEGLPAPIITWEKDQVTLPEEPRLIVLPNGVLQILDVQESDAGPYRCVATNSAR QHFSQEALLSVAHRGSLASTRGQDVVIVAAPENTTVVSGQSVVMECVASADPTPFVSWVRDGKPISTDVIVLG RTNLLIANAQPWHSGVYVCRANKPRTRDFATAAAELRVLLAAPAITQAPEALSRTRASTARFVCRASGEPRPA LRWLHNGAPLRPNGRVKVQGGGGSLVITQIGLQDAGYYQCVAENSAGMACAAASLAVVVREGLPSAPTRVTAT PLSSSAVLVAWERPEMHSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTELQVRDLEPNTDYEFYVVAYSQLGA SRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVKYKIEYGLGKEGEWGDQIFSTEVR GNETQLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPP HPTQISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVKLVAFNKHEDG YAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKIVNYTVRFSPWGLRNASLVT YYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPT EPNGEIVEYLILYSSNHTQPEHQWTLLTTQGNIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQE KLSDSLDMHSVTGIIVGVCLGLLCLLACMCAGLRRSPHRESLPGLSSTATPGNPALYSRARLGPPSPPAAHEL ESLVHPHPQDWSPPPSDVEDRAEVHSLMGGGVSEGRSHSKRKISWAQPSGLSWAGSWAGCELPQAGPRPALTR ALLPPAGTGQTLLLQALVYDAIKGNGRKKSPPACRNQVEAEVIVHSDFSASNGNPDLHLQDLEPEDPLPPEAP DLISGVGDPGQGAAWLDRELGGCELAAPGPDRLTCLPEAASASCSYPDLQPGEVLEETPGDSCQLKSPCPLGA SPGLPRSPVSSSA 196 WO 2004/000997 PCT/US2003/017512 DNA Sequence I ORF Str:AGa OF Stop: end of sequence. ATGGCGCGGGGGGACGCCGGCCGCGGCCGCGGGCTCCTCGCGTTGACCTTCTGCCTGTTGGCCGCGCGCGGGG AGCTGCTGTTGCCCCAGGAGACGACTGTGGAGCTGAGCTGTGGAGTGGGGCCACTGCAAGTGATCCTGGGCCC AGAGCACGCTGCAGTGCTAAACTGTAGCCTGGGGGCTGCTGCCGCTGGACCCCCCACCAGGGTGACCTGGAGC AAGGATGGGGACACCCTGCTGGAGCACGACCACTTACACCTGCTGGCCAATGGTTCCCTGTGGCTGTCCCAGC CACTAGCACCCAATGGCAGTGACGAGTCAGTCCCTGAGGCTGTGGGGGTCATTGAAGGCAACTATTCGTGCCT AGCCCACGGNCCCCCTCGAGTGCTGGCCAGCCAGACTGCTGTCGTCAAGCTTGCCAGTCTCGCAGACTTCTCT CTGCACCCGGAGTCTCAGACGGTGGAGGAGAACGGGACAGCTCGCTTTGAGTGCCACATTGAGGGCTGCCAG CTCCCATCATTACTTGGGAGAAGGACCAGGTGACATTGCCTGAGGAGCCTCGGCTCATCGTGCTTCCCACGG CGTCCTTCAGATCCTGGATGTTCAGGAGAGTGATGCAGGCCCCTACCGCTGCGTGGCCACCAACTCAGCTCGC CAGCACTTCAGCCAGGAGGCCCTACTCAGTGTGGCCCACAGAGGTTCCCTGGCGTCCACCAGGGGGCAGGACG TGGTCATTGTGGCAGCCCCAGAGAACACCACAGTGGTGTCTGGCCAGAGTGTGGTGATGGAATGTGTGGCCTC AGCTGACCCCACCCCTTTTGTGTCCTGGGTCCGAGACGGGAAGCCCATCTCCACAGATGTCATCGTCCTGGGC CGCACCAACCTACTAATTGCCAACGCGCAGCCCTGGCACTCCGGCGTCTATGTCTGCCGCGCCAGCCCC GCACGCGCGACTTCGCCACTGCAGCCGCTGAGCTCCGTGTGCTGCTAGCGGCTCCCGCCATCACTCAGGCGCC CGAGGCGCTGTCGCGGACGCGGGCGAGCACAGCGCGCTTCGTGTGCCGCGCGTCGGGGGAGCCGCGGCCAGCG CTGCGCTGGCTGCACAACGGGGCGCCGCTGCGGCCCAACGGGCGCGTCAAGGTCCAGGGCGGCGGTGGCAGCC TGGTCATCACACAGATCGGCCTGCAGGACGCCGGCTACTACCAGTGCGTGCTGAGACGCGCGGGAATGGC GTGCGCTGCCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACG CCACTGAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCACAGCGAGCAGATCATCGGCTTCT CTCTCCACTACCAGAAGGCACGGGGTATGGACATGTGcATACCAkGTTTGCAGTGACACGACACCACAGA ACTACAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTGGTGGCCTACTCCCAGCTGGGAGCC AGCCGCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTCCAGCACCCCAGCTCTCCCTGT CCAGCCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAGCCTGAGCAATGGGCAGGTGGT GAAGTACAAGATAGAATACGGTTTGGGAAAGGAAGATCAGATTTTCTCTACTGAGGTGCGAGGAAATGAGACA CAGCTTATGCTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTACAGCAGCCGGCT TCGGGGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGTCCCTTTTGCCCC TGCAGAGTTGAAGGTGCAGGCAAAGATGGAGTCCCTGGTCGTGTCATGGCAGCCACCCCCTCACCCCACCCAG ATCTCTGGCTACAAACTATATTGGCGGGAGGTGGGGGCTGAGGAGGAGGCCAATGGCGATCGCCTGCCAGGGG GCCGTGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGCTCAAAGAAAGTGAAGCAGTATGAGCTGACCCA GCTAGTCCCTGGCC4GGCTGTACGAGGTGAAGCTCGTGGCTTTCAACA-ACATGAGGATGGCTATGCAGCAGTG TGGAArGGCAAGACGGAGAAGGCGCCGGCACCAGACATGCCTATCCAGAGGGGACCACCCCTGCCTCCAGCCC ACGTCCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGGAAAGCCAGATTTCACACAGTCAA GATTGTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCAGGAATGCCTCCCTGGTCACCTATTACAGTTCT GGAGAAGACATCCTCATTGGCGGCTTGAAGCCATTCACCAAATACGAGTTTGCAGTGCAGTCTCACGGCGTGG ACATGGATGGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGTCCCTCCACACCCCCATCCGA CCTGCGACTGAGCCCCCTGACACCGTCCACGGTTCGGCTGCACTGGTGCCCCCCCACAAGCCACGGGGAG ATCGTGGAGTATCTGATCCTGTACACCAGCAACCACACGCAGCCTGAGCACCAGTGGACCTTGCTCACCACGC AGGGTGAGGGAAACATCTTCAGTGCTGAGGTCCATGGCCTGGAGAGCGACACTCGGTACTTCTTCAAGATGGG GGCGCGCACAGAGGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAGACTGTCA GACTCGCTGGACATcGCACTCAGTCACGGGCATCATCGTGGGTGTCTGCCTGGGCCTCCTCTGCCTCCTGGCCT GCATGTGTGCTGGCCTGCGCCGCAGCCCCCACAGGGAATCCCTCCCAGGCCTGTCCTCCACCGCCACCCCCGG GAATCCCGCGCTGTACTCCAGAGCTCGGCTTGGCCCCCCCAGCCCCCCAGCTGCCCATGAATTGGAGTCCCTT GTGCACCCCCATCCCCAGGACTGGTCCCCGCCACCCTCAGACGTGGAGGACAGGGCTGAAGTGCACAGCCTTA TGGGTGGCGGTGTTTCTGAAGGCCGGAGTCACTCCAAAGAAACGTAGTGCTCA.CCAGCGGGCTGAGCTG CGCTGGTTCCTGGGCAGGCTGTGAGCTGCCCCAGGCAGGCCCCCGGCCGGCTCTGACCCGGGCCCTGCTGCCC CCTGCTGGAACTGGGCAGACGCTGTTGCTGCAGGTTCTCTGCTCTGA TCAGGGCAATGGGAGAGAAGTCACCCCCAGCCTGCAGGAACCAGGTGGAGGCTGAAGTCATTGTCCACTCT GACTTTAGTGCATCTAACGGGAACCCTGACCTCCATCTCCAAGACCTGGAGCCTGAGGACCCCCTGCCTCCAG AGGCTCCTGATCTCATCTCGGGTGTTGGGGATCCAGGGCAGGGGGCAGCCTGGCTGGACAGGGAGTTGGGAGG GTGTGAGCTGGCAGCCCCCGGGCCAGACAGACTTACCTGCTTGCCAGAGGCAGCCAGTGCTTCCTGCTCCTAC CCGGACCTCCAGCCAGGCGAGG.TGCTAGAGGAGACCCCTGGAGATAGCTGCCAGCTCAAATCCCCCTGCCCTC TAGGAGCCAGCCCAGGCCTGCCCAGATCCCCGGTCTCCTCCTCT 197 WO 2004/000997 PCT/US2003/017512 NOV11b,CG55379-01 SEQDNO:136 1247aa W at 133821.810D Protein Sequence MARGDAGRGRGLLALTFCLLAARGELLLPQETTVELSCGVGPLQVILGPEQAAVLNCSLGAAAAGPPTRVTWS KDGDTLLEHDHLHLLANGSLWLSQPLAPNGSDESVPEAVGVIEGNYSCLAHGPPRVLASQTAVVKLASLADFS LHPESQTVEENGTARFECHIEGLPAPIITWEKDQVTLPEEPRLIVLPNGVLQILDVQESDAGPYRCVATNSAR QHFSQEALLSVAHRGSLASTRGQDVVIVAAPENTTVVSGQSVVMECVASADPTPFVSWVRDGKPISTDVIVLG RTNLLIANAQPWHSGVYVCRANKPRTRDFATAAAELRVLLAAPAITQAPEALSRTRASTARFVCRASGEPRPA LRWLHNGAPLRPNGRVKVQGGGGSLVITQIGLQDAGYYQCVAENSAGMACAAASLAVVVREGLPSAPTRVTAT PLSSSAVLVAWERPEMHSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTELQVRDLEPNTDYEFYVVAYSQLGA SRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVKYKIEYGLGKEDQIFSTEVRGNET QLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPPHPTQ ISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVKLVAFNKHEDGYAAV WKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKIVNYTVRFSPWGLRNASLVTYYSS GEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGE IVEYLILYSSNHTQPEHQWTLLTTQGEGNIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLS DSLDMHSVTGIIVGVCLGLLCLLACMCAGLRRSPHRESLPGLSSTATPGNPALYSRARLGPPSPPAAHELESL VHPHPQDWSPPPSDVEDRAEVHSLMGGGVSEGRSHSKRKVSAQPSGLSWAGSWAGCELPQAGPRPALTRALLP PAGTGQTLLLQVLCSDQGNGRKKSPPACRNQVEAEVIVHSDFSASNGNPDLHLQDLEPEDPLPPEAPDLISGV GDPGQGAAWLDRELGGCELAAPGPDRLTCLPEAASASCSYPDLQPGEVLEETPGDSCQLKSPCPLGASPGLPR SPVSSS OVI1c, 258065951 ISBQ IDNO: 137 1609bp DNA Sequence OR Start: at 1 ORF Stop: at 1609 GGTACCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACGCCAC TCAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCACAGCGAGCAGATCATCGGCTTCTCTCT CCACTACCAGAAGGCACGGGGCATGGACAATGTGGAATACCAGTTTGCAGTGAACAACGACACCACAGAACTA CAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTGGTGGCCTACTCCCAGCTGGGAGCCAGCC GCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTGCAGCACCCCAGCTCTCCCTGTCCAG CCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAC-CCTGAGCAATGGGCAGGTGGTGAAG TACAAGATAGAATACGGTTTGGGAAAGGAAGATCAGATTTTCTCTACTGAGGTGCGAGGAAATGAGACACAGC TTATGCTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTACAGCAGCCGGCTTCGG GGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGTCCCTTTTGCCCCTGCA GAGTTGAAGGTGCAGGCAAAGATGGAGTCCCTGGTCGTGTCATGGCAGCCACCCCCTCACCCCACCCAGATCT CTGGCTACAAACTATATTGGCGGCAGGTGGGGGCTGAGGAGGAGGCCAATGGCGATCGCCTGCCAGGGGGCCG TGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGGCTCAAGAAGAAAGTGAAGCAGTATGAGCTGACCCAGCTA GTCCCTGGCCGGCTGTACGAGGTGAAGCTCGTGGCTTTCAACAAACATGAGGATGGCTATGCAGCAGTGTGGA AGGGCAAGACGGAGAAGGCGCCGGCACCAGACATGCCTATCCAGAGGGGACCACCCCTGCCTCCAGCCCACGT CCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGGAAAAAGCCAGATTTCACCACAGTCAAGATT GTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCAGGAATGCCTCCCTGGTCACCTATTACACCAGTTCTG GAGAAGACATCCTCATTGGCGGCTTGAAGCCATTCACCAAATACGAGTTTGCAGTGCAGTCTCACGGCGTGGA CATGGATGGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGGCCCTCCACACCCCCATCCGAC CTGCGACTGAGCCCCCTGACACCGTCCACGGTTCGGCTGCACTGGTGCCCCCCCACAGAGCCCAACGGGGAGA TCGTGGAGTATCTGATCCTGTACAGCAGCAACCACACGCAGCCTGAGCACCAGTGGACCTTGCTCACCACGCA GGGAAACATCTTCAGTGCTGAGGTCCATGGCCTGGAGAGCGACACTCGGTACTTCTTCAAGATGGGGGCGCGC ACAGAGGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAGAAGCTGTCAGACTCGG TCG 5 198 WO 2004/000997 PCT/US2003/017512 NOVIlc, 258065951 0SEQ IDNO: 138 536 aa MW at 59532.7kD Protein Sequence GTASLAVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMHSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTEL QVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVK YKIEYGLGKEDQIFSTEVRGNETQLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPA ELKVQAKMESLVVSWQPPPHPTQISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQL VPGRLYEVKLVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKI VNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSD LRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTPEHQWTLLTTQGNIFSAEVHGLESDTRYFFKMGAR TEVGPGPFSRLQDVITLQEKLSDSV NOV 11d, 209886264 SEQ ID NO: 139 1611 bp DNA Sequence ORF Start: at i ORF Stop: end of sequence GGTACCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACGCCAC TGAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCCCAGCGAGCAGATCATCGGCTTCTCTCT CCACTACCAGAAGGCACGGGGCATGGACAATGTGGAATACCAGTTTGCAGTGAACAACGACACCACAGAACTA CAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTOGTGGCCTACTCCCAGCTGGGAGCCAGCC GCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTGCAGCACCCCAGCTCTCCCTGTCCAG CCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAGCCTGAGCAATGGGCAGGTGGTGAAG TACAAGATAGAATACGGTTTGGGAAAGGAAGATCAGATTTTCTCTACTGAGGTGCGAGGAAATGAGACACAGC TTATGTTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTACAGCAGCCGGCTTCGG GGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGTCCCTTTTGCCCCTGCA GAGTTGAAGGTGCAGGCAAAGATGGAGTCCCTGGTCGTATCATGGCAGCCACCCCCTCACCCCACCCAGATCT CTGGCTACAAACTATATTGGCGGGAGGTGGGGGCTGAGGAGGAGGCCAATGGCGATCGCCTGCCAGGGGGCCG TGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGGCTCAAGAAGAAAGTGAAGCAGTATGAGCTGACCCAGCTA GTCCCTGGCCGGCTGTACGAGGTGAAGCTCGTGGCTTTCAACAAACATGAGGATGGCTATGCAGCAGTGTGGA AGGGCAAGACGGAGAAGGCGCCGGCACCAGACATGCCTATCCAGAGGGGACCACCCCTGCCTCCAGCCCACGT CCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGGAAAAAGCCAGATTTCACCACAGTCAAGATT GTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCAGGAATGCCTCCCTGGTCACCTATTACACCAGTTCTG GAGAAGACATCCTCATTGGCGGCTTGAAGCCATTCACCAAATACGAGTTTGCAGTGCAGTCTCACGGCGTGGA CATGGATGGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGGCCCTCCACACCCCCATCCGAC CTGCGACTGAGCCCCCTGACGCCGTCCACGGTTCGGCTGCACTGGTGCCCCCCCACAGAGCCCAACGGGGAGA TCGTGGAGTATCTGATCCTGTACAGCAGCAACCACACGCAGCCTGAGCACCAGTGGACCTTGCTCACCACGCA GGGAAACATCTTCAGTGCTGAGGTCCATGGCCTGGAGAGCGACACTCGGTACTTCTTCAAGATGGGGGCGCGC ACAGAGGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAGAAGCTGTCAGACTCGG TCGAC 5 NOV11d, 209886264 SEQ ID NO: 140 537 aa at 59607.7kD Protein Sequence E GTASLAVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTEL QVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVK YKIEYGLGKEDQIFSTEVRGNETQLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSKVPFAPA ELKVQAKMESLVVSWQPPPHPTQISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQL VPGRLYEVKLVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKI VNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSD LRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQWTLLTTQGNIFSAEVHGLESDTRYFFKMGAR TEVGPGPFSRLQDVITLQEKLSDSVD 199 WO 2004/000997 PCT/US2003/017512 NOV11e, 209886345 ISEQ ID NO: 141 1672 bp DNA Sequence _ ORF Start: at 1 _ORF Stop: at 1672 GGTACCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACGCCAC TGAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCCCAGCGAGCAGATCATCGGCTTCTCTCT CCACTACCAGAAGGCACGGGGCATGGACAATGTGGAATACCAGTTTGCAGTGAACAACGACACCACAGAACTA CAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTGGTGGCCTACTCCCAGCTGGGAGCCAGCC GCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTGCAGCACCCCAGCTCTCCCTGTCCAG CCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAGCCTGAGCAATGGGCAGGTGGTGAAG TACAAGATAGAATACGGTTTGGGAAAGGAAGATCAGATTTTCTCTACTGAGGTGCGAGGAAATGAGACACAGC TTATGTTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTACAGCAGCCGGCTTCGG GGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGTCCCTTTTGCCCCTGCA GAGTTGAAGGTGCAGGCAAGGATGGAGTCCCTGGTCGTGTCATGGCAGCCACCCCCTCACCCCACCCAGATCT CTGGCTACAAACTATATTGGCGGGAGGTGGGGGCTGAGGAGGAGGCCAATGGCGATCGCCTGCCAGGGGGCCG TGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGGCTCAAGAAGAAAGTGAAGCAGTATGAGCTGACCCAGCTA GTCCCTGGCCGGCTGTACGAGGTGAAGCTCGTGGCTTTCAACAAACATGAGGATGGCTATGCAGCAGTGTGGA AGGGCAAGACGGAGAAGGCGCCGGCACCAGACATGCCTATCCAGAGGGGACCACCCCTGCCTCCAGCCCACGT CCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGGAAAAAGCCAGATTTCACCACAGTCAAGATT GTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCAGGAATGCCTCCCTGGTCACCTATTACACCAGTTCTG GAGAAGACATCCTCATTGGCGGCTTGAAGCCATTCACCAAATACGAGTTTGCAGTGCAGTCTCACGGCGTGGA CATGGATCGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGGCCCTCCACACCCCCATCCGAC CTGCGACTGAGCCCCCTGACGCCGTCCACGGTTCGGCTGCACTGGTGCCCCCCCACAGAGCCCAACGGGGAGA TCGTGGAGTATCTGATCCTGTACAGCAGCAACCACACGCAGCCTGAGCACCAGTGGACCTTGCTCACCACGCA GGGAAACATCTTCAGTGCTGAGGTCCATGGCCTGGAGAGCGACACTCGGTACTTCTTCAAGATGGGGGCGCGC ACAGAGGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAGAAGCTGTCAGACTCGG TCGACAGCTTCTCCTGGAGCGTGATCACAGCCCCTCGCGCACCACCACGGCCAGCGACGCGGTACC NOV11e, 209886345 1SEQ IDWNO 1 557 at 61878.3kD Protein Sequence _ GTASLAVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTEL QVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVK YKIEYGLGKEDQIFSTEVRGNETQLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPA ELKVQARMESLVVSWQPPPHPTQISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQL VPGRLYEVKLVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKI VNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSD LRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQWTLLTTQGNIFSAEVHGLESDTRYFFKMGAR TEVGPGPFSRLQDVITLQEKLSDSVDSFSWSVITAPRAPPRPATR~Y 5 NOV11f, 209886357 ISEQ ID NO: 143 1611bp DNA Sequence tORF Start: at 1 ORF Stop: end of sequence GGTACCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACGCCAC TGAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCCCAGCGAGCAGATCATCGGCTTCTCTCT CCACTACCAGAAGGCACGGGGCATGGACAATGTGGAATACCAGTTTGCAGTGAACAACGACACCACAGAACTA CAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTGGTGGCCTACTCCCAGCTGGGAGCCAGCC GCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTGCAGCACCCCAGCTCTCCCTGTCCAG CCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAGCCTGAGCAATGGGCAGGTGGTGAAG TACAAGATAGAATACGGTTTGGGAAAGGAAGATCAGATTTTCTCTACTGAGGTGCGAGGAAATGAGACACAGC TTATGTTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTACAGCAGCCGGCTTCGG GGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGTCCCTTTTGCCCCTGCA GAGTTGAAGGTGCAGGCAAAGATGGAGTCCCTGGTCGTGTCATGGCAGCCACCCCCTCACCCCACCCAGATCT CTGGCTACAAACTATATTGGCGGGAGGTGGGGGCTGAGGAGGAGGCCAATGGCGATCGCCTGCCAGGGGGCCG TGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGGCTCAAGAAGAAAGTGAAGCAGTATGAGCTGACCCAGCTA GTCCCTGGCCGGCTGTACGAGGTGAAGCTCGTGGCTTTCAACAAACATGAGGATGGCTATGCAGCAGTGTGGA AGGGCAAGACGGAGAAGGCGCCGGCACCAGACATGCCTATCCAGAGGGGACCACCCCTGCCTCCAGCCCACGT 200 WO 2004/000997 PCT/US2003/017512 CCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGAAAAAGCCAGATTTCACCACAGTCAAGATT GTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCAGGAATGCCTCCCTGGTCACCTATTACACCAGTTCTG GAGAAGACATCCTCATTGGCGGQTTGAAGCCATTCACCAAATACGAGTTTGCAGTGCAGTCTCACGGCGTGGA CATGGATGGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGGCCCTCCACACCCCCATCCGAC CTGCGACTGAGCCCCCTGACGCCGTCCACGGTTCGGCTGOCACTGGTGCCCCCCCACAGAGCCCAACGGGGAGA TCGTGGAGTATCTGATCCTGTACAGCAGCAACCACACGCAGCCTGAGCACCAGTGGACCTTGCTCACCACGCA GGGAAACATCTTCAGTGCTGAGGTCCATGGCCTGGAGAGCGACACTCGGTACTTCTTCAAGATGGGGGCGCGC ACAGAGGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAGAAGCTGTCAGACTCGG TCGAC NOV11f, 209886357 SEQ ID NO: 144 537 aa IMW at 59607.7kD Protein Sequence I GTASLAVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTEL QVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVK YKIEYGLGKEDQIFSTEVRGNETQLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPA ELKVQAKMESLVVSWQPPPHPTQISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQL VPGRLYEVKLVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKI VNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSD LRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQWTLLTTQGNIFSAEVHGLESDTRYFFKMGAR TEVGPGPFSRLQDVITLQEKLSDSVD OV11g, CG55379-02 SEQ ID NO: 145 11611 bp DNA Sequence ORF Start: at 7 IORF Stop: at 1606 GGTACCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACGCCAC TGAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCCCAGCGAGCAGATCATCGGCTTCTCTCT CCACTACCAGAAGGCACGGGGCATGGACAATGTGGAATACCAGTTTGCAGTGAACAACGACACCACAGAACTA CAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTGGTGGCCTACTCCCAGCTGGGAGCCAGCC GCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTGCAGCACCCCAGCTCTCCCTGTCCAG CCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAGCCTGAGCAATGCGCAGGTGGTGAAG TACAAGATAGAATACGGTTTGGGAAAGGAAGATCAGATTTTCTCTACTGAGGTGCGAGGAAATGAGACACAGC TTATGTTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTACAGCAGCCGGCTTCGG GGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGTCCCTTTTGCCCCTGCA GAGTTGAAGGTGCAGGCAAAGATGGAGTCCCTGGTCGTATCATGGCAGCCACCCCCTCACCCCACCCAGATCT CTGGCTACAAACTATATTGGCCGGACGTGGGGGCTGAGGAGGAGGCCAATGGCGATCGCCTGCCAGGGGGCCG TGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGGCTCAAGAAGAAAGTGAAGCAGTATGAGCTGACCCAGCTA GTCCCTGGCCGGCTGTACGAGGTGAAGCTCGTGGCTTTCAACAAACATGAGGATGGCTATGCAGCAGTGTGGA AGGGCAAGACGGAGAAGGCGCCGGCACCAGACATGCCTATCCAGAGGGGACCACCCCTGCCTCCAGCCCACGT CCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGGAAAAAGCCAGATTTCACCACAGTCAAGATT GTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCACGAATGCCTCCCTGGTCACCTATTACACCAGTTCTG GAGAAGACATCCTCATTGGCGGCTTGAAGCCATTCACCAAATACGAGTTTGCAGTGCAGTCTCACGGCGTGGA CATGGATGGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGGCCCTCCACACCCCCATCCGAC CTGCGACTGAGCCCCCTGACGCCGTCCACGGTTCGGCTGCACTGGTGCCCCCCCACAGAGCCCAACGGGGAGA TCGTGGAGTATCTGATCCTGTACAGCAGCAACCACACGCAGCCTGAGCACCAGTGGACCTTGCTCACCACGCA GGGAAACATCTTCAGTGCTGACGTCCATGGCCTGGAGAGCGACACTCGGTACTTCTTCAAGATGGGGGCGCGC ACAGAGGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAGAAGCTGTCAGACTCGG TCGAC 5 201 WO 2004/000997 PCT/US2003/017512 NOV11g, CG55379-02 3SEQ ID NO: 146 533aa MW at 59235.4kD Protein Sequence ASLAVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTELOV RDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVKYK IEYGLGKEDQIFSTEVRGNETQLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAEL KVQAKMESLVVSWQPPPHPTQISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKQYELTQLVP GRLYEVKLVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKIVN YTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSDLR LSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTPEHQWTLLTTQGNIFSAEVHGLESDTRYFFKMGARTE VGPGPFSRLQDVITLQEKLSDS NOV11h, CG55379-03 SEQ ID NO: 147 1672bp DNA Sequence ORF Start: at 7 ORF Stop: at 1606 GGTACCGCGTCGCTGGCCGTGGTGGTGCGCGAGGGGCTGCCCAGCGCCCCCACGCGGGTCACTGCTACGCCAC TGAGCAGCTCCGCTGTGTTGGTGGCCTGGGAGCGGCCCGAGATGCCCAGCGAGCAGATCATCGGCTTCTCTCT CCACTACCAGAAGGCACGGGGCATGGACAATGTGGAATACCAGTTTGCAGTGAACAACGACACCACAGAACTA CAGGTTCGGGACCTGGAACCCAACACAGATTATGAGTTCTACGTGGTGGCCTACTCCCAGCTGGGAGCCAGCC GCACCTCCACCCCAGCACTGGTGCACACACTGGATGATGTCCCCAGTGCAGCACCCCAGCTCTCCCTGTCCAG CCCCAACCCTTCGGACATCAGGGTGGCGTGGCTGCCCCTGCCCCCCAGCCTGAGCAATGGGCAGGTGGTGAAG TACAAGATAGAATACGGTTTGGGAAAGGAAGATCAGATTTTCTCTACTGAGGTGCGAGGAAATGAGACACAGC TTATGTTGAACTCGCTTCAGCCAAACAAGGTGTATCGAGTACGGATTTCGGCTGGTACAGCAGCCGGCTTCGG GGCCCCCTCCCAGTGGATGCATCACAGGACGCCCAGTATGCACAACCAGAGCCATGTCCCTTTTGCCCCTGCA GAGTTGAAGGTGCAGGCAAGGATGGAGTCCCTGGTCGTGTCATGGCAGCCACCCCCTCACCCCACCCAGATCT CTGGCTACAAACTATATTGGCGGGAGGTGGGGGCTGAGGAGGAGGCCAATGGCGATCGCCTGCCAGGGGGCCG TGGAGACCAGGCTTGGGATGTGGGGCCTGTCCGGCTCAAGAAGAAAGTGAAGCAGTATGAGCTGACCCAGCTA GTCCCTGGCCGGCTGTACGAGGTGAAGCTCGTGGCTTTCAACAAACATGAGGATGGCTATGCAGCAGTGTGGA AGGGCAAGACGGAGAAGGCGCCGGCACCAGACATGCCTATCCAGAGGGGACCACCCCTGCCTCCAGCCCACGT CCATGCGGAATCAAACAGCTCCACATCCATCTGGCTTCGGTGGAAAAAGCCAGATTTCACCACAGTCAAGATT GTCAACTACACTGTGCGCTTCAGCCCCTGGGGGCTCAGGAATGCCTCCCTCGTCACCTATTACACCAGTTCTG GAGAAGACATCCTCATTGGCGGCTTGAAGCCATTCACCAAATACGAGTTTGCAGTGCAGTCTCACGGCGTGGA CATGGATGGGCCTTTCGGCTCTGTGGTGGAGCGCTCCACCCTGCCTGACCGGCCCTCCACACCCCCATCCGAC CTGCGACTGAGCCCCCTGACGCCGTCCACGGTTCGGCTGCACTGGTGCCCCCCCACAGAGCCCAACGGGGAGA TCGTGGAGTATCTGATCCTGTACAGCAGCAACCACACGCAGCCTGAGCACCAGTGGACCTTGCTCACCACGCA GGGAAACATCTTCAGTGCTGAGGTCCATGGCCTGGAAGCGACACTCGGTACTTCTTCAAGATGGGGGCGCGC ACAGACGTGGGACCTGGGCCTTTCTCCCGCCTGCAGGATGTGATCACGCTCCAGGAGAAGCTGTCAGACTCGG TCGACAGCTTCTCCTGGAGCGTGATCACAGCCCCTCGCGCACCACCACGGCCAGCGACGCGGTACC 5 NOV11 h, CG55379-03 ISEQ ID NO: 148 533 aa MW at 59263.4kD Protein Sequence ASLAVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFAVNNDTTELQV RDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNPSDIRVAWLPLPPSLSNGQVVKYK IEYGLGKEDQIFSTEVRGNETQLMLNSLQPNKVYRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAEL KVQARMESLVVSWQPPPHPTQISGYKLYWREVGAEEBANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVP GRLYEVKLVAFNKHEDGYAAVWKGKTEAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFTTVKIVN YTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGSVVERSTLPDRPSTPPSDLR LSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQWTLLTTQGNIFSAEVHGLESDTRYFFKMGARTE VGPGPFSRLQDVITLQEKLSDS 202 WO 2004/000997 PCT/US2003/017512 A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 1 lB. Table 11B. Comparison of the NOV11 protein sequences. NOVIla MARGDAGRGRGLLALTFCLLAARGELLLPQETTVELSCGVGPLQVILGPEQAAVLNCSLG NOVilb MARGDAGRGRGLLALTFCLLAARGELLLPQETTVELSCGVGPLQVILGPEQAAVLNCSLG NOV11c ----------------------------------------------------------- NOVIlcd ----------------------------------------------------------- NOV11e ----------------------------------------------------------- NOV11f ----------------------------------------------------------- NOV11g ----------------- ---------------------------- ---------- NOV11~h ----------------------------------------------------------- NOV11a AAAAGPPTRVTWSKDGDTLLEHDHLHLLPNGSLWLSQPLAPNGSDESVPEAVGVIEGNYS NOV11b AAAAGPPTRVTWSKDGDTLLEHDHLHLLANGSLWLSQPLAPNGSDESVPEAVGVIEGNYS NUV11c -------- ------------------------------------------------ - NOVIld ----------------------------------------------------------- NOVile -------------------------------------------------- NUV11f ----------------------------------------------------------- NOVllf NOVIIg ----------------------------------------------------------- NOV11h ----------------------------------------------------------- NOV11a CAAHAGPLGPTRVTWSKDGDTLLEHDHFLHLLPNGSLWLSQPLAPNGSDESVPEAVGVIEGNYSDQ NOVIlb CLAAAAGPPRVTWSDGDLASQTAVVKLASLADFSLHPELANGSLWLSQPLAPNGSDRFECHIEGLPAPIITWEKDQYS NOV11c ---------------------------------------------------------- NOVIcd ---------------------------------------------------------- NOVIIde ---------------------------------------------------------- NOVIef ----------------------------------------------------------- NOVIlf NOVIIg ----------------------------------------------------------- NOV1L1h ----------------------------------------------------------- NOVllh NOVIla VTLPEEPRLVLASQTAPNGVLQILDVQESDAGPYRCESQTVEENGTARFSQEALLSVAHRGSLASTRPITWEKDQ NOVIlb VTCLAHPEEPRLGVASQTAVLQLDVQESDAGPYRCVATNSGARQHFSQEALLSVAHRGSAPISTRITWEKDQ NOVlic NGV11c ----------------------------------------------------------- NOVild ----------------------------------------------------------- NOVIle ----------------------------------------------------------- NOVllf NOV11~f ---------------------------------------------------

--------

NOVIlg ----------------------------------------------------------- NOV1L1h ----------------------------------------------------------- NOVllh NOVIIa VTLPEEPLGQDVVIVAAPENTTVVSGQSVVMECVASADPTPFVSWVRDGKPISTDVIVLGRTNLLIAN NOVIlb VTLPEPLGQDVVIVAAPENTTVVSGQSVVMECVASADPTPFVSWVRDGKPISTDVIVLGRTNLLIAN NOV11c ----------------------------------------------------------- NOVIcd ----------------------------------------------------------- NOVIld NOVIIe ----------------------------------------------------------- NOV11f ----------------------------------------------------------- NOV11g ------------------------- ---------------------------------- NOV11h ----------------------------------------------------------- NOVllg NOVllh NOV11a AQPWHSGVYVCRANKPRTRDFATAAAELRVLLAAPAITQAPEALSRTRASTDVIVLGRTNLLIFVCRASG NOVIlb AQPWHSGVYVCRANKPRTRDFATAAAELRVLLAAPAITQAPEALSRTRASTDVVLGRTNLLIANSG NOV11c -------------------------------------------------------- NOVIld ----------------------------------------------------------- NOV11e ----------------------------------------------------------- 203 NOVIle NOVllf NOVllg NOVllh NOVI la AQPWHSGVYVCRANKPRTRDFATAAAELRVLLAAPAITQAPEALSRTRASTARFVCRASG NOVI lb AQPWHSGVYVCRANKPRTRDFATAAAELRVLLAAPAITQAPEALSRTRASTARFVCRASG NOVllc NOVild NOVile 203 WO 2004/000997 PCT/US2003/017512 NOVlf ------------------------------------

----------

NOVlg ---------------------------------------------------------- NOVl1h--------------------------------------------------------- NOVIla EPRPALRWLHNGAPLRPNGRVKVQGGGGSLVITQIGLQDAGYYQCVAENSAGMACAAASL NOV11b EPRPALRWLHNGAPLRPNGRVKVQGGGGSLVITQIGLQDAGYYQCVAENSAGMACAAASL NOV11c - -------------------------------------------------------- GTASL NOVIld ------------------------------------------------------- GTASL NOVIle ------------------------------------------------------- GTASL NOVlf ------------------------------------------------------- GTASL NOVllg --------------------------------------------------------- ASL NOVlh --------------------------------------------------------- ASL NOV11a AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMHSEQIIGFSLHYQKARGMDNVEYQFA NOV11Ib AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMHSEQIIGFSLHYQKARGMDNVEYQFA NOV11c AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMHSEQIIGFSLHYQKARGMDNVEYQFA NOVIlid AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFA NOVIle AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFA NOVIlf AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFA NOVllg AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFA NOV11h AVVVREGLPSAPTRVTATPLSSSAVLVAWERPEMPSEQIIGFSLHYQKARGMDNVEYQFA NOV11a VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOVlb VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOV11c VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOV11d VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOV11e VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOV11f VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOVllg VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOV11h VNNDTTELQVRDLEPNTDYEFYVVAYSQLGASRTSTPALVHTLDDVPSAAPQLSLSSPNP NOV11a SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKEGEWGDQIFSTEVRGNETQLMLNSLQPNKV NOVllb SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKE ---- DQIFSTEVRGNETQLMLNSLQPNKV NOV11c SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKE ---- DQIFSTEVRGNETQLMLNSLQPNKV NOV11d SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKE ---- DQIFSTEVRGNETQLMLNSLQPNKV NOVIle SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKE ---- DQIFSTEVRGNETQLMLNSLQPNKV NOV11f SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKE ----DQIFSTEVRGNETQLMLNSLQPNKV NOVllg SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKE ---- DQIFSTEVRGNETQLMLNSLQPNKV NOV11h SDIRVAWLPLPPSLSNGQVVKYKIEYGLGKE ---- DQIFSTEVRGNETQLMLNSLQPNKV NOV11a YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPPHPT NOV11b YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPPHPT NOV11c YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPPHPT NOV11d YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPPHPT NOV11e YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQARMESLVVSWQPPPHPT NOV11f YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPPHPT NOVIig YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQAKMESLVVSWQPPPHPT NOV11h YRVRISAGTAAGFGAPSQWMHHRTPSMHNQSHVPFAPAELKVQARMESLVVSWQPPPHPT NOVila QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOVIlb QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOV11c QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOViId QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOV11e QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOVIIf QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOV1lg QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOV11h QISGYKLYWREVGAEEEANGDRLPGGRGDQAWDVGPVRLKKKVKQYELTQLVPGRLYEVK NOVIla LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT 204 WO 2004/000997 PCT/US2003/017512 NOV11b LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT NOV11c LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT NOVIId LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT NOVIle LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT NOV11f LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT NOVlIg LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT NOV11h LVAFNKHEDGYAAVWKGKTEKAPAPDMPIQRGPPLPPAHVHAESNSSTSIWLRWKKPDFT NOV11a TVKIVNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOV11b TVKIVNYTVRFSPWGLRNASLVTYYSS-GEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOV11c TVKIVNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOVIid TVKIVNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOVile TVKIVNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOVIif TVKIVNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOVIig TVKIVNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOVIlh TVKIVNYTVRFSPWGLRNASLVTYYTSSGEDILIGGLKPFTKYEFAVQSHGVDMDGPFGS NOVila VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQW NOVilb VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQW NOV11ic VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQW NOVlId VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQW NOVIle VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQW NOV11f VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQW NOVllg VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTQPEHQW NOVIlh VVERSTLPDRPSTPPSDLRLSPLTPSTVRLHWCPPTEPNGEIVEYLILYSSNHTOPEHQW NOVIla TLLTTQG--NIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDSLDMH NOVIlb TLLTTQGEGNIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDSLDMH NOV11c TLLTTQG--NIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDSV-- NOV11d TLLTTQG--NIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDSVD- NOVIle TLLTTQG--NIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDSVDSF NOVIlf TLLTTQG--NIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDSVD- NOVllg TLLTTQG--NIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDS--- NOV11h TLLTTQG--NIFSAEVHGLESDTRYFFKMGARTEVGPGPFSRLQDVITLQEKLSDS --- NOV11a SVTGIIVGVCLGLLCLLACMCAGLRRSPHRESLPGLSSTATPGNPALYSRARLGPPSPPA NOV11b SVTGIIVGVCLGLLCLLACMCAGLRRSPHRESLPGLSSTATPGNPALYSRARLGPPSPPA NOV11c --------------------------------------------------------- NOV1ld ----------------------------------------------------------- NOV11e SWSVITAPRAPPRPATRY----------------------------------------- NOV11f ---------------------------------------------------------- NOVllg ---------------------------------------------------------- NOVIlh --------------------------------------------------------- NOV11a AHELESLVHPHPQDWSPPPSDVEDRAEVHSLMGGGVSEGRSHSKRKISWAQPSGLSWAGS NOV11b AHELESLVHPHPQDWSPPPSDVEDRAEVHSLMGGGVSEGRSHSKRK-VSAQPSGLSWAGS NOV11c ----------------------------------------------------------- NOV11d -------------------------------------------------------- NOVIle ---------------------------------------------------------- NOV11f ---------------------------------------------------------- NOVllg ------------------------------------------------------- NOVIlh .---------------------------------------------------------- NOV11a WAGCELPQAGPRPALTRALLPPAGTGQTLLLQALVYDAIKGNGRKKSPPACRNQVEAEVI NOVl1b WAGCELPQAGPRPALTRALLPPAGTGQTLLLQVLCSD--QGNGRKKSPPACRNQVEAEVI NOV11c ---------------------------------------------------------- NOVIld ----------------------------------------------------------- NOVIle ---------------------------------------------------------- NOVlf ----------------------------------------------------------- 205 WO 2004/000997 PCT/US2003/017512 NOV11g ----------------------------------------------------------- NOV11h ----------------------------------------------------------- NOVIla VHSDFSASNGNPDLHLQDLEPEDPLPPEAPDLISGVGDPGQGAAWLDRELGGCELAAPGP NOVilb VHSDFSASNGNPDLHLQDLEPEDPLPPEAPDLISGVGDPGQGAAWLDRELGGCELAAPGP NOV11c ----------------------------------------------------------- NOVIld ---------------------------------------------------------- NOVle --------------------------------------------

---------

NOVIlf ------------------------------------ ------ ----- NOVlg ----------------------------------------------

-----------

NOVIlh --------------------------------------------------------- NOVIla DRLTCLPEAASASCSYPDLQPGEVLEETPGDSCQLKSPCPLGASPGLPRSPVSSSA NOV11b DRLTCLPEAASASCSYPDLQPGEVLEETPGDSCQLKSPCPLGASPGLPRSPVSSS NOV11c ------------------------------------------------------- NOV11d ------------------------------------------------------- NOVle --------------- ----------------------------------- NOV11f ------------------------------------------------------- NOVllg ------------------------------------------------------ NOVlh ------------------------------------------------------- NOVila (SEQ ID NO: 134) NOV11b (SEQ ID NO: 136) NOVllc (SEQ ID NO: 138) NOV11d (SEQ ID NO: 140) NOVIle (SEQ ID NO: 142) NOV11f (SEQ ID NO: 144) NOV1lg (SEQ ID NO: 146) NOV11h (SEQ ID NO: 148) Further analysis of the NOV11 a protein yielded the following properties shown in Table 11C. Table 11C. Protein Sequence Properties NOV11a SignalP analysis: Cleavage site between residues 25 and 26 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 10; pos.chg 3; neg.chg 1 H-region: length 12; peak value 10.30 PSG score: 5.90 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): 1.11 possible cleavage site: between 24 and 25 >>> Seems to have a cleavable signal peptide (1 to 24) ALOM: Klein et al's method for TM region allocation Init position for calculation: 25 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 1 INTEGRAL Likelihood =-11.89 Transmembrane 963 - 979 PERIPHERAL Likelihood = 0.90 (at 321) ALOM score: -11.89 (number of TMSs: 1) 206 WO 2004/000997 PCT/US2003/017512 MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 12 Charge difference: -5.0 C(-2.0) - N( 3.0) N >= C: N-terminal side will be inside >>> membrane topology: type la (cytoplasmic tail 980 to 1254) MITDISC: discrimination of mitochondrial targeting seq R content: 4 Hyd Moment(75): 11.83 Hyd Moment(95): 5.63 G content: 5 D/E content: 2 S/T content: 1 Score: -4.74 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 33 ARGIEL NUCDISC: discrimination of nuclear localization signals pat4: none pat7: PVRLKKK (4) at 696 bipartite: none content of basic residues: 8.2% NLS Score: -0.13 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: ARGD none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: too long tail Dileucine motif in the tail: found LL at 1097 LL at 1107 checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 55.5 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues 207 WO 2004/000997 PCT/US2003/017512 Final Results (k = 9/23): 55.6 %: endoplasmic reticulum 22.2 %: Golgi 11.1 %: plasma membrane 11.1 %: extracellular, including cell wall >> prediction for CG55379-04 is end (k=9) A search of the NOV11 a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D. 5 Table 11D. Geneseq Results for NOV11a NOVla Geneseq Protein/Organism/Length [Patent Residues/ Idenities/ Expect Identifier #, Date] Match Similarities for the Value Matched Region Residues AAG65914 Amino acid sequence of GSK gene Id 1..1254 1248/1255 (99%) 0.0 27142 - Homo sapiens, 1250 aa. 1..1250 1249/1255 (99%) [WO200172961-A2, 04-OCT-2001] AAU77405 Human NOV1 protein, homologue of 1..1253 1237/1255 (98%) 0.0 NOPE/PUNC Ig proteins - Homo 1..1247 1239/1255 (98%) sapiens, 1247 aa. [WO200206329-A2, 24-JAN-2002] AAE05251 Mouse Nope (neighbour ofpunc ell) 1..1253 1093/1256 (87%) 0.0 protein - Mus musculus, 1252 aa. 1..1249 1146/1256 (91%) [WO200149714-A2, 12-JUL-2001] ABP69002 Human polypeptide SEQ ID NO 332..1254 919/923 (99%) 0.0 1049 - Homo sapiens, 980 aa. 62..980 919/923 (99%) [WO200270539-A2, 12-SEP-2002] AAE05252 Mouse Nope (neighbour ofpunc ell) 24..958 843/937 (89%) 0.0 extracellular domain - Mus musculus, 1..932 879/937 (92%) 932 aa. [WO200149714-A2, 12-JUL-2001] In a BLAST search of public sequence databases, the NOV1 la protein was found to have homology to the proteins shown in the BLASTP data in Table 11E. 208 WO 2004/000997 PCT/US2003/017512 Table lIE. Public BLASTP Results for NOV11a Protein NOVila Protein NOV11a Identities/ Accession Protein/Organism/Length Residues/ Similarities for the Expect Number MatchResidues Matched Portion Value Residues Q8TDY8 HDDM36 - Homo sapiens 1..1254 1248/1255 (99%) 0.0 (Human), 1250 aa. I..1250 1249/1255 (99%) Q9EQS9 DDM36 - Mus musculus (Mouse), 1..1253 1100/1256 (87%) 0.0 1252 aa. 1..1249 1151/1256 (91%) Q9EQS8 DDM36E - Mus musculus (Mouse), 1..1253 1100/1256 (87%) 0.0 1253 aa. 1..1250 1151/1256 (91%) Q9JLI1 Neighbor of Punc ell protein - Mus 1..1253 1093/1256 (87%) 0.0 musculus (Mouse), 1252 aa. 1..1249 1146/1256 (91%) Q9HCE4 Hypothetical protein KIAA1628 - 332..1254 919/923 (99%) 0.0 Homo sapiens (Human), 980 aa 62..980 919/923 (99%) ......... (fragm ent). PFam analysis predicts that the NOV1 la protein contains the domains shown in the Table 1 IF. 5 Table 11F. Domain Analysis of NOVIla Identities/ Pfam Domain NOV11 a Match Region Similarities Expect Value for the Matched Region ig 157..214 15/61 (25%) 4.2e-07 42/61 (69%) ig 258..313 19/59 (32%) 1.3e-08 42/59 (71%) ig 349..407 18/62 (29%) 2.5e-05 42/62 (68%) fn3 429..515 27/88 (31%) 3.le-21 72/88 (82%) fn3 527..617 25/92 (27%) 1.3e-12 62/92 (67%) fn3 634..733 28/103 (27%) 1.4e-08 72/103 (70%) fn3 754..839 24/88 (27%) 4.7e-09 57/88 (65%) fn3 851..939 28/91 (31%) 1.7e-14 !_73/91 (80%) 209 WO 2004/000997 PCT/US2003/017512 Example 12. The NOVI2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A. Table 12A. NOV12 Sequence Analysis NOV12a, CG55688-01 SEQ ID NO: 149 1887 bp DNA Sequence ORF Start: ATG at 81 ORF Stop: TAA at 1224 GCGCACGGCCTGTCCGCTGCACACCAGCTTGTTGGCGTCTTCGTCGCCGCGCTCGCCCCGGGCTACTCCTGCG CGCCACAATGAGCTCCCGCATCGCCAGGGCGCTCGCCTTAGTCGTCACCCTTCTCCACTTGACCAGGCTGGCG CTCTCCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCGCCGGGAGTCGGGCTGGTCC GGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAAAACGCAGCCCTGCGA CCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATCTGCAGAGCTCAGTCA GAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTCCAGCCCAACTGTAAACATC AGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCTGTGTCCCCAAGAACTATCTCTCCCCAACTTGGG CTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGTCTGTGACGAGGATAGTATC AAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGTAAGGAGCTGGGATTCGATGCCTCCGAGGTGGAGTTGA CGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGATCCCTGTTTTTGGAATGGAGCC TCGCATCCGATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTCATGGTCCCAGTGCTCAAAG ACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGACAACCCTGAGTGCCGCCTTGTGAAAGAAACCCGGA TTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAGCCTGAAAAAGGGCAAGAAATGCAGCAAGACCAA CAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTGTGAAGAAATACCGGCCCAAGTACTGC GGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAGATGCGGTTCCGCTGCGAAG ATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGTCCTGCAAATGCAACTACAACTGCCCGCATGCCAA TGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGGGACTAATGCTACCTGGGTTT CCAGGGCACACCTAGACAAACAAGGGAGAAGAGTGTCAGAATCAGAATCATGGAGAAAATGGGCGGGGGTGGT GTGGGTGATGGGACTCATTGTAGAAAGGAAGCCTTGCTCATTCTTGAGGAGCATTAAGGTATTTCGAAACTGC CAAGGGTGCTGGTGCGGATGGACACTAATGCAGCCACGATTGGAGAATACTTTGCTTCATAGTATTGGAGCAC ATGTTACTCCTTCATTTTGGAGCTTGTGGAGTTGATGACTTTCTGTTTTCTGTTTGTAAATTATTTGCTAAGC ATATTTTCTCTAGGCTTTTTTCCTTTTGGGGTTCTACAGTCGTAAAAGAGATAATAAGATTAGTTGGACAGTT TAAAGCTTTTATTCGTCCTTTGACAAAAGTAAATGGGAGGGCATTCCATCCCTTCCTGAAGGGGGACACTCCA TGAGTGTCTGTGAGAGGCAGCTATCTGCACTCTAAACTGCAAACAGAAATCAGGTGTTTTAAGACTGAATGTT TTATTTATCAAAATGTAGCTTTTGGGGAGGGAGGGGAAATGTAATACTGGAATAATTTGTAAATGATTTTAAT TTTATATTCAGTGAAAAGATTTTATTTATGGAATTAACCATTTAATAAAGAAATATTTACCT 5 NOV12a, CG55688-01 SEQ ID NO: 150 381 aa MW at 42069.1kD Protein Sequence MSSRIARALALVVTLLHLTRLALSTCPAACHCPLAPKCAPVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHT KGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPOELSLPNLGCP NPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRIPVFGMEPRI RYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKS PEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHAEA AFPFYRLFNDIHKFRD 210 WO 2004/000997 PCT/US2003/017512 NOV12b, 254087906 JSEQUDNO:151 '1158bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence AGATCTACCATCAGCTCCCGCATCGCCAGGGCGCTCGCCTTAGTCGTCACCCTTCTCCACTTGACCAGGCTGG CGCTCTCCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCGCCGGGAGTCGGGCTGGT CCGGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAAAACGCAGCCCTGC GACCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATCTGCAGAGCTCAGT CAGAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTCCAGCCCAACTGTAAACA TCAGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCTGTGTCCCCAAGAACTATCTCTCCCCAACTTG GGCTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGTCTGTGACGAGGATAGTA TCAAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGCAAGGAGCTGGGATTCGATGCCTCCGAGGTGGAGTT GACGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGCTCCCTGTTTTTGGAATGGAG CCTCGCATCCTATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTCATGGTCCCAGTGCTCAA AGACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGACAACCCTGAGTGCCGCCTTGTGAAAGAAACCCG GATTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAGCCTGAAAAAGGGCAAGAAATGCAGCAAGACC AAGAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTGTGAAGAAATACCGGCCCAAGTACT GCGGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAGATGCGGTTCCGCTGCGA AGATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGTCCTGCAAATGCAACTACAACTGCCCGCATGCC AATGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGGGACCTCGAG NOV12b, 254087906 ffSEQ ID NO: 152 386 aa MW at 42612.7kD Protein Sequence RSTMSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPC DHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNL GCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGME PRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKT KKSPEPVRFTYAGCLSVRKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSMVMMIQSCKCNYNCPHA NEAAFPFYRLFNDIHKFRDLE 5 NOV12c, 259278648 SEQDNO:153 204 bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence AGATCTTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTCCAGCCCAACTGTAAACATCAGTGCA CATGTATTGATGGCGCCGTOGGCTGCATTCCTCTGTGTCCCCAAGAACTATCTCTCCCCAACTTGGGCTGTCC CAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGACGAGTGGGTCTGTCTCGAG NOV12c, 259278648 ISEQ ID NO: 154 68 aa 1MWat7576.6kD Protein Sequence I RSCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEWVCLE 211 WO 2004/000997 PCT/US2003/017512 NOV12d, 259280032 SEQIDNO: 155 228 bp DNA Seqec quence ORF Start: at 1 ORF Stop: end of sequence AGATCTTGCCCCGCTGCCTOCCACTGCCCCCTGCAGGCGCCCAAGTGCGCGCCGGGAGTCGGGCTGGTCCGGG ACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAAAACGCAGCCCTGCGACCA CACCAAGGGGCTOGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATCTGCAGAGCTCAGTCAAG GGCCTCGAG NOV12d, 259280032 10BQDD40: 156 76aa 1MWat7856.9kD Protein Sequence RSCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTPCDHTKGLECNFGASSTALKGICRAQSE GLE 5 NOV12e, 254756530 BQID NO:157 228bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence AGATCTTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCGCCGGGAGTCGGGCTGGTCCGGG ACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAAAACGCAGCCCTGCGACCA CACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATCTGCAGAGCTCAGTCAGAG GGCCTCGAG NOV12e, 254756530 jSEQIDNO: 158 7 MWat 7856.9kD Protein Sequence RSCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTLKGICRAQSE GLE NOV12f, 229509618 :SEQ ID NO: 159 1228bp DNA Sequence ORF Start: at 3 OP Stop: at 1227 TGTACAAGAAAGCTGGGTCGGCGCGCCCACCCTTCACCACCATGAGCTCCCGCATCGCCAGGGCGCTCGCCTT AGTCGTCACCCTTCTCCACTTGACCAGGCTGGCGCTCTCCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAG GCGCCCAAGTGCGCGCCGGGAGTCGGGCTGGTCCGGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGC TCAACGAGGACTGCAGCAAAACGCAGCCCTGCGACCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTC CACCGCTCTGAAGGGGATCTGCAGAGCTCAGTCAGAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAA AACGGGGAAAGTTTCCAGCCCAACTGTAAACATCAGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTC TGTGTCCCCAAGAACTATCTCTCCCCAACTTGGCTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTG CTGCGAGGAGTGGGTCTGTGACGAGGATAGTATCAAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGCAAG GAGCTGGGATTCGATGCCTCCGAGGTGGAGTTGACGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCT CACTGAAGCGGCTCCCTGTTTTTGGAATGGAGCCTCGCATCCTATACAACCCTTTACAAGGCCAGAAATGTAT TGTTCAAACAACTTCATGGTCCCAGTGCTCAAAGACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGAC AACCCTGAGTGCCGCCTTGTGAAAGAAACCCGGATTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCA GCCTGAAAAAGGGCAAGAAATGCAGCAAGACCAAGAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATG TTTGAGTGTGAAGAAATACCGGCCCAAGTACTGCGGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTG ACCAGGACTGTGAAGATGCGGTTCCGCTGCGAAGATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGT CCTGCAAATGCAACTACAACTGCCCGCATGCCAATGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACAT TCACAAATTTAGGGACAAGGGTGGGCGCGCCCTTTCTCGAGTACGGCGGCCGCGGAGCCT 10 212 WO 2004/000997 PCT/US2003/017512 NOV12f,229509618 SEQ ID NO: 160 408 aa MW at 45009.5kD Protein Sequence YKKAGSARPPFTTMSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQL NEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPL CPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSS LKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSS LKKGKKCSKTKKSPEPVRFTYAGCLSVKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQS CKCNYNCPHANEAAFPFYRLFNDHKFRDKGGRALSRVRRPRS NOV12g, 229509658 SEQIDNO: 161 1111 bp DNA Sequence ORF Start ORF Stop: end of sequence AGGCTCCGCGGCCGCCCCCTTCACCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCG CCGGGAGTCGGGCTGGTCCGGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCA GCAAAACGCAGCCCTGCGACCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGG GATCTGCAGAGCTCAGTCAGAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTC CAGCCCAACTGTAAACATCAGTOCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCTGTGTCCCCAAGAAC TATCTCTCCCCAACTTGGGCTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGT CTGTGACGAGGATACTATCAAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGCAAGGAGCTGGGATTCGAT GCCTCCGAGGTGGAGTTAACGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGCTCC CTGTTTTTGGAATGGAGCCTCGCATCCTATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTC ATGGTCCCAGTGCTCAAAGACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGACAACCCTGAGTGCCGC CTTGTGAAAGAAACCCGGATTTGTGAGGTGCGGCCTTGTGGACAGCCAGTTACAGCAGCCTGAAAAAGGGCA AGAAATGCAGCAAGACCAAAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTTGAAGAA ATACCGGCCCAAGTACTGCGGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAG ATGCGGTTCCGCTGCGAAGATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGTCCTGCAAATGCAACT ACAACTGCCCGCATGCCAATGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGGGA CAAGGGTGGGCGCGCC 5 NOV12g, 229509658 ISEQ ID NO: 162 370 aa MW at 40610.3kD Protein Sequence GSAAAPFTTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKG ICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWV CDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTS WSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVKK YRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD KGGRA 213 WO 2004/000997 PCT/US2003/017512 NOV12h, CG55688-02 SEQ ID NO: 163 11068 bp DNA Sequence jORF Start: at 1 lORF Stop: end of sequence ACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCGCCGGGAGTCGGGCTGGTCCGGGACG GCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAAAACGCAGCCCTGCGACCACAC CAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATCTGCAGAGCTCAGTCAGAGGGC AGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTCCAGCCCAACTGTAAACATCAGTGCA CATGTATTGATGGCGCCGTGGGCTGCATTCCTCTGTGTCCCCAAGAACTATCTCTCCCCAACTTGGGCTGTCC CAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGTCTGTGACGAGGATAGTATCAAGGAC CCCATGGAGGACCAGGACGGCCTCCTTGGCAAGGAGCTGGGATTCGATGCCTCCGAGGTGGAGTTGACGAGAA ACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGCTCCCTGTTTTTGGAATGGAGCCTCGCAT CCTATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTCATGGTCCCAGTGCTCAAAGACCTGT GGAACTGGTATCTCCACACGAGTTACCAATGACAACCCTGAGTGCCGCCTTGTGAAAGAAACCCGGATTTGTG AGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAGCCTGAAAAAGGGCAAGAAATGCAGCAAGACCAAGAAATC CCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTGTGAAGAAATACCGGCCCAAGTACTGCGGTTCC TGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAGATGCGGTTCCGCTGCGAAGATGGGG AGACATTTTCCAAGAACGTCATGATGATCCAGTCCTGCAAATGCAACTACAACTGCCCGCACGCCAATGAAGC AGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGG NOV12h, CG55688-02 SEQ ID NO: 164 356 aa MW at 39322.9kD Protein Sequence TCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEG RPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKE PMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTC GTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVKKYRPKYCGS CVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFR 5 NOV12i,CG55688-03 SEQUNO: 165 1198tp DNA Sequence ORF Start: at 2 ORF Stop: end of sequence GTACAAAAAAGCAGGCTCCGCGGCCGCCCCCTTCACCACCATGAGCTCCCGCATCGCCAGGGCGCTCGCCTTA GTCGTCACCCTTCTCCACTTGACCAGGCTGGCGCTCTCCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGG CGCCCAAGTGCGCGCCGGGAGTCGGGCTGGTCCGGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCT CAACGAGGACTGCAGCAAAACGCAGCCCTGCGACCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCC ACCGCTCTGAAGGGGATCTGCAGAGCTCAGTCAGAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAA ACGGGGAAAGTTTCCAGCCCAACTGTAAACATCAGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCT GTGTCCCCAAGAACTATCTCTCCCCAACTTGGGCTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGC TGCGAGGAGTGGGTCTGTGACGAGGATAGTATCAAGGACCCCATCGAGGACCAGGACGGCCTCCTTGGCAAGG AGCTGGGATTCGATGCCTCCGAGGTGGAGTTGACGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTC ACTGAAGCGGCTCCCTGTTTTTGGAATGGAGCCTCGCATCCTATACAACCCTTTACAAGGCCAGAAATGTATT GTTCAAACAACTTCATGGTCCCAGTGCTCAAAGACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGACA ACCCTGAGTGCCGCCTTGTGAAAGAAACCCGGATTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAG CCTGAAAAAGGGCAAGAAATGCAGCAAGACCAAGAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGT TTGAGTGTGAAGAAATACCGGCCCAAGTACTGCGGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGA CCAGGACTGTGAAGATGCGGTTCCGCTGCGAAGATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGTC CTGCAAATGCAACTACAACTGCCCGCATGCCAATGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATT CACAAATTTAGGGACAAGGGTGGGCGCGCC 214 WO 2004/000997 PCT/US2003/017512 OVI2i, CG55688-03 SEQ ID NO: 166 1399 aa MW at43790.1kD Protein Sequence YKKAGSAAAPFTTMSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQL NEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPL CPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSS LKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSS LKKGKKCSKTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKMVMMIQS CKCNYNCPHANEAAFPFYRLFNDIHKFRDKGGRA NOV12j, CG55688-04 SEQ IDNO: 167 1111 bp DNA Sequence OIEStart: at 2 ORF Stop: end of sequence AGGCTCCGCGGCCGCCCCCTTCACCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCG CCGGGAGTCGGGCTGGTCCGGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCA GCAAAACCCAGCCCTGCGACCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGG GATCTGCAGAGCTCAGTCAGAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTC CAGCCCAACTGTAAACATCAGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCTGTGTCCCAAGAAC TATCTCTCCCCAACTTGGGCTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGT CTGTGACGAGGATAGTATCAAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGCAAGGAGCTGGGATTCGAT GCCTCCGAGGTGGAGTTAACGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGCTCC CTGTTTTTGGAATGGAGCCTCGCATCCTATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTC ATGGTCCCAGTGCTCAAAGACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGACAACCCTGAGTGCCGC CTTGTGAAAGAAACCCGGATTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAGCCTGAAAAAGGGCA AGAAATGCAGCAAGACCAAGAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTGTGAAGAA ATACCGGCCCAAGTACTGCGGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAG ATGCGGTTCCGCTGCGAAGATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGTCCTGCAAATGCAACT ACAACTGCCCGCATGCCAATGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGGGA CAAGGGTGGGCGCGCC 5 NOV12j, CG55688-04 SEQ ID NO: 168 370 aa MW at 40610.3kD Protein Sequence GSAAAPFTTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKG ICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWV CDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTS WSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVRK YRPKYCGSCVDGRCCTPLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD KGGRA 215 WO 2004/000997 PCT/US2003/017512 NOV12k, CG55688-05 SEQ ID NO: 169 1174 bp DNA Sequence ORFStart: ATG at 23 _ORF Stop: at 1166 GAATTCGCCCTTCACCAGATCTATGAGCTCCCGCATCGCCAGGGCGCTCGCCTTAGTCGTCACCCTTCTCCAC TTGACCAGGCTGGCGCTCTCCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCGCCGG GAGTCGGGCTGGTCCGGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAA AACGCAGCCCTGCGACCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATC TGCAGAGCTCAGTCAGAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTCCAGC CCAACTGTAAACATCAGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCTGTGTCCCCAAGAACTATC TCTCCCCAACTTGGGCTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGTCTGT GACGAGGATAGTATCAAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGCAAGGAGCTGGGATTCGATGCCT CCGAGGTGGAGTTGACGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGCTCCCTGT TTTTGGAATGGAGCCTCGCATCCTATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTCATGG TCCCAGTGCTCAAAGACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGACAACCCTGAGTGCCGCCTTG TGAAAGAAACCCGGATTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAGCCTGAAAAAGGGCAAGAA ATGCAGCAAGACCAAGAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTGTGAAGAAATAC CGGCCCAAGTACTGCGGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAGATGC GGTTCCGCTGCGAAGATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGTCCTGCAAATGCAACTACAA CTGCCCGCATGCCAATGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGGGACCTC GAGGGC NOV12k, CG55688-05 SEQ ID NO: 170 381 aa MW at 42026.1kD Protein Sequence MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHT KGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCP NPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRI LYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKS PEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEA AFPFYRLFNDIHKFRD 5 NOV121, CG55688-06 SEQ IDNO: 171 1168 bp DNA Sequence IORF Start: ATG at 14 lORF Stop: TAG at 1157 CACCGGATCCACCATGAGCTCCCGCATCGCCAGGGCGCTCGCCTTAGTCGTCACCCTTCTCCACTTGACCAGG CTGGCGCTCTCCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCGCCGGCAGTCGGGC TGGTCCGGGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAAAACGCAGCC CTGCGACCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATCTGCAGAGCT CAGTCAGAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTCCAGCCCAACTGTA AACATCAGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCTGTGTCCCCAAGAACTATCTCTCCCCAA CTTGGGCTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGTCTGTGACGAGGAT AGTATCAAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGCAAGGAGCTGGGATTCGATGCCTCCGAGGTGG AGTTGACGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGCTCCCTGTTTTTGGAAT GGAGCCTCGCATCCTATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTCATGGTCCCAGTGC TCAAAGACCTGTGGAACTGGTATCTCCACACGAGTTACCAATGACAACCCTGAGTGCCGCCTTGTGAAAGAAA CCCGGATTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAGCCTAAAAAGGGCAAGAAATGCAGCAA GACCAAGAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTGTGAAGAAATACCGGCCCAAG TACTGCGGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAGATGCGGTTCCGCT GCGAAGATGGGGAGACATTTTCCAAGAACGTCATGATGATCCAGTCCTGCAAATGCAACTACAACTGCCCGCA TGCCAATGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGGGACTAGGTCGACGGC 216 WO 2004/000997 PCT/US2003/017512 NOV121, CG55688-06 SEQ ID NO: 172 1381 aa MW at 42026. lkD Protein Sequence I MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHT KGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCP NPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLIKRLPVFGMEPRI LYNPLQGQKCIVQTTSWSCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTRKS PEPVRPTYAGCLSVRKYRPKYCGSCVDGRCCTPOLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEA AFPFYRLFNDIHKFRD NOV12m, SNP13376428 of SEQ ID NO: 173 1887 bp CG55688-01, DNA Sequence ORF Start: ATG at 81 ORF Stop: TAA at 1224 SNP Pos: 571 SNP Change: A to G GCGCACGGCCTGTCCGCTGCACACCAGCTTGTTGGCGTCTTCGTCGCCGCGCTCGCCCCGGGCTACTCCTGCG CGCCACAATGAGCTCCCGCATCGCCAGGGCGCTCGCCTTAGTCGTCACCCTTCTCCACTTGACCAGGCTGGCG CTCTCCACCTGCCCCGCTGCCTGCCACTGCCCCCTGGAGGCGCCCAAGTGCGCGCCGGGAGTCGGGCTGGTCC GGACGGCTGCGGCTGCTGTAAGGTCTGCGCCAAGCAGCTCAACGAGGACTGCAGCAAAACGCAGCCCTGCGA CCACACCAAGGGGCTGGAATGCAACTTCGGCGCCAGCTCCACCGCTCTGAAGGGGATCTGCAGAGCTCAGTCA GAGGGCAGACCCTGTGAATATAACTCCAGAATCTACCAAAACGGGGAAAGTTTCCAGCCCAACTGTAAACATC AGTGCACATGTATTGATGGCGCCGTGGGCTGCATTCCTCTTGTCCCCAACGAACTATCTCTCCCCAACTTGGG CTGTCCCAACCCTCGGCTGGTCAAAGTTACCGGGCAGTGCTGCGAGGAGTGGGTCTGTGGCGAGGATAGTATC AAGGACCCCATGGAGGACCAGGACGGCCTCCTTGGTAAGGAGCTGGGATTCGATGCCTCCGAGGTGGAGTTGA CGAGAAACAATGAATTGATTGCAGTTGGAAAAGGCAGCTCACTGAAGCGGATCCCTGTTTTTGGAATGGAGCC TCGCATCCGATACAACCCTTTACAAGGCCAGAAATGTATTGTTCAAACAACTTCATGGTCCCAGTGCTCAAAG ACCTGTGGAACTGGTATCTCCACACCAGTTACCAATGACAACCCTGAGTGCCCCTTGTGAAAGAAACCCGGA TTTGTGAGGTGCGGCCTTGTGGACAGCCAGTGTACAGCAGCCTGAAAAAGGGCAAGAAATGCAGCAAGACCAA GAAATCCCCCGAACCAGTCAGGTTTACTTACGCTGGATGTTTGAGTGTGAAGAAATACCGGCCCAAGTACTGC GGTTCCTGCGTGGACGGCCGATGCTGCACGCCCCAGCTGACCAGGACTGTGAAGATGCGGTTCCGCTGCGAAG ATGGGGAGACATTTTCCAAGAACGTCATATGATCCAGTCCTGCAAATGCAACTACAACTGCCCGCATGCCAA TGAAGCAGCGTTTCCCTTCTACAGGCTGTTCAATGACATTCACAAATTTAGGGACTAAATGCTACCTGGGTTT CCAGGGCACACCTAGACAAACAAGGGAGAAGAGTGTCAGAATCAGAATCATGGAGAAAATGGGCGGGGGTGGT GTGGGTGATGGGACTCATTGTAGAAAGGAAGCCTTGCTCATTCTTGAGGAGCATTAAGGTATTTCOAAACTGC CAAGGGTGCTGGTGCGGATGGACACTAATGCAGCCACGATTGGAGAATACTTTGCTTCATAGTATTGG3AGCAC ATGTTACTGCTTCATTTTGGAGCTTGTGGAGTTGATGACTTTCTGTTTTCTGTTTGTAAATTATTTGCTAAGC ATATTTTCTCTAGGCTTTTTTCCTTTTGGGGTTCTACAGTCGTAAAAGAGATAATAAGATTAGTTGGACAGTT TAAAGCTTTTATTCGTCCTTTGACAAAAGTAAATGGGAGGGCATTCCATCCCTTCCTGAAGGGGGACACTCCA TGAGTGTCTGTGAGAGGCAGCTATCTGCACTCTAA.ACTGCAA.ACAGAAATCAGGTGTTTTAAGACTGAATGTT TTATTTATCAAAATGTAGCTTTTGGGGAGGGAGGGGAAATGTAATACTGGAATAATTTGTAAATGATTTTAAT TTTATATTCAGTGAAAAGATTTTATTTATGGAATTAACCATTTAATAAAGAAATATTTACCT 5 NOV12m, SNP13376428 of SEQ IDNO: 174 j381 aa MW at 42011.lkD CG55688-01, Protein Sequence SNP Pos: 164 SNP Change: Asp to Gly MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHT KGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCP NPRLVKVTGQCCEEWVCGEDS IKDPMEDQDGLLGELGFDASEVELTRNNELIAVGKGSSLKRIPVFGMEPRI RYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKS PEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPOLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEA AFPFYRLFNDIHKFRD 217 WO 2004/000997 PCT/US2003/017512 A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 12B. Table 12B. Comparison of the NOV12 protein sequences. NOV12a -------------MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVR NOV12b ----------RSTMSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVR NOV12c --------------------------------------- RSCEYNSRIYQNGESFQPNCKHQC NOVI2d --------------------------------------- RSCPAACHCPLEAPKCAPGVGLVR NOV12e --------------------------------------- RSCPAACHCPLEAPKCAPGVGLVR NOV12f YKKAGSARPPFTTMSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVR NOV12g ---------------------------- GSAAAPFTTCPAACHCPLEAPKCAPGVGLVR NOV12h ---------------------------------------- TCPAACHCPLEAPKCAPGVGLVR NOV12i YKKAGSAAAPFTTMSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVR NOV12j ---------------------------- GSAAAPFTTCPAACHCPLEAPKCAPGVGLVR NOV12k -------------MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVR NOV121 -------------MSSRIARALALVVTLLHLTRLALSTCPAACHCPLEAPKCAPGVGLVR NOV12a DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12b DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12c TCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCLE--------------- NOV12d DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGLE------- NOV12e DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGLE------- NOV12f DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12g DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12h DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12i DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12j DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12k DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV121 DGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIY NOV12a QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12b QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12c ----------------------------------------------------------- NOV12d ----------------------------------------------------------- NOV12e ----------------------------------------------------------- NOV12f QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12g QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12h QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12i QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12j QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12k QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV121 QNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDS NOV12a IKDPMEDQDGLLGKELGEDASEVELTRNNELIAVGKGSSLKRIPVFGMEPRIRYNPLQGQ NOV12b IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ NOV12c ----------------------------------------------------------- NOV12d ---------------------------------------------------------- NOV12e ----------------------------------------------------------- NOV12f IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ NOV12g IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ NOV12h IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ NOV12i IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ NOV12j IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ NOV12k IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ NOV121 IKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQ 218 WO 2004/000997 PCT/US2003/017512 NOV12a KCIVQTTSWSQCSKTCGTGISTRVTDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV12b KCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS N O V 12c - - - - - - - - - - - - - - - - - - - - - - - - - - - - - N O V 12d - - - - - - - - - - - - - - - - - - - - - - - - - - - - - N O V 12e - - - - - - - - - - - - - - - - - - - - - - - - - - - - - NOV12f KCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV12g KCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV12h KCIVQTTSWSQCSKTCGTGI STRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV12 i KCTVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV12j KCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV12k KCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV121 KCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCS NOV12 a KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNV NOV12b KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNV N OV 12c - - - - - - - - - - - - - - - - - - - - - - - - - - - - - N O V 12d - - - - - - - - - - - - - - - - - - - - - - - - - - - - - N OV 12e - - - - - - - - - - - - - - - - - - - - - - - - - - - - - NOV12 f KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNV NOV12 g KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNV NOV12h KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNV NOV12 i KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNV NOV12 j KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKV NOV12k KTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNV NOV12 1 KTKKSPEPVPRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETSKMV NOV12a MMIQSCKCNYNCPIIANEAAFPFYRLFNDIHKFRD-------------- NOV12b MMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRDLE ----------- N OV 12c - - - - - - - - - - - - - - - - - - - - - - - N OV 12d - - - - - - - - - - - - - - - - - - - - - - - N OV 12e - - - - - - - - - - - - - - - - - - - - - - - NOV12Ei MMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRDKGGRALSRVRRPRS NOV12g MMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRDKGGRA--------- NOV12h MMIQSCKCNYNCPHANEAAFPFYRLFNDI-KFR--------------- NOV12 i MMIQSCKCNYNCPHNEAAFPFYRLFNDIKFRDKGGRA-------- NOV12j MMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRDKGGRA-------- NOV12k MMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD-------------- N0V121 MMIQSCKCNYNCPI{ANEAAFPFYRLFNDIEKFRD-------------- NOV12a (SEQ ID NO: 150) NOV12b (SEQ ID NO: 152) NOV12c (SEQ ID NO: 154) NOV12d (SEQ ID NO: 156) NOV12e (SEQ ID NO: 158) NOV12f (SEQ ID NO: 160) NOV12g (SEQ ID NO: 162) NOV12h (SEQ ID NO: 164) NOV12j (SEQ ID NO: 166) NOV12j (SEQ ID NO: 168) NOV12k (SEQ ID NO: 170) NOV121 (SEQ IO NO: 172) Further analysis of the NOVI 2a protein yielded the following properties shown in Table 12C. 219 WO 2004/000997 PCT/US2003/017512 Table 12C. Protein Sequence Properties NOV12a SignalP analysis: Cleavage site between residues 25 and 26 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 7; pos.chg 2; neg.chg 0 H-region: length 12; peak value 10.04 PSG score: 5.64 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -1.17 possible cleavage site: between 21 and 22 >>> Seems to have a cleavable signal peptide (1 to 21) ALOM: Klein et al's method for TM region allocation Init position for calculation: 22 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 5.73 (at 124) ALOM score: 5.73 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 10 Charge difference: -1.0 C( 2.0) - N( 3.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 3 Hyd Moment(75): 7.35 Hyd Moment(95): 12.47 G content: 0 D/E content: 1 S/T content: 6 Score: 0.47 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 57 VRDIGC NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 13.9% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXPRR-like motif in the N-terminus: SSRI KKXX-like motif in the C-terminus: HKFR SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none 220 WO 2004/000997 PCT/US2003/017512 Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 56.5 %: mitochondrial 17.4 %: extracellular, including cell wall 17.4 %: nuclear 8.7 %: cytoplasmic >> prediction for CG55688-01 is mit (k=23) A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12D. 5 221 WO 2004/000997 PCT/US2003/017512 Table 12D. Geneseq Results for NOV12a NOV12a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region ABG76937 Human protein, comprising CYR61, 1..381 381/381 (100%) 0.0 designated SEC1 - Homo sapiens, 381 1..381 381/381 (100%) aa. [WO200255705-A2, 18-JUL-2002] ABB05438 Human Cyr61 protein SEQ ID NO:2 - 1.381 379/381 (99%) 0.0 Homo sapiens, 381 aa. 1..381 380/381 (99%) [WO200198359-A2, 27-DEC-2001] AAE18107 Human connective tissue growth 1..381 379/381 (99%) 0.0 factor-2 (CTGF-2) - Homo sapiens, 1..381 380/381 (99%) 381 aa. [WO200204480-A2, 17-JAN-2002] AAU79761 Human Cyr61 protein - Homo 1..381 379/381 (99%) 0.0 sapiens, 381 aa. [WO200226193-A2, 1..381 380/381 (99%) 04-APR-2002] AAB90773 Human shear stress-response protein 1.381 379/381 (99%) 0.0 SEQ ID NO: 46 - Homo sapiens, 381 1..381 380/381 (99%) aa. [WO200125427-A1, 12-APR-2001] In a BLAST search of public sequence databases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12E. 5 222 WO 2004/000997 PCT/US2003/017512 Table 12E. Public BLASTP Results for NOV12a Protein NOV12a Identities/ Protein Residues/ Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion 000622 CYR61 protein precursor 1..381 379/381 (99%) 0.0 (Cysteine-rich, angiogenic inducer, 61) 1..381 380/381 (99%) (Insulin-like growth factor-binding protein 10) (GIG1 protein) - Homo sapiens (Human), 381 aa. CAC60183 Sequence 3 from Patent WO0155210 - 1..381 377/381 (98%) 0.0 Homo sapiens (Human), 381 aa. 1..381 379/381 (98%) CAD42176 Sequence 1 from Patent EP1217067 - 1..373 358/374 (95%) 0.0 Homo sapiens (Human), 374 aa 1..374 360/374 (95%) (fragment). Q9ES72 CYR61 protein precursor 1..381 348/383 (90%) 0.0 (Cysteine-rich, angiogenic inducer, 61) 1..379 358/383 (92%) (Insulin-like growth factor-binding protein 10) - Rattus norvegicus (Rat), 379 aa. P18406 CYR61 protein precursor 1..381 348/383 (90%) 0.0 (Cysteine-rich, angiogenic inducer, 61) 1..379 358/383 (92%) (Insulin-like growth factor-binding protein 10) (3CH61) - Mus musculus (Mouse), 379 aa.

--

PFam analysis predicts that the NOV12a protein contains the domains shown in the Table 12F. 5 Table 12F. Domain Analysis of NOV12a Identities/ Pfam Domain NOV12a Match Region Similarities Expect Value for the Matched Region IGFBP 26..97 32/85 (38%) 1.4e-25 60/85 (71%) vwc 100..163 35/85 (41%) 2.4e-26 60/85 (71%) tsp_1 231..272 16/53 (30%) 5.6e-11 36/53 (68%) Cys knot 279..376 25/115 (22%) 1.5e-29 88/115 (77%) 223 WO 2004/000997 PCT/US2003/017512 Example 13. The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A. Table 13A. NOV13 Sequence Analysis NOV13a, CG506768-01 SEQ ID NO: 175 1214bp DNA Sequence ORF Start: ATG at 60 ORFStop: TAG at 1155 CTCCTTTCTTCCCTCTCCAGAAGTCCATTGGAATATTAAGCCCAGGAGTTGCTTTGGGGATGGCTGGAAGTGC AATGTCTTCCAAGTTCTTCCTAGTGGCTTTGGCCATATTTTTCTCCTTCGCCCAGGTTGTAATTGAAGCCAAT TCTTGGTGGTCGCTAGGTATGAATAACCCTGTTCAGATGTCAGAAGTATATATTATAGGAGCACAGCCTCTCT GCAGCCAACTGGCAGGACTTTCTCAAGGACAGAAGAAACTGTGCCACTTGTATCAGGACCACATGCAGTACAT CGGAGAAGGCGCGAAGACAGGCATCAAAGAATGCCAGTATCAATTCCGACATCGAAGGTGGAACTGCAGCACT GTGGATAACACCTCTGTTTTTGGCAGGGTGATGCAGATAGGCAGCCGCGAGACGGCCTTCACATACGCGGTGA GCGCAGCAGGGGTGGTGAACGCCATGAGCCGGGCGTGCCGCGAGGGCGAGCTGTCCACCTGCGGCTGCAGCCG CGCCGCGCGCCCCAAGGACCTGCCGCGGGACTGGCTCTGGGGCGGCTGCGGCGACAACATCGACTATGGCTAC CGCTTTGCCAAGGAGTTCGTGGACGCCCGCGAGCGGGAGCGCATCCACGCCAAGGGCTCCTACGAGAGTGCTC GCATCCTCATGAACCTGCACAACAACGAGGCCGGCCGCAGGACGGTGTACAACCTGGCTGATGTGGCCTGCAA GTGCCATGGGGTGTCCGGCTCATGTAGCCTGAAGACATGCTGGCTGCAGCTGGCAGACTTCCGCAAGGTGGGT GATGCCCTGAAGGAGAAGTACGACAGCGCGGCGGCCATGCGGCTCAACAGCCGGGGCAAGTTGGTACAGGTCA ACAGCCGCTTCAACTCGCCCACCACACAAGACCTGGTCTACATCGACCCCAGCCCTGACTACTGCGTGCGCAA TGAGAGCACCGGCTCGCTGGGCACGCAGGGCCGCCTGTGCAACAAGACGTCGGAGGGCATGGATGGCTGCGAG CTCATGTGCTGCGGCCGTGGCTACGACCAGTTCAAGACCGTGCAGACGGAGCGCTGCCACTGCAAGTTCCACT GGTGCTGCTACGTCAAGTGCAAGAAGTGCACGGAGATCGTGGACCAGTTTGTGTGCAAGTAGTGGGTGCCACC CAGCACTCAGCCCCGCCCCCAGGACCCGCTTATTTATAGAAAGTAC 5 NOV13a, CG56768-01 SEQ ID NO: 176 365 aa at 40886.3kD Protein Sequence MAGSAMSSKFFLVALAIFFSFAQVVIEANSWWSLGMNNPVQMSEVYIIGAQPLCSQLAGLSQGQKKLCHLYQD HMQYIGEGAKTGIKECQYQFRHRRWNCSTVDNTSVFGRVMQIGSRETAFTYAVSAAGVVNAMSRACREGELST CGCSRAARPKDLPRDWLWGGCGDNIDYGYRFAKEFVDARERERIHAKGSYESARILMNLHNNEAGRRTVYNLA DVACKCHGVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLVYIDPSPD YCVRNESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFHWCCYVKCKKCTEIVDQFVCK NOV13b, CG56768-02 ISEQ ID NO: 177 1026bp DNA Sequence ORF Start: at 7 ORF Stop: at 1021 GGATCCGCCAATTCTTGGTGGTCGCTAGGTATGAATAACCCTGTTCAGATGTCAGAAGTATATATTATAGGAG CACAGCCTCTCTGCAGCCAACTGGCAGGACTTTCTCAAGGACAGAAGAAACTGTGCCACTTGTATCAGGACCA CATGCACTACATCGGAGAAGGCGCGAAGACAGGCATCAAAGAATGCCAGTATCAATTCCGACATCGAAGGTGG AACTGCAGCACTGTGGATAACACCTCTGTTTTTGGCAGGGTGATGCAGATAGGCAGCCGCGAGACGGCCTTCA CATACGCGGTGAGCGCAGCAGGGGTGGTGAACGCCATGAGCCGGGCGTGCCGCGAGGGCGAGCTGTCCACCTG CGGCTGCAGCCGCGCCGCGCGCCCCAAGGACCTGCCGCGGGACTGGCTCTGGGGCGGCTGCGGCGACAACATC GACTATGGCTACCGCTTTGCCAAGGAGTTCGTGGACGCCCGCGAGCGGGAGCGCATCCACGCCAAGGGCTCCT ACGAGAGTGCTCGCATCCTCATGAACCTGCACAACAACGAGGCCGGCCGCAGGACGGTGTACAACCTGGCTGA TGTGGCCTGCAAGTGCCATGGGGTGTCCGGCTCATGTAGCCTGAAGACATGCTGGCTGCAGCTGGCAGACTTC CGCAAGGTGGGTGATGCCCTGAAGGAGAAGTACGACAGCGCGGCGGCCATGCGGCTCAACAGCCGGGGCAAGT TGGTACAGGTCAACAGCCGCTTCAACTCGCCCACCACACAAGACCTGGTCTACATCGACCCCAGCCCTGACTA CTGCGTGCGCAATGAGAGCACCGGCTCGCTGGGCACGCAGGGCCGCCTGTGCAACAAGACGTCGGAGGGCATG GATGGCTGCGACCTCATGTGCTGCGGCCGTGGCTACGACCAGTTCAAGACCGTGCAGACGGAGCGCTGCCACT GCAAGTTCCACTGGTGCTGCTACGTCAAGTGCAAGAAGTGCACGGAGATCGTGGACCAGTTTGTGTGCAAGCT CGAG 224 WO 2004/000997 PCT/US2003/017512 NOV13b, CG56768-02 SEQ IDNO: 178 1338 aa MW at 37991.8kD Protein Sequence 13 ANSWWSLGMNNPVQMSEVYIIGAQPLCSQLACLSQGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNC STVDNTSVFGRVMQIGSRETAFTYAVSAAGVVNAMSRACREGELSTCGCSRAARPKDLPRDWLWGGCGDNIDY GYRFAKEFVDARERERIUAKGSYESARILMNLHNNEAGRRTVYNLADVACKCHGVSGSCSLKTCWLQLADFRK VGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLVYIDPSPDYCVRNESTGSLGTQGRLCNKTSEGMDG CELMCCGRGYDQFKTVQTERCHCKFHWCCYVKCKKCTEIVDQFVCK NOV13c, CG56768-03 jSEQ ID NO: 179 1215 bp DNA Sequence . jORF Start: at 16 ORF Stop: TAG at 1156 GCTCCTTTCTTCCCTCTCCAGAAGTCCATTGGAATATTAAGCCCAGGAGTTGCTTTGGGGATGGCTGGAAGTG CAATGTCTTCCAAGTTCTTCCTAGTGGCTTTGGCCATATTTTTCTCCTTCGCCCAGGTTGTAATTGAAGCCAA TTCTTGGTGGTCGCTAGGTATGAATAACCCTGTTCAGATGTCAGAAGTATATATTATAGGAGCACAGCCTCTC TGCAGCCAACTGGCAGGACTTTCTCAAGGACAGAAGAAACTGTGCCACTTGTATCAGGACCACATGCAGTACA TCGGAGAAGGCGCGAAGACAGGCATCAAAGAATGCCAGTATCAATTCCGACATCGAAGGTGGAACTGCAGCAC TGTGGATAACACCTCTGTTTTTGGCAGGGTGATGCAGATAGGTAGCCGCGAGACGGCCTTCACATACGCGGTG AGCGCAGCAGGGGTGGTGAACGCCATGAGCCGGGCGTGCCGCGAGGGCGAGCTGTCCACCTGCGGCTGCAGCC GCGCCGCGCGCCCCAAGGACCTGCCGCGGGACTGGCTCTGGGGCGGCTCCGGCGCCACCAACAAAAAAGGCTA CCGCTCCGCCAAGGAGATCGTGCACGCCCGCGAACGAGGACGCATCCACGCCAAGGGCTCCTACGAGAGTGCT CGCATCCTCATGAACCTGCACAACAACGAGGCCGGCCGCAGGACGGTGTACAACCTGGCTGATGTGGCCTGCA AGTGCCATGGGGTGTCCGGCTCATGTAGCCTGAAGACATGCTGGCTGCAGCTGGCAGACTTCCGCAAGGTGGG TGATGCCCTGAAGGAGAAGTACGACAGCGCGGCGGCCATGCGGCTCAACAGCCGGGGCAAGTTGGTACAGGTC AACAGCCGCTTCAACTCGCCCACCACACAAGACCTGGTCTACATCGACCCCAGCCCTGACTACTGCGTGCGCA ATGAGAGCACCGGCTCGCTGGGCACGCAGGGCCGCCTGTGCAACAAGACGTCGGAGGGCATGGATGGCTGCGA GCTCATGTGCTGCGGCCGTGGCTACGACCAGTTCAAGACCGTGCAGACGGAGCGCTGCCACTGCAAGTTCCAC TGGTGCTGCTACGTCAAGTGCAAGAAGTGCACGGAGATCGTGGACCAGTTTGTGTGCAAGTAGTGGGTGCCAC CCAGCACTCAGCCCCGCTCCCAGGACCCGCTTATTTATAGAAAGTAC 5 NOV13c, CG56768-03 SEQ ID NO: 180 380aa MW at 42082.8kD Protein Sequence LQKSIGILSPGVALGMAGSAMSSKFFLVALAIFFSFAQVVIEANSWWSLGMNNPVQMSEVYIIGAQPLCSQLA GLSQGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNCSTVDNTSVFGRVMQIGSRETAFTYAVSAAGV VNAMSRACREGELSTCGCSRAARPKDLPRDWLWGGSGATNKKGYRSAKEIVHARERGRIHAKGSYESARILMN LHNNEAGRTVYNLADVACKCHGVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFN SPTTQDLVYIDPSPDYCVRNESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFHWCCYV KCKKCTEIVDQFVCK A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 13B. 225 WO 2004/000997 PCT/US2003/017512 Table 13B. Comparison of the NOV13 protein sequences. NOV13a --------------- MAGSAMSSKFFLVALAIFFSFAQVVIEANSWWSLGMNNPVQMSEV NOV13b ----------------- ----------------------- ANSWWSLGMNNPVQMSEV NOV13c LQKSIGILSPGVALGMAGSAMSSKFFLVALAIFFSFAQVVIEANSWWSLGMNNPVQMSEV NOV13 a YIIGAQPLCSQLAGLSQGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNCSTVDN NOV13b YIIGAQPLCSQLAGLSQGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNCSTVDN NOV13c YIIGAQPLCSQLAGLSQGQKKLCHLYQDHMQYIGEGAKTGIKECQYQFRHRRWNCSTVDN NOV13a TSVFGRVMQIGSRETAFTYAVSAAGVVNAMSRACREGELSTCGCSRAARPKDLPRDWLWG NOV13b TSVFGRVMQIGSRETAFTYAVSAAGVVNAMSRACREGELSTCGCSRAARPKDLPRDWLWG NOV13c TSVFGRVMQIGSRETAFTYAVSAAGVVNAMSRACREGELSTCGCSRAARPKDLPRDWLWG NOV13a GCGDNIDYGYRFAKEFVDARERERIHAKGSYESARILMNLHNNEAGRRTVYNLADVACKC NOVI3b GCGDNIDYGYRFAKEFVDARERERIHAKGSYESARILMNLHNNEAGRRTVYNLADVACKC NOV13c GSGATNKKGYRSAKEIVHARERGRIHAKGSYESARILMNLHNNEAGRRTVYNLADVACKC NOV13a HGVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLV NOV13b HGVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLV NOV13c HGVSGSCSLKTCWLQLADFRKVGDALKEKYDSAAAMRLNSRGKLVQVNSRFNSPTTQDLV NOV13a YIDPSPDYCVRNESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFK NOV13b YIDPSPDYCVRNESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFH NOV13c YIDPSPDYCVRNESTGSLGTQGRLCNKTSEGMDGCELMCCGRGYDQFKTVQTERCHCKFH NOV13a WCCYVKCKKCTEIVDQFVCK NOV13b WCCYVKCKKCTEIVDQFVCK NOV13c WCCYVKCKKCTEIVDQFVCK NOV13a (SEQ ID NO: 176) NOV13b (SEQ ID NO: 178) NOV13c (SEQ ID NO: 180) Further analysis of the NOVI 3a protein yielded the following properties shown in Table 13C. 5 Table 13C. Protein Sequence Properties NOV13a SignalP analysis: Cleavage site between residues 28 and 29 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 9; pos.chg 1; neg.chg 0 H-region: length 17; peak value 11.46 PSG score: 7.06 GvH: von Heijne's method for signal seq. recognition GvHI score (threshold: -2.1): 2.33 possible cleavage site: between 22 and 23 >>> Seems to have a cleavable signal peptide (1 to 22) ALOM: Klein at al's method for TM region allocation Init position for calculation: 23 226 WO 2004/000997 PCT/US2003/017512 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 4.51 (at 45) ALOM score: 4.51 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 11 Charge difference: -3.0 , C(-1.0) - N( 2.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 3.30 Hyd Moment(95): 2.27 G content: 1 D/E content: 1 S/T content: 4 Score: -5.10 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: RHRR (3) at 94 pat7: none bipartite: none content of basic residues: 12.6% NLS Score: -0.29 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 55.5 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues 227 WO 2004/000997 PCT/US2003/017512 Final Results (k = 9/23): 22.2 %: extracellular, including cell wall 22.2 %: vacuolar 22.2 %: mitochondrial 22.2 %: endoplasmic reticulum 11.1%: Golgi >> prediction for CG56768-01 is exc (k=9) A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13D. 5 Table 13D. Geneseq Results for NOV13a NOV13a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE34041 WNT-4 protein - Unidentified, 365 aa. 1..365 365/365 (100%) 0.0 [WO200290992-A2, 14-NOV-2002] 1..365 365/365 (100%) ABP58342 Human cell growth, differentiation 1..365 365/365 (100%) 0.0 and death protein CGDD-13 - Homo 1..365 365/365 (100%) sapiens, 365 aa. [WO200297032-A2, 05-DEC-2002] ABU56526 Lung cancer-associated polypeptide 1..365 365/365 (100%) 0.0 #119 - Unidentified, 365 aa. 1.365 365/365 (100%) [WO200286443-A2, 31-OCT-2002] ABU55887 Human WNT-5A protein - Homo 1..365 365/365 (100%) 0.0 sapiens, 365 aa. [WO200277204-A2, 1..365 365/365 (100%) 03-OCT-2002] ABU04874 Human expressed protein tag (EPT) 1..365 365/365 (100%) 0.0 #1540 - Homo sapiens, 365 aa. 1..365 365/365 (100%) [WO200278524-A2, 10-OCT-2002] In a BLAST search of public sequence databases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13E. 228 WO 2004/000997 PCT/US2003/017512 Table 13E. Public BLASTP Results for NOV13a Protein NOV13a Identities/ Accession Protein/Organism/Length Residues/ Similarities for the Expect Number MatchResidues Matched Portion Value Residues P41221 Wnt-5a protein precursor - Homo 1..365 365/365 (100%) 0.0 sapiens (Human), 365 aa. 1..365 365/365 (100%) Q8VCV6 Wnt-5a protein - Mus musculus 2..365 361/364 (99%) 0.0 (Mouse), 380 aa. 17.380 362/364 (99%) Q8BMF9 WNT-5A protein precursor - Mus 2..365 360/364 (98%) 0.0 musculus (Mouse), 380 aa. 17..380 361/364 (98%) Q8BM17 WNT-5A protein precursor - Mus 6..365 358/360 (99%) 0.0 musculus (Mouse), 360 aa. 1..360 359/360 (99%) Q9QXQ7 Wnt-5a protein precursor - Rattus 2..365 358/364 (98%) 0.0 norvegicus (Rat), 379 aa. 17..379 360/364 (98%) PFam analysis predicts that the NOV1 3a protein contains the domains shown in the Table 13F. 5 Table 13F. Domain Analysis of NOV13a Identities/ Pfam Domain NOV13a Match Region Similarities Expect Value for the Matched Region wnt 53..365 189/352 (54%) 2e-212 295/352 (84%) Example 14. The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A. 10 229 WO 2004/000997 PCT/US2003/017512 Table 14A. NOV14 Sequence Analysis NOV14a, CG57054-03 SEQ ID NO: 181 j1215bp DNA Sequence IORF Start: ATG at 55 ORF Stop: TGAt1165 CCAAACCACTGGAGGTCCTGATCGATCTGCCCACCGGAGCCTCCGGGCTTCGACATGCTGGAGGAGCCCCGGC CGCGGCCTCCGCCCTCGGGCCTCGCGGGTCTCCTGTTCCTGGCGTTGTGCAGTCGGGCTCTAAGCAATGAGAT TCTGGGCCTGAAGTTGCCTGGCGAGCCGCCGCTGACGGCCAACACCGTGTGCTTGGCGCTGTCCGGCCTGAGC AAGCGGCAGCTAGGCCTGTGCCTGCGCAACCCCGACGTGACGGCGTCCGCGCTTCAGGGTCTGCACATCGCGG TCCACGAGTGTCAGCACCAGCTGCGCGACCAGCGCTGGAACTGCTCCGCGCTTGAGGGCGGCGGCCGCCTGCC GCACCACAGCGCCATCCTCAAGCGGGCCTGGTGTAGGGGAAGGCTTGGACACCCAAATGGTTTCCGAGAAAGT GCTTTTTCCTTCTCCATGCTGGCTGCTGGGGTCATGCACGCAGTAGCCACGGCCTGCAGCCTGGGCAAGCTGG TGAGCTGTGGCTGTGGCTGGAAGGGCAGTGGTGAGCAGGATCGGCTGAGGGCCAAACTGCTGCAGCTGCAGGC ACTGTCCCGAGGCAAGAGTTTCCCCCACTCTCTGCCCAGCCCTGGCCCTGGCTCAAGCCCCAGCCCTGGCCCC CAGGACACATGGGAATGGGGTGGCTGTAACCATGACATGGACTTTGGAGAGAAGTTCTCTCGGGATTTCTTGG ATTCCAGGGAAGCTCCCCGGGACATCCAGGCACGAATGCGAATCCACAACAACAGGGTOGGGCGCCAGGTGGT AACTGAAAACCTGAAGCGGAAATGCAAGTGTCATGGCACATCTGGCAGCTGCCAGTTCAAGACAAATTCTGGA GCCTTCCAGCCCCGTCTGCGTCCCCGTCGCCTCTCAGGAGAGCTGGTCTACTTTGAGAAGTCTCCTGACTTCT GTGAGCGAGACCCCACTATGGGCTCCCCAGGGACAAGGGGCCGGGCCTGCAACAAGACCAGCCGCCTGTTGGA TGGCTGTGGCAGCCTGTGCTGTGGCCGTGGGCACAACGTGCTCCGGCAGACACGAGTTGAGCGCTGCCATTGC CGCTTCCACTGGTGCTGCTATGTGCTGTGTGATGAGTGCAAGGTTACAGAGTGGGTGAATGTGTGTAAGTGAG GGTCAGCCTTACCTTGGGGCTGGGGAAGAGGACTGTGTGAGAGGGGT NOV14a, CG57054-03 SEQ ID NO: 182 370 aa MW at 40782.4kD Protein Sequence MLEEPRPRPPPSGLAGLLFLALCSRALSNEILGLKLPGEPPLTANTVCLALSGLSKRQLGLCLRNPDVTASAL QGLHIAVHECQHQLRDQRWNCSALEGGGRLPHHSAILKRAWCRGRLGHPNGFRESAFSFSMLAAGVMHAVATA CSLGKLVSCGCGWKGSGEQDRLRAKLLQLQALSRGKSFPHSLPSPGPGSSPSPGPQDTWEWGGCNHDMDFGEK FSRDFLDSREAPRDIQARMRIHNNRVGRQVVTENLKRKCKCHGTSGSCQFKTNSGAFQPRLRPRRLSGELVYF EKSPDFCERDPTMGSPGTRGRACNKTSRLLDGCGSLCCGRGHNVLRQTRVERCHCRFHWCCYVLCDECKVTEW VNVCK 5 NOV14b, CG57054-01 SEQ ID NO: 183 1091 bp DNA Sequence ORF Start: at 3 ORF Stop: TGA at 1038 CCAACACCGTGTGCTTGACGCTGTCCGGCCTGAGCAAGCGGCAGCTAGGCCTGTGCCTGCGCA'CCCCGACGT GACGGCGTCCGCGCTTCAGGGTCTGCACATCGCGOTCCACGAGTGTCAGCACCAGCTGCGCGACCAGCGCTGG AACTGCTCCGCGCTTGAGGGCGGCGGCCGCCTGCCGCACCACAGCGCCATCCTCAAGCGCGGTTTCCGAGAAA GTGCTTTTTCCTTCTCCATGCTGGCTGCTGGGGTCATGCACGCAGTAGCCACGGCCTGCGGCCTGGGCAAGCT GGTGAGCTGTGGCTGTGGCTGGAAGGGCAGTGGTGAGCAGGATCGGCTGAGGGCCAAACTGCTGCAGCTGCAG GCACTGTCCCGAGGCAAGAGTTTCCCCCACTCTCTGCCCAGCCCTGGCCCTGGCTCAAGCCCCAGCCCTGGCC CCCAGGACACATGGGAATGGGGTGGCTGTAACCATGACATGGACTTTGGAGAGAGTTCTCTCGGGATTTCTT GGATTCCAGGGAAGCTCCCCGGRACATCCAGGCACGAATGCGAATCCACAACAACAGGGTGGGGCGCCAGGTG GTAACTGAAAACCTGAAGCGGAAATGCAAGTTCATGCACATCAGGCAGCTGCCAGTTCAAGACATGCTGGA GGGCGGCCCCAGAGTTCCGGGCAGTGGGGGCGGCGTTGAGGGAGCGGCTGGGCCGGGCCATCTTCATTGATAC CCACAACCGCAATTCTGGAGCCTTCCAGCCCCGTCTGCGTCCCCGTCGCCTCTCAGGAGAGCTGGTCTACTTT GAGAAGTCTCCTGACTTCTGTGAGCGAGACCCCACTATGGGCTCCCCAGGGACAAGGGGCCGGGCCTGCAACA AGACCAGCCGCCTGTTGGATGGCTGTGGCAGCCTGTGCTGTGGCCGTGGGCATAACGTGCTCCGGCAGACACG AGTTGAGCGCTGCCATTGCCGCTTCCACTGGTGCTGCTATGTGCTGTGTGATGAGTGCAAGGTTACAGAGTGG GTGAATGTGTGTAAGTGAGGGTCAGCCTTAGCCTTGGGGGCTGGGGAAGAGGACTGTGTGAGAGGGGCG 230 WO 2004/000997 PCT/US2003/017512 NOV14b, CG57054-01 SEQ ID NO: 184 345 aa MW at 38351.4kD Protein Sequence NTVCLTLSGLSKRQLGLCLRNPDVTASA LQGLHIAPHECQHQLRDQRWNCSALEGGGRLPKHSAILKRGFRS AFSFSMLAAGVMRAVATACGLGKLVSCGCGWKGSGEQDRLRAKLLQLQALSRGKSFPHSLPSPGPGSSPSPGP QDTWEWGGCNHDMDFEKFSRDFLDSREAPRDIQARMRIHNNRVGRQVVTENLKRKCKCHGTSGSCQFKTCWR AAPEFRAVGAALRERLGRAIFIDTHNRNSGAFQPRLRPRRLSGELVYFEKSPDFCERDPTMGSPGTRGRACNK TSRLLDGCGSLCCGRGHNVLRQTRVERCHCRFHWCCYVLCDECKVTEWVNVCK NOV14c, CG57054-02 SEQ ID NO: 185 1317 bp DNA Sequence ORF Start: ATG at 55 ORF Stop: TGA at 1222 CCAAACCACTGGAGGTCCTGATCGATCTGCCCACCGGAGCCTCCGGGCTTCGACATGCTGGAGGAGCCCCGGC CGCGGCCTCCGCCCTCGGGCCTCGCGGGTCTCCTGTTCCTGGCGTTGTGCAGTCGGGCTCTAAGCAATGAGAT TCTGGGCCTGAAGTTGCCTGGCGAGCCGCCGCTGACGGCCAACACCGTGTGCTTGACGCTGTCCGGCCTGAGC AAGCGGCAGCTAGGCCTGTGCCTGCGCAACCCCGACGTGACGGCGTCCGCGCTTCAGGGTCTGCACATCGCGG TCCACGAGTGTCAGCACCAGCTGCGCGACCAGCGCTGGAACTGCTCCGCGCTTGAGGGCGGCGGCCGCCTGCC GCACCACAGCGCCATCCTCAAGCGCGGTTTCCGAGAAAGTGCTTTTTCCTTCTCCATGCTGGCTGCTGGGGTC ATGCACGCAGTAGCCACGGCCTGCAGCCTGGGCAAGCTGGTGAGCTGTGGCTGTGGCTGGAAGGGCAGTGGTG AGCAGGATCGGCTGAGGGCCAAACTGCTGCAGCTGCAGGCACTGTCCCGAGGCAAGAGTTTCCCCCACTCTCT GCCCAGCCCTGGCCCTGGCTCAAGCCCCAGCCCTGGCCCCCAGGACACATGGGAATGGGGTGGCTGTAACCAT GACATGGACTTTGGAGAGAAGTTCTCTCGGGATTTCTTGGATTCCAGGGAAGCTCCCCGGGACATCCAGGCAC GAATGCGAATCCACAACAACAGGGTGGGGCGCCAGGTGGTAACTGAAAACCTGAAGCGGAAATGCAAGTGTCA TGGCACATCAGGCAGCTGCCAGTTCAAGACATGCTGGAGGGCGGCCCCAGAGTTCCGGGCAGTGGGGGCGGCG TTGAGGGAGCGGCTGGGCCGGGCCATCTTCATTGATACCCACAACCGCAATTCTGGAGCCTTCCAGCCCCGTC TGCGTCCCCGTCGCCTCTCAGGAGAGCTGGTCTACTTTGAGAAGTCTCCTGACTTCTGTGAGCGAGACCCCAC TATGGGCTCCCCAGGGACAAGGGGCCGGGCCTCAACAAGACCAGCCGCCTGTTGGATGGCTGTGGCAGCCTG TGCTGTGGCCGTGGGCACAACGTGCTCCGGCAGACACGAGTTGAGCGCTGCCATTGCCGCTTCCACTGGTGCT GCTATGTGCTGTGTGATGAGTGCAAGGTTACAGAGTGGGTGAATGTGTGTAAGTGAGGGTCAGCCTTACCTTG GGGGCTGGGGAAGAGGACTGTGTGAGAGGGGCGCCTTTTCAGCCCTTTGCTCTGATTTCCTTCCAAGGTCACT CTT 5 NOV14c, CG57054-02 SEQ ID NO: 186 389 aa MW at 42999.9kD Protein Sequence MLEEPRPRPPPSGLAGLLFLALCSRALSNEILGLKLPGEPPLTANTVCLTLSGLSKRQLGLCLRNPDVTASAL QGLHIAVHECQHQLRDQRWNCSALEGGGRLPHHSAILKRGFRESAFSFSMLAAGVMHAVATACSLGKLVSCGC GWKGSGEQDRLRAKLLQLQALSRGKSFPHSLPSPGPGSSPSPGPQDTWEWGGCNHDMDFGEKFSRDFLDSREA PRDIQARMRIHNNRVGRQVVTENLKRKCKCHGTSGSCQFKTCWRAAPEFRAVGAALRERLGRAIFIDTHNRNS GAFQPRLRPRRLSGELVYFEKSPDFCERDPTMGSPGTRGRACNKTSRLLDGCGSLCCGRGHNVLRQTRVERCH CRPHWCCYVLCDECKVTEWVNVCK A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 14B. 231 WO 2004/000997 PCT/US2003/017512 Table 14B. Comparison of the NOV14 protein sequences. NOV14a MLEEPRPRPPPSGLAGLLFLALCSRALSNEILGLKLPGEPPLTANTVCLALSGLSKRQLG NOV14b -------------------------------------------- NTVCLTLSGLSKRQLG NOV14c MLEEPRPRPPPSGLAGLLFLALCSRALSNEILGLKLPGEPPLTANTVCLTLSGLSKRQLG NOV14a LCLRNPDVTASALQGLHIAVHECQHQLRDQRWNCSALEGGGRLPHHSAILKRAWCRGRLG NOVI4b LCLRNPDVTASALQGLHIAVHECQHQLRDQRWNCSALEGGGRLPHHSAILKR ---- G-- NOV14c LCLRNPDVTASALQGLHIAVHECQHQLRDQRWNCSALEGGGRLPHHSAILKR --..-- G-- NOV14a HPNGFRESAFSFSMLAAGVMHAVATACSLGKLVSCGCGWKGSGEQDRLRAKLLQLQALSR NOV14b - - - -FRESAFSFSMLAAGVMHAVATACGLGKLVSCGCGWKGSGEQDRLRAKLLQLQALSR NOV14c ---- FRESAFSFSMLAAGVMHAVATACSLGKLVSCGCGWKGSGEQDRLRAKLLQLQALSR NOV14a GKSFPHSLPSPGPGSSPSPGPQDTWEWGGCNHDMDFGEKFSRDFLDSREAPRDIQARMRI NOV14b GKSFPHSLPSPGPGSSPSPGPQDTWEWGGCNHDMDFGEKFSRDFLDSREAPRDIQARMRI NOV14c GKSFPHSLPSPGPGSSPSPGPQDTWEWGGCNHDMDFGEKFSRDFLDSREAPRDIQARMRI NOV14a HNNRVGRQVVTENLKRKCKCHGTSGSCQFKT-

----------------------------

NOVl4b HNNRVGRQVVTENLKRKCKCHGTSGSCQFKTCWRAAPEFRAVGAALRERLGRAIFIDTHN NOV14c HNNRVGRQVVTENLKRKCKCHGTSGSCQFKTCWRAAPEFRAVGAALRERLGRAIFIDTHN NOV14a -NSGAFQPRLRPRRLSGELVYFEKSPDFCERDPTMGSPGTRGRACNKTSRLLDGCGSLCC NOV14b RNSGAFQPRLRPRRLSGELVYFEKSPDFCERDPTMGSPGTRGRACNKTSRLLDGCGSLCC NOV14c RNSGAFQPRLRPRRLSGELVYFEKSPDFCERDPTMGSPGTRGRACNKTSRLLDGCGSLCC NOV14a GRGHNVLRQTRVERCHCRFHWCCYVLCDECKVTEWVINVCK NOV14b GRGHNVLRQTRVERCHCRFHWCCYVLCDECKVTEWVNVCK NOV14c GRGHNVLRQTRVERCHCRFHWCCYVLCDECKVTEWVNVCK NOV14a (SEQ ID NO: 182) NOV14b (SEQ ID NO: 184) NOVl4c (SEQ ID NO: 186) Further analysis of the NOV14a protein yielded the following properties shown in Table 14C. 5 Table 14C. Protein Sequence Properties NOV14a SignalP analysis: Cleavage site between residues 29 and 30 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 8; pos.chg 2; neg.chg 2 H-region: length 16; peak value 10.20 PSG score: 5.80 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): 2.10 possible cleavage site: between 28 and 29 >>> Seems to have a cleavable signal peptide (1 to 28) ALOM: Klein et al's method for TM region allocation Init position for calculation: 29 232 WO 2004/000997 PCT/US2003/017512 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 0.58 (at 134) ALOM score: 0.58 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 14 Charge difference: -1.0 C( 0.0) - N( 1.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 9.19 Hyd Moment(95): 7.93 G content: 0 D/E content: 2 S/T content: 0 Score: -6.41 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: RPRR (4) at 281 pat7: PRLRPRR (3) at 278 bipartite: none content of basic residues: 14.1% NLS Score: 0.04 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: found RLRAKLLQL at 167 VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination prediction: nuclear Reliability: 89 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues 233 WO 2004/000997 PCT/US2003/017512 Final Results (k = 9/23): 65.2 %: nuclear 17.4 %: mitochondrial 13.0 %: extracellular, including cell wall 4.3 %: cytoplasmic >> prediction for CG57054-03 is nuc (k=23) A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14D. 5 Table 14D. Geneseq Results for NOV14a NOV14a Identities/ Geneseq Protein/Organism/Length [Patent Residues/ Similarities for Expect Identifier #, Date] Match the Matched Value Residues Region AAE34046 WNT-10B protein - Unidentified, 1..370 357/400 (89%) 0.0 389 aa. [WO200290992-A2, 1..389 357/400 (89%) 14-NOV-2002] ABU55892 Human WNT-10B protein - Homo 1..370 357/400 (89%) 0.0 sapiens, 389 aa. [WO200277204-A2, 1..389 357/400 (89%) 03-OCT-2002] AAW08928 Wnt-10b protein - Homo sapiens, 1..370 355/400 (88%) 0.0 389 aa. [WO9640910-Al, 1..389 355/400 (88%) 19-DEC-1996] AAR53689 HR2 polypeptide - Homo sapiens, 1..370 348/400 (87%) 0.0 389 aa. [WO9411510-A2, 1..389 351/400 (87%) 26-MAY-1994J AAY28559 Wnt-10a polypeptide #1 - Homo 5..370 224/415 (53%) e-128 sapiens, 417 aa. [WO9938966-A1, 14..417 276/415 (65%) L 05-AUG-1999] In a BLAST search of public sequence databases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14E. 234 WO 2004/000997 PCT/US2003/017512 Table 14E. Public BLASTP Results for NOV14a Protein NOV14a Identities/ Accession Protein/Organism/Length Residues/ Similarities for Expect Number Match the Matched Value Residues Portion 000744 Wnt-10b protein precursor (Wnt-12) 1.370 358/400 (89%) 0.0 - Homo sapiens (Human), 389 aa. 1.389 358/400 (89%) P48614 Wnt-10b protein precursor (Wnt-12) 1..370 348/400 (87%) 0.0 - Mus musculus (Mouse), 389 aa. 1.389 351/400 (87%) Q9GZT5 Wnt-10a protein precursor - Homo 5..370 224/415 (53%) e-128 sapiens (Human), 417 aa. 14..417 276/415 (65%) JC7693 soluble-type glycoprotein WNT10A 5..370 223/415 (53%) e-127 - human, 417 aa. 14..417 275/415 (65%) P43446 Wnt-10a protein precursor - 22..370 210/384 (54%) e-122 Brachydanio rerio (Zebrafish) (Danio 72..442 270/384 (69%) rerio), 442 aa. PFam analysis predicts that the NOV14a protein contains the domains shown in the Table 14F. 5 Table 14F. Domain Analysis of NOV14a Identities/ Pfam Domain NOV14a Match Region Similarities Expect Value for the Matched Region wnt 47..370 150/384 (39%) 3.3e-117 266/384 (69%) Example 15. The NOV15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 15A. 10 235 WO 2004/000997 PCT/US2003/017512 Table 15A. NOV15 Sequence Analysis NOV15a, CG57431-03 SEQ ID NO: 187 651 bp DNA Sequence OPJPStart: ATG at 10 ORF Stop: TAG at 445 ACCGCCGCTATGGTCTCCGTGCCTACCACCTGGTGCTCCGTTGCGCTAGCCCTGCTCGTGGCCCTGCATGAAG GGAAGGGCCAGGCTGCTGCCACCCTGGAGCAGCCAGCGTCCTCATCTCATGCCCAAGGCACCCACCTTCGGCT TCGCCGTTGCTCCTGCAGCTCCTGGCTCGACAAGGAGTGCGTCTACTTCTGCCACTTGGACATCATCTGGGTG AACACTCCTGAACAGACAGCTCCTTACGGCCTGGGAAACCCGCCAAGACGCCGGCGCCGCTCCCTGCCAAGGC GCTGTCAGTGCTCCAGTGCCAGGGACCCCACCTGTGCCACCTTCTGCCTTCGAAGGCCCTGGGACATTTCCAC AGTCAAGAGCCTCTTTGCCAAGCGACAACAGGAGGCCATGCGGGAGCCTCGGTCCACACATTCCAGGTGGAGG AAGAGATAGTGTCGTGAGCTGGAGGAACATTGGGAAGGAACCCCGCGGGGAGAGAGGAGGAGAGAAGTGGCCA GGGCTTGTGGACTCTCTGCCTGCTTCCTGGACCGGGGCCTTGGTCCCAGACAGCTGGACCCATTTGCCAGGAT TGGCACAGGCTCCCTGGTGAGGGAGCCTCGTCCAAGGCAGTTCTGTGTCCTCGCACTGCCCAGGGAA NOVI5a, CG57431-03 SEQ ID NO: 188 145 aa MW at 16563.8kD Protein Sequence MVSVPTTWCSVALALLVALHEGKGQAAATLEOPASSSHAQGTHLRLRRCSCSSWLDKECVYFCHLDIIWVNTP EQTAPYGLGNPPRRRRRSLPRRCQCSSARDPTCATFCLRRPWDISTVKSLFAKRQQEAMREPRSTHSRWRKR 5 NOV15b, CG57431-02 S9 556 bp DNA Sequence ORF Start: ATG at 11 ORF Stop: TAG at 545 TACCGCCGCTATGGTTTCCGTGCCTAGCACCTGGTGCTCCGTTGCGCTAGCCCTGCTCGTGGCCCTGCATGAA GGGAAGGGCCAGGCTGCTGCCACCCTGGAGCAGCCAGCGTCCTCATCTCATGCCCAAGGCACCCACCTTCGGC TTCGCCGTTGCTCCTGCAGCTCCTGGCTCGACAAGGAGTGCGTCTACTTCTGCCACTTGGACATCATCTGGGT GAACACTCCTGAACAGACAGCTCCTTACGGCCTGGGAAACCCGCCAAGACGCCGGCGCCGCTCCCTGCCAAGG CGCTGTCAGTGCTCCAGTGCCAGGGACCCCGCCTGTGCCACCTTCTGCCTTCGAAGGCCCTGGACTGAAGCCG GGGCAGTCCCAAGCCGGAAGTCCCCTGCAGACGTGTTCCAGACTGGCAAGACAGGGGCCACTACAGGAGAGCT TCTCCAAAGGCTGAGGGACATTTCCACAGTCAAGAGCCTCTTTGCCAAGCGACAACAGGAGGCCATGCGGGAG CCTCGGTCCACACATTCCAGGTGGAAGGAGAGATAGTGTCGTGAA NOVI5b, CG57431-02 SEQ IDNO: 190 178 aa MW at 19918.5kD Protein Sequence MVSVPSTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECVYFCHLDIIWVNTP EQTAPYGLGNPPRRRRRSLPRRCQCSSARDPACATFCLRRPWTEAGAVPSRKSPADVFQTGKTGATTGELLQR LRDISTVKSLFAKRQQEAMREPRSTHSRWKER 236 WO 2004/000997 PCT/US2003/017512 NOV15c, CG57431-01 ISEQ ID NO: 191 668bp DNA Sequence ORF Start: ATG at 40 _ORF Stop: TAG at 574 CTCCCTGCTCCAGTCCAGCCTGCGCGCTCCACCGCCGCTATGGTTTCCGTGCCTAGCACCTGGTGCTCCGTTG CGCTAGCCCTGCTCGTGGCCCTGCATGAAGGGAAGGGCCAGGCTGCTGCCACCCTGGAGCAGCCAGCGTCCTC ATCTCATGCCCAAGGCACCCACCTTCGCCTTCGCCGTTGCTCCTGCAGCTCCTGGCTCGACAAGGAGTGCGTC TACTTCTGCCACTTGGACATCATCTGGGTGAACACTCCTGAACAGACAGCTCCTTACGGCCTGGGAAACCCGC CAAGACGCCGGCGCCGCTCCCTGCCAAGGCGCTGTCAGTGCTCCAGTGCCAGGGACCCCGCCTGTGCCACCTT CTGCCTTCGAAGGCCCTGGACTGAAGCCGGGGCAGTCCCAAGCCGGAAGTCCCCTGCAGACGTGTTCCAGACT GGCAAGACAGGGGCCACTACAGGAGAGCTTCTCCAAAGGCTGAGGGACATTTCCACAGTCAAGAGCCTCTTTG CCAAGCGACAACAGGAGGCCATGCGGGAGCCTCGGTCCACACATTCCAGGTOGAGGAAGAGATAGTGTCGTGA GCTGGAGGAACATTGGGAAGGAAGCCCGCGGGGAGAGAGGAGGAGAGAAGTGGCCAGGGCTTGTGGACTCTCC TGCTGCTTTCT NOV15c, CG57431-01 SEQ ID NO: 192 178 aa MW at 19945.6kD MVSVPSTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECVYFCHLDIIWVNTP EQTAPYGLGNPPRRRRRSLPRRCQCSSARDPACATFCLRRPWTEAGAVPSRKSPADVFQTGKTGATTGELLQR LRDISTVKSLFAKRQQEAMREPRSTHSRWRKR 5 NOV15d, CG57431-04 jSEQ ID NO: 193 1964 bp DNA Sequence ORF Start ATG at 10 ORF Stop: TAG at 322 ACCCCCGCTATGGTCTCCGTGCCTACCACCTGGTGCTCCGTTGCGCTAGCCCTGCTCGTGGCCCTGCATGAAG GGAAGGGCCAGGCTGCTGCCACCCTGGAGCAGCCAGCGTCCTCATCTCATGCCCAAGGCACCCACCTTCGGCT TCGCCGTTGCTCCTGCAGCTCCTGGCTCGACAAGGAGTGCGTCTACTTCTGCCACTTGGACATCATCTGGGTG AACACTCCTGAGGACATTTCCACAGTCAAGAGCCTCTTTGCCAAGCGACAACAGGAGGCCATGCGGGAGCCTC GGTCCACACATTCCAGGTGGAGGAAGAGATAGTGTCGTGAGCTGGAGGAACATTGGGAAGGAAGCCCGCGGGG AGAGAGGAGGAGAGAAGTGGCCGGGGCTTGTGGACTCTCTGCCTGCTTCCTGGACCGGGGCCTTGGTCCCAGA CAGCTGGACCCATTTGCCAGGATTGGCACAAGCTCCCTGGTGAGGGAGCCTCGTCCAAGGCAGTTCTGTGTCC TCGCACTGCCCAGGGAAGCCCTCGGCCTCCAGACTGCGGAGCAGCCTCCAGTGCTGGCTGCTGGCCCACAGCT CTGCTGGAAGAACTGCATGGGGAGTACATTCATCTGGAGGCTGCGTCCTGAGGAGTGTCCTGTCTGCTGGGCT ACAAACCAGGAGCGACCGTGCAGCCACGAACACGCATGCCTCAGCCAGCCCCGGAGGCTGGATGGCTCCCCTG AGGCTGGCATCCTGGCTGGCTGTGTCCTCTCCAGCTTTCCCTCCCCAGAGTTCTTGCACCCTCATTCCCTCGG GACCCTCCCAGTGAGAAGGGCCTGCTCTGCTTTTCCTGTCTGTATATAACTTATTTGCCCTAAGAACTTTGAG AATCCCAATTATTTATTTTAATGTATTTTTTAGACCCTCTATTTACCTGCGAACTTGTGTTTATAATAAATGA GGAAACAGAAAAAAA NOV15d, CG57431-04 SEQ ID NO: 194 104aa 1MWatl1793.4kD Protein Sequence MVSVPTTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECVYFCHLDIIWVNTP EDISTVKSLFAKRQQEAMREPRSTHSRWRKR A ClustalW comparison of the above protein sequences yields the following sequence 10 alignment shown in Table 15B. 237 WO 2004/000997 PCT/US2003/017512 Table 15B. Comparison of the NOV15 protein sequences. NOVS15a MVSVPTTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECV NOV15b MVSVPSTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECV NOV15c MVSVPSTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECV NOV15d MVSVPTTWCSVALALLVALHEGKGQAAATLEQPASSSHAQGTHLRLRRCSCSSWLDKECV NOV15a YFCHLDIIWVNTPEQTAPYGLGNPPRRRR ------------------------------- NOV15b YFCHLDIIWVNTPEQTAPYGLGNPPRRRRRSLPRRCQCSSARDPACATFCLRRPWTEAGA NOV15c YFCHLDIIWVNTPEQTAPYGLGNPPRRRRRSLPRRCQCSSARDPACATFCLRRPWTEAGA NOV15d YFCHLDIIWVNT-------------------------------------------- NOV15a ---SLPRRCQCSSARDPTCATFCLRRPWDISTVKSLFAKRQQEAMREPRSTHSRWRKR NOV15b VPSRKSPADVFQTGKTGATTGELLQRLRDISTVKSLFAKRQQEAMREPRSTHSRWKER NOV15c VPSRKSPADVFQTGKTGATTGELLQRLRDISTVKSLFAKRQQEAMREPRSTHSRWRKR NOVl5d ------------------------- PEDISTVKSLFAKRQQEAMREPRSTHSRWRKR NOV15a (SEQ ID NO: 188) NOV15b (SEQ ID NO: 190) NOV15c (SEQ ID NO: 192) NOV15d (SEQ ID NO: 194) Further analysis of the NOV1 5a protein yielded the following properties shown in Table 15C. 5 Table 15C. Protein Sequence Properties NOV15a SignalP analysis: Cleavage site between residues 25 and 26 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 0; pos.chg 0; neg.chg 0 H-region: length 20; peak value 9.73 PSG score: 5.33 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -1.24 possible cleavage site: between 24 and 25 >>> Seems to have a cleavable signal peptide (1 to 24) ALOM: Klein et al's method for TM region allocation Init position for calculation: 25 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) - fixed PERIPHERAL Likelihood = 7.85 (at 54) ALOM score: 7.85 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 12 Charge difference: -1.5 C(-0.5) - N( 1.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 1.71 Hyd Moment(95): 1.49 G content: 0 238 WO 2004/000997 PCT/US2003/017512 D/E content: 1 S/T content: 4 Score: -4.94 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: PRRR (4) at 85 pat4: RRRR (5) at 86 pat4: RRRR (5) at 87 pat7: PPRRRRR (5) at 84 pat7: PRRRRRS (5) at 85 bipartite: none content of basic residues: 16.6% NLS Score: 1.27 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: KKXX-like motif in the C-terminus: RWRK SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: nuclear Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 55.6 %: extracellular, including cell wall 33.3 %: nuclear 11.1 %: cytoplasmic >> prediction for CG57431-03 is exc (k=9) 239 WO 2004/000997 PCT/US2003/017512 A search of the NOV1 5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15D. 5 Table 15D. Geneseq Results for NOV15a NOV15a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE15748 Human endothelin 2 (EDN2) - Homo 1.145 144/178 (80%) 3e-79 sapiens, 178 aa. [WO200190118-A2, 1..178 144/178 (80%) 29-NOV-2001] AAR23784 Precursor ET-2 sequence - Homo 1..145 144/178 (80%) 3e-79 sapiens, 178 aa. [EP484017-A, 1..178 144/178 (80%) 06-MAY-1992] AAR20231 Human endothelin-2 vasoconstrictor 1..145 144/178 (80%) 3e-79 peptide - Homo sapiens, 178 aa. 1.178 144/178 (80%) S[EP468337-A, 29-JAN-1992] AAR60320 Pre-pro-vasoactive intestinal 6..120 89/115 (77%) 3e-51 contractor protein - Mus musculus, 3..117 99/115 (85%) 160 aa. [JP06169774-A, 21-JUN-1994] AAR60319 Pre-pro-vasoactive intestinal 6..120 89/115 (77%) 3e-51 contractor protein - Mus musculus, 3..117 99/115 (85%) 160 aa. [JP06169774-A, 21-JUN-1994] In a BLAST search of public sequence databases, the NOV1 5a protein was found to have homology to the proteins shown in the BLASTP data in Table 15E. 240 WO 2004/000997 PCT/US2003/017512 Table 15E. Public BLASTP Results for NOV15a Protein NOV15a Identities/ Protein Residues/ Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion P20800 Endothelin-2 precursor (ET-2) - 1..145 144/178 (80%) 8e-79 Homo sapiens (Human), 178 aa. 1..178 144/178 (80%) BAC54893 Preproendothelin-2 - Equus caballus 1..145 116/178 (65%) 2e-60 (Horse), 178 aa. 1..178 123/178 (68%) Q8MJW9 Preproendothelin-2 - Mustela putorius 1..144 108/177 (61%) 2e-56 furo (Ferret), 178 aa. 1..177 120/177 (67%) P23943 Endothelin-2 precursor (ET-2) 4..145 103/175 (58%) 4e-53 (Vasoactive intestinal contractor) 2..176 114/175 (64%) (VIC) - Rattus norvegicus (Rat), 176 aa. S17194 endothelin 2 precursor - mouse, 160 6.120 89/115 (77%) 8e-51 aa. 3..117 99/115 (85%) PFam analysis predicts that the NOV15a protein contains the domains shown in the Table 15F. 5 Table 15F. Domain Analysis of NOV15a Identities/ Pfam Domain NOV15a Match Region Similarities Expect Value for the Matched Region endothelin 44..74 28/31 (90%) 5.4e-19 29/31 (94%) Example 16. The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A. 10 241 WO 2004/000997 PCT/US2003/017512 Table 16A. NOV16 Sequence Analysis NOV16a, CG59253-01 ISEQ ID NO: 195 1894 bp DNA Sequence ORF Start: ATG at 46 ORF Sop: TAG at 1474 TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTATTCAAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGAC TTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAA ATGAAATGCCCAAAACAGAAGTAATACCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAA CTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAG ATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATG ATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGA TGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGAT GGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAAT ATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTC CCGCGTGGCCCGCATATGTAAAAACCACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTT CTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAG ACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTC TGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCA GATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCC TTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGAT GGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCC ATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGG TACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTA CAACCATGCAAAGTAGGTATATGTTACGAGAACGCCCTTCAGCACTGCTCAAAAATTTTCGGCATGTATTTCA TCTAGTCATGTCCTTTTGGTCCTCTAAATTAGCAGTGGTTTGGCATAATAGTGTTTTGTGTTTTTTTTCTCAT TGAAATAAATCTTGGGTTTGTTTTTTTCCCGAGCCTGCTAGGGCGAGGGGGGTGAATGGTTGATGAGTTTAAA AATAATGCAGCCCTTGTTTTTCACCTGTAGAATATGAGAACATTTTAACAGCACCTCTCTTATCTTGCAGATA TATTCCAAGATGCTACATGCAGCAGACAGCTGTGAGCTTGCATACACACACACACAAATATACATGCACATAC ATACACAGATGTAGTACTAGTTAAGTATTTCCTTCCTATCTTTAATAAGTAAGAGAATATTTAGACCA NOV16a, CG59253-01 SEQ ID NO: 196 1476 aa MW at 54216.4kD Protein Sequence MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAG RDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCR YYRLSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYD EPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFF YFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKP RPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTV IFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK 5 242 WO 2004/000997 PCT/US2003/017512 NOV16b, 194877881 ISEQ ID NO: 197 1383bp DNA Sequence ORF Start: at 1 ORF Stop: end of sequence GGATCCGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGACTATCACTATTCAAGGCAATATCCGG TTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGACTTTCAGCTGATGTTGAAAATTCGAGA CACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAAATGAAATGCCCAAAACAGAAGTAATA CCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAACTGTGCTATGAAAGGCAAGCATAAAG ATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAGATGGTTTTTGTTTGTGGTACCAATGC ATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATGATGGGGAAGAAATTAGTGGCCTGGCA AGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGATGGGAAGCTGTATTCTGCCACAGTGG CTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGATGGATCTGCCCTTCGCACAATAAAATA TGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAATATGGAAACTATGTCTATTTCTTCTTT CGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTCCCGCGTGGCCCGCATATGTAAAAACG ACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTTCTAAAGGCTCGCCTGAACTGTTCTGT CCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAGACATAATACAAATCAATGGCATCCCC ACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTCTGCTGTCTGTGCATTTAGCATGGATG ACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCAGATTCTGTTTGGACAGCAGTTCCCGA AGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCCTTGCCGAAGCTTATAAAACCTCCATC GATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGATGGACTCTGCCGTTCCACCCATTGCCG ATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCCATCTCAGTGGACCATTCAGCCGGACC CTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGGTACTTAAAGTTCTGGCAAAGACCAGT CCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTACAACCATGCAAAGTGCCTCGAG NOV16b, 194877881 .SEQ ID NO: 198 aa MW at 52370.OkD Protein Sequence 4 GSVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVI PNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLA RCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFF REIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQSITDIIQINGIP TVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKPRPGCCAKHGLAEAYKTSI DFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTS PFSLNDSVLLEEIEAYNHAKCLE 5 243 WO 2004/000997 PCT/US2003/017512 NOV16c, CG59253-02 S9EQ ID NO: 199 3205 bp DNA Sequence JORF Start: ATG at 46 ORF Stop: TAG at 3151 TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TATCGTAGTTC~,TAGCGCGCTCTAGTAGACCTAATTG CTATCACTGTAAGTCGTCTAGGCAATATCCGGTTTTTAGAGGACGCCCTTAGGCAATGATCGCAGCACAGG CTGGACTTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGCAGGGATCACTTTATAAGTAA ACTATAAGCAACGATAAGCAAAATAAGCACAAACGAC AGAAACTGTGCTATGAAAGGCAACATAATGAATCCACACTTTATCAGTATTTGTTCCAGAC GAGGTGTTGTGGTCATCTCAT~-TTTGTCAAGTATCTA AATATGATGGGGAAGAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGAOACCATGTTGCCCTCTT TGCTGATGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAJAGCATG GGTGATGGATCTGCCCTTCGCACAATAATATGATTCCAATGGATAAAAAGCCACACTTTCTTCATGCCA TAATTGACAGCATCTTTGGATGTTGAAATATAGAGCG GTATTCCCGCGTGGCCCGCATATGTAAACGACATGGGTGGTTCCCAGCGGGTCCTGGGACACTGGACT TCATTTCTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTA TTACAGACATAATACAAATCA.ATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCATAGCATCCC TGTCGTTTTCTTGAGAGCTGAAGATAAGCGTAGACGA ACCAATTTTGCGATCCA(AAAGGCAGCAGCGCGTTCAA ACGCTCGACTTAACCACATCCGTAATTTATACATTAC CCTGATGGACTCTGCCGTTCCACCCATTCCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTG ACGGCCATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGA\GCTG GCATGGTACTTAAAGTTCTGGCAGACCAGTCCTTTCTCTTTGACGACAGCGTATTACTGAGAGATTGA AGCAACAGAATCGGTAATAGAAAAAGCTTATCGTGTA GATCACCACGCTTTATATGTGGCGTTCTCTAGCTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATG GATCATGTAAAAAGTCTTGTATTGCATCTCGTGACCCGTATTGTGGCTGCTTAAGCCAGGGATCCTGTGGTAG AGTGACCCCAAACCACAGTGCTAGATATGAACAAGACACAGPMTCGGCACACAGCTCATCTAGGGGAC TGCCATGCATATGAACCATATGAACCTCGTGTTGGCTCACTGAAAGCCATTTGCTATTTATTATTATTTTTAA AAAGCACCTTATTCACATTGTCCCATGTGTCTATTTCAGGTGTACGATGGGAAGTCCAGTCTGGAGAGTCCAA CCAGATGGTCCACATGAATGTCCTCATCACCTGTGTCTTTGCTGCTTTTGTTTTGGGGGCATTCATTGCAGGT GTGATTCGTTGGCTTTTCGAACGAGTCTAGTCGGCGC AGCTCCGCCATGATTGCACGAGTTTTAACCGCAGAAC ACGAATATTCAATTTGACTCACATGAAACACCCAGAA ACTAATCCATGGTAATGGACCATCGAGGGCAACCTCCAGAGTTGGCTGCTCTTCCTACTCCTGAGTCTACAC CCTCTACGAACTCGCAGAACATAAAGCCTGCTGGTCA GAAGAACCCCTCAGTTTTTTCCGTCTAGTCCGCCACCTCATTCCCCATTAAGTCATGGGCTATCCCCAGT GCATTCTCATCACAGCAACCTTTTAATCAGTAAACGA AGAAGCTTCAAAACATTGATCACCCTCTCACAAAGTCATCCAGTAAGAGAGATCACCGGCGTTCTGTTGATTC CAAAACTATACCTAGACGAGCCATGACCAACACTGAA ATCCAGATGGCACACCAGACTTAATGCTGGATCCCATGGGATCGATTCTGAGGTCCCACCTAGTCCCTA ACCGGGAGGCATCGCTATACTCCCCTCCTTCAACTCTCCCCAGAATAGCCC.ACCAAGCGAGTGGATGTCCC CACCCTGGCCAGCTTTGAGCAGGTACCAATCTCAAGA TCTATATCTGCTATGCCTAAAACTTAACTCACCA-TGGTGTTTTGTTATCCAGACAGCCTAGTATGACC GTGGAGGATATATGCOCACCCCCACTGGGGCGAAGGTGGACTATATTCAGGGAACACCAGTGAGTGTTCATCT GCAGCCTTCCCTCTCCAGACAGAGCAGCTACACCAGTATGCACTCTTCCTAGGACGGACTAGAGGACG CCGTCCTTAAAACCTGACGTGCCACCAAGCCTTCCTTTGTTCCTCAACCCCATCTGTCAGACCACTGAACA AATACACATACTAGGCCTCAAGTGTGCTATTCCCATGTGGCTTTATCCTGTCCGTGTTGTTGAGAG 244A WO 2004/000997 PCT/US2003/017512 NOVI6c, CG59253-02 ~ SEQ IDN 20 1105a jIatllS5912.6kD Protein Sequence MRVFLLCAYILLLMVSQLRAVSFP IEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYI AGRDQYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAIAKGKMKDECHNFIKVFVPRDEMVFVCGTNAFNPM CRYVTEDEIGACFAQNAFDKYAVDLSAIRMDSLTKDK IKEPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLK{WTSFLKARLNCSVPGDS FFYFDVLQSITDI IQINGI PTVVGVFTTQLNSI PGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVP KPRPGCCAKHGLEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNY TVIFVGSEAGP4VLKVLAKTSPFSLNDSVLLEEIEAYNHAKCSAENEEDKKVISLQLDKDHHALYVAFSSCIIR IPLSRCERYGSCKKSCIASRDPYCGWLSQGSCGRVPNHSAGYEQDTEFGNTAHLGDCHYEPYEGRVGSLK AICYLLLFLKSTLFTLSHVSISGVRWEVQSGESNQMVNVLITCVAFVLGAFIAGVAVYCYRDMFVRKNR KIHKDAFSAQSCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKELPPNGDTKSMVMDHRGQPPEL AAILPTPESTPVLHQKTLQAMKSHSEKAHGHGASRKETPQFFPSSPPPHPLSHGHIPSAIVLPNATHJDYNTSF SNSNAHKEKKLQNIDHPLTKSSSKRDHRRSVDSRNTLNDLLKLNDPNSNPKAIMGDIQMHQNJMLDPMGS MSEVPPVPNREASLYSPPSTLPRNSPTKRVDVPTTPGVPMTSLERQRGYHSSQPHISAPKNNSPNGV LIJSRQPSMNRGGYMPTPTGAKVDYIQGTPVSVHLQPSLSRQSSYTSNGTLPRTGLRTPSLKPDVPPKPSFVP IQTPSVRPLNKYTY ~NOV16d, 19181l565 HSE IDN:21 ]713 bp {DNASequence fRStr:a ORF Stop: end of sequence GGATCCGTCAGCTTTCCTGAAGATGATAACCCCTTAATACTGTCGACTATCACTATTCAGGCATATCCGG TTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACA GGCTGGACTTTCAGCTGATGTTGAAAATTCGAGA CAATTTTGTGGGACATTTCGAATAATAAGCAACGATAT CCACAAATAAGCACAAACGACAAACGGTTAAGAGAAA ATGAATGCCACAACTTTATCAAGTATTTGTTCCAGAACGATGAGATGGTTTTTGTTTGTGGTACCATGC ATTCAATCCCATGTGTAGATACTACAGTTGAGTACCTTAGATATGATGGGAGATTAGTGGCCTGGCA AGATGCCCATTTGATGCCAGACAACCAATGTTGCCCTCTTTGCTGATGGAAGCTGTATTCTGCCACAGTGG CTGACTTCTTGGCCAGCGATGCCGTTATTTATCG-kGCATGGGTGATGGATCTGCCCTTCGCACATAJAATA TGATTCCAAATGGATAAAGAGCCACACTTTCTTCATGCCATAGATATGGAACTATGTCTATTTCTTCTTT CGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTCCCGCGTGGCCCGCATATGTAAAAACG ACATGGGTGGTTCCCAGCGTCCTGGAGAACACTGGACTTCATTTCTAAGGCTCGGCTGAACTGTTCTGT CCTGGTCTTTTCTGTTCGATTTAAAAATCATATGACC ACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAcGCATCCCTGGTTCTGCTGTCTGTGCATTTAGCATGGATG ACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCAGATTCTGTTTGGACAGCAGTTCCCGA AGACAAAGTGCCAACCCAAGCCTGCTGTTGTGCAACACGGCCTTGCCGAAGCTTATAAAACCTCCATC GATTTCCCGGATGAAACTCTGTCGTTCATCAAATCTCATCCCCTGATGGACTCTGCCGTTCCACCCATTGCCG ATGAGCCCTGOTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCCATCTCAGTGGACCATTCAGCCGGACC CTACCAGAACTACACAGTCATCTTTGTTGGCTCTAAGCTGGQATGGTACTTAGTTCTGGCA;AOACCAT CCTCCTGAGCGGATCGAGGTGACTCACTCAGGATCGG ATGAGGAAGACAAAAAGGTCATCTCATTACAGTTGGATAAAGATCACCACGCTTTATATGTGGCGTTCTCTAG CTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATGGATCATGTAAAGTCTTGTATTGCTCTCGT GACCCGTATTGTGGCTGGTTAAGCCAGGGATCCTGTGGTAGAGTGACCCCAGGGATGCTTGCTGAGGATATG AACAAGACACAGAATTCGGCAACACAGCTCATCTAC3GGGACTGCCATGGTGTACGATGGGAAGTCCAGTCTGG AGAGTCCAACCAGATG3GTCCACATGAATCTCGAG 5 245 WO 2004/000997 PCT/US2003/017512 NOV16d, 191815765 SQID NO 20 7a M at6535.4kcD Protein Sequence GSVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAGGDQVYTVNLNEMPKTEVI PNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLA RCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFF REIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSPLKARLNCSVPGDSFFYFDVLQSITDIIQINGIP TVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKPRPGCCAKHGLAEAYKTSI DFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTS PFSLNDSVLLEEIEAYNHAKCNAENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASR DPYCGWLSQGSCGRVTPGMLAEGYEQDTEFGNTAHLGDCHGVRWEVQSGESNQMVHMNLE INOV16e, CG59253-03 .SEQID NO: 203 1383 bp IDNA Sequence ORF Start: at 7 ORF Stop: at 1375 GGATCCGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGACTATCACTATTCAAGGCAATCCGG TTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGACTTTCAGCTGATGTTGAAAATTCGAGA CACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAAATGAAATGCCCAAAACAGAAGTAATA CCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAACTGTGCTATGAAAGGCAAGCATAAAG ATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAGATGGTTTTTGTTTGTGGTACCAATGC ATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATGATGGGGAAGAAATTAGTGGCCTGGCA AGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGATGGGAAGCTGTATTCTGCCACAGTGG CTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGATGGATCTGCCCTTCGCACAATAAAATA TGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAATATGGAAACTATGTCTATTTCTTCTTT CGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTCCCGCGTGGCCCGCATATGTAAAAACG ACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTTCTAAAGGCTCGGCTGAACTGTTCTGT CCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAGACATAATACAAATCAATGGCATCCCC ACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTCTGCTGTCTGTGCATTTAGCATGGATG ACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCAGATTCTGTTTGGACAGCAGTTCCCGA AGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCCTTGCCGAAGCTTATAAAACCTCCATC GATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGATGGACTCTGCCGTTCCACCCATTGCCG ATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACCCCATCTCAGTGGACCATTCAGCCGGACC CTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGGTACTTAAGTTCTGGCAAAGACCAGT CCTTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTACAACCATGCAAAGTGCCTCGAG 5 NOV16e, CG59253-03 SEQ ID NO: 204 456 aa MW at 51880.5kD Protein Sequence VSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIPN KKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARC PFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFRE IAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQSITDIIQINGIPTV VGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKPRPGCCAKHGLAEAYKTSIDF PDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTVIFGSEAGMVLKVLAKTSPF SLNDSVLLEEIEAYNHAK 246 WO 2004/000997 PCT/US2003/017512 NOV16f, CG59253-04 [SEQ ID NO: 205 1713 bp DNA Sequence ORF Start: at 7 IORF Stop: at 1708 GGATCCGTCAGCTTTCCTAAGATGATGAACCCCTTAATACTGTCGACTATCACTATTCAAGGCAATATCCGG TTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGACTTTCAGCTGATGTTGAAAATTCGAGA CACACTTTATATTGCTGGCGGGGATCAAGTTTATACAGTAAACTTAAATGAAATGCCCAAAACAGAAGTAATA CCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAACTGTGCTATGAAAGGCAAGCATAAAG ATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAGATGGTTTTTGTTTGTGGTACCAATGC ATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATGATGGGGAAGAAATTAGTGGCCTGGCA AGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGATGGGAACCTGTATTCTGCCACAGTGG CTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGATGGATCTGCCCTTCGCACAATAAAATA TGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAATATGGAAACTATGTCTATTTCTTCTTT CGAGAAATCGCTGTCGAACALTAATALATTTAGGCAAGGCTGTGTATTCCCGCGTGGCCCGCATATGTAAAAACG ACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTTCTAAAGGCTCGGCTGAACTGTTCTGT CCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAGACATAATACAAATCAATGG3CATCCCC ACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTCTGCTGTCTGTGCATTTAGCATGGATG ACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCAGATTCTGTTTGGACAGCAGTTCCCGA AGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCCTTGCCGAAGCTTATAAAACCTCCATC GATTTCCCGGATGAAACTCTGTCGTTCATCAAATCTCATCCCCTGATGGACTCTGCCGTTCCACCCATTGCCG ATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCCATCTCAGTGGACCATTCAGCCGGACC CTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGGTACTTAAAGTTCTGGCAAAGACCAGT CCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTACAACCATGCAAAGTGCAATGCTGAGA ATGAGGAAGACAAAAAGGTCATCTCATTACAGTTGGATAAAGATCACCACGCTTTATATGTGGCGTTCTCTAG CTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATGGATCATGTAAAAAGTCTTGTATTGCATCTCGT GACCCGTATTGTGGCTGGTTAAGCCAGGGATCCTGTGGTAGAGTGACCCCAGGGATGCTTGCTGAAGGATATG AACAAGACACAGAATTCGGCAACACAGCTCATCTAGGGGACTGCCATGGTGTACGATGGGAAGTCCAGTCTGG AGAGTCCAACCAGATGGTCCACATGAATCTCGAG NOV16f, CG59253-04 SEQ ID NO: 206 567aa MWat64149.1kD Protein Sequence VSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQ RLDFQLMLKIRDTLYAGGDQVYVLNEMPKTEVIPN KKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARC PFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLEAIEYGNYVYFFFRE IAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQSITDIIQINGIPTV VGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKPRPGCCAKHGLAEAYKTSIDF PDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTVIFYGSEAGMVLKVLAKTSPF SLNDSVLLEEIEAYNHAKCNAENEEDKKVISLQLDKDHEALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDP YCGWLSQGSCGRVTPGMLAEGYEQDTEFGNTAHLGDCHGVRWEVQSGESNQMVHMN 5 NOV16g, CG59253-05 ISEQ ID NO: 207 12191 bp DNA Sequence AORF Start: ATG at 46 O1Y Stop: TGA at 2182 TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTGTAAGTCGTCTAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGG CTGGACTTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAA ACTTAAATGAAATGCCCAAAACAGAAGTAATATGGCAACAGAAACTGACATGGCGATCAAGACAACAGGATCG AGAAAACTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAAC GATGAGATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGGTAAGTACCTTAG AATATGATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTT TGCTGATGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATG GGTGATGGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCA TAGAATATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGT GTATTCCCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACT TCATTTCTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTA 247 WO 2004/000997 PCT/US2003/017512 TTACAGACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCC TGGTTCTGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAA ACTCCAGATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAAC ACGGCCTTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCC CCTGATGGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTG ACGGCCATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTG GCATGGTACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGA AGCCTACAACCATGCAAAGTGCAGTGCTGAGAATGAGGAAGACAAAAAGGTCATCTCATTACAGTTGGATAAA GATCACCACGCTTTATATGTGGCGTTCTCTAGCTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATG GATCATGTAAAAAGTCTTGTATTGCATCTCGTGACCCGTATTGTGGCTGGTTAAGCCAGGGATCCTGTGGTAG AGTGACCCCAGGGATGCTGCTGTTAACCGAAGACTTCTTTGCTTTCCATAACCACAGTGCTGAAGGATATGAA CAAGACACAGAATTCGGCAACACAGCTCATCTAGGGGACTGCCATGAAATTTTGCCTACTTCAACTACACCAG ATTACAAAATATTTGGCGGTCCAACATCTGGTGTACGATGGGAAGTCCAGTCTGGAGAGTCCAACCAGATGGT CCACATGAATGTCCTCATCACCTGTGTCTTTGCTGCTTTTGTTTTGGGGGCATTCATTGCAGGTGTGGCAGTA TACTGCTATCGAGACATGTTTGTTCGGAAAAACAGAAAGATCCATAAAGATGCAGAGTCCGCCCAGTCATGCA CAGACTCCAGTGGAAGTTTTGCCAAACTGAATGGTCTCTTTGACAGCCCTGTCAAGGAATACCAACAGAATAT TGATTCTCCTAAACTGTATAGTAACCTGCTAACCAGTCGGAAAGAGCACGAATTCAGCGGCCGCTGAATTCTA G NOV16g, CG59253-05 SEQ IDNO: 208 712 aa MW at 80536.8kD Protein Sequence MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYI AGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPM CRYYRVSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKW IKEPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDS FFYFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVP KPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNY TVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCSAENEEDKKVISLQLDKDHHALYVAFSSCIIR IPLSRCERYGSCKKSCIASRDPYCGWLSQGSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCH EILPTSTTPDYKIFGGPTSGVRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRKNRKIH KDAESAQSCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKEHEFSGR NOV16h, CG59253-06 SEQ ID NO: 209 3196 bp DNA Sequence I IORF Start: ATG at 46 JORF Stop: TAG at 3142 TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTGTAAGTCGTCTAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGG CTGGACTTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAA ACTTAAATGAAATGCCCAAAACAGAAGTAATATGGCAACAGAAACTGACATGGCGATCAAGACAACAGGATCG AGAAAACTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAAC GATGAGATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGGTAAGTACCTTAG AATATGATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTT TGCTGATGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATG GGTGATGGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCA TAGAATATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGT GTATTCCCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACT TCATTTCTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCACTCTA TTACAGACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCC TGGTTCTGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAA ACTCCAGATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAAC ACGGCCTTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCC CCTGATGGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTG ACGGCCATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTG GCATGGTACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGA AGCCTACAACCATGCAAAGTGCAGTGCTGAGAATGAGGAAGACAAAAAGGTCATCTCATTACAGTTGGATAAA 248 WO 2004/000997 PCT/US2003/017512 GATCACCACGCTTTATATGTGGCGTTCTCTAGCTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATG GATCATGTAAAGTCTTGTATTGCATCTCGTGACCCGTATTGTGGCTGGTTAGCCAGGATCCTGTGGTAG AGGCCAGAGTCGTACAGCTTTCTCAACAATCGAGTTA CAGACAAGAATTCGGCACACAGCTCATCTAGGGGACTGCCATGAAATTTTGCCTACTTCAACTACACCAG ATTACAAATATTTGGCGGTCCAACATCTGGTGTACGATGGAGTCCAGTCTGGAGAGTCCACCAGATGGT CCACATGAATGTCCTCATCACCTGTGTCTTTGCTGCTTTTGTTTTGGGGCATTCATTGCAGGTGTGGCAGTA TACTGCTATCGAGACATGTTTGTTCGGAAAAACAGAAAGATCCATAAAGATGCAGAGTCCGCCCAGTCATGCA CAATCGGAGTTCAATATGCCTTAACCGCAGATCACGAA TGATTCTCCTAAA.CTGTATAGTAACCTGCTAACCAGTCGGAAAGAGCTACCAcCACTGGAGATTCTAAAJTCC ATGGTAATGGACCATCGAGGGCAACCTCCAGAGTTGGCTGCTCTTCCTACTCCTGAGTCTACACCCGTGCTTC ACAAGCCGAGCTAGGC~CGAAGCAGCAGACTAGAAAA CCCTCAGTTTTTTCCGTCTAGTCCGCCACCTCATTCCCCATTAGTATGGGCATATCCCCAGTGCCATTGTT CTTCCAATGCTACCCATGACTACAACACGTCTTTCTCAAACTCCAATGCTCACAOGCTG.AAGAAGCTTC AAAACATTGATCACCCTCTCACAAAGTCATCCAGTAAGAGAGATCACCGGCGTTCGTTGATTCCAGATAC CCTCAATGATCTCCTrGAAGCATCTGAATGACCCAAATAGTAACCCCXAAGCCATCATGGGAGACATCCAGATG GCACACCAGAACTTATGCTGGATCCCATGGGATCGATGTCTGAGGTCCCACCTAAGTCCCTACCGGGAGG CATCGCTATACTCCCCTCCTTCAACTCTCCCCAGAAATIAGCCCAACCAAGCGAGTGGATGTCCCCACCACTCC TGGAGTCCCAATGACTTCTCTGGAALAGACAAAGAGGTTATCACAAAA-ATTCCTCCCAGAGGCACTCTATATCT GCTATCCCTAAAAACTTAAACTCACCAAATGGTGTTTTGTTATCCAGACAGCCTAGTATGAACCGTGGAGGAT ATATGCCCACCCCCACTGGGGCGAAGGTGGACTATATTCAGGGAACACCAGTGAGTGTTCATCTGCAGCCTTC CCTCTCCAGACAGAGCAGCTACACCAGTAATGGCACTCTTCCTAGGACGGcGACTAGAGGACGCCGTCCTTA AACCTGACGTGCCACCAAAGCCTTCCTTTTTCCTCACCCCATCTGTCAGACACTGACAATACACAT ACTAGGCCTCAAGTGTGCTATTCCCATGTGGCTTTATCCTGTCCGTGTTGTTGAGAG NOV16b, CG59253-06 SE DN:20 13 a t152.k Protein Sequence MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQ2RLDFQLMLKIRDTLYI AGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAKGKKECHNFIKVFVPRJNDEMIJFVCGTNAFNPM CRYVTEDEIGACFAQNAFDKYAVDLSAIRMDSLTKDK IKPFHIYNVFFEAENLKVSVRCNMGQVEHTFKRNSPD FFYFDVLQS ITDI IQINGIPTVVGVFTTQLNSI PGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVP KPRPGCCAKGAEAYKTSIDFPDETLSFIKSPLMDSAVPPIADEWF~TKTRVRYRLTAISVDHSAGPYQNY TVFGEGVKLKSFLDVLEEYHKSBEDKILLKHAYASCI IPLREYSKSISDY LQSGVPGLLEFAHHAGEDBGTHGC EILPTSTTPDYKIFGGPTSGVRWEVQSGESNQMVHNLITCVFAFVLAFIAGVAVYCYRDMFVRQRKIH KDAESAQSCTDSSGSFAKLNGLFDSPVKEYQQIDSPKLYNLLTSRKELPPNGDSKSVMDHRGQPPL PTETVHKLAKHEAGGSKTQFSPPSLHHPAVPAHYTPN NAKEKQIHLKSKDRSDRTNLKLDNNKIGIMHNMDMSS VPKPRALSPTPNPKVVTPVMSEQGHNSRSSMKLSNVL RQPSMGGYMPTPTGAKVDYIQGTPVSVHLQPSLSRQSSYTSNGTLPRTGLKRTPSLKPDVPPKPSFVPQTP SV'RPLNKYTY 249 WO 2004/000997 PCT/US2003/017512 NOV1i, CG59253-07 ISEQ I NO: 211 . 2359 bp DNA Sequence ORF Start: ATG at 46 CORFStop:TGAat2350 TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTGTAAGTCGTCTAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGG CTGGACTTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAA ACTTAAATGAAATGCCCAAAACAGAAGTAATATGGCAACAGAAACTGACATGGCGATCAAGACAACAGGATCG AGAAACTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAAC GATGAGATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGGTAAGTACCTTAG A GATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTT TGCTGATGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATG GGTGATGGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCA TAGAATATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGT GTATTCCCGCGTGGCCCGCATATGTAAAAACGACATGGGTGTTCCCAGCGGGTCCTGGAGAAACACTGGACT TCATTTCTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTA TTACAGACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCC TGGTTCTGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAA ACTCCAGATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTOGCTGTTGTGCAAAAC ACGGCCTTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCC CCTGATGGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTG ACGGCCATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTG GCATGGTACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGA AGCCTACAACCATGCAAAGTGCAGTGCTGAGAATGAGGAAGACAAAAAGGTCATCTCATTACAGTTGGATAAA GATCACCACGCTTTATATGTGGCGTTCTCTAGCTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATG GATCATGTAAAAAGTCTTGTATTGCATCTCGTGACCCGTATTGTGGCTGGTTAAGCCAGGGATCCTGTGGTAG AGTGACCCCAGGGATGCTGCTGTTAACCGAAGACTTCTTTGCTTTCCATAACCACAGTGCTGAAGGATATGAA CAGACACAGAATTCGGCAACACAGCTCATCTAGGGGACTGCCATGAAATTTTGCCTACTTCAACTACACCAG ATTACAAAATATTTGGCGGTCCAACATCTGACATGGAGGTATCTTCATCTTCTGTTACCACANGGCAAGTAT CCCAGAAATCACACCTAAAGTGATTGATACCTGGAGACCTAAACTGACAAGCTCTCGGAAATTTGTAGTTCAA GATGATCCAAACACTTCTGATTTTACTGATCCTTTATCGGGTATCCCAAAGGGTTACGATGGGAAGTCCAGT CTGGAGAGTCCAACCAGATGGTCCACATGAATGTCCTCATCACCTGTGTCTTTGCTGCTTTTGTTTTGGGGGC ATTCATTGCAGGTGTGGCAGTATACTGCTATCGAGACATGTTTGTTCGGAAAAACAGAAAGATCCATAAAGAT GCAGAGTCCGCCCAGTCATGCACAGACTCCAGTGGAAGTTTTGCCAAACTGAATGGTCTCTTTGACAGCCCTG TCAAGGAATACCAACAGALATATTGATTCTCCTAAACTGTATAGTAACCTGCTAACCAGTCGGAAAGAGCACGA ATTCAGCGGCCGCTGAATTCTAG NOV16i, CG59253-07 SEQ ID NO: 212 768 aa MW at 86672.6kD Protein Sequence -S I MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYI AGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPM CRYYRVSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKW IKEPHFLHAIEYGNYVYFFFREIAVEHNNLGRAVYS:RVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDS FFYFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVP KPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNY TVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCSAENEEDKKVISLQLDKDHHALYVAFSSCIIR IPLSRCERYGSCKKSCIASRDPYCGWLSQGSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCH EILPTSTTPDYKIFGGPTSDMEVSSSSVTTMASIPEITPKVIDTWRPKLTSSRKFVVQDDPNTSDFTDPLSGI PKGVRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRKNRKIHKDAESAQSCTDSSGSFA KLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKEHEFSGR 5 250 WO 2004/000997 PCT/US2003/017512 ROV16j, CG59253-08 SEQ ID NO: 213 3364bp DNA Sequence ORF Start: ATG at 46 JORF Stop- TAG at 3310 TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTGTAAGTCGTCTAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGG CTGGACTTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAA ACTTAAATGAAATGCCCAAAACAGAAGTAATATGGCAACAGAAACTGACATGGCGATCAAGACAACAGGATCG 4GAAAACTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAAC GATGAGATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGGTAAGTACCTTAG AATATGATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTT TGCTGATGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATG 3GTGATGGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCA TAGAATATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGT GTATTCCCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACT TCATTTCTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTA TTACAGACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCC TGGTTCTGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAA ACTCCAGATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAAC ACGGCCTTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCC CCTGATGGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTG ACGGCCATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTG GCATGGTACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGA AGCCTACAACCATGCAAAGTGCAGTGCTGAGAATGAGGAAGACAAAAAGGTCATCTCATTACAGTTGGATAAA GATCACCACGCTTTATATGTGGCGTTCTCTAGCTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATG GATCATGTAAAAAGTCTTGTATTGCATCTCGTGACCCGTATTGTGGCTGGTTAAGCCAGGGATCCTGTGGTAG AGTGACCCCAGGGATGCTGCTGTTAACCGAAGACTTCTTTGCTTTCCATAACCACAGTGCTGAAGGATATGAA CAAGACACAGAATTCGGCAACACAGCTCATCTAGGGGACTGCCATGAAATTTTGCCTACTTCAACTACACCAG ATTACAAAATATTTGGCGGTCCAACATCTGACATGGAGGTATCTTCATCTTCTGTTACCACAATGGCAAGTAT CCCAGAAATCACACCTAAAGTGATTGATACCTGGAGACCTAAACTGACAAGCTCTCGGAAATTTGTAGTTCAA GATGATCCAAACACTTCTGATTTTACTGATCCTTTATCGGGTATCCCAAAGGGTGTACGATGGGAAGTCCAGT CTGGAGAGTCCAACCAGATGGTCCACATGAATGTCCTCATCACCTGTGTCTTTGCTGCTTTTGTTTTGGGGGC ATTCATTGCAGGTGTGGCAGTATACTGCTATCGAGACATGTTTGTTCGGAAAAACAGAAAGATCCATAAAGAT GCAGAGTCCGCCCAGTCATGCACAGACTCCAGTGGAAGTTTTGCCAAACTGAATGGTCTCTTTGACAGCCCTG TCAAGGAATACCAACAGAATATTGATTCTCCTAAACTGTATAGTAACCTGCTAACCAGTCGGAAAGAGCTACC ACCCAATGGAGATACTAAATCCATGGTAATGGACCATCGAGGGCAACCTCCAGAGTTGGCTGCTCTTCCTACT CCTGAGTCTACACCCGTGCTTCACCAGAAGACCCTGCAGGCCATGAAGAGCCACTCAGAAAAGGCCCATGGCC ATGGAGCTTCAAGGAAAGAAACCCCTCAGTTTTTTCCGTCTAGTCCGCCACCTCATTCCCCATTAAGTCATGG GCATATCCCCAGTGCCATTTTCTTCCAAATGCTACCCATGACTACAACACGTCTTTCTCAAACTCCAATGCT CACAAAGCTGAAAAGAAGCTTCAAAACATTGATCACCCTCTCACAAAGTCATCCAGTAAGAGAGATCACCGGC GTTCTGTTGATTCCAGAAATACCCTCAATGATCTCCTGAAGCATCTGAATGACCCAAATAGTAACCCAAAGC CATCATGGGAGACATCCAGATGGCACACCAGAACTTAATGCTGGATCCCATGGGATCGATGTCTGAGGTCCCA CCTAAAGTCCCTAACCGGGAGGCATCGCTATACTCCCCTCCTTCAACTCTCCCCAGAAATAGCCCAACCAAGC GAGTGGATGTCCCCACCACTCCTGAGTCCCAATGACTTCTCTGGAAAGACAAAGAGGTTATCACAAAAATTC CTCCCAGAGGCACTCTATATCTGCTATGCCTAAAAACTTAAACTCACCAAATGGTGTTTTGTTATCCAGACAG CCTAGTATGAACCGTGGAGGATATATGCCCACCCCCACTGGGCCGAAGGTGGACTATATTCAGGGAACACCAG TGAGTGTTCATCTGCAGCCTTCCCTCTCCAGACAGAGCAGCTACACCAGTAATGGCACTCTTCCTAGGACGGG ACTAAAGAGGACGCCGTCCTTAAAACCTGACGTGCCACCAAAGCCTTCCTTTGTTCCTCAAACCCCATCTGTC AGACCACTGAACAAATACACATACTAGGCCTCAAGTGTGCTATTCCCATGTGGCTTTATCCTGTCCGTGTTGT TGAGAG 251 WO 2004/000997 PCT/US2003/017512 OVl6j, CG59253-08 SEQ IDNO: 214 1088 aa iM at121674.9kD Protein Sequence MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYI AGRDQVYTVNENEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPM CRYYRVSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKW IKEPHFLHAIEYGNYVYFFFREIAVENNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDS FFYFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVP KPRPGCCAKHGLAEAYKTSIDFPDETLSIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNY TVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCSAENEEDKKVISLQLDKDHHALYVAFSSCIIR IPLSRCERYGSCKKSCIASRDPYCGWLSQGSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCH EILPTSTTPDYKIFGGPTSDMEVSSSSVTTMASIPEITPKVIDTWRPKLTSSRKFVVQDDPNTSDFTDPLSGI PKGVRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRKNRKIHKDAESAQSCTDSSGSFA KLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKELPPNGDTKSMVMDHRGQPPELAALPTPESTPVLHQKTLQAM KSHSEKAHGHGASRKETPQFFPSSPPPHSPLSHGHIPSAIVLPNATHDYNTSFSNSNARKAEKKLQNIDHPLT KSSSKRDHRRSVDSRNTLNDLLKHLNDPNSNPKAIMGDIQMAHQNLMLDPMGSMSEVPPKVPNREASLYSPPS TLPRNSPTKRVDVPTTPGVPMTSLERQRGYHKNSSQRHSISAMPKNLNSPNGVLLSRQPSMNRGGYMPTPTGA KVDYIQGTPVSVHLQPSLSRQSSYTSNGTLPRTGLKRTPSLKPDVPPKPSFVPQTPSVRPLNKYTY 252 WO 2004/000997 PCT/US2003/017512 NOV16k, CG59253-09 SEQ ID NO: 215 3231 bp DNA Sequence ORF Start: ATG at 10 JORF Stop: TGA at 3229 CGCAGATCTATGAGGGTCTTCCTGCTTTGTGCCTACATACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCA GCTTTCCTGAAGATGATGAAQCCCTTAATACTGTCGACTATCACTATTCAAGGCAATATCCGGTTTTTAGAGG ACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGACTTTCAGCTGATGTTGAAAATTCGAGACACACTTTAT TGCTGGCAGGGATCAAGTTTATACAGTAAACTTAAATGAAATGCCCAAAACAGAAGTAATACCAAACAAGA AACTGACATGGCGATCAAGACAACAGGATCGAGAAAACTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCA CAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAGATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCC ATGTGTAGATACTACAGGTTGAGTACCTTAGAATATGATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCAT TTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGATGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTT GGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGATGGATCTGCCCTTCGCACAATAAAATATGATTCCAAA TGGATAAAAGAGCCACACTTTCTTCATGCCATAGAATATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCG CTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTCCCGCGTGGCCCGCATATGTAAAAACGACATGGGTGG TTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTTCTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGAT TCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAGACATAATACAAATCAATGGCATCCCCACTGTGGTCG GGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTCTGCTGTCTGTGCATTTAGCATGGATACATTGAAAA AGTATTCAAAGGACCGTTTAAGGAACAGAAAACTCCAGATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTG CCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCCTTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGG ATGAAACTCTGTCATTCATCAAATCTCATCCCCTGATGGACTCTGCCGTTCCACCCATTGCTGATGAGCCCTG GTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCCATCTCAGTGGACCATTCAGCCGGACCCTACCAGAAC TACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGGTACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTT TGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTACAACCATGCAAAGTGCAGTGCTGAGAATGAGGAAGA CAAAAAGGTCATCTCATTACAGTTGGATAAAGATCACCACGCTTTATATGTGGCGTTCTCTAGCTGCATTATC CGCATCCCCCTCAGTCGCTGTGAGCGTTATGGATCATGTAAAAAGTCTTGTATTGCATCTCGTGACCCGTATT TGGCTGGTTAAGCCAGGGATCCTGTGGTAGAGTGACCCCAGGGATGCTTGCTGAAGGATATGAACAAGACAC AGAATTCGGCAACACAGCTCATCTAGGGGACTGCCATGAAATTTTGCCTACTTCAACTACACCAGATTACAAA ATATTTGGCGGTCCAACATCTGACATGGAGGTATCTTCATCTTCTGTTACCACAATGGCAAGTATCCCAGAAA TCACACCTAAAGTGATTGATACCTGGAGACCTAAACTGACAAGCTCTCGGAAATTTGTAGTTCAAGATGATCC AAACACTTCTGATTTTACTGATCCTTTATCGGGTATCCCAAAGGGTGTACGATGGGAAGTCCAGTCTGGAGAG TCCAACCAGATGGTCCACATGAATGTCCTCATCACCTGTGTCTTTGCTGCTTTTGTTTTGGGGGCATTCATTG CAGGTGTGGCAGTATACTGCTATCGAGACATGTTTGTTCGGAAAAACAGAAAGATCCATAAAGATGCAGAGTC CGCCCAGTCATGCACAGACTCCAGTGGAAGTTTTGCCAAACTGAATGGTCTCTTTGACAGCCCTGTCAAGGAA TACCAACAGAATATTGATTCTCCTAAACTGTATAGTAACCTOCTAACCAGTCGGAAAGAGCTACCACCCAATG GAGATACTAAATCCATGGTAATGGACCATCGAGGGCAACCTCCAGAGTTGGCTGCTCTTCCTACTCCTGAGTC TACACCCGTGCTTCACCAGAAGACCCTGCAGGCCATGAAGAGCCACTCAGAAAAGGCCCATGGCCATGGAGCT TCAAGGAAAGAAACCCCTCAGTTTTTTCCGTCTAGTCCGCCACCTCATTCCCCATTAAGTCATGGGCATATCC CCAGTGCCATTGTTCTTCCAAATGCTACCCATGACTACAACACGTCTTTCTCAAACTCCAATGCTCACAAAGC TGAAAAGAAGCTTCAAAACATTGATCACCCTCTCACAAAGTCATCCAGTAAGAGAGATCACCGGCGTTCTGTT GATTCCAGAAATACCCTCAATGATCTCCTGAAGCATCTGAATGACCCAAATAGTAACCCAAAGCCATCATGG GAGACATCCAGATGGCACACCAGAACTTAATGCTGGATCCCATGGGATCGATGTCTGAGGTCCCACCTAAAGT CCCTAACCGGGAGGCATCGCTATACTCCCCTCCTTCAACTCTCCCCAGAAATAGCCCAACCAAGCGAGTGGAT GTCCCCACCACTCCTGGAGTCCCAATGACTTCTCTGGAAAGACAAAGAGGTTATCACAAAAATTCCTCCCAGA GGCACTCTATATCTGCTATGCCTAAAAACTTAAACTCACCAAATGGTGTTTTGTTATCCAGACAGCCTAGTAT GAACCGTGGAGGATATATGCCCACCCCCACTGGGGCGAAGGTGGACTATATTCAGGGAACACCAGTGAGTGTT CATCTGCAGCCTTCCCTCTCCAGACAGAGCAGCTACACCAGTAATGGCACTCTTCCTAGGACGGGACTAAAGA GGACGCCGTCCTTAAAACCTCACGTGCCACCAAAGCCTTCCTTTGTTCCTCAAACCCCATCTGTCAGACCACT GAACAAATACACATACTGA 253 WO 2004/000997 PCT/US2003/017512 OVI6k, CG59253-09 SEQ D NO: 216 1073aa 'MW at 119870.9kD Protein Sequence MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAG RDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCR YYRLSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIK EPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFF YFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKP RPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTV IFYGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNKAKCSAENEEDKKVISLQLDKDHHALYVAFSSCIIRIP LSRCERYGSCKKSCIASRDPYCGWLSQGSCGRVTPGMLAEGYEQDTEFGNTAHLGDCHEILPTSTTPDYKIFG GPTSDMEVSSSSVTTMASIPEITPKVIDTWRPKLTSSRKFVVQDDPNTSDFTDPLSGIPKGERWEVQSGESNQ MVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRKNRKIHKDAESAQSCTDSSGSFAKLNGLFDSPVKEYQQ NIDSPKLYSNLLTSRKELPPNGDTKSMVMDHRGQPPELAALPTPESTPVLHQKTLQAMKSHSEKAHGHGASRK ETPQFFPSSPPPHSPLSHGHIPSAIVLPNATHDYNTSPSNSNAHKAEKKLQNIDHPLTKSSSKRDHRRSVDSR NTLNDLLKHLNDPNSNPKAIMGDIQMAHQNLMLDPMGSMSEVPPKVPNREASLYSPPSTLPERSPTKRVDVPT TPGVPMTSLERQRGYHKNSSQRHSISAMPKNLNSPNGVLLSRQPSMNRGGYMPTPTGAEVDYIQGTPVSVHLQ PSLSRQSSYTSNGTLPRTGLKRTPSLKPDVPPKPSFVPQTPSVRPLNKYTY NOVI 61, CG59253-10 ISEQ ID NO: 217 1950 bp DNA Sequence jORF Start: at 10 IORF Stop: at 1942 CGCAGATCTGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGACTATCACTATTCAAGGCAATATC CGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGACTTTCAGCTGATGTTGAAAATTCG AGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAAATGAAATGCCCAAAACAGAAGTA ATACCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAACTGTGCTATGAAAGGCAAGCATA AAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAGATGGTTTTTTTTGTGGTACCAA TGCATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATGATGGGAAGAAATTAGTGGCCTG GCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGATGGGAAGCTGTATTCTGCCACAG TGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGATGGATCTGCCCTTCGCACAATAAA ATATCATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAATATGGAAACTATGTCTATTTCTTC TTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTCCCGCGTGGCCCGCATATGTAAAA ACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTTCTAAAGGCTCGGCTGAACTGTTC TGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAGACATAATACAAATCAATGGCATC CCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTCTGCTGTCTGTGCATTTAGCATGG ATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCAGATTCTGTTTGGACAGCAGTTCC CGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCCTTGCCGAAGCTTATAAAACCTCC ATCGATTTCCCGCATGAAACTCTGTCATTCATCAAATCTCATCCCCTGATGGACTCTGCCGTTCCACCCATTG CTGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCCATCTCAGTGGACCATTCAGCCGG ACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGGTACTTAAAGTTCTGGCAAAGACC AGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTACAACCATGCAAAGTGCAGTGCTG AGAATGAGGAAGACAAAAAGGTCATCTCATTACAGTTGGATAAACATCACCACGCTTTATATGTGGCGTTCTC TAGCTGCATTATCCGCATCCCCCTCAGTCGCTGTGAGCGTTATGGATCATGTAAAAAGTCTTGTATTGCATCT CGTGACCCGTATTGTGGCTGGTTAAGCCAGGGATCCTGTGGTAGAGTGACCCCAGGGATGCTGCTGTTAACCG AAGACTTCTTTGCTTTCCATAACCACAGTGCTGAAGGATATGAACAAGACACAGAATTCGGCAACACAGCTCA TCTAGGGGACTGCCATGAAATTTTGCCTACTTCAACTACACCAGATTACAAAATATTTGGCGGTCCAACATCT GACATGGAGGTATCTTCATCTTCTGTTACCACAATGGCAAGTATCCCAGAAATCACACCTAAAGTGATTGATA CCTGGAGACCTAAACTGACAAGCTCTCGGAAATTTGTAGTTCAAGATGATCCAAACACTTCTGATTTTACTGA TCCTTTATCGGGTATCCCAAAGGGTGTACGATGGGAAGTCCAGCTCGAGGCG 5 254 WO 2004/000997 PCT/US2003/017512 NOV161, CG59253-10 SEQ ID NO: 218 644 aa MW at 72707.5kD Protein Sequence VSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIPN KKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARC PFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFRE IAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQSITDIIQINGIPTV VGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKPRPGCCAKHGLAEAYKTSIDF PDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPF SLNDSVLLEEIEAYNHAKCSAENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDP YCGWLSQGSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCHEILPTSTTPDYKIFGGPTSDME VSSSSVTTMASIPEITPKVIDTWRPKLTSSRKFVVQDDPNTSDFTDPLSGIPKGVRWEVQ NOV16m, SNP13381547 of SEQ ID NO: 219 1894 bp CG59253-01, DNA Sequence ORF Start: ATG at 46 ORF Stop: TAG at 1474 SNP Pos: 215 SNP Change: T to C TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTATTCAAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCCGGAC TTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAA ATGAAATGCCCAAAACAGAAGTAATACCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAA CTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAG ATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATG ATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGA TGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGAT GGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAAT ATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTC CCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTT CTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAG ACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTC TGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCA GATTCTGTTTGGACAGCAGTTCCCGAACACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGOCAAAACACGGCC TTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGAT GGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCC ATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGG TACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTA CAACCATGCAAAGTAGGTATATOTTACGAGAACGCCCTTCAGCACTGCTCAAAAATTTTCGGCATGTATTTCA TCTAGTCATGTCCTTTTGGTCCTCTAAATTAGCAGTGGTTTGGCATAATAGTGTTTTGTGTTTTTTTTCTCAT TGAAATAAATCTTGGGTTTGTTTTTTTCCCGAGCCTGCTAGGGCGAGGGGGGTGAATGGTTGATGAGTTTAAA AATAATGCAGCCCTTGTTTTTCACCTGTAGAATATGAGAACATTTTAACAGCACCTCTCTTATCTTGCAGATA TATTCCAAGATGCTACATGCAGCAGACAGCTGTGAGCTTGCATACACACACACACAAATATACATGCACATAC ATACACAGAATGTAGTACTAGTTAAGTATTTCCTTCCTATCTTTAATAAGTAAGAGAATATTTAGACCA 5 NOV16m, SNP13381547 of SEQ JDNO: 220 1476 aa MW at 54200.4kD CG59253-01, Protein Sequence SNP Pos: 57 SNP Change: Leu to Pro MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHYSRQYPVFRCRPSGNESQHRPDFQLMLKIRDTLYIAG RDQVYTVNLNEMPKTVIPNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCR YYRLSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIK EPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFF YFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKP RPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTV TFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK 255 WO 2004/000997 PCT/US2003/017512 NOV16n, SNP13378936 of SEQ ID NO: 221 1894 bp CG59253-01, DNA Sequence ORF Start: ATG at 46 ORF Stop: TAG at 1474 SNP Pos: 865 SNP Change: T to C TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTATTCAAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGAC TTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAALACTTAA ATGAAATGCCCAAAACAGAAGTAATACCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAA CTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAG ATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATG ATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGA TGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGAT GGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAAT ATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTC CCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACCGGACTTCATTT CTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAG ACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTC TGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCA GATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCC TTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGAT GGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCC ATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGG TACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTA CAACCATGCAAAGTAGGTATATGTTACGAGAACGCCCTTCAGCACTGCTCAAAAATTTTCGGCATGTATTTCA TCTAGTCATGTCCTTTTGGTCCTCTAAATTAGCAGTGGTTTGGCATAATAGTGTTTTGTGTTTTTTTTCTCAT TGAAATAAATCTTGGGTTTGTTTTTTTCCCGAGCCTGCTAGGGCGAGGGGGGTGAATGGTTGATGAGTTTAAA AATAATGCAGCCCTTGTTTTTCACCTGTAGAATATCAGAACATTTTAACAGCACCTCTCTTATCTTGCAGATA TATTCCAAGATGCTACATGCAGCAGACAGCTGTGAGCTTGCATACACACACACACAAATATACATGCACATAC ATAACAAAGTAGTACTAGTTAAGTATTTCCTTCCTATCTTTAATAAGTAAGAGAATATTTAGACCA NOV16n, SNP13378936 of SEQ ID NO: 222 476 aa [MW at 54186.4kD CG59253-1, Protein Sequence ISNP Pos: 274 JSNP Change: Trp to Arg MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAG RDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCR YYRLSTLEYDGEEISLARCPFDARTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIK EPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHRTSFLKARLNCSVPGDSFF YFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKP RPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTV IFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK 5 256 WO 2004/000997 PCT/US2003/017512 OV16o, SNP13378935 of SEQ IDNO: 223 1894 bp CG59253-01, DNA Sequence iORF Start: ATG at 46 ORF Stop: TAG at 1474 SNP Pos: 965 SNP Change: A to G TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTATTCAAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGAC TTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAA ATGAAATGCCCAAAACAGAAGTAATACCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAA CTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAG ATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATG ATGGGGAAGAAATTAGTGGCCTGGCAAATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGA TGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGAT GGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAAT ATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTC CCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTT CTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAG ACATAATACAAATCAGTGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTC TGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCA GATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCC TTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGAT GGACTCTGCCGTTCCACCCATTOCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCC ATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGG TACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTA CAACCATGCAAAGTAGGTATATGTTACGAGAACGCCCTTCAGCACTGCTCAAAAATTTTCGGCATGTATTTCA TCTAGTCATGTCCTTTTGGTCCTCTAAATTAGCAGTGGTTTGGCATAATAGTGTTTTGTGTTTTTTTTCTCAT TGAAATAAATCTTGGGTTTGTTTTTTTCCCGAGCCTGCTAGGGCGAGGGGGGTGAATGGTTGATGAGTTTAAA AATAATGCAGCCCTTGTTTTTCACCTGTAGAATATGAGAACATTTTAACAGCACCTCTCTTATCTTGCAGATA TATTCCAAGATGCTACATGCAGCAGACAGCTGTGAGCTTGCATACACACACACACAAATATACATGCACATAC ATACACAGAATGTAGTACTAGTTAAGTATTTCCTTCCTATCTTTAATAAGTAAGAGAATATTTAGACCA NOV16o, SNP13378935 of SEQ ID NO: 224 476 aa MW at 54189.4kD CG59253-01, Protein Sequence SNP Pos: 307 SNP Change: Asn to Ser MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAG RDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCR YYRLSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIK EPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFF YFDVLQSITDIIQISGIPTVVGVTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKP RPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTV IFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK 5 257 WO 2004/000997 PCT/US2003/017512 ROV16p SNP13381569 of SEQ ID NO: 225 1894 bp CG59253-01, DNA Sequence ORF Start: ATG at 46 _ORF Stop: TAG at 1474 SNP Pos: 1351 JSNP Change: T to C TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTATTCAAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGAC TTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAA ATGAAATGCCCAAAACAGAAGTAATACCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAA CTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAG ATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATG ATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGA TGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGAT GGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAAT ATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTC CCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTT CTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAG ACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTC TGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCA GATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCC TTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGAT GGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCC ATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACCACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGG TACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTA CAACCATGCAAAGTAGGTATATGTTACGAGAACGCCCTTCAGCACTGCTCAAAAATTTTCGGCATGTATTTCA TCTAGTCATGTCCTTTTGGTCCTCTAAATTAGCAGTGGTTTGGCATAATAGTGTTTTGTGTTTTTTTTCTCAT TGAAATAAATCTTGGGTTTGTTTTTTTCCCGAGCCTGCTAGGGCGAGGGGGGTGAATGGTTGATGAGTTTAAA AATAATGCAGCCCTTGTTTTTCACCTGTAGAATATGAGAACATTTTAACAGCACCTCTCTTATCTTGCAGATA TATTCCAAGATGCTACATGCAGCAGACAGCTGTGAGCTTGCATACACACACACACAAATATACATGCACATAC ATACACAGAATGTAGTACTAGTTAAGTATTTCCTTCCTATCTTTAATAAGTAAGAGAATATTTAGACCA NOV16p, SNP13381569 of ISEQ ID NO: 226 476 aa MW at 54190.4kD CG59253-01, Protein Sequence SNP Pos: 436 SNP Change: Tyr to His MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAG RDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCR YYRLSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIK EPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSPLKARLNCSVPGDSFF YFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKP RPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNHTV IFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK 5 258 WO 2004/000997 PCT/US2003/017512 NOV16q, SNP13382528 of SEQ ID NO: 227 1894 bp CG59253-01, DNA Sequence ORF Start: ATG at 46 ORF Stop: TAG at 1474 SNP Pos: 1838 SNP Change: T to C TGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTCTTCCTGCTTTGTGCCTACA TACTGCTGCTGATGGTTTCCCAGTTGAGGGCAGTCAGCTTTCCTGAAGATGATGAACCCCTTAATACTGTCGA CTATCACTATTCAAGGCAATATCCGGTTTTTAGAGGACGCCCTTCAGGCAATGAATCGCAGCACAGGCTGGAC TTTCAGCTGATGTTGAAAATTCGAGACACACTTTATATTGCTGGCAGGGATCAAGTTTATACAGTAAACTTAA ATGAAATGCCCAAAACAGAAGTAATACCCAACAAGAAACTGACATGGCGATCAAGACAACAGGATCGAGAAAA CTGTGCTATGAAAGGCAAGCATAAAGATGAATGCCACAACTTTATCAAAGTATTTGTTCCAAGAAACGATGAG ATGGTTTTTGTTTGTGGTACCAATGCATTCAATCCCATGTGTAGATACTACAGGTTGAGTACCTTAGAATATG ATGGGGAAGAAATTAGTGGCCTGGCAAGATGCCCATTTGATGCCAGACAAACCAATGTTGCCCTCTTTGCTGA TGGGAAGCTGTATTCTGCCACAGTGGCTGACTTCTTGGCCAGCGATGCCGTTATTTATCGAAGCATGGGTGAT GGATCTGCCCTTCGCACAATAAAATATGATTCCAAATGGATAAAAGAGCCACACTTTCTTCATGCCATAGAAT ATGGAAACTATGTCTATTTCTTCTTTCGAGAAATCGCTGTCGAACATAATAATTTAGGCAAGGCTGTGTATTC CCGCGTGGCCCGCATATGTAAAAACGACATGGGTGGTTCCCAGCGGGTCCTGGAGAAACACTGGACTTCATTT CTAAAGGCTCGGCTGAACTGTTCTGTCCCTGGAGATTCGTTTTTCTACTTTGATGTTCTGCAGTCTATTACAG ACATAATACAAATCAATGGCATCCCCACTGTGGTCGGGGTGTTTACCACGCAGCTCAATAGCATCCCTGGTTC TGCTGTCTGTGCATTTAGCATGGATGACATTGAAAAAGTATTCAAAGGACGGTTTAAGGAACAGAAAACTCCA GATTCTGTTTGGACAGCAGTTCCCGAAGACAAAGTGCCAAAGCCAAGGCCTGGCTGTTGTGCAAAACACGGCC TTGCCGAAGCTTATAAAACCTCCATCGATTTCCCGGATGAAACTCTGTCATTCATCAAATCTCATCCCCTGAT GGACTCTGCCGTTCCACCCATTGCCGATGAGCCCTGGTTCACAAAGACTCGGGTCAGGTACAGACTGACGGCC ATCTCAGTGGACCATTCAGCCGGACCCTACCAGAACTACACAGTCATCTTTGTTGGCTCTGAAGCTGGCATGG TACTTAAAGTTCTGGCAAAGACCAGTCCTTTCTCTTTGAACGACAGCGTATTACTGGAAGAGATTGAAGCCTA CAACCATCCAAGATAGGTATATGTTACGAGAACGCCCTTCAGCACTGCTCAAAAATTTTCGGCATGTATTTCA TCTAGTCATGTCCTTTTGGTCCTCTAAATTAGCAGTGGTTTGGCATAATAGTGTTTTGTGTTTTTTTTCTCAT TGAAATAAATCTTGGGTTTGTTTTTTTCCCGAGCCTGCTAGGGCGAGGGGGGTGAATGGTTGATGAGTTTAAA AATAATGCAGCCCTTGTTTTTCACCTGTAGAATATGAGAACATTTTAACAGCACCTCTCTTATCTTGCAGATA TATTCCAAGATGCTACATGCAGCAGACAGCTGTGAGCTTGCATACACACACACACAAATATACATGCACATAC ATACACAGATGCAGTACTAGTTAAGTATTTCCTTCCTATCTTTATAGTAGAGATATTTAGACCA NOV16q, SNP13382528 of ISEQ IDNO:228 476 aa MW at 54216.4kD CG59253-01, Protein Sequence SNP Change: no change MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHYSRQYPVFRGRPSGNESQHRLDFQLMLKIRDTLYIAG RDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDECHNFIKVFVPRNDEMVFVCGTNAFNPMCR YYRLSTLEYDGEEISGLARCPFDARQTNVALFADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIK EPHFLHAIEYGNYVYFFFREIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFF YFDVLQSITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVPEDKVPKP RPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVRYRLTAISVDHSAGPYQNYTV IFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK 5 A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 16B. 259 WO 2004/000997 PCT/US2003/017512 Table 16B. Comparison of the NOV16 protein sequences. NOV16a MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHY--SRQYPVFRGRPSGNESQHRLD NOV16b ------------------GSVSFPEDDEPLNTVDYHY--SRQYPVFRGRPSGNESQHRLD NOV16c MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLD NOV16d ------------------GSVSFPEDDEPLNTVDYHY--SRQYPVFRGRPSGNESQHRLD NOV16e --------------------VSFPEDDEPLNTVDYHY--SRQYPVFRGRPSGNESQHRLD NOV16f --------------------VSFPEDDEPLNTVDYHY--SRQYPVFRGRPSGNESQHRLD NOV16g MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLD NOV16h MRVFLLCAYILLLTVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLD NOV16i MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLD NOV16j MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHCKSSRQYPVFRGRPSGNESQHRLD NOV16k MRVFLLCAYILLLMVSQLRAVSFPEDDEPLNTVDYHY--SRQYPVFRGRPSGNESQHRLD NOV161 -------------------- VSFPEDDEPLNTVDYHY--SRQYPVFRGRPSGNESQHRLD NOV16a FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDEC NOVI6b FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDEC NOV16c FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDEC NOV16d FQLMLKIRDTLYIAGGDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDEC NOV16e FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDEC NOV16f FQLMLKIRDTLYIAGGDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDEC NOV16g FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDEC NOV16h FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDEC NOV16i FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDEC NOV16j FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIWQQKLTWRSRQQDRENCAMKGKHKDEC NOV16k FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDEC NOV161 FQLMLKIRDTLYIAGRDQVYTVNLNEMPKTEVIPNKKLTWRSRQQDRENCAMKGKHKDEC NOV16a HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARCPFDARQTNVALF NOV16b HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARCPFDARQTNVALF NOV16c HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRVSTLEYDGEEISGLARCPFDARQTNVALF NOV16d HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARCPFDARQTNVALF NOV16e HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARCPFDARQTNVALF NOV16f HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARCPFDARQTNVALF NOV16g HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRVSTLEYDGEEISGLARCPFDARQTNVALF NOV16h ERFIKVFVPRNDEMVFVCGTNAFNPMCRYYRVSTLEYDGEEISGLARCPFDARQTNVALF NOV16i HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRVSTLEYDGEEISGLARCPFDARQTNVALF NOV16j HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRVSTLEYDGEEISGLARCPFDARQTNVALF NOV16k HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARCPFDARQTNVALF NOV161 HNFIKVFVPRNDEMVFVCGTNAFNPMCRYYRLSTLEYDGEEISGLARCPFDARQTNVALF NOVi6a ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16b ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16c ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16d ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16e ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16f ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYONYVYFFFR NOVI6g ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16h ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16i ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16j ADGKUYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLHAIEYGNYVYFFFR NOV16k ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLKAIEYGNYVYFFFR NOV161 ADGKLYSATVADFLASDAVIYRSMGDGSALRTIKYDSKWIKEPHFLKAIEYGNYVYFFFR NOV16a ]BIVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSPFYFDVLQ NOV16b EIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOV16c EIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOV16d EIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ 260 WO 2004/000997 PCT/US2003/017512 NOV16e ELAVEKRNLGKAVYSRVARICKNDMGGSQRVLEKHWTSPLKARLNCSVPGDSFFYPDVLQ NOV16f EIAVEHNULGKAVYSRVARICKNDMGGSQRVLEKHWTSLKARLNCSVPGDSFFYFDVLQ NOV16g EIAVERNNLGXAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOViGh EIAVEHNNLGKAVYSRVARICKNUMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOV16i BIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOV16j EIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOV16k EIAVEHNNLGKAVYSRVARICKNDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOV161 EIAVEHNNLKAVYSRARICKDMGGSQRVLEKHWTSFLKARLNCSVPGDSFFYFDVLQ NOV16a SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16b SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16c SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16d SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOVIGe SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV1Gf SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV1Gg SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16h SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16i SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16j SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16k SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEVFKGRFKEQKTPDSVWTAVP NOV161 SITDIIQINGIPTVVGVFTTQLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTPDSVWTAVP NOV16a EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16b EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16c EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16d EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSPIKSHPLMDSAVPPIADEPWFTKTRVR NOV16e EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16f EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16g EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16h EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16i EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16j EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16k EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV161 EDKVPKPRPGCCAKHGLAEAYKTSIDFPDETLSFIKSHPLMDSAVPPIADEPWFTKTRVR NOV16a YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK- NOV16b YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCL NOVIGc YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCS NOV16d YRLTAISVDHSAGPYONYTVIFYGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCN NOV16e YRLTAISVDHSAGPYQNYTVIFYGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAK- NOV16f YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCN NOV16g YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCS NOV16h YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPSLNDSVLLEEIAYNHAKCS NOV16i YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCS NOV16j YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIAYNHAKCS NOV16k YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCS NOV161 YRLTAISVDHSAGPYQNYTVIFVGSEAGMVLKVLAKTSPFSLNDSVLLEEIEAYNHAKCS NOV16a --------------------------------------------- - - NOV16b E------------------------------------------- -- NOV16c AENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16d AENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16e ---------------------------- NOV16f AENEEDKKVISLQLDKDHKALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16g AENEEDKKVISLQLDKDHALYVAPSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16h AENEEDKKVISLQLDKDHHALYAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16i AENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16j AENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16k AENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ 261 WO 2004/000997 PCT/US2003/017512 NOV161 AENEEDKKVISLQLDKDHHALYVAFSSCIIRIPLSRCERYGSCKKSCIASRDPYCGWLSQ NOV16a ----------------------------- NOV16b ------------------------------------------------ NOV16c GSCGRVTP------------- NHSAEGYEQDTEFGNTAHLGDCHAYEPYEGR------- NOV16d GSCGRVTP------------- GMLAEGYEQDTEFGNTAHLGD

-----------------

NOV16e -------------------------------- NOV16f GSCGRVTP-------------

GMLAEGYEQDTEFGNTAHLGD-----------------

NOV16g GSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCHEILPTS-------- NOV16h GSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCHEILPTS--------- NOV16i GSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCHEILPTS--------- NOV16j GSCGRVTPGMLLLTEDFFAFHNHSAEGYEQDTEFGNTAHLGDCHEILPTS--------- NOV16k GSCGRVTP------------ GMLAEGYEQDTEFGNTAHLGDCHEILPTSTTPDYKIFGG NOV161 GSCGRVTPGMLLLTEDFFAFHNIHSAEGYEQDTEFGNTAHLGDCHEILPTS--------- NOV16a ------------------------ - - - - - - - - - - - - - - - - NOV16b ---- ----------------------.. . . NOV16c ---------------------------------- VGSLKAICYLLLFLKSTLFTLSHVSISG NOV16d --------------------------------------------------------- CHG NOV16e ------------------------------ NOV16f --------------------------------------------------------- CHG NOV16g -------------------- ------------------------- TTPDYKIFGGPTSG NOV16h ---------------------------------------------- TTPDYKIFGGPTSG NOV16i -----------------------------------------------

TTP---------

NOV16j ---------------------------------------------------

TTP---------

NOV16k PTSDMEVSSSSVTTMASIPEITPKVIDTWRPKLTSSRKFVVQDDPNTSDFTDPLSGIPKG NOV161 --------------------------------------------------

TTP---------

NOV16a

---------------------

NOV16b

----------------------

NOV16c VRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRRKIHKDAESAQ NOVI6d VRWEVQSGESNQMVHMNLE------------------- NOV16e --------------------------------- NOV16f VRWEVQSGESNQMVHMN----------------------- NOV16g VRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRKNRKIHKDAESAQ NOV16h VRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRKNRKIHKDAESAQ NOV16i -DYKIFGGPTSDMEVSSSSVTTMAS----IPEITPKVIDTWRPKLTSSRKFVVQDDPNTS NOV16j -DYKIFGGPTSDMEVSSSSVTTMAS ---- IPEITPKVIDTWRPKLTSSRKFVVQDDPNTS NOVI6k VRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYRDMFVRKNRKIHKDAESAQ NOV161 -DYKIFGGPTSDMEVSSSSVTTMAS ----IPEITPKVIDTWRPKLTSSRKFVVQDDPNTS NOV16a ---------------- ------------- - - - - - - - - - - - - - NOV16b --------------------------------- NOV16c SCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKELPPNGDTKSMVMDHRGQP NOV16d ---------------- -- -- - - - - - - - - - - - - - NOV16e ---- -- ------- - - - - - - - - - - - - - - - - - - - - - NOV16f ------------------.. . . . . . . . . . . NOV16g SCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKEHEFSGR----------- NOV16h SCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKELPPNGDSKSMVMDHRGQP NOV16i DFTDP------LSGIPKGVRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYR NOV16j DFTDP------ LSGIPKGVRWEVQSGESNQMVHMNVLITCVFAAFVLGAFIAGVAVYCYR NOV16k SCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKELPPNGDTKSMVMDHRGQP NOV161 DFTDP------LSGIPKGVRWEVQ ----- ------------ NOV16a ------------ ------------ - - -- - NOV16b ------------ - --- -- ---- - - - - - - - - - - - - - - - NOV16c PELAALPTPESTPVLHQKTLQAMKSHSEKAHGHGASRKETPQFFPSSPPPHSPLSHGHIP NOV16d ----------------------------- NOV16e ----------------------------------- 262 WO 2004/000997 PCT/US2003/017512 NOV16f ---------------- NOV16g -------------. NOV16h PELAALPTPESTPVLHQKTLQAMKSHSEKAHGHGASRKETPQFFPSSPPPHSPLSHGHIP NOV16i DMFVRKNRKIHKDAESAQSCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKE NOV16j DMFVRKNRKIHKDAESAQSCTDSSGSFAKLNGLFDSPVKEYQQNIDSPKLYSNLLTSRKE NOV16k PELAALPTPESTPVLHQKTLQAMKSHSEKAHGHGASRKETPQFFPSSPPPHSPLSHGHIP NOV161 ------------------ - - - - - - - - - - - - - - - - - - - NOV16a ------------------ -- - - - - - - - - - - - - - - NOV16b ------------------.... NOV16c SAIVLPNATHDYNTSFSNSNAHKAEKKLQNIDHPLTKSSSKRDHRRSVDSRNTLNDLLYH NOV16d --------------. NOV16e ------------.. . . . . . . . . . . . . . NOV16f --------------........ NOV16g --------------.. .. . . . . . . . . . NOVI6h SAIVLPNATHDYNTSFSNSNAHKAEKKLQNIDHPLTKSSSKRDHRRSVDSRNTLNDLLKH NOV16i HEFSGR--------------------------------- NOVI6j LPPNGDTKSMVMDHRGQPPELAALPTPESTPVLHQKTLQAMKSHSEKAHGHGASRKETPQ NOV16k SAIVLPNATHDYNTSFSNSNAHKAEKKLQNIDHPLTKSSSKRDHRRSVDSRNTLNDLLKH NOV161 -------------------- NOV16a ----------------------........ NOV16b ------------------------------ NOV16c LNDPNSNPKAIMGDIQMAHQNLMLDPMGSMSEVPPKVPNREASLYSPPSTLPRNSPTKRV NOV16d ------------ ------ - - - - - - - - - - NOV16e --------------- --- - - - - - - - - - - - - - - - - - - NOV16f -------------.. . . . . . . . . . . . . . NOV16g ------------- - - - - - - - - - - - - - - - - NOV16h LNDPNSNPKAIMGDIQMAHQNLMLDPMGSMSEVPPKVPNREASLYSPPSTLPRNSPTKRV NOV16i ----- ------ ----------- - - - - - - - - NOV16j FFPSSPPPHSPLSHGHIPSAIVLPNATHDYNTSFSNSNAHKAEKKLQNIDHPLTKSSSKR NOV16k LNDPNSNPKAIMGDIQMAHQNLMLDPMGSMSEVPPKVPNREASLYSPPSTLPRNSPTKRV NOV161 ----------------------- - - - - - - - - - - - - - - - - - NOV16a ---------------- ------.. . . . . NOV16b ----------------------- - - - - - - - - - - NOV16c DVPTTPGVPMTSLERQRGYHKNSSQRHSISAMPKNLNSPNGVLLSRQPSMNRGGYMPTPT NOV16d -------------------. NOV16e --------------- --- - - - - - - - - - - - - - - - - - - NOV16f --------------------- - - - - - - - - - - NOV16g -------------------.. . NOV16h DVPTTPGVPMTSLERQRGYHKNSSQRHSISAMPKNLNSPNGVLLSRQPSMNRGGYMPTPT NOV16i --------------------------------- NOV16j DHRRSVDSRNTLNDLLKHLNDPNSNPKAIMGDIQMAHQNLMLDPMGSMSEVPPKVPNREA NOV16k DVPTTPGVPMTSLERQRGYHKNSSQRHSISAMPKNLNSPNGVLLSRQPSMNRGGYMPTPT NOV161 ---------------.... NOV16a ------------------- - - - - - - - - - - - - - - - - - - NOV16b --------------------- -....... NOV16c GAKVDYIQGTPVSVHLQPSLSRQSSYTSNGTLPRTGLKRTPSLKPDVPPKPSFVPQTPSV NOV16d -------------------- - - - - - - - - - - - - - - - - - - NOV16e ----------------- - - - - - - - - - - - - - NOV16f -------- --- - - - - - - - - - - - - - - - - - - - - - - NOV16g --- --------- ---- - - - - - - - - - - - - - - - - - - - NOV16h GAKVDYIQGTPVSVHLQPSLSRQSSYTSNGTLPRTGLKRTPSLKPDVPPKPSFVPQTPSV NOV16i -- - - ---- - --- -- - - - - - - - NOV16j SLYSPPSTLPRNSPTKRVDVPTTPGVPMTSLERQRGYHKNSSQRHSISAMPKNLNSPNGV NOV16k GAKVDYIQGTPVSVHLQPSLSRQSSYTSNGTLPRTGLKRTPSLKPDVPPKPSFVPQTPSV NOV161 ----------------------------------- 263 WO 2004/000997 PCT/US2003/017512 NOV16a ------------ -- - - - - - - - - - - - - - - - - NOV16b --------------- - - - - - - - - - - - - - - NOVl6c RPLNKYTY--------- - - - - - - - - - - - - - - - - - - - - NOV16d --------------- - - - - - - - - - - - - - - - - - - - - - NOV16e ------------- - - - - - - - - - -7- - - - - - - NOV16f ------------ NOVI6g ------- --.. . . . . . . . . . . . . . . . . . NOV16h RPLNKYTY------ . . . . .. .. . . . . NOV16i ------- ----- - - - - - - - - - - - - - - - - - - - - - - NOV16j LLSRQPSMNRGGYMPTPTGAKVDYIQGTPVSVHLQPSLSRQSSYTSNGTLPRTGLKRTPS NOV16k RPLNKYTY------- ........... NOV161 -------------- - - - - NOV16a -------------------- NOV16b

-----------------

NOV16c ------------------ NOV16d ------------------ NOV16e --------------------- NOV16f -------------------- NOV16g -------------------- NOV16h ---------------- NOV16i ------------- NOV16j LKPDVPPKPSFVPQTPSVRPLNKYTY NOV16k ------------------ NOV161 -------------------- NOV16a (SEQ ID NO: 196) NOV16b (SEQ ID NO: 198) NOV16c (SEQ ID NO: 200) NOV16d (SEQ ID NO: 202) NOV16e (SEQ ID NO: 204) NOV16f (SEQ ID NO: 206) NOV16g (SEQ ID NO: 208) NOV16h (SEQ ID NO: 210) NOV16i (SEQ ID NO: 212) NOV16j (SEQ ID NO: 214) NOV16k (SEQ ID NO: 216) NOV161 (SEQ ID NO: 218) Further analysis of the NOV 16a protein yielded the following properties shown in Table 16C. Table 16C. Protein Sequence Properties NOV16a SignalP? analysis: Cleavage site between residues 21 and 22 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 2; pos.chg 1; neg.chg 0 H-region: length 16; peak value 9.62 PSG score: 5.22 GvK: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -0.82 264 WO 2004/000997 PCT/US2003/017512 possible cleavage site: between 20 and 21 >>> Seems to have a cleavable signal peptide (1 to 20) ALOM: Klein et al's method for TM region allocation Init position for calculation: 21 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 0 PERIPHERAL Likelihood = 1.75 (at 300) ALOM score: -0.32 (number of TMSs: 0) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 10 Charge difference: -5.0 C(-3.0) - N( 2.0) N >= C: N-terminal side will be inside MITDISC: discrimination of mitochondrial targeting seq R content: 2 Hyd Moment(75): 6.62 Hyd Moment(95): 8.11 G content: 0 D/E content: 1 S/T content: 2 Score: -2.26 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 29 LRAIVS NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 12.0% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: RVFL none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none 265 WO 2004/000997 PCT/US2003/017512 NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 89 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 21.7 %: mitochondrial 21.7 %: endoplasmic reticulum 17.4 %: extracellular, including cell wall 13.0 %: vacuolar 8.7 %: cytoplasmic 8.7 %: Golgi 8.7 %: nuclear >> prediction for CG59253-01 is mit (k=23) A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16D. 5 Table 16D. Geneseq Results for NOV16a NOV16a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE23981 Human LP221 secreted protein - 1..476 476/476 (100%) 0.0 Homo sapiens, 476 aa. 1..476 476/476 (100%) [WO200226801-A2, 04-APR-2002] AAG79413 CADHP-2, Incyte ID No: 1..476 476/476 (100%) 0.0 7596315CD1 -Homo sapiens, 1017 1..476 476/476 (100%) aa. [WO200259312-A2, 01-AUG-2002] ABG79172 Human semaphorin-like protein #1 - 1..476 476/476 (100%) 0.0 Homo sapiens, 476 aa. 1..476 476/476 (100%) [WO200264791-A2, 22-AUG-2002] AAG63213 Amino acid sequence of a human 1..476 475/476 (99%) 0.0 semaphorin-like polypeptide - Homo 1..476 475/476 (99%) sapiens, 1086 aa. [WO200153466-A1, 26-JUL-2001] ABG79177 Human semaphorin-like protein #5 - 1..476 471/478 (98%) 0.0 Homo sapiens, 1088 aa. 1..478 473/478 (98%) [WO200264791-A2, 22-AUG-2002] 266 WO 2004/000997 PCT/US2003/017512 In a BLAST search of public sequence databases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16E. Table 16E. Public BLASTP Results for NOV16a NOV16a Protein Residues/ Identities/ Expect Accession Protein/Organism/Length Match Similarities for the Value Number Residues Matched Portion Q8NFY6 Semaphorin 6D isoform 2 - Homo 1..476 476/476 (100%) 0.0 sapiens (Human), 998 aa. 1..476 476/476 (100%) Q8NFY5 Semaphorin 6D isoform 3 - Homo 1..476 476/476 (100%) 0.0 sapiens (Human), 1017 aa. 1..476 476/476 (100%) Q8NFY3 Semaphorin 6D isoform 1 - Homo 1..476 476/476 (100%) 0.0 sapiens (Human), 1011 aa. 1..476 476/476 (100%) Q8NFY7 Semaphorin 6D short isoform - 1..476 476/476 (100%) 0.0 Homo sapiens (Human), 476 aa. 1..476 476/476 (100%) Q9P249 Hypothetical protein KIAA1479 - 1..476 476/476 (100%) 0.0 Homo sapiens (Human), 1022 aa 12..487 476/476 (100%) (fragm ent). .................. 5 PFam analysis predicts that the NOV16a protein contains the domains shown in the Table 16F. Table 16F. Domain Analysis of NOV16a Identities/ Pfam Domain NOV16a Match Region Similarities Expect Value for the Matched Region Sema 59..476 197/494 (40%) 1.3e-173 348/494 (70%) Example 17. 10 The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A. 267 WO 2004/000997 PCT/US2003/017512 Table 17A. NOV17 Sequence Analysis NOV17a, CG95430-02 SEQ ID NO: 229 954 bp DNA Sequence ORF Start: at 7 ORF Stop: at 949 GGATCCCAGGACACCTGCAGGCAAGGGCACCCTGGGATCCCTGGGAACCCCGGTCACAATGGTCTGCCTGGAA GAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGGGGAA GGATGGGACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGGTGAT CAAGGCTCAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAAGGCCTCC GAGGAGAGACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGCCAAG GGGCAACATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCCCAAG GGAGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAG GAGAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAG CAAGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACA GCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGGA ATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGA CCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAG AGGTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGC TCGAG NOV17a, CG95430-02 SEQ ID NO: 230 314 aa MW at 32420.0kD Protein Sequence QDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQG SRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGE AGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNHYDTAA GKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERF NGLFADEDDDTTFTGFLLFSSP 5 NOV17b, CG95430-04 ISEQ ID NO: 231 1026 bp DNA Sequence ORF Start: ATG at 16 ORF Stop: TGA at 1015 TCTGTCATCTGAACCATGAGGATCTGGTGGTTTCTGCTTGCCATTGAAATCTGCACAGGGAACATAAACTCAC AGGACACCTGCAGGCAAGGGCACCCTGGCATCCCTGGGAACCCCGGTCACAATGGTCTGTCTGGAAGAGATGG ACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGGGGAAGGATGGG ACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGGTGATCAAGGCT CAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAGGGCCTCCGAGGAGA GACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGCCAAGGGGCAAC ATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCCCAAAGGAGAAG CTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAGGAGAGAA AGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCAAGTTT CCTTCTTCAGATATGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGCAGCGG GGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGGAATGTTCA GGTGTCTTTGGTCAAAAATGGAGTAAAAATACTOCACACCAAAGATGCTTACATGAGCTCTGAGGACCAGGCC TCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAGAGGTTCA ATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCAGTGACAGAG GAGA 268 WO 2004/000997 PCT/US2003/017512 NOVi7, CG95430-04 SEQ ID NO: 232 -333 aa MW at 34735.7kD Protein Sequence MRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLSGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEK GERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETCPQGQKGNKGDVGPTGPEGPRGNIGPLG PTGLPGPMGPIGKPGPKGEAGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDM PIKFDKILYNEFNHYDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIV LQLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSQ NOV17c, CG95430-01 SEQ ID NO: 233 818 bp DNA Sequence ORF Start: ATG at 35 ORF Stop: TGA at 728 TCCCTCTTTCAGTTCAGAGTCTGTCATCTGAACCATGAGGATCTGGTGGCTTCTGCTTGCCATTGAAATCTGC ACAGGGAACATAAACTCACAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATG GTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGTAAGCCTGGTCCCAAAGG AGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAGGA GAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCA AGTTTCCTTCTTCAGATATGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGC AGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGAAAT GTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACC AGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAGAG GTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGTGA CAGAGGAGAGTTTAAAAATCCGCCACACCATCCATCAGAATCAGCTTGGGATGAACTTATTCAGATGGTTTTA CTTTATTAATTCCTC 5 NOV17c, CG95430-01 SEQ IDNO: 234 231 aa MW at 24946.0kD Protein Sequence MRIWWLLLAIEICTGNINSQDTCRQGHPGIPCNPGHNGLPGRDGRDGAKGDKGDAGKPGPKGEAGPTGPQGEP GVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDMPIKFDKILYNEFNHYDTAAGKFTCHIAGV YYFTYHITVFSRNVQSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERFNGLFADEDDD TTFTGFLLFSOP OV7d, 319194717 ISEQ ID NO: 235 1024 bp DNA Sequence _ORF Start: at 2 jORF Stop: TGA at 1013 CACCGGATCCACCATCAGGATCTGGTGGTTTCTGCTTGCCATTGAAATCTGCACAGGGAACATAAACTCTCAG GACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATGGTCTGCCTGGAAGAGATGGAC GAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGGGGAAGGATGGGAC GAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGGTGATCAAGGCTCA AGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAACGCCTCCGAGGAGAGA CTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGCCAAGGGGCAACAT TGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCCCAAGGGAGAAGCT GGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGCTGGAAAGGAGATCGAGGAGAGAAAG GGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCAAGTTTCC TTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACACACCGGG AAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGGAATGTTCAGG TGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACCAGGCCTC TGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAAGGTTCAAT GGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGTGAGTCGACG GC 269 WO 2004/000997 PCT/US2003/017512 N Ed, 319194717 SEQ ID NO: 236 1337 aa IMW at 35001.OkD Protein Sequence I . TGSTMRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGT SGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNI GPLGPTGLPGPMGPIGKPGPKGEAGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFP SSDVPIKFDKILYNEFNHYDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQAS GGIVLQLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGFLLFSSP NOV17e, CG95430-03 1SE ID NO: 237 1405 bp DNA Sequence ORF Start: at7 OR Stop: at 400 GGATCCGCTTTCACTGTGGGGCTCACGGTGCTGAGCAAGTTTCCTTCTTCAGATATGCCCATTAAATTTGATA AGATCCTGTATAACGAATTCAACCATTATGATACAGCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTA TTACTTCACCTACCACATCACTGTTTTCTCCAGGAATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATA CTGCACACCAAAGATGCTTACATGAGCTCTGAGGACCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCG GGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAGAGGTTCAATGGCTTGTTTGCTGATGAGGACGATGACAC AACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGCTCGAG 5 NOV17e, CG95430-03 SEQ ID NO: 238 aa at 14607.4kD Protein Sequence AFTVGLTVLSKFPSSDMPIKFDKILYNEFNHYDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILH TKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSP NOV17f, CG95430-05 SEQ ID NO: 239bp DNA Sequence ORF Start: ATG at 143 ORF Stop: TGA at 1061 CAGTATCTGGGTCCAGCCTGCAGCCTTAGGGTCCAGGTGATGTTACCGTGTGTGTGGCCCTTCTTCACAGTGG CCTCCTAGAAAAACAAGACCCTGACTCAAAGAACACCTCTCACTACATTCAGAGTCTGTCATCTGAACCATGA GGATCTGGTGGCTTCTGCTTGCCATTGAAATCTGCACAGGGAACATAAACTCACAGGACACCTGCAGGCAAGG GCACCCTGGAATCCCTGGGAACCCCGGTCACAATGGTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGT GACAAACGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGGGGAAGGATGGGACGAGTGGAGAGAAGGGAG AACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGGTGATCAAGGCTCAAGAGGATCCCCAGGAAA ACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAAGGCCTCCGAGGAGAGACTGGGCCTCAGGGCAG AAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGCCAAGGGGCAACATTGGGCCTTTGGGCCCAA CTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCCCAAGGGAGAAGCTGGACCCACGGGGCCCCA GGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAGGAGAGAAAGGGAAAATCGGTGAGACT CTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCAAGTTTCCTTCTTCAGATGTGCCCA TTAAATTTGATAAGATCCACATCACTGTTTTCTCCAGGAATGTTCAGGTGTCTTTGGTCAAAAACGGAGTAAA AATACTGCACACCAGAGATGCTTACGTGAGCTCTGAGGACCAGGCCTCTGGCAGCATTGTCCTGCAGCTGAAG CTCGGGGATGAGATGTGGCTGCAGGTGACAGGAGGAGAGAGGTTCAATCGCTTGTTTGCTGATGAGGACGATG ACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCAGTGACAGAGGAGAGTTTATAAATCTGCCAGACCATC CATCAGAATCAGCTTGGGATGAACTTATTCAGATGGTTTTACTTTATTAATTCA 10 270 WO 2004/000997 PCT/US2003/017512 NOV17f, CG95430-05 SEQ ID NO: 240 306 aa MW at 31546.2kD Protein Sequence MRIWWLLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEK GERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLG PTGLPGPMGPIGKPGPKGEAGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDV PIKFDKIHITVFSRNVQVSLVKNGVKILHTRDAYVSSEDQASGSIVLQLKLGDEMWLQVTGGERFNGLFADED DDTTFTGFLLFSSQ NOV17g, C95430-06 SEQ IDNO: 241 j889 bp DNA Sequence iORF Start: ATG at 16 ORF Stop: TGA at 880 TCTGTCATCTGAACCATGAGGATCTGGTGGTTTCTGCTTGCCATTGAAATCTGCACAGGGAACATAAACTCAC AGGACACCTGCAGGCAAGGGCACCCTGGCATCCCTGGGAACCCCGGTCACAATGGTCTGTCTGGAAGAGATGG ACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGGGGAAGGATGGG ACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGGTGATCAAGGCT CAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAAGGCCTCCGAGGAGA GACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGAT CGAGGAGAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGC TGAGCAAGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGA TACAGCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCGCTGTTTTCTCC AGCAATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTG AGGACCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGG AGAGAGGTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGC CAGTGACAGAGGA 5 NOVl7g, CG95430-06 SEQ ID NO: 242 :288 aa MW at 30497.9kD Protein Sequence MRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLSGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEK GERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGEPGVRGIRGWKGDRGEKG KIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNHYDTAAGKFTCHIAGVYYFTYHIAVFSSNVQV SLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSQ NOV17h, CG95430-07 SEQ ID NO: 243 961 bp DNA Sequence ORF Start: at 11 ORF Stop: at 953 CACCAGATCTCAGGACACCTGCAGGCAAGGGCACCCTGGGATCCCTGGGAACCCCGGTCACAATGGTCTGCCT GGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGG GGAAGGATGGGACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGG TGATCAAGGCTCAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAAGGC CTCCGAGGAGAGACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGC CAAGGGGCAACATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCC CAAGGGAGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGAT CGAGGAGAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGC TGAGCAAGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGA TACAGCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCC AGGAATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTG AGGACCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCCGGGATGAGGTGTGGCTGCAGGTGACAGGAGG AGAGAGGTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGC CCGGTCGACGGC 271 WO 2004/000997 PCT/US2003/017512 NOV17h, CG95430-07 SEQ ID NO: 244 314 aa MW at 32420.OkD Protein Sequence QDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQG SRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGE AGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNHYDTAA GKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERF NGLFADEDDDTTFTGFLLFSSP INOV17i, CG95430-08 SEQ ID NO: 245 04b IDNA Sequence OEStart: ATG t1 R tp G at 1013 CACCGGATCCACCATGAGGATCTGGTGGTTTCTGCTTGCCATTGAAATCTGCACAGGGAACATAAACTCTCAG GACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATGGTCTGCCTGGAAGAGATGGAC GAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGGGGAAGGATGGGAC GAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGGTGATCAAGGCTCA AGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAAGGCCTCCGAGGAGAGA CTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGCCAAGGGGCAACAT TGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCCCAAGGGAGAAGCT GGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGAATAAGAGGCTGGAAAGGAGATCGAGGAGAGAAAG GGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCAAGTTTCC TTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGCAGCGGGG AAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGGAATGTTCAGG TGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACCAGGCCTC TGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAGAAGTTCAAT GGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGTGAGTCGACG 5 NOV17i, CG95430-08 SEQ ID NO: 246 1-MW ata 34654.7kD Protein Sequence 3a MRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEK GERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLG PTGLPGPMGPIGKPGPKGEAGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDV PIKFDKILYNEFNHYDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIV LQLKLGDEVWLQVTGGEKFNGLFEDDDTTFTGFLLFSSP 272 WO 2004/000997 PCT/US2003/017512 NOV17j, CG95430-09 ISEQ ID NO: 247 1964 bp DNA Sequence JORF Start: at 11 fORF Stop: TAG at 953 CACCAGATCTCAGGACACCTGCAGCAAGGGCACCCTGGGATCCCTGGGAACCCCGGTCACAATGGTCTGCCT GGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGG GGAAGGATGGGACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGG TGATCAAGGCTCAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAAGGC CTCCGAGGAGAGACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGC CAAGGGGCAACATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCC CAAGGGAGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGAT CGAGGAGAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGC TGAGCAAGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGA TACAGCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCC AGGAATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTG AGGACCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGG AGAGAGGTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGC CCGTAGGTCGACGGC NOV17j, CG95430-09 SEQ ID NO: 248 314 aa 1W at 32420.OkD Protein Sequence QDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQG SRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGE AGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNHYDTAA GKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERF NGLFADEDDDTTFTGFLLFSSP 5 NOV17k, CG95430-10 SEQ ID NO: 249 1024 bp DNA Sequence ORF Start: ATG at 17 ORF Stop: at 1016 CACCAGATCTCCCACCATGAGGATCTGGTGGTTTCTGCTTCCCATTGAAATCTGCACAGGGAACATAAACTCT CAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATGGTCTGCCTGGAAGAGATG GACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGGCAGCCCGGGGAAGGATGG GACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGCATCAAAGGTGATCAAGGC TCAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGGAGAGAAAGGCCTCCGAGGAG AGACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCCTGAGGGGCCAAGGGGCAA CATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAGCCTGGTCCCAAGGGAGAA GCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGOCTGGAAAGGAGATCGAGGAGAGA AAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCAAGTT TCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGCAGCG GGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGGAATGTTC AGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACCAGGC CTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATCAGGTGTGGCTGCAGGTGACAGGAGGAGAGAAGTTC AATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGCTCGAGG GC 273 WO 2004/000997 PCT/US2003/017512 NOV17k, CG95430-10 SEQ ID NO: 250 333 aa MW at 34654.7kD Protein Sequence _ I MRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEK GERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLG PTGLPGPMGPIGKPGPKGEAGPTPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDV PIKFDKILYNEFNHYDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIV LQLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGFLLFSSP NOV171, CG95430-11 SEQ ID NO: 251 1045 bp DNA Sequence RF Start: ATG at 14 ORF Stop: TAA at 1034 CACCAGATCTACCATGGGCCACCATCACCACCATCACAGGATCTGGTGGTTTCTGCTTGCCATTGAAATCTGC ACAGGGAACATAAACTCTCAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATG GTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAGGACGTCCTGG CAGCCCGGGGAAGGATGGGACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGAAGCAAAAGGC ATCAAAGGTGATCAAGGCTCAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGGCCCATGGAG AGAAGGCCTCCGAGGAGAGACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTCCCACTGGTCC TGAGGGGCCAAGGGGCAACATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCCTATTGGAAAG CCTGGTCCCAAGGGAGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGCGAATAAGAGGCTGGA AAGGAGATCGAGGAGAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCT CACGGTGCTGAGCAAGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAAC CATTATGATACAGCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTG TTTTCTCCAGGAATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACAT GAGCTCTGAGGACCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCCCGGATGAGGTGTGGCTGCAGGTG ACAGGAGGAGAGAAGTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGT TCAGCAGCCCGTAACTCGAGGGC 5 NOVI71, CG95430-11 SEQ ID NO: 252 340 aa MW at 35534.6kD Protein Sequence MGHHHHHHRIWWFLLATEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGK DGTSGEKGERCADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPR GNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLS KFPSSDVPIKFDKILYNEFNHYDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSED QASGGIVLQLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGFLLFSSP 274 WO 2004/000997 PCT/US2003/017512 NOV17m, CG95430-12 DEQ NO: 253 982 bp DNA Sequence -ORF Start: at 11 ORF Stop: TAA at 971 CACCAGATCTCACCACACCACCATCACCAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCC GGTCACAATGGTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGACCAG GACGTCCTGGCAGCCCGGGGAAGGATGGGACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGA AGCAAAAGGCATCAAAGGTGATCAAGGCTCAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGG CCCATGGGAGAGAAAGGCCTCCGAGGAGAGACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTC CCACTGGTCCTGAGGGGCCAAGGGGCAACATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCC TATTGGAAAGCCTGGTCCCAAGGGAGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATA AGAGGCTGGAAAGGAGATCGAGGAGAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCA CTGTGGGGCTCACGGTGCTGAGCAAGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAA CGAATTCAACCATTATGATACAGCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTAC CACATCACTGTTTTCTCCAGGAATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAG ATGCTTACATGAGCTCTGAGGACCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTG GCTGCAGGTGACAGGAGGAGAGAAGTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGG TTCCTTCTGTTCAGCAGCCCGTAACTCGAGGGC OVI7m, CG95430-12 SEQ ID NO: 254 320 aa MW at 33214.9kD Protein Sequence HHHHHHQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGEPGRPGSPGKDGTSGEKGERGADGKVEAKG IKGDQGSRGSPGKHGPKGLAGPMGEKGLRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGK PGPKGEAGPTGPQGEPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFN YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQV TGGEKFNGLFADEDDDTTFTGFLLFSSP 5 NOV17n, CG95430-13 SEQ ID NO: 255 982bp DNA Sequence ORF Start: at 11 ORF Stop: TAA at 971 CACCAGATCTCACCATCACCACCCACCAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCC GGTCACAATGGTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGAGAACCAG GACGTCCTGGCAGCCCGGGGAAGGATGGGACGAGTGGAGAGAAGGGAGAACGAGGAGCAGATGGAAAAGTTGA AGCAAAAGGCATCAAAGGTGATCAAGGCTCAAGAGGATCCCCAGGAAAACATGGCCCCAAGGGGCTTGCAGGG CCCATGGGAGAGAAAGGCCTCCGAGGAGAGACTGGGCCTCAGGGGCAGAAGGGGAATAAGGGTGACGTGGGTC CCACTGGTCCTGAGGGGCCAAGGGGCAACATTGGGCCTTTGGGCCCAACTGGTTTACCGGGCCCCATGGGCCC TATTGGAAAGCCTGGTCCCAAGGGAGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATA AGAGGCTGGAAAGGAGATCGAGGAGAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCA CTGTGGGGCTCACGGTGCTGAGCAAGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAA CGAATTCAACCATTATGATACAGCAGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTAC CACATCACTGTTTTCTCCAGGAATGTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAG ATGCTTACATGAGCTCTGAGGACCAGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTG GCTGCAGGTGACAGGAGGAGAGAGGTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGG TTCCTTCTGTTCAGCAGCCCGTAACTCGAGGGC 275 WO 2004/000997 PCT/US2003/017512 NOV17o, CG95303742o SEQ ID NO:1 257 818I bp :jMWa 34.k Protein01 DeunAc euneeFSat T a 5 OFSo:TAa 2 TCCCTCTTTCAGTTCGGAGCTGEKCATCTGPCAGQGNGDVCGPTGPGPRTTCGTGCATGPATGCG HAAGGACTCCAYGGACACCTGCAGSLVGCVGGCACTGGAYTCCCTGGIVLQCCCGTCACLT TCCTCGTTCAGTGTTCATGATGAG ATCTG CGTGTTCCTGCATTGAACC AGCGGCTGCATCCGCACTGCAGCCGGGGAGAGGGTCCTGGGTGACCGGGTCAGAGAG GTCTGCTGGTTGTGAGAGCGACGAATGACATTAGGGTTCGACCTTTTCGGCCCGTCAG CAGAAGGGAGAAAATCGCACTCATCCAAGTGCTTGATGGTTATCAGGTTTA CGTTTATTATTCTTCCTAATGTAACTTAACATCACTAGTCG GTTCAATGGCTTGTTICTGSQTCRGGIPNHNGATACATTCCGGAGTCCTTCTGTCGAGGQG CAFTYAGTTSRVQVSLVGVKILHCTCAMSEDAASAGGGIOGGDETLQVTGG AFGLADEDDD CTTFTATTAATTCCTC INOV17o, SNP1337912 of SEQ IDNO: 259 881a bpa298.k CG943-0 rotinSeuece SNP Pos: 23 JSNP Change: Le to Ah TCCTCTTAEIAGCTGCTCCTHPIGNPCAGNLPGGTCGAKGTGCCTTCGTGCATGPTCGC GVGRWGREGIELLKATGTLKPSMIFKLNFHDAGFCIG YYTHTFRVVLKGKLTDYSEQSGVQKGEWQTGRNLAED TGE7TTCAGTGGTCTGTCAC~TGATGAGTACTGGGCCTCTGCTTGCTGATCTGC AAGGGCTCTACCATCGCAGCTGAGCCGGGACCCGGATCCCTGGGTACCGGTCACAAG GTCTCTGGCTTGTTTGCGAGAGACGAATGACATAAGGGATGCCTTGTAGCGCCCAGG AGAGCGGAGTAAGGCCGCCAGGGCCATCCAGGAGTCGATGGATGGCTTGATTGGATCGGTA CGTTTCTTATTCTTCCTAATGTAACTTAACATCACTAGTCG AGGGGAATCCGGCAATGCGGGTTTTCTCACTCCCACCTTTT276GAA WO 2004/000997 PCT/US2003/017512 NOV17p, SNP13381828 of SEQ ID NO: 260 231 aa MW at 24946.OkD CG95430-01, Protein Sequence SNP Pos: 67 SNP Change: Thr to Thr MRIWWLLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGKPGPKGEAGPTGPQGEP GVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDMPIKFDKILYNEFNHYDTAAGKFTCHIAGV YYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERFNGLFADEDDD TTFTGFLLFSS P NOV17q, SNP13379125 of SEQ IDNO: 261 818 bp CG95430-01, DNA Sequence ORF Start: ATG at 35 ORF Stop: TGA at 728 N P Pos: 383 SNP Change: A to G TCCCTCTTTCAGTTCAGAGTCTGTCATCTGAACCATGAGGATCTGGTGGCTTCTGCTTGCCATTGAAATCTGC ACAGGGAACATAAACTCACAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATG GTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGTAAGCCTGGTCCCAAAGG AGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAGGA GAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCA AGTTTCCTTCTTCAGATGTGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGC AGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGAAAT GTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACC AGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAGAG GTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGTGA CAGAGGAGAGTTTAAAAATCCGCCACACCATCCATCAGAATCAGCTTGGGATGAACTTATTCAGATGGTTTTA CTTTATTAATTCCTC NOV17q, SNP13379125 of ISEQIDNO:262 231 aa MWat24913.9kD CG95430-01, Protein Sequence ISNP Pos: 117 . SNP Change: Met to Val MRIWWLLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDCRDGAKGDKGDAGKPGPKGEAGPTGPQGEP GVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNHYDTAAGKFTCHIAGV YYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERFNGLFADEDDD TTFTGFLLFSSP 5 NOV17r, SNP13381827 of SEQ ID NO: 263 818bp CG95430-01, DNA Sequence ORF Start: ATG at 3 ORF Stop: TGA at 728 SNP Pos: 650 SNP Change: G to A TCCCTCTTTCAGTTCAGAGTCTGTCATCTGAACCATGAGGATCTGGTGGCTTCTGCTTGCCATTGAAATCTGC ACAGGGAACATAAACTCACAGGACACCTGCAGGCAAGGGCACCCTOGAATCCCTGGGAACCCCGGTCACAATG GTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGTAAGCCTGGTCCCAAAGG AGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAGGA GAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCA AGTTTCCTTCTTCAGATATGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGC AGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGAAAT GTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACC AGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAAGAGAGAG GTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGTGA CAGAGGAGAGTTTAAAAATCCGCCACACCATCCATCAGAATCAGCTTGGGATGAACTTATTCAGATGGTTTTA CTTTATTAATTCCTC 277 WO 2004/000997 PCT/US2003/017512 NOV17r, SNP13381827 of : SEQ IDNO: 264 231 aa MW at 25045.1kD CG95430-01, Protein Sequence _ SNP Pos: 206 SNP Change: Gly to Arg MRIWWLLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAGDKGDAGKPGPKGEAGPTGPQGEP GVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDMPIKFDKILYNEFNHYDTAAGKFTCHIAGV YYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGRERFNGLFADEDDD TTFTGFLLFSSP NOV17s, SNP13381822 of SEQ ID NO: 265 818 bp CG95430-01, DNA Sequence ORF Start: ATG at 35 ORF Stop: TGA at 728 SNP Pos: 687 SNP Change: A to G TCCCTCTTTCAGTTCAGAGTCTGTCATCTGAACCATGAGGATCTGGTGGCTTCTGCTTGCCATTGAAATCTGC ACAGGGAACATAAACTCACAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATG GTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGTAAGCCTGGTCCCAAAGG AGAAGCTOGACCCACGCGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAGGA GAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCA AGTTTCCTTCTTCAGATATGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGC AGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGAAAT GTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACC AGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAGAG GTTCAATGGCTTGTTTGCTGATGAGGACGGTGACACAACTTTCACAGGGTTCCTTCTGTTCAGCAGCCCGTGA CAGAGGAGAGTTTAAAAATCCGCCACACCATCCATCAGAATCAGCTTGGGATGAACTTATTCAGATGGTTTTA CTTTATTAATTCCTC 5 NOV17s, SNP13381822 of ISEQ ID NO: 266 1231 aa MW at 24887.9kD CG95430-01, Protein Sequence SNP Pos: 218 SNP Change: Asp to Gly MRIWWLLLATEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGKPGPKGEAGPTGPQGEP GVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDMPIKFDKILYNEFNHYDTAAGKFTCHIAGV YYFTYHITVFSRNVQVSLVKl\GVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERFNGLFADEDGD TTFTGFLLFSSP NOV17t, SNP13381826 of SEQ ID NO: 267 818bp CG95430-01, DNA Sequence ORF Start: ATG at 35 ORE Stop: TGA at 728 SNP Pos: 717 SNP Change: T to C TCCCTCTTTCAGTTCAGAGTCTGTCATCTGAACCATGAGGATCTGGTGGCTTCTGCTTGCCATTGAAATCTGC ACAGGGAACATAAACTCACAGGACACCTGCAGGCAAGGGCACCCTGGAATCCCTGGGAACCCCGGTCACAATG GTCTGCCTGGAAGAGATGGACGAGACGGAGCGAAGGGTGACAAAGGCGATGCAGGTAAGCCTGGTCCCAAAGG AGAAGCTGGACCCACGGGGCCCCAGGGTGAGCCAGGAGTCCGGGGAATAAGAGGCTGGAAAGGAGATCGAGGA GAGAAAGGGAAAATCGGTGAGACTCTAGTCTTGCCAAAAAGTGCTTTCACTGTGGGGCTCACGGTGCTGAGCA AGTTTCCTTCTTCAGATATGCCCATTAAATTTGATAAGATCCTGTATAACGAATTCAACCATTATGATACAGC AGCGGGGAAATTCACGTGCCACATTGCTGGGGTCTATTACTTCACCTACCACATCACTGTTTTCTCCAGAAAT GTTCAGGTGTCTTTGGTCAAAAATGGAGTAAAAATACTGCACACCAAAGATGCTTACATGAGCTCTGAGGACC AGGCCTCTGGCGGCATTGTCCTGCAGCTGAAGCTCGGGGATGAGGTGTGGCTGCAGGTGACAGGAGGAGAGAG GTTCAATGGCTTGTTTGCTGATGAGGACGATGACACAACTTTCACAGGGTTCCTTCTGTCCAGCAGCCCGTGA CAGAGGAGAGTTTAAAAATCCGCCACACCATCCATCAGAATCAGCTTGGGATGAACTTATTCAGATGGTTTTA CTTTATTAATTCCTC 10 278 WO 2004/000997 PCT/US2003/017512 NOV17t, SNP13381826 of SEQ IDNO: 268 231 a MW at 24885.9kD CG95430-01, Protein Sequence SNP Pos: 228 SNP Change:Phe to Ser MRIWWLLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKGDAGKPGPKGEAGPTGPQGEP GVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDMPIKFDKILYNEFNHYDTAAGKFTCHIAGV YYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVLQLKLGDEVWLQVTGGERFNGLFADEDDD TTFTGFLLSSSP A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 17B. 5 Table 17B. Comparison of the NOV17 protein sequences. NOV17a ------------------------- QDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17b -------- MRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLSGRDGRDGAKGDKG NOV17c -------- MRIWWLLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17d ---TGSTMRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17e -----------.------------------------------------------- NOV17f ------- MRIWWLLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17g -------- MRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLSGRDGRDGAKGDKG NOV17h ------------------------- QDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17i .------- MRIWWFLLAIEICTGNINSQDTCRQGHPGIPONPGHNGLPGRDGRDGAKGDKG NOV17j ------------------------- QDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17k ------- MRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV171 MGHHHHHHRIWWFLLAIEICTGNINSQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOVI7m -------------------- HHHHHHQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17n -------------------- HHHHHHQDTCRQGHPGIPGNPGHNGLPGRDGRDGAKGDKG NOV17a DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17b DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17c DAGKPG ------------------------------------------

PKGEAGPTG--

NOV17d DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17e --------------------------------------------------------- NOV17f DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17g DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17h DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17i DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17j DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17k DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV171 DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17m DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17n DAGEPGRPGSPGKDGTSGEKGERGADGKVEAKGIKGDQGSRGSPGKHGPKGLAGPMGEKG NOV17a LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV17b LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOVI7c - ------ PQG--------------------- ------ - ---- --- - NOV17d LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV17e -------------------------------------------------- NOV17f LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV17g LRGETGPQGQKGNKG ...........................-------------------------------------------- NOV17h LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGTGPQG NOV17i LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV17j LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV17k LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV171 LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG 279 WO 2004/000997 PCT/US2003/017512 NOV17m LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV17n LRGETGPQGQKGNKGDVGPTGPEGPRGNIGPLGPTGLPGPMGPIGKPGPKGEAGPTGPQG NOV17a EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17b EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDMPIKFDKILYNEFNH NOV17c EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDMPIKFDKILYNEFNH NOV17d EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17e -----------------------------AFTVGLTVLSKFPSSDMPIKFDKILYNEFNH NOV17f EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVOLTVLSKFPSSDVPIKFDK------- NOV17g EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17h EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKPPSSDVPIKFDKILYNEFNH NOV17i EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17j EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17k EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV171 EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17m EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17n EPGVRGIRGWKGDRGEKGKIGETLVLPKSAFTVGLTVLSKFPSSDVPIKFDKILYNEFNH NOV17a YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17b YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17c YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17d YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17e YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17f --------------- I-----HITVFSRNVQVSLVKNGVKILHTRDAYVSSEDQASGSIVL NOV17g YDTAAGKFTCHIAGVYYFTYHIAVFSSNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17h YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17i YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17j YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17k YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV171 YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17m YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17n YDTAAGKFTCHIAGVYYFTYHITVFSRNVQVSLVKNGVKILHTKDAYMSSEDQASGGIVL NOV17a QLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSP NOV17b QLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSQ NOV17c QLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSP NOV17d QLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGFLLFSSP NOV17e QLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSP NOV17f QLKLGDEMWLQVTGGERFNGLFADEDDDTTFTGFLLFSSQ NOV17g QLKLGDEVWLQVTGGERFNGLPADEDDDTTFTGPLLFSSQ NOV17h QLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSP NOV17i QLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGFLLFSSP NOV17j QLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSP NOV17k QLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGFLLFSSP NOV171 QLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGPLLFSSP NOV17m QLKLGDEVWLQVTGGEKFNGLFADEDDDTTFTGFLLFSSP NOV17n QLKLGDEVWLQVTGGERFNGLFADEDDDTTFTGFLLFSSP NOV17a (SEQ ID NO: 230) NOV17b (SEQ ID NO: 232) NOV17c (SEQ ID NO: 234) NOV17d (SEQ ID NO: 236) NOV17e (SEQ ID NO: 238) NOV17f (SEQ ID NO: 240) NOV17g (SEQ ID NO: 242) NOV17h (SEQ ID NO: 244) NOV17i (SEQ ID NO: 246) NOV17j (SEQ ID NO: 248) NOV17k (SEQ ID NO: 250) 280 WO 2004/000997 PCT/US2003/017512 NOV171 (SEQ ID NO: 252) NOV17m (SEQ ID NO: 254) NOV17n (SEQ ID NO: 256) Further analysis of the NOV1 7a protein yielded the following properties shown in Table 17C. Table 17C. Protein Sequence Properties NOV17a SignalP analysis: No Known Signal Sequence Predicted PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 5; pos.chg 1; neg.chg 1 H-region: length 17; peak value 0.39 PSG score: -4.01 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -14.34 possible cleavage site: between 52 and 53 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 2.17 (at 177) ALOM score: 2.17 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 2 Hyd Moment(75): 8.45 Hyd Moment(95): 12.46 G content: 6 D/E content: 2 S/T content: 1 Score: -6.71 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 15 CRQIGH NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 12.4% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: DTCR none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none 281 WO 2004/000997 PCT/US2003/017512 RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 76.7 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 56.5 %: cytoplasmic 21.7 %: nuclear 8.7 %: mitochondrial 4.3 %: Golgi 4.3 %: vacuolar 4.3 %: plasma membrane >> prediction for CG95430-02 is cyt (k=23) A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17)D. 5 282 WO 2004/000997 PCT/US2003/017512 Table 17D. Geneseq Results for NOV17a NOV17a Identities/ Geneseq Protein/Organism/Length [Patent#, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAO16580 Energen-related secreted protein - 1..314 313/314 (99%) 0.0 C2P - Unidentified, 333 aa. 20..333 314/314 (99%) [WO2003009865-A1, 06-FEB-2003] AAO16571 C2P secreted protein - Unidentified, 1..314 313/314 (99%) 0.0 333 aa. [WO2003009861-A1, 20..333 314/314 (99%) 06-FEB-2003] ABB80582 Human sbg1033026Clq protein #1 - 1..314 313/314 (99%) 0.0 Homo sapiens, 333 aa. 20..333 314/314 (99%) [WO200222802-AI, 21 -MAR-20021 AAE28184 Human GMG-3 protein - Homo 1..314 313/314 (99%) 0.0 sapiens, 333 aa. [WO200266505-A2, 20..333 314/314 (99%) 29-AUG-2002] AAE28185 Human GMG-4 protein - Homo 1..313 307/313 (98%) 0.0 sapiens, 333 aa. [WO200266505-A2, 20..332 310/313 (98%) 29-AUG-2002] In a BLAST search of public sequence databases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17E. 5 283 WO 2004/000997 PCT/US2003/017512 Table 17E. Public BLASTP Results for NOV17a NOV17a Protein Residues Identities/ Expect Accession Protein/Organisnim/Length Match Similarities for the Value Number Rdues Matched Portion Residues Q8IUU4 Hypothetical protein - Homo 1.314 314/314 (100%) 0.0 sapiens (Human), 333 aa. 20..333 314/314 (100%) CAD57042 Sequence 1 from Patent 1..314 313/314 (99%) 0.0 W002066505 - Homo sapiens 20..333 314/314 (99%) (Human), 333 aa. CAD57043 Sequence 3 from Patent 1..313 307/313 (98%) 0.0 W002066505 - Homo sapiens 20..332 310/313 (98%) (Human), 333 aa. CAD57045 Sequence 7 from Patent 1..313 267/313 (85%) e-164 W002066505 - Mus musculus 20..329 284/313 (90%) (Mouse), 330 aa. CAD57046 Sequence 9 from Patent 1..313 260/313 (83%) e-158 W002066505 - Mus musculus 20..322 277/313 (88%) (Mouse), 323 aa. PFam analysis predicts that the NOV17a protein contains the domains shown in the Table 17F. 5 Table 17F. Domain Analysis of NOV17a Identities/ Pfam Domain NOV17a Match Region Similarities Expect Value for the Matched Region Collagen 5..63 29/60 (48%) 8.8e-11 45/60 (75%) Collagen 65..123 25/60 (42%) 2.2e-07 40/60 (67%) Collagen 124..183 28/60 (47%) 0.00021 38/60 (63%) Clq 184..310 58/141 (41%) 7.2e-42 S98/141 (70%) Example 18. The NOV18 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 18A. 10 284 WO 2004/000997 PCT/US2003/017512 Table 18A. NOV18 Sequence Analysis NOV18a,CG97111-01 SEQ ID NO: 269 1019 bp DNA Sequence IORF Start: ATG at 54 ORF Stop: TAG at 531 GGTTCCAGGAACTCAGGATCTGCAGTGAGGACCAGACACCACTGATTGCAGGAATGTGTTCCCTCCCCATGGC AAGATACTACAGAATTAAATATGCAGACCAGAAGGCTCTATACACAAGAGATGOCCAGCTGCTGGTGGGAGAT CCTGTTGCAGACAACTGCTGTGCAGAGAAGATCTGCATACTTCCTAACAGAGGCTTGGCCCGCACCAAGGTCC CCATTTTCCTGGGGATCCAGGGAGGGAGCCGCTGCCTGGCATGTGTGGAGACAGAAGAGGGGCCTTCCCTACA GCTGGAGCCATCCACCTTGCCCCCACAGGATGTGAACATTGAGGAACTGTACAAAGGTGGTGAAGAGGCCACA CGCTTCACCTTCTTCCAGAGCAGCTCAGGCTCCGCCTTCAGGCTTGAGGCTGCTGCCTGGCCTGGCTGGTTCC TGTGTGGCCCGGCAGAGCCCCAGCAGCCAGTACAGCTCACCAAGGAGAGTGAGCCCTCAGCCCGTACCAAGTT TTACTTTGAACAGAGCTGGTAGGGAGACAGGAAACTGCGTTTTAGCCTTGTGCCCCCAAACCAAGCTCATCCT GCTCAGGGTCTATGGTAGGCAGAATAATGTCCCCCGAAATATGTCCACATCCTAATCCCAAGATCTGTGCATA TGTTACCATACATGTCCAAAGAGGTTTTGCAAATGTGATTATGTTAAGGATCTTGAAATGAGGAGACAATCCT GGGTTATCCTTGTGGGCTCAGTTTAATCACAAGAAGGAGGCAGGAAGGGAGAGTCAGAGAGAGAATGGAAGAT ACCATGCTTCTAATTTTGAAGATGGAGTGAGGGGCCTTGAGCCAACATATGCAGGTGTTTTTAGAAGGAGGAA AAGCCAAGGGAACGGATTCTCCTCTATAGTCTCCGGAAGGAACACAGCTCTTGACACATGGATTTCAGCTCAG TGACACCCATTTCAGACTTCTGACCTCCACAACTATAAAATAATAAACTTGTGTTATTGTAAACCTCTGG NOVI8a, CG97111-01 SEQ IDNO: 270 159 aa MW at 17706.9kD Protein Sequence MCSLPMARYYRIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLGIQGGSRCLACVET EEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESE PSARTKFYFEQSW 5 NOV18b, CG97111-02 SEQ ID NO: 271 499 bp DNA Sequence ORF Start: ATG at 16 ORF Stop: TAG at 472 CCACTGATTGCAGGAATGTGTTCCCTCCCCATGGCAAGATACTACATAATTAAATATGCAGACCAGAAGGCTC TATACACAAGAGATGGCCAGCTGCTGGTGGGAGATCCTGTTGCAGACAACTGCTGTGCAGAGAAGATCTGCAT ACTTCCTAACAGAGGCTTGGCCCGCACCAAGGTCCCCATTTTCCTGGGGATCCAGGGAGGGAGCCGCTGCCTG GCATGTGTGGAGACAGAAGAGGGGCCTTCCCTACAGCTGGAGGATGTGAACATTGAGGAACTGTACAAAGGTG GTGAAGAGGCCACACGCTTCACCTTCTTCCAGAGCAGCTCAGGCTCCGCCTTCAGGCTTGAGGCTGCTGCCTG GCCTGGCTGGTTCCTGTGTGGCCCGGCAGAGCCCCAGCAGCCAGTACAGCTCACCAAGGAGAGTGAGCCCTCA GCCCGTACCAAGTTTTACTTTOAACAGAGCTGGTAGGGAGACAGGAAACTGCGTTTTAGCC NOV18b, CG97111-02 SEQ ID NO: 272 152 aa MW at 16943.lkD Protein Sequence MCSLPMARYYIIKYADQKALYTRDGQLLVGDPVADNCCAEKrCILPNRGLARTKVPIFLGIQGGSRCLACVET EEGPSLQLEDVNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESEPSARTKF YFEQSW 285 WO 2004/000997 PCT/US2003/017512 NOV18c, CG97111-03 SEQ ID NO: 273 483bp DNA Sequence ORF Start at 3 _ ORF Stop: TAG at 465 CACTGTCATACTGTTTCAGAATTAAATATGCAGACCAGAAGGCTCTATCACAAGAGATGGCCAGCTGCTGGT GGGAGATCCTGTTGCAGACAACTGCTGTGCAGAGAAGATCTGCATACTTCCTAACAGAGGCTTGGCCCGCACC AAGGTCCCCATTTTCCTGGGGATCCAGGGAGGGAGCCGCTGCCTGGCATGTGTGGAGACAGAAGAGGGGCCTT CCCTACAGCTGGAGdCATCCACCTTGCCCCCACAGGATGTGAACATTGAGGAACTGTACAAAGGTGGTGAAGA GGCCACACGCTTCACCTTCTTCCAGAGCAGCTCAGGCTCCGCCTTCAGGCTTGAGGCTGCTGCCTGGCCTGGC TGGTTCCTGTGTGGCCCGGCAGAGCCCCAGCAGCCAGTACAGCTCACCAAGGAGAGTGAGCCCTCAGCCCGTA CCAAGTTTTACTTTGAACAGAGCTGGTAGGGAGACAGGAAACTGC NOV18c, CG97111-03 SEQ ID NO: 274 154 aa MW at 17104.2kD 'Protein Sequence I LSYCFRIKYADQKALYTRDGQLLVGDPVADNCCAKICILPNRGLARTKVPIFLGIQGGSRCLACVETEEGPS LQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESEPSART KFYFEQSW 5 NOVI8d, SNP13382516 of SEQ ID NO: 275 1019bp 1CG971 1-01, DNA Sequence ORF Start: ATG at 54 ORF Stop: TAG at 531 SNP Pos: 125 SNP Change: T to C GGTTCCAGGAACTCAGGATCTGCAGTGAGGACCAGACACCACTGATTGCACGAATGTGTTCCCTCCCCATGGC AAGATACTACAGAATTAAATATGCAGACCAGAAGGCTCTATACACAAGAGACGGCCAGCTGCTGGTGGGAGAT CCTGTTGCAGACAACTGCTGTGCAGAGAAGATCTGCATACTTCCTAACAGAGGCTTGGCCCGCACCAAGGTCC CCATTTTCCTGGGGATCCAGGGAGGGAGCCGCTGCCTGGCATGTGTGGAGACGAAGAGGGGCCTTCCCTACA GCTGGAGCCATCCACCTTGCCCCCACAGGATGTGAACATTGAGGAACTGTACAAAGGTGGTGAAGAGGCCACA CGCTTCACCTTCTTCCAGAGCAGCTCAGGCTCCGCCTTCAGGCTTGAGGCTGCTGCCTGGCCTGGCTGGTTCC TGTGTGGCCCGGCAGAGCCCCAGCAGCCAGTACAGCTCACCAAGGAGAGTGAGCCCTCAGCCCGTACCAAGTT TTACTTTGAACAGAGCTGGTAGGGAGACAGGAAACTGCGTTTTAGCCTTGTGCCCCCCCAAGCTCATCCT GCTCAGGGTCTATGGTAGGCAGAATAATGTCCCCCGAAATATGTCCACATCCTAATCCCAAGATCTGTGCATA TGTTACCATACATGTCCAAAGAGGTTTTGCAAATGTGATTATGTTAAGGATCTTGAAATGAGGAGACAATCCT GGGTTATCCTTGTGGGCTCAGTTTAATCACAAGAAGGAGGCAGGAAGGGAGAGTCAGAGAGACAATGGAAGAT ACCATGCTTCTAATTTTGAAGATGGAGTGAGGGGCCTTGAGCCAACATATGCAGGTGTTTTTAGAAGGAGGAA AAGCCAAGGGAACGGATTCTCCTCTATAGTCTCCGGAAGGAACACAGCTCTTGACACATGGATTTCAGCTCAG TGACACCCATTTCAGACTTCTGACCTCCACAACTATAAAATAATAAACTTGTGTTATTGTAAACCTCTGG NOV18d, SNPl3382516 oSEQ ID NO 26 19a MWt17706.9kD CG971 11-01, Protein Sequence SNP Po change: Asp to Asp -MCS-LPMARYY-RIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLGIQGGSRCLACVET EEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESE PSARTKFYFEQSW 286 WO 2004/000997 PCT/US2003/017512 NOV18e, SNP13382517 of SEQ ID NO: 277 1019 bp CG97111-01, DNA Sequence ORF Start: ATG at 54 ORF Stop: TAG at 531 SNP Pos: 184 SNP Change: T to C GGTTCCAGGAACTCAGGATCTGCAGTGAGGACCAGACACCACTGATTGCAGGAATGTGTTCCCTCCCCATGGC AAGATACTACAGAATTAAATATGCAGACCAGAAGGCTCTATACACAAGAGATGGCCAGCTGCTGGTGGGAGAT CCTGTTGCAGACAACTGCTGTGCAGAGAAGATCTGCAACTTCCTAACAGAGGCTTGGCCCGCACCAAGGTCC CCATTTTCCTGGGGATCCAGGGAGGGAGCCGCTGCCTGGCATGTGTGGAGACAGAAGAGGGGCCTTCCCTACA GCTGGAGCCATCCACCTTGCCCCCACAGGATGTGAACATTGAGGAACTGTACAAAGGTGGTGAAGAGGCCACA CGCTTCACCTTCTTCCAGAGCAGCTCAGGCTCCGCCTTCAGGCTTGAGGCTGCTGCCTGGCCTGGCTGGTTCC TGTGTGGCCCGGCAGAGCCCCAGCAGCCAGTACAGCTCACCAAGGAGAGTGAGCCCTCAGCCCGTACCAAGTT TTACTTTGAACAGAGCTGGTAGGGAGACAGGAAACTGCGTTTTAGCCTTGTGCCCCCAAACCAAGCTCATCCT GCTCAGGGTCTATGGTAGGCAGAATAATGTCCCCCGAAATATGTCCACATCCTAATCCCAAGATCTGTGCATA TGTTACCATACATGTCCAAAGAGGTTTTGCAAATGTGATTATGTTAAGGATCTTGAAATGAGGAGACAATCCT GGGTTATCCTTGTGGGCTCAGTTTAATCACAAGAAGGAGGCAGGAAGGGAGAGTCAGAGAGAGAATGGAAGAT ACCATGCTTCTAATTTTGAAGATGGAGTGAGGGGCCTTGAGCCAACATATGCAGGTGTTTTTAGAAGGAGGAA AAGCCAAGGGAACGGATTCTCCTCTATAGTCTCCGGAAGGAACACAGCTCTTGACACATGGATTTCAGCTCAG

I'GACACCCATTTCAGACTTCTGACCTCCACAACTATAAAATAATAAACTTGTGTTATTGTAAACCTCTGG

NOV8e, SNP13382517 of SEQ ID NO: 278 _159 aa MW at 17694.9kD CG97111-01, Protein Sequence SNP Pos: 44 SNP Change: le to Thr MCSLPMARYYRIKYADQKLYTRDGQLLVGPV NCCAEKICTLPNRGLARTKVPIFLGIQGGSRCLACVET EEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESE PSARTKFYFEQSW NOV8f, SNP13382518 of SEQ ID NO: 279 1019 bp CG9711 1-01, DNA Sequence ORF Start: ATG at 54 ORF Stop: TAG at 531 ~SPos: 205 - SNP Change: Cto A GGTTCCAGGACTCAGGATCTGCAGTGAGGACCAGACACCACTGATTGCAGGAATGTGTTCCCTCCCCATGGC AAGATACTACAGAATTAAATATGCAGACCAGAAGGCTCTATACACAAGAGATGGCCAGCTGCTGGTGGGAGAT CCTGTTGCAGACAACTGCTGTGCAGAGAAGATCTGCATACTTCCTAACAGAGGCTTGGACCGCACCAAGGTCC CCATTTTCCTGGGGATCCAGGGAGGGAGCCGCTGCCTGGCATGTGTGGAGACAGAAGAGGGGCCTTCCCTACA GCTGGAGCCATCCACCTTGCCCCCACAGGATGTGAACATTGAGGAACTGTACAAAGGTGOTGAAGAGGCCACA CGCTTCACCTTCTTCCAGAGCAGCTCAGGCTCCGCCTTCAGGCTTGAGGCTGCTGCCTGGCCTGGCTGGTTCC TGTGTGGCCCGGCAGAGCCCCAGCAGCCAGTACAGCTCACCAAGGAGAGTGAGCCCTCAGCCCGTACCAAGTT TTACTTTGAACAGAGCTGGTAGGGAGACAGGAAACTGCGTTTTAGCCTTGTGCCCCCAAACCAAGCTCATCCT GCTCAGGGTCTATGGTAGGCAGaTAATGTCCCCCGAAATATGTCCACATCCTAATCCCAAGATCTGTGCATA TGTTACCATACATGTCCAAAGAGGTTTTGCAAATGTGATTATGTTAAGGATCTTGAAATGAGGAGACAATCCT GGGTTATCCTTGTGGGCTCAGTTTAATCACAAGAAGGAGGCAGGAAGGGAGAGTCAGAGAGAGAATGGAGAT ACCATGCTTCTAATTTTGAAGATGGAGTGAGGGGCCTTGAGCCAACATATGCAGGTGTTTTTAGAAGGAGGAA AAGCCAAGGGAACGGATTCTCCTCTATAGTCTCCGGAAGGAACACAGCTCTTGACACATGGATTTCAGCTCAG TGACACCCATTTCAGACTTCTGACCTCCACAACTATAAAATAATAAACTTGTGTTATTGTAAACCTCTGG 5 NOV18f, SNP13382518 of SEQ ID NO: 280 159 aa at 17750.9kD CG97111-01, Protein Sequence ISNP Pos: 51 SNP Change: Ala to Asp MCSLPMRYYRIKADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLDRT PI LGIQGGSRCLACVET EEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESE PSARTKFYFEQSW 287 WO 2004/000997 PCT/US2003/017512 A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 18B. Table 18B. Comparison of the NOV18 protein sequences. NOV18a MCSLPMARYYRIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIPLG NOV18b MCSLPMARYYIIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLG NOV18c ----- LSYCFRIKYADQKALYTRDGQLLVGDPVADNCCAEKICILPNRGLARTKVPIFLG NOV18a IQGGSRCLACVETEEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLE NOV18b IQGGSRCLACVETEEGPSLQLE------- DVNIEELYKGGEEATRFTFFQSSSGSAFRLE NOV18c IQGGSRCLACVETEEGPSLQLEPSTLPPQDVNIEELYKGGEEATRFTFFQSSSGSAFRLE NOV18a AAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSW NOV18b AAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSW NOV18c AAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSW NOV18a (SEQ ID NO: 270) NOV18b (SEQ ID NO: 272) NOV18c (SEQ ID NO: 274) 5 Further analysis of the NOVI 8a protein yielded the following properties shown in Table 18C. Table 18C. Protein Sequence Properties NOV18a SignalP analysis: No Known Signal Sequence Predicted PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 11; pos.chg 2; neg.chg 0 H-region: length 1; peak value -13.22 PSG score: -17.62 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -5.73 possible cleavage site: between 39 and 40 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 2.07 (at 55) ALOM score: 2.07 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 2 Hyd Moment(75): 8.63 Hyd Moment(95): 6.96 . G content: 0 D/E content: 1 S/T content: 1 Score: -2.42 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 21 YRIIKY NUCDISC: discrimination of nuclear localization signals 288 WO 2004/000997 PCT/US2003/017512 pat4: none pat7: none bipartite: none content of basic residues: 10.1% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: found ILPN at 44 RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 55.5 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues

-------------------------

Final Results (k = 9/23): 47.8 %: nuclear 39.1 %: mitochondrial 4.3 %: vacuolar 4.3 %: vesicles of secretory system 4.3 %: cytoplasmic >> prediction for CG97111-01 is nuc (k=23) A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D. 5 289 WO 2004/000997 PCT/US2003/017512 Table 18D. Geneseq Results for NOV18a NOV18a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region ABP52020 NOVINTRA A homologous amino 10..159 149/150 (99%) 6e-86 acid sequence SEQ ID NO:63 - Homo 9..158 150/150 (99%) sapiens, 158 aa. [US2002068279-A1, 06-JUN-2002] ABP51984 Human IL-1 receptor antagonist 10..159 149/150 (99%) 6e-86 protein NOVINTRA A SEQ ID NO:8 - 5..154 150/150 (99%) Homo sapiens, 154 aa. [US2002068279-A1, 06-JUN-2002] AAB84999 Human interleukin-1 receptor 10..159 149/150 (99%) 6e-86 antagonist (NOVINTRA A) 5..154 150/150 (99%) polypeptide - Homo sapiens, 154 aa. [WO200140291-A2, 07-JUN-2001] AAU98463 Novel human interleukin-1 related 1..159 151/159 (94%) le-84 polypeptide - Homo sapiens, 152 aa. 1..152 151/159 (94%) [WO200250113-A2, 27-JUN-20021 AAM50219 Interleukin-1 receptor antagonist 1..159 151/159 (94%) le-84 related protein splice variant - Homo 20..171 151/159 (94%) sapiens, 171 aa. [WO200142304-A1, 14-JUN-2001] In a BLAST search of public sequence databases, the NOV1 8a protein was found to have homrnology to the proteins shown in the BLASTP data in Table 18E. 5 290 WO 2004/000997 PCT/US2003/017512 Table 18E. Public BLASTP Results for NOVI8a Protein NOV18a Identities/ Acession Protein/OrganismL/Length Residues/ Similarities for Expect cesi Match the Matched Value Number Residues Portion CAC43507 Sequence 5 from Patent WO0142304 - 1..159 151/159 (94%) 4e-84 Homo sapiens (Human), 171 aa. 20.171 151/159 (94%) Q8WWZ1 Interleukin 1 family member 10 1..159 151/159 (94%) 4e-84 (IL-1F10) (Interleukin-1 receptor 1..152 151/159 (94%) antagonist-like FILl theta) (Interleukin-1 theta) (IL-1 theta) (FILl theta) (Interleukin-1 HY2) (IL-1HY2) (Interleukin-1 receptor antagonist FKSG75) - Homo sapiens (Human), 152 aa. CAC21779 Sequence 3 from Patent WO0071719 - 1..159 149/159 (93%) 7e-83 Homo sapiens (Human), 169 aa 18..169 149/159 (93%) (fragment). CAC21778 Sequence 1 from Patent WO0071719 - 1..159 149/159 (93%) 7e-83 Homo sapiens (Human), 152 aa. 1..152 149/159 (93%) Q8R459 Interleukin 1 family member 10 1..158 123/158 (77%) 3e-65 (IL-1F10) - Mus musculus (Mouse), 152 1..151 133/158 (83%) aa. PFam analysis predicts that the NOV 18a protein contains the domains shown in the Table 18F. 5 Table 18F. Domain Analysis of NOV18a Identities/ Pfam Domain NOV18a Match Region Similarities Expect Value for the Matched Region IL1 12..159 42/153 (27%) 2e-16 97/153 (63%) Example 19: 10 The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A. 291 WO 2004/000997 PCT/US2003/017512 Table 19A: NOV19a, pCR2.1 - CG10132038.0.67- S540u2, a domain SEQ IDNO: 281 1377 bp of CG50513-05 TGGGAACATAATCCTTGGACTGCATGTTCCGTGTCCTGTGGAGGAGGGATTCAGAGACGGAGCTTTGTGTGTG TAGAGGAATCCATGCATGGAGAGATATTGCAGGTGGAAGAATGGAAGTGCATGTACGCACCCAAACCCAAGGT TATGCAAACTTGTAATCTGTTTGATTGCCCCAAGTGGATTGCCATGGAGTGGTCTCAGTGCACAGTGACTTGT GGCCGAGGGTTACGGTACCGGGTTGTTCTGTGTATTAACCACCGCGGAGAGCATGTTGGGGGCTGCAATCCAC AACTGAAGTTACACATCAAAGAAGAATGTGTCATTCCCATCCCGTGTTATAAACCAAAAGAAAAAAGTCCAGT GGAAGCAAAATTGCCTTGGCTGAAACAAGCACAAGAACTAGAAGAGACCAGAATAGCAACAGAAGAACCAACG TTCATTCCAGAACCCTGGTCAGCCTGCAGTACCACGTGTGGGCCGGGTGTGCAGGTCCGTGAGGTGAAGTGCC GTGTGCTCCTCACATTCACGCAGACTGAGACTGAGCTGCCCGAGGAAGAGTGTGAAGGCCCCAAGCTGCCCAC CGAACGGCCCTGCCTCCTGGAAGCATGTGATGAGAGCCCGGCCTCCCGAGAGCTAGACATCCCTCTCCCTGAG GACAGTGAGACGACTTACGACTGGGAGTACGCTGGGTTCACCCCTTGCACAGCAACATGCGTGGGAGGCCATC AAGAAGCCATAGCAGTGTGCTTACATATCCAGACCCAGCAGACAGTCAATCGACAGCTTGTGTGATATGGTCCA CCGTCCTCCAGCCATGAGCCAGGCCTGTAACACAGAGCCCTGTCCCCCCAGGTGGCATGTGGGCTCTTGGGGG CCCTGCTCAGCTACCTGTGGAGTTGGAATTCAGACCCGAGATGTGTACTGCCTGCACCCAGGGGAGACCCCTG CCCCTCCTGAGGAGTGCCGAGATGAAAAGCCCCATGCTTTACAAGCATGCAATCAGTTTGACTGCCCTCCTGG CTGGCACATTGAAGAATGGCAGCAGTGTTCCAGGACTTGTGGCGGGGGAACTCAGAACAGAAGAGTCACCTGT CGGCAGCTGCTAACGGATGGCAGCTTTTTGAATCTCTCAGATGAATTGTGCCAAGGACCCAAGGCATCGTCTC ACAAGTCCTGTGCCAGGACAGACTGTCCTCCACATTTAGCTGTGGGAGACTGGTCGAAGTGTTCTGTCAGTTG TGGTGTTGGAATCCAGAGAAGAAAGCAGGTGTGTCAAAGGCTGGCAGCCAAAGGTCGGCGCATCCCCCTCAGT GAGATGATGTGCAGGGATCTACCAGGGCTCCCTCTTGTAAGATCTTGCCAGATGCCTGAGTGC NOV18f, SNP13382518of [SEQIDNO:282 458 aa I CG97111-01, Protein Sequence EHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEWKCMYAPKPKVMQTCNLFDCPKWIAMEWSQCTVTCG RGLRYRVVLCINHRGEHVGGCNPQLKLHIKEECVIPIPCYKPKEKSPVEAKLPWLKQAQELEETRIATEEPTF IPEPWSACSTTCGPGVQVREVKCRVLLTFTQTETELPEEECEGPKLPTERPCLLEACDESPASRELDIPLPED SETTYDWEYAGFTPCTATCVGGHQEAIAVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGP CSATCGVGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQQCSRTCGGGTQNRRVTCR QLLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQRLAAKGRRIPLSE MMCRDLPGLPLVRSCQMPEC 5 Example B: Sequencing Methodology and Identification of NOVX Clones 1. GeneCalling T M Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen 10 and described by Shimkets, et al., "Gene expression analysis by transcript profiling coupled to a gene database query" Nature Biotechnology 17:198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or 15 cell lines. Cells and cell lines may have been treated with biological or chemical agents 292 WO 2004/000997 PCT/US2003/017512 that regulate gene expression, for example, growth factors, chemokines or steroids. The eDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique 5 cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the 10 restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment. 2. SeqCalling T M Technology: cDNA was derived from various human 15 samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The eDNA thus derived was then 20 sequenced using CuraGen's proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as 25 components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations. 3. PathCalling M Technology: The NOVX nucleic acid sequences are 30 derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen 293 WO 2004/000997 PCT/US2003/017512 Corporation's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof. The laboratory screening was performed using the methods summarized below: cDNA libraries were derived from various human samples representing multiple 5 tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the 10 appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, CA) were then transferred from E.coli into a CuraGen Corporation proprietary yeast strain (disclosed in U. S. Patents 6,057,101 and 6,083,693, incorporated herein by reference in their entireties). 15 Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corporation proprietary library of human sequences was used to screen multiple Gal4-AD fusion eDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the eDNA insert boundaries. Such PCR 20 product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the 25 extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations. Physical clone: the cDNA fragment derived by the screening procedure, covering 30 the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the eDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by 294 WO 2004/000997 PCT/US2003/017512 the mating of both CuraGen Corporation proprietary yeast strains N106' and YULH (U. S. Patents 6,057,101 and 6,083,693). 4. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted 5 sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs. 10 5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward 15 the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length eDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. 20 These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal 25 cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with 30 other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence 295 WO 2004/000997 PCT/US2003/017512 traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein. 6. Physical Clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and 5 refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding 10 the full-length protein. The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes. Example C: Quantitative expression analysis of clones in various cells and tissues 15 The quantitative expression of various NOV genes was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ-PCR) performed on an Applied Biosystems (Foster City, CA) ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence 20 Detection System. RNA integrity of all samples was determined by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs (degradation 25 products). Control samples to detect genomic DNA contamination included RTQ-PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon. RNA samples were normalized in reference to nucleic acids encoding 30 constitutively expressed genes (i.e., P-actin and GAPDH). Alternatively, non-normalized RNA samples were converted to single strand eDNA (sscDNA) using Superscript II (Invitrogen Corporation, Carlsbad, CA, Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 ptg of total 296 WO 2004/000997 PCT/US2003/017512 RNA in a volume of 20 pl or were scaled up to contain 50 gg of total RNA in a volume of 100 ptl and were incubated for 60 minutes at 42 0 C. sscDNA samples were then normalized in reference to nucleic acids as described above. 5 Probes and primers were designed according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default reaction condition settings and the following parameters were set before selecting primers: 250 nM primer concentration; 58o-60o C primer melting temperature (Tm) range; 59' C primer optimal 10 Tm; 20 C maximum primer difference (if probe does not have 5' G, probe Tm must be 100 C greater than primer Tm; and 75 bp to 100 bp amplicon size. The selected probes and primers were synthesized by Synthegen (Houston, TX). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final 15 concentrations were: 900 nM forward and reverse primers, and 200nM probe. Normalized RNA was spotted in individual wells of a 96 or 384-well PCR plate (Applied Biosystems, Foster City, CA). PCR cocktails included a single gene-specific probe and primers set or two multiplexed probe and primers sets. PCR reactions were 20 done using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 480 C for 30 minutes followed by amplification/PCR cycles: 950 C 10 min, then 40 cycles at 950 C for 15 seconds, followed by 600 C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) and 25 plotted using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression was the reciprocal of the RNA difference multiplied by 100. CT values below 28 indicate high expression, between 28 and 32 indicate moderate expression, between 32 and 35 indicate low expression and above 35 30 reflect levels of expression that were too low to be measured reliably. 297 WO 2004/000997 PCT/US2003/017512 Normalized sscDNA was analyzed by RTQ-PCR using 1X TaqMan@ Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification and analysis were done as described above. 5 Panels 1, 1.1, 1.2, and 1.3D Panels 1, 1.1, 1.2 and 1.3D included 2 control wells (genomic DNA control and chemistry control) and 94 wells of eDNA samples from cultured cell lines and primary normal tissues. Cell lines were derived from carcinomas (ca) including: lung, small cell 10 (s cell var), non small cell (non-s or non-sm); breast; melanoma; colon; prostate; glioma (glio), astrocytoma (astro) and neuroblastoma (neuro); squamous cell (squamr); ovarian; liver; renal; gastric and pancreatic from the American Type Culture Collection (ATCC, Bethesda, MD). Normal tissues were obtained from individual adults or fetuses and included: adult and fetal skeletal muscle, adult and fetal heart, adult and fetal kidney, adult 15 and fetal liver, adult and fetal lung, brain, spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. The following abbreviations are used in reporting the results: metastasis (met); pleural effusion (pl. eff or pl effusion) and * indicates established from metastasis. 20 General_ScreeningPanel_vl.4, vl.5, vl.6 and vl.7 Panels 1.4, 1.5, 1.6 and 1.7 were as described for Panels 1, 1.1, 1.2 and 1.3D, above except that normal tissue samples were pooled from 2 to 5 different adults or 25 fetuses. Panels 2D, 2.2, 2.3, and 2.4 Panels 2D, 2.2, 2.3 and 2.4 included 2 control wells and 94 wells containing RNA 30 or eDNA from human surgical specimens procured through the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI), Ardais (Lexington, MA) or Clinomics BioSciences (Frederick, MD). Tissues included human malignancies and in some cases matched adjacent normal tissue (NAT). 298 WO 2004/000997 PCT/US2003/017512 Information regarding histopathological assessment of tumor differentiation grade as well as the clinical stage of the patient from which samples were obtained was generally available. Normal tissue RNA and cDNA samples were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics and Invitrogen 5 (Carlsbad, CA). T HASS Panel vl.0 The HASS Panel v1.0 included 93 cDNA samples and two controls including: 81 10 samples of cultured human cancer cell lines subjected to serum starvation, acidosis and anoxia according to established procedures for various lengths of time; 3 human primary cells; 9 malignant brain cancers (4 medulloblastomas and 5 glioblastomas); and 2 controls. Cancer cell lines (ATCC) were cultured using recommended conditions and included: breast, prostate, bladder, pancreatic and CNS. Primary human cells were obtained from 15 Clonetics (Walkersville, MD). Malignant brain samples were gifts from the Henry Ford Cancer Center. ARDAIS Panel vl.O and vl.1 20 The ARDAIS Panel v1.0 and vl.1 included 2 controls and 22 test samples including: human lung adenocarcinomas, lung squamous cell carcinomas, and in some cases matched adjacent normal tissues (NAT) obtained from Ardais (Lexington, MA). Unmatched malignant and non-malignant RNA samples from lungs with gross histopathological assessment of tumor differentiation grade and stage and clinical state of 25 the patient were obtained from Ardais. ARDAIS Prostate vI.0 ARDAIS Prostate vl.0 panel included 2 controls and 68 test samples of human 30 prostate malignancies and in some cases matched adjacent normal tissues (NAT) obtained from Ardais (Lexington, MA). RNA from unmatched malignant and non-malignant prostate samples with gross histopathological assessment of tumor differentiation grade and stage and clinical state of the patient were also obtained from Ardais. 299 WO 2004/000997 PCT/US2003/017512 ARDAIS Kidney vl.0 ARDAIS Kidney vl.0 panel included 2 control wells and 44 test samples of human renal cell carcinoma and in some cases matched adjacent normal tissue (NAT) obtained 5 from Ardais (Lexington, MA). RNA from unmatched renal cell carcinoma and normal tissue with gross histopathological assessment of tumor differentiation grade and stage and clinical state of the patient were also obtained from Ardais. ARDAIS Breast vl.0 10 ARDAIS Breast v1.0 panel included 2 control wells and 71 test samples of human breast malignancies and in some cases matched adjacent normal tissue (NAT) obtained from Ardais (Lexington, MA). RNA from unmatched malignant and non-malignant breast samples with gross histopathological assessment of tumor differentiation grade and stage and clinical state of the patient were also obtained from Ardais. 15 Panels 3D, 3.1 and 3.2 Panels 3D, 3.1, and 3.2 included two controls, 92 cDNA samples of cultured human cancer cell lines and 2 samples of human primary cerebellum. Cell lines (ATCC, 20 National Cancer Institute (NCI), German tumor cell bank) were cultured as recommended and were derived from: squamous cell carcinoma of the tongue, melanoma, sarcoma, leukemia, lymphoma, and epidermoid, bladder, pancreas, kidney, breast, prostate, ovary, uterus, cervix, stomach, colon, lung and CNS carcinomas. 25 Panels 4D, 4R, and 4.1D Panels 4D, 4R, and 4.1D included 2 control wells and 94 test samples of RNA (Panel 4R) or cDNA (Panels 4D and 4.1D) from human cell lines or tissues related to inflammatory conditions. Controls included total RNA from normal tissues such as colon, lung (Stratagene, La Jolla, CA), thymus and kidney (Clontech, Palo Alto, CA). Total 30 RNA from cirrhotic and lupus kidney was obtained from BioChain Institute, Inc., (Hayward, CA). Crohn's intestinal and ulcerative colitis samples were obtained from the National Disease Research Interchange (NDRI, Philadelphia, PA). Cells purchased from Clonetics (Walkersville, MD) included: astrocytes, lung fibroblasts, dermal fibroblasts, 300 WO 2004/000997 PCT/US2003/017512 coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, and human umbilical vein endothelial. These primary cell types were activated by incubating with various cytokines (IL-1 beta ~1-5 ng/ml, TNF 5 alpha -5-10 ng/ml, IFN gamma -20-50 ng/ml, IL-4 -5-10 ng/ml, IL-9 -5-10 ng/ml, IL-13 5-10 ng/ml) or combinations of cytokines as indicated. Starved endothelial cells were cultured in the basal media (Clonetics, Walkersville, MD) with 0.1% serum. Mononuclear cells were prepared from blood donations using Ficoll. LAK cells 10 were cultured in culture media [DMEM, 5% FCS (Hyclone, Logan, UT), 100 PiM non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5 x 10 -5 M (Gibco), and 10 mM Hepes (Gibco)] and interleukin 2 for 4-6 days. Cells were activated with 10-20 ng/ml PMA and 1-2 Ig/ml ionomycin, 5-10 ng/ml IL-12, 20-50 ng/ml IFN gamma or 5-10 ng/ml IL-18 for 6 hours. 15 In some cases, mononuclear cells were cultured for 4-5 days in culture media with -5 gg/ml PHA (phytohemagglutinin) or PWM (pokeweed mitogen; Sigma-Aldrich Corp., St. Louis, MO). Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing them 1:1 at a final concentration 20 of-2x1 0 6 cells/ml in culture media. The MLR samples were taken at various time points from 1- 7 days for RNA preparation. Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet (Miltenyi Biotec, Auburn, CA) according to the 25 manufacturer's instructions. Monocytes were differentiated into dendritic cells by culturing in culture media with 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culturing monocytes for 5-7 days in culture media with -50 ng/ml 10% type AB Human Serum (Life technologies, Rockville, MD) or MCSF (Macrophage colony stimulating factor; R&D, Minneapolis, MN). Monocytes, 30 macrophages and dendritic cells were stimulated for 6 or 12-14 hours with 100 ng/ml lipopolysaccharide (LPS). Dendritic cells were also stimulated with 10 gg/ml anti-CD40 monoclonal antibody (Pharmingen, San Diego, CA) for 6 or 12-14 hours. 301 WO 2004/000997 PCT/US2003/017512 CD4+ lymphocytes, CD8+ lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. CD45+RA and CD45+RO CD4+ lymphocytes were isolated 5 by depleting mononuclear cells of CD8+, CD56+, CD14+ and CD19+ cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO Miltenyi beads were then used to separate the CD45+RO CD4+ lymphocytes from CD45+RA CD4+ lymphocytes. CD45+RA CD4+, CD45+RO CD4 +and CD8+ lymphocytes were cultured in culture media at 106 cells/ml in culture plates precoated overnight with 0.5 pg/ml 10 anti-CD28 (Pharmingen, San Diego, CA) and 3 gg/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CDS+ lymphocytes, isolated CD8+ lymphocytes were activated for 4 days on anti-CD28, anti-CD3 coated plates and then harvested and expanded in culture media with IL-2 (1 ng/ml). These CD8+ cells were activated again with plate bound 15 anti-CD3 and anti-CD28 for 4 days and expanded as described above. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. Isolated NK cells were cultured in culture media with 1 ng/ml IL-2 for 4-6 days before RNA was prepared. 20 B cells were prepared from minced and sieved tonsil tissue (NDRI). Tonsil cells were pelleted and resupended at 106 cells/ml in culture media. Cells were activated using 5 tg/ml PWM (Sigma-Aldrich Corp., St. Louis, MO) or -10 jtg/ml anti-CD40 (Pharmingen, San Diego, CA) and 5-10 ng/ml IL-4. Cells were harvested for RNA preparation after 24, 48 and 72 hours. 25 To prepare primary and secondary Thl/Th2 and Trl cells, umbilical cord blood CD4+ lymphocytes (Poietic Systems, German Town, MD) were cultured at 105-10 6 cells/ml in culture media with IL-2 (4 ng/ml) in 6-well Falcon plates (precoated overnight with 10 Ig/ml anti-CD28 (Pharmingen) and 2 pg/ml anti-CD3 (OKT3; ATCC) 30 then washed twice with PBS). To stimulate Thl phenotype differentiation, IL-12 (5 ng/ml) and anti-IL4 (1 Pg/ml) were used; for Th2 phenotype differentiation, IL-4 (5 ng/ml) and anti-IFN gamma (1 302 WO 2004/000997 PCT/US2003/017512 pg/ml) were used; and for Trl phenotype differentiation, EL-10 (5 ng/ml) was used. After 4-5 days, the activated Thl, Th2 and Trl lymphocytes were washed once with DMEM and expanded for 4-7 days in culture media with IL-2 (1 ng/ml). Activated Thl, Th2 and Trl lymphocytes were re-stimulated for 5 days with anti-CD28/CD3 and cytokines as 5 described above with the addition of anti-CD95L (1 Pg/ml) to prevent apoptosis. After 4-5 days, the Thl, Th2 and Trl lymphocytes were washed and expanded in culture media with IL-2 for 4-7 days. Activated Thl and Th2 lymphocytes were maintained for a maximum of three cycles. RNA was prepared from primary and secondary Thl, Th2 and Trl after 6 and 24 hours following the second and third activations with plate-bound 10 anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures. Leukocyte cells lines Ramos, EOL-1, KU-812 were obtained from the ATCC. EOL-1 cells were further differentiated by culturing in culture media at 5 x10 5 cells/ml with 0.1 mM dbcAMP for 8 days, changing the media every 3 days and adjusting the cell 15 concentration to 5 xl 05 cells/ml. RNA was prepared from resting cells or cells activated with PMA (10 ng/ml) and ionomycin (1 pg/ml) for 6 and 14 hours. RNA was prepared from resting CCD 1106 keratinocyte cell line (ATCC) or from cells activated with -5 ng/ml TNF alpha and 1 ng/ml IL-1 beta. RNA was prepared from resting NCI-H292, airway epithelial tumor cell line (ATCC) or from cells activated for 6 and 14 hours in 20 culture media with 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13, and 25 ng/ml IFN gamma. RNA was prepared by lysing approximately 107 cells/ml using Trizol (Gibco BRL) then adding 1/10 volume of bromochloropropane (Molecular Research Corporation, Cincinnati, OH), vortexing, incubating for 10 minutes at room temperature and then 25 spinning at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was placed in a 15 ml Falcon Tube and an equal volume ofisopropanol was added and left at -200 C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min and washed in 70% ethanol. The pellet was redissolved in 300 gl of RNAse-free water with 35 pl buffer (Promega, Madison, WI) 5 gl DTT, 7 gl RNAsin and 8 il DNAse and incubated at 370 C 30 for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down, placed in RNAse free water and stored at -800 C. 303 WO 2004/000997 PCT/US2003/017512 AI comprehensive panel vl.0 Autoimmunity (AI) comprehensive panel vl.0 included two controls and 89 cDNA test samples isolated from male (M) and female (F) surgical and postmortem human tissues that were obtained from the Backus Hospital and Clinomics (Frederick, MD). 5 Tissue samples included : normal, adjacent (Adj); matched normal adjacent (match control); joint tissues (synovial (Syn) fluid, synovium, bone and cartilage, osteoarthritis (OA), rheumatoid arthritis (RA)); psoriatic; ulcerative colitis colon; Crohns disease colon; and emphysmatic, asthmatic, allergic and chronic obstructive pulmonary disease (COPD) lung. 10 Pulmonary and General inflammation (PGI) panel v1.0 Pulmonary and General inflammation (PGI) panel vl.0 included two controls and 39 test samples isolated as surgical or postmortem samples. Tissue samples include: five normal lung samples obtained from Maryland Brain and Tissue Bank, University of 15 Maryland (Baltimore, MD), International Bioresource systems, IBS (Tuscon, AZ), and Asterand (Detroit, MI), five normal adjacent intestine tissues (NAT) from Ardais (Lexington, MA), ulcerative colitis samples (UC) from Ardais (Lexington, MA); Crohns disease colon from NDRI, National Disease Research Interchange (Philadelphia, PA); emphysematous tissue samples from Ardais (Lexington, MA) and Genomic Collaborative 20 Inc. (Cambridge, MA), asthmatic tissue from Maryland Brain and Tissue Bank, University of Maryland (Baltimore, MD) and Genomic Collaborative Inc (Cambridge, MA) and fibrotic tissue from Ardais (Lexinton, MA) and Genomic Collaborative (Cambridge, MA). 25 AI.05 chondrosarcoma AI.05 chondrosarcoma plates included SW1353 cells (ATCC) subjected to serum starvation and treated for 6 and 18 h with cytokines that are known to induce MMP (1, 3 and 13) synthesis (e.g. ILibeta). These treatments included: IL-lbeta (10 ng/ml), IL-lbeta + TNF-alpha (50 ng/ml), IL-lbeta + Oncostatin (50 ng/ml) and PMA (100 ng/ml). 30 Supernatants were collected and analyzed for MMIP 1, 3 and 13 production. RNA was prepared from these samples using standard procedures. 304 WO 2004/000997 PCT/US2003/017512 Panels 5D and 51 Panel 5D and 5I included two controls and cDNAs isolated from human tissues, human pancreatic islets cells, cell lines, metabolic tissues obtained from patients enrolled 5 in the Gestational Diabetes study (described below), and cells from different stages of adipocyte differentiation, including differentiated (AD), midway differentiated (AM), and undifferentiated (U; human mesenchymal stem cells). Gestational Diabetes study subjects were young (18 - 40 years), otherwise healthy 10 women with and without gestational diabetes undergoing routine (elective) Caesarean section. Uterine wall smooth muscle (UT), visceral (Vis) adipose, skeletal muscle (SK), placenta (P1) greater omentum adipose (GO Adipose) and subcutaneous (SubQ) adipose samples (<1 cc) were collected, rinsed in sterile saline, blotted and flash frozen in liquid nitrogen. Patients included: Patient 2, an overweight diabetic Hispanic not on insulin; 15 Patient 7-9, obese non-diabetic Caucasians with body mass index (BMI) greater than 30; Patient 10, an overweight diabetic Hispanic, on insulin; Patient 11, an overweight nondiabetic African American; and Patient 12, a diabetic Hispanic on insulin. Differentiated adipocytes were obtained from induced donor progenitor cells 20 (Clonetics, Walkersville, MD). Differentiated human mesenchymal stem cells (HuMSCs) were prepared as described in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr 2 1999: 143-147. mRNA was isolated and sscDNA was produced from Trizol lysates or frozen pellets. Human cell lines (ATCC, NCI or German tumor cell bank) included: kidney proximal convoluted tubule, uterine 25 smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells and adrenal cortical adenoma cells. Cells were cultured, RNA extracted and sscDNA was produced using standard procedures Panel 51 also contains pancreatic islets (Diabetes Research Institute at the 30 University of Miami School of Medicine). 305 WO 2004/000997 PCT/US2003/017512 Human Metabolic RTQ-PCR Panel Human Metabolic RTQ-PCR Panel included two controls (genomic DNA control and chemistry control) and 211 cDNAs isolated from human tissues and cell lines relevant 5 to metabolic diseases. This panel identifies genes that play a role in the etiology and pathogenesis of obesity and/or diabetes. Metabolic tissues including placenta (P1), uterine wall smooth muscle (Ut), visceral adipose, skeletal muscle (Sk) and subcutaneous (SubQ) adipose were obtained from the Gestational Diabetes study (described above). Included in the panel are: Patients 7 and 8, obese non-diabetic Caucasians; Patient 12 a diabetic 10 Caucasian with unknown BMI, on insulin (treated); Patient 13, an overweight diabetic Caucasian, not on insulin (untreated); Patient 15, an obese, untreated, diabetic Caucasian; Patient 17 and 25, untreated diabetic Caucasians of normal weight; Patient 18, an obese, untreated, diabetic Hispanic; Patient 19, a non-diabetic Caucasian of normal weight; Patient 20, an overweight, treated diabetic Caucasian; Patient 21 and 23, overweight 15 non-diabetic Caucasians; Patient 22, a treated diabetic Caucasian of normal weight; Patient 23, an overweight non-diabetic Caucasian; and Patients 26 and 27, obese, treated, diabetic Caucasians. Total RNA was isolated from metabolic tissues including: hypothalamus, liver, 20 pancreas, pancreatic islets, small intestine, psoas muscle, diaphragm muscle, visceral (Vis) adipose, subcutaneous (SubQ) adipose and greater omentum (Go) from 12 Type HII diabetic (Diab) patients and 12 non diabetic (Norm) at autopsy. Control diabetic and non-diabetic subjects were matched where possible for: age; sex, male (M); female (F); ethnicity, Caucasian (CC); Hispanic (HI); African American (AA); Asian (AS); and BMI, 20-25 25 (Low BM), 26-30 (Med BM) or overweight (Overwt), BMI greater than 30 (Hi BMI) (obese). RNA was extracted and ss cDNA was produced from cell lines (ATCC) by standard methods. 30 CNS Panels CNS Panels CNSD.01, CNS Neurodegeneration V1.0 and CNS Neurodegeneration V2.0 included two controls and 46 to 94 test cDNA samples isolated from postmortem 306 WO 2004/000997 PCT/US2003/017512 human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital). Brains were removed from calvaria of donors between 4 and 24 hours after death, and frozen at -80 0 C in liquid nitrogen vapor. 5 Panel CNSD.01 Panel CNSD.01 included two specimens each from: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy (PSP), Depression, and normal controls. Collected tissues included: cingulate gyrus (Cing Gyr), temporal pole (Temp Pole), globus palladus (Glob palladus), substantia nigra (Sub Nigra), 10 primary motor strip (Brodman Area 4), parietal cortex (Brodman Area 7), prefrontal cortex (Brodman Area 9), and occipital cortex (Brodman area 17). Not all brain regions are represented in all cases. Panel CNS Neurodegeneration V1.0 15 The CNS Neurodegeneration V 1.0 panel included: six Alzheimer's disease (AD) brains and eight normals which included no dementia and no Alzheimer's like pathology (control) or no dementia but evidence of severe Alzheimer's like pathology (Control Path), specifically senile plaque load rated as level 3 on a scale of 0-3; 0 no evidence of plaques, 3 severe AD senile plaque load. Tissues collected included: hippocampus, temporal 20 cortex (Brodman Area 21), parietal cortex (Brodman area 7), occipital cortex (Brodman area 17) superior temporal cortex (Sup Temporal Ctx) and inferior temporal cortex (Inf Temproal Ctx). Gene expression was analyzed after normalization using a scaling factor calculated 25 by subtracting the Well mean (CT average for the specific tissue) from the Grand mean (average CT value for all wells across all runs). The scaled CT value is the result of the raw CT value plus the scaling factor. Panel CNS Neurodegeneration V2.0 30 The CNS Neurodegeneration V2.0 panel included sixteen cases of Alzheimer's disease (AD) and twenty-nine normal controls (no evidence of dementia prior to death) including fourteen controls (Control) with no dementia and no Alzheimer's like pathology and fifteen controls with no dementia but evidence of severe Alzheimer's like pathology 307 WO 2004/000997 PCT/US2003/017512 (AH3), specifically senile plaque load rated as level 3 on a scale of 0-3; 0 no evidence of plaques, 3 severe AD senile plaque load. Tissues from the temporal cortex (Brodman Area 21) included the inferior and superior temporal cortex that was pooled from a given individual (Inf & Sup Temp Ctx Pool). 5 A. CG103945-02: Semaphorin semr2. Expression of gene CG103945-02 was assessed using the primer-probe set Ag7442, described in Table AA. Results of the RTQ-PCR runs are shown in Tables AB and AC. Table AA. Probe Name A%7442 10 Primers Sequences Length Start SEQ Length Position ID No Forward gaaagccttccagcaccat- 19 128 283 Probe TET-5' -tggatggaaacattttccagatacctcc-3 -TAMRA 28 148 284 Reverse 5 ' -gcccagaaagatggcagag-3' 19 189 285 Table AB. General screening panel vl.7 Column A - Rel. Exp.(%) Ag7442, Run 318350211 Tissue Name A Tissue Name A Adipose 100.0 Gastric ca. (liver met.) NCI-N87 0.0 HUVEC 16.6 Stomach 0.6 Melanoma* Hs688(A).T 0.0 Colon ca. SW-948 2.7 Melanoma* Hs688(B).T 0.5 Colon ca. SW480 .0.0 Melanoma (met) SK-MEL-5 1.7 Colon ca. (SW480 met) SW620 5.1 Testis 2.1 Colon ca. HT29 0.0 Prostate ca. (bone met) PC-3 0.0 Colon ca. HCT-116 19.1 Prostate ca. DU145 1.9 Colon cancer tissue 0.9 Prostate pool 1.5 Colon ca. SWll16 5.9 Uterus pool 0.5 Colon Ca. Colo-205 0.0 Ovarian ca. OVCAR-3 0.0 Colon ca. SW-48 0.0 Ovarian ca. (ascites) SK-OV-3 0.0 Colon_ [4.1 Ovarian ca. OVCAR-4 11.7 Small Intestine 0.8 Ovarian ca. OVCAR-5 7.2 Fetal Heart 2.0 Ovarian ca. IGROV-1 2.9 Heart 1.3 Ovarian ca. OVCAR-8 5.8 Lymph Node pool 1 2.1 Ovary 13.6 Lymph Node pool 2 20.7 Breast ca. MCF-7 0.0 Fetal Skeletal Muscle 16.8 308 WO 2004/000997 PCT/US2003/017512 Breast ca. MDA-MB-231 6.0 Skeletal Muscle pool 1.1 Breast ca. BT-549 0.0 Skeletal Muscle 9.7 Breast ca. T47D 11.0 Spleen 9.0 Breast pool 5.7 Thymus 1.1 Trachea 13.0 CNS cancer (glio/astro) SF-268 0.0 Lung 66.0 CNS cancer (glio/astro) T98G 0.0 Fetal Lung 12.3 CNS cancer (neuro;met) SK-N-AS 0.0 Lung ca. NCI-N417 0.0 cNS cancer (astro) SF-539 0.9 Lung ca. LX-1 0.0 CNS cancer (astro) SNB-75 0.0 Lung ca. NCI-H146 0.0 CNS cancer (glio) SNB-19 0.9 Lung ca. SHP-77 17.8 CNS cancer (glio) SF-295 0.0 Lung ca. NCI-H23 o.7 Brain (Amygdala) 3.1 Lung ca. NCI-H460 1.3 Brain (Cerebellum) 22.4 Lung ca. HOP-62 0.0 Brain (Fetal) 6.2 Lung ca. NCI-H522 4.4 Brain (Hippocampus) 4.5 Lung ca. DMS-114 .0.8 Cerebral Cortex pool 5.1 Liver 0.0 Brain (Substantia nigra) 2.0 Fetal Liver 1.9 Brain (Thalamus) 4.1 Kidney pool 28.7 Brain (Whole) 129.7 Fetal Kidney 7.2 Spinal Cord .2.3 Renal ca. 786-0 0.0 Adrenal Gland 2.8 Renal ca. A498 0.0 Pituitary Gland 1.6 Renal ca. ACHN 0.0 Salivary Gland 20.2 Renal ca. UO-31 0.0 Thyroid 7.5 Renal ca. TK-10 0.0 Pancreatic ca. PANC-1 0.6 Bladder 6.1 Pancreas pool 0.0 Table AC. Panel 4.1D Column A - Rel. Exp.(%) Ag7442, Run 306067441 Tissue Name A Tissue Name A Secondary Th1 act 0.0 HUVEC IL-lbeta 4.7 Secondary Th2 act 4.4 IHUVEC IFN gamma 0.0 Secondary Trl act 0.0 HUVEC TNF alpha + IFN gamma 0.0 Secondary T hl rest 0 J0 HUVEC TNF alpha + IL4 2.6 Secondary Th2 rest .0 HUVEC IL-1 113.4 Secondary Trl rest 0.0 Lung Microvascular EC none 100.0 Primary l act .. 0.0 Lung Microvascular EC TNFalpha+ IL-lbeta 48.3 Primary Th2 act 0.0 Microvascular Dermal EC none 30.4 Primary Trl act 0.0 Microsvasular Dermal EC TNFalpha + IL-lbeta 19.9 Primary ThI rest 10.0 Bronchial epithelium TNFalpha + ILlbeta 0.0 Primay Th2 rest 0.0 Small airway epithelium none 0.0 Primary Trl rest 00 Small airway epithelium TNFalpha + IL-ibeta 0.0 309 WO 2004/000997 PCT/US2003/017512 CD45RA CD4 lymphocyte act 0.0 Coronery artery SMC rest 0.0 CD45RO CD4 lymphocyte act 0.0 Coronery artery SMC TNFalpha + IL-1beta 0.0 CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 lymphocyte rest 0.0 Astrocytes TNFalpha + IL-l beta 0.0 Secondary CD8 lymphocyte act 0.0 KU-812 (Basophil) rest 0.0 CD4 lymphocyte none 0.0 KU-812 (Basophil) PMA/ionomycin 5.0 2ry Thl/Th2/Trl anti-CD95 CH11 0.0 CCD1 106 (Keratinocytes) none 0.0 LAK cells rest 0.0 jCCD1 106 (Keratinocytes) TNFalpha+ IL-tbeta 0.0 LAK cells IL-2 0.0 Liver cinrrhosis 11.9 LAK cells IL-2+IL-12 0.0 NCI-H292 none 0.0 LAK cells IL-2+IFN gamma 0.0 -NCI-H292 EL-4 0.0 LAK cells IL-2+ IL-i 8 l0.0 NCI-H292 IL-9 0.0 LAK cells PMA/ionomrnycin 0.0 NCI-H292 IL-13 0.0 NK Cells IL-2 rest 0.0 NCI-H292 IFN gamma 0.0 Two Way MLR 3 day 0.0 HPAEC none 4.7 Two Way MLR 5 day 0.0 HPAEC TNF alpha + IL-1 beta 5.2 Two Way MLR 7 day 0.0 Lung fibroblast none 0.0 PBMC rest 0.0 Lung fibroblast TNF alpha + IL-I beta 0.0 PBMC PWM 0.0 Lung fibroblast IL-4 0.0 PBMC PHA-L 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) none 0.0 Lung fibroblast EL-13 0.0 Ramos cell) ionomycin 0.0 Lung fibroblast IFN gamma 0.0 B lymphocytes PWM 0.0 Dermal fibroblast CCD1070 rest 0.0 B lymphocytes CD40L and IL-4 0.0 Dermal fibroblast CCD1070 TNF alpha 0.0 EOL-1 dbcAMP 6.1 Dermal fibroblast CCD107o IL-1 beta 0.0 EOL-1 dbcAMP PMA/ionomycin 4.2 Dermal fibroblast IFN gamma 0.0 Dendritic cells none 0.0 Dermal fibroblast IL-4 0.0 Dendritic cells LPS 3.6 Dermal Fibroblasts rest .5.6 Dendritic cells anti-CD40 0.0 Neutrophils TNFa+LPS .. 0.0 Mongocytes rest 0.0 .Neutrophils rest 0.0 Monocytes LPS 0.0 Colon 14.5 Macrophages rest 0.0 Lung 0.0 Macrophages LPS 0.0 Thymus 0.0 HUVEC none 0.0 Kidney HUVEC starved 11.0 Generalscreening._panelv1.7 Summary: Ag7442 Highest expression of the CG103945-02 gene was detected in adipose tissue (CT=29.5). In addition, significant expression of this gene was also seen in skeletal muscle and thyroid. Therapeutic 5 modulation of the activity of this gene or its protein product is useful in the treatment of metabolic disorders, including diabetes and obesity. 310 WO 2004/000997 PCT/US2003/017512 Moderate levels of expression of this gene were also seen in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of central nervous 5 system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. Moderate to low expression of this gene was seen in number of cancer cell lines derived from colon, lung, breast and ovarian cancers. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of colon, lung, breast 10 and ovarian cancers. Panel 4.1D Summary: Ag7442 Highest expression of this gene was seen in lung microvascular endothelium (CT=33.6) and its expression was down-regulated upon activation of these cells. Endothelial cells are known to play important roles in inflammatory responses by altering the expression of surface proteins that are involved in 15 activation and recruitment of effector inflammatory cells. Higher expression of this gene in resting cells suggests a role for this gene in the maintenance of the integrity of the lung microvasculature. Therapeutic modulation of the activity of this gene or its protein product is beneficial for the treatment of diseases associated with damaged microvasculature including heart diseases or inflammatory diseases, such as psoriasis, asthma, and chronic 20 obstructive pulmonary diseases. B. CG106951-01 and CG106951-04: Semaphorin 5B. Expression of gene CG106951-01 and CG106951-04 was assessed using the primer-probe sets Agl216, described in Tables BA. 311 WO 2004/000997 PCT/US2003/017512 Table BA. Probe Name Ag1216 Primers Sequences Length Start SEQ D Position No Forward 5'-cccgaagaatgaaaagtacaca-3' 122 3351 286 Probe TET-5.-cccatggaattcaagaccctgaacaa-3'-TAMRA 26 3373 287 Reverse 5' -aatgggtagaagttggctctgt-3 ' 22 3419 288 Table BB. AI comprehensive panel vl.0 5 Column A - Rel. Exp.(%) Ag1216, Run 233667803 Tissue Name A Tissue Name A 110967 COPD-F 10.4 112427 Match Control Psoriasis-F 29.7 110980 COPD-F 23.5 112418 Psoriasis-M 8.4 110968 COPD-M 13.6 112723 Match Control Psoriasis-M 2.2 110977 COPD-M 64.6 112419 Psoriasis-M 16.3 110989 Emphysema-F 35.4 112424 Match Control Psoriasis-M 24.0 110992 Emphysema-F 13.5 112420 Psoriasis-M 41.5 110993 Emphysema-F 27.4 112425 Match Control Psoriasis-M 43.5 110994 Emphysema-F 5.6 104689 (MF) OA Bone-Backus - 35.6 .110995 Emphysema-F 15.3 104690 (MF) Adj "Normal" Bone-Backus 12.5 110996 Emphysema-F 7.2 104691 (MF) OA Synovium-Backus 14.9 110997 Asthma-M 9.2 104692 (BA) OA Cartilage-Backus 0.0 111001 Asthma-F 24.0 104694 (BA) OA Bone-Backus 10.5 111002 Asthma-F 26.6 104695 (BA) Adj "Normal" Bone-Backus 5.7 111003 Atopic Asthma-F 35.1 104696 (BA) OA Synovium-Backus 6.7 111004 Atopic Asthma-F 24.1 1 04700 (SS) OA Bone-Backus 6.0 111005 Atopic Asthrna-F 14.0 104701 (SS) Adj "Normal" Bone-Backus 5.8 111006 Atopic Asthma-F 3.2 104702 (SS) OA Synovium-Backus 48.3 111417 Allergy-M 18.0 117093 OA Cartilage Rep7 23.5 112347 Allergy-M 0.5 112672 OA Bone5 26.1 112349Normal Lung-F 0.5 112673 OA Synovium5 14.0 112357Normal Lung-F 56.6 112674 OA Synovial Fluid cells5 12.6 1n2354Normal Lung-M 14.0117100 OA Cartilage Repl4 6.7 112374 Crohns-F 42.3 112756 OA Bone9 100.0 112389 Match Control Crohns-F 61.6 112757 OA Synovium9 2.1 112375 Crohns-F 25.7 112758 OA Synovial Fluid Cells9 28.9 112732 Match Control Crohns-F 7.5 117125 RA Cartilage Rep2 5.2 1 12 7 2 5 Crohns-M 3.1 113492 Bone2 RA 5.0 112387 Match Control Crohns-M 160.7 113493 Synovium2 RA 16.2 112378 Crohns-M 0.8 113494 Syn Fluid Cells RA 16.5 112390 Match Control Crohns-M 24.5 113499 Cartilage4 RA 13.2 312 WO 2004/000997 PCT/US2003/017512 112726 Crohns-M 24.1 113500 Bone4 RA 9.2 112731 Match Control Crohns-M 12.4 113501 Synovium4 RA _12.6 112380 Ulcer Col-F 18.6 113502 Syn Fluid Cells4 RA 8.9 112734 Match Control Ulcer Col-F 30.6 113495 Cartilage3 RA 5.6 112384 Ulcer Col-F 45.7 113496 Bone3 RA 8.3 112737 Match Control Ulcer Col-F 16.5 113497 Synovium3 RA 4.7 112386 Ulcer Col-F 13.8 113498 Syn Fluid Cells3 RA 5.1 112738 Match Control Ulcer Col-F 3.0 117106 Normal Cartilage Rep20 10.7 112381 Ulcer Col-M 1.5 113663 Bone3 Normal 1.1 112735 Match Control Ulcer Col-M 8.8 113664 Synovium3 Normal 0.0 112382 Ulcer Col-M 25.7 113665 Syn Fluid Cells3 Normal 0.9 112394 Match Control Ulcer Col-M 21.2 117107 Normal Cartilage Rep22 12.6 112383 Ulcer Col-M 142.6 113667 Bone4 Normal 4.3 112736 Match Control Ulcer Col-M 22.8 113668 Synovium4 Normal 10.4 112423 Psoriasis-F 43.8 113669 Syn Fluid Cells4 Normal 7.0 Table BC. General screening panel vi.4 Column A - ReL Exp.(%) Ag1216, Run 212696280 Tissue Name _ A Tissue Name A Adipose 1.3 Renal ca. TK-10 0.1 Melanoma* Hs688(A).T 0.0 Bladder 1.0 Melanoma* Hs688(B).T 0.0 Gastric ca. (liver met.) NCI-N87 0.1 Melanoma* M14 0.0 Gastric ca. KATO II 0.0 Melanoma* LOXIMVI 0.0 Colon ca. SW-948 0.0 Melanoma* SK-MEL-5 0.0 IColon ca. SW480 10.0 Squamous cell carcinoma SCC-4 0.1 Colon ca.* (SW480 met) SW620 0.2 Testis Pool 0.4 Colon ca. HT29 0.0 Prostate ca.* (bone met) PC-3 .0.0 Colon ca. HCT-1 16 0.1 Prostate Pool .

1.0 Colon ca. CaCo-2 0.4 Placenta 1.8 Colon cancer tissue 0.5 Uterus Pool 0.8 Colon ca. SW 116 0.0 Ovarian ca. OVCAR-3 18.8 Colon ca. Colo-205 0.0 Ovarian ca. SK-OV-3 0.0 Colon ca. SW-48 0.0 Ovarian ca. OVCAR-4 0.0 Colon Pool .0 Ovarian ca. OVCAR-5 0.6 Small Intestine Pool 1.0 Ovarian ca. IGROV-1 0.5 Stomach Pool 1.0 Ovarian ca. OVCAR-8 0.3 Bone Marrow Pool 1.0 Ovary 1.8 Fetal Heart 12.9 Breast ca. MCF-7 0.1 Heart Pool 0.9 Breast ca. MDA-MB-231 0.0 Lymph Node Pool 1.9 Breast ca. BT 549 15.2 Fetal Skeletal Muscle 12.8 Breast ca. T47D I4 Skeletal Muscle Pool0.4 313 WO 2004/000997 PCT/US2003/017512 Breast ca. MDA-N 10.0 Spleen Pool 0.1 Breast Pool 2.1 Thymus Pool 1.0 Trachea 0.7 CNS cancer (glio/astro) U87-MG 0.0 Lung 0.3 CNS cancer (glio/astro) U-118-MG 2.0 Fetal Lung 10.3 CNS cancer (neuro;met) SK-N-AS 2.1 Lung ca. NCI-N417 0.0 CNS cancer (astro) SF-539 01 Lung ca. LX-1 0.0 CNS cancer (astro) SNB-75 4 Lung ca. NCI-H146 0.2 CNS cancer (glio) SNB-19 0.3 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.0 Lung ca. A549 0.0 Brain (Amygdala) Pool 3.6 Lung ca. NCI-H526 . Brain (cerebellum) 3.7 Lung ca. NCI-H23 0.2 Brain (fetal) 30.1 Lung ca. NCI-H460 0.0 Brain (Hippocampus) Pool 3.6 Lung ca. HOP-62 0.0 Cerebral Cortex Pool 65 Lung ca. NCI-H522 0.2 Brain (Substantia nigra) Pool 4.6 Liver 0.1 Brain (Thalamus) Pool 6.0 Fetal Liver 1.9 Brain (whole) 13.0 Liver ca. HepG2 0. Spinal Cord Pool 1.2 Kidney Pool 0.8 Adrenal Gland 2.0 Fetal Kidney_ 16.6 Pituitarygland Pool 0.5 Renal ca. 786-0 100.0 Salivary Gland 0.1 Renal ca. A498 3.6 Thyroid (female) 0.2 Renal ca. ACHN .1 Pancreatic ca. CAPAN2 I Renal ca. UO-31 10 Pancreas Pool 4 Table BD. Panel 3D Column A - Rel. Exp.(%) Ag1216, Run 182098855 Tissue Name A Tissue Name Daoy- Medulloblastoma 0.9 Ca Ski- Cervical epidermoid carcinoma.0 (metastasis) TE671- Medulloblastoma 0.0 ES-2- Ovarian clear cell carcinoma 0.0 D283 Med- Medulloblastoma 2.8 Ramos- Stimulated with PMA/ionomycin 6h 0.0 PFSK-1- Primitive Neuroectodermal 0.9 Ramos- Stimulated with PMA/ionomycin 14h 0.0 XF-498- CNS 0.0 MEG-0 1- Chronic myelogenous leukemia 00 (megokaryoblast) SNB-78- Glioma3 .7 Raji- Burkitt's lymphoma 1.4 SF-268- Glioblastoma 0.0 Daudi- Burkitt's lymphoma 0.0 T98G- Glioblastoma 0.0 U266- B-cell plasmacytoma . 0.0 SK-N-SH- Neuroblastoma (metastasis) 2.7 CA46- Burkitt's lymphoma .0 SF-295- Glioblastoma 0.0 RL- non-Hodgkin's B-cell lymphoma 0.0 Cerebellum 1.3 JM -pre-B-cell lymphoma 0.0 Cerebellum 5.0 Jurkat- T cell leukemia 0.0 314 WO 2004/000997 PCT/US2003/017512 NCI-H292- Mucoepidermoid lung 1.7 TF-I1- Erythroleukemia 0.0 carcinoma DMS-114- Small cell lung cancer 0.8 HUT 78- T-cell lymphoma 0.0 DMS-79- Small cell lung cancer 1 00.0 U937- Histiocytic lymphoma . 0.0 NCI-H146- Small cell lung cancer 3.3 KU-812- Myelogenous leukemia 0.0 NCI-H526- Small cell lung cancer 0.0 769-P- Clear cell renal carcinoma 1.9 NCI-N417- Small cell lung cancer 0.0 Caki-2- Clear cell renal carcinoma 2.1 NCI-H82- Small cell lung cancer 3.6 SW 839- Clear cell renal carcinoma 8.8 NCI-H157- Squamous cell lung cancer 0.0 Rhabdoid kidney tumor 0.2 (metastasis) NCI-HI 155- Large cell lung cancer 0.0 Hs766T- Pancreatic carcinoma (LN metastasis) 0.0 NCI-H1299- Large cell lung cancer 0.0 CAPAN-1- Pancreatic adenocarcinoma (liver 0.0 NCI-H1299- Large cell lung cancer 0.0 meats)00 metastasis) SU86.86- Pancreatic carcinoma (liver NCI-H727- Lung carcinoid 0.0 metastasis) 2.8 NCI-UMC-11- Lung carcinoid 0.0 BxPC-3- Pancreatic adenocarcinoma 0.0 LX-1- Small cell lung cancer 0.0 HPAC- Pancreatic adenocarcinoma 0.0 Colo-205- Colon cancer 0.0 MIA PaCa-2- Pancreatic carcinoma 0.0 KM1l2- Colon cancer 0.0 CFPAC-1- Pancreatic ductal adenocarcino0ma 0.0 KM22- Colon cancer 0.0 PANC-1- Pancreatic epithelioid ductal KM20L2- Colon cancer 0.0 1.7,~ cm m carcinoma NCI-H716- Colon cancer 0.0 T24- Bladder carcinma (transitional cell) 0.0 SW-48- Colon adenocarcinoma 0.0 5637- Bladder carcinoma 2.0 SWi 116- Colon adenocarcinoma 0.0 .HT-1197- Bladder carcinoma .0.0 LS 174T- Colon adenocarcinoma 0.0 IUM-UC-3- Bladder carcinma (transitional cell) 0.6 SW-948- Colon adenocarcinoma 0.0 A204- Rhabdomyosarcoma 0.0 SW-480- Colon adenocarcinoma 0.0 HT-1080- Fibrosarcoma 0.0 NCI-SNU-5- Gastric carcinoma 0.0 MG-63- Osteosarcoma 0.0 KATO III- Gastric carcinoma 0.0 SK-LMS-1- Leiomyosarcoma (vulva) 0.

0 .CI-SN.U-16- Gastric carcinoma 00 SJRH30- Rhabdomyosarcoma (met to bone 0.0 NCI-SNU-16- Gastric carcinoma 0.0 0.0row marrow) NCI-SNU-1- Gastric carcinoma 0.0 A431- Epidermoid carcinoma .. 0.0 RF-1- Gastric adenocarcinoma 0.0 WM266-4- Melanoma 0.0 RF-48- Gastric adenocarcinoma 0.3 DU 145- Prostate carcinoma (brain metastasis) 0.0 MKN-45- Gastric carcinoma 0.0 MDA-MB-468- Breast adenocarcinoma 0.8 NCI-N87- Gastric carcinoma 0.6 SCC-4- Squamous cell carcinoma of tongue 0. .0 OVCAR-5- Ovarian carcinoma 0.0 SCC-9- Squamous cell carcinoma of tongue 0.8 RL95-2- Uterine carcinoma 0O.0 SCC-15- Squamous cell carcinoma of tongue 0.0 HelaS3- Cervical adenocarcinoma 0.0 CAL 27- Squamous cell carcinoma of tongue 0.0 315 WO 2004/000997 PCT/US2003/017512 Table BE. Panel 4D Column A - Rel. Exp.(%) Ag1216, Run 140426332 Column B - Rel. Exp.(%) Ag1216, Run 144134834 Tissue Name A B Tissue Name A Secondary Thl act 0.0 0.0 HUVEC IL-lbeta 0.0 1.3 Secondary Th2 act 0.0 0.0 HUVEC IFN gamma 0.0 0.0 Secondary Trl act 0.0 0.0 HUVEC TNF alpha + IFN gamma 0.0 0.0 Secondary Thl rest 0.0 O0HUVEC TNF alpha + IL4 0.0 0.0 Secondary Th2 rest 0.0 0.0 HUVEC IL-11 0.9 0.0 Secondary Trl rest 0.0 .0 Lung Microvascular EC none 0.0 0.0 Primary ThIl act 0.00.0 Lung Microvascular EC TNFalpha + 0.0 0.0 IL-lbeta Primary Th2 act 0.0 0.0 Microvascular Dermal EC none 0.0 0.0 Primary Trl act 0.0 .0Microsvasular Dermal EC TNFalpha + 0.0 0.0 IL-lbeta Primary Thl rest O.o 0.0 Bronchial epithelium TNFalpha + ILlbeta 2.3 31.9 Primary Th2 rest 1.10.0Small airway epithelium none 1.8 .0 Primary Trl rest 0.00.9 Small airway epithelium TNFalpha + 2.7 2.5 IL-lbeta CD45RA CD4 lymphocyte act 0.00.0 Coronery artery SMC rest 0.0 0.0 CD45RO CD4 lymphocyte act 0.8 0.0 Coronery artery SMC TNFalpha + 0.0 0.0 IL-Ibeta __ o CD8 lymphocyte act O 0.0 Astrocytes rest 2.8 63 Secondary CD8 lymphocyte rest 0.0 1.3 Astrocytes TNFalpha + IL-lbeta 5. 13.5 Secondary CD8 lymphocyte act 0.0 0.0 KU-812 (Basophil) rest 0.0 0.0 CD4 lymphocyte none 0.0 0.9 KU-812 (Basophil) PMA/ionomycin 0.0 0.0 2 ry Thl/Th2/Trl ani-CD95 CH1 .0 0.0 CCD1106 (Keratinocytes) none 1.4 0.0 LAK cells rest 0.0 0.0 CCD1106 (Keratinocytes) TNFalpha + 0.0 4.1 IL-ibeta LAK cells IL-2 0.0 Liver cirrhosis 1.9 2.3 LAK cells IL-2+IL-12 0.0 1.9 Lupus kidney 5.9 10.3 LAK cells IL-2+IFN gamma 1.1 0.0 NCI-H292 none 1.6 0.0 LAK cells IL-2+ IL-18 0.0 0.0 NCI-H292 IL-4 0.7 0.0 LAK cells PMA/ionomycin 0.00.0 NCI-H292 IL-9 0.0 2.8 NK Cells IL-2 rest 0.0 0.0 NC1-H11292 IL-13 0.0 0.0 Two Way MLR 3 day 0.0 0.0 NCI-H292 IFN gamma 0.0 0.0 Two Way MLR 5 day 0 I 0.0 HPAEC none 0.0 0.0 Two Way MLR 7 day 0.0 0.0 HPAEC TNF alpha + IL-1 beta 0.0 0.0 PBMC rest 0.0 0.0 Lung fibroblast none 0.0 0.0 PBMC PWM 2.8 2.5 Lung fibroblast TNF alpha + IL-1 beta o.0 0.0 PBMC PHA-L 0.0 3.1 Lung fibroblast IL-4 0.0 0.0 Ramos (B13 cell) none 0.0 0.0 Lung fibroblast IL-900 0.0 Ramos (B cell) ionomycin 0.0 0.0 Lung fibroblast IL-13 0.0 0.0 316 WO 2004/000997 PCT/US2003/017512 B lymphocytes PWM 0.0 0.0 Lung fibroblast IFN gamma 0.0 0.0 B lymphocytes CD40L and IL-4 1.1 0.0 Dermal fibroblast CCD 1070 rest 0.0 0.0 EOL-1 dbAMP .00.0 00 Dermal fibroblast CCD1070 TNF alpha 0.0 0.0 EOL-1 dbcAMP PMA/ionomycin 0.0 0.0 Dermal fibroblast CCD1070 IL-1 beta 0.0 0.0 Dendritic cells none 0.0 10.0 Dermal fibroblast IFN gamma 0.0 0.0 Dendritic cells LPS 0.0 0.0 Dermal fibroblast IL-4 0.0 1.5 Dendritic cells anti-CD40 0.0 i0.0 IBD Colitis 2 0.0 1.2 Monocytes rest 0.0 0.0 IBD Crohn's 1.4 4.0 Monocytes LPS 0.0 0.0 Colon 3.4 2.7 Macrophages rest 0.0 0.0 Lung 52.1 42.3 Macrophages LPS 0.8 0.0 Thymus 100.0 1i00.0 HUVEC none 0.0 0.0 Kidney 1.6 0.0 HUTVEC starved 0.0 0.0 Table BF. Panel 5 Islet Column A - Rel. Exp.(%) Ag1216, Run 237228676 Tissue Name A Tissue Name A 97457 Patient-02go adipose 41.8 94709 Donor 2 AM - A adipose 0.0 97476 Patient-07skskeletal muscle 36.3 94710_Donor 2 AM - B adipose 0.0 97477 Patient-07ut uterus 34.9 94711_Donor 2 AM - C_adipose 0.0 97478 Patient-07pl_placenta 100.0 94712 Donor 2 AD - Aadipose 99167 Bayer Patient 1 0.0 94713 Donor 2 AD - Badipose 0.0 97482_Patient-08ut uterus 23.5 94714_Donor 2 AD - C adipose 0.0 97483 Patient-08plplacenta 31 94742_Donor 3 U - AMesenchymal Stem 0.0 943Pin-_ placn Cells 94743_Donor 3 U - B Mesenchymal Stem 97486_ Patient-09sk skeletal muscle 9.1 94743Donor 3 U - BMesenchymal Stem 0.0 Cells 97487 Patient-09ut uterus 81.2 94730_Donor 3 AM - A adipose 0.0 97488 Patient-09pl_placenta 26.6 94731 Donor 3 AM - B adipose 0.0 97492 Patient-10ut uterus 75.3 94732 Donor 3 AM - C_adipose 0.0 97493 Patient-10plplacenta 50.0 94733 Donor 3 AD - Aadipose 0.0 97495 Patient-l go_adipose 57. 94734 Donor 3 AD - B adipose 0.0 97496 Patient-1lsk skeletal muscle 34.2 94735 Donor 3 AD - Cadipose 0.0 97497 Patient- 11lut uterus 89.5 77138 Liver _HepG2untreated 0.0 97498Patient-lplplacenta 177.9 73556_Heart Cardiac stromal cells 97498_Patient-11lpl__placenta 77.9 m 0.0 __ (primary) 97500 Patient-12go_adipose 70.7 81735 Small Intestine 2 9

.

3 72409 Kidney Proximal Convoluted 97501 Patient-12sk skeletal muscle 43. 72409 KidneyProximal Convoluted 0.0 I Tubule 97502_Patient-12ututerus 97.3 82685_Small intestineDuodenum 6.9 97503 Patient-12pl_placenta 24.5 90650 Adrenal Adrenocortical adenoma 17.7 317 WO 2004/000997 PCT/US2003/017512 94721 Donor 2 U - AMesenchymal 0.0 72410 Kidney HRCE 5.5 Stem Cells -_KdeHRE5 94722 Donor 2 U - B Mesenchymal Stem 0.

0 72411 Kidney HRE 4.9 Cells 94723_Donor 2 U - CMesenchymal Stem 0.0 73139 Uterus Uterine smooth muscle cells 0.0 Cells

I

Table BG. general oncology screening panel v 2.4 Column A - Rel. Exp.(%) Agl216 Run 259733296 Tissue Name A Tissue Name A Colon cancer 1 0.9 Bladder cancer NAT 2 0.1 Colon cancer NAT 1 0.5 Bladder cancer NAT 3 0.0 Colon cancer 2 0.2 Bladder cancer NAT 4 0.6 Colon cancer NAT 2 0.3 Prostate adenocarcinoma 1 0.9 Colon cancer 3 0.7 Prostate adenocarcinoma 2 0.1 Colon cancer NAT 3 0.4 Prostate adenocarcinoma 3 0.1 Colon malignant cancer 4 1.3 Prostate adenocarcinoma 4 0.5 Colon normal adjacent tissue 4 0.2 Prostate cancer NAT 5 10.2 Lung cancer 1 _ _10.7 Prostate adenocarcinoma 6 0.1 Lung NAT 1 0.1 Prostate adenocarcinoma 7 0.0 Lung cancer 2 10.8 Prostate adenocarcinoma 8 0.1 Lung NAT 2 0.1 Prostate adenocarcinoma 9 Squamous cell carcinoma 3 2.0 Prostate cancer NAT 10 0.1 Lung NAT 3 0.0 Kidney cancer 1 77.9 metastatic melanoma I 1.4 .KidneyNAT 1 5.7 Melanoma 2 0.0 Kidney cancer 2 100.0 Melanoma 3 0.5 Kidney NAT 2 3.4 metastatic melanoma 4 2.7 Kidney cancer 3 46.0 metastatic melanoma 5 8.0 Kidney NAT 3 2.4 Bladder cancer 1 0.2 Kidney cancer 4 85.3 Bladder cancer NAT 1 0.0 KidneyNAT 4 1.2 Bladder cancer 2 0.3 5 Alcomprehensive panel vl.0 Summary: Agl216 Highest expression of the CG106951-01 and CG106951-04 genes was detected in a sample orthoarthritis bone (CT=31.2). Moderate to low levels of expression of these genes were detected in samples derived from normal and orthoarthitis/ rheumatoid arthritis bone, cartilage, synovium and synovial fluid samples, as well as in normal lung, COPD lung, emphysema, atopic asthma, 10 asthma, allergy, Crohn's disease (normal matched control and diseased), ulcerative colitis 318 WO 2004/000997 PCT/US2003/017512 (normal matched control and diseased), and psoriasis (normal matched control and diseased). Therapeutic modulation of the activity of these genes or their protein products will ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid 5 arthritis and osteoarthritis. General screening_panel vl.4 Summary: Agl216 Highest expression of these genes was detected in renal cancer cell line 786-0 (CT=26.4). High to moderate expression of these genes was also seen in number of cancer cell lines derived from ovarian, breast, brain and kidney cancers. Therapeutic modulation of the activity of these genes or their 10 protein products is useful in the treatment of these cancers. Among tissues with metabolic or endocrine function, these genes were expressed at moderate to low levels in pancreas, adipose, adrenal gland, pituitary gland, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therapeutic modulation of the activity of these genes or their protein products is useful in the treatment of 15 endocrine/metabolically related diseases, such as obesity and diabetes. In addition, these genes were expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of the activity of these genes or their protein products is useful in the treatment of central 20 nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. The CGI 06951-01 and CG1 06951-04 genes were also expressed at higher levels in fetal (CTs=29-32) liver, lung, heart, kidney and skeletal muscle when compared to adult tissues (CTs=33-37). The relative overexpression of these genes in fetal tissue suggests 25 that the expressed proteins may enhance growth or development of these tissues in the fetus and thus may also act in a regenerative capacity in the adult. Therapeutic modulation of the activity of these genes or their protein products is useful in treatment of liver, lung, kidney, heart and skeletal muscle related diseases. 319 WO 2004/000997 PCT/US2003/017512 Panel 3D Summary: Ag1216 Moderate expression of these genes were detected mainly in a lung cancer DMS-79 cell line (CT=30.4). Therapeutic modulation of the activity of these genes or their protein products is useful in the treatment of lung cancer. Panel 4D Summary: Agl216 Highest expression of these genes was detected in thymus 5 (CTs=31-32). These genes also show low expression in normal lung as well as in astrocytes and bronchial epithelium treated with TNF-cc and IL-113. Therapeutic modulation of the activity of these genes or their protein products is useful in the treatment of inflammatory diseases including asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis. 10 Panel 5 Islet Summary: Ag1216 Highest expression of these genes were detected in placenta (CT=34). Low expression of these genes was also seen in adipose and uterus. Please see panel 1.4 for further discussion of these genes. General oncology screening panel v 2.4 Summary: Agl216 Highest expression of these genes was detected in a kidney cancer sample (CT=27). Expression of these genes 15 was higher in 4/4 kidney cancer, 3/3 colon cancer, and 3/3 lung cancer samples relative to corresponding normal adjacent tissue. In addition, significant expression of these genes was also seen in metastatic melanoma and prostate cancers. Gene or protein expression levels are useful as a marker to detect the presence of these cancers. Therapeutic modulation of the activity of these genes or their protein products using nucleic acid, 20 protein, antibody or small molecule drugs is useful in the treatment of kidney, lung, colon, metastatic melanoma and prostate cancers. C. CG124756-01: Complement component 1, q subcomponent, beta polypeptide. Expression of gene CG124756-01 was assessed using the primer-probe set 25 Ag4901, described in Table CA. Results of the RTQ-PCR runs are shown in Tables CB and CC. 320 WO 2004/000997 PCT/US2003/017512 Table CA. Probe Name Ag4901 ... .Start SEQ ID Primers SequencesLength Position No Forward 5-ccacgtgatcaccaacatg-3 19 503 289 Probe TET-5'-aacaacaattatgagccccgcagtg-3'-TAMRA 25 522 290 5Reverse s -tggcgtggtaggtgaagtagta-3' 22 576 29 Table CB. CNS neurodegeneration vl.0 5 Column A - Rel. Exp.(%) Ag4901, Run 224996029 Tissue Name A Tissue Name A AD I Hippo 7.9 Control (Path) 3 Temporal Ctx 10.2 AD 2 Hippo [72.7 Control (Path) 4 Temporal Ctx 17.4 AD 3 Hippo 39.0 AD 1 Occipital Ctx 39.8 AD 4 Hippo 123.3 AD 2 Occipital Ctx (Missing) 0.4 'A D 5 i p po_.................... ... . .. -A D 3 O c c ip it a l , 1 3 .2 AD 6 Hippo 7.6 AD 4 Occipital Ctx 18.6 Control 2 Hippo 63.3 AD 5 Occipital Ctx 39.8 Control 4 Hippo 65.5 AD 6 Occipital Ctx 20.2 Control (Path) 3 Hippo 23.8 Control 1 Occipital Ctx 7.1 AD 1 Temporal Ctx 62.9 Control 2 Occipital Ctx 21.9 AD 2 Temporal Ctx 43.8 Control 3 Occipital Ctx 24.7 AD 3 Temporal Ctx 25.9 Control 4 Occipital Ctx 27.5 AD 4 Temporal Ctx 33.0 Control (Path) 1 Occipital Ctx 11.0 AD 5 Inf Temporal Ctx 30 8 Control (Path) 2 Occipital Ctx 11.7 AD 5 Sup Temporal Ctx 71.7 Control (Path) 3 Occipital Ctx 0.9 AD 6 Inf Temporal Ctx 100.0 Control (Path)4 Occipital Ctx 15.8 AD 6 Sup Temporal Ctx 79.6 Control 1 Panrietal Ctx 26.8 Control 1 Temporal Ctx 22.8 Control 2 Parietal Ctx 38.4 Control 2 Temporal Ctx 53.2 Control 3 Parietal Ctx 27.7 Control 3 Temporal Ctx 49.3 Control (Path) 1 Parietal Ctx 12.5 Control 3 Temporal Ctx 160 Control (Path) 2 Parietal Ctx 14.0 Control (Path) 1 Temporal Ctx 18.3 Control (Path) 3 Parietal Ctx 3.0 Control (Path) 2 Temporal Ctx 21.8 Control (Path) 4 Parietal Ctx 19.9 321 WO 2004/000997 PCT/US2003/017512 Table CC. General screening panel v1.6 Column A - Rel. Exp.(%) Ag4901, Run 277231336 Tissue Name A ITissue Name A Adipose 35.8 Renal ca. TK-10 0.0 Melanoma* Hs688(A).T 0.0 Bladder 100.0 Melanoma* Hs688(B).T 0.0 Gastric ca. (liver met.) NCI-N87 0.0 Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* LOXIMVI 0.0 Colon ca. SW-948 0.0 Melanoma* SK-MEL-5 0.0 Colon ca. SW480 0.0 Squamous cell carcinoma SCC-4 0.0 Colon ca.* (SW480 met) SW620 0.0 Testis Pool 9.9 Colon ca. HT29 0.0 Prostate ca.* (bone met) PC-3 0.0 Colon ca. HCT-1 16 0.0 Prostate Pool 11.5 Colon ca. CaCo-2 0.0 Uterus Pool 1.0 Colon ca. SW1 116 0.0 Ovarian ca. OVCAR-3 0.0 Colon ca. Colo-205 0.2 Ovarian 7v ca. SK-OV-3 0.0 Colon ca. SW-48 0.0 Ovarian ca. OVCAR-4 0.0 Colon Pool 11.6 Ovarian c7a. OVCAR-5 0.0 Small Intestine Pool 6.8 Ovarian ca. IGROV-1 0.0 Stomach Pool 14.8 Ovarian ca. OVCAR-8 0.0 Bone Marrow Pool 12.7 Ovary .21.6 Fetal Heart 1.9 Breast ca. MCF-7 0.0 Heart Pool 5.1 Breast ca. MDA-MB-231 0.0 Lymph Node Pool - 11.1 Breast ca. BT 549 0.0 Fetal Skeletal Muscle 7.3 Breast ca. T47D 0.0 Skeletal Muscle Pool 2.0 Breast ca. MDA-N o0.0 Spleen Pool 27.2 Breast Pool 8.0 Thymus Pool 13.2 Trachea 19.8 CNS cancer (glio/astro) U87-MG 0.0 Lung 2.3 CNS cancer (glio/astro) U-118-MG 0.1 Fetal Lung 13.9 CNS cancer (neuro;met) SK-N-AS 0.0 Lung ca. NCI-N417 0.0 CNS cancer (astro) SF-539 10.0 Lung ca. LX-1 0.0 CNS cancer (astro) SNB-75 0.0 Lung ca. NCI-H146 0.0 CNS cancer (glio) SNB-19 0.0 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.

0 Lung ca A549 0.0 Brain (Amygdala) Pool 7.8 Lung ca. NCI-H526 0.0 Brain (cerebellum) 26.8 L ung ca. NCI-H23 0.0 Brain (fetal) 8.1 Lung ca. NCI-H460 0.0 Brain (Hippocampus) Pool 13.2 Lung ca. HOP-62 0.0 ICerebral Cortex Pool 18.2 Lung ca. NCI-1-1522 i Brain (Substantia nigra) Pool 8.4 322 WO 2004/000997 PCT/US2003/017512 Liver 18.4 Brain (Thalamus) Pool 8.3 Fetal Liver 55.9 Brain (whole) 22.4 Liver ca. HepG2 0.0 Spinal Cord Pool 18.3 Kidney Pool 14.1 Adrenal Gland 55.1 Fetal Kidney 4.7 Pituitary gland Pool 3.9 Renal ca. 786-0 0.0 Salivary Gland .5.8 Renal ca. A498 0.0 Thyroid (female) 6.8 Renal ca. ACHN 0.0 Pancreatic ca. CAPAN2 0.0 [Renal ca. UO-31 0 Pancreas Pool 6.9 CNSneurodegeneration_vl.0 Summary: Ag4901 Expression of the CG124756-01 gene was upregulated in the temporal cortex of Alzheimer's disease patients compared to normal patients. Inhibition of this gene or its protein product is useful in the treatment of 5 Alzheimer's disease and can decrease neuronal death. Generalscreening_panelvl.6 Summary: Ag4901 The highest expression of this gene was detected in bladder (CT=26). In addition, this gene was expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of the activity of this gene or 10 its protein product is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. This gene was also expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Thereapeutic modulation of the activity of 15 this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. High expression of this gene was also seen in a colon cancer cell line. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of 20 colon cancer. D. CG50353-01: 129293352_EXT, Wnt 7a like protein. Expression of gene CG50353-01 was assessed using the primer-probe set Ag3093, described in Table DA. Results of the RTQ-PCR runs are shown in Tables DB and DC. 323 WO 2004/000997 PCT/US2003/017512 Table DA. Probe Name Ag3093 Primers Sequences Length Start SEQ ID Primers Sequences Length Position No Forward s' -ctgtgacctcatgtgctgtg-3' 20 909 292 Probe TET5 _gtggctacaacacccaccagtacgc-3' -TAMRA 25 932 . 293 ReverseS5' -acatagcagcaccagtggaa-3' 20 982294 Table DB. Panel 1.3D 5 Column A - Rel. Exp.(%) Ag3O93, Run 167985246 Tissue Name A issue Name Liver adenocarcinoma .8 Kidney (fetal) 0.1 Pancreas 0.0 Renal ca. 786-0 02 Pancreatic ca. CAPAN 2 1.7 Renal ca. A498 0.0 Adrenal gland 0.0 Renal ca. RXF 393 0.4 Thyroid 0.0 Renal ca. ACHN 0.0 Salivary gland 0.0 Renal ca. UO-31 0.5 Pituitary gland 10.0 Renal ca. TK-10 0.0 Brain (fetal) 3.6 Liver 0.0 Brain (whole) 1.5 Liver (fetal) 0.0 Brain (amygdala) 1 8 Liver ca. (hepatoblast) HepG2 0.0 Brain (cerebellum) 0.9 Lung 0.2 Brain (hippocampus) 1.4 Lung (fetal) 0.9 Brain (substantia nigra) 0.9 Lung ca. (small cell) LX-1 0.0 Brain (thalamus) 0.0 Lung ca. (small cell) NCI-H69 0.2 Cerebral Cortex 5 Lung ca. (s.cell var.) SHP-77 0.0 Spinalcord 0.6 Lung ca. (large cell)NCI-H460 0.0 glio/astro U87-MG 0.6 Lung ca. (non-sm. cell) A549 0.2 glio/astro U-118-MG 0.0 Lung ca. (non-s.cell) NCI-H23 0.0 astrocytoma SW1783 0.0 Lung ca. (non-s.cell) HOP-62 0.0 neuro*; met SK-N-AS 00 Lung ca. (non-s.cl) NCI-H522 0.0 astrocytoma SF-539 0.2 Lung ca. (squam.) SW 900 0.0 astrocytoma SNB-75 0.1 Lung ca. (squam.) NCI-H596 0.3 glioma SNB-19 0.0 Mammary gland 0.0 glioma U251 Breast ca.* (pl.ef) MCF-7 0.2 glioma SF-295 0.0 Breast ca.* (pl.ef) MDA-MB-231 0.0 Heart (fetal) 0.0 Breast ca.* (pl.ef) T47D 0.0 Heart 0.0 Breast ca. BT-549 0.0 Skeletal muscle (fetal) 0.0 Breast ca. MDA-N 0. Skeletal muscle 0.0 Ovary 0.0 Bone marrow 0.0 Ovarian ca. OVCAR-3 0.1 324 WO 2004/000997 PCT/US2003/017512 Thymus 0.0 Ovarian ca. OVCAR-4 37.1 Spleen 0.3 Ovarian ca. OVCAR-5 0.7 Lymph node 0.0 Ovarian ca. OVCAR-8 0.0 Colorectal 0.0 Ovarian ca. IGROV-1 6.8 Stomach 0.0 Ovarian ca.* (ascites) SK-OV-3 100.0 Small intestine .0 Uterus 0.0 Colon ca. SW480 0.4 Placenta 0.0 Colon ca.* SW620(SW480 met) 1.4 Prostate 0.0 Colon ca. HT29 0.0 Prostate ca.* (bone met)PC-3 2.0 Colon ca. HCT-1 16 0.0 Testis 0.3 SColon ca. CaCo-2 0.2 Melanoma Hs688(A).T 0.0 Colon ca. tissue(ODO3866) 0.0 Melanoma* (met) Hs688(B).T 0.0 Colon ca. HCC-2998 0.1 Melanoma UACC-62 0.0 Gastric ca.* (liver met) NCI-N87 0.5 Melanoma M14 0.0 Bladder 0.0 Melanoma LOX IMVI 0.0 Trachea 0.1 Melanoma* (met) SK-MEL-5 .0 Kidney Adipose 0 Table DC. Panel 4D Column A - Rel. Exp.(%) Ag3093, Run 164392077 Tissue Name A Tissue Name A Secondary Thil act 0.0 HUVEC IL-lbeta 0.0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Trl act 0.0 HUVEC TNF alpha + IFN gamma 0.01 Secondary Thl rest 0.0HUVEC TNF alpha + ILT4 0.0 Secondary Th2 rest 0.0 HUVEC IL-1 1 0.0 Secondary Trl rest 0.0 Lung Microvascular EC none 0.0 Primary Th1 act 0.0 Lung Microvascular EC TNFalpha + IL-lbeta 0.0 Primary Th2 act 0.0 Microvascular Dermal EC none 0.0 Primary Trl act 00 Microsvasular Dermal EC TNFalpha + IL-lbeta 0.0 Primary Thl rest 0.0 Bronchial epithelium TNFalpha + ILlbeta 57.4 Primary Th2 rest 0.0 Small airway epithelium none 17.7 Primary Trl rest 0.0 Small airway epithelium TNFalpha + IL-1beta 100.0 CD45RA CD4 lymphocyte act 0Coronery artery SMC rest0.0 CD45RO CD4 lymphocyte act 0.0 Coronery artery SMC TNFalpha + IL-lbeta 0.0 CD8 lymphocyte act 0.0 Astrocytes rest .0 Secondary CD8 lymphocyte rest 0.0 Astrocytes TNFalpha + IL-lbeta 0.0 Secondary CD8 lymphocyte act 0.0KU-812 (Basophil) rest 0.0 CD4 lymphocyte none 4.9 KU-812 (Basophil) PMA/ionomycin 1.2 2 ry Thl/Th2/Trl anti-CD95 CH11 0.0 CCD1106 (Keratinocytes) none 47.6 LAK cells rest 0.0 CCD1106 (Keratinocytes) TNFalpha + IL-lbeta 33.7 LAK cells IL-2 00 Liver cirrhosis 1.4 325 WO 2004/000997 PCT/US2003/017512 LAK cells IL-2+1L-12 0.0 [Lupus kidney 0.0 LAK cells IL-2+IFN gamma 0.0 NCI-H292 none 4.1 LAK cells IL-2+ IL-18 0.0 NCI-H292 IL-4 4.8 LAK cells PMA/ionomycin 0.0 NCI-H292 IL-9 1. NK Cells IL-2 rest 0.0 NCI-H292 IL-13 2.5 Two Way MLR 3 day O.0 NCI-H292 IFN gamma 1.6 Two Way MLR 5 day 0.0 HPAEC none 0.0 Two Way MLR 7 day 00 HPAEC TNF alpha + IL-1 beta 0.0 PBMC rest 35 Lung fibroblast none 0.0 PBMC PWM 0.8 Lung fibroblast TNF alpha + IL-1 beta 0.0 PBMC PHA-L 0.0 Lung fibroblast1-4 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) ionomycin 0.0 Lung fibroblast IL-13 0.0 B lymphocytes PWM 0.0 Lung fibroblast IFN gamma 0.0 B lymphocytes CD40L and IL-4 0.0 Dermal fibroblast CCDI1070 rest 0.0 EOL-1 dbcAMP 0.0 Dermal fibroblast CCD1070 TNF alpha0.0 EOL-1 dbcAMP PMA/ionomycin 0.0 Dermal fibroblast CCD1070 IL-1 beta 0.0 Dendritic cells none 0.0 Dermal fibroblast IFN gamma 0.0 Dendritic cells LPS 0.0 Dermal fibroblast IL-4 0.0 Dendritic cells anti-CD40 0.0 IBD Colitis 2 0.0 Monocytes rest 0.0 IBD Crohn's 0.0 Monocytes LPS 0.0 Colon 1.0 Macrophages rest 0.0 Lung . Macrophages LPS 0.0Thymus 0.0 HUVEC none 0.0 Kidney 0.0 JHUVEC starved 0.0 Panel 1.3D1) Summary: Ag3093 Highest expression of the CG50353-01 gene was detected in the SK-OV-3 ovarian cancer cell line derived from ascites fluid (CT=30.28). This gene was also expressed in two additional ovarian cancer cell lines. Gene or protein 5 expression levels are useful as a marker for ovarian cancer or for ascites. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of ovarian cancer. Panel 4D Summary: This gene was expressed at the highest level in TNF alpha + IL-1 beta-treated small airway epithelial cells (CT=32.6) and bronchial epithelial cells as well 10 as in CCD1106 keratinocytes, independent of treatment. Expression of this gene in keratinocytes suggests that it is important in skin disorders including psoriasis. Expression of this gene in airway/bronchial cell types suggests that this gene also plays a role in 326 WO 2004/000997 PCT/US2003/017512 inflammatory lung disorders, including, for example, chronic obstructive pulmonary disease (COPD), asthma, allergy and emphysema. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of skin disorders, such as psoriasis, and inflammatory lung disorders, including COPD, asthma, allergy and 5 emphysema. E. CG50709-03 and CG50709-05: WNT14B Expression of genes CG50709-03 and CG50709-05 was assessed using the primer-probe sets Ag2262, and Ag2316, described in Tables EA, and EB. Results of the RTQ-PCR runs are shown in Tables EC, ED, EE, and EF. 10 Table EA. Probe Name Ag2262 S..Start SEQUI Primers Sequences Length Position SEQNo Forward 5'-gacctggtgtacatggagga-3 20 _ 875 295 Probe TET-5'-cttctgccggcccagcaagtact-3 '-TAMRA23 904 296 Reverse 5' -gagcacaccctacctgctg-3' t:19. 936 297 Table EB. Probe Name A2316 PrimersSequences L Start SEQ ID Primers Sequences Length Position No Forward 5'-gtccaagagaggaaacaagga-3 21 71 298 Probe jTET-5 -cacaatacccacgtgggcatcaag- 3 ' -TAMRA 24 1614 299 Reverse 5'-gtcctgaggccactcttcac-3' 20 641 300 15 Table EC. Ardais Kidney 1.0 Column A - el. Exp.(%) Ag2262, Run 369787102 Tissue Name A Tissue Name A Kidney cancer( 10A8) T0.0 Kidney cancer(10C6) 0.0 Kidney NAT(10A9) 1.1 Kidney cancer(10C9) 0.0 Kidney cancer(1OAA) 18.9 Kidney cancer(1 0D I) 4.0 Kidney NAT(10AB) 15.3 Kidney cancer(10CA) 1.9 Kidney cancer(10AC) 2.2 Kidney cancer(10D2) 2.2 Kidney NAT(10AD) .100.0 Kidney cancer(10CB) 1.0 Kidney cancer(10B6)... 1.8 Kidney cancer(10D4) 1.8 Kidney NAT(10B7) 4.5 Kidney cancer(10CD) 1.5 327 WO 2004/000997 PCT/US2003/017512 Kidney cancer(10B8) 0.3 Kidney cancer(10D5) 0.0 Kidney NAT(10B9) 4.1 Kidney cancer(10CE) 2.6 Kidney cancer(10BC) 5.1 Kidney cancer(10D6) 1.0 Kidney NAT(10BD) 54.7 Kidney cancer(10CF) 1.2 Kidney cancer(1iO0BE) 0.2 Kidney cancer(10D8) 1.1 Kidney NAT(10BF) 32.3 Kidney cancer(10CC) 1.2 Kidney cancer(10C2) 0.1 Kidney cancer(10D3) 4.2 Kidney NAT(10C3) 1i1.7 Kidney NAT(10D9) 15.2 Kidney cancer(10C4) 0.0 KidneyNAT(10DB) 19.5 Kidney NAT(10C5) _ 8.2 KidneyNAT(10DC) 8.7 Kidney cancer(10B4) 0.5 Kidney NAT(10DD) 22.1 Kidney cancer(10C8) 11.3 Kidney NAT(10DE) 10.2 Kidney cancer(0DO) 10.9 Kidney NAT(1OB1) . 2.7 Kidney cancer(10CO) 0.3 Kidney NAT(10DA) 19.3 Table ED. Panel 1.3D Column A - Rel. Exp.(%) Ag2262, Run 150719071 Column B - Rel. Exp.(%) Ag2262, Run 167966858 Column C - Rel. Exp.(%) Ag2316, Run 162185396 Tissue Name A B C Tissue Name A B C Liver adenocarcinoma j0.0 6.7 0.0 Kidney (fetal) 24.0 100.0 50.0 Pancreas 0.0 0.0 Renal ca. 786-0 0.0 0.0 0.0 Pancreatic ca. CAPAN 2 10.0 0.0 0.0 Renal ca. A498 0.0 12.6 0.0 Adrenal gland 1.9 0. 0.0 Renal ca. RXF 393 00 00 0.0 Thyroid 2.2 0.0 0.0 Renal ca. ACHN 0.0 0.0 0.0 Salivary gland 0.3 0.0 0.0 Renal ca. UO-31 0.2 0.0 0.0 Pituitary gland 0.0 8.0 0.0 Renal ca. TK-10 0.0 0.0 0.0 Brain (fetal) 0.0 1.0 0.0 Liver 0.0 0.0 0.0 Brain (whole) 5.2 0.0 26.2 Liver (fetal) 0.0 0.0 0.0 Brain (amygdala) 6.8 3.8 11.5 Liver ca. (hepatoblast) HepG2 0.0 0.0 0.0 Brain (cerebellum) 1.0 6.4 0.0 Lung 6.8 0.0 19.3 Brain (hippocampus) 16.5 0.0 . ung (fetal) 8.5 0.0 6.8 Brain (substantia nigra) 2.0 0.0 0.0 Lung ca. (small cell) LX-1 0.0 0.0 0.0 Brain (thalamus) 4.9 11.2 57.:0 Lung ca. (small cell) NCI-H69 10.3 0.0 0.0 ......... .... ... .... ......... .......... ... ... ......... ... .......................... .... ..... . ...... .. . ..... ... .... .. 5 6 Cerebral Cortex 2.5 13.3 3.3 Lung ca. (s.cell var.) SHP-77 2.5 6.9 0.0 Spinal cord 3.3 9.2 6.8 Lung ca. (large cell)NCI-H460 0.0 0.0 0.0 glio/astro U87-MG 0.0 0.0 0.0 Lung ca. (non-sm. cell) A549 0.0 6.4 0.0 glio/astro U-118-MG 0.0 0.0 0.0 Lung ca. (non-s.cell)NCI-H23 0.0 0.0 0.0 astrocytoma SW1783 0.0 0.0 0.0 Lung ca. (non-s.cell) HOP-62 0.0 0.0 0.0 neuro*; met SK-N-AS 0.0 0.0 0.0 Lung ca. (non-s.el) NCI-H522 2.8 0.0 0.0 astrocytoma SF-539 0.0 0.0 10.0 Lung ca. (squam.) SW 900 10.0 0.0 0.0 astrocytoma SNB-75 . 0 0.0 0.0 Lung ca. (squam.) NCI-H596 0.0 0.0 0.0 328 WO 2004/000997 PCT/US2003/017512 glioma SNB-19 0.0 0.0 0.0 Mammary gland 0.0 0.0 0.0 glioma U251 0.0 0.0 0.0 Breast ca.* (pl.ef) MCF-7 0.0 0.0 0.0 glioma SF-25 0.0 0.0 0.0 Breast ca.* (pl.ef) 0.0 0.0 0.0 glioma F-295MDA-MB-231 Heart (fetal) 2.0 0.0 33.4 Breast ca.* (pl.ef) T4 7 D 0.0 0.0 0.0 Heart 0.0 6.7 9.6 Breast ca. BT-549 0.0 0.0 0.0 Skeletal muscle (fetal) 2.5 0.0 8.2 Breast ca. MDA-N 1.0 0.0 0.0 sk-eletal muscle 0.0 0.0 0.0 Ovary 0.0_ 0.0 6.4 Bone marrow 0.9 0.0 0.0 Ovarian ca. OVCAR-3 0.0 0.0 0.0 Thymus [0.0 0.0 0.0 Ovarian ca. OVCAR-4 0.0 0.0 0.0 Spleen 100.0 65.5 100.0 Ovarian ca. OVCAR-5 0.0 0.0 0.0 Lymph node 0.0 0.0 0.0 Ovarian ca. OVCAR-8 0.0 0.0 0.0 Colorectal 10.8 19.8 0.0 ovarian ca. IGROV-1 0.0 0.0 0.0 Stomach 2.7 0.0 0.0 Oaan ca.* (ascites) 0.0 0.0 0.0 Stomach 2.7 0.0 0.0 SK-OV-3 Small intestine 6.4 0.0 0.0 Uterus 0.0 0.0 0.0 Colon ca. SW480 0.0 0.0 0.0 Placenta 0.6 7.1 0.0 ECoon ca.* SW620(SW480 1.2 0.0 0.0 Prostate 0.0 1.8 4.9 met) 12 0 Colon ca. HT29 0.0 0.0 0.0 Prostate ca.* (bone mnet)PC-3 0.0 0.0 0.0 Colon ca. HICT-i 16 0.0 .0.0 0.0 Testis 1.7 0.0 7.2 Colon ca. CaCo-2 2.5 6.6 0.0 Melanoma Hs688(A).T 0.0 0.0 0.0 Colon ca. tissue(ODO3866) 0.0 0.0 0.0 Melanoma* (met) Hs688(B).T 0.0 0.0 0.0 Colon ca. HCC-2998 0.0 0.0 0.0 Melanoma UACC-62 0.0 0.0 0.0 Gastric ca.* (liver met) 0.0 14.7 0.0 Melanoma M14 0.0 0.0 0.0 NCI-N87 I Bladder 0.0 6.5 16.2 Melanoma LOX IMVI 0.0 0.0 0.0 Trachea 5.0 0.0 6.0 Melanoma* (met) SK-MEL-5 0.0 0.0 0.0 Kidney 14.9 7.9 31.0 Adipose [0.0 0.0 7.6 Table EE. Panel 2D Column A - Rel. Exp.(%) Ag2262, Run 150943107 Tissue Name A Tissue Name A Normal Colon 14.2 Kidney Margin 8120608 24.0 ICC Well to Mod Diff(ODO3866) 14.2 Kidney Cancer 8120613 0.0 CC Margin (ODO3866) 0.0 Kidney Margin 8120614 46.3 CC Gr.2 rectosigmoid (ODO3868) 0.0 Kidney Cancer 90103200.0 CC Margin (ODO3868) 0.0 Kidney Margin 9010321 16.5 CC Mod Diff (ODO3920) 0.0 Normal Uterus 16.4 CC Margin (ODO3920) 0.8 Uterus Cancer 064011 0.0 CC Gr.2 ascend colon (0DO3921) 0.0 Normal Thyroid 15.6 CC Margin (OD03921) 0.9 Thyroid Cancer 064010 j. 329 WO 2004/000997 PCT/US2003/017512 CC from Partial Hepatectomy (ODO4309) 0.0 Thyroid Cancer A302152 6.8 Mets Thyroid Cancer A302152 6.8 Liver Margin (ODO4309) 1.1 Thyroid Margin A302153 0.0 Colon mets to lung (OD04451 -01) 7.3 Normal Breast 9.3 Lung Margin (OD04451-02) 0.0 Breast Cancer (0D04566) 0.0 ormal Prostate 6546-1 18.6 Breast Cancer (OD04590-01) 4.8 Prostate Cancer (OD04410) 10.2 Breast Cancer Mets (OD04590-03) 8.5 0 Breast Cancer Metastasis .0 Prostate Margin (OD04410) 0.0 (OD04655-05) . Prostate Cancer (OD04720-01) 0.0 Breast Cancer 064006 7.2 Prostate Margin (OD04720-02) 9.8 Breast Cancer 1024 0.0 Normal Lung 061010 22.5 Breast Cancer 9100266 0.7 Lung Met to Muscle (ODO4286) 6.1 Breast Margin 9100265 0.0 Muscle Margin (ODO4286) 0.0 Breast Cancer A209073 0.0 Lung Malignant Cancer (OD03126) 5.4 _Breast Margin A209073 0.0 Lung Margin (OD03126) 0.0 Normal Liver 0.0 Lung Cancer (0D04404) 7.6 Liver Cancer 064003 0.0 Lung Margin (OD04404) 3.8 Liver Cancer 1025 5.6 Lung Cancer (OD04565) 10.0 Liver Cancer 1026 2.4 Lung Margin (OD04565) 1.0.0 Liver Cancer 6004-T 0.0 Lung Cancer (OD04237-01) 0.0 Liver Tissue 6004-N 8.7 Lung Margin (OD04237-02) 6.9 Liver Cancer 6005-T 0.0 Ocular Mel Met to Liver (ODO43 10) 1.1 Liver Tissue 6005-N 0.0 Liver Margin (0DO43 10) .28.5 .Normal Bladder 0.0 Melanoma Mets to Lung (OD04321) 0.0 Bladder Cancer 1023 0.0 LungMargin (OD04321) 0.0 Bladder Cancer A302173 18.3 Normal Kidney 100.0 Bladder Cancer (OD04718-01) 0.0 Bladder Normal Adjacent Kidney Ca, Nuclear grade 2 (OD04338) 15.2 (OBladder Normal Adjacent471803) 0.0 _____________________________J___ j(0D04718-03) Kidney Margin (OD04338) 40.3 Normal Ovary 0.0 Kidney Ca Nuclear grade 1/2 (OD04339) 0.0 Ovarian Cancer 064008 7.5 Kidney Margin (OD04339) 50.0 Ovarian Cancer (ODO4768-07) 00 Kidney Ca, Clear cell type (OD04340) 0.0 Ovary Margin (OD04768-08) 10.0 Kidney Margin (OD04340) 31.2 Normal Stomach 113.8 Kidney Ca, Nuclear grade 3 (OD04348) 0.0 Gastric Cancer 9060358 0.0 Kidney Margin (OD04348) 29.9 Stomach Margin 9060359 0.0 Kidney Cancer (OD04622-01) .0.0 Gastric Cancer 9060395 0.0 Kidney Margin (OD04622-03) 58.6 Stomach Margin 9060394 0.0 Kidney Cancer (OD04450-01) 10.0 Gastric Cancer 9060397 0.0 Kidney Margin (0D04450-03) 95.9 Stornach Margin 9060396 0.0 Kidney Cancer 8120607 0.0 Gastric Cancer 064005 0.0 330 WO 2004/000997 PCT/US2003/017512 Table EF. Panel 4D Column A - Rel. Exp.(%) Ag2262, Run 150981162 Column B - Rel. Exp.(%) Ag2316, Run 164037437 Tissue Name A B Tissue Name A B Secondary Thl act 0.0 0.0 HUVEC IL-lbeta 0.0 0.0 Secondary Th2 act 0.0 0.0 HUVEC IFN gamma 0.0 0.0 Secondary Trl act 0.0 0.0 HUVEC TNF alpha + IFN gamma 11.6 0.0 Secondary Th rest 0.0 0.0 HUVEC TNF alpha + IL4A 0.0 0.0 Secondary Th2 rest 0.0 0.0 HUVEC IL-11 8.7 0.0 Secondary Trl rest 0.0 0.0 Lung Microvascular EC none 0.0 00 Primary Th act 00 00 Lung Microvascular EC TNFalpha + 0.0 0.0 Primary Th1 act 0 IL-lbeta Primary Th2 act 00 0.0 Microvascular Dermal EC none 0.0 0.0 Primary T act 1.8 Microsvasular Dermal EC TNFalpha + 0.0 0.0 Primary Trl act 1 IL-lbeta Bronchial epithelium TNFalpha + Primary Thl rest ILlbeta 0 0.0 Primary Th2 rest 0.0 0.0 Small airway epithelium none 00 0.0 Small airway epithelium TNFalpha + Primary Trl rest 0.0 0.0 IL-beta 0.0 0.0 CD45RA CD4 lymphocyte act 0 Coronery artery SMC rest 0.0 0.0 CD45RO CD4 lymphocyte act Coronery artery SMC TNFalpha + 0 IL-lbeta CD8 lymphocyte act 0.0 0.0 Astrocytes rest.0 0.0 Secondary CD8 lymphocyte rest 0 0.0 Astrocytes TNFalpha + IL-lbeta 0.0 0.0 Secondary CD8 lymphocyte act 0.0 10.0 KU-812 (Basophil) rest 0.0 25.3 CD4 lymphocyte none 0.0 0.0 KU-812 (Basophil) PMA/ionomycin 0.0 0 2ry Thl/h2/Trlanti-CD95 0.0 0.0 CCD1106 (Keratinocytes) none 0.0 0.0 CH1 I LAK cells rest 0.0 0.0 CCD1 106 (Keratinocytes) TNFalpha + 0.0 0.0 LAK cells rest 0IL-lbeta LAK cells IL-2 0.0 0.0 Liver cirrhosis 0.0 0.0 LAKcells IL-2+IL-12 0.0 0O.0 Lupus kidney 0.0 21.9 LAK cells IL-2+IFN gamma 17.3 0.0 N CI-H292 none 0.0 0.0 ILAK cells IL-2+ IL-18 0.0 0.0 NCI-H292 IL-4 0.0 0.0 LAK cells PMA/ionomycin 0.0 0.0 NCI-H292 IL-9 0.0 0.0 NK Cells IL-2 rest 0.0 0.0 NCI-H292 IL-13 0.0 0.0 Two Way MLR 3 day 0.0 0.0 NCI-H292 IFN gannmma 0.0 0.0 Two Way MLR 5 day 17.1 0.0 HPAEC none0.0 0.0 Two Way MLR 7 day 0.0 0.0 HPAEC TNF alpha + IL-1 beta 1.3 0.0 PBMC rest 0.0 0.0 Lung fibroblast none 0.0 0.0 PBMC PWM 0.0 0.0 Lung fibroblast TNF alpha + IL-i beta 0.0 0.0 PBMC PHA-L 0.0 0.0 Lung fibroblast IL-4 0.0 0.0 Ramos (B cell) none 0. 0.0 Lung fibroblast IL-9 0.0 0.0 331 WO 2004/000997 PCT/US2003/017512 Ramos (B cell)ijonomycin 0.0 0.0 Lung fibroblast IL-13 0.0 0.0 Slymiphocytes PWM 10.0 0.0 Lung fibroblast IFN gamma 0.0 0.0 B lymphocytes CD40L and IL-4 0.0 0.0 Dermal fibroblast CCD1070 rest 0.0 0.0 EOL-1 dbcAMP 0.0 0.0 Dermal fibroblast CCD1070 TNF alpha 09.0 0.0 EOL-1 dbcAMP PMA/ionomycin 0.0 0.0 Dermal fibroblast CCD1070 IL-1 beta 0.0 j0.0 Dendritic cells none 0.0 0.0 Dermal fibroblast IFN gamma 00 0.0 Dendritic cells LPS 2.9 0.0 Dermal fibroblast IL-4 0.0 0.0 Dendritic cells anti-CD40 0.0 0.0 IBD Colitis 2 0.0 0.0 Monocytes rest 0.0 0.0 IBD Crohn's .0.0 0.0 Monocytes LPS 0. 0.0 Colon _100.0 12.7 Macrophages rest 8.0. Lung 72.2 0.0 Macrophages LPS 0.0 0.0 Thymus 47.3 100.0 HUVEC none .00.0 Kidney 0.0 0.0 HUVEC starved 1.8 0.0 Ardais Kidney 1.0 Summary: Ag2262 Highest expression of the CG50709-03 and CG50709-05 genes was detected in a normal kidney sample (CT=27.6). In many cases, expression of these genes was higher in normal adjacent kidney samples relative to the 5 tumors. The results from Panel 1.3D indicate that these genes were also more highly expressed in fetal as compared to adult kidney. This expression profile suggests that the function of these genes is to drive and/or maintain differentiation of kidney epithelium, since loss of differentiation is a hallmark of kidney cancer. Gene or protein expression levels are useful to distinguish normal kidney from kidney cancer. Therapeutic 10 modulation of the activity of these genes or their protein products using nucleic acid, protein, antibody, or small molecule drugs is useful in the treatment of kidney cancer. Panel 1.3D Summary: Ag2262 Significant expression of these genes was seen mainly in spleen and fetal kidney (CTs=30-32) with upregulated expression in fetal relative to adult kidney. Please see Ardias Kidney vl.0 panel for further discussion of these genes. 15 Panel 2D Summary: Ag2262 Expression of these genes was highest in a sample derived from normal kidney tissue (CT=32.6) and was generally higher in normal kidney tissue relative to adjacent malignant tissue. This expression profile is in agreement with that seen in the Ardias kidney vl.0 panel. Therapeutic modulation of these genes or their protein products using nucleic acid, protein, antibody or small molecule drugs that increase the 20 activity of these genes is useful in the treatment of kidney cancers. 332 WO 2004/000997 PCT/US2003/017512 Panel 4D Summary: Ag2316 Significant expression of these genes was seen exclusively in thymus (CT=33). These genes encode variants of a Wntl4B-like protein; other members of this protein family are known to regulate cell differentiation. The encoded Wnt 14-like proteins may play an important role in T cell development. Therapeutic 5 modulation of the activity of these genes or their protein products is useful to modulate immune function (T cell development) and for organ transplant, AIDS treatment or post chemotherapy immune reconstitiution. Ag 2262 The Wnt 14B variant recognized by this probe-primer set was significantly expressed in colon, lung and thymus (CT=33-34.7). This gene may play an 10 important role in the normal homeostasis of these tissues. Therapeutic modulation of the activity of this gene or its protein product is useful in maintaining or restoring normal function to these organs during inflammation. F. CG53054-02: WNT-14 PROTEIN PRECURSOR Expression of gene CG53054-02 was assessed using the primer-probe sets Ag2261 15 and Ag3035, described in Tables FA and FB. Results of the RTQ-PCR runs are shown in Tables FC, FD, FE, FF, FG, FH, FI and FJ. Table FA. Probe Name Ag2261 Prim Sequences Length Start SEQ ID ers SequencesPosition No Forward 5' -ggatgactcgcctagcttct-3' 20 882 301 Probe TET-5'-gccgtaggtgccaccgtgagaag- 3'-TAMPA 23 935 ........ 302 Reverse 5 -agcagatgctctcgcagtt-3' 19 958 303 20 Table FB. Probe Name Ag3035 S tart SEQ ID Primers Sequences Length Position No Forward 5-acagcagaagttcgtcaag-3' _ 20 527 304 Probe TET-5 ' -agacggtcaagcaaggatctgcgag-3 ' -TAMRA 25 559 305 Reverse js-cacgaggttgttegtggaagt-3' 120 593 306 333 WO 2004/000997 PCT/US2003/017512 Table FC. Al comprehensive panel vl.0 Column A - Rel. Exp.(%) Ag3035, Run 311087483 Tissue Name A -Tissue Name A 110967 COPD-F 13.1 112427 Match Control Psoriasis-F 84.1 110980 COPD-F 44.1 112418 Psoriasis-M 11.5 110968 COPD-M 32.3 112723 Match Control Psoriasis-M 2.6 110977 COPD-M 100.0 112419 Psoriasis-M 17.3 110989 Emphysema-F 48.0 112424 Match Control Psoriasis-M 99 110992 Emphysema-F 28.7 112420 Psoriasis-M 45.1 110993 Emphysema-F 17.9 112425 Match Control Psoriasis-M 36.1 1109935 Emphysema-F 507.3 110425 M )A j N r a"BoeB cu 10....... .................. . 2........." 110994 Emphysema-F 7.4 104689 (MF) OA Bone-Backus 16.6 110995 Emphysema-F 50.3 104690 (MF) Adj "Normal" Bone-Backu s 10.2 110996 Emphysema-F 17.3 104691 (MF) OA Synovium-Backus 27.9 110997 Asthma-M 1.6 104692 (BA) OA Cartilage-Backus 0.0 111001 Asthma-F 13.1 104694 (BA) OA Bone-Backus 21.3 111002 Asthma-F _ 46.7 104695 (BA) Adj "Normal" Bone-Backus 8.1 111003 Atopic Asthma-F 25.3 104696 (BA) OA Synovium-Backus 22.1 111004 Atopic Asthma-F 44.4 104700 (SS) OA Bone-Backus 6.0 111005 Atopic Asthma-F 22.4 104701 (SS) Adj "Normal" Bone-Backus 12.4 111006 Atopic Asthma-F 6.9 104702 (SS) OA Synovium-Backus 39.5 111417 Allergy-M 22.1 117093 OA Cartilage Rep7 21.3 112347 Allergy-M 2.2 112672 OA Bone5 17.9 112349 Normal Lung-F 0.9 112673 OA Synovium5 10.1 112357 Normal Lung-F 76.8 112674 OA Synovial Fluid cellS 7.6 112354 Normal Lung-M 11.3 117100 OA Cartilage Repl4 12.8 112374 Crohns-F 30.1 112756 OA Bone9 24.0 112389 Match Control Crohns-F 20.6 112757 OA Synovium9 49.3 112375 Crohns-F 29.9 112758 OA Synovial Fluid Cells9 5.7 112732 Match Control Crohns-F 14.3 117125 RA Cartilage Rep2 17.3 112725 Crohns-M 6.4 113492 Bone2 RA 25.5 112387 Match Control Crohns-M 18.8 113493 Synovium2 RA 163 112378 Crohns-M 1.6 113494 Syn Fluid Cells RA 16.8 112390 Match Control Crohns-M 25.

9 113499 Cartilage4 RA 13.1 112726 Crohns-M 14.1 113500 Bone4 RA 21.8 112731 Match Control Crohns-M 25.9 113501 Synovium4 RA 13.9 112380 Ulcer Col-F 33.0 113502 Syn Fluid Cells4 RA 6.8 112734 Match Control Ulcer Col-F 19.2 113495 Cartilage3 RA 14.4 112384 Ulcer Col-F 21.8 113496 Bone3 RA 13.9 112737 Match Control Ulcer Col-F 3.6 113497 Synovium3 RA 10.0 112386 Ulcer Col-F 10.8 1113498 Syn Fluid Cells3 RA 23.0 112738 Match Control Ulcer Col-F 25.5 117106 Normal Cartilage Rep20 15.5 334 WO 2004/000997 PCT/US2003/017512 112381 Ulcer Col-M 0.2 113663 Bone3 Normal 0.0 112735 Match Control Ulcer Col-M 1.9 113664 Synovium3 Normal 0.0 112382 Ulcer Col-M 14.4 113665 Syn Fluid Cells3 Normal 0.1 112394 Match Control Ulcer Col-M 3.1 117107 Normal Cartilage Rep22 3.6 112383 Ulcer Col-M 31.6 113667 Bone4 Normal 18.3 112736 Match Control Ulcer Col-M 11.3 113668 Synovium4 Normal 16.4 112423 Psoriasis-F 7.1 113669 Syn Fluid Cells4 Normal 43.8 Table FD. Oncology cell line screening panel v3.2 Column A - Rel. Exp.(%) Ag3035, Run 259180377 s N eA Tissue Name A T Nm A 94905 -Daoy Medulloblastonma/Cerebellum ssc 0.2 94954_Ca SkiCervical epidermoid 8.4 DNA carcinoma (metastasis)_sscDNA 94906_TE671 Medulloblastom/Cerebellumnssc 0.5 94955 ES-2_Ovarian clear cell 0.0 DNA carcinoma sscDNA 94907 D283 0.2 94957 Ramos/6h stim Stimulated with 0.0 Med Medulloblastoma/Cerebellum sscDNA PMA/ionomycin 6h sscDNA . 94908 PFSK-1 Primitive 0.0 94958 Ramos/14h stim Stimulated 0.0 Neuroectodermal/Cerebellum sscDNA ... with PMA/ionomycin 14h sscDNA 94909 XF-498CNSsscDNA 0.2 94962 MEG-01 Chronic myelogenous 0 94909_XF-498CNS_sscDNA 0.2 leukemia (megokaryoblast)sscDNA 0.0 9490 S 8 ' " . . 94963 Raji Burkitt's 94910_SNB-78_CNS/gliomasscDNA 0.5 lymphoma sscDNA0.0 ................ ... ........... ... 94964_DaudiBurkitt's0. 94911_SF-268_CNS/glioblastomasscDNA 0.3 94964ymphDmasscDN

A

iBurkitt's 0.0 - ~lymphoma sscDNAI 94912T98GGlioblastomasscDNA 0.5 94965 U266 B-cell 94912 T98GGlioblastomasscDNA 0.5 plasmacytoma/myeloma sscDNA 0.0 96776_SK-N-SHNeuroblastoma 0.0 94968CA46_Burkitt's 0.0 (metastasis) sscDNA lymphoma sscDNA . .... - " ... .. [... .0694970_RL non-Hodgkin's B-cell 94913 SF-295 CNS/glioblastomasscDNA 0.6 94970R non-Hodgkin's B-cell 0.0 _ - - lymloa ,,ss-,N 32565NT2 poolsscDNA 94972JMlpre-B-cell 132565_NT2 poolsscDNA 3.9 ymphoma/leukemiasscDNA. 94914 Cerebellum sscDNA 0.7 94973 Jurkat T cell leukemia sscDNA 0.0 96777 Cerebellum sscDNA 0.8 94974 TF-1 Erythroleukemia _sscDNA 0.0 94916 NCI-H292 Mucoepidemoid lung 11.7 94975 HUT 78_T-cell 0.1 carcinoma _sscDNA lymphoma sscDNA . 949 DMS114 Smal cell lung 0.3 94977_U937_Histiocytic 0.0 49cancer DMsscDNA ll cell lung 0.3 lymphoma sscDNA 94918 DMS-79_Small cell lung 100. 94980 _KU-812_Myelogenous 1.3 cancer/neuroendocrine sscDNA 0 leukemia sscDNA 94919_NCI-H146_Small cell lung 16.4 94981_769-P_Clear cell renal 19 cancer/neuroendocrine sscDNA carcinoma sscDNA 94920 NCI-H526 Small cell lung 0.0 94983 Caki-2_Clear cell renal 1.8 cancer/neuroendocrinesscDNA . . carcinoma sscDNA 335 WO 2004/000997 PCT/US2003/017512 94921 NCI-N417 Small cel lung 0.0 94984_SW 839_Clear cell renal 0.8 cancer/neuroendocrine_sscDNA 0 carcinomasscDNA 94923_NCI-H82_Small cell lung' 0.4 94986 G401 Wilms' tumor sscDNA 04 cancer/neuroendocrine_sscDNA 94924 NCI-H157 Squamous cell lung cancer 2.4 126768 293 cells sscDNA 1.9 (metastasis)_sscDNA 94925 NCI-H1155_Large cell lung 15.5 94987 Hs766T Pancreatic carcinoma 2.1 cancer/neuroendocrine sscDNA (LN metastasis)-._ssDNA 94988_CAPAN-lPancreatic 94926_NCI-H1299_Large cell lung 3.4 adenocarcinoma (liver 3.2 cancer/neuroendocrine sscDNA metastasis)_sscDNA 94989 SU86.86 Pancreatic carcinoma 94927_NCI-H727 Lung carcinoidsscDNA 9 (liver metastasis) sscDNA 1.6 ...... 94990_BxPC-3_Pancreatic 94928_NCI-UMC-11 Lung carcinoid_sscDNA 20.2 9499adenocarcomancreatic 30 _ adenoaiom sscDNA 94991 HPAC Pancreatic 94929 LX-1_Small cell lung cancer sscDNA 0.0 adenocarcinomasscDNA 0.9 94992_MIA PaCa-2__Pancreatic 94930_Colo-205_Colon cancer_sscDNA 0.0 carcinoma sscDNA 94993 CFPAC-1Pancreatic ductal 94931 _KM12 Colon cancersscDNA .0 adenoaroma sDNA0.2 92 . 1 2 94994_PANC-1 Pancreatic epithelioid 22. 94932_KM20L2_Colon cancer_sscDNA 0.0 ductal carcinoma sscDNA 94996 T24 Bladder carcinma 94933 NCI-H716_Colon cancer sscDNA . (transitiona cell)_sscDNA 0. 94935 W oo adm s94997_5637_Bladder SW-48 Colon adenocarcinomasscDNA 0.0 carcinoma sscDNA 94936 _SW1116_Colon 1. 94998_HT-1197_Bladder 12. adenocarcinoma sscDNA carcinoma sscDNA 94937LS 174TColon 0. 94999_UM-UC-3_1Bladder carcinma 0.0 adenocarcinoma scDNA (transitional ell)_sscDNA 94938 SW-948 Colon 0. 95000_A204_Rhabdomyosarcomassc 0.0 adenocarcinoma sscDNA DNA 94939_SW-480_Colon 0.0 95001 _HT-1080_Fibrosarcoma_sscDN 1.6 adenocarcinoma sscDNA A 9494 -SN1- r cA.9 95002 MG-63 Osteosarcoma 14. 94940NCI-SNU-5Gastric carcinoma _ssDNA (bone) sscDNA 7 1937_ Som 0.3 95003_SK-LMS-1 Leiomyosarcoma 0.0 112197KATO III Stomach ssDNA0.3 (vulva )_sscDNA -______________________j .(vulva)_ssDNA 94943_NCI-SNU-16_Gastric 0. 95004_ SJRH30_ Rhabdomyosarcoma 1.3 carcinomassDNA (met to bone marrow) sscDNA 49i4*4" 9-3- -S4- c o so 0 95005_A431 Epidermoid - - - carcinoma__sseDNA 94944 NCI-SNU-1 Gastric carcinoma sscDNA 2.9 carcinoma sscDNA 5.9 94946 RF-1 Gastric adenocarcinoma sscDNA0.0 95007_WM266-4 Melanoma sscDNA 0.0 94946 RF-48 Gastric aeoacnm sDA00907VW6- eaoascN . 94947 _ RF-48_Gastric 0.0 112195 DU 145 Prostate-sscDNA 1.1 adenocarcinoma sscDNA 112195DU 145ProstatesscDN 8 N 06 95012 MDA-MB-468_Breast 96778 MKN-45 Gastric carcinoma sscDNA L. adenocarcinoma sscDNA 2.2 336 WO 2004/000997 PCT/US2003/017512 94949 NCI-N87 Gastric carcinoma sscDNA 3.9 112196 SSC-4 Tongue sscDNA 2.6 94951 OVCAR-5 Ovarian carcinoma sscDNA 1.3 112194_SSC-9 TonguesscDNA 33 94952_ RL95-2 Uterine carcinoma sscDNA 3.0 112191 SSC-15 TonguesscDNA 1.8 94953 HelaS3 Cervical 1.7 95017_CAL 27 Squamous cell 1.2 adenocarcinoma sscDNA carcinoma of tongue sscDNA Table FE. Panel 1.3D Column A - Rel. Exp.(%) Ag2261, Run 150631675 Column B - Rel. Exp.(%) Ag2261, Run 152887692 Column C - Rel. Exp.(%) Ag3035, Run 167597764 Tissue Name A B C Tissue Name A B C Liver adenocarcinoma 22.4 19.6 71.2 Kidney (fetal) 2.1 0.0 2.7 Pancreas 3.9 2.5 2.8 Renal ca. 786-0 j0.0 0.0 0.0 Pancreatic ca. CAPAN 2 5 3.5 9.5 Renal ca. A498 102 5.3 9.2 Adrenal gland 2.1 0.6 2.0 Renal ca. RXF 393 0.0 0.0 Thyroid 7.0 9.8 3.9 Renal ca. ACHN 0.0 2.2 0.0 Salivary gland 1.9 2.1 4.2 Renal ca. UO-31 0.0 0.0 0.0 Pituitary gland 1.0 22 6.7 Renal ca. TK-10 00 0. 0.0 Brain (fetal) 6.8 4. 10. Liver 00 0.0 0.0 Brain (whole) 4.8 3.0 1.4 Liver (fetal) 76 0.0 0.0 Brain (amygdala) 4.6 5.3 1.5 Liver ca. (hepatoblast) HepG2 0.0 0.0 Brain (cerebellum) 1.6 1.6 2.0 Lung 143 158 92 Brain (hippocampus) 7.5 11.3 0.6 Lung (fetal) 15.1 15.4 7.4 Brain (substantia nigra) 1.2 2.6 1.3 Lung ca. (small cell) LX- 1 6 00 00 Brain (thalamus) 2.5 1.7 2.6 Lung ca. (small cell) NCI-H69 29 191 312 Cerebral Cortex 0.0 0.0 5.0 Lung ca. (s.cell var.) SHP-77 11.0 5.1 37.4 Spinal cord 1.7 2.1 2.7 Lung ca. (large cell)NCI-H46010.0 0 0. glio/astro U87-MG 0.0 0.0 0.0 Lung ca. (non-sm. cell) A549 0.0 1.2 1.6 glio/astroU-118-MG 55.1 50.3 42.9 Lung ca. (non-s.cell) NCI-H23 0.0 1.3 0.8 astrocytoma SW1783 0.0 7.5 0.0 Lung ca. (non-s.cell) HOP-62 0.0 1.7 0.0 neuro*; met SK-N-AS 0.0 0.0 0.7 Lung ca. (non-s.cl) NCI-H5228.0 83 7.3 astrocytoma SF-539 1.9 4.7 9.9 Lung ca. (squam.) SW 900 4.0 0. 1.8 astrocytoma SNB-75 2.0 4.9 6.9 Lung ca. (squam.) NCI-H596 15.8 10.2 58.2 glioma SNB-19 6.7 2.4 3.7 Mammary gland 7.2 4.1 4.4 glioma U251 2.1 4.5 16.8 Breast ca.* (pl.ef) MCF-7 1.7 3.4 7.3 glioma SF-295 10.0 0.6 4.6 Breast ca.* (pl.ef) 23.2 19.6 19.2 :_1_ _- MDA-MB-231 2 Heart (fetal) 111 9.9 38.2 Breast ca. (pl.ef)T47D 4.3 5.8 21.8 Heart 4.9 6.0 15.2 Breast ca. BT-549 _ 0.0 4.2 2.2 Skeletal muscle (fetal) 100.0 100.0 85.3 Breast ca. MDA-N 0.0 0.0 0.0 Skeletal muscle 5.5 8.4 39.8 Ovary 13.6 3.1 18.1 one marrow 0.0 0.0 0.7 Ovarian ca. OVCAR-3 1.1 1.0 5.6 337 WO 2004/000997 PCT/US2003/017512 hymus 10.0 3.9 6.4 Ovarian ca. OVCAR-4 0.0 0.0 J0.7 Spleen 3.8 4.2 1.6 Ovarian ca. OVCAR-5 0.0 0.0 11.5 Lymphnode 5.0 1.1 1.4 Ovarian ca. OVCAR-8 1.3 4.3 4.1 Colorectal 3.4 5.4 6.8 Ovarian ca. IGROV-1 0.0 0.0 8.1 Stomach 6.0 15.4 3.1 Ovarian ca.* (ascites) 7.5 16.0 100.0 ... . ..... i sK-ov-3 ... . Small intestine 15.9 18.7 23 Uterus 17.815.1 9.9 Colon ca. SW480 24.3 15.3 11.6 Placenta .6 8.2 2.1 Colon ca.* SW620(SW480 0.0 0.0 2.1 Prostate 3 6 5.3 0.6 met) I Colon ca. HIT29 0.0 0.0 0.0 Prostate ca.* (bone met)PC-3 1.7 1.5 6.1 Colon ca. HCT-1 16 3.8 0.6 3.3 Testis 21.9 14.6 1.6 Colon ca. CaCo-2 0.0 0.8 0.3 Melanoma Hs688(A).T -3.1 47 1.4 Colon ca. issue(OD03866) 2.3 0.0 1.6 Melanoma* (met) Hs688(B).T 0.4 13 0.0 Colon ca. HCC-2998 0.0 0.0 1.6 Melanoma UACC-62 00 0.0 0.0 Gastric ca.* Giver met) 16.7 14.9 15.3 Melanoma M14 0.0 0.0 0.0 NCI-N87 . . . . . . . . . Bladder 16 32 3.0 Melanoma LOX IMVI 0.0 0.0 0.0 Trachea 24.3 337 5.7 Melanoma* (met) SK-MEL-5 0.0 [2.0 0.7 Kidney 0.0 0.0 0.0 Adipose 6.7 7.2 21.2 Table FF. Panel 2D Column A - Rel. Exp.(%) Ag2261, Run 150811744 Column B - Rel. Exp.(%) Ag2261, Run 152887693 Tissue Name A B Tissue Name A B Normal Colon 19.1 19.8 Kidney Margin 81206082.4 0.0 CC Well to Mod Diff (ODO3866) 0.0 15.8 Kidney Cancer 8120613 _14.6 7.3 CC Margin (ODO3866) 19.5 12.5 Kidney Margin 8120614 4.8 1.5 CC Gr.2 rectosigmoid (ODO3868) 3.8 1.4 Kidney Cancer 901032000 0.0 CC Margin (ODO3868) 2.6 5.1 Kidney Margin 9010321 0.0 CC Mod Diff(ODO3920) 6.0 2.9 Normnal Uterus 9.7 2.8 CC Margin (ODO3920) 23.8 6.4 Uterus Cancer 064011 85.9 .5 CC Gr.2 ascend colon (ODO3921) 9.3 2.2 Normal Thyroid 15.2 7.3 CC Margin (ODO3921) 16.8 11.7 Thyroid Cancer 064010 0.0 3.0 CC from Partial Hepatectomy 2.4 0.0 Thyroid Cancer A302152 1.9 1.2 (ODO4309) Mets Liver Margin (ODO4309) 2.6 0.0 Thyroid Margin A302153 12.6 2.8 Colon mets to lung (OD04451-01) 7.9 4.5 Normal Breast 16.2 2.7 Lung Margin (OD04451-02) 11.3 12.9 Breast Cancer (OD04566) 85 29.7 Normal Prostate 6546-1 6.3 2.6 Breast Cancer (OD04590-01) 37.6 23.8 Breast Cancer Mets 2 Prostate Cancer (OD04410) 17.8 7.3 4590-03) 100024. 338 WO 2004/000997 PCT/US2003/017512 Prostate Margin (OD04410) 10.7 7.4 Breast Cancer Metastasis 94.0 45.4 (ODO46S5-05) Prostate Cancer (OD04720-01) 4.7 4.4 Breast Cancer 064006 25.7 24.8 Prostate Margin (OD04720-02) 13.9 5.6 Breast Cancer 1024 23.2 7.1 Normal Lung 061010 36.6 14.3 Breast Cancer 9100266 33.0 7.5 Lung Met to Muscle (ODO4286) 1.0 0.0 Breast Margin 9100265 7.6 7.6 Muscle Margin (OD0O4286) 31.0 38.2 Breast Cancer A209073 13.9 0.9 Lung Malignant Cancer (OD03126) 81.8 100.0 Breast Margin A209073 2.5 0.0 Lung Margin (OD03126) 35.8 18.2 Normal Liver 0.0 0.0 Lung Cancer (OD04404) 57.0 39.5 Liver Cancer 064003 0.0 0.0 Lung Margin (OD04404) 9.4 118 Liver Cancer 1025 .4.8 1.7 Lung Cancer (OD04565) 37.1 42.0 Liver Cancer 1026 7.1 0.0 Lung Margin (OD04565) 22.7 9.3 Liver Cancer 6004-T 4.8 0.0 Lung Cancer (OD04237-01) 5.3 6.4 Liver Tissue 6004-N 4.4 1.8 Lung Margin (OD04237-02) 78.5 32.8 Liver Cancer 6005-T 0.0 6.0 Ocular Mel Met to Liver (ODO43 10) 0.0 0.0 Liver Tissue 6005-N 0.0 1.8 Liver Margin (ODO43 10) .. 0.0 Normal Bladder 2.4 3.0 Melanoma Mets to Lung (OD04321) 13.0 0.0 iBladder Cancer 1023 .... 8.5 4.9 Lung Margin (OD04321) 96.6 50.0 Bladder Cancer A302173 17.0 1118 Normal Kidney 0.0 00 Bladder Cancer (OD04718-01) 10.0 5.7 Kidney Ca, Nuclear grade 2 00 0.0 Bladder Normal Adjacent 19.3 27.5 (OD04338) 0.0 0.0 (OD04718-03) 19.3 27.5 Kidney Margin (OD04338) 4.0 4.6 Normal Ovary 13.6 12.4 Kidney Ca Nuclear grade 1/20.0 3.3 Ovarian Cancer 064008 37.9 2.1 (OD04339) 0.0 3.3 Ovarian Cancer 064008 37.9 2.1 Kidney Margin (OD04339) 18.7 0.0 Ovarian Cancer (OD04768-07) 18.4 3.7 Kidney Ca, Clear cell type (0D04340) 8.8 111.7 Ovary Margin (OD04768.08) 283 2 Kidney Margin (OD04340) 0.0 2.0 Normal Stomach 48.3 17.3 Kidney Ca, Nuclear grade 3 3540 Gastric Cancer 9060358 0.0 . (0D04348) 3.5 4.0 G Cne9035.. 0 Kidney Margin (OD04348) 2.0 1.7 Stomach Margin 9060359 9 3.0 Kidney Cancer (OD04622-01) 9.3 0.0 Gastric Cancer 9060395 2 i0.7 10.114 Kidney Margin (OD04622-03) 0.0 6.3 Stomach Margin 9060394 10- 12.2 Kidney Cancer (OD04450-01) 0.0 00 Gastric Cancer 9060397 8.7 1.5 Kidney Margin (ODO4450-03) 0.0 00 . Stomach Margin 9060396 7.5 6.2 Kidney Cancer 8120607 00 07 Gastric Cancer 064005 10.7 4.8 339 WO 2004/000997 PCT/US2003/017512 Table FG. Panel 4.1D Column A - Rel. Exp.(%) Ag3035, Run 190944495 Column B - Rel. Exp.(%/o) Ag3035, Run 259180379 Tissue Name A B Tissue Name A B Secondary Thl act 0.0 0.0 HUVEC IL-lbeta 1.7 0.0 Secondary Th2 act 0.0 0.0 HUVEC IFN gamma . 0.8 11.8 Secondary Trl act 0.0 0.0 HUVEC TNF alpha+IFN gamma 0.2 0.0 Secondary Thl rest 0.0 0.0 HUVEC TNF alpha + IL4 0.6 4.5 Secondary Th2 rest 0.0 2.0 HUVEC IL-11 1.1 17.2 Secondary Trl rest 0.0 0.0 Lung Microvascular EC none 2.7 7.2 Primary act 0.0 0.0 Lung Microvascular EC TNFalpha + 0.6 0.0 Primary Th1 act i0.0 0.0E-bt0. 00 SIL-lbeta Primary Th2 act 0.0 0.0 Microvascular Dermal EC none 3.8 0.0 Primary T act 0.0 0.0 Microsvasular Dermal EC TNFalpha + 1.2 0.0 Primary Trl act 0.0 0.0 IL-lbeta 1.2 0.0 P..rimary Th rest 0.0 .0 Bronchial epithelium TNFalpha + 3.7 5.0 Primary Th1 rest 0.0 0.0 ILlbeta3 Primary Th2 rest 0.0 0.0 Small airway epithelium none 1.9 10.7 Primary Tr rest 0.0 0.0 Small airway epithelium TNFalpha + 4.0 24.5 V IL-lbeta CD45RA CD4 lymphocyte act 0.0 2.3 Coronery artery SMC rest 0.2 2.2 CD45RO CD4 lymphocyte act 0.0 0.0 Coronery artery SMC TNFalpha + 0.0 0.0 SIL-lbeta CD8 lymphocyte act 0.0 0.0 Astrocytes rest 2.4 7.9 Secondary CD8 lymphocyte rest 0.0 0.0 Astrocytes TNFalpha+ IL-lbeta 1.3 0.0 Secondary CD8 lymphocyte act 0.0 0.0 KU-812 (Basophil) rest 0.0 2.3 CD4 lymphocyte none __ 0.0 0.0 KU-812 (Basophil) PMA/ionomycin 2.1 4.5 2ry Thl/Th2/Trl anti-CD95 0.0 0.0 CCDl 106 (Keratinocytes) none 22.2 100.0 C H 11 ....... .... LAK cells rest 0.0 4.7 CCDl 06 (Keratinocytes)TNFalpha+ 18.8 52.5 LAK cells rest 10.0 j4.T IL-lbeta 1 LAK cells IL-2 00 0.0 Liver cirrhosis 0.7 4.2 LAK cells IL-2+IL-1 2 0.0 0.0 NCI-H292 none 10.4_ 0. LAK cells IL-2+IFN gamma 0.0 0.0 NCI-H292 IL4 1.5 0.0 LAK cells IL-2+ IL-18 0.0 3.0 NCI-H292 IL-9 2.0 8.8 LAK cells PMAJionomycin 11.0 42.0 NCI-H292 IL-13 1.4 17.8 NK Cells IL-2 rest 0.0 5.2 NCI-H292 IFN gamma 1.5 6.9 Two Way MLR 3 day 0.0 0.0 HPAEC none 3.1 18.7 Two Way MLR 5 day 0.0 0.0 HPAEC TNF alpha + IL-1 beta 0.5 0.0 Two Way MLR 7 day 0.0 10.0 Lung fibroblast none 6.2 29.9 PBMC rest 0.0 0.0 Lung fibroblast TNF alpha + IL-1 beta 2.1 0.0 PBMC PWM 0.5 0.0 Lung fibroblast IL-4 4.2 9.8 PBMC PHA-L 0.4 . 0 Lung fibroblast IL-9 ... 3253 340 WO 2004/000997 PCT/US2003/017512 Ramios (B cell) none 0.0 0.0 Lung fibroblastlL-13 4.0 3.9 B lymphocytes PWM 0.0 0.0 Dermal fibroblast CCD1070 rest 0.4 0.0 B lymphocytes CD40L and IL-4 0.0 0.0 Dermal fibroblast CCD1070 TNF alpha 0.9 4.1 EOL- dbcAMP 0.0 2.7 Dermal fibroblast CCD1070 IL-1 beta 2.9 0.0 EOL-l dbcAMP PMA/ionomycin 1.0 1.7 Dermal fibroblast IFN gamma 5.8 41.8 Dendritic cells none 0.0 10.0 Dermalfibroblast IL-4 17.2 624 Dendritic cells LPS 0.0 0.0 Dermal Fibroblasts rest 4.8 12.9 Dendritic cells anti-CD40 10.0 .0 eutrophils TNFa+LPS 1.0 0.0 Monocytes rest .O.0 0.0 Neutrophils rest 2.2 2.3 Monocytes LPS 0.6 10.0 Colon .2.6 0.0 Macrophages rest 10.0 0.0 Lung 8.8 0.0 Macrophages LPS 0.0 0.0 Thymus 17.1 1.8 HUVEC none 2.4 7.6 Kidney 100.0 0.0 HUVEC starved 8.8 _22.1 Table FH. Panel 4D Column A - Rel. Exp.(%) Ag2261, Run 152887762 Column B - Rel. Exp.(%) Ag3035, Run 165242424 Tissue Name A B Tissue Name A B Secondary Th1 act 0.0 2.1 HUVEC IL-1beta 0.0 1.7 Secondary Th2 act 0.0 0.0 HUVEC IFN gamma 3. 11.5 Secondary Trl act 0.0 4.2 HUVEC TNF alpha + IFN gamma 0.0 3.1 Secondary Thl rest 0.0 0.0 HUVEC TNF alpha + IL4 4 3 1.1 Secondary Th2 rest 0.0 2.3 HUVEC IL-11 4.0 11.2 Secondary Trl rest 0.0 0.0 Lung Microvascular EC none 7.2 8.1 Pia at0 0.Lung Microvascular EC TNFalpha + 0.0 0.0 Primary Th1 act 0.0 0.0 IL-lbeta Primary Th2 act 0.0 0.0 Microvascular Dermal EC none 8.4 14.5 Primary TO act 0.0 0.0 Microsvasular Dermal EC TNFalpha + 0.0 2.2 Pa 00 IL-lbeta Primary Thl rest 10.0 0.0Bronchial epithelium TNFalpha + 0.0 16.3 Primary Thl rest 0.0 0.0 ILlbeta .0 16.3 Primary Th2 rest 0.0 0.0 Small airway epithelium none 5.9 18.8 Primary T rest . J.0 Small airway epithelium TNFalpha+ 24.3 58.6 Primary Trl rest 00 . IL-lbeta CD45RA CD4 lymphocyte act 0.0 0.0 Coronery artery SMC rest 0.0 2.0 CD45RO CD4 lymphocyte act 0.0 0.0 Coronery artery SMC TNFalpha + .0 .0 D45RO CD4 lymphocyte act .0 0.0 IL-lbeta .0 0.0 CD8 lymphocyte act 0.0 0.0 Astrocytes rest 3.3 13.5 Secondary CD8 lymphocyte rest J. 0.7 Astrocytes TNFalpha + IL-ibeta 0.0 8.6 Secondary CD8 lymphocyte act 1.6 0.0 KU-812 (Basophil) rest ---- 0.0 0.0 CD4 lymphocyte none 10.0 '0.0 KU-812 (Basophil) PMA/ionomycin 0.0 9. 341 WO 2004/000997 PCT/US2003/017512 2ry Thl/Th2/Trlanti-CD95 0.0 1.4 CCD1106 (Keratinocytes) none 47.3 100.0 CH11 LAK cells rest 35 0 CCD1106 (Keratinocytes) TNFalpha + 90 53.6 LAK cells rest IL-1beta LAK cells IL-2 0.00.0 Liver cirrhosis 32.8 9.4 LAK cells IL-2+IL-12 0.0 0.0 Lupus kidney 0.0 1.6 LAK cells IL-2+IFN gamma 0.0 4.0 NCI-H292 none 3.8 3.4 LAK cells IL-2+ IL-18 0.0 0.0 NCI-H292 IL-4 8.0 19.5 LAK cells PMA/ionomycin 26.1 50.7 NCI--1292 IL-9 0.0 4.2 NK Cells IL-2 rest 0.0 0.0 NCI-H292 IL-13 13.8 7.0 Two Way MLR 3 day 0.0 0.0 NCI-H292 IFN gamma 16.2 5.7 Two Way MLR 5 day 0.0 0.0 HPAEC none 6.7 30.1 Two Way MLR 7 day 0.0 0.0 HPAEC TNF alpha + IL-1 beta .0 0.0 PBMC rest 0.0 0.0 Lung fibroblast none 7.6 42.0 PBMC PWM 0.0 0.0 Lung fibroblast TNF alpha + IL-1 beta 3.1 6.3 PBMC PHA-L 0.0 0.0 Lung fibroblast IL-4 4.3 34.2 Ramos (B cell) none 0.0 0.0 Lung fibroblast IL-9 12.7 27.5 Ramos (B cell) ionomycin 0.0 0.0 Lung fibroblast IL-13 6.

8 19.9 B lymphocytes PWM 0.0 . Lung fibroblast IFN gamma 30.4 51.1 B lymphocytes CD40L and IL-4 3.1 0.0 Dermal fibroblast CCD1070 rest 0.0 2.8 EOL-1 dbcAMP 0.0 0.0 Dermal fibroblast CCD1070 TNF alpha 5.2 19.6 EOL-1 dbcAMP PMA/ionomycin 3.5 2.7 Dermal fibroblast CCD1070 IL-1 beta 0.0 2.0 Dendritic cells none 0.0 0.0 Dermal fibroblast IFN gamma 28.5 32.1 Dendritic cells LPS 0.0 0.0 Dermal fibroblast IL-4 42.9 91.4 Dendritic cells anti-CD40 0.0 0.0 IBD Colitis 2 2.2 5.5 Monocytes rest 0.0 0.0 IBD Crohn's 3.1 9.6 Monocytes LPS 0.0 0.0 Colon 100.0 58.6 Macrophages rest 0.0 0.0 Lung 36.3 26.1 Macrophages LPS 0.0 0.0 Thymus 0.0 HUVEC none 0.0 17.7 Kidney 4.0 33.0 HUVEC starved 17.4 51.1 Table FI. Panel 5 Islet Column A - Rel. Exp.(%) Ag3035, Run 259234350 Tissue Name A Tissue Name A 97457 Patient-02go adipose 19.3 94709 Donor 2 AM - A adipose 0.8 97476 Patient-07sk skeletal muscle 13.0 94710_Donor 2 AM - B _adipose 0.0 97477 Patient-07ut uterus 5.3 94711 Donor 2 AM - C adipose 1.8 97478 Patient-07pl_placenta 1.4 94712 Donor 2 AD - A adipose 5.3 99167 Bayer Patient 1 89.5 94713_Donor 2 AD - B_adipose 3.2 97482 Patient-08ut uterus 9.6 94714 Donor 2 AD - C_adipose 0.0 342 WO 2004/000997 PCT/US2003/017512 97483Patient-08plplacenta 7. 94742 Donor 3 U - A Mesenchymal Stem 2.6 3Patient-08plplacenta Cells 97486_Patient-09sk skeletal muscle 10.7 94743_Donor 3 U - BMesenchymal Stem 2.6 Cells 97487 Patient -9ut uterus 4.7 94730_Donor 3 AM - A adipose 0.8 97488 Patient-09plplacenta 3.6 94731 Donor 3 AM - B adipose 1.7 97492 Patient-O10ut uterus 6.1 94732 Donor 3 AM - C adipose 1.5 97493 Patient-l10plplacenta _ 6.8 94733 -Donor 3 AD -A adipose 4.8 97495 Patient-1il go adipose 1.6 94734 Donor 3 AD - B adipose 2.0 97496 Patient- lsk skeletal muscle ?2. 94735 Donor 3 AD - C adipose 2.5 97497 Patient-iut uterus 3.2 77138 Liver HepG2untreated 0.0 97498Patient-11plplacenta 1.8 73556 _Heart Cardiac stromal cells 0.0 9a (primary) 97500 Patient-12go adipose 8.5 81735 Small Intestine 15.6 97501 Patient-12sk skeletal muscle 100.0 72409 Kidney Proximal Convoluted 0.0 __________________________ Tubule 97502 Patient-12ut uterus 2.2 82685 Small intestine Duodenum 5.9 97503 Patient-12plplacenta 0.0 90650 Adrenal Adrenocortical adenoma 2.9 94721 Donor 2 U - A Mesenchymal Stem Cells -0.0 72410_KidneyHRCE 7.5 94722- Donor 2 U - B Mesenchymal Stem 5 72411 dney RE 3.3 94723 Donor 2U-CMesenchyal Stem ,CellsDnr - CMesenhymal 1.5 i7 3 13 9 _UterusUterine smooth muscle cells 0.0 Table FJ. general oncology screening panel v 2.4 .. . . Column A - Rel. Exp.(%) Ag3035 Run 259737910 Tissue NameA Tissue Name A Colon cancer 1 7.6 Bladder cancer NAT 2 0.0 Colon cancer NAT 1 14.7 Bladder cancer NAT 3 0.0 Colon cancer 2 3.7 Bladder cancer NAT4 25. Colon cancer NAT 2 10.0 Prostate adenocarcinoma 1 8.3 Colon cancer 3 7.3 Prostate adenocarcnoma 2 1.6 Colon cancer NAT 3 25.9 Prostate adenocarcinoma 3 3.4 Colon malignant cancer 4 1.7 Prostate adenocarcinoma 4 9.5 Colon normal adjacent tissue 4 1.6 Prostate cancer NAT 5 2.4 Lung cancer 1 9.5 Prostate adenocarcinoma 6 0.0 Lung NAT 1 2.9 Prostate adenocarcinoma 7 4.9 Lung cancer 2 42.3 Prostate adenocarcinoma 8 - 0.0 Lung NAT 2 23.3 Prostate adenocarcinoma 9 20.6 Squamous cell carcinoma 3 73.7 Prostate cancer NAT 10 0.4 Lung NAT 3 1.3 Kidney cancer 1 1.9 metastatic melanoma 1 37.1 .. KidneyNAT 1 8.1 343 WO 2004/000997 PCT/US2003/017512 Melanoma 2 9.4 Kidney cancer 2 34.4 Melanoma 3 1.4 .Kidney NAT 2 7.6 metastatic melanoma 4 100.0 Kidney cancer 3 12.9 metastatic melanoma 5 39.8 Kidney NAT 3 4.5 Bladder cancer 1 2.9 Kidney cancer 4 .13.4 Bladder cancer NAT 1 0.0 Kidney NAT 4 5.9 Bladder cancer 2 3.2 In Alcomprehensive panelvl.0 Summary: Ag3035 Highest expression of the CG53054-02 gene was detected in a COPD sample (CT=30). This gene shows widespread expression in this panel. Moderate levels of expression of this gene were detected in 5 samples derived from normal and orthoarthitis/ rheumatoid arthritis bone, cartilage, synovium and synovial fluid samples, as well as from normal lung, COPD lung, emphysema, atopic asthma, asthma, allergy, Crohn's disease (normal matched control and diseased), ulcerative colitis (normal matched control and diseased), and psoriasis (normal matched control and diseased). Therapeutic modulation of the activity of this gene or its 10 protein product will ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders, including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis. Oncology_celllinescreening_panel_v3.2 Summary: Ag3035 Highest expression of this gene was seen in lung cancer cell line DMS-79 (CT=28.6). Moderate to low 15 expression of this gene was also seen in number of cancer cell lines derived from tongue, bone, bladder, pancreatic, cervical, uterine, gastric, colon and lung cancer. Gene or protein expression levels are useful as a marker to detect the presence of these cancers. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of these cancers. 20 Panel 1.3D Summary: Ag2261 This gene was expressed at moderate levels in a number of metabolic tissues, with highest overall expression seen in fetal skeletal muscle (CTs=30.4-31.8). The higher levels of expression in fetal skeletal muscle when compared to adult skeletal muscle suggests that the protein product encoded by this gene may be useful in treating muscular dystrophy, Lesch-Nyhan syndrome, myasthenia gravis and 25 other conditions that result in weak or dystrophic muscle. This gene was also expressed in adipose, thyroid and heart. Since biologic cross-talk between adipose and thyroid is a 344 WO 2004/000997 PCT/US2003/017512 component of some forms of obesity, therapeutic modulation of the activity of this gene or its protein product is useful for the treatment of metabolic disease, including obesity and Type 2 diabetes. Ag3035 This probe/primer set recognizes a distinct portion of this gene that shows 5 a distinctive expression pattern when compared to Ag2261. This observation may indicate that the probe/primer sets can distinguish splice variants of this gene. In contrast to the results obtained with Ag2261, expression of this gene was highest in an ovarian cancer cell line (CT = 30.6). As was the case for Ag2261, expression of this gene using Ag3035 was also relatively high in fetal skeletal muscle. However, Ag3035 showed higher levels 10 of gene expression in adult skeletal muscle as well as in adult and fetal heart. Most other expression is similar using both probe/primer sets. Please see Ag2261 for additional information. Panel 2D Summary: Ag2261 This gene was consistently expressed in samples of breast cancer, uterine cancer and lung cancer relative to their respective normal adjacent tissue 15 controls. Gene or protein expression levels are useful as marker to detect breast, uterine and lung cancers. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of breast, lung or uterine cancers. Panel 4.1D Summary: Ag3035 This probe/primer set recognizes a distinct portion of this 20 gene and shows a distinctive expression pattern relative to probe/primer set Ag2261 in this panel. This observation may indicate that the probe/primer sets can distinguish splice variants of this gene. In contrast to the results obtained with Ag2261 (see panel 4D summary), expression of this gene was highest in normal kidney (CT = 30.6). The other expression results for this panel were similar using both probe/primer sets. This gene 25 encodes a WNT-14 homolog and was expressed at moderate to low levels in unstimulated or cytokine-activated keratinocytes as well as in lung and dermal fibroblast preparations (CTs=29-34). Therapeutic modulation of the activity of this gene or its protein product will reduce or eliminate the symptoms of chronic obstructive pulmonary disease, asthma, emphysema, or psoriasis. In addition, due to its known effects on development of 30 vertebrate joints, the protein encoded this gene will reduce or eliminate the symptoms of osetoarthritis (Christine Hartmann and Clifford J. Tabin, 2001, Wnt-14 Plays a Pivotal 345 WO 2004/000997 PCT/US2003/017512 Role in Inducing Synovial Joint Formation in the Developing Appendicular Skeleton Cell, Vol 104, 341-35). Panel 4D Summary: Ag2261 This gene was expressed at low levels in colon (CT=33.5). Low but significant levels of expression were also seen in normal lung, keratinocytes and 5 dermal fibroblasts. This gene or the Wnt-14 protein encoded by it may play an important role in the normal homeostasis of these tissues. Therapeutic modulation of the activity of this gene or its protein product is useful to maintain or restore normal function to these organs during inflammation. Panel 5 Islet Summary: Ag3035 Highest expression of this gene was seen in sample of 10 skeletal muscle from a diabetic patient (CT=31.8). Significant expression of this gene was also seen in pancreatic islet cells. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of metabolic related disease such as obesity and diabetes, especially type II diabetes. 15 General oncology screening panel v_2.4 Summary: Ag3035 Highest expression of this gene was detected in a metastatic melanoma sample (CT=31.3). Expression of this gene was also upregulated in prostate, lung and kidney cancers when compared to their appropriate normal adjacent tissue. Gene or protein expression levels are useful for the detection of prostate cancer, lung cancer, kidney cancer and metastatic melanoma. 20 Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful for the treatment of these cancers. G. CG53473-02: NEUROMEDIN B-32 PRECURSOR Expression of gene CG53473-02 was assessed using the primer-probe set Ag235, described in Table GA. Results of the RTQ-PCR runs are shown in Tables GB and GC. 25 Table GA. Probe Name Ag235 PnerSequences Length Start Position SEQ ID No IForward 5 -ttccagcccatccccatt-3' 18 225 307 Probe TET-5' -ccccacacctccctgagggacc-3 -TAMRA 22 j253 308 Reverse 5,'-cagatcatgactcagctgcagtc-3' 23 278 309 346 WO 2004/000997 PCT/US2003/017512 Table GB. Panel 1.2 Column A - Rel. Exp.(%) Ag235, Run 119215838 Column B - Rel. Exp.(%) Ag235, Run 122741595 Tissue Name A B Tissue Name A B Endothelial cells 4.6 4.0 Renal ca. 786-0 0.3 0.2 Heart (Fetal) 07 1.8 Renal ca. A498 4.3 1.5 Pancreas 20.6 0.6 Renal ca. RXF 393 8.7 5.3 Pancreatic ca. CAPAN 2 4.3 2.7 Renal ca. ACHN 2.2 1.0 Adrenal Gland 100.0 100.0 Renal ca. UO-31 0.6 0.3 Thyroid 722 6.2 Renal ca. TK-10 .4 0.8 Salivary gland 12.6 13.8 Liver 0.4 1. Pituitary gland 23.3 2.7 Liver (fetal) 1.7 Brain (fetal) 13.7 7.7 Liver ca. (hepatoblast) HepG2 1.7 1.4 Brain (whole) 11.7 12.3 Lung 3.4 3.3 Brain (amygdala) 5.7 8.2 Lung (fetal) 2.9 2.0 Brain (cerebellum) .11.9 Lung ca. (small cell) LX-1 7.8 1.5 Brain (hippocampus) 11.3 26.2 Lung ca. (small cell) NCI-H69 0.3 0.2 Brain (thalamus) 4.2 11.9 Lung ca. (s.cell var.) SHP-77 3.8 1.4 Cerebral Cortex 3.9 19.5 Lung ca. (large cell)NCI-H460 .0 11.8 Spinal cord 17.4 19.5 Lung ca. (non-sm. cell) A549 6.9 1.7 glio/astro U87-MG 43.2 16.3 Lung ca. (non-s.cell) NCI-H23 12.9 24.1 lio/astro U- 118-MG 1.0 0.3 Lung ca. (non-s.cell) HOP-62 2.4 0.5 astrocytoma SW1783 1.9 0.6 Lung ca. (non-s.cl)NCI-H522 27.0 4.0 neuro*; met SK-N-AS 29.3 10.7 Lung ca. (squam.) SW 900 6.0 2.4 astrocytoma SF-539 1.2 0.3 Lung ca. (squam.) NCI-H596 1.0 0.3 astrocytoma SNB-75 0.0 0.3 Mammary gland 39.5 20.3 glioma SNB-19 25.2 11.8 Breast ca.* (pl.ef) MCF-7 24.0 13.0 glioma U251 5.3 2.8 Breast ca.* (pl.ef) MDA-MB-231 0.9 0.5 glioma SF-295 0.2 0.1 Breast ca.* (pl. ef) T47D 0.9 4.3 Heart 9.9 8.5 Breast ca. BT-549 11.5 8.5 Skeletal Muscle 8.7 2.7 Breast ca. MDA-N 13.7 8.9 Bone marrow 1.3 0.7 Ovary 5.8 1.8 Thymus 0.4 0.3 Ovarian ca. OVCAR-3 .0 0.8 Spleen 1.8 1.1 Ovarian ca. OVCAR-4 1.1 0.3 Lymph node 1.1 .0 Ovarian ca. OVCAR-5 9.0 6.5 Colorectal Tissue 0.0 0 3 Ovarian ca. OVCAR-8 1.0 1.3 Stomach 2.6 2.4 Ovarian ca. IGROV-1 10.7 3.7 Small intestine 1.4 1.3 Ovarian ca. (ascites) SK-OV-3 20 1.7 Colon ca. SW480 1.0 0.1 Uterus 2.9 2.1 Colon ca.* SW620 (SW480 met) 9.2 0.8 Placenta 1.8 1.1 Colon ca. HT29 25.3 .Prostate 4 Colon ca. HCT-116 4.8 2.0 Prostate ca.* (bone met) PC-3 28 17 347 WO 2004/000997 PCT/US2003/017512 Colon ca. CaCo-2 8.0 3.7 Testis 33.2 5.0 Colon ca. Tissue (0DO3866) 0.8 1.1 Melanoma Hs688(A).T 1.5 02 Colon ca. HCC-2998 42.3 14.3 Melanoma* (met) Hs688(B).T 1.7 0.2 Gastric ca.* (liver met) NCI-N87 54.7 18.3 Melanoma UACC-62 1.5 0.4 Bladder 11.7 3.5 MelanomaM14 5.5 2.5 Trachea 5.6 4.0 Melanoma LOX IMVI 6.4 1.3 Kidney 6.7 9.1 Melanoma* (met) SK-MEL-5 6.9 2.0 Kidney (fetal) 6.8 6.4 Table GC. Panel 2D Column A - Rel. Exp.(%) Ag235, Run 145728457 Tissue Name A Tissue Name A Normal Colon 3.3 Kidney Margin 8120608 1.7 CC Well to Mod Diff (ODO3866) 3.1 Kidney Cancer 8120613 10.1 CC Margin (ODO3866) 0.8 Kidney Margin 8120614 4.0 CC Gr.2 rectosigmoid (ODO3868) 1.2 Kidney Cancer 9010320 100.0 CC Margin (ODO3868) 0.4 Kidney Margin 9010321 7.2 CC Mod Diff (OD03920) 3.0 Normal Uterus 1.3 CC Margin (ODO3920) 0.7 Uterus Cancer 064011 3.1 CC Gr.2 ascend colon (ODO3921) 1.4 Normal Thyroid 66.4 CC Margin (ODO3921) 1.1 Thyroid Cancer 064010 4.5 CC from Partial Hepatectomy (ODO4309) 5.5 Thyroid Cancer A302152 6.9 Mets Liver Margin (ODO4309) 0 Thyroid Margin A302153 9.9 Colon mets to lung (OD04451-01) 3.0 Normal Breast 7.4 Lung Margin (OD04451-02) 3.0 Breast Cancer (OD04566) 0.7 Normal Prostate 6546-1 9.1 Breast Cancer (OD04590-01) 5.4 Prostate Cancer (OD04410) 2.7 Breast Cancer Mets (OD04590-03) 11.8 Pr t Breast Cancer Metastasis 1.4 Prostate Margin (ODO4410) 0 (OD04655-05) Prostate Cancer (OD04720-01) 1.1 Breast Cancer 064006 1.5 Prostate Margin (OD04720-02) 20 Breast Cancer 1024 8 Normal Lung 061010 5.1 Breast Cancer 9100266 1.7 Lung Met to Muscle (ODO4286) 7.8 Breast Margin 9100265 0.9 Muscle Margin (ODO4286) 2.0 Breast Cancer A209073 1.1 Lung Malignant Cancer (OD03126) 6.3 Breast Margin A209073 2.4 Lung Margin (OD03126) 6.7 Normal Liver .7 Lung Cancer (OD04404) 37.1 Liver Cancer 064003 0.7 Lung Margin (OD04404) 4.5 Liver Cancer 1025 0.8 Lung Cancer (OD04565) 4.6 Liver Cancer 1026 1.9 Lung Margin (OD04565) .0 Liver Cancer 6004-T 0.8 Lung Cancer (OD04237-01) 8.4 Liver Tissue 6004-N 7.8 348 WO 2004/000997 PCT/US2003/017512 Lung Margin (OD04237-02) 2.8 iver Cancer 6005-T 2.6 Ocular Mel Met to Liver (ODO4310) 1.6 Liver Tissue 6005-N 0.7 Liver Margin (ODO4310) 0.6 Normal Bladder 4.5 Melanoma Mets to Lung (OD04321) 0.4 Bladder Cancer 1023 2.2 Lung Margin (OD04321) 2.5 Bladder Cancer A302173 4.2 Normal Kidney 1.3 Bladder Cancer (OD04718-O0) 16.5 Kidney Ca, Nuclear grade 2 (OD04338) 5.9 Bladder Normal Adjacent 2.6 (OD04718-03) Kidney Margin (OD04338) 2.7 Normal Ovary 5.0 Kidney Ca Nuclear grade 1/2 (OD04339) 14.0 Ovarian Cancer 064008 6.7 Kidney Margin (OD04339) 5.0 Ovarian Cancer (OD04768-07) 10.2 Kidney Ca, Clear cell type (0D04340) 15.9 Ovary Margin (OD04768-08) 0.1 Kidney Margin (OD04340) 3.8 (Normal Stomach 2.6 Kidney Ca, Nuclear grade 3 (OD04348) 4.6 Gastric Cancer 9060358 0.0 Kidney Margin (OD04348) J0.9 Stomach Margin 9060359 0.4 Kidney Cancer (OD04622-01) 86.5 Gastric Cancer 9060395 3.2 Kidney Margin (OD04622-03) 16 Stomach Margin 9060394 2.2 Kidney Cancer (OD04450-01) 4.5 Gastric Cancer 9060397 9.2 Kidney Margin (OD04450-03) 1.3Stomach Margin 9060396 2.7 Kidney Cancer 8120607 1.5 Gastric Cancer 064005 2.8 Panel 1.2 Summary: Ag235 Highest expression of the CG53473-02 gene was seen in adrenal gland (CTs=23-26). Significant expression of this gene was also detected in pancreas, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the 5 gastrointestinal tract. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. In addition, this gene was expressed at high to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, 10 thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. High expression of this gene was also seen in a number of cancer cell lines derived 15 from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Gene or protein expression levels are useful as a 349 WO 2004/000997 PCT/US2003/017512 marker for these cancers. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, melanoma and brain cancers. Panel 2D Summary: Ag235 Highest expression of this gene was detected in a kidney 5 cancer sample (CT=27.9). This gene was overexpressed in a number of kidney, gastric, ovarian, bladder, breast and lung cancers relative to the appropriate normal tissues. Gene or protein expression levels are useful for the detection of these cancers. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of kidney, gastric, ovarian, 10 bladder, breast and lung cancer. H. CG55184-03: Cerebellin Expression of gene CG55184-03 was assessed using the primer-probe set Agl 161, described in Table HA. Results of the RTQ-PCR runs are shown in Tables HB, HC, HD and HE. 15 Table HA. Probe Name Ag1161 et IStart SEQID Primers Sequences Length Positio n SEQ ID Primers_ _........Position No Forward 5-aactccaaggtcgccttct-3' 1 9 205 310 Probe TET-5' -aaccacgagccatccgagatgag-3' -TAMRA '23 241 311 Reverse 5'-agtaaatgatgccgtcttgt-3' 21 266 312 Table HB. CNS neurodegeneration vl.0 Column A - Rel. Exp.(%) Ag1161, Run 206992277 ColumnB -Rel. Exp.(%) Agll61, Run 230512498 Tissue Name A B Tissue Name A B AD 1 Hippo 15.

6 5.6 Control (Path) 3Temporal Ctx 22.5 33.2 AD 2 Hippo 55.9 49.7 Control (Path) 4 Temporal Ctx 43.2 44.8 AD 3 Hippo 20.6 15.1 AD 1 Occipital Ctx 20.7 22.2 AD 4 Hippo 100.0 100.0 AD 2 Occipital Ctx (Missing) 0.9 0.8 AD5 Hippo ............... 31.0 40.9 AD 3 Occipital Ctx 27.2 26.2 AD 6 Hippo 8.2 8.2 AD 4 Occipital Ctx 59.5 70.2 Control 2 Hippo 29.3 30.4 AD 5 Occipital Ctx - 34.4 37.9 Control 4 Hippo 10.7 10.0 AD 6 Occipital Ctx 12.8 10.7 350 WO 2004/000997 PCT/US2003/017512 Control (Path) 3 Hippo 19.8 16.0 Control 1 Occipital Ctx 19.

9 15.8 AD 1 Temporal Ctx 10.3 8.7 Control 2 Occipital Ctx 22.5 18.9 AD 2 Temporal Ctx 25.0 25.9 Control 3 Occipital Ctx 45.4 1192 AD3Temporal x . 31.2 36.3 -iControl 4 Occipital Ctx 20.0 24.7 AD 4 Temporal Ctx 44.8 38.4 Control (Path) 1 Occipital Ctx 30.6 35.4 AD 5 Inf Temporal Ctx 25.2 25.0 Control (Path) 2 Occipital Ctx 49.3 48.6 AD 5 Sup Temporal Ctx 17.8 19.5 Control (Path) 3 Occipital Ctx 6.6 _8.9 AD 6 Inf Temporal Ctx 16.4 16.4 Control (Path) 4 Occipital Ctx 41.8 49.0 AD 6 Sup Temporal Ctx 25.2 26.6 Control 1 Parietal Ctx 29.1 0.1 Control 1 Temporal Ctx 30.6 42.6 Control 2 Parietal Ctx 2 1 .9 19.5 Control 2 Temporal Ctx 129.3 31.6 Control 3 Parietalf Ctx 40.1 46.7 Control 3 Temporal Ctx 69.7 58.6 Control (Path) 1 Parietal Ctx 54.7 49.7 Control 3 Temporal Ctx 29.1 29.1 Control (Path) 2 Parietal Ctx 46. 947.6 Control (Path) 1 Temporal Ctx 41.8 40.3 -Control (Path) 3 Parietal Ctx 123.2118.6 Control (Path) 2 Temporal Ctx 50.0 44.8 Control (Path) 4 Parietal Ctx 43.2 45.7 Table HC. General screening panel vl.7 Column A - Rel. Exp.(%) Agl161, Run 317667428 Tissue Name A Tissue Name Adipose 0.4 Gastric ca. (liver met.) NCI-N87 0.0 HUVEC Stomach 0.0 Melanoma* Hs688(A).T 0.0 Colon ca. SW-948 0.1 Melanoma* Hs688(B).T 0.0 Colon ca. SW480 0.0 Melanoma (met) SK-MEL-5 0.0 Colon ca. (SW480 met) SW620 0.0 Testis 5.6 Colon ca. HT29 0.0 Prostate ca. (bone met) PC-3 0.0 Colon ca. HCT-116 0.0 Prostate ca. DU145 0.0 Colon cancer tissue 01 Prostate pool 0.1 Colon ca. SWI116 0.0 Uterus pool 0.1 Colon ca. Colo-205 00 Ovarian ca. OVCAR-3 0 0Colon ca. SW-48 0.0 Ovarian ca. (ascites) SK-OV-3 0.0 Colon 0.0 Ovarian ca. OVCAR-4 0.0 Small Intestine 0.3 Ovarian ca. OVCAR-5 0.0 Fetal Heart 0.0 Ovarian ca. IGROV-1 0.0 Heart 0.2 Ovarian ca. OVCAR-8 0.0 Lymph Node pool 10.8 Ovary 12.6Lymph Node pool2 0.1 Breast ca. MCF-7 0.1 Fetal Skeletal Muscle 0.2 Breast ca. MDA-MB-231 0.0 Skeletal Muscle pool 0.6 Breast ca. BT-549 0.0 jSkeletal Muscle 1.8 Breast ca. T47D 0.0 Spleen 3.2 Breast pool 0.8 Thymus 1.1 Trachea 0.6 CNS cancer (glio/astro) SF-268 0.0 351 WO 2004/000997 PCT/US2003/017512 Lung 0.2 CNS cancer (glio/astro) T98G 0.0 Fetal Lung 0.7 CNS cancer (neuro;met) SK-N-AS 0.1 Lung ca. NCI-N417 0.0 CNS cancer (astro) SF-539 0.0 Lung ca. LX-1 0.0 CNS cancer (astro) SNB-75 0.0 Lung ca. NCI-H146 0.3 CNS cancer (glio) SNB-19 0.0 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.0 Lung ca. NCI-H23 0.0 Brain (Amygdala) 60.3 Lung ca. NCI-H460 0.0 Brain (Cerebellum) 0.8 Lung ca. HOP-62 0.0 Brain (Fetal) 20.6 Lung ca. NCI-H522 0.0 Brain (Hippocampus) 21.3 Lung ca. DMS-114 0.0 Cerebral Cortex pool 36.9 Liver -0.8 Brain (Substantia nigra) 26.6 Fetal Liver A04 Brain (Thalamus) 42.6 Kidney pool 2.7 Brain (Whole) 100.0 Fetal Kidney 3.4 Spinal Cord 1.9 Renal ca. 786-0 0.0 Adrenal Gland 36.6 Renal ca. A498 0.0 iPituitary Gland 0.0 Renal ca. ACHN 0.0 Salivary Gland 0.0 Renal ca. UO-31 0.0 Thyroid 10 Renal ca. TK-10 0.0 Pancreatic ca. PANC-1 .0.0 Bladder 0.4 Pancreas pool 0.8 Table HD. Panel 2.2 Column A - Rel. Exp.(%) Ag1161, Run 173769890 Tissue Name A Tissue Name A Normal Colon 4.8 Kidney Margin (OD04348) 14.0 Colon cancer (OD06064) 0.0 Kidney malignant cancer (OD06204B) 15.2 Colon Margin (OD06064) 0.0 Kidney normal adjacent tissue 8.8 (OD06204E) 8.8 Colon cancer (OD06159) 0.0 Kidney Cancer (OD04450-01) 0.0 Colon Margin (OD06159) 0.0 Kidney Margin (0D04450-03) 4.9 Colon cancer (OD06297-04) 0.0 Kidney Cancer 8120613 J0.0 Colon Margin (OD06297-05) 0.0 Kidney Margin 8120614 5.2 CC Gr.2 ascend colon (ODO3921) 0.0 Kidney Cancer 9010320 21.5 CC Margin (OD03921) 4.7 Kidney Margin 9010321 0.0 Colon cancer metastasis (OD06104) 0.0 Kidney Cancer 8120607 5.2 Lung Margin (OD06104) 3.6 Kidney Margin 8120608 0.0 Colon mets to lung (OD04451-01) 0. Normal Uterus 3.6 Lung Margin (OD04451-02) 4.0 Uterine Cancer 064011 0.0 Normal Prostate 4.5 ormal Thyroid (.O Prostate Cancer (OD04410) 0.0 Thyroid Cancer 064010 40.9 Prostate Margin (OD04410) 0.0 Thyroid Cancer A302152 9.0 352 WO 2004/000997 PCT/US2003/017512 Normal Ovary 26.4 Thyroid Margin A302153 3.7 j)Varian cancer (OD06283-03) _ Normal Breast 0 Ovarian Margin (OD06283-07) 100.0 Breast Cancer (OD04566) 5.2 Ovarian Cancer 064008 47.6 Breast Cancer 1024 0.0 Ovarian cancer (OD06145) 35.4 Breast Cancer (OD04590-01) 8.6 Ovarian Margin (OD06145) 33.2 Breast Cancer Mets (OD04590-03) 0.5 Ovarian cancer (OD06455-03) 0.0 Breast Cancer Metastasis (OD04655-05) 0.0 Ovarian Margin (OD06455-07) 22.2 Breast Cancer 064006 5.3 Normal Lung 53 Breast Cancer 9100266 0.0 Invasive poor diff, lung adeno . Breast Margin 9100265 8.1 (ODO4945-01 Lung Margin (ODO4945-03) 0.0 Breast Cancer A209073 9.7 Lung Malignant Cancer (ODO3126) 00 Breast Margin A2090734 10.4 Lung Margin (OD03126) 4.4 Breast cancer (OD06083) 4.7 Lung Cancer (OD05014A) 0.0 Breast cancer node metastasis (OD06083) 7.7 Lung Margin (OD05014B) 10.2 Normal Liver 17.6 Lung cancer (OD06081) 0.0 Liver Cancer 10260.0 Lung Margin (OD06081) 0.0 Liver Cancer 102517.9 Lung Cancer (OD04237-01) 0.0 Liver Cancer 6004-T 0.0 Lung Margin (OD04237-02) 45.4 Liver Tissue 6004-N 15.7 Ocular Melanoma Metastasis 0.0 Liver Cancer 6005-T 0.0 Ocular Melanoma Margin (Liver) 6.1 Liver Tissue 6005-N 0.0 Melanoma Metastasis 0.0 Liver Cancer 064003 0.0 Melanoma Margin (Lung) 4.7 Normal Bladder 0.0 Normal Kidney 0.0 Bladder Cancer 1023 0.0 Kidney Ca, Nuclear grade 2 (OD04338) 8.4 Bladder Cancer A302173 0.0 Kidney Margin (OD04338) 0.0 Normal Stomach 0.0 Kidney Ca Nuclear grade 1/2 (OD04339) 2.2 ... Gastric Cancer 9060397 0. Kidney Margin (OD04339) 27.7 Stomach Margin 9060396 8.7 Kidney Ca, Clear cell type (OD04340) 33.9 Gastric Cancer 9060395 .. .7 Kidney Margin (OD04340) 8.8 Stomach Margin 9060394 0.0 Kidney Ca, Nuclear grade 3 (OD04348) 9.7 Gastric Cancer 064005 0.0 Table HE. Panel 4D Column A - Rel. Exp.(%) Ag1161, Run 139841942 Tissue Name A Tissue Name A Secondary Thl act 0.0 HUVEC IL-1beta 0 Secondary Th2 act 0.0 HUVEC TNF alpha + N gamma. Secondary Trl act 0.0 HVC TNF alpha + IFN gamma 0.0 Secondary Thl rest 0.0 HUVEC TNF alpha + IL4 j0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Trl rest 0.0 Lung Microvascular EC none 0.0 353 WO 2004/000997 PCT/US2003/017512 Primary Thl act 0.0 Lung Microvascular EC TNFalpha+ IL-lbeta 0.0 Primary Th2 act 0.0 Microvascular Dermal EC none 0.0 Primary Trl act 0.0 Microsvasular Dermal EC TNFalpha + IL-lbeta 0.0 Primary Thl rest 0.0 Bronchial epithelium TNFalpha + ILlbeta 0.0 Primary Th2 rest 0.0 Small airway epithelium none 0.0 Primary Trl rest 0.0 Small airway epithelium TNFalpha + IL-lbeta 0.0 CD45RA CD4 lymphocyte act 0.0 Coronery artery SMC rest 0.0 CD45RO CD4 lymphocyte act 0.0 Coronery artery SMC TNFalpha + IL-lbeta 0.0 CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 lymphocyte rest 0.0 Astrocytes TNFalpha + IL- lbeta0.0 Secondary CD8 lymphocyte act 0.0 KU-812 (Basophil) rest 0.0 CD4 lymphocyte none 0.0 KU-812 (Basophil) PMA/ionomycin 0.0 2ry Thl/Th2/Trlanti-CD95 CH11 0.0 CCD1106 (Keratinocytes) none O.0 LAK cells rest 0.0 CCD1 106 (Keratinocytes) TNFalpha + IL-lbeta 0.0 LAK cells IL-2 0.0 Liver cirrhosis 68.3 LAK cells IL-2+TL-12 0.0 Lupus kidney 26.6 LAK cells IL-2+IFN gamma 0.0 NCI-H292 none 0.0 LAK cells IL-2+ IL-18 0.0 NCI-H292 IL-4 0.0 LAK cells PMA/ionomycin 0.0 NCI-H292 IL-9 0.0 NK Cells IL-2 rest 0.0 NCI-H292 IL-13 0.0 Two Way MLR 3 day 0.0 NCI-H292 IFN gamma 0.0 Two Way MLR 5 day 0.0 HPAEC none 0.0 Two Way MLR 7 day0.0 HPAEC TNF alpha + IL-1 beta 0.0 PBMC rest 0.0 Lung fibroblast none 0.0 PBMC PWM 0.0 Lung fibroblast TNF alpha + IL-1 beta 0.0 PBMC PHA-L 0.0 Lung fibroblast IL-4 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) ionomycin 0.0 Lung fibroblast IL-13 0.0 B lymphocytes PWM 0.0 Lung fibroblast IFN gamma 0.0 B lymphocytes CD40L and IL-4 0.0 Dermal fibroblast CCD 1070 rest 0. EOL-1 dbcAMP 0.0 Dermal fibroblast CCD1070 TNF alpha 0.0 EOL-1 dbcAMP PMAlionomycin 0.0 Dermal fibroblast CCD1070 IL-1 beta 0.0 Dendritic cells none 0.0 Dermal fibroblast IFN gamma .0 Dendritic cells LPS 0.0 Dermal fibroblast IL-4 0.0 Dendritic cells anti-CD40 0.0 IBD Colitis 2 0.0 Monocytes est 0.0 IBD Crohn's8.8 Monocytes LPS 0.0 Colon 81.8 Macrophages rest 0.0 Lung 100.0 Macrophages LPS 18.2 Thymus 26.2 HUJVEC none 0.0 Kidney HUVEC starved 0.0 354 WO 2004/000997 PCT/US2003/017512 CNSneurodegeneration_vl.0 Summary: Ag1 161 Expression of the CG55184-03 gene was down-regulated in the temporal cortex of Alzheimer's disease patients when compared with normal patients. Therefore, up-regulation of this gene or its protein product or treatment with specific agonists for this receptor is useful in reversing the 5 dementia/memory loss and neuronal death associated with this disease. General_screeningpanelvl.7 Summary: Ag1 161 Highest expression of this gene was detected in whole brain (CT=26). This gene showed brain preferential expression with high expression seen in all the regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and 10 spinal cord. Gene or protein expression levels are useful as a marker for brain. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. Moderate to low expression of this gene was also seen in tissues with 15 metabolic/endocrine function including pancreas, adipose, adrenal gland, thyroid, skeletal muscle, liver and small intestine. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. Panel 2.2 Summary: Agl 161 Highest expression of this gene was detected in normal 20 ovarian tissue (CT=32). Expression of this gene was upregulated in normal ovarian and lung samples relative to corresponding cancer samples. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of ovarian and lung cancers. Low expression of this gene was also detected in a thyroid cancer sample. 25 Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of thyroid cancer. Panel 4D Summary: AgI 161 This gene was expressed at low levels in normal lung and colon (CTs=34). Expression of this gene was downregulated in the colon from a Crohn's 355 WO 2004/000997 PCT/US2003/017512 disease patient was reduced. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of inflammatory bowel diseases, such as Crohn's. Low expression of this gene was also seen in liver cirrhosis sample. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of 5 liver cirrhosis. I. CG55274-05: Diazepam-binding inhibitor Expression of gene CG55274-05 was assessed using the primer-probe set Ag497, described in Table IA. Results of the RTQ-PCR runs are shown in Tables IB and IC. Table IA. Probe Name Ag497 10 ....... Start SEQ Primers Sequences Length Position P No Forward 5'-gcagcatggaccctccaa-3 18 181 313 Probe TET-5 -acactcgttgcatcttcctttgacaactt- 3-TAM 0 201 34 Reverse 5 -tcggctcttttgcCttagaaata-3' 23 234 315 Table IB. Panel 1.1 Column A - Rel. Exp.(%) Ag497, Run 121136178 Tissue Name A Tissue Name A Adrenal gland 0.0 Renal ca. UO-31 0.0 Bladder 0.0 Renal ica. RXF 393 0.0 Brain (amygdala) 0.0 iver 0.0 Brain (cerebellum) 0.0 Liver (fetal) -0.0 Brain hippocampusu) 0.0 Liver ca. (hepatoblast) HepG2 0.0 Brain (substantia nigra) 0.. 0 Lung .......... 0 Brain (thalamus) 0.0 Lung (fetal) 0.0 Cerebral Cortex 0o.0 Lung ca. (non-s.cell) HOP-62 0.0 Brain (fetal) 0.0 Lung ca. (large cell)NCI-H460 0.0 Brain (whole) 0.0 Lung ca. (non-s.cell) NCI-H23 0.0 glio/astro U-118-MG 0.0 Lung ca. (non-s.cl) NCI-H522 0.0 astrocytoma SF-539 .0 Lung ca. (non-sm. cell) A549 0.0 astrocytoma SNB-75 10.0 Lung ca. (s.cell var.) SHP-77 0.0 astrocytoma SW1783 0.0 Lung ca. (small cell) LX-1 0.0 glioma U251 0.0 jLung ca. (small cell) NCI-H69 12.0 glioma SF-295 .. 0.0 jLung ca. (squam.) SW 900 0.0 356 WO 2004/000997 PCT/US2003/017512 glioma SNB-19 0.0 Lunmg ca. (squam.) NCI-H596 0.0 gliolastro U87-MG 0.0 Lymph node 0.0 neuro*; met SK-N-AS 0.0 Spleen 0 .0 Mammary gland 0.0 Thymus 0.0 Breast ca. BT-549 0.0 Ovary 00 Breast ca. MDA-N 00 Ovarian ca. IGROV-1 0.0 Breast ca.* (pl.ef) T47D 0.0 Ovarian ca. OVCAR-3 0.0 Breast ca.* (pl.ef) MCF-7 0. Ovarian ca. OVCAR-4 0.0 Breast ca.* (pl.ef) MDA-MB-231 0.0 Ovarian ca. OVCAR-5 100.0 Small intestine O varian ca. OVCAR-8 0.0 Colorectal 0.0 Ovarian ca.* (ascites) SK-OV-3 0.0 Colon ca. HT29 0.0 Pancreas 0.0 Colon ca. CaCo-2 0.0 Pancreatic ca. CAPAN 2 0.0 Colon ca. HCT-15 0.0 Pituitary gland 0.0 Colon ca. HCT-116 0.0 Placenta 0.0 Colon ca. HCC-2998 0. Prostate 0.0 Colon ca. SW480 0.0 Prostate ca.* (bone met) PC-3 0.0 Colon ca.* SW620 (SW480 met) .0 Salivary gland 0.0 Stomach 0.0 Trachea 0.0 Gastric ca. (liver met) NCI-N87 0.0 Spinal cord 0.0 Heart 0.0 Testis 0.0 Skeletal muscle (Fetal) 0.0 Thyroid 0.0 Skeletal muscle 0.0 Uterus 0.0 Endothelial cells 0.0 Melanoma M14 0.0 Heart (Fetal) 0.0 Melanoma LOX IMVI 0.0 Kidney 0.0 Melanoma UACC-62 0.0 Kidney (fetal) 0.0 Melanoma SK-MEL-28 0.0 Renal ca. 786-0 0.0 Melanoma* (met) SK-MEL-5 0.0 Renal ca. A498 0.0 Melanoma Hs688(A).T 0.0 Renal ca. ACHN 0.0 Melanoma* (met) Hs688(B).T 0.0 Renal -ca. TK-10 0.0 Table IC. Panel 5 Islet Column A - Rel. Exp.(%/o) Ag497, Run 323591176 Tissue Name A Tissue Name A 97457_Patient-02go_adipose 0.0 94709_Donor 2 AM - Aadipose 0.0 97476 Patient-07sk skeletal muscle 0.0 94710_Donor 2 AM - B _adipose 0.0 97477 Patient-07ut uterus 0.0 94711 Donor 2 AM - Cadipose 0.0 97478 Patient-07plplacenta 0.0 94712 Donor 2 AD - Aadipose - 0.0 99167_Bayer Patient 1 0.0 94713_Donor 2 AD - B_adipose 0.0 97482 Patient-08ututerus 0.0 94714_Donor 2 AD -C adipose 0.0 357 WO 2004/000997 PCT/US2003/017512 94742_Donor 3 U - AMesenchymal Stem 0.0 97483_Patient-08pl_placenta 0.0 Cells 0.0 ..... ............... ............. ................. ............. 94743 D onor 3 U -B MVesenchya l Stem 97486_Patient-09sk_ skeletal muscle 0.0 9474Cells3Donor 3 U - BMesenchymal Stem0.0 - Cells 97487 Patient-09ut uterus 0.0 94730 Donor 3 AM - A adipose 10.5 97488 Patient-09pl_placenta 0.0 94731 Donor 3 AM - B adipose 0.0 97492 Patient-O10ut uterus 0.0 94732 Donor 3 AM - C adipose 0.0 97493 Patient-10plplacenta 12.5 94733 Donor 3 AD- A adipose 0.0 97495 Patient-i Igo adipose 0.0 94734 Donor 3 AD - Badipose 24.1 97496 Patient-1 lskskeletal muscle 6.3 94735 Donor 3 AD - Cadipose 0.0 97497 Patient-int uterus 0.0 77138 Liver HepG2untreated 0.0 97498Patient- plplacenta 0.0 73556 Heart Cardiac stromal cells 0.0 97498_Patient-11lpl_placenta 0.0 0pia-y ... 0... (primary) 97500 Patient-12go adipose 0.0 81735 Small Intestine 20.7

..

1 . .72409 Kidney Proximal Convoluted 97501_Patient-12skskeletal muscle 100.0 72409 KidnTubule yroximal Convoluted 0.0 ____________________________________________ ______JTubule 97502 Patient-1i2ut uterus .8.1 82685 Small intestineDuodenum 0.0 97503 Patient-12pl_placenta 10.0 90650 Adrenal Adrenocortical adenoma 0.0 94721 Donor 2 U - AMesenchymal 1.3 72410 Kidney HRCE 0.0 Stem Cells 94722 Donor 2 U - B Mesenchymal Stem 0.

0 72411 Kidney HRE 0.0 Cells 94723_Donor 2 U - C Mesenchymal Stem 0.0 73139 UterusUterine smooth muscle cells 0.0 Cells_ Panel 1.1 Summary: Ag497 Low expression of the CG55274-05 gene was restricted to the ovarian cancer cell line OVCAR-5 (CT=33.6). Gene or protein expression levels are useful as a marker to detect the presence of ovarian cancer. Therapeutic modulation of the 5 activity of this gene or its protein product is useful in the treatment of ovarian cancer. Panel 5 Islet Summary: Ag497 Low expression of this gene was mainly detected in a skeletal muscle sample from a diabetic patient on insulin (CT=33.6). The CG55274-05 gene encodes Diazepam-binding inhibitor, a member of the endozepine/acetyl CoA binding protein (ACBP)/diazepam binding inhibitor (DBI) family. ACBP is known to 10 affect intracellular calcium levels via release from the sarcoplasmic reticulum in muscle, via the ryanodine receptor, and possibly the mitochondria (Fulceri R, Knudsen J, Giunti R, Volpe P, Nori A, Benedetti A. Fatty acyl-CoA-acyl-CoA-binding protein complexes activate the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum. Biochem J 1997 Jul 15;325 (Pt 2):423-8; Fulceri R, Giunti R, Knudsen J, Leuzzi R, Kardon T, 15 Benedetti A. Rapamycin inhibits activation of ryanodine receptors from skeletal muscle by 358 WO 2004/000997 PCT/US2003/017512 the fatty acyl CoA-acyl CoA binding protein complex. Biochem Biophys Res Commun 1999 Oct 22;264(2):409-12). Since the activity of many metabolic enzymes is regulated by intracellular calcium, ACBP could play an important role in many aspects of energy metabolism. Furthermore, the peptides produced from ACBP act as hormones or paracrine 5 factors to influence metabolism globally. One ACBP-derived peptide (octadecaneuropeptide: ODN - ACBP33-50) exerts this action through several mechanisms. One mechanism influences nutrient absorption through the stimulation of CCK secretion and the subsequent secretion by the exocrine pancreas (Herzig KH; Schon I; Tatemoto K; Ohe Y; Li Y; Folsch UR; Owyang C. Diazepam binding inhibitor is a 10 potent cholecystokinin-releasing peptide in the intestine. Proc. Nat. Acad. Sci. 1996; 93: 7927-7932). At the same time ODN inhibits glucose-stimulated insulin secretion from the endocrine pancreas [10]. In addition, intracerebroventricular administration of ODN has anorexigenic effects in rats (de Mateos-Verchere JG, Leprince J, Tonon MC, Vaudry H, Costentin J. The octadecaneuropeptide [diazepam-binding inhibitor (33-50)] exerts potent 15 anorexigenic effects in rodents. Eur J Pharmacol 2001 Mar 2;414(2-3):225-31). Full-length ACBP and peptides derived from the parent polypeptide participate in several different feedback loops influencing metabolism at many levels. Based upon the specific expression of this gene in skeletal muscle from diabetic patient and that ODN has broad-ranging effects on physiologic processes, ODN-related peptides from the 20 CG55274-05 gene, encoding an ACBP-like protein, are potential protein therapeutics for the treatment of metabolic disorders such as obesity and diabetes. J. CG55379-01 and CG55379-04: hNOPE Expression of gene CG55379-01 and CG55379-04 was assessed using the primer-probe set Ag902, described in Table JA. Results of the RTQ-PCR runs are shown 25 in Tables JB, JC, JD, JE, JF, JG and JH. Table JA. Probe Name Ag902 Primrs.............Start SEQ ID Primers Sequences Length Position No Forward 5' -atcaaacagctccacatccat-3 '21 228 9 316 Probe TET-5"-aaaagccagatttcaccacagtcaag-3' -TAMRA 26 2324 317 Reverse 5' -agcgcacagtgtagttgacaat-3' "... 22 28___ 359 WO 2004/000997 PCT/US2003/017512 Table JB. CNS neurodegeneration v1.0 Column A - Rel. Exp.(%) Ag902, Run 207567448 Tissue Name A Tissue NameA AD 1 Hippo 53.2 Control (Path) 3 Temporal Ctx 34.9 AD 2 Hippo 62.4 Control (Path) 4 Temporal Ctx 27.2 AD 3 Hippo 270 AD 1 Occipital Ctx 24.8 AD 4 Hippo 38.2 AD 2 Occipital Ctx (Missing) 4.6 AD 5 Hippo 19.8 AD 3 Occipital Ctx 268 AD6 Hippo 63.3 AD 4 Occipital Cx 293 Control 2 Hippo 31.9 AD 5 Occipital Ctx 22.4 Control 4 Hippo 100.0 AD 6 Occipital Ctx 20.9 Control (Path) 3 Hippo 28.5 Control 1 Occipital Ctx 29.1 AD 1 Temporal Ctx 503 Control 2 Occipital Ctx 24.3 AD 2 Temporal Ctx 56 Control 3 Occipital Ctx 24.8 AD 3 Temporal Ctx 41.2 Control 4 Occipital Ctx 56.6 AD 4 Temporal Ctx 5.4 Control (Path) 1 Occipital Ctx 31.2 AD 5 Inf Temporal Ctx 27.2 Control (Path) 2 Occipital Ctx 7.2 AD 5 Sup Temporal Ctx 48.0 Control (Path) 3 Occipital Ctx 26.8 AD 6 Inf Temporal Ctx 38.7 Control (Path) 4 Occipital Ctx 19.5 AD 6 Sup Temporal Ctx 46.0 Control 1 Parietal Ctx 30.1 Control 1 Temporal Ctx 17.4 Control 2 Parietal Ctx 41.2 Control 2 Temporal Ctx 25.0 Control 3 Parietal Ctx 28.7 Control 3 Temporal Ctx 25.0 Control (Path) 1 Parietal Ctx 25.5 Control 3 Temporal Ctx 53.6 Control (Path) 2 Parietal Ctx 34.6 Control (Path) 1 Temporal Ctx 23.5 Control (Path) 3 Parietal Ctx 45.4 Control (Path) 2 Temporal Ctx 27.7 Control (Path) 4 Parietal Ctx 29.9 Table JC. General screening panel v1.4 5 Column A - Rel. Exp.(%) Ag902, Run 214145283 Tissue Name A issue Name A Adipose 2.6 Renal ca. TK-10 [32.8 Melanoma* Hs688(A).T 9.1 Bladder 3.9 Melanoma* Hs688(B).T 8.7 Gastric ca. (liver met.) NCI-N87 0.2 Melanoma* M-14 0.2 Gastric ca. KATO III 0.1 Melanoma* LOXIMVI ... 0.0 Colon ca. SW-948 0.2 Melanoma* SK-MEL-5 0.5 Colon ca. SW480 6.4 Squamous cell carcinoma SCC-4 0.2 Colon ca.* (SW480 met) SW620 4.0 Testis Pool 14.2 Colon ca. HT29 0.0 Prostate ca.* (bone met) PC-3 3.0 Colon ca. HCT-116 0.4 Prostate Pool 1.6 Colon ca. CaCo-2 7.0 360 WO 2004/000997 PCT/US2003/017512 Placenta 63.3 Colon cancer tissue 4.4 Uterus Pool 2.4 Colon ca. SW1116 0.0 Ovarian ca. OVCAR-3 0.4 Colon ca. Colo-205 0.1 Ovarian ca. SK-OV-3 4.5 Colon ca. SW-48 0.0 Ovarian ca. OVCAR-4 3.4 Colon Pool 6.8 Ovarian ca. OVCAR-5 6.9 Small Intestine Pool 6.4 Ovarian ca. IGROV-1 1.4 Stomach Pool 10.9 Ovarian ca. OVCAR-8 14.7 Bone Marrow Pool 9.6 Ovary 26.6 Fetal Heart 7 Breast ca. MCF-7 4 Heart Pool 48 Breast ca. MDA-MB-231 9.9 LymphNode Pool 13.5 Breast ca. BT 549 1.2 Fetal Skeletal Muscle 67.8 Breast ca. T47D 12.2 Skeletal Muscle Pool 25.7 Breast ca. MDA-N 0.0 Spleen Pool 29 Breast Pool 12.9 Thymus Pool 9.9 Trachea 3.6 CNS cancer (glio/astro) U87-MG 10.2 Lung 10.6 CNS cancer (glio/astro) U-118-MG 24.7 Fetal Lung 75.8 CNS cancer (neuro;met) SK-N-AS 14.0 Lung ca. NCI-N417 0.9 CNS cancer (astro) SF-539 94 Lung ca. LX-1 3.8 CNS cancer (astro) SNB-759.2 Lung ca. NCI-H146 0.3 CNS cancer (glio) SNB-19 1.4 Lung ca. SHP-77 1.6 CNS cancer (glio) SF-295 4.6 Lung ca. A549 5.5 Brain (Amygdala) Pool 8.5 Lung ca. NCI-H526 1.1 Brain (cerebellum) 6.7 Lung ca. NCI-H23 7.3 Brain (fetal) 62.0 Lung ca.NCI-H460 0.4 Brain (Hippocampus) Pool 19.5 Lung ca. HOP-62 3.1 Cerebral Cortex Pool 8.7 Lung ca. NCI-H522 47.6 Brain (Substantia nigra) Pool 10.2 Liver 0.0 Brain (Thalamus) Pool 12.8 Fetal Liver 29.1 Brain (whole) 111. Liver ca. HepG2 0.2 Spinal Cord Pool 20.9 Kidney Pool 11.0 Adrenal Gland _ 32.8 Fetal Kidney 22.8 Pituitary gland Pool 12.7 Renal ca. 786-0 0.7 Salivary Gland 0.5 Renal ca. A498 0.6 Thyroid (female) 6.9 Renal ca. ACHN 72 Pancreatic ca. CAPAN2 100.0 Renal ca. UO-31 45.7 Pancreas Pool 5.3 361 WO 2004/000997 PCT/US2003/017512 Table JD. HASS Panel vl.0 Column A- Rel. Exp.(%) Ag902, Run 273142965 Tissue Name A Tissue Name A MCF-7 C1 01 U87-MG Fl (B) _ _ MCF-7 C2 0.1 U87-MG F2 0 MCF-7 C3 0.1 U87-MG F3 33 MCF-7 C4 0.1 U87-MG F4 0.2 MCF-7 C5 0.1 U87-MG F5 2.3 MCF-7 C6 0.1 U87-MG F6 11.6 MCF-7 C7 0.1 U87-MG F7 0.9 MCF-7 C9 0.0 U87-MG F8 4.4 MCF-7 C10 0.1 U87-MG F9 0.7 MCF-7 C11 0.1 U87-MG F10 2.0 MCF-7 C12 0.2 U87-MG F 1 11.4 MCF-7 C13 0.2 U87-MG F12 18 MCF-7 C15 0.0 U87-MG F13 30 MCF-7 C16 0.2 U87-MG F14 9.7 MCF-7 C17 0.2 U87-MG F15 1.5 T24 D1 0.0 U87-MG F16 2.4 T24 D2 0.0 U87-MG F17 3.0 T24 D3 0.1 LnCAP Al 0.1 T24 D4 0.0 LnCAP A2 0.1 T24 D5 0.0 LnCAP A3 0.0 T24 D6 0.1 LuCAP A4 0.0 T24 D7 0.1 LnCAP A5 0.0 T24 D9 0.2 LnCAP A6 0.0 T24 D10 0.0 LnCAP A7 0.0 T24 D11 0.2 LnCAP A8 0.2 T24 D12 0.1 LnCAP A9 0.2 T24 D13 0.0 LnCAP A10 0.0 T24 D15 0.0 LnCAP Al l 0.4 T24 D16 0.1 LnCAP A12 0.0 T24D17 0.4 LnCAP A13 0.0 CAPaN B1 70.7 LnCAP A14 0.2 CAPaN B2 45.1 LnCAP A15 0.3 CAPaN B3 23.3 LnCAPA16 0.1 CAPaN B4 31.6 LnCAP A17 0.3 CAPaN B5 67.4 Primary Astrocytes 10.0 CAPaN B6 50.3 Primary Renal Proximal Tubule Epithelial cell A2 10.2 CAPaN B7 34.2 Primary melanocytes AS 0.0 CAPaN B8 69.3 126443 - 341 medullo 0.5 362 WO 2004/000997 PCT/US2003/017512 CAPaN B9 78.5 126444 - 487 medullo 19.6 CAPaN B10 47.0 126445 - 425 medullo 7.5 APaN 79.0 126446 - 690 medullo 14.7 CAPaN B12 45.1 126447 - 54 adult glioma 10.4 CAPaN B13 .38.7 126448 - 245 adult glioma 3.6 CAPaN B14 42.0 126449 - 317 adult glioma 100.0 CAPaN B15 45.1 126450- 212 glioma 52.1 CAPaN B16 52.9 126451 -456 glioma 23.0 CAPaN B17 52.9 Table JE. Panel 2D Column A - Rel. Exp.(%) Ag902, Run146087175 Column B - Rel. Exp.(%) Ag902, Run 151091474 Tissue Name A Tissue Name A B Normal Colon 89 Kidney Margin 8120608 0.5 0.8 CC Well to Mod Diff (ODO3866) 4.1 5.0 Kidney Cancer 8120613 1.6 0.9 CC Margin (ODO3866) 5.9 3.6 Kidney Margin 8120614 1.5 1.2 CC Gr.2 rectosigmoid (ODO3868) 0 Kidney Cancer 9010320 90 .3 CC Margin (ODO3868) .3 1.2 Kidney Margin 9010321 5.1 4.1 CC Mod Diff (ODO3920) 19.6 19.5 Normal Uterus 9.5 6.7 CC Margin (ODO3920) 6.2 93 Uterus Cancer 064011 20.9 18.9 CC Gr.2 ascend colon (OD03921) 25.9 34.2 Normal Thyroid 42.9 41.2 CC Margin (ODO3921) 6.7 7.2 Thyroid Cancer 064010 11.8 16.6 CC from Partial Hepatectomy 3.3 2.6 Thyroid Cancer A302152 12.8 9.9 (ODO4309) Mets Liver Margin (ODO4309) 0 Thyroid Margin A302153 9.5 14.4 Colon mets to lung (OD04451-01) 5.0 2 Normal Breast 16.5 18.9 Lung Margin (OD04451-02) 0.6 O Breast Cancer (OD04566) .5 4.0 Normal Prostate 6546-1 4.8 3.0 Breast Cancer (OD04590-01) 5.7 3.1 Breast Cancer Mets Prostate Cancer (OD04410) 3.5 3.9 D04590 ).9 Prostate Margin (0D0441 0) 6.0 6.8 {ratCne eatss5.43. Breast Cancer Metastasis Prostate Margin (OD4410) (OD04655-05) 5... Prostate Cancer (OD04720-01) 0.9 1.2 Breast Cancer 064006 11.3 8.4 Prostate Margin (OD04720-02) 6.3 2.4 Breast Cancer 1024 284 Normal Lung 061010 16.5 18.6 Breast Cancer 9100266 1.1 1.2 Lung Met to Muscle (ODO4286) 31.4 28.1 Breast Margin 9100265 21.9 27.9 Muscle Margin (ODO4286) 53.6 66.4 Breast Cancer A209073 i 2 7

.

2 9

.

5 Lung Malignant Cancer (OD03126) 8.7 10.0 Breast Margin A209073 20.4 71 Lung Margin (OD03126) 8.8 4.6 Normal Liver 0. 0.3 Lung Cancer (OD04404) 7.2 9.2 Liver Cancer 064003 0.3 0.8 Lg Margin (D044047.9 Liver Cancer 1025 0.0 0.0 363 WO 2004/000997 PCT/US2003/017512 Lung Cancer (ODO4565) 4.6 4.3 Liver Cancer 1026 2.8 3.2 Lung Margin (OD04565) 1.7 0.9 Liver Cancer 6004-T . 0.2 0.4 Lung Cancer (OD04237-01) 22.4 16.8 Liver Tissue 6004-N 2.1 0.3 Lung Margin (OD04237-02) 1.5 1.9 Liver Cancer 6005-T 1.1 3.9 Ocular Mel Met to Liver (OD043 10) 1.4 1.4 Liver Tissue 6005-N 0.5 .0.0 Liver Margin (0DO4310) 0.1 02 Normal Bladder 13 .1 10.7 iMelanoma Mets to Lung (0D04321) 0.3 0.6 Bladder Cancer 1023 1 _2.5 Lung Margin (OD04321) 1.2 2.1 Bladder Cancer A302173 3.5 4.7 Normal Kidney 3.6 4.7 Bladder Cancer (OD04718-01) 6.1 7.6 Kidney Ca, Nuclear grade 2 78 722 Bladder Normal Adjacent 339 24.7 78.5 72.2 33.9.24.7 (OD04338) (OD04718-03) Kidney Margin (OD04338) 4.2 6.0 Normal Ovary 43.5 48.0 OvarianyCanerNucD04ar8grad4.613. Kidney Ca Nuclear grade 1/2 62.0 54.3 Ovarian Cancer 064008 32.1 26.4 (OD04339) Kidney Margin (OD04339) 3.0 2.9 Ovarian Cancer (D0O4768-07) 4.6 3.3 Kidney Ca, Clear cell type (OD04340) 0.5 1.2 Ovary Margin (OD04768-08) 5.7 4.7 Kidney Margin (OD04340) 3.5 3.7 Normal Stomach 13.6 16.7 Kidney Ca, Nuclear grade 3 7.5 9.5 Gastric Cancer 9060358 12.1 16.5 (OD04348) Kidney Margin (OD04348) 3.1 4.2 Stomach Margin 9060359 8.5 9.9 Kidney Cancer (OD04622-01) 100.0 100.0 Gastric Cancer 9060395 14.5 12.9 Kidney Margin (OD04622-03) 0.0 0.6 Stomach Margin 9060394 14.1 14.1 Kidney Cancer (OD04450-01) 11.2 12.7 Gastric Cancer 9060397 6.3 8.2 Kidney Margin (OD04450-03) 2.0 3.2 Stomach Margin 9060396 3 3... ... 3 [Kidney Cancer 8120607 7.1 6.7 Gastric Cancer 06400 1.9 6.4 Table JIF. Panel 3D Column A - Rel. Exp.(%) Ag902, Run 164844768 Tissue Name A Tissue Name A Daoy- Medulloblastoma 4.8 Ca Ski- Cervical epidemoid carcinoma Daoy- Medulloblastoma (metastasis) 0.0 TE671- Medulloblastoma39.8 ES-2- Ovarian clear cell carcinoma 0.0 D283 Med- Medulloblastoma 49.3 Ramos- Stimulated with PMAlionomycin 6h 0.0 PFSK- - Primitive Neuroectodermal 0.0 Ramos- Stimulated with PMAlionomycin 14h 0.0 MEG-01- Chronic myelogenous leukemia 2.2 (megokaryoblast) SNB-78- Glioma 12.6 Raji- Burkitt's lymphoma 0.0 SF-268- Glioblastoma 0.8 Daudi- Burkitt's lymphoma 0.8 T98G- Glioblastoma 0.0 U266- B-cell plasmacytoma 0.0 SK-N-SH- Neuroblastoma (metastasis) 0.5 CA46- Burkitt's lymphoma 1.3 SF-295- Glioblastoma 1.2 RL- non-Hodgkin's B-cell lymphoma 0.0 1 Cerebellum 8.1 JM1- pre-B-cell lymphoma 0.0 364 WO 2004/000997 PCT/US2003/017512 Cerebellum 4.4 Jurkat- T cell leukemia 0.0 NCI-H292- Mucoepidermoid lung 0.7 TF-1- Erythroleukemia 0.6 carcinoma DMS-114- Small cell lung cancer 9.7 HUT 78- T-cell lymphoma 0.8 DMS-79- Small cell lung cancer 24.5 U937- Histiocytic lymphoma 0.7 NCI-H146- Small cell lung cancer 2.2 KU-812- Myelogenous leukemia 0.0 NCI-H526- Small cell lung cancer 11.4 769-P- Clear cell renal carcinoma 0.0 NCI-N417- Small cell lung cancer 5.3 Caki-2- Clear cell renal carcinoma 5.8 NCI-H1182- Small cell lung cancer 13.1 SW 839- Clear cell renal carcinoma 1.7 NCI-H157- Squamous cell lung cancer 0.0 Rhabdoid kidney tumor 25.2 (m etastasis)..... ................. ... NCI-H1 155- Large cell lung cancer 16.2 Hs766T- Pancreatic carcinoma (LN CI-H1155- Large cell lung cancer 16.2 metastasis) 3.9 NCI-1299- Large cell lung cancer 2.4 CAPAN-1- Pancreatic adenocarcinoma (liver 3.1 NCI-H1299- Large cell lung cancer 2.4 metastasis) NCI-H727- Lung carcinoid 1.7 SU86.86- Pancreatic carcinoma (liver 25.9 NCI-H727- Lung carcinoid 1.7 metastasis) 25.9 NCI-UMC-11- Lung carcinoid 3.1 BxPC-3- Pancreatic adenocarcinoma 0.0 LX-1- Small cell lung cancer 5.1 HPAC- Pancreatic adenocarcinoma 2.9 Colo-205- Colon cancer 1.6 MIA PaCa-2- Pancreatic carcinoma 0.0 KM12- Colon cancer 0.0 CFPAC-1- Pancreatic ductal adenocarcinoma 6.3 KM2 .... .... ..... r .... PANC-1- Pancreatic epithelioid ductal 8.5 KM2L2- Colcarcinoma NCI-H716- Colon cancer 1i00.0 T24- Bladder carcinma (transitional cell) 0.0 SW-48- Colon adenocarcinoma 0.0 5637- Bladder carcinoma 0.0 SW1116- Colon adenocarcinoma 0.0 HT-1 197- Bladder carcinoma 0.0 LS 174T- Colon adenocarcinoma 8.8 UM-UC-3- Bladder carcinma (transitional 0.0 cell) SW-948- Colon adenocarcinoma 0.0 A204- Rhabdomyosarcoma 0.5 SW-480- Colon adenocarcinoma 0.0 HT-1080- Fibrosarcoma 3.7 NCI-SNU-5- Gastric carcinoma 5.4 MG-63- Osteosarcoma 7.9 KATO III- Gastric carcinoma 1.9 SK-LMS-1- Leiomyosarcoma (vulva) 2.2 NCI-SNU-16- Gastric carcinoma 107 SJRH30- Rhabdomyosarcoma (met to bone NCI-SNU-16- Gastric carcinoma 10.7 mro)33.4 marrow) NCI-SNU-1l- Gastric carcinoma 0.0 A431- Epidermoid carcinoma 0.0 RF1- Gastric adenocarcinoma 07 WM266-4- Melanoma 08 RF-48- Gastric adenocarcinoma 1.4 DU 145- Prostate carcinoma (brain metastasis) 0.8 MKN-45- Gastric carcinoma 0.9 MDA-MB-468- Breast adenocarcinoma 0.0 NCI-N87- Gastric carcinoma 0.0 SCC-4- Squamous cell carcinoma of tongue 1.3 OVCAR-5- Ovarian carcinoma 1.0 SCC-9- Squamous cell carcinoma of tongue 0.0 IRL95 2- Uterine carcinoma 10.0 ISCC-15- Squamous cell carcinoma of tongue 0.0 [HelaS3- Cervical adenocarcinoma 0.7 CAL 27- Squamous cell carcinoma of tongue 0.0 365 WO 2004/000997 PCT/US2003/017512 Table JG. Panel 4.1D Column A - Rel. Exp.(%) Ag902, Run 184565260 Tissue Name A Tissue Name A Secondary Thl act 0.0 HIJUVEC IL-lbeta 00 Secondary Th2 act 0.0 HUVEC IFN gamma 1 Secondary Tr act 0.2 HUVEC TNF alpha + IFN gamma 00 Secondary Thl rest 0.2 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.3 HUVEC IL-11 0.0 Secondary Trl rest 0.0 Lung Microvascular EC none 0.4 Primary Thl act 0.0 Lung Microvascular EC TNFalpha + IL-lbeta 03 Primary Th2 act 0.1 Microvascular Dermal EC none 0.0 Primary Trl act 0.0 Microsvasular Dermal EC TNFalph + IL-lbet Primary Thl rest 04 Bronchial epithelium TNFalpha + ILibeta 2.4 Primary Th2 rest Small airway epithelium none 1.6 Primary Trl rest 0.0 Small airway epithelium TNFalpha + IL-lbeta 0.4 CD45RA CD4 lymphocyte act 1.7 Coronery artery SMC rest 0.9 CD45RO CD4 lymphocyte act 0.2 Coronery artery SMC TNFalpha + IL-lbeta .4 CD8 lymphocyte act 0.0 Astrocytes rest 13.3 Secondary CD8 lymphocyte rest 0.3 Astrocytes TNFalpha + IL-ibeta 9.8 Secondary CD8 lymphocyte act 0.0 KU-812 (Basophil) rest 0.0 CD4 lymphocyte none 0.0 KU-812 (Basophil) PMA/ionomycin 0.0 2 ry Thlh2/Tr1l anti-CD95 CH11 .3 CCD1106 (Keratinocytes) none 0.3 LAK cells rest 0.0 CCD1106 (Keratinocytes) TNFalpha + IL-lbeta 0.0 LAK cells IL-2 0.0 Liver cirrhosis 0.1 LAK cells IL-2+IL-12 0.0 NCI-H292 none 0.5 LAK cells IL-2+IFN gamma 0.5 NCI-H292 IL-4 0.0 LAK cells IL-2+ IL-18 0.7 NCI-H292 IL-9 1.0 LAK cells PMA/ionomycin 0.0 NCI-H292 IL-13 0.0 NK Cells IL-2 rest 10.8 NCI-1H292 IFN gamma 0.3 Two Way MLR 3 day 0.8 HPAEC none 0.0 Two Way MLR 5 day 0.0 HPAEC TNF alpha + IL-1 beta 0.0 Two Way MLR 7 day . Lung fibroblast none 4.2 PBMC rest 0.0 Lung fibroblast TNF alpha + IL-1 beta 14.5 PBMC PWM 0.0 Lung fibroblast IL-4 4.1 PBMC PHA-L 0.0 Lung fibroblast IL-9 3.0 Ramos (B cell) none . Lung fibroblast IL-13 4.2 amos (B cell) ionomycin 0.0 Lung fibroblast IFN gamma 4.2 B lymphocytes PWM 0.0 Dermal fibroblast CCD1070 rest 3.6 B lymphocytes CD40L and L -4 0.2 Dermal fibroblast CCD1070 TNF alpha 1.5 EOL-1 dbcAMP 0.0 Dermal fibroblast CCD1070 IL-1 beta 2.2 EOL-1 dbcAMP PMA/ionomycin 0 Dermal fibroblast IFN gamma 9.5 366 WO 2004/000997 PCT/US2003/017512 Dendritic cells none 0.0 Dermal fibroblast IL-4 30.4 Dendritic cells LPS 100.0 Dermal Fibroblasts rest 6.1 Dendritic cells anti-CD40 0.0 Neutrophils TNFa+LPS 0.0_ Monocytes rest 0.0 Neutrophils rest 0.0 Monocytes LPS 0.8 Colon 0.9 Macrophages rest 6.9 Lung 3.1 Macrophages LPS 1.0 Thymus8.4 HUVEC none 0.0 Kidney .1.5 1-UVEC starv d 10.0 Table JHI. Panel 5D Column A - Rel. Exp.(%) Ag902, Run 258659600 Tissue Name A Tissue Name A 97457 Patient-02go adipose 2.0 94709 Donor 2 AM - A adipose 1. 97476 Patient-07sk skeletal muscle 12.9 94710 Donor 2 AM- B adipose 3.0 97477 Patient-07ut uterus 0.0 94711 Donor 2 AM - C adipose 3.5 97478 Patient-07pl placenta 39.5 94712 Donor 2 AD - A adipose 5.0 97481 Patient-08skskeletal muscle 8.8 94713 Donor 2 AD -B _adipose 6.6 97482_Patient-08ut uterus .8 94714 Donor 2 AD - C adipose 6. 97483 Patient-08plplacenta 25.2 94742_Donor 3 U - A_Mesenchymal Stem 2. .- pCells 97486Patient-9skskeletal muscle 9.0 94743 _Donor 3 U - BMesenchymal Stem 6.0 97486_Patient-09skskeletal muscle Cells 97487 Patient-09ut uterus 2.3 94730_Donor 3 AM - A_adipose 3.4 97488_Patient-09plplacenta 27.5 94731 Donor 3 AM - Badipose 2.8 97492 Patient-10ut uterus 0.6 94732 Donor 3 AM - C_adipose 3.1 97493_Patient-10plplacenta 80.7 94733 Donor 3 AD - Aadipose 9.5 97495 Patient-llgo adipose 2.7 94734 Donor 3 AD - Badipose 3.3 97496_Patient-ilsk skeletal muscle 4.0 94735 Donor 3 AD - Cadipose 8.0 97497_Patient-1 lututerus 0.0 77138 _Liver HepG2untreated 6.2 97498 Patient-lplplacenta 57.4 73556 HeartCardiac stromal cells 0. 97498_Patient-11pl_placenta (primary) 0 97500 Patient-12go_adipose 5.1 81735_Small Intestine 5.0 97501Patient-2skskeletalmuscle 100.0 72409 KidneyProximal Convoluted 2.6 750_Patient-12 skskeletalmuscle Tubule 97502 Patient-12ut uterus 1.3 82685 Small intestine Duodenum 1.2 97503 Patient-12plplacenta 35.4 90650 Adrenal Adrenocortical adenoma .4 94721_Donor 2 U - A_Mesenchymal 3.5 72410 Kidney HRCE 12.7 Stem Cells _ 94722 Donor 2 U - BMesenchymal Stem 1.8 72411 KidneylHRE 36.9 94723_Donor 2 U - C_Mesenchymal 73tem nn Cells -7_ KinytR 723_Donor 2 U -CMesenchymal Stem 3. 73139 Uterus Uterine smooth muscle cells 4.2 Cells Uteu 367 WO 2004/000997 PCT/US2003/017512 CNS_neurodegenerationvl.0 Summary: Ag902 Expression of the CG55379-01 and CG55379-04 genes was upregulated in the temporal cortex of Alzheimer's disease patients compared to normal patients. Therefore, therapeutic modulation of the activity of these 5 genes or their protein products using nucleic acid, protein, antibody and small molecule drugs is useful decreasing neuronal death that accompanies Alzheimer's disease. General_screening_panel vyl.

4 Summary: Ag902 Highest expression of these genes was detected in pancreatic cancer cell line CAPAN2 (CT=27). Moderate levels of expression of these genes were also seen in cluster of cell lines derived from gastric, 10 colon, lung, renal, breast, ovarian, prostate, and brain cancers and melanomas. Gene or protein expression levels are useful as a marker to detect the presence of these cancers. Therapeutic modulation of the activity of these genes using nucleic acid, protein, antibody or small molecule drugs will be effective in the treatment of pancreatic, gastric, colon, lung, renal, breast, ovarian, prostate, melanoma and brain cancers. 15 Among tissues with metabolic or endocrine function, these genes were expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therapeutic modulation of the activity of these genes or their protein products is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. 20 In addition, these gene variants were expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. The protein encoded by this gene is a homolog of mouse NOPE protein, which functions as a guidance receptor in the developing CNS (Salbaum JM, Kappen C., 2000, Cloning and expression of nope, a new 25 mouse gene of the immunoglobulin superfamily related to guidance receptors. Genomics. 64(1):15-23, PMID: 10708514). Therapeutic modulation of the activity of these genes or their protein products is useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. 368 WO 2004/000997 PCT/US2003/017512 Expression of these genes was higher in fetal tissues relative to adult tissues, especially in fetal liver, lung, and brain. The relative overexpression of these genes in fetal tissue indicates that the encoded proteins may enhance liver, lung and brain growth or development in the fetus and thus may also act in a regenerative capacity in the adult. 5 Therefore, therapeutic modulation of these genes and/or encoded proteins is useful in treatment of liver, lung and brain related diseases. IIASS Panel vl.0 Summary: Ag902 Highest expression of the CG55379-01 and CG55379-04 genes was detected in glioma (CT=28). Moderate to low levels of expression of these variants were also seen in pancreatic cancer cell line CAPaN and glioblastoma/ 10 astrocytoma cell lines. The expression of these genes was not altered by oxygen deprivation, acidic conditions or a serum-starved environment. Therapeutic modulation of the activity of these variants are useful in the treatment of pancreatic cancer, medulloblastoma and glioma. Panel 2D Summary: Ag902 Highest expression of these genes was detected in a kidney 15 cancer sample (CTs=30). The CG55379-01 and CG55379-04 genes were overexpressed in 7/9 kidney cancer and 2/4 colon cancer samples relative to the corresponding normal adjacent tissues. Gene or protein expression levels are useful in the diagnosis of kidney and colon cancer. Therapeutic modulation of the activity of these variants or their protein products using nucleic acid, protein, antibody and small molecule drugs are useful in the 20 treatment of kidney cancer. Panel 3D Summary: Ag902 Highest expression of the CG55379-01 and CG55379-04 genes was detected in a colon cancer cell line (CT=30). These variants were also expressed in cancer cell lines derived from kidney, lung, brain, pancreas and bone cancers. This observation indicates a possible role for this gene in the pathogenesis of these 25 cancers. Please see panel 2D for further discussion of this gene. Panel 4.1D Summary: Ag902 Highest expression of these genes was detected in activated dendritic cells (CT=30). The expression of these variants was also induced in LPS-stimulated dendritic cells and in IL-4-stimulated dermal fibroblasts. Low expression of this gene was also seen in astrocytes and normal thymus. The CG55379-01 and 30 CG55379-04 genes encodes variants homologous to the mouse NOPE protein, a guidance 369 WO 2004/000997 PCT/US2003/017512 receptors (Salbaum JM, Kappen C., 2000, Cloning and expression of nope, a new mouse gene of the immunoglobulin superfamily related to guidance receptors. Genomics. 64(1):15-23, PMID: 10708514). These proteins may act as a receptor for dendritic cells and dermal fibroblasts and may control interactions between these cells and other cell 5 types during antigen presentation or apoptosis similar to netrins (Livesey F.J., 1999, . Netrins and netrin receptors. Cell Mol. Life Sci. 56: 62-68, PMID: 11213262). Therapeutic modulation of the activity of these variants or their protein products are useful in blocking inflammation in diseases such as asthma, arthritis, psoriasis, allergy and other diseases in which dendritic cell or dermal fibroblasts play important roles. 10 Panel 5D Summary: Ag902 Highest expression of these genes was seen in placenta of a diabetic patient on insulin (CT=32.3). Significant expression of these genes were also seen in placenta from diabetic and non-diabetic patients. Please see panel 1.4 for further discussion of this gene. K. CG55688-01: Cyr61 15 Expression of gene CG55688-01 was assessed using the primer-probe set Ag1 148, described in Table KA. Results of the RTQ-PCR runs are shown in Tables KB, KC, KD, KE, KF and KG. Table KA. Probe Name Ag1148 Start ISEQ Primers Sequences Length Position ID No Position ID No Forward 5'-gtgtctgtgagaggcagctatc-3' 22 1683 319 Probe TET-5 '-tgcactctaaactgcaaacagaaatcagg-3 '-TAMRA 29 1705 320 Reverse 5 -'ccccaaaagctacattttgata-3' 22 1758 321 20 Table KB. HASS Panel vl.O Column A -Rel. Exp.(%) Ag1148, Run 268362647 Tissue Name A Tissue Name A MCF-7 C1 1.4 U87-MG F1 (B) 0.3 MCF-7 C2 0.8 U87-MG F2 0.9 MCF-7 C3 0.3 U87-MG F3 0.5 MCF-7 C4 0.7 U87-MG F4 1.8 MCF-7 C 0.4 U87-MG F58 370 WO 2004/000997 PCT/US2003/017512 MCF-7 C6 0.8 U87-MG F6 1.3 MCF-7 C7 0.3 U87-MG F7 1.8 MCF-7 C9 1.0 U87-MG F8 0.2 MCF-7 C10 0.

3 U87-MG F9 5.0 MCF-7 C11 0.1 U87-MG F10 4.0 MCF-7 C12 0.5 U87-MG Fl1 1.4 MCF-7 C13 0.3 U87-MG F12 20.3 MCF-7 C15 0.7 U87-MG F13 2.8 MCF-7 C16 3.7 U87-MG F14 0.4 MCF-7 C17 2.4 U87-MG F15 16 T24 Dl 65.5 U87-MG F16 25.7 T24 D2 47.3 U87-MG F17 34.2 T24 D3 34.2 LnCAP Al 1.4 1T24 D4 97.9 LnCAP A2 0.7 T24 D5 38.7 LnCAP A3 0.5 T24 D6 100.0 LnCAP A4 0.7 T24 D7 52.1 LnCAP A5 0.4 T24 D9 33.2 LnCAP A6 1.3 T24 D10 20.7 LnCAP A7 0.4 T24 D11 35.8 LnCAP A8 0.6 T24 D12 92.7 LnCAP A9 0.3 T24 D13 29.3 LnCAP A10 1.2 T24 D15 67.8 LnCAP All 1.2 T24 D16 74.7 LnCAP A12 0.2 T24 D17 62.9 LnCAP A13 0.4 CAPaN B1 1.7 LnCAP A14 0.1 CAPaN B2 1.2 LnCAP A15 0.1 CAPaN B3 0.3 LnCAP A16 0.7 CAPaN B4 0.7 LnCAP A17 0.6 CAPaN B5 0.6 Primary Astrocytes 52.1 CAPaN B6 2.7 Primary Renal Proximal Tubule Epithelial cell A2 14.0 CAPaN B7 1.2 Primary melanocytes A5 25.2 CAPaN B8 0.3 126443 - 341 medullo 0.1 CAPaN B9 2.1 126444 - 487 medullo_ 1.7 CAPaN B10 2.4 126445 - 425 medullo 1.7 CAPaN B 11 .1 126446 - 690 medullo 0.4 CAPaN B12 3.4 126447 - 54 adult glioma 29.7 CAPaN B13 2.3 126448 - 245 adult glioma 2.6 CAPaN B14 0.4 126449 - 317 adult glioma 2.4 CAPaN B15 2.7 126450 - 212 glioma 6.8 CAPaN B16 3.7 126451 - 456 glioma 0.3 CAPaN B17 6.7 371 WO 2004/000997 PCT/US2003/017512 Table KC. PGI1.0 Column A - Rel. Exp.(%) Ag1148, Run 398125354 TissueName A Tissue Name A 162191 Normal Lung 1 (IBS) 0.8 162185 Emphysema Lung 12 (Ardais) 73.7 160468 MD lung 1.3 162184 Emphysema Lung 13 (Ardais) 44.4 156629 MI Lung 13 0.3 162183_Emphysema Lung 14 (Ardais) 100.O 162570Normal Lung 4 (Aastrand) 08 162188 _Emphysema Lung 15 (Genomic 65.1 _162570_Normal Lung 4 (Aastrand) 0__.8 ,Collaborative)65.1 162571_Normal Lung 3 (Aastrand) 0 0 162177_NAT UC Colon 1(Ardais) 4.9 162187_Fibrosis Lung 2 (Genomic 9.3 162176 UC Colon 1(Ardais) 8.1 Collaborative) 151281 Fibrosis lung 11(Ardais) 78.5 162179 NATUC Colon2(Ardais) 4.4 162186_Fibrosis Lung 1 (Genomic 93.3 162178 UC Colon 2(Ardais) 36.3 Collaborative) 162190 Asthma Lung 4 (Genomic 17.8 162181 NAT UC Colon 3(Ardais) 31.6 Collaborative) _ ATUCon3(das31 160467 Asthma Lung 13 (MD) 0.7 162180 UC Colon 3(Ardais) 24.5 137027 _Emphysema Lung 1 (Ardais) 0.8 162182 NAT UC Colon 4 (Ardais) 2.7 137028 Emphysema Lung 2 (Ardais) 3.5 137042_UC Colon 1108 4.8 137040 Emphysema Lung 3 (Ardais) 24.1 137029 UC Colon 8215 14.4 137041 Emphysema Lung 4 (Ardais) 3.4 137031 UC Colon 8217 33.9 137043 _Emphysema Lung 5 (Ardais) 12.5 137036 UC Colon 1137 10.2 142817 Emphysema Ltmung 6 (Ardais) 34.2 137038_UC Colon 1491 43.2 142818 Emphysema Lung 7 (Ardais) 16.7 137039 UC Colon 1546 92.0 142819 Emphysema Lung 8 (Ardais) 36.9 162593 Crohn's 47751 (NDRI) _ O.2 142820 Emphysema Lung 9 (Ardais) 3.2 162594 NAT Crohn's 47751 (NDRI) 0.9 142821_Emphysema Lung 10 (Ardais) 21.0 Table KD. Panel 1.3D 5 Column A - Rel. Exp.(%) Agl148, Run 151759893 Tissue Name A Tissue Name A Liver adenocarcinoma 4.5 Kidney (fetal) 9.9 Panceas 1.8 Renal ca. 786-0 13.0 Pancreatic ca. CAPAN 2 0.6 Renal ca. A498 11.1 Adrenal gland 6.3 Renal ca. RXF 393 20.2 Thyroid 11.2 Renal ca.ACHN 17.2 Salivary gland 1.5 Renal ca. UO-31 26.1 Pituitary gland 1.3 Renal ca. TK-10 10.2 Brain (fetal) 0.8 Liver 1.90 Brain (whole) 11.4 Liver (fetal 8.0 Brain (amygdala) 0.8 Liver ca. (hepatoblast) HepG2 0.9 372 WO 2004/000997 PCT/US2003/017512 Brain (cerebellum) 0.1 Lung 45.4 Brain (hippocampus) 5.9 Lung (fetal)4.9 Brain (substantia nigra) 1.7 Lung ca. (small cell) LX-1 0.1 Brain (thalamus) 1.2 Lung ca. (small cell) NCI-H69 0.0 Cerebral Cortex 1.5 Lung ca. (s.cell var.) SHP-77 0.0 Spinal cord 2.0 Lung ca. (large cell)NCI-H460 0.2 glio/astro U87-MG 0.7 Lung ca. (non-sm. cell) A549 0.2 glio/astro U-118-MG 19.6 Lung ca. (non-s.cell) NCI-H23 2.8 astrocytoma SW1783 21.8 Lung ca. (non-s.cell) HOP-62 1.

9 neuro*; met SK-N-AS 0.8 Lung ca. (non-s.cl) NCI-H522 12.2 astrocytoma SF-539 16.3 Lung ca. (squam.) SW 900 2.7 astrocytoma SNB-75 11.3 Lung ca. (squam.) NCI-H596 0.0 glioma SNB-19 . Mammary gland 4 glioma U251 10.2 Breast ca.* (pl.ef) MCF-7 0.1 glioma SF-295 5.6 Breast ca.* (pl.ef) MDA-MB-231 16.7 Heart (fetal) 28.9 Breast ca.* (pl.ef) T47D 1.3 Heart 9.5 Breast ca. BT-549 11.1 Skeletal muscle (fetal) 14.1 Breast ca. MDA-N 0.3 Skeletal muscle 3.3 Ovary 16.3 Bone marrow 1.7 Ovarian ca. OVCAR-3 1.6 Thymus 1.2 Ovarian ca. OVCAR-4 1.7 Spleen 12.6 Ovarian ca. OVCAR-5 1.9 Lymph node 21.3 Ovarian ca. OVCAR-8 12.6 Colorectal 8.6 Ovarian ca. IGROV-1 1.8 Stomach 5.2 Ovarian ca.* (ascites) SK-OV-3 3.5 Small intestine 9.9 Uterus 11.0 Colon ca. SW480 2.6 Placenta 9. Colon ca.* SW620(SW480 met) 0.1 Prostate 57 Colon ca. HT29 P01 rostate ca.* (bone met)PC-3 1.9 Colon ca. HCT-116 1.0 Testis 3.8 Colon ca. CaCo-2 0.7 Melanoma Hs688(A).T 100.0 Colon ca. tissue(ODO3866) 9.8 Melanoma* (met) Hs688(B).T 88.3 olon ca. HCC-2998 0.6 Melanoma UACC-62 0.2 Gastric ca.* (liver met) NCI-N87 3.0 Melanoma M14 0.1 Bladder 2.5 Melanoma LOX IMVI Trachea 17.9 Melanoma* (met) SK-MEL-5 0.1 Kidney 1.8 Adipose 45.4 373 WO 2004/000997 PCT/US2003/017512 Table KE. Panel 2D Column A - Rel. Exp.(%) Ag1148, Run 145375638 Column B - Rel. Exp.(%) Ag1148, Run 147104767 Tissue Name A B Tissue Name _A B Normal Colon 5.0 15.7 Kidney Margin 8120608 6.3 6.6 CC Well to Mod Diff (ODO3866) 3.9 14.6 Kidney Cancer 8120613 826 0.6 0.7. CC Margin (ODO3866) 9.0 23.7 Kidney Margin 8120614 1.1 4.0 CC Gr.2 rectosigmoid (ODO3868) 0.7 11.7 Kidney Cancer 9010320 4.3 14.6 CC Margin (ODO3868) 3.3 5.6 Kidney Margin 9010321 4.7 6.7 CC Mod Diff(ODO3920) 0.4 11.0 Normal Uterus 33.2 25.5 CC Margin (ODO3920) 3.0 5.9 Uterus Cancer 064011 72.7 44.1 C C Gr.2 ascend colon (ODO3921) 67.4 14.3 Normal Thyroid 8.6 11.2 CC Margin (ODO3921) 3.5 11.3 Thyroid Cancer 064010 8.4 5.0 CC from Partial Hepatectomy 2.3 6.0 Thyroid Cancer A302152 5.5 4.9 (ODO4309) Mets Liver Margin (ODO4309) 0.9 3.5 Thyroid Margin A302153 40.1 35.4 Colon mets to lung (OD04451-01) 4.

2 3.9__ Normal Breast 25.3 123.2 Lung Margin (OD04451-02) 1.7 .3.5 Breast Cancer (OD04566) 4.2 2.5 Normal Prostate 6546-1 4.9 5.1 Breast Cancer (OD04590-01) 1.5 3.8 ~Breast Cancer Mets Prostate Cancer (OD04410) 21.9 29.9 Breast Cancer Mets 16.4 9.7 S(0D04590-03) 1 __ Prostate Margin (OD04410) 39.2 30.8 Breast Cancer Metastasis 3.1 2.3 ) 14931 5Breast Cancer ~ ~ Prostate Cancer (0D04720-01). - 9.7 -8.6 IBreast Cancer 064006 5.0 5. Prostate Margin (0D04720-02 . 44.4 east ac 1024 1.6 5.1 Normal Lung 061010 19.3 21.5 Breast Cancer 9100266 5.2 3.9 Lung Met to Muscle (0DO4286) 2.8 2.6 Breast Margin 9100265 6.7 5.1 Muscle Margin (ODO4286) 12.3 8.0 Breast Cancer A209073 8.8 5.6 Lung Malignant Cancer (OD03126) 10.0 1.0 Breast Margin A209073 1.0 1.8 Lung Margin (OD03126) 17.6 32.3 Normal Liver 0.6 0.6 Lung Cancer (0D04404) .4.7 11.7 Liver Cancer 064003 0.2 0.8 Lung Margin (OD04404) 3.0 7.2 Liver Cancer 1025 1.6 4.7 Lung Cancer (0D04565) , 4.0 2.8 Liver Cancer 1026 1.4 3.6 Lung Margin (OD04565) 11.8 4.7 Liver Cancer 6004-T 2.2 4.1 Lung Cancer (OD04237-01) 5.1 5.1 Liver Tissue 6004 -N 0.3 12.1 Lung Margin (OD04237-02) 7.2 21.6 Liver Cancer 6005-T 2.0 4.4 Ocular Mel Met to Liver (ODO4310) 0. Liver Tissue 6005-N 10 1.8 Liver Margin (ODO4310) 6.9 5.2 Normal Bladder 6.2 8.9 Melanoma Mets to Lung (OD04321) 3.0 2.9 Bladder Cancer 1023 3.8 4.6 Lung Margin (OD04321) 33.2 37.4 Bladder Cancer A302173 0.8 2.4 Normal Kidney 11.2 21.5 Bladder Cancer (OD04718-01) 62 9.7 374 WO 2004/000997 PCT/US2003/017512 Kidney Ca, Nuclear grade 2 11.8 17.2 Bladder Normal Adjacent 50.0 100.0 (OD04338) (OD04718-03) Kidney Margin (OD04338) 17.8 34.6 Normal Ovary 1.6 7.5 Kidney Ca Nuclear grade 1/2 2.6 5.2 Ovarian Cancer 064008 26.1 69.3 (OD04339) Kidney Margin (OD04339) 15.8 15.4 Ovarian Cancer (OD04768-07) 7.7 18.0 Kidney Ca, Clear cell type (OD04340) 100.0 59.0 Ovary Margin (OD04768-08) 75.8 62.0 Kidney Margin (OD04340) 36.1 57.0 Normal Stomach 2.6 8.0 Kidney Ca, Nuclear grade 3 2.6 2.0 Gastric Cancer 9060358 0.5 1.5 (OD04348) Kidney Margin (ODO4348) 25.3 14.5 Stomach Margin 9060359 2.5 7.0 Kidney Cancer (OD04622-01) 32.8 15.5 Gastric Cancer 9060395 1.5 6.0 Kidney Margin (OD04622-03) 6.2 3.7 Stomach Margin 9060394 2.1 8.7 Kidney Cancer (OD04450-01) 12.5 19.1 Gastric Cancer 9060397 4.4 16.7 Kidney Margin (OD04450-03) 19.5 114.8 Stomach Margin 9060396 0.6 1.9 JKidney Cancer 8120607 3.8 2.9 Gastric Cancer 064005 2.0 7.0 Table KF. Panel 3D Column A - Rel. Exp.(%) Ag1148, Run 163476715 Tissue Name A Tissue Name A Daoy- Medulloblastoma 153 Ca Ski- Cervical epidermoid carcinoma DaoyMedllobastoa _ 15 (metastasis) TE671- Medulloblastoma 0.0 ES-2- Ovarian clear cell carcinoma 26.8 D283 Med- Medulloblastoma 1.5 Ramos- Stimulated with PMA/ionomycin 6h 0.0 PFSK-1- Primitive Neuroectodermal 3.4 Ramos- Stimulated with PMA/ionomycin 14h 0.1 ~T MEG-01- Chronic myelogenous leukemia (megokaryoblast) SNB-78- Glioma 25.2 Raji- Burkitt's lymphoma 0.1 SF-268- Glioblastoma 60.3 Daudi- Burkitt's lymphoma 0.2 T98G- Glioblastoma 19.2 U266- B-cell plasmacytoma 0.0 SK-N-SH- Neuroblastoma (metastasis) 13.0 CA46- Burkitt's lymphoma 0.0 SF-295- Glioblastoma 3.5 RL- non-Hodgkin's B-cell lymphoma 0.0 Cerebellum 0.3 JM1- pre-B-cell lymphoma 0.0 Cerebellum 0.1 Jurkat- T cell leukemia 0.0 NCI-H292- Mucoepidermoid lung 100.0 TF-1- Erytroleukemia 0.3 carcinoma DMS-1 14- Small cell lung cancer 2.7 HUT 78- T-cell lymphoma 0.0 DMS-79- Small cell lung cancer 0.2 U937- Histiocytic lymphoma 0.0 NCI-H146- Small cell lung cancer 0.0 KU-812- Myelogenous leukemia 10.2 NCI-H526- Small cell lung cancer 0.0 769 -P- Clear cell renal carcinoma 17.7 NCI-N417- Small cell lung cancer 0.0 Caki-2- Clear cell renal carcinoma 1.7 NCI-H82- Small cell lung cancer 0.1 SW 839- Clear cell renal carcinoma 71.7 375 WO 2004/000997 PCT/US2003/017512 NCI-H157- Squamous cell lung cancer 42.0 Rhabdoid kidney tumor 3.0 (metastasis)_ NCI-1155- Large cell lung cancer 05 Hs766T- Pancreatic carcinoma (LN 154 NCI-H1155- Large cell lung cancer 0.5 metastasis) CI-H1299- Large cell lung cancer 235 CAPAN-1 - Pancreatic adenocarcinoma (liver 6 NCI-H1299- Large cell lung cancer 235 metastasis) SU86.86- Pancreatic carcinoma (liver 14.6 NCI-H727- Lung carcinoid metastasis) NCI-MC-11- Lung carcinoid 0.1 BxPC-3- Pancreatic adenocarcinoma 3.6 LX-1- Small cell lung cancer 0.0 HPAC- Pancreatic adenocarcinoma 4.0 Colo-205- Colon cancer 0.0 MIA PaCa-2- Pancreatic carcinoma 3.4 KM12- Colon cancer 0.9 CFPAC-1- Pancreatic ductal adenocarcinoma 28.3 KM2L2- Colon cancer 0 PANC-1- Pancreatic epithelioid ductal 16.2 KM20L2- Colon cancer carcinoma carcmnoma NCI-H716- Colon cancer . T24- Bladder carcinma (transitional cell) 1.1 SW-48- Colon adenocarcinoma 0.0 5637- Bladder carcinoma 3.1 SW1116- Colon adenocarcinoma 0.5 HT-1 197- Bladder carcinoma 14. LS 174T- Colon adenocarcinoa 0.8 UM-UC-3- Bladder carcinma (transitional 4.6 LS 174T- Colon adenocarcinoma 0 cell) SW-948- Colon adenocarcinoma 0.0 A204- Rhabdomyosarcoma 0.7 SW-480- Colon adenocarcinoma .0 HT-1080- Fibrosarcoma 15.8 NCI-SNU-5- Gastric carcinoma . MG-63- Osteosarcoma 53.2 KTO III- Gastric carcinoma 0.7 SK-LMS-1- Leiomyosarcoma (vulva) 55.5 S SJRH30- Rhabdomyosarcoma (met to bone 1.7 NCI-SNU-16- Gastric carcinoma 163 marrow) NCI-SNU-1- Gastric carcinoma 04 A431- Epidermoid carcinoma 1.6 RF-1- Gastric adenocarcinoma 00 WM266-4- Melanoma 0.5 RF-48- Gastric adenocarcinoma 0.0 DU 145- Prostate carcinoma (brain metastasis) 1.8 MKN-45- Gastric carcinoma 1.6 MDA-MB-468- Breast adenocarcinoma 1.8 NCI-N87- Gastric carcinoma 10 SCC-4- Squamous cell carcinoma of tongue 1.3 OVCAR-5- Ovarian carcinoma 0.9 SCC-9- Squamous cell carcinoma of tongue 1.0 RL95-2- Uterine carcinoma 1.4 SCC-15- Squamous cell carcinoma of tongue 1.3 HelaS3- Cervical adenocarcinoma 1.6 CAL 27- Squamous cell carcinoma of tongue 20.7 Table KG. Panel 4D Column A - Rel. Exp.(%) Ag1148, Run 145386435 Tissue Name A Tissue Name A Secondary Thl act 0.0 HUVEC IL-lbeta 17.7 Secondary Th2 act 0.0 HUVEC IFN gamma 40.3 Secondary Trl act 0.0 HUVEC TNF alpha + IFN gamma .30.1 Secondary Thl rest 0.0 HUVEC TNF alpha + IL4 42.6 Secondary Th2 rest 0.0 .HUVEC IL-11 19.8 Secondary Trl rest j.0 Lung Microvascular EC none 63.7 376 WO 2004/000997 PCT/US2003/017512 Primary Thl act -0.1 .Lung Microvascular EC TNFalpha + IL-lbeta 46.7 Primary Th2 act 0.3 Microvascular Dermal EC none 93.3 Primary Trl act 0.5 Microsvasular Dermal EC TNFalpha + IL-Ibeta 71.7 Primary ThI rest 0.5 Bronchial epithelium TNFalpha + ILbeta 16.7 Primary Th2 rest _0.4 Small airway epithelium none 5.3 Primary Trl rest 0.1 Small airway epithelium TNFalpha + IL-1beta 29.5 CD45RA CD4 lymphocyte act 39.0 Coronery artery SMC rest 46.0 [CD45RO CD4 lymphocyte act 0.1 1Coronery artery SMC TNFalpha + IL-lbeta 48.0 CD8 lymphocyte act 0.1 lAstrocytes rest 13.0 Secondary CD8 lymphocyte rest 0.0 lAstrocytes TNFalpha + IL-lbeta ........ 28.7 Secondary CD8 lymphocyte act 0.0 KU-812 (Basophil) rest 0.2 CD4 lymphocyte none 0.0 KU-812 (Basophil) PMA/ionomycin 0.7 2ry Thl/Th2/Trl anti-CD95 CHI 1 0.3 CCD1106 (Keratinocytes) none LAK cells rest 0.0 CCDI 106 (Keratinocytes) TNFalpha+ IL-lbeta 12.7 LAK cells IL-2 0.1 Liver cirrhosis 17.1 LAK cells IL-2+IL-12 0.3 Lupus kidney 2.5 LAK cells IL-2+IFN gamma 0.4 NCI-H292 none 23.7 LA cells IL-2+ IL-18 0.0 NCI-H292 IL-4 12.3 LAK cells PMA/ionomycin 0.3 NCI-H292 IL-9 11.7 N Cells IL-2 rest 0 .0 NCI-H292 IL-13 12.2 Two Way MLR 3 day 0.1 NCI-H292 IFN gamma 13.5 Two Way MLR 5 day 0.2 HPAEC none 42.3 Two Way MLR 7 day 0.0 HPAEC TNF alpha + IL-i beta 51.8 PBMC rest 0.0 Lung fibroblast none 24.8 PBMC PWM 0.4 Lung fibroblast TNF alpha+ IL-1 beta 6.7 PBMC PHA-L 0.3 Lung fibroblast IL-4 41.8 Ramos (B cell) none 0.7 Lung fibroblast IL-9 32.8 Ramos (B cell) ionomycin 1.4 Lung fibroblast IL-13 _89.5 B lymphocytes PWM 1.0 Lung fibroblast IFN gamma 69.3 B lymphocytes CD40L and IL-4 0.6 Dermal fibroblast CCD1070 rest 100.0 EOL-1 dbcAMP 0.3 Dermal fibroblast CCDI1070 TNF alpha 77.9 EOL-1 dbcAMP PMA/ionomycin 0.4 Dermal fibroblast CCD1070 IL-1 beta 95.3 Dendritic cells none 0.0 Dermal fibroblast IFN gamma 5.8 Dendritic cells LPS 10.0 Dermal fibroblast IL-4 8.0 Dendriti cesanti-CD40 10.1 IBD Colitis 2 13.0 Monocytes rest 0.1 IBD Crohn's 15.3 Monocytes LPS 0.1 Colon 2.5 Macrophages rest 0.2 Lung 11.4 Macrophages LPS 10.0 Thymus 9.1 IHUVEC none 149.3 Kidney 2.6 HUVEC starved 41.2 377 WO 2004/000997 PCT/US2003/017512 HASS Panel vl.0 Summary: Ag1 148 Expression of the CG55688-01 gene was highest in T24 cells (CT=27.9). This gene was also expressed at significant level in CaPaN and U87 cancer cell lines, as well as in primary astrocytes, renal epithelial cells and melanocytes in culture. Gene expression was induced by a combination of low oxygen 5 tension and acidic pH in U8 cell lines, suggesting a regulation in vivo may also occur in regions of low pH and low oxygen. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of cancer. PGI1.0 Summary: Ag1 148 Highest expression of this gene was detected in emphysema lung (CT=25.2). High expression of this gene was also detected in lung fibrosis, asthma, 10 emphysema and ulcerative colitis samples. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of lung fibrosis, asthma, emphysema and ulcerative colitis. Panel 1.3D Summary: Ag1 148 The expression of this gene was highest in a sample derived from a melanoma cell line (Hs.688(A).T) (CT=27). In addition, there is significant 15 expression in a related melanoma cell line (Hs.688(B).T) as well as a cluster of brain cancer cell lines and renal cancer cell lines. T Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of melanoma, renal cancer or brain cancer. This panel shows significant expression of this gene in metabolic tissues, including 20 adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle and adult and fetal liver. The CG55688-01 gene encodes CYR61, which belongs to the insulin-like growth factor binding protein family and may play myriad roles in metabolic regulation. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful for the treatment of metabolic and endocrine 25 diseases, including obesity and Types 1 and 2 diabetes. In addition, this gene was expressed at low levels in several brain regions including hippocampus, cortex, substantia nigra, thalamus, amygdala, and the fetal brain. Cry61 is an immediate early gene that has been implicated in memory formation and synaptic plasticity (Albrecht C, von Der Kammer H, Mayhaus M, Klaudiny J, Schweizer M, Nitsch 30 RM, Muscarinic acetylcholine receptors induce the expression of the immediate early 378 WO 2004/000997 PCT/US2003/017512 growth regulatory gene CYR61. J Biol Chem 2000 Sep 15;275(37):28929-36). It has also been shown to be upregulated during the development of the hippocampus, which is a critical brain region for the formation of long-term memory (Chung KC, Ahn YS. Expression of immediate early gene cyr61 during the differentiation of immortalized 5 embryonic hippocampal neuronal cells. Neurosci Lett 1998 Oct 23;255(3):155-8). Therefore, this gene, expressed protein, antibodies or small molecule drug targeting this gene or gene product is useful in the treatment of dementia (Alzheimer's, vascular, etc) or for memory enhancement. Panel 2D Summary: Agl 148 Highest expression of this gene was found in normal 10 bladder tissue and a kidney cancer sample (CTs=28). In addition, there was significant expression of this gene associated with ovarian and prostate derived tissues and a number of kidney samples. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of kidney cancer, ovarian cancer or prostate cancer. Panel 3D Summary: Ag1 148 Highest expression of this gene was detected in lung 15 cancer cell line NCI-H292 (CT=28). Significant expression of this gene was also seen in a number of cancer cell lines derived from brain, renal, pancreatic, bladder cancers and sarcomas. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of these cancers. Panel 4D Summary: Ag1 148 This gene, a Cyr61 homolog, was expressed at moderate 20 levels (CTs=28-32) in resting and cytokine-stimulated HUVEC, lung microvascular endothelial cells, coronary artery smooth muscle cells, bronchial epithelial cells, small airway epithelial cells, astrocytes, pulmonary artery endothelial cells, lung fibroblasts, and dermal fibroblasts. Based upon this expression pattern and a role for Cyr61 in vascular biology (Babic AM, Kireeva ML, Kolesnikova TV, Lau LF CYR61, a product of a growth 25 factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci US A 1998 May 26;95(11):6355-60), therapeutic modulation of the acitivity of this gene or its protein product is useful in the treatment of inflammatory or autoimmune diseases, including Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or 30 psoriasis. 379 WO 2004/000997 PCT/US2003/017512 L. CG56768-01: Wnt-5A Expression of gene CG56768-01 was assessed using the primer-probe set Ag1450, described in Table LA. Results of the RTQ-PCR runs are shown in Tables LB, LC, LD and LE. 5 Table LA. Probe Name Ag1450 ig Start SEQ ID Primers Sequences Length Position No Forward 5'-ccaagttcttcctagtggcttt-3' 22 82 322 Probe TET-5 -tttctccttcgcccaggttgtaattg-3 -TMPA 26 113 324 Reverse 5 -atacctagcgaccaccaagaat-3' 22 145 Table LB. Ardais Panel 1.1 Column A Rel. Exp.(%) Agl450, Run'306913817 Tissue Name A TissueName A Lung adenocarcinomna SI A 9.0 Lung SCC SI A 1.8 Lung adenocarcinoma SI B 3.0 Lung SCC SI B NAT 3.2 Lung adenocarcinoma SI B NAT 2.5 Lung SCC SI C 1.1 Lung adenocarcinoma SI C 0.6 Lung SCC SI C NAT 11.8 Lung adenocarcinoma SI C NAT 2.3 Lung SCC SI D 100.0 Lung adenocarcinoma SI A 1.1 Lung SCC SI D NAT 0.5 Lung adenocarcinoma SII A NAT 2.2 Lung SCC SII A 3.8 Lung adenocarcinoma SII C NAT 5.9 Lung SCC SII B 11.3 Lung adenocarcinoma SI A 55 Lung SCC Sill A 3. 0 Lung adenocarcinoma SIII B .2.8 Lung SCC SHI A NAT 1.3 Lung adenocarcinoma SIII C 7.7 10 Table LC. Panel 1.2 Column A - Rel. Exp.(%) Ag1450, Run 140179432 Column B - Rel. Exp.(%) Ag1450, Run 140448122 Tissue Name A B Tissue Name A B Endothelial cells 0.5 0.5 Renal ca. 786-0 5 Heart (Fetal) 1.5 2.1 Renal ca. A498 0.5 0.9 Pancreas 0.2 10.6 Renal ca..RXF 393 0.8 1.-4 Pancreatic ca. CAPAN 2 0.0 0.0 Renal ca. ACHN 0.9 1.2 Adrenal Gland 0.9 1.2 Renal ca. UO-31 6.6 10.4 Thyroid 0.3 0.3 Renal ca. TK-10 02 0.2_ Salivary gland 21.6 20.0 Liver .7 0.9 380 WO 2004/000997 PCT/US2003/017512 Pituitary gland 2.3 0.2 Liver (fetal) .3 0.4 Brain (fetal) 0.2 0.1 Liver ca. (hepatoblast) HepG2 0.0 0.0 Brain (whole) 0.1 0.1 Lung 0.1 0.5 Brain (amygdala) 0.4 0.5 Lung (fetal) 0.2 0.3 Brain (cerebellum) 0.6 0.4 Lung ca. (small cell) LX-1 0.0 0.0 Brain (hippocampus) 1.2 1.4 Lung ca. (small cell) NCI-H69 0.2 03 Brain (thalamus) 0.6 0.6 Lung ca. (s.cell var.) SHP-77 0.1 0.1 Cerebral Cortex 3.3 4.6 Lung ca. (large cell)NCI-H460 20.0 27.7 Spinal cord 0.2 0.1 Lung ca. (non-sm. cell) A549 0.1 0.1 glio/astro U87-MG 51.8 64.6 Lung ca. (non-s.cell) NCI-H23 0.2 0.3 glio/astro U-118-MG 46.3 55.5 Lung ca. (non-s.cell) HOP-62 70.7 582 astrocytoma SW1783 13.4 14.1 Lung ca. (non-s.cl) NCI-H522 1.7 2.4 neuro*; met SK-N-AS 2.1 .2.0 Lung ca. (squam.) SW 900 12.8 22.5 astrocytoma SF-539 3.1 2.5 Lung ca. (squam.)NCI-H596 0.6 1.0 astrocytoma SNB-75 120 102 Mammary gland 1.1 1.3 glioma SNB-19 04 11 Breast ca.* (pl.ef) MCF-7 0.2 0.2 glioma U251 2.9 40 Breast ca.* (pl.ef) MDA-MB-231 0.0 0.0 glioma SF-295 100.0 100.0 Breast ca.* (pl. ef) T47D 0.0 Heart 4.1 5.6 Breast ca. BT-549 1.3 1.3 Skeletal Muscle 5.6 7.7 Breast ca. MDA-N 0.0 0.0 Bone marrow 0.1 0.1 Ovary 10.7 19.3 Thymus 0.2 0.1 Ovarian ca. OVCAR-3 18.016.3 Spleen 0.4 0.6 Ovarian ca. OVCAR-4 14.5 16.5 Lymph node 0.1 0.1 Ovarian ca. OVCAR-5 1.4 1.5 Colorectal Tissue o.8 .7 varian ca. OVCAR-8 2.5 2.6 Stomach 0.2 0.6 Ovarian ca. IGROV-1 15.6 9.4 Small intestine 3.4 3.4 Ovarian ca. (ascites) SK-OV-3 1.3 2.4 Colon ca. SW480 10.2 18.3 Uterus 3.5 2.5 Colon ca.* SW620 (SW480 met) 0.0 0.0 Placenta 8.7 1.2 Colon ca. HT29 0.0 0.0 Prostate 2.0 2.9 Colon ca. HCT-1 16 0.0 0.0 Prostate ca.* (bone met) PC-3 17.2 17.4 Colon ca. CaCo-2 1.1 1.2 Testis 0.

2 0.4 Colon ca. Tissue (ODO3866) 1.2 1.3 Melanoma Hs688(A).T 17.2 22.2 Colon ca. HCC-2998 0.8 0.9 Melanoma* (met) Hs688(B).T 16.2 18.7 Gastric ca.* (liver met) NCI-N87 0.0 0.1 Melanoma UACC-62 2.2 2.7 Bladder 4.6 8.1 Melanoma MI4 0.8 1.0 Trachea 0.9 0.1 Melanoma LOX IMVI 4.7 5.6 Kidney 5.8 5.6 Melanoma* (met) SK-MEL-5 0.510.8 Kidney (fetal) 15.1 4.6 381 WO 2004/000997 PCT/US2003/017512 Table LD. Panel 2D Colmn A - Rel. Exp.(%) Ag1450, Run 145090529 Column B - Rel. Exp.(%) Ag1450, Run 148500417 Tissue Name IA B Tissue Name A B Normal Colon 13.7 10.8 Kidney Margin 8120608 3.8 1.5 CC Well to Mod Diff(OD03866) 20.7 15.8 Kidney Cancer 8120613 0.4 0.4 CC Margin (ODO3866) 9.8 5.1 Kidney Margin 8120614 8.0 5.2 CC Gr.2 rectosigmoid (OD03868) 14.2 8.4 Kidney Cancer 9010320 f0.7 7.0 CC Margin (ODO3868) 3.6 1.6 Kidney Margin 9010321 11.6 5.4 CC Mod Diff (ODO3920) 12.2 10.7 Normal Uterus 11.2 5.9 CC Margin (ODO3920) 1.9 2.2 Uterus Cancer 064011 59.9 37.4 CC Gr.2 ascend colon (ODO3921) 29.9 33.7 Normal Thyroid 16.3 5.7 CC Margin (ODO3921) 9.1 6.7 Thyroid Cancer 064010 33.0 17.0 CC from Partial Hepatectomy 5.3 4.9 Thyroid Cancer A302152 14.4 9.2 (ODO4309) Mets Liver Margin (ODO4309) 4.5 4.7 Thyroid Margin A302153 11.9 7.9 Colon mets to lung (0D04451-01) 9.3 _4.4 Normal Breast 20.3 10.8 Lung Margin (OD04451-02) 12.3 5.9 Breast Cancer (OD04566) 10.7 5.8 Normal Prostate 6546-1 15.4 5.7 Breast Cancer (OD04590-01) 10.4 7.1 8. .Breast Cancer Mets Prostate Cancer (OD04410) 21.0 8.7 BOD04590-03) 7.6 3.0 ____________________ i~ 8.7 (ODO4590-03) Breast Cancer Metastasis Prostate Margin (OD04410) 42.6 33.4 (ODO4655-05) 7.4 5.4 Prostte Cncer(0D0720- 1) 22.2(0D04655-05) .P Prostate Caucer (ODO4720-01) 23.5 22.2 Breast Cancer 064006 13.9 9.4 Prostate Margin (0D04720-02) . 32.l 25.2 Breast Cancer 1024 .40.9 jj25.9 Normal Lung 061010 15.7 12.0 Breast Cancer 9100266 9.8 5.4 Lung Met to Muscle (ODO4286) 1.1 0.8 Breast Margin 9100265 13.8 10.7 Muscle Margin (ODO4286) 1.6 0.3 Breast Cancer A209073 45.7 33.0 Lung Malignant Cancer (OD03126) 40.9 20.7 Breast Margin A209073 11.0 5.6 Lung Margin (OD03126) 20.3 15.9 Normal Liver 4.2 2.6 Lung Cancer (OD04404) 100.0 100.0 Liver Cancer 064003 0.6 I0.3 Lung Margin (OD04404) 27.2 25.9 Liver Cancer 1025 2.9 2.5 Lung Cancer (OD04565) 31.4 29.3 Liver Cancer 1026 7.3 6.3 Lung Margin (OD04565) 6.8 5.1 Liver Cancer 6004-T 7.0 2.2 Lung Cancer (0pD04237-0l) .1 4.3 Liver Tissue 6004-N 0.7 0.7 Lung Margin (OD04237-02) 11.3 7.0 Liver Cancer 6005-T 11.8 5.7 Ocular Mel Met to Liver (0D043 10) 10.0 0.0 Liver Tissue 6005-N "0 j 0.7 Liver Margin (OD043 10) 4.1 1.5 Normal Bladder 12.1 11.7 Melanoma Mets to Lung (OD04321) 7.6 4.8 .ladder Cancer 1023 4.9 2.9 Lung Margin (OD04321) 33.9 20.4 B1ladder Cancer A302173 . 59.5 27.4 Normal Kidney 19.9 9.2 Bladder Cancer (0D04718-01) 12.8 1.7 382 WO 2004/000997 PCT/US2003/017512 Kidney Ca, Nuclear grade 2 32.5 25.3 Bladder Normal Adjacent 2.8 0.7 (ODO4338) (OD04718-03) Kidney Margin (OD04338) 9.8 7.9 Normal Ovary 29.7 19.8 Kidney Ca Nuclear grade 1/2 29.5 23.7 Ovarian Cancer 064008 25.2 30.8 (OD04339) Kidney Margin (OD04339) 3.6 2.3 Ovarian Cancer (OD04768-07) 2.8 2.5 Kidney Ca, Clear cell type (0D04340) 4.0 3.7 Ovary Margin (OD04768-08) 4.0 2.6 Kidney Margin (0D04340) 14.8 9.3 Normal Stomach 6.7 5.4 Kidney Ca, Nuclear grade 3 4.5 3.0 Gastric Cancer 9060358 4.9 1.6 (OD04348) Kidney Margin (OD04348) 8.0 4.5 Stomach Margin 9060359 7.1 5.0 Kidney Cancer (OD04622-01) 4.5 4.1 Gastric Cancer 9060395 30.1 25.5 Kidney Margin (0D04622-03) 11.8 4.2 Stomach Margin 9060394 1.5 5.6 Kidney Cancer (OD04450-01) 26.4 12.9 Gastric Cancer 9060397 18.3 21.9 Kidney Margin (OD04450-03) 13.7 5.0 Stomach Margin 9060396 3.7 1.8 Kidney Cancer 8120607 1.7 1.0 Gastric Cancer 064005 16.3 18.0 Table LE. Panel 4.1D Column A - Rel. Exp.(%) Ag1450, Run 181080827 Tissue Name IA Tissue Name A Secondary Th1 act 0.3 IHUVEC IL-1beta 0.1 Secondary Th2 act 0.3 HUVEC IFN gamma 0.2 Secondary Trl act 10.3 HUVEC TNF alpha + IFN gamma 0.7 Secondary Th rest 0.3 HUVEC TNF alpha + 1L4 0.

5 Secondary Th2 rest 0.0 HUVEC IL-l 1 0.4 Secondary Trl rest 0.1 Lung Microvascular EC none 0.2 Primary Thl act 0.0 Lung Microvascular EC TNFalpha + IL-lbeta 0.4 Primary Th2 act 0.0 Microvascular Dermal EC none 0.0 Primary Trl act 0.0 Microsvasular Dermal EC TNFalpha + IL-lbeta 0.1 Primary Thl rest 0.0 Bronchial epithelium TNFalpha + ILlbeta 3.7 Primary Th2 rest 0.0 Small airway epithelium none 5.0 Primary Tr rest 0.0 Small airway epithelium TNFalpha + IL-beta 0.4 CD45RA CD4 lymphocyte act 44.4 Coronery artery SMC rest 2.4 CD45RO CD4 lymphocyte act 0.0 Coronery artery SMC TNFalpha + IL-Ibeta 3.3 CD8 lymphocyte act 0.0 Astrocytes rest _ ____2.8 Secondary CD8 lymphocyte rest 0.1 Astrocytes TNFalpha + IL-lbeta 10.8 Secondary CD8 lymphocyte act 0.0 KU-812 (Basophil) rest 0.3 CD4 lymphocyte none 0.0 KU-812 (Basophil) PMA/ionomycin .0.5 2ry Thl/Th2/Trl anti-CD95 CH1 1 0.0 CCD1106 (Keratinocytes) none 13.0 LAK cells rest .2 CCD1106 (Keratinocytes) TNFalpha + IL-lbeta 1.3 LAK cells IL-2 0.0 Liver cirrhosis 0.4 LAK cells IL-2+IL-12 0.1 NCI-H292 none 0.0 383 WO 2004/000997 PCT/US2003/017512 LAK cells IL-2+IFN gamma 0.0 NCI-H292 IL-4 0.1 LAK cells IL-2+ IL-18 0.1 NCI-H292 IL-9 0.3 LAK cells PMA/ionomycin 0.1 NCI-H292 IL-13 2.3 NK Cells IL-2 rest 0.1 NCI-H292 IFN gamma 0.2 Two Way MLR 3 day 0.2 HPAEC none 0.0 Two Way MLR 5 day 1.2 HPAEC TNF alpha + IL-1 beta 0.5 Two Way MLR 7 day 0.1 Lung fibroblast none 38.2 PBMC rest 0.0 Lung fibroblast TNF alpha + IL-1 beta 75.3 PBMC PWM 2.9 Lung fibroblast 1L-4 39.0 PBMC PHA-L 1.5 Lung fibroblast IL-9 71.7 Ramos (B cell) none 0.0 Lung fibroblast IL-13 25.0 Ramos (B cell) ionomycin 0.0 Lung fibroblast IFN gamma 41.2 B lymphocytes PWM 0.1 Dermal fibroblast CCD1070 rest 84.1 B lymphocytes CD40L and IL-4 0.4 Dermal fibroblast CCD1070 TNF alpha 76.8 EOL-1 dbcAMP 0.0 Dermal fibroblast CCD1070 IL-1 beta 100.0 EOL-1 dbcAMP PMA/ionomycin 0.0 Dermal fibroblast IFN gamma 8.9 Dendritic cells none 2.5 Dermal fibroblast IL-4 10.6 Dendritic cells LPS 20.6 Dermal Fibroblasts rest 6.1 Dendritic cells anti-CD40 10.7 Neutrophils TNFa+LPS 1.1 Monocytes rest 0.0 Neutrophils rest 1.5 Monocytes LPS 20.4 Colon 0.9 Macrophages rest 0.2 Lung 3.6 Macrophages LPS 9 Thymus 1.7 HUVEC none 0.0 Kidney 2.6 HUVEC starved 0.0 Ardais Panel 1.1 Summary: Ag1450 Highest expression of the CG56768-01 gene was seen in a lung cancer sample (CT=21). Expression of this gene was higher in this cancer sample relative to the normal adjacent tissue sample (CT=29). Gene or protein expression 5 levels are useful for the detection of lung cancer. Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of lung cancer. Panel 1.2 Summary: Ag1450 Highest expression of this gene was detected in glioma cell line SF-295 (CT=22). This gene was overexpressed in cell lines derived from CNS 10 malignancies when compared to the low to moderate expression in the samples derived from normal CNS tissue. In addition, there was consistently high expression of this gene in melanoma cell lines, ovarian cancer cell lines and lung cancer cell lines. The CG56768-01 gene encodes a putative Wnt5a-like protein. The Wnrit genes belong to a 384 WO 2004/000997 PCT/US2003/017512 family of protooncogenes with at least 13 known members that are expressed in species ranging from Drosophila to man. The name Wnt denotes the relationship of this family to the Drosophila segment polarity gene 'wingless' and to its vertebrate ortholog, Intl, a mouse protooncogene (OMIM 164975, 164820). Therapeutic modulation of the activity of 5 this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful for the treatment of brain cancer, melanoma, ovarian cancer and/or lung cancer. Significant levels of expression of this gene were detected in all the regions of the brain examined including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, 10 cerebral cortex, and spinal cord. Wnt-5A signalling is believed to play a critical role in cadherin-mediated cell organization. Cadherins can act as axon guidance and cell adhesion proteins, specifically during development and in the response to injury. Therapeutic modulation of the activity of this gene or its protein product is useful in inducing a compensatory synaptogenic response to neuronal death in Alzheimer's disease, Parkinson's 15 disease, Huntington's disease, spinocerebellar ataxia, progressive supranuclear palsy, ALS, head trauma, stroke, or any other disease/condition associated with neuronal loss. Among tissues with metabolic or endocrine function, this gene was expressed at moderate levels in pancreas, adrenal gland, thyroid, pituitary and liver. In addition, this gene was expressed at high levels in skeletal muscle (CT = 27). These observations 20 suggest that the Wnt-5A-like protein encoded by this gene may be secreted from skeletal muscle as a paracrine or endocrine signalling molecule acting on other insulin-responsive tissues (i.e., adipose and pancreatic beta cells). Therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of metabolic diseases involving skeletal muscle, including 25 Type 2 diabetes. Panel 2D Summary: AgI450 Highest expression of this gene was detected in a lung cancer sample (CTs=28-29). This gene was overexpressed in number of cancer tissues relative to the adjacent normal colon, lung, kidney, breast, and stomach. These results are consistent with the observation that the Wnt-5A gene appears to be up-regulated in a 30 number of human malignancies (lozzo R.V., Eichstetter I., Danielson K.G., 1995, Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res. 55: 385 WO 2004/000997 PCT/US2003/017512 3495-3499). Therapeutic modulation of the activity of this gene or its protein product is of use in the treatment of colon, lung, kidney, breast or gastric cancers. Panel 4.1D Summary: Agl450 Highest expression of this gene was detected in IL-1 beta activated dermal fibroblasts (CT=26). This gene was expressed mainly in fibroblasts and 5 in LPS-activated monocytes, macrophages and dendritic cells. WNTs are secreted signalling molecules that regulate cell fate and behavior and are involved in embryonic development and hematopoiesis. During inflammation, the Wnt5a-like protein encoded by this gene could potentiate the inflammatory response by acting as an autocrine factor and stimulating monocyte differentiation into dendritic cells as well as by allowing dendritic 10 cells to mature into potent antigen presenting cells. Alternatively, this gene may influence the differentiation of other cell types in the microenvironment including synovial tissues (Sen M., Lauterbach K., E1-Gabalawy H., Firestein G.S., Corr M., Carson D.A., 2000, Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 97: 2791-2796). Therapeutic modulation of the activity of this gene 15 or its protein product using nucleic acid, protein, antibody or small molecule drugs is important in reducing or blocking inflammation associated with rheumatoid arthritis, asthma, allergy, psoriasis, IBD and Crohn's disease. M. CG59253-01 and CG59253-02: Semaphorin precursor Expression of gene CG59253-01 and CG59253-02 was assessed using the 20 primer-probe sets Agl492 and Ag2441, described in Tables MA and MB. Results of the RTQ-PCR runs are shown in Tables MC, MD, ME and MF. CG59253-01 represents a full-length physical clone. Table MA. Probe Name Ag1492 rs S Start SEQ ID Primers Sequences Length Position No Forward 5'-ctgaagctggcatggtacttaa-3' 22 501 325 Probe TET-5' -cagtcctttctctttgaacgacagcg-3 '-TAMRA 26 460 326 [Reverse 5' -ttgtaggcttcaatctcttaca-3' 22 432 327 25 386 WO 2004/000997 PCT/US2003/017512 Table MB. Probe Name Ag2441 ~Start SEQ Primers Sequences Length St SEQ I Position ED No Forward s5 -tgctatgaaaggcaagcataa-3 ' 21 1506 328 Probe ITET-5 -tgaatgccacaactttatcaaagtatttg-3' -TAMRA 29 1474 329 Reverse 5'-aaaaccatctcatcgtttcttg-3' 22 1449 330 Table MC. AI comprehensive panel vl.0 5 Column A - Rel. Exp.(%) Ag1492, Run 248065288 Tissue Name A Tissue Name A 110967 COPD-F 7.5 112427 Match Control Psoriasis-F 13.6 110980 COPD-F 12.4 112418 Psoriasis-M 7.0 110968 COPD-M 4.4 112723 Match Control Psoriasis-M 67.4 110977 COPD-M 13.1 112419 Psoriasis-M 14.1 110989 Emphysema-F 4.5 112424 Match Control Psoriasis-M 7.9 110992 Emphysema-F _ 1.8 112420 Psoriasis-M 9.2 110993 Emphysema-F 18.0 1.12425 Match Control Psoriasis-M 15.5 110994 Emphysema-F 3.1 104689 (MF) OA Bone-Backus 77.9 110995 Emphysema-F 4.5_ 104690 (MF) Adj "Normal" Bone-Backus 52.5 110996 Emphysema-F 0.1 104691 (MF) OA Synovium-Backus 60.3 110997 Asthma-M 12.2 104692 (BA) OA Cartilage-Backus 13.4 111001 Asthma-F 8.0 104694 (BA) OA Bone-Backus 158.6 111002 Asthma-F 9.2 104695 (BA) Adj "Normal" Bone-Backus 40.6 111003 Atopic Asthma-F 6.4 104696 (BA) OA Synovium-Backus 50.0 111004 Atopic Asthma-F 4.8 104700 (SS) OA Bone-Backus 50.7 111005 Atopic Asthma-F 4.7 104701 (SS) Adj "Normal" Bone-Backus 49.0 111006 Atopic Asthma-F 0.8 104702 (SS) OASynovium-Backus . 130.8 111417 Allergy-M 5.6 117093 OA Cartilage Rep7 7.3 112347 Allergy-M 4.9 112672 OA Bone5 9.8 112349 Normal Lung-F 5.4 112673 OA Synovium5 5.5 112357 Normal Lung-F 100.0 112674 OA Synovial Fluid cells5 3.3 112354NormalLung-M 49.7 117100 OA Cartilage Repl4 1.5 112374 Crohns-F 3.2 112756 OA Bone9 9.9 112389 Match Control Crohns-F .212 112757 OA Synovium9 13.8 112375 Crohns-F 3.9 112758 OA Synovial Fluid Cells9 4.5 112732 Match Control Crohns-F 1.7 117125 RA Cartilage Rep2 9.2 112725 Crohns-M 5.7 f113492 Bone2 RA 19.3 112387 Match Control Crohns-M 7.3 ]113493 Synovium2 RA 17.7 112378 Crohns-M 19.2 113494 Syn Fluid CellsRA 24.0 112390 Match Control Crohns-M 3.0 113499 Cartilage4 RA 36.3 387 WO 2004/000997 PCT/US2003/017512 112726 Crohns-M 16.7 113500 Bone4 RA 43.5 112731 Match Control Crohns-M 6.3 113501 Synovium4 RA j34.9 112380 Ulcer Col-F 5.6 113502 Syn Fluid Cells4 RA 15.4 112734 Match Control Ulcer Col-F 1.4 113495 Cartilage3 RA 27.2 112384 Ulcer Col-F 12.2 113496 Bone3 RA 19.3 112386 Ulcer Col-F 3.0 113498 Syn Fluid Cells3 RA 27.4 112738 Match Control Ulcer Col-F 9.4 117106 Normal Cartilage Rep20 0.6 112381 Ulcer Col-M 2.9 113663 Bone3 Normal 6.9 112735 Match Control Ulcer Col-M 29.1 113664 Synovium3 Normal 1.8 112382 Ulcer Col-M 33.0 113665 Syn Fluid Cells3 Normal 4.3 112394 Match Control Ulcer Col-M 5.2 117107 Normal Cartilage Rep22 4.6 112383 Ulcer Col-M 4.1 1113667 Bone4 Normal 17.6 112736 Match Control Ulcer Col-M 11.2 113668 Synovium4 Normal 16.8 112423 Psoriasis-F 14.4 113669 Syn Fluid Cells4 Normal 6.7 Table MD. Panel 1.3D Column A - Rel. Exp.(%) Ag1492, Run 165529502 Column B -Rel. Exp.(%) Ag2441, Run 159616039 Column C - Rel. Exp.(%) Ag2441, Run 165534561 Tissue Name A B C Tissue Name A C jC Liver adenocarcinoma 0.0 0.0 0.0 Kidney (fetal) 14.9 7.8 12.2 Pancreas 4.5 1.4 4.5 Renal ca. 786-0 3.9 1.8 1.2 Pancreatic ca. CAPAN 2 0.0 0.0 0.0 Renal ca. A498 0.6 0.3 0.0 Adrenal gland 2.8 0.8 _2.5 Renal ca. RXF 393 9.8 2.2 6.8 Thyroid 4.9 3.3 2.1 Renal ca. ACHN 0.0 0.0 0.0 Salivary gland 2.0 1.1 2.3 Renal ca. UO-31 0.2 0.2 0.7 Pituitary gland 9.2 6.6 2.9 Renal ca. TK-10 0.0 0.00.0 Brain (fetal) 44.4 12.1 26.4 Liver 4.4 0.9 2.9 Brain (whole) 100.0 20.0 81.2 Liver (fetal) 4.4 1.3 3.1 Brain (amygdala) 127.7 16.8 25.5 Liver ca. (hepatoblast) HepG2 10.0 1.0 0.0 Brain (cerebellum) 88 27.2 Lung 5.0 11.4 14.4 Brain (hippocampus) 50.0 77.9 26.2 Lung (fetal) 7.3 7.4 13.5 Brain (substantia nigra) 42.9 7.6 24.8 Lung ca. (small cell) LX-1 0.0 0.0 0.0 Brain (thalamus) 52.1 15.3 30.1 Lung ca. (small cell) NCI-H69 4.0 23.0 18.4 Cerebral Cortex ,43.2 70.2 23.0 Lung ca. (s.cell var.) SHP-77 14.7 21.5 15.6 Spinal cord 18.7 8.0 14.2 Lung ca. (large cell)NCI-H460 2.2 0.3 0.7 glio/astro U87-MG 2.4 3.2 1.5 Lung ca. (non-sm. cell) A549 0.0 10.0 0.0 glio/astro U-1 18-MG 77.4 100.0 100.0 Lung ca. (non-s.cell) NCI-H23 0.0 0.0 0.0 astrocytoma SW1783 0.0 0.6 0.3 Lung ca. (non-s.cell) HOP-62 1.3 0.9 1.4 neuro*; met SK-N-AS 11.3 19.8 2.2 Lung ca. (non-s.cl) NCI-H.522 10.0 0.0 .0.0 astrocytoma SF-539 10.0 0.0 0.0 Lung ca. (squam.) SW 900 5.0 4.1 5.1 388 WO 2004/000997 PCT/US2003/017512 astrocytoma SNB-75 5.4 3.8 62 Lung ca. (squam.) NCI-H596 9.9 7.1 13.7 glioma SNB-19 3.3 4.6 3.9 Mammary gland _ 20.2 10.1 6.9 glioma U251 15.8 3.3 10.6 Breast ca.* (pl.ef) MCF-7 0.0 0.0 0.1 glioma SF-295 10.2 10.7 14.3 Breast ca.* (pl.ef) 0.0 0.3 0.3 glioma SF-295 10.2 10.7 14.3 MDA-MB-231 _ I Heart (fetal) 4.4 10.8 2.5 Breast ca.* (pl.ef) T47D 0.0 0.0 0.0 Heart 4.1 1.3 5.1 Breast ca. BT-549 0.0 0.0 0.0 Skeletal muscle (fetal) 4.1 35.8 1.3 Breast ca. MDA-N 0.6 2.3 0.3 Skeletal muscle 34.2 4.5 28.3 Ovary 9.8 20.6 3.8 Bone marrow 1.3 1.7 0.3 Ovarian ca. OVCAR-3 5.6 3.3 6.3 Thymus 1.3 0.7 1.7 Ovarian ca. OVCAR-4 0.0 0.0 0.0 Spleen 1.2 1.1 2.5 Ovarian ca. OVCAR-5 0.3 0.0 0.0 Lymph node 3.9 1.8 3.0 Ovarian ca. OVCAR-8 0.8_ 1.8 0.7 Colorectal 15.2 10.4 6.3 Ovarian ca. IGROV-1 0.0 0.0 0.0 C o lo ~ k t~ " ........................................................... .!P 4 6 ........ O..... ... .... ......... 0 0 ..... Stomach 6

.

0 2.3 4.3 varian ca.* (ascites) 0.0 0.0 0.0 a 6SK-OV-3 Small intestine 19.3 10.6 10.7 Uterus 3.3 0.9 3.7 Colon ca. SW480 0.0 0.0 0.0 Placenta 17.8 14.8 8.1 Colon ca.* SW620(SW480 0.2 0.0 0.0 Prostate 3.7 0.6 1.4 met) Colon ca. HT29 0.0 0.0 0.0 Prostate ca.* (bone met)PC-3 1.4 2.2 4.8 Colon ca. HCT-116 0.5 0.0 0.0 Testis 1.8 0.8 1.3 Colon ca. CaCo-2 0.5 0.6 0.0 Melanoma Hs688(A).T 0.0 0.0 0.1 Colon ca. tissue(OD03866) 0.2 1.9 2.1 Melanoma* (met) Hs688(B).T 0.0 0.5 10.6 Colon ca. HCC-2998 0.0 0.0 10.0 Melanoma UACC-62 5.7 0.9 2.3 Gastric ca.* (liver met) 0.0 0.0 0.0 Melanoma M14 6.1 1.3 9.2 NCI-N87 I..._ Bladder 3.4 1.7 3.4 Melanoma LOX IMVI 0.0 0.0 0.0 Trachea 1.5 2.4 1.4 IMelanoma* (met) SK-MEL-5 2.0 2.3 1.3 Kidney 113.0 4.2 120.6 Adipose 8.3 15.719.8 Table ME. Panel 2D Column A - Rel. Exp.(%) Ag2441, Run 159616246 Tissue Name A Tissue Name A Normal Colon 48.6 Kidney Margin 8120608 2.6 CC Well to Mod Diff(0OD03866) 0.6 Kidney Cancer 8120613 0.4 CC Margin (ODO3866) 6.6 Kidney Margin 8120614 11.5 CC Gr.2 rectosigmoid (ODO3868) 0.9 Kidney Cancer 9010320 1.7 CC Margin (ODO3868) 1.2 Kidney Margin 9010321 11.3 CC Mod Diff (ODO3920) 0.5 Normal Uterus 0.9 CC Margin (ODO3920) 9.1 Uterus Cancer 064011 3.4 CC Gr.2 ascend colon (ODO3921) 10.9 Normal Thyroid .39 389 WO 2004/000997 PCT/US2003/017512 CC Margin (OD03921) 6.7 Thyroid Cancer 064010 2.0 CC from Partial Hepatectomy (ODO4309) 2.0 Thyroid Cancer A302152 0.6 Mets Liver Margin (ODO4309) 3.5 Thyroid Margin A302153 10.8 Colon mets to lung (OD04451-01) 0.6 NJormal Breast 12.2 Lung Margin (OD04451-02) 3.5 Breast Cancer (0D04566) 0.4 Normal Prostate 6546-1 1.4 Breast Cancer (OD04590-01) 7

.

3 Prostate Cancer (OD04410) 2.9 Breast Cancer Mets (OD04590-03) 4.8 Prostate Margin (D04410) Breast Cancer Metastasis 3.6 Prostate Margin (OD_4410) 8.0 (OD04655-05) 3.6 Prostate Cancer (OD04720-01) 6.6 Breast Cancer 064006 2.0 Prostate Margin (OD04720-02) 13.3 Breast Cancer 1024 5.4 Normal Lung 061010 ___ 14.4 IBreast Cancer 9100266 2.1 Lung Met to Muscle (ODO4286) 0.1 Breast Margin 9100265 7.4 Muscle Margin (ODO4286) 4.5 Breast Cancer A209073 8.5 Lung Malignant Cancer (OD03126) 43 Breast Margin A209073 13.8 Lung Margin (OD03126) 15.0 Normal Liver 2.7 Lung Cancer (OD04404) 8.4 Liver Cancer 064003 0.1 Lung Margin (0D04404) 3.7 jiver Cancer 1025 2.3 Lung Cancer (OD04565) .1 Liver Cancer 1026 0.7 Lu Marg. (ODO4565) 4.7 Liver Cancer 6004-T 4.0 Lung Cancer (OD04237-01) 1.2 Liver Tissue 6004-N 0.

3 Lung Margin (OD04237-02) 5.6 Liver Cancer 6005-T 0.5 Ocular Mel Met to Liver (ODO4310) 2.7 Liver Tissue 6005-N 0.6 Liver Margin (ODO4310) 3.0 Normal Bladder 4.7 Melanoma Mets to Lung (OD04321) 0.7 Bladder Cancer 1023 0.1 Lung Margin (OD04321) 8.0 Bladder Cancer A302173 4.9 Normal Kidney 100.0 Bladder Cancer (OD04718-01) 0.0 Kidney Ca, Nuclear grade 2 (D04338) 3.6 Bladder Normal Adjacent 2.8 Kidney Ca, Nuclear grade 2 (OD4338) 3.6 (OD04718-03) . Kidney Margin (OD04338) 32.5 Normal Ovary 7.2 Kidney Ca Nuclear grade 1/2 (OD04339) 0.5 Ovarian Cancer 064008 6.8 Kidney Margin (OD04339) 26.8 Ovarian Cancer (OD04768-07) 0.2 Kidney Ca, Clear cell type (OD04340) 3.8 Ovary Margin (OD04768-08) 1.0 Kidney Margin (OD04340) 35.4 Normal Stomach 6.3 Kidney Ca, Nuclear grade 3 (OD04348) 0.2 Gastric Cancer 9060358 1.6 Kidney Margin (OD04348) 15.7 Stomach Margin 9060359 2.1 Kidney Cancer (OD04622-01) 1.1 Gastric Cancer 9060395 4.2 Kidney Margin (OD04622-03) 4.2 Stomach Margin 9060394 4.2 Kidney Cancer (OD04450-01) 8.0 Gastric Cancer 9060397 1.6 Kidney Margin (OD04450-03) 25.0 Stomach Margin 9060396 0.5 Kidney Cancer 8120607 0.6 IGastric Cancer 064005 8.9 390 WO 2004/000997 PCT/US2003/017512 Table MF. Panel 4D Column A - Rel. Exp.(%) Ag1492, Run 162778150 Column B - Rel. Exp.(%) Ag2441, Run 159616279 Tissue Name A B Tissue Name A B Secondary Thl act 0.0 0.0 HUVEC IL-1beta 12.5 9.6 Secondary Th2 act 0.0 [0.0 HUVEC IFN gamma 5.5 6.2 Secondary Trl act 0.0 0.0 HUVEC TNF alpha + IFN gamma 3.6 1.9 Secondary Thi rest 0.0 0.0 H UVEC TNF alpha + IL4 5.6 5.0 Secondary Th2 rest 0.0 0.0 HUVEC IL-11 8.5 ~6.5 Secondary Trl rest 0.0 0.0 Lung Microvascular EC none 0.4 0.1 Primary Th act 0.0 00 Lung Microvascular EC TNFalpha + 0.0 0.0 Primary Thlact 0.0 0.0 IL-lbeta Primary Th2 act .... 0.0 0.0 Microvascular Dermal EC none 0.1 0.1 Primary T act 0.0 0.0 Microsvasular Dermal EC TNFalpha + 0.0 0.0 Primary Trl act0.0. E-bt00 00 SIL-lbeta Prima Th rest 0.0 .0 Bronchial epithelium TNFalpha + 2.1 2.7 Primary Thl rest i0.0 0.0 lILlbeta Primary Th2 rest 0.0 0.0 Small airway epithelium none 0.5 0.5 .Primary T .. rest . ISmall airway epithelium TNFalpha + 1.1 0.8 Primary Trl rest 0.0 0.0 !IL-lbeta 1.1 0.8 CD45RA CD4 lymphocyte act 0.4 0.6 Coronery artery SMC rest 1.2 1.5 Coronery artery SMC TNFalpha + 0.4 0.3 CD45RO CD4 lymphocyte act 0.0 0.0 IL-lbeta 0.4 0.3 CD8 lymphocyte act 0.0 0.0 Astrocytes rest 1.5 1.3 Secondary CD8 lymphocyte rest 0.0 0.0 Astrocytes TNFalpha + IL-lbeta 0.0 0.1 Secondary CD8 lymphocyte act 0.0 0.0 KU-812 (Basophil) rest 0.0 0.0 CD4 lymphocyte none [0.0 0.0 KU-812 (Basophi) PMA/ionomycin 0.0 0.0 2 ry Thl/Th2/Trlanti-CD95 0.0 0.0 CCD1 106 (Keratinocytes) none 0.9 0.5 CH11I S CCD1106 (Keratinocytes) TNFalpha + LAK cells rest 0.0 0.0 IL-1beta 0.0 0.1 LAK cells IL-2 0.0 0.0 Liver cirrhosis 5.7 2.6 LAK cells IL-2+IL-12 100 1 0.0 Lupus kidney 4 .5 24 LAK cells IL-2+IFN gamma 0.0 0.0 NCI-H292 none 5.3 4.9 LAK cells IL-2+ IL-18 0.0 0.0 NCI-H292 IL-4 3.0 4.9 LAK cells PMAionomycin 0.0 0.0 NCI-H292 IL-9 5.2 5.3 NK Cells IL-2 rest 0.0 0.0 NCI-H292 IL-13 2.5 1.6 Two Way MLR 3 day 0.0 0.0 NCI-H292 IFN gamma 1.8 0.0 Two Way MLR 5 day 0.0 0.0 HPAEC none 3.7 5.2 Two Way MLR 7 day 0.0 0.0 HPAEC TNF alpha + IL-1 beta 6.5 4.3 PBMC rest 0.0 0.0 Lung fibroblast none 16.2 10.4 PBMC PWM .0.2 0.0 Lung fibroblast TNF alpha + IL-1 beta 81.2 .65.5 PBMC PHA-L 1 0.0 0.0 Lung fibroblast IL-4 12.0 112.9. 391 WO 2004/000997 PCT/US2003/017512 Ramos (B cell) none 0.0 0.0 Lung fibroblast IL-9 22.2 13.3 Ramos (B cell) ionomycin 0.0 0.0 Lung fibroblast IL-13 7

.

9 5.9 B lymphocytes PWM 0.3 0.0 Lung fibroblast IFN gamma 10.2 7.8 B lymphocytes CD40L and IL-4 0.4 0.3 Dermal fibroblast CCD1070 rest 3.3 2.4 EOL-1 dbcAMP 0.0 0.0 Dermnal fibroblast CCD1070 TNF alpha 2.5 4.5 EO1 - dbcA4P PMA/ionomycin 0.0 0.0 Dermal fibroblast CCD1070 IL-1 beta 6.0 5.1 IDendritic cells none 0.0 0.0 Dermal fibroblast IFN gamma 12.1 0.7 Dendritic cells LPS 0.1 0.0 Dermal fibroblast IL-4 91..7.7 Dendritic cells anti-CD40 0.0 0.1 IBD Colitis 2 1 .7 0.2 Monocytes rest 0.0 0.0 IBD Crohnm's 13.7 7.7 Monocytes LPS 0. 0 0.0 Colon 98.6 95.3 Macrophages rest 0.0 0.3 Lung 17.2 6.0 Macrophages LPS 0.0 (.O Thymus 100.0 100.0 EC e 11.6 5.8 Kidney 6.3 4.2 HUVEC starved 19.3 18.0 AI_comprehensive panel_vl.0 Summary: Ag1492 Highest expression of the CG59253-01 and CG59253-02 genes was detected in normal lung (CT=27.6). Significant expression of these genes was detected in samples derived from normal and orthoarthitis/ 5 rheumatoid arthritis bone, cartilage, synovium and synovial fluid samples, normal lung, COPD lung, emphysema, atopic asthma, asthma, allergy, Crohn's disease (normal matched control and diseased), ulcerative colitis (normal matched control and diseased), and psoriasis (normal matched control and diseased). Therapeutic modulation of the activity of these gene variants or their protein products is useful in the treatment of autoimmune and 10 inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis Panel 1.3D Summary: Agl492/Ag2441 The CG59253-01 and CG59253-02 genes encode a semaphorin homolog that had brain-preferential expression. Highest expression of these variants was seen in the brain and a brain cancer cell line (CTs=28-29). 15 Semaphorins can act as axon guidance proteins, specifically as chemorepellents that inhibit CNS regenerative capacity. Manipulation of levels of these gene variants or their protein products is useful in inducing a compensatory synaptogenic response to neuronal death in Alzheimer's disease, Parkinson's disease, Huntington's disease, spinocerebellar ataxia, progressive supranuclear palsy, multiple sclerosis, ALS, head trauma, stroke, or 20 any other disease/condition associated with neuronal loss. Therapeutic modulation of the 392 WO 2004/000997 PCT/US2003/017512 activity of these gene variants or their protein products using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of brain cancer. This gene was also moderately expressed in several metabolic tissues, including pancreas, adrenal, thyroid, pituitary, adult and fetal heart, adult and fetal skeletal muscle, 5 adult and fetal liver, and adipose. Gene or protein expression levels are important for the pathogenesis, diagnosis, and/or treatment of metabolic diseases including obesity and Types 1 and 2 diabetes. Panel 2D Summary: Ag2441 Highest expression of the CG59253-01 and CG59253-02 gene variants was detected in normal kidney (CT=27.6). These variants were more highly 10 expressed in normal kidney samples relative to the matched kidney cancers. Gene or protein levels are useful to distinguish normal kidney from kidney cancer. These genes encode variants of the semaphorin SEMA6D protein. The semaphorin family of proteins is characterized as cell surface receptors for their ligands, the pillins, and is involved largely in cell guidance (Tamagnone L, Comoglio PM. Signaling by semaphorin receptors: cell 15 guidance and beyond. Trends Cell Biol 2000 Sep;10(9):377-83). Semaphorins have been implicated in general invasive growth and potentially even tube formation (Comoglio PM, Tamagnone L, Boccaccio C. Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. Exp Cell Res 1999 Nov 25;253(1):88-99). Thus, semaphorins are likely agents to promote the differentiation of cells. Normal kidney 20 cells undergo a great deal of tubular morphogenesis. Therefore, the extracellular domain of these protein products may act to promote growth arrest and differentiation of the cancer cells through interaction with a membrane bound ligand or ligand complexed with plexins. Therapeutic modulation of the activity of these gene variants or their protein products using nucleic acid, protein, antibody or small molecule drugs is of use in the 25 treatment of kidney cancer. Panel 4D Summary: Agl492/2441 Highest expression of the CG59253-01 and CG59253-02 gene variants was detected in thymus (CTs=27-28). Significant expression of these variants was also seen activated lung fibroblasts cells, HUVEC, HPAEC, activated bronchial epithelium, NCI-H292 cell, dermal fibroblasts, IBD Crohn's, liver cirrhosis and 30 lupus samples, normal tissues colon and thymus. Therapeutic modulation of the activity of 393 WO 2004/000997 PCT/US2003/017512 these gene variants or their protein products is useful to reduce or eliminate the symptoms of chronic obstructive pulmonary disease, asthma, emphysema, and ulcerative colitis N. CG95430-01: AdipoQ-like Expression of gene CG95430-01 was assessed using the primer-probe set Ag4020, 5 described in Table NA. Results of the RTQ-PCR runs are shown in Tables NB, NC, ND, NE and NF. Table NA. Probe Name Ag4020 L ,Start SEQ ID Primers Sequences Length PoStart SEQ D No L ______ _______________________________________ Position No Forward 5'-cacattgctggggtctattact-3' 22 458 331 Probe TET-5 ' -tcacctaccacatcactgttttctcca-3"' -T 27 480 332 Probe -T27 480 332 AMRA lReverse 5' -ttttgaccaaagacacctgaac-3' 22 1512 . 333 10 Table NB. CNS neurodegeneration vl.0 Column A - Rel. Exp.(%) Ag4020, Run 212393803 Tissue Name A Tissue Name A AD 1 Hippo 40.1 Control (Path) 3 Temporal Ctx 7.6 AD 2 Hippo 19.3 Control (Path) 4 Temporal Ctx 7.7 AD 3 Hippo 22.2 AD 1 Occipital Ctx 5.8 AD 4 Hippo 26.4 AD 2 Occipital Ctx (Missing) 12.5 AD 5 Hippo 4.9 AD 3 Occipital Ctx 4.8 AD 6 Hippo 10.O AD 4 Occipital Ctx 3.9 Control 2 Hippo 26.8 AD 5 Occipital Ctx 3.5 Control 4 Hippo 21.2 AD 6 Occipital Ctx Control (Path) 3 Hippo 14.9 Control 1 Occipital Ctx 7.3 AD 1 Temporal Ctx 11.1 Control 2 Occipital Ctx 3.9 AD 2 Temporal Ctx 0.3 Control 3 Occipital Ctx 16.7 AD 3 Temporal Ctx 6.0 Control 4 Occipital Ctx 1. AD 4 Temporal Ctx 15.8 Control (Path) 1 Occipital Ctx 12.5 AD 5 Inf Temporal Cx 9.8 Control (Path) 2 Occipital Ctx .3.1 AD 5 Sup Temporal Ctx 31.2 Control (Path) 3 Occipital Ctx 2.8 AD 6 Inf Temporal Ctx 13.7 Control (Path) 4 Occipital Ctx 6.7 AD 6 Sup Temporal Ctx 8.0 Control 1 Parietal Ctx 3.3 Control 1 Temporal Ctx 2.4 Control2 Parietal Ctx 7.5 Control 2 Temporal Ctx 3.2 Control 3 Parietal Ctx 9.5 Control 3 Temporal Ctx 8.9 Control (Path) 1 Parietal Ctx 8.4 394 WO 2004/000997 PCT/US2003/017512 Control 3 Temporal Ctx 0.8 Control (Path) 2 Parietal Ctx 6.1 Control (Path) 1 Temporal Ctx 6.0 Control (Path) 3 Parietal Ctx 6.0 Control (Path) 2 Temporal Ctx 4.3 Control (Path) 4 Parietal Ctx 4.7 Table NC. Oncology cell line screening panel v3.1 Column A - Rel. Exp.(%) Ag4020, Rn 22254637 Tissue Name A Tissue Name A Ca Ski Cervical epidermoid carcinoma Daoy Medulloblastoma/Cerebellum 1.1 Ca SkiCervical epidermoid carcinoma 7.9 (metastasis) TE671 Medulloblastom/Cerebellum 0.0 ES-2_Ovarian clear cell carcinoma 2.4 Ramos/6h stim_ Stimulated with . D283 Med Medulloblastoma/Cerebellum 3.3 Ramos/6h stim Stimulated with 0.0 PMA/ionomycin 6h PFSK-1 Primitive 0.0 Ramos/14h stim Stimulated with 0 Neuroectodermal/Cerebellum PMAlionomycin 14h F-498CNS 10.3 MEG-01 _Chronic myelogenous leukemia 1.4 F C(megokaryoblast) SNB-78 CNS/glioma 0.0 RajiBurkitt's lymphoma 0.0 SF-268 CNS/glioblastoma 18.7 Daudi Burkitt's lymphoma 0.0 T98G Glioblastoma 5.4 U266 B-cell plasmacytoma/myeloma 0.0 SK-N-SH Neuroblastoma (metastasis) 2.9 CA46_Burkitt's lymphoma 1.2 SF-295 CNS/glioblastoma 0.0 RL non-Hodgkin's B-cell lymphoma 0.0 Cerebellum 6.7 JM1_pre-B-cell lymphoma/leukemia2.0 Cerebellum 2.5 Jurkat T cell leukemia 7.5 NCI-H292_ Mucoepidermoid lung ca. 7.7 TF-l_Erythroleukemnia 2.3 DMS-1 14 Small cell lung cancer 8.5 HUT 78_T-cell lymphoma 1.7 DMS-79_ Small cell lung 1.6 U937 Histiocytic lymphoma 9.2 cancer/neuroendocrine NCI-H 146 _Small cell lung 152 1lk . Nci-11146 _Small cell lung 4.5 KU-812 Myelogenous leukemia 7.7 cancer/neuroendocrine NCI-H526_Small cell lung NCI-H526Small cell lung 5.5 769-P Clear cell renal ca. 0.0 NCI-N417_Small cell lung 1.7 Caki-2 Clear cell renal ca. 13.5 cancer/neuroendocrine NCI-H82_ Small cell lung 9.3 SW 839 Clear cell renal ca. 0.0 cancer/neuroendocrine NCI-Hs15)7Suamous cell lung cancer 0.0 G401 Wilms' tumor 0.9 (metastasis) NCI-H1155_Large cell lung NCI-H1155_ Large cell lung 6.2 Hs766TPancreatic ca. (LN metastasis) 21.3 cancer/neuroendocrine NCI-H1299_Large cell lung 5.2 CAPAN-1_Pancreatic adenocarcinoma (liver 0.0 cancer/neuroendocrine . metastasis) NCI-727 Lung carcinoid . SU86.86 _Pancreatic carcinoma (liver 0.9 NCI-H727_Lung carcinoid 0.0 meatss 0.9 metastasis) NCI-UMC-1 1_Lung carcinoid 1.2 IBxPC-3_ Pancreatic adenocarcinoma [7.7 395 WO 2004/000997 PCT/US2003/017512 LX-1 Small cell lung cancer 1.6 HPACPancreatic adenocarcinoma 1.0 Colo-205 Colon cancer 18.6 MIA PaCa-2_Pancreatic ca. 0.0 KM12_Colon cancer 11.0 CFPAC-1 Pancreatic ductal adenocarcinoma 71.2 KM20L2_Colon cancer 1.1 PANC-1 Pancreatic epithelioid ductal ca. 3.0 NCI-H716_Colon cancer 6.3 1T24 Bladder ca. (transitional cell) 0.0 W-48_Colon adenocarcinoma 3.7 5637 Bladder ca. 1.9 SW1116 Colon adenocarcinoma 11.7 HT-1197 Bladder ca. 0.0 LS 174TColon adenocarcinoma 27.9 UM-UC-3 Bladder ca. (transitional cell) 0.0 SW-948 Colon adenocarcinoma 42 A204 Rhabdomyosarcoma 6.2 SW-480 Colon adenocarcinoma 2.0 HT-1080 Fibrosarcoma 30.6 NCI-SNU-5 Gastric ca. 9.9 MG-63 Osteosarcoma (bone) 4.2 KATO IIIStomach _9.3 SK-LMS-l1Leiomyosarcoma (vulva) 7.3 CI-SNU-1 Gastric ca. 47 SJRH30 Rhabdomyosarcoma (met to bone NCI-SNU-16_Gastric ca. 4.7 ro4.4 marrow) NCI-SNU-1 Gastric ca. 9.2 A43 lEpidermoid ca. 100.0 RF-1_Gastric adenocarcinoma 1.2 WM266-4_Melanoma 1.9 RF-48_Gastric adenocarcinoma 7.6 DU 145 _Prostate 0.7 MKN-45 Gastric ca. 20.3 MDA-MB-468_Breast adenocarcinoma 0.0 NCI-N87_Gastric ca. 14.4 SSC-4 Tongue 1.5 OVCAR-5 Ovarian ca. 0.0 SSC-9 Tongue 10.0 RL95-2 Uterine carcinoma 2.3 SSC-15 Tongue 1.2 HelaS3 Cervical adenocarcinoma 10.1 CAL 27_Squamous cell ca. of tongue 2.9 Table ND. Panel 4.1D Column A - Rel. Exp.(%) Ag4020, Run 171614122 Tissue Name A Tissue Name A Secondary Thl act 2.4 HUVEC IL-lbeta 1.1 Secondary Th2 act 10.7 HUVEC IFN gamma 0.0 Secondary Trl act 1.5 HUVEC TNF alpha + IFN gamma 1.0 Secondary Thl rest 1.9 HUVEC TNF alpha + IL4 1.0 Secondary Th2 rest 2.5 HUVEC IL-11 0.7 Secondary Trl rest 0.0 Lung Microvascular EC none 1.0 Primary Thl act 1.5 Lung Microvascular EC TNFalpha + IL-lbeta 0.0 Primary Th2 act 3.6 Microvascular Dermal EC none 1.4 Primary Trl act 1.6 Microsvasular Dermal EC TNFalpha + IL-lbeta 0.0 Primary Thl rest 1.3 Bronchial epithelium TNFalpha + ILlbeta 5.0 Primary Th2 rest 10.6 Small airway epithelium none 0.0 Primary Tr rest _.____ 0.0 Small airway epithelium TNFalpha + I-lbeta 2.9 CD45RA CD4 lymphocyte act 3.4 Coronery artery SMC rest 1.2 CD45RO CD4 lymphocyte act 3.2 Coronery artery SMC TNFalpha + IL-lbeta 2.5 CD8 lymphocyte act 1.4 Astrocytes rest 3.6 Secondary CD8 lymphocyte rest 4.9 lAstrocytes TNFalpha + IL-lbeta 1.5 396 WO 2004/000997 PCT/US2003/017512 Secondary CD8 lymphocyte act 0.0 KU-812 (Basophil) rest 6.9 CD4 lymphocyte none 0.0 KU-812 (Basophil) PMA/ionomycin 0.0 2ry Thl/Th2/Trlanti-CD95 CH11 0.0 CCD1106 (Keratinocytes) none 8.5 LAK cells rest 2.1 CCD1106 (Keratinocytes) TNFalpha + IL-lbeta 1.3 LAK cells IL-2 6.3 Liver cirrhosis 6.6 LAK cells IL-2+1L-12 2.3 NCI-H292 none 2.5 LAK cells IL-2+IFN gamma 2.3 NCI-H1292 IL-4 0.0 LAK cells IL-2+ IL-18 2.4 NCI-H292 IL-9 1.8 LAK cells PMA/ionomycin 10.6 NCI-H292 IL-13 5.9 NK Cells IL-2 rest 60NCI-H292 IFN gamma 0.9 Two Way MLR 3 day 1.6 HPAEC none 35 Two Way MLR 5 day 0.0 HPAEC TNF alpha + IL-1 beta 2.6 Two Way MLR 7 day 0.0 Lung fibroblast none 64.6 PBMC rest 1.1 Lung fibroblast TNF alpha + IL-1 beta 1.8 PBMC PWM 0.0 Lung fibroblast IL-4 25.5 PBMC PHA-L 0.0 Lung fibroblast IL-9 14.8 Ramos (B cell) none 0.0 Lung fibroblast 1L-13 26.1 Ramos (B cell) ionomycin 0.0 Lung fibroblast IFN gamma 33.4 B lymphocytes PWM 0.0 Dermal fibroblast CCD1070 rest 3.3 B lymphocytes CD40L and IL-4 0.0 Dermal fibroblast CCD1070 TNF alpha 4.3 EOL-1 dbcAMP0.0 Dermal fibroblast CCD1070 IL-1 beta 2.8 EOL-1 dbcAMP PMA/ionomycin 0.0 Dermal fibroblast IFN gamma 1.2 Dendritic cells none 2.9 Dermal fibroblast IL-4 1.4 Dendritic cells LPS 0.0 Dermal Fibroblasts rest 10.5 Dendritic cells anti-CD40 2.6 Neutrophils TNFa+LPS 00 Monocytes rest 2.0 Neutrophils rest 1.2 Monocytes LPS 0.0 Colon 3.0 Macrophages rest 2.2 Lung 10.0 Macrophages LPS 2.1 Thymus 19.6 HUVEC none 0.0 Kidney 100.0 HUJVEC starved 0.9 Table NE. Panel 5 Islet Column A - Rel. Exp.(%) Ag4020, Run 223675497 Tissue Name A Tissue Name A 97457_Patient-02go adipose 22.5 94709_Donor 2 AM - A_adipose 2.2 197476 Patient-07skskeletal muscle 41.8 94710 Donor 2 AM - B_adipose 0.

0 97477 Patient-07ut uterus 5.3 94711 Donor 2 AM - C adipose 0.8 j 97478 Patient-07pl placenta 2.7 94712_Donor 2 AD - Aadipose 0.0 99167 Bayer Patient 1 0.0 94713 Donor 2 AD- Badipose 5.1 97482 Patient-08ut uterus 5.2 94714 Donor 2 AD- C adipose 0.0 397 WO 2004/000997 PCT/US2003/017512 97483Patient-8plplacenta 4.6 94742 Donor 3 U - AMesenchymal Stem 1.4 97483_Patient-08p1_acenta 4.6 Cells 97486 Patient-09sk skeletal muscle 15.2 94743Donor 3 U - BMesenchymal Stem 0.0 Cells 97487 Patient-09ut uterus 21.9 94730 Donor 3 AM - A adipose 4.3 97488 Paient-09pl_placenta 4.5 94731 Donor 3 AM - B adipose 3.7 97492 Patient-lO0ut uterus 1__ 12.2 94732 Donor 3 AM - C adipose 0.0 97493_ Patient-10plplacenta 4.5 94733 Donor 3 AD - A adipose 0.0 97495_Patient-11 go _adipose 31.4 94734_Donor 3 AD - Badipose 1.6 97496_Patient-1 lsk skeletal muscle 38.2 94735 Donor 3 AD - C adipose 0.0 97497 Patient-llut uterus 8.4 77138 Liver HepG2untreated 5.3 97498 Patient-lplplacenta 2.2 73556_HeartCardiac stromal cells 97498 Patient-11pl placenta 2.2 (pia) -0.0 _ .(primary)0 97500_Patient-12go adipose 45.4 81735 Small Intestine 12.8 72409_Kidney P'roximal Convoluted 0. 97501 Patient-12sk skeletal muscle 100.0 e Proximal Convoluted 0.0 -- Tubule 97502 Patient-12ut uterus 15.4 82685 Small intestine Duodenum 4.4 97503_Patient-12pl_placenta _6.0 90650 Adrenal Adrenocortical adenoma 0.0 94721 Donor 2 U - AMesenchymal 0.0 72410 KidneyHRCE 0.0 Stem Cells -_. -74_ _ RC0. 94722_Donor 2 U - BMesenchymal Stem 0.9 72411 Kidney HRE 0.0 Cells - 94723_Donor 2 U - CMesenchymal Stem 1.3 73139 Uterus Uterine smooth muscle cells 5.5 Cells o 2I_ e - .... Table NF. general oncology screening panel v 2.4 Column A - Rel. Exp.(%) Ag4020 Run 259744763 Tissue Name A Tissue Name A Colon cancer 1 20.0 Bladder cancer NAT 2 1.8 Colon cancer NAT 1 1.1 Bladder cancer NAT 3 1.1 Colon cancer 2 11.0 Bladder cancer NAT 4 27.4 Colon cancer NAT 2 8.0 Prostate adenocarcinoma 1 8.9 Colon cancer 3 27.4 Prostate adenocarcinoma 2 12.3 Colon cancer NAT 3 49.0 Prostate adenocarcinoma 3 20.9 Colon malignant cancer 4 28.1 Prostate adenocarcinoma 4 4.6 Colon normal adjacent tissue 4 4.6 Prostate cancer NAT 5 11.6 Lung cancer 1 3.4 Prostate adenocarcinoma 6 37.9 Lung NAT 1 3.2 Prostate adenocarcinoma 7 24.7 Lung cancer 2 68.8 Prostate adenocarcinoma 8 5.5 Lung NAT 2 .8.2 Prostate adenocarcinoma 9 17.8 Squamous cell carcinoma 3 9.7 Prostate cancer NAT 10 29.7 Lung NAT 3 2.1 Kidney cancer 1 8.7 metastatic melanoma 1 33.4 KidneyNAT 1 [6.3 398 WO 2004/000997 PCT/US2003/017512 Melanoma 2 5.3 Kidney cancer 2 82.4 Melanoma 3 11.3 Kidney NAT 2 18.4 metastatic melanoma 4 40.3 Kidney cancer 3 7.3 metastatic melanoma 5 100.0 Kidney NAT 3 7.1 Bladder cancer 1 10.3 Kidney cancer 4 8.5 Bladder cancer NAT 1 0.0 KidneyNAT 4 5.5 Bladder cancer 2 5.5 CNSneurodegenerationvl.0 Summary: Ag4020 The CG95430-01 gene was not differentially expressed in the Alzheimer's disease samples represented on this panel. However, this gene was expressed in the brain, with highest expression in the 5 hippocampus of an Alzheimer's patient (CT=31.4). Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy. Oncology_cell_line_sereeningpanelv3.1 Summary: Ag4020 Highest expression of 10 the CG95430-01 gene was detected in an epidermoid carcinoma cell line (CT=32.6). Low expression of this gene was also seen in cell lines derived from fibrosarcoma, pancreatic ductal adenocarcinoma, pancreatic, colon and gastric cancers. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of these cancers. Panel 4.1D Summary: Ag4020 This gene was most highly expressed in a normal kidney 15 sample (CT=32.3). Low but significant levels of expression were also seen in untreated and cytokine activated lung fibroblasts and thymus. These results suggest that this gene is involved in the homeostasis of the lung, thymus, and kidney. Down-regulated expression of this gene in cytokine-activated lung fibroblasts indicates that modulation of this gene and its protein product will help to maintain or restore function to the lung during 20 inflammation. Panel 5 Islet Summary: Ag4020 The CG95430-01 gene was expressed in adipose and skeletal muscle (CTs=31-34). This gene encodes a putative adiponectin [also known as adipocyte complement-related protein (ACRP-30), AdipoQ, apMl (adipose most abundant transcript 1) or GBP28 (28 kDa gelatin binding protein)], a member of the Clq family. 25 This protein is induced over 100-fold in adipocyte differentiation (Scherer et al., J Biol 399 WO 2004/000997 PCT/US2003/017512 Chem 1995 Nov 10;270(45):26746-9) and is involved in adipocyte signaling (Hu et al., J Biol Chem 1996 May 3;271(18):10697-703). Like other members of the Clq family, it forms a homotrimer and the crystal structure indicates that it likely arose from tumor necrosis factor (TNF; Shapiro and Scherer,Curr Biol 1998 Mar 12;8(6):335-8). Ionomycin 5 increases expression of adiponectin and dibutyryl cAMP and TNF-alpha reduce expression and secretion in 3T3-L1 adipocytes (Kappes and Loffler, Horm Metab Res 2000 Nov-Dec;32(11-12):548-54). Levels of adiponectin are decreased in obese humans (Arita et al., Biochem Biophys Res Commun 1999 Apr 2;257(1):79-83) and mice (Hu et al., J Biol Chem 1996 May 3;271(18):10697-703). A proteolytic cleavage product of 10 adiponectin is reported to increase fatty acid oxidation in muscle and causes weight loss in mice. (Fruebis et al., Proc Natl Acad Sci U S A 2001 Feb 13;98(4):2005-10). A missense mutation in the protein was correlated with a markedly low plasma adiponectin level (Takahashi et al., Int J Obes Relat Metab Disord 2000 Jul;24(7):861-8). Recent papers have shown that adiponectin reverses insulin resistance in mouse models of lipoatrophy 15 and obesity (Yamauchi et al., Nature Med 2000; 7(8): 941-6), and that it enhances insulin action on the liver (Berg et al., ibid, 947-53). In addition, circulating levels of adiponectin have been shown to be lower in obese than in lean subjects and lower in diabetic patients than in non-diabetic patients, with particularly low levels in subjects with coronary artery disease. Furthermore, in patients who were subjected to a weight loss program that 20 resulted in a 10% reduction of their body mass index, circulating adiponectin levels increased significantly. (Berg AH. Trends Endocrinol Metab. 2002 Mar;13(2):84-9). Based on the homology of CG95430-01 to adiponectin and its expression profile, therapeutic modulation of the activity of this gene or its protein product using nucleic acid, protein, antibody or small molecule drugs is useful for the treatment of obesity, type II 25 diabetes and/or their secondary complications. Adiponectin also seems to have additional cardiovascular and immune system effects. Levels of this protein are reduced in a cohort of Japanese patients with coronary artery disease (CAD), which correlates with the modulation of endothelial adhesion molecules on treatment of human aortic endothelial cells with adiponectin (Ouchi et al., 30 Circulation 1999 Dec 21-28;100(25):2473-6). This protein is found adhering to vascular walls after injury (Okamoto et al. Horm Metab Res 2000 Feb;32(2):47-50) and presence of adiponectin suppresses the macrophage to foam cell transformation (Ouchi et al., 400 WO 2004/000997 PCT/US2003/017512 Circulation 2001 Feb 27;103(8):1057-63). In addition, levels of adiponectin are lower in diabetic subjects with CAD relative to non-diabetic subjects or diabetic subjects without CAD (Hotta et al., Arterioscler Thromb Vase Biol 2000 Jun;20(6):1595-9), indicating that lower levels of adiponectin may be an indicator of macroangiopathy in diabetes. 5 Moreover, this protein negatively regulates the growth of myelomonocytic precursors (in part by inducing apoptosis) and macrophage function (Yokota et al., Blood 2000 Sep 1;96(5):1723-32), potentially via the complement 1Q receptor C 1 qRp. The C 1q family of proteins includes the complement subunit C q, gliacolin, Clq-related protein, cerebellin, CORS26 etc., all of which are secreted proteins. These 10 proteins share a common domain, the Clq domain, at the C terminus and collagen triple helix repeats at the C terminus. The repeats enable the proteins to form homotrimers and possibly oligomers. Members of this family have been implicated in tissue differentiation, immune regulation, energy homeostasis, synaptic function and in diseases such as obesity and neurodegeneration. Therapeutic modulation of the activity of this gene or its protein 15 product using nucleic acid, protein, antibody or small molecule drugs is useful in the prevention and/or treatment of obesity and diabetes. Furthermore, development of human monoclonal antibodies that inhibit this Adipo-Q like protein is useful in the therapeutic treatment of cachexia that occurs in many forms of cancer. General oncology screening panel v_2.4 Summary: Ag4020 This gene was most 20 highly expressed in a metastatic melanoma (CT=32.7). Significant levels of expression were also seen in a lung cancer and a kidney cancer when compared to normal adjacent tissue. Gene or protein expression levels are useful as a diagnostic marker to detect the presence of these cancers. Therapeutic modulation of the activity of this gene or its protein product is useful in the treatment of kidney cancer, lung cancer, and melanoma. 25 0. CG95430-02 and CG95430-04 Expression of genes CG95430-02 and CG95430-04 was assessed using the primer-probe set Ag7140, described in Table OA. Results of the RTQ-PCR runs are shown in Table OB. CG95430-02 and CG95430-04 represent the physical clones for mature and full-length gene respectively. 30 401 WO 2004/000997 PCT/US2003/017512 Table OA. Probe Name Ag7140 Start SEQ ID) Primers Sequences Length PoStart SEQ No D Position No Forward 5'-tttctccaggaatgttcaggt-3' 21 720 334 Probe TET-5 ' -actgcacaccaaagatgcttacatga-3 ' -TAMRA 26 768 335 Reverse g5'-cagaggcctggtcctca-3' 17 '798 .336 . Table OB. General screening panel vl.7 5 Column A - Rel. Exp.(%) Ag7140, Run 318037557 Tissue Name A Tissue Name A Adipose 100.0 Gastric ca. (liver met.) NCI-N87 0.0 HUVEC 0.0 Stomach 0.8 Melanoma* Hs688(A).T 0.0 Colon ca. SW-948 0.2 Melanoma* Hs688(B).T 0.0 Colon ca. SW480 0.0 Melanoma (met) SK-MEL-5 0.0 Colon ca. (SW480 met) SW620 0.0 Testis 0.0 Colon ca. HT29 0.0 Prostate ca. (bone met) PC-3 0.0 Colon ca. HCT-116 0.0 Prostate ca. DU145 0.0 Colon cancer tissue 0.4 Prostate pool 0.1 Colon ca. SW1116 0. Uterus pool 1.3 Colon ca. Colo-205 0.0 Ovarian ca. OVCAR-3 0.0 Colon ca. SW-48 0.0 Ovarian ca. (ascites) SK-OV-3 0.0 Colon 1.8 Ovarian ca. OVCAR-4 0.0 Small Intestine 2.0 Ovarian ca. OVCAR-5 0.9 Fetal Heart 12.3 Ovarian ca. IGROV-1 0.8 Heart 13.4 Ovarian ca. OVCAR-8 0.0 Lymph Node pool 1 0.3 Ovary 24.3 Lymph Node pool 2 21.5 Breast ca. MCF-7 0.0 Fetal Skeletal Muscle 30.6 Breast ca. MDA-MB-231 0.0 Skeletal Muscle pool 9.6 Breast ca. BT-549 0.0 Skeletal Muscle 49.3 Breast ca. T47D 0.0 Spleen 1.5 Breast pool 0.1 Thymus 0.4 Trachea 2.4 CNS cancer (glio/aslro) SF-2680.0 Lung 1.7 CNS cancer (glio/astro) T98G 0.0 Fetal Lung 2.0 CNS cancer (neuro;met) SK-N-AS 0.0 Lung ca. NCI-N417 1.1 CNS cancer (astro) SF-539 0.0 Lung ca. LX-1 0.0 CNS cancer (astro) SNB-75 0.0 Lung ca. NCI-H146 1.3 CNS cancer (glio) SNB-19 0.0 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.0 Lung ca. NCI-H23 0.0 Brain (Amygdala) 0.4 Lung ca. NCI-H460 0.0 Brain (Cerebellum) 0.0 402 WO 2004/000997 PCT/US2003/017512 Lung ca. HOP-62 0.0 Brain (Fetal) 1.8 Lung ca. NCI-H522 1.4 Brain (Hippocampus) 1.6 Lung ca. DMS-114 0.0 Cerebral Cortex pool 0.5 Liver 0.1 Brain (Substantia nigra) 0.2 Fetal Liver 0.0 Brain (Thalamus) 0.8 Kidney pool 4.5 Brain (Whole) 0.7 Fetal Kidney 2.7 Spinal Cord 0.2 Renal ca. 786-0 0.0 Adrenal Gland 1.0 Renal ca. A498 0.0 Pituitary Gland 0.0 Renal ca. ACHN .0 Salivary Gland 0.8 Renal ca. UO-31 0.0 Thyroid 2.5 Renal ca. TK-10 0.0 Pancreatic ca. PANC-1.6 Bladder 5 pool .0 Generalscreeningpanel_vl.7 Summary: Ag7140 Highest expression of the CG95430-02 and CG95430-04 gene variants was detected in adipose tissue (CT=28.9). Moderate to low expression of these variants was also seen in number of tissues that 5 contribute to metabolism including thyroid, skeletal muscle, heart, small intestine, and colon. Therapeutic modulation of the activity of these gene variants or their protein products using nucleic acid, protein, antibody or small molecule drugs is useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. P. CG97111-01: Interleukin-1 receptor antagonist protein precursor 10 Expression of gene CG97111-01 was assessed using the primer-probe sets Ag4106 described in Tables PA. Results of the RTQ-PCR runs are shown in Tables PB and PC. Table PA. Probe Name Ag4106 Pri Sequences L Start SEQ ID Pri s Sequences Length Position No Forward s5'-cctctatagtctccgsaaggaa-3' 22 897 1337 Probe TET-5'-tggatttcagctcagtgacacccatt-3'-TAMRA 26 -935 1338 Reverse 5'-gttgtggaggtcagaagtctga-31 22 961 339 15 403 WO 2004/000997 PCT/US2003/017512 Table PB. General screening panel vl.4 Column A - Rel. Exp.(%) Ag4106, Run 219446784 Tissue Name A Tissue Name A Adipose 0.0 Renal ca. TK-10 0.0 Melanoma* Hs688(A).T 00 Bladder0.0 Melanoma* Hs688(B).T 0.0 Gastric ca. (liver met.) NCI-N87 .0. Melanoma* M14 0.0 Gastric ca. KATO III 0.0 Melanoma* LOXIMVI 0.0 Colon ca. SW-948 0.0 Melanoma* SK-MEL-5 0.0 Colon ca. SW480 0.0 Squamous cell carcinoma SCC-4 5.1 Colon ca.* (SW480 met) SW620 0.0 Testis Pool 0.0 Colon ca. HT29 0.0 Prostate ca.* (bone met) PC-3 0.) Colon ca. HCT-116 0.0 Prostate Pool 0.0 Colon ca. CaCo-2 0.0 Placenta 0.0 Colon cancer tissue 9.7 Uterus Pool 0.0 Colon ca. SW1116 0.0 Ovarian ca.OVCAR-3 12.8 Colon ca. Colo-205 0. varian ca. SK-OV-3 0.0 Colon ca. SW-480 0 Ovarian ca. OVCAR-4 0.0 Colon Pool 0.0 Ovarian ca. OVCAR-5 0.0 Small Intestine Pool 3.3 Ovarian ca. IGROV-1 0.0 Stomach Pool 0.0 Ovarian ca. OVCAR-8 0.O Bone Marrow Pool 0.0 Ovary 0.0 Fetal Heart 0.0 Breast ca. MCF-7 0.0 Heart Pool 0.0 Breast ca. MDA-MB-231 0.0 Lymph Node Pool 0.0 Breast ca. BT 549 0.0 Fetal keletal Muscle 0.0 Breast ca. T47D 0.0 Skeletal Muscle Pool 0.0 Breast ca. MDA-N 0.0 Spleen Pool 0.0 BreastPool 0.0 Thymus Pool 100.0 Trachea 3.1 CNS cancer (glio/astro) U87-MG 24.8 Lung 0.0 CNS cancer (glio/astro) U-118-MG 0.0 Fetal Lung 2.2 CNS cancer (neuro;met) SK-N-AS 0.0 Lung ca. NCI-N417 0.0 CNS cancer (astro) SF-539 0.0 Lung ca. LX-1 0.0 CNS cancer (astro) SNB-75 0.0 Lung ca. NCI-H146 0.0 CNS cancer (glio) SNB-19 0.0 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.0 Lung ca. A549 0.0 Brain (Amygdala) Pool 0.0 Lung ca. NCI-H526 0.0 Brain (cerebellum) 0.0 Lung ca. NCI-H23 0.0 Brain (fetal) 0.0 Lung ca. NCI-H460 0.0 Brain (Hippocampus) Pool 0.0 Lung ca. HOP-62 0.0 Cerebral Cortex Pool0. Lung ca. NCI-H522 0.0 Brain (Substantia nigra) Pool 5.7 404 WO 2004/000997 PCT/US2003/017512 Liver 0.0 Brain (Thalamus) Pool 0.0 Fetal Liver 0.0 Brain (whole) 0.0 Liver ca. HepG2 0.0 Spinal Cord Pool 0.0 Kidney Pool 0.0 Adrenal Gland 0.0 Fetal Kidney 0.0 Pituitary gland Pool 0.0 Renal ca. 786-0 0.0 Salivary Gland 0.0 Renal ca. A498 0.0 Thyroid (female) 0.0 Renal ca. ACHN 0.0 Pancreatic ca. CAPAN2 0.0 Renal ca. UO-31 0.0 Pancreas Pool 0.0 Table PC. Panel 4.1D Column A - Rel. Exp.(%) Ag4106, Run 172569366 Tissue Name A Tissue Name Secondary Thi act 10.0 HUVECIL-lbeta0 Secondary Th2 act 0.0 HUVEC IFN gamma 0.0 Secondary Trl act 0.0 HUVEC TNF alpha + IFN gamma 0.0 Secondary Thl rest 0.0 HUVEC TNF alpha + IL4 0.0 Secondary Th2 rest 0.0 HUVEC IL-11 0.0 Secondary Trl rest 0.0 Lung Microvascular EC none 0.0 Primary Thl act 6.0 Lung Microvascular EC TNFalpha + IL-Ibeta 0.0 Primary Th2 act 0.0 Microvascular Dermal EC none 0.0.......... Primary Trl act 0.0 Microsvasular Dermal EC TNFalpha + IL-lbeta 0.0 Primary Thl rest 0.0 Bronchial epithelium TNFalpha + ILlbeta 7.6 Primary Th2 rest 0.0 Small airway epithelium none 11.1 Primary Trl rest 2.3 Small airway epithelium TNFalpha + IL-lbeta 0.0 CD45RA CD4 lymphocyte act 0.0 Coronery artery SMC rest 0.0 CD45RO CD4 lymphocyte act 0.0 Coronery artery SMC TNFalpha + IL-beta 0.0 CD8 lymphocyte act 0.0 Astrocytes rest 0.0 Secondary CD8 lymphocyte rest 0.0 Astrocytes TNFalpha + IL-Ibeta 2.2 Secondary CD8 lymphocyte act 0.0 KU-812 (Basophil) rest 0.0 CD4 lymphocyte none 0.0 KU-812 (Basophil) PMA/ionomycin 0.0 2 ry Thl/Th2/Trl anti-CD95 CH11 0.0 CCD1106 (Keratinocytes) none 9.5 LAK cells rest 0.0 CCD1106 (Keratinocytes) TNFalpha + IL-lbeta 0.0 LAK cells IL-2 0.0 Liver cinrrhosis 5.3 LAK cells IL-2+IL-12 0.0 NCI-H292 none 10.0 LAK cells IL-2+IFN gamma -0.0 NCI-H292 IL-4 0.0 LAK cells IL-2+ IL-18 0.0 NCI-H292 IL-9 0.0 LAK cells PMA/ionomycin 10.4 NCI-H292 IL-13 0.0 NK Cells IL-2 rest 0.0 NCI-H292 IFN gamma 0.0 Two Way MLR 3 day 5.2 HPAEC none 0.0 Two Way MLR 5 day 0.0 HPAEC TNF alpha + IL-1 beta 0.0 Two Way MLR 7 day 0.0 Lung fibroblast none 0.0 405 WO 2004/000997 PCT/US2003/017512 PBMC rest 0.0 Lung fibroblast TNF alpha + IL-1 beta 0.0 PBMC PWM . Lung fibroblast IL-4 _ PBMC PHA-L 0.0 Lung fibroblast IL-9 0.0 Ramos (B cell) none 0.0 Lung fibroblast IL-13 0.0 Ramos (B cell) ionomycin 0.0 Lung fibroblast IFN gamma 0.0 B lymphocytes PWM 5.0 Dermal fibroblast CCD1070 rest 0.0 B lymphocytes CD40L and L-4 0.0 Dermal fibroblast CCD1070 TNF alpha 0.0 EOL-1 dbcAMP 0.0 Dermal fibroblast CCD1070 IL-1 beta 0.0 EOL-1 dbcAMP PMA/ionomycin 0.0 Dermal fibroblast IFN gamma .0 Dendrti cells none 0.0 Dermal fibroblast IL-4 0. Dendritic cells LPS 0.0 Dermal Fibroblasts rest 0.0 Dendritic cells anti-CD40 0.0 Neutrophil TNFa+LPS 0.0 Monocytes rest 0.0 Neutrophils rest 0.0 Monocytes LPS 0.0 Colon 5.4 Macrophages rest 0 Lung 7.6 Macrophages LPS 0.0 Thymus 9.3 HUVEC none 0.0 Kidney 100.0 HUVEC starved 0.0 General_screening_panelvl.4 Summary: Ag4106 Significant expression of the CG97111-01 gene was seen mainly in thymus (CT=33.4). This gene may therefore play an important role in T cell development. Gene or protein expression levels are useful for the 5 detection of thymus. Therapeutic modulation of the activity of this gene or its protein product is useful to modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitiution. Panel 4.1D Summary: Ag4106 Significant expression of this gene was seen in a normal kidney sample (CT=33.4). Therapeutic modulation of the activity of this gene or its 10 protein product is useful to modulate kidney function and for the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis. OTHER EMBODIMENTS 15 Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is 406 WO 2004/000997 PCT/US2003/017512 contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art 5 with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims. 407

Claims (59)

1. An isolated polypeptide comprising the mature form of an amino acid sequenced selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141.

2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141.

3. An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141.

4. An isolated polypeptide, wherein the polypeptide comprises an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141.

5. The polypeptide of claim 1 wherein said polypeptide is naturally occurring.

6. A composition comprising the polypeptide of claim 1 and a carrier.

7. A kit comprising, in one or more containers, the composition of claim 6.

8. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein the therapeutic comprises the polypeptide of claim 1. 408 WO 2004/000997 PCT/US2003/017512

9. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising: (a) providing said sample; (b) introducing said sample to an antibody that binds immunospecifically to the polypeptide; and (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.

10. A method for determining the presence of or predisposition to a disease associated with altered levels of expression of the polypeptide of claim 1 in a first mammalian subject, the method comprising: a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and b) comparing the expression of said polypeptide in the sample of step (a) to the expression of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease, wherein an alteration in the level of expression of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.

11. A method of identifying an agent that binds to the polypeptide of claim 1, the method comprising: (a) introducing said polypeptide to said agent; and (b) determining whether said agent binds to said polypeptide.

12. The method of claim 11 wherein the agent is a cellular receptor or a downstream effector. 409 WO 2004/000997 PCT/US2003/017512

13. A method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of the polypeptide of claim 1, the method comprising: (a) providing a cell expressing the polypeptide of claim 1 and having a property or function ascribable to the polypeptide; (b) contacting the cell with a composition comprising a candidate substance; and (c) determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition in the absence of the substance, the substance is identified as a potential therapeutic agent.

14. A method for screening for a modulator of activity of or of latency or predisposition to a pathology associated with the polypeptide of claim 1, said method comprising: (a) administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of claim 1, wherein said test animal recombinantly expresses the polypeptide of claim 1; (b) measuring the activity of said polypeptide in said test animal after administering the compound of step (a); and (c) comparing the activity of said polypeptide in said test animal with the activity of said polypeptide in a control animal not administered said polypeptide, wherein a change in the activity of said polypeptide in said test animal relative to said control animal indicates the test compound is a modulator activity of or latency or predisposition to, a pathology associated with the polypeptide of claim 1.

15. The method of claim 14, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene. 410 WO 2004/000997 PCT/US2003/017512

16. A method for modulating the activity of the polypeptide of claim 1, the method comprising contacting a cell sample expressing the polypeptide of claim 1 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

17. A method of treating or preventing a pathology associated with the polypeptide of claim 1, the method comprising administering the polypeptide of claim 1 to a subject in which such treatment or prevention is desired in an amount sufficient to treat or prevent the pathology in the subject.

18. The method of claim 17, wherein the subject is a human.

19. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141, or a biologically active fragment thereof.

20. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141.

21. The nucleic acid molecule of claim 20, wherein the nucleic acid molecule is naturally occurring.

22. A nucleic acid molecule, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO: 2n-l, wherein n is an integer between 1 and 141.

23. An isolated nucleic acid molecule encoding the mature form of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 141. 411 WO 2004/000997 PCT/US2003/017512

24. A composition comprising an isolated nucleic acid molecule, said molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 141, and a carrier.

25. The nucleic acid molecule of claim 20, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 141, or a complement of said nucleotide sequence.

26. A vector comprising the nucleic acid molecule of claim 20.

27. The vector of claim 26, further comprising a promoter operably linked to said nucleic acid molecule.

28. A cell comprising the vector of claim 26.

29. An antibody that immunospecifically binds to the polypeptide of claim 1.

30. The antibody of claim 29, wherein the antibody is a monoclonal antibody.

31. The antibody of claim 29, wherein the antibody is a humanized antibody.

32. A method for determining the presence or amount of the nucleic acid molecule of claim 20 in a sample, the method comprising: (a) providing said sample; (b) introducing said sample to a probe that binds to said nucleic acid molecule; and (c) determining the presence or amount of said probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.

33. The method of claim 32 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type. 412 WO 2004/000997 PCT/US2003/017512

34. The method of claim 33 wherein the cell or tissue type is cancerous.

35. A method for determining the presence of or predisposition to a disease associated with altered levels of expression of the nucleic acid molecule of claim 20 in a first mammalian subject, the method comprising: a) measuring the level of expression of the nucleic acid in a sample from the first mammalian subject; and b) comparing the level of expression of said nucleic acid in the sample of step (a) to the level of expression of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of expression of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

36. A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141.

37. The method of claim 36 wherein the cell is a bacterial cell.

38. The method of claim 36 wherein the cell is an insect cell.

39. The method of claim 36 wherein the cell is a yeast cell.

40. The method of claim 36 wherein the cell is a mammalian cell.

41. A method of producing the polypeptide of claim 2, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising a nucleic 413 WO 2004/000997 PCT/US2003/017512 acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 141.

42. The method of claim 41 wherein the cell is a bacterial cell.

43. The method of claim 41 wherein the cell is an insect cell.

44. The method of claim 41 wherein the cell is a yeast cell.

45. The method of claim 41 wherein the cell is a mammalian cell.

46. An isolated polypeptide comprising an amino acid sequence at least 95% similar to SEQ ID NO: 2, wherein said amino acid sequence comprises at least one amino acid substitution, wherein said substitution is at amino acid position 43 when numbered in accordance with SEQ ID NO: 2.

47. An isolated nucleic acid molecule comprising an nucleic acid sequence at least 95% similar to SEQ ID NO: 1, wherein said nucleic acid sequence comprises at least one nucleic acid substitution, wherein said substitution is at nucleic acid position 135 when numbered in accordance with SEQ ID NO: 1.

48. An isolated polypeptide comprising an amino acid sequence at least 95% similar to SEQ ID NO: 14, wherein said amino acid sequence comprises at least one amino acid substitution, wherein said substitution is at the amino acid position selected from the group consisting of 8, 54, 56, 92, 207, 240, 706, 891 and 923 when numbered in accordance with SEQ ID NO: 14.

49. An isolated nucleic acid molecule comprising an nucleic acid sequence at least 95% similar to SEQ ID NO: 13, wherein said nucleic acid sequence comprises at least one nucleic acid substitution, wherein said substitution is at the nucleic acid position selected from the group consisting of 272, 410, 416, 523, 869, 967, 2366, 2921 and 3018 when numbered in accordance with SEQ ID NO: 13. 414 WO 2004/000997 PCT/US2003/017512

50. An isolated polypeptide comprising an amino acid sequence at least 95% similar to SEQ ID NO: 58, wherein said amino acid sequence comprises at least one amino acid substitution, wherein said substitution is at the amino acid position selected from the group consisting of 23, 56, 105, 125, 160, 183 and 215 when numbered in accordance with SEQ ID NO: 58.

51. An isolated nucleic acid molecule comprising an nucleic acid sequence at least 95% similar to SEQ ID NO: 57, wherein said nucleic acid sequence comprises at least one nucleic acid substitution, wherein said substitution is at the nucleic acid position selected from the group consisting of 181, 278,426, 485, 591, 661 and 756 when numbered in accordance with SEQ ID NO: 57.

52. An isolated polypeptide comprising an amino acid sequence at least 95% similar to SEQ ID NO: 80, wherein said amino acid sequence comprises at least one amino acid substitution, wherein said substitution is at amino acid position 219 when numbered in accordance with SEQ ID NO: 80.

53. An isolated nucleic acid molecule comprising an nucleic acid sequence at least 95% similar to SEQ ID NO: 79, wherein said nucleic acid sequence comprises at least one nucleic acid substitution, wherein said substitution is at nucleic acid position 685 when numbered in accordance with SEQ ID NO: 79.

54. An isolated polypeptide comprising an amino acid sequence at least 95% similar to SEQ ID NO: 92, wherein said amino acid sequence comprises at least one amino acid substitution, wherein said substitution isat amino acid position 470 when numbered in accordance with SEQ ID NO: 92.

55. An isolated nucleic acid molecule comprising an nucleic acid sequence at least 95% similar to SEQ ID NO: 91, wherein said nucleic acid sequence comprises at least one nucleic acid substitution, wherein said substitution is at nucleic acid position 1874 when numbered in accordance with SEQ ID NO: 91. 415 WO 2004/000997 PCT/US2003/017512

56. An isolated polypeptide comprising an amino acid sequence at least 95% similar to SEQ ID NO: 100, wherein said amino acid sequence comprises at least one amino acid substitution, wherein said substitution is at the amino acid position selected from the group consisting of 11, 112 and 145 when numbered in accordance with SEQ ID NO: 100.

57. An isolated nucleic acid molecule comprising an nucleic acid sequence at least 95% similar to SEQ ID NO: 99, wherein said nucleic acid sequence comprises at least one nucleic acid substitution, wherein said substitution is at the nucleic acid position selected from the group consisting of 80, 383 and 482 when numbered in accordance with SEQ ID NO: 99.

58. An isolated polypeptide comprising an amino acid sequence at least 95% similar to SEQ ID NO: 122, wherein said amino acid sequence comprises at least one amino acid substitution, wherein said substitution is at the amino acid position selected from the group consisting of 12, 38, 54, 65, 66, 69, 80, 90, 91, 96, 100, 101, 102, 114, 122, 125, 126, 134, 135, 144, 148, 154, 155 and 156 when numbered in accordance with SEQ ID NO: 122.

59. An isolated nucleic acid molecule comprising an nucleic acid sequence at least 95% similar to SEQ ID NO: 121, wherein said nucleic acid sequence comprises at least one nucleic acid substitution, wherein said substitution is at the nucleic acid position selected from the group consisting of 35, 112, 160, 194, 197, 206, 240, 269, 273, 287, 298, 301,305, 340, 365, 374, 376, 400,404,431, 442, 461, 463 and 468 when numbered in accordance with SEQ ID NO: 121. 416